<SEC-DOCUMENT>0001213900-21-012577.txt : 20210301
<SEC-HEADER>0001213900-21-012577.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301164210
ACCESSION NUMBER:		0001213900-21-012577
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wize Pharma, Inc.
		CENTRAL INDEX KEY:			0001218683
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880445167
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52545
		FILM NUMBER:		21698607

	BUSINESS ADDRESS:	
		STREET 1:		24 HANAGAR ST
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527713
		BUSINESS PHONE:		972 472 260 0536

	MAIL ADDRESS:	
		STREET 1:		24 HANAGAR ST
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OphthaliX, Inc.
		DATE OF NAME CHANGE:	20120207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DENALI CONCRETE MANAGEMENT INC
		DATE OF NAME CHANGE:	20030213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2020_wizepharmainc.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746; ANNUAL&nbsp;REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended: December 31,
2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744; TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _____________
to _____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No. 000-52545</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wize Pharma, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-top: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88-0445167</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of<BR>
&nbsp;incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer <BR>
Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24 Hanagar Street, Hod Hasharon, Israel</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4527708</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;+972 (72) 260-0536</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities Registered pursuant to Section
12(b) of the Act:&nbsp;<B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities Registered pursuant to Section
12(g) of the Exchange Act:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Common Stock, par
value $0.001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Title of each class)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&nbsp;&#9744;&nbsp;&nbsp;No&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.&nbsp; Yes&nbsp;&#9744;&nbsp;&nbsp;No&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.&nbsp; Yes&nbsp;&#9746;&nbsp;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files).&nbsp; Yes&nbsp;&#9746;&nbsp;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo;, &ldquo;smaller
reporting company&rdquo;, and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer:&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 52%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer:&nbsp;&nbsp;&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer: &#9746;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting
    company:&nbsp;&nbsp;&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth
    company:&nbsp;&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared
or issued its audit report. &#9744;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&nbsp;&#9744;&nbsp;&nbsp;No&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting and non-voting common
equity held by non-affiliates of the registrant was $1,961,169 computed by reference to the price at which the common equity was
last sold, as of the last business day of the registrant&rsquo;s most recently completed second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2021, there were 33,052,951 shares of the registrant&rsquo;s Common Stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOCUMENTS
INCORPORATED BY REFERENCE:&nbsp;</B>NONE&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; width: 10%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 80%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5</FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6</FONT></TD>
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7</FONT></TD>
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A</FONT></TD>
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8</FONT></TD>
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9</FONT></TD>
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A</FONT></TD>
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B</FONT></TD>
    <TD><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10</FONT></TD>
    <TD><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11</FONT></TD>
    <TD><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12</FONT></TD>
    <TD><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13</FONT></TD>
    <TD><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, Director Independence</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14</FONT></TD>
    <TD><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15</FONT></TD>
    <TD><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16</FONT></TD>
    <TD><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary</FONT></A></TD>
    <TD STYLE="text-align: center">83</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">84</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INTRODUCTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Throughout this Annual
Report, unless otherwise designated, the terms &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, the &ldquo;Company&rdquo;,
&ldquo;Wize&rdquo; and &ldquo;our company&rdquo; refer to Wize Pharma, Inc., a Delaware corporation, its wholly-owned Israeli subsidiary,
Wize Pharma Ltd. (&ldquo;<B>Wize Israel</B>&rdquo;), its wholly-owned Delaware subsidiary, Wize NC Inc. (&ldquo;<B>Wize NC</B>&rdquo;),
and the wholly-owned subsidiary of Wize NC, OcuWize Ltd. (&ldquo;<B>OcuWize</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All dollar amounts
refer to U.S. dollars unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless derived from Wize&rsquo;s financial statements or otherwise
indicated, U.S. dollar translations of New Israeli Shekels (&ldquo;<B>NIS</B>&rdquo;) amounts presented in this Annual Report are
translated using the rate of NIS&nbsp;3.28 to one U.S. dollar, the exchange rate reported by the Bank of Israel for February 25,
2021.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 5, 2018, we
effected a reverse stock split of our Common Stock at a ratio of one for twenty-four (1:24) (the &ldquo;<B>Reverse Stock Split</B>&rdquo;).
Unless otherwise indicated, all share and per share amounts included in this Annual Report reflect the effects of the Reverse Stock
Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Statements made
in this Annual Report concerning the contents of any contract, agreement or other document are summaries of such contracts, agreements
or documents and are not complete descriptions of all of their terms.&nbsp; If we filed any of these documents as an exhibit to
this Annual Report or to any registration statement or annual report that we previously filed, you may read the document itself
for a complete description of its terms, and the summary included herein is qualified by reference to the full text of the document
which is incorporated by reference into this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Unless otherwise
indicated, information contained in this Annual Report concerning our industry and the markets in which we operate, including our
competitive position and market opportunity, is based on information from our own management estimates and research, as well as
from industry and general publications and research, surveys and studies conducted by third parties. Management estimates are derived
from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which
we believe to be reasonable. Our management estimates have not been verified by any independent source, and we have not independently
verified any third-party information. In addition, assumptions and estimates of our and our industry&rsquo;s future performance
are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in Item
1A &ldquo;Risk Factors&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Wize Pharma, Inc.<SUP>&reg;</SUP>,
the Wize logo and other trademarks or service marks of Wize appearing in this Annual Report are the property of Wize Pharma, Inc.
or its subsidiaries. Trade names, trademarks and service marks of other companies appearing in this Annual Report are the property
of their respective holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>IMPORTANT NOTE REGARDING THE PENDING
TRANSACTION WITH COSMOS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December 30, 2020, we entered into a Bid Implementation Agreement
(as amended, the &ldquo;Bid Agreement&rdquo;) with Cosmos Capital Limited, a digital infrastructure provider based in&nbsp;Sydney,
Australia (&ldquo;Cosmos&rdquo;). Pursuant to the Bid Agreement, we commenced an off-market takeover offer under applicable Australian
laws (the &ldquo;Offer&rdquo;),&nbsp;whereby we are offering 61.11 shares of our common stock in exchange for each one outstanding
share of Cosmos. Immediately following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos
shareholders are expected to own approximately 87.65% of the outstanding common stock of Wize, while Wize existing stockholders
are expected to remain the owners of approximately 10.75% of the outstanding common stock of Wize, each on a fully diluted basis
and including warrants to be issued to Wize&rsquo;s financial advisor to the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Pursuant to the Bid Agreement, prior to the Closing Date, Wize
will enter into a Contingent Value Rights Agreement (the &ldquo;CVR Agreement&rdquo;) with Cosmos, certain of Wize&rsquo;s subsidiaries
(the &ldquo;Wize Subsidiaries&rdquo;), a person designated by Wize prior to the Closing Date as the Holders&rsquo; Representative
(as defined herein), and the Rights Agent (as defined therein). Pursuant to the CVR Agreement, at the Closing Date, each Wize pre-Closing
securityholder will receive one non-transferable CVR for each outstanding share of common stock of Wize and for each share of common
stock of Wize underlying other convertible securities and warrants, held as of 4:01&nbsp;p.m. Eastern Time on the day immediately&nbsp;<FONT STYLE="background-color: white">before
the Effective Time (as defined in the CVR Agreement). Each CVR will represent the right to receive a pro rata share of any consideration
that may be received by Wize or the Wize Subsidiaries in connection with Wize&rsquo;s existing LO2A (as defined below) business.
In particular, CVR holders will be entitled to any consideration (whether cash, stock, assets or otherwise) that Wize or the Wize
Subsidiaries (or any of its Affiliates or shareholders) receives in connection with an LO2A Transaction, which, as defined in the
CVR Agreement, includes (i) a sale of any of the Wize Subsidiaries to a third party and/or (ii) the partnering, licensing, sublicensing,
distribution, reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third party, less transaction expenses
and customary deductions as detailed in the CVR agreement, including a deduction of up to $300,000 that the Wize Subsidiaries undertook
to incur in the development of the LO2A Technology at the request of the Holders&rsquo; Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2021,
we lodged a Bidder&rsquo;s Statement with the Australian Securities and Investments Commission to commence the Offer and, on February
16, 2021, we announced that the Offer became unconditional and that we plan to consummate the transactions contemplated by the
Bid Agreement and the Offer on or about March 9, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Unless indicated otherwise by the context, the discussion in
this Annual Report regarding our future business plans and activities, including, without limitation, risk factors, does not take into account the effect of the consummation
of the Offer and related transactions, including the termination of directors and executive officers contemplated thereunder (collectively,
the &ldquo;Cosmos Transaction&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><I>For
further information on the Cosmos Transaction, including the Bid Agreement, the Offer, the CVR Agreement, the Stock Restriction
Agreement, the PIPE Agreements and related transactions, see in &ldquo;Item 1 &ndash; BUSINESS &ndash; Overview &ndash; Cosmos
Transaction&rdquo; below and our Current Reports on Form 8-K filed with the SEC on January 5, 2021, January 19, 2021 and February
16, 2021, which are incorporated herein by reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report
on Form 10-K (this &ldquo;<B>Annual Report</B>&rdquo;) contains forward-looking statements, about our expectations, beliefs or
intentions regarding, among other things, our product development efforts, business, financial condition, results of operations,
strategies or prospects. Forward-looking statements can be identified by the use of forward-looking words such as &ldquo;believe&rdquo;,
&ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;plan&rdquo;, &ldquo;may&rdquo;, &ldquo;should&rdquo; or &ldquo;anticipate&rdquo;
or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate
strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various
filings made by us with the United States Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;), press releases or
oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors
could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking
statements, including, but not limited to, the factors summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Annual Report identifies important factors which could cause our actual results to differ materially from those indicated by the
forward-looking statements, particularly those set forth under Item 1A - &ldquo;RISK FACTORS&rdquo; below. The risk factors included
in this Annual Report are not necessarily all of the important factors that could cause actual results to differ materially from
those expressed in any of our forward-looking statements. Given these uncertainties, you are cautioned not to place undue reliance
on such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied
in such forward-looking statements include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing and anticipated
    completion of the Cosmos Transaction;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expected benefits
    of and potential value created by the Cosmos Transaction for our stockholders;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may need to raise
    additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to
    obtain and will dilute current stockholders&rsquo; ownership interests;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our current pipeline
    is based on a single compound known as LO2A (&ldquo;<B>LO2A</B>&rdquo;), which is an artificial tear preparation containing
    0.015% sodium hyaluronate (&ldquo;<B>SH</B>&rdquo;), and on the continuation of our license to commercialize LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to
    expand our rights under our license agreement for LO2A may have a detrimental effect on our business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation,
    timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to advance our product candidate into clinical trials or to successfully complete our preclinical studies or clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our receipt of regulatory approvals for our product candidate, and the timing of other regulatory filings and approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical development, commercialization and market acceptance of LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain corporate collaborations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the implementation of our business model and strategic plans for our business and product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering LO2A and its ability to operate our business without infringing the intellectual property rights of others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates of our expenses, future revenues, and capital requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competitive companies, technologies and our industry; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic, including on our clinical trials, the demand for our products, our ability to operate and on overall economic conditions; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements as to the impact of the political and security situation in Israel on our business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this Annual Report and
are expressly qualified in their entirety by the cautionary statements included in this Annual Report. We undertake no obligations
to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect
the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_002"></A>ITEM 1. BUSINESS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>General</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage
biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (&ldquo;DES&rdquo;).
We have in-licensed certain rights to purchase, market, sell and distribute a&nbsp;formula known as LO2A, a drug developed for
the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (&ldquo;CCH&rdquo;) and Sj&ouml;gren&rsquo;s
syndrome (&ldquo;Sj&ouml;gren&rsquo;s&rdquo;). In May 2015, Wize Israel entered into an Exclusive Distribution and Licensing Agreement
(as amended, the &ldquo;License Agreement&rdquo;), with Resdevco Research and Development Company Ltd. (&ldquo;Resdevco&rdquo;).
Pursuant to the License Agreement, Resdevco granted to Wize Israel (and thereafter, to OcuWize) an exclusive license to develop
in the United States, under the LO2A licensed technology, products in the field of ophthalmic disorders, to mutually agree upon
a manufacturer and to purchase, market, sell and distribute LO2A in finished product form in the licensed territories in the field
of ophthalmic disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LO2A is currently registered
and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and
ophthalmological symptoms of Sj&ouml;gren&rsquo;s and in the Netherlands for the treatment of DES and protection from dry eye as
a result of Sj&ouml;gren&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to focus on marketing LO2A as a treatment
for DES and other ophthalmic inflammations, including CCH and / or Sj&ouml;gren&rsquo;s, in the United States, and in additional
territories, subject to obtaining the appropriate regulatory file for each such territory and purchasing the rights to market,
sell and distribute LO2A in those additional territories (collectively, the &ldquo;Licensed Territories&rdquo;). We believe that
the potential for the most economic success is in marketing LO2A for the treatment of DES patients suffering from CCH and/or Sj&ouml;gren&rsquo;s.
The registration process in certain countries, including the United States, requires us to conduct additional clinical trials,
in addition to the Phase II clinical trial that we have completed and the Phase IV clinical trial which we completed in May 2020,
and with respect to which, we published topline data on November 12, 2020, as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan, subject to
successful studies results, to engage local or multinational distributors to handle the distribution of LO2A or engage in such
other strategic transactions that may monetize our rights in our LO2A licensed technology. In particular, we intend to (i) engage,
subject to obtaining the requisite rights in LO2A, pharmaceutical companies or distributors around the world with relevant marketing
capabilities in the pharmaceutical field, in order for such pharmaceutical companies to sell LO2A, with us prioritizing those territories
where we may expedite the registration process of LO2A based on existing knowledge and studies previously conducted on LO2A, without
requiring additional studies, or (ii) explore other strategic transactions with pharmaceutical companies or others that will monetize
our rights in the LO2A licensed technology.&nbsp;However, there is no assurance whether we will be able to consummate any such
transactions and, even if we did, what will be the timing or terms thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
November 2018, we completed a phase II multi-center trial at five different medical centers in Israel (the &ldquo;Phase II Multi-Center
Trial&rdquo;). The Phase II Multi-Center Trial was a randomized, double-blind, placebo-controlled study carried out in parallel
groups that evaluated the safety and efficacy of LO2A for patients suffering from moderate to severe CCH. The primary efficacy
endpoint for the Phase II Multi-Center Trial was the change from baseline in lissamine green conjunctival staining score at 3 months;
secondary endpoints include change from baseline in lissamine green conjunctival staining score at 1 month, change from baseline
in LIPCOF score at 1 and 3 months, change from baseline in TFBUT at 1 and 3 months and change from baseline in OSDI questionnaire
score at 1 and 3 months. Safety endpoints include adverse events recorded throughout the trial, best-corrected visual acuity, slit
lamp biomicroscopy findings, undilated fundoscopy findings and intraocular pressure measurements. We consulted with ophthalmology
consultants from the United States in the preparation of the protocol for the Phase II Multi-Center Trial. In November 2018 we
received the top line results for the Phase II Multi-Center Trial which describe analysis of the primary endpoint. The originally
planned primary analysis was based upon recruitment of a sample size of 62 patients. Analysis was performed on the 49 fully evaluable
patients using a mixed model with repeated measures (MMRM) and utilized all post baseline observations, (1-month and 3-month follow-ups)
demonstrating statistical significance between the LO2A group and the placebo group (P=0.0079). The planned primary endpoint analysis
compared average reduction in LGCS score from baseline to three months. This analysis also demonstrated a strong trend towards
significance (P=0.0713) with average reduction in LGCS score between baseline and 3 months of -3.5 and -1.6 in the LO2A and placebo
groups, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
May 2020, we completed a phase IV multi-center trial at five different medical centers in Israel (the &ldquo;Phase IV Multi-Center
Trial&rdquo;). The Phase IV Multi-Center Trial evaluated the safety and efficacy of LO2A for symptomatic improvement of DES in
69 adult patients with Sj&ouml;gren&rsquo;s. Enrolled patients were randomized in a 1:1 ratio to one of two treatment groups, LO2A
or Systane<SUP>&reg;</SUP> Ultra UD. The Phase IV Multi-Center Trial was designed to support our clinical approval pathway for
LO2A for the treatment of DES in patients with Sj&ouml;gren&rsquo;s within certain markets including the U.S. We announced the
topline results of such trial on November 12, 2020, as described below.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Cosmos Transaction</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in; background-color: white">On December 30,
2020, we entered into the Bid Agreement with Cosmos, which was subsequently amended on January 18, 2021 for the primary purpose
of simplifying the Offer structure. Under the Bid Agreement (as amended), the parties agreed that Wize would commence the Offer,
an off-market takeover offer under applicable Australian laws, to acquire all of the Cosmos Shares in exchange for 61.11 Wize shares
of common stock for each Cosmos Share, being the Offer Consideration.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Under
the Bid Agreement, 22.33 Wize shares of common stock out of the Offer Consideration will be &ldquo;Restricted Stock&rdquo;
subject to a Stock Restriction Agreement to be entered into at the Closing Date and 38.78 Wize shares of common stock will be
&ldquo;Covered Securities&rdquo;. A Cosmos shareholder who accepts the Offer (an &ldquo;Accepting Shareholder&rdquo;) will
not be permitted to sell or encumber their Restricted Stock until December 31, 2021 (the &ldquo;Milestone Date&rdquo;). In
addition, an Accepting Shareholders may not exercise voting rights in respect of Restricted Stock from the date of issuance
of the Offer Consideration until the Milestone Date. An Accepting Shareholder is entitled to sell or encumber its Covered
Securities. However, if (subject to certain limited exceptions) an Accepting Shareholder sells or encumbers any of its
Covered Securities before the Milestone Date, Wize has an option to repurchase a pro rata proportion of the Restricted Stock
for the lower of $0.0001 and the fair market value of the Restricted Stock. The Restricted Stock (and any dividends thereon)
will be held by Wize in escrow for the Accepting Shareholder&rsquo;s benefit until such time as the Restricted Stock is
repurchased by Wize or all restrictions thereon lapse. If any Restricted Stock is repurchased under Wize&rsquo;s repurchase
option, a pro rata proportion of the dividend on the Restricted Stock shall be retained by Wize. The Offer Consideration, comprising the Restricted Stock and the Covered Securities, will be <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exempt
from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) pursuant to Section
4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder because, among other things, the transaction
did not involve a public offering, the investors are accredited investors, the investors are taking the securities for investment
and not resale and the Company took appropriate measures to restrict the transfer of the securities, and pursuant to Regulation
S of the Securities Act to non-U.S. investors</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Immediately following
the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos shareholders are expected to own approximately
87.65% of the outstanding common stock of Wize, while Wize existing stockholders are expected to remain the owners of approximately
10.75% of the outstanding common stock of Wize, each on a fully diluted basis and including warrants to be issued to Wize&rsquo;s
financial advisor to the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Pursuant to the Bid Agreement, prior to the Closing Date, Wize
will enter into a Contingent Value Rights Agreement (the &ldquo;CVR Agreement&rdquo;) with Cosmos, certain of Wize&rsquo;s subsidiaries
(the &ldquo;Wize Subsidiaries&rdquo;), a person designated by Wize prior to the Closing Date as the Holders&rsquo; Representative
(as defined herein), and the Rights Agent (as defined therein). Pursuant to the CVR Agreement, at the Closing Date, each Wize pre-Closing
securityholder will receive one non-transferable, on a contractual basis only, contingent value right (&ldquo;CVR&rdquo;) for each
outstanding share of common stock of Wize and for each share of common stock of Wize underlying other convertible securities and
warrants, held as of 4:01&nbsp;p.m. Eastern Time on the day immediately&nbsp;<FONT STYLE="background-color: white">before the Effective
Time (as defined in the CVR Agreement). Each CVR will represent the right to receive a pro rata share of any consideration that
may be received by Wize or the Wize Subsidiaries in connection with Wize&rsquo;s existing LO2A business. In particular, CVR holders
will be entitled to any consideration (whether cash, stock, assets or otherwise) that Wize or the Wize Subsidiaries (or any of
its Affiliates or shareholders) receives in connection with an LO2A Transaction, which, as defined in the CVR Agreement, includes
(i) a sale of any of the Wize Subsidiaries to a third party and/or (ii) the partnering, licensing, sublicensing, distribution,
reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third party, less transaction expenses and customary
deductions as detailed in the CVR agreement, including a deduction of up to $300,000 that the Wize Subsidiaries undertook to incur
in the development of the LO2A Technology at the request of the Holders&rsquo; Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
Bid Agreement also contains certain covenants to be performed at or following the Closing Date, including, among others, (i) agreement
that the Board of Directors of Wize immediately following the Closing Date will consist, subject to certain exceptions, of three
members to be designated by Cosmos and one member to be designated by Wize; (ii) covenants that Wize will seek, following the Closing
Date, stockholder approval to be renamed Cosmos Capital, Inc. (or similar name), and to effect a reverse share split of Wize&rsquo;s
common stock; (iii) covenants that Wize will establish an incentive compensation program with respect to 40,000,000 shares of its
common stock, to be granted promptly following the Closing Date, in the form of performance-based RSUs, performance rights or indeterminate
rights based on the performance milestone criteria and allocation set in the Bid Agreement (the &ldquo;Post-Closing Incentive Plan&rdquo;),
50% of which are to be granted to personnel specified by Wize prior to the Closing Date and the remainder to be granted to personnel
of Cosmos (see also Item 9B below); (iv) an obligation by Wize to terminate or procure the termination of each of the current employment
or consulting agreements of Wize with Mr. Mark Sieczkarek, the Chairman of Wize Board of Directors, Mr. Noam Danenberg, the Chief
Executive Officer of Wize, Mr. Or Eisenberg, the Chief Financial Officer of Wize, and another part-time employee related to Mr.
Danenberg; and (v) an obligation by Wize to use its reasonable commercial efforts to enter into new, part time, consulting agreements
with Mr. Danenberg and Mr. Eisenberg in a form to be agreed between Wize and Cosmos.&nbsp;In this respect, it should be noted that
Wize, Cosmos and each of Mr. Danenberg and Mr. Eisenberg agreed on the form of such consulting agreements, whereby Mr. Danenberg
and Mr. Eisenberg will provide part time consulting services to Wize following the Closing Date for monthly compensation of US$10,000
and US$7,500, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">Concurrently
with the execution of the Bid Agreement, we entered into Securities Purchase Agreements (the &ldquo;PIPE Agreements&rdquo;) with
certain accredited investors (the &ldquo;PIPE Investors&rdquo;), including Mr. Noam Danenberg, our CEO. Pursuant to the PIPE Agreements,
we agreed to sell to the PIPE Investors, and the PIPE Investors agreed to purchase from us, in a private placement, an aggregate
of 25,000,000 shares of common stock for a purchase price of $0.12 per share, or aggregate gross proceeds of $3.0 million, which,
in the case of Mr. Danenberg, may be satisfied by waiving outstanding amounts owed by the Company or its subsidiaries to Mr. Danenberg
pursuant to his consulting agreement with our subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 1, 2021,
we lodged a Bidder&rsquo;s Statement with the Australian Securities and Investments Commission to commence the Offer and, on February
16, 2021, we announced that the Offer became unconditional and that we plan to consummate the transactions contemplated by the
Bid Agreement and the Offer on or about March 9, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Unless indicated
otherwise by the context, the discussion in this Annual Report regarding our future business plans and activities does not take
into account the effect of the consummation of the Offer and related transactions (collectively, the &ldquo;Cosmos Transaction&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><I>For
further information on the Cosmos Transaction, including the Bid Agreement, the Offer, the CVR Agreement, the Stock
Restriction Agreement, the PIPE Agreements and related transactions, see our Current Reports on Form 8-K filed with the SEC
on January 5, 2021, January 19, 2021 and February 16, 2021, which are incorporated herein by
reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The Bonus/LO2A Transaction</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the information
under &ldquo;ITEM 7 &ndash; Liquidity and Capital Resources &ndash; <I>The Bonus/LO2A Transaction</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Series B Preferred
Stock and Redemption</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the information
under &ldquo;ITEM 7 &ndash; Liquidity and Capital Resources &ndash; <I>Series B Preferred Stock and Redemption</I>.&rdquo;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Copernicus</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 4, 2019,
the Company entered into an exclusive license agreement with Copernicus Therapeutics, Inc. (&ldquo;Copernicus&rdquo;), a U.S.-based
privately held gene therapy company (the &ldquo;Copernicus License Agreement&rdquo;). The execution of the Copernicus License
Agreement and the grant of license are subject to the satisfaction of certain customary closing conditions, including the completion
of a due diligence investigation of Copernicus and its technology to our satisfaction. As of today, this license agreement was
not executed, and we view this agreement as terminated, although we have reserved $50,000 as a possible payment to Copernicus
which was never made.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Corporate Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 21, 2017, we
entered into an Agreement and Plan of Merger (as amended, the &ldquo;2017 Merger Agreement&rdquo;), with Bufiduck Ltd., a company
formed under the laws of the State of Israel and our wholly owned subsidiary (the &ldquo;Merger Sub&rdquo;) and Wize Israel, which
contemplated the merger of Merger Sub with and into Wize Israel, with Wize Israel continuing as the surviving entity and becoming
our wholly owned subsidiary (the &ldquo;2017 Merger&rdquo;). The 2017 Merger was consummated on November 15, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate headquarters
are located in Hod Hasharon, Israel. Our telephone number is +(972)-72-2600536, and our website address is www.wizepharma.com.
The website is an inactive textual reference only, and not an active hyperlink. The information on or that can be accessed through
our website is specifically not incorporated by reference into this Annual Report, and is not a part of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Market Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, through OcuWize,
have licensed certain rights to purchase, market, sell and distribute LO2A for the treatment of DES and other ophthalmological
illnesses, including CCH and Sj&ouml;gren&rsquo;s in the United States, and have an option to purchase the rights to additional
territories as further described below under &ldquo;Item 1. BUISNESS &mdash; LO2A License Agreement&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DES is an eye disease
caused by eye dryness, which, in turn, is caused by either decreased tear production or increased tear film evaporation. The tear
film is comprised of the lower mucous layer which helps the tear film adhere to the eyes, a middle layer of water and an upper
oil layer that seals the tear film and prevents evaporation. The tear film keeps the eye moist, creates a smooth surface for light
to pass through the eye, nourishes the front of the eye and provides protection from injury and infection. DES is usually caused
by aqueous tear deficiency, or inadequate tear production, whereby the lachrymal gland, the gland that secretes the aqueous layer
of the tear film, does not produce sufficient tears to keep the entire conjunctiva, or the tissue inside the eyelids that covers
the sclera, and cornea covered by a complete layer of tear film. In rare cases, aqueous tear deficiency may be a symptom of collagen
vascular diseases, including rheumatoid arthritis, Wegener&rsquo;s granulomatosis, an incurable form of vasculitis (the inflammatory
destruction of blood vessels), systemic lupus erythematosus, an autoimmune connective tissue disease, Sj&ouml;gren&rsquo;s, an
autoimmune process in which patients suffer from mouth and eye dryness, and autoimmune diseases associated with Sj&ouml;gren&rsquo;s.
DES can also be caused by abnormal tear composition resulting in rapid evaporation or premature destruction of tears. Additional
causes include, but are not limited to, age, use of certain drugs and the use of contact lenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DES is characterized
by eye irritation symptoms, blurred and fluctuating vision, tear film instability, increased tear osmolarity and ocular surface
epithelial disease. DES causes constant ocular discomfort, typically dryness, burning, a sandy-gritty eye irritation and a decrease
in visual function. Over an extended period of time, DES can lead to tiny abrasions on the surface of the eyes. In advanced cases,
the epithelium undergoes pathologic changes, namely squamous metaplasia, a non-cancerous change of surface-lining cells, and loss
of goblet cells, which secrete mucin, which in turn dissolves in water to form mucous. Some severe cases result in thickening of
the corneal surface, corneal erosion, epithelial defects, corneal ulceration (sterile and infected), corneal neovascularization,
or excessive ingrowth of blood vessels, corneal scarring, corneal thinning, and even corneal perforation. In the most severe cases,
DES may result in deterioration of vision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a GlobalData DES
report (the &ldquo;GlobalData Report&rdquo;), it was estimated that in 2016, pharmaceutical sales within the DES market were approximately
$2.2 billion across the 8 major markets, with the United States contributing 79.6% of these sales, and GlobalData expects that
by 2026 those sales are expected to grow to $5.6 billion. According to the GlobalData Report, the major drivers of growth of DES
include the introduction of novel drugs, an increasingly aging society and increasing urbanized living with greater use of computers
and better disease awareness leading to increased diagnosis and treatment rates. In addition, extended viewing of television, computer
and smartphone screens, weather conditions, exposure to air conditioning and increased life expectancy are additional factors that
contribute to the increase in the number of those suffering from DES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CCH refers to the presence
of redundant folds of loose conjunctiva. CCH is thought to be caused by both a gradual thinning and stretching of the conjunctiva
that accompanies age and a loss of adhesion between the conjunctiva and underlying sclera due to the dissolution of Tenon&rsquo;s
capsule. A correlation may also exist between eye inflammation and CCH, though it is unclear if this correlation is causal. CCH
may also be associated with previous surgery, blepharitis, Meibomian gland disorder, Ehlers-Danlos Syndrome and aqueous tear deficiency.
The resulting loose, excess conjunctiva may mechanically irritate the eye and disrupt the tear film and its outflow, leading to
dry eye and excess tearing. Most patients with CCH complain of foreign body sensation, tearing, difficulty reading, blurred vision,
&ldquo;red eyes&rdquo; and general irritation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lid Parallel Conjunctival
Folds (&ldquo;LIPCOF&rdquo;) grading measures the number and severity of the lid-parallel conjunctival folds. LIPCOF grade 0 signifies
the absence of conjunctival folds, LIPCOF grade 1 signifies just one conjunctival fold, LIPCOF grade 2 signifies for multiple conjunctival
folds, not extending beyond the tear meniscus, and LIPCOF grade 3 signifies multiple conjunctival folds extending above the tear
meniscus. The LIPCOF grades show a strong correlation with both the subjective and objective complaints of DES, as well as with
the severity of the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The treatment of LIPCOF
grade 3 CCH usually requires invasive therapies like surgery or treatment of the conjunctival folds with argon laser or with heat
cauterization. A previous study conducted by Resdevco Ltd., a company controlled by Professor Shabtay Dikstein, the inventor of
LO2A (&ldquo;Resdevco&rdquo;) in 2013, has shown Conheal&reg; (Hungarian brand name for LO2A) to be effective in reducing the severity
of CCH as measured by a reduction in the (i) LIPCOF score, (ii) Oxford scheme grade and (iii) ocular surface disease index (&ldquo;OSDI&rdquo;)
and an increase in tear film break-up time (&ldquo;TFBUT&rdquo;). This raises the possibility that vision-related quality of life
can be significantly improved by conservative therapies even in severe CCH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is little epidemiological
data for CCH. A community based study in Shanghai reported that in patients over the age of 60, 4% had&nbsp;LIPCOF grade 3 CCH
and 16% had LIPCOF grade 2 CCH. In the EU, about 20% of the population is over the age of 65. From the aforementioned data, it
might be assumed, as presented in a study conducted by Dr. Huba J. Kiss and J&aacute;nos N&eacute;meth, that in the total EU population,
0.8% have LIPCOF grade 3 CCH and 3.2% have LIPCOF grade 2 CCH. Since DES complaints occur in 5.5% to 33.7% of the population, Dr.
Kiss and N&eacute;meth further assumed that the incidence of the CCH-caused DES in the population is about one-third of all DES
cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sj&ouml;gren&rsquo;s
is a heterogeneous, chronic, inflammatory, autoimmune disease characterized by lymphocytic infiltration of exocrine glands and
expression of autoantibodies including antinuclear antibody (ANA), anti-Ro (also termed anti SSA), anti-La (also termed anti SSB)
as well as rheumatoid factor (RF). Hypergammaglobulinemia is common as well. Sj&ouml;gren&rsquo;s may be an isolated disease, termed
primary Sj&ouml;gren&rsquo;s or may accompany another autoimmune diseases, such as lupus, rheumatoid arthritis, or scleroderma,
thus termed secondary Sj&ouml;gren&rsquo;s. Clinical presentation varies from mild symptoms such as classic sicca symptoms of dry
eyes (xerophthalmia), dry mouth (xerostomia) and parotid gland enlargements to severe systemic symptoms involving multiple organ
systems such as fever, fatigue, malaise, arthritis, arthralgia, myalgia, interstitial lung disease, kidney disease, gastrointestinal
disease and neurological manifestations. Sj&ouml;gren&rsquo;s treatment is highly individualized and is based on a patient&rsquo;s
disease severity, organ involvement and previous response. Mild forms of Sj&ouml;gren&rsquo;s may be treated symptomatically with
artificial tears and salivary flow stimulation. More severe, systemic manifestations may be treated with high-dose glucocorticoids
and immunosuppressive or cytotoxic drugs to suppress the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Estimations of Sj&ouml;gren&rsquo;s
prevalence vary from 2.5 million to 4 million patients (Sj&ouml;gren&rsquo;s Syndrome Foundation) in the United States alone, with
a worldwide estimate of up to 7.7 million in the seven major markets (United States, France, Germany, Italy, Spain, the UK and
Japan) by the year 2024 (Global Data Report). Sj&ouml;gren&rsquo;s affects mostly middle aged women (40-50 years of age) with a
female to male prevalence ratio of 9:1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Global Data estimates
the drug sales for Sj&ouml;gren&rsquo;s in 2014 were approximately $1.1 billion across the markets covered in its forecast. By
the end of the forecast period of 2024, sales are estimated to grow to $2.2 billion across the markets covered in its forecast
with a Compound Annual Growth Rate of 7.2%. The market size estimate in 2014 includes Salagen (pilocarpine) and Evoxac (cevimeline),
the only two agents to ever be approved for Sj&ouml;gren&rsquo;s, and the use of off-label agents, such as biologics approved for
other autoimmune diseases, and systemic and topical immunosuppressants and corticosteroids. This growth is expected to be driven
by the anticipated approval of Orencia for use in patients with Sj&ouml;gren&rsquo;s in the United States and the EU in 2021 and
Japan in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LO2A License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, Wize Israel
entered into an Exclusive Distribution and Licensing Agreement with Resdevco (as amended, the &ldquo;LO2A License Agreement&rdquo;).
In August 2016, Wize Israel and Resdevco entered into an agreement pursuant to which Wize Israel assigned all of its rights and
obligations under the LO2A License Agreement to OcuWize. Pursuant to the LO2A License Agreement, Resdevco granted to Wize Israel
(and thereafter, to OcuWize) an exclusive license to develop in the United States, under the LO2A licensed technology, products
in the field of ophthalmic disorders, to mutually agree upon a manufacturer and to purchase, market, sell and distribute LO2A in
finished product form in the Licensed Territories in the field of ophthalmic disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LO2A License Agreement
also grants Wize Israel the right to purchase Resdevco&rsquo;s agreements with its existing distributors of LO2A in Germany, Hungary,
Netherlands and Switzerland (the &ldquo;Reserved Territories&rdquo;) for (10) ten times the greater of the net royalties received
in the previous twelve (12) months or the minimum royalty payment under such agreements. The LO2A License Agreement furthermore
grants Wize Israel a right of first negotiation with potential distributors to whom Resdevco may in the future grant distribution
rights to LO2A outside of the Reserved Territories and the Licensed Territories, subject to the payment of royalties to Resdevco.
The LO2A License Agreement provides that Wize Israel is required to pay to Resdevco certain royalties for sales in the Licensed
Territories based on an agreed-upon price per unit as well as certain minimum royalty payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LO2A License Agreement
has an initial term of seven years that expires in May 2022, and, unless Wize Israel provides prior notice of at least twelve (12)
months terminating the agreement, the LO2A License Agreement renews automatically each year. Wize Israel may terminate the LO2A
License Agreement prior to May 2022, subject to certain conditions, including, a 180 days prior notice to Resdevco, and penalty
payment of $100,000, depending on the timing of termination. The LO2A License Agreement may also be terminated by either party
upon the occurrence of certain other customary termination triggers, including material breaches of the LO2A License Agreement
by either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LO2A License Agreement
contains other provisions, including representations and warranties of the parties, reporting, confidentiality and other covenants,
such as an undertaking by Wize Israel not to sell competing products in the Licensed Territories during the term of the agreement
and for five years thereafter. The LO2A License Agreement further provides that any improvements or modifications made by Wize
Israel to LO2A or any related intellectual property or know-how shall belong to Resdevco and Wize Israel shall receive a license
to distribute and sell the same in the Licensed Territories on the same terms set forth in the LO2A License Agreement.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 6, 2017,
Resdevco granted to Wize Israel, sole rights to commercialize LO2A in China. By agreement dated September 25, 2017, Wize Israel
and Resdevco agreed that Wize Israel&rsquo;s sole rights to commercialize LO2A in China would be limited to one year if by September
6, 2018, Wize Israel had not signed a distribution agreement for LO2A in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 26, 2017
Wize Israel, entered into an amendment to the LO2A License Agreement (the &ldquo;Third Amendment&rdquo;). The Third Amendment includes:
(i) China in the list of Licensed Territories, (ii) the commercial terms of the parties with respect to the activities of Wize
Israel in China, including the minimum annual royalty payments from Wize Israel to Resdevco, and, (iii) an undertaking by Wize
Israel to include in the Chinese Distribution Agreement, that the Chinese Distributor will transfer the Chinese market license
to Resdevco upon termination of the distribution agreement. On May 31, 2018, we entered into an Exclusive Distribution Agreement
with HPGC Medical Co., Ltd. (the &ldquo;Chinese Distributer&rdquo;), pursuant to which the Chinese Distributor will distribute
LO2A in China (the &ldquo;Chinese Distribution Agreement&rdquo;). Although the Chinese Distribution Agreement is in force, we have
not started yet to operate in the Chinese market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 8, 2018,
Wize Israel entered into a Memorandum of Understanding (the &ldquo;MOU&rdquo;) with Resdevco. Pursuant to the MOU, Resdevco granted
to Wize Israel (and its permitted assignees) an exclusive royalty bearing license to sell and distribute worldwide, excluding the
United States, Israel, Ukraine, Switzerland, Germany, Netherlands and China (the &ldquo;Additional Territories&rdquo;), under the
LO2A licensed technology, products in the field of ophthalmic disorders, under the terms and conditions set forth in the MOU. The
MOU provides that it will terminate by June 30, 2019 if the Company has not completed certain clinical trials by such date. The
Company did not complete such trials within such time period, and the MOU terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 8, 2019,
Wize Israel entered into an amendment to the LO2A License Agreement with Resdevco (the &ldquo;Resdevco Amendment&rdquo;). Pursuant
to the terms and subject to the conditions set forth in the Resdevco Amendment, the royalties payable by Wize Israel to Resdevco
shall be reduced from $475,000 per year to $150,000 per year for the years ended 2019 and 2020. Further, the Resdevco Amendment
provides that a one-time payment to Resdevco by Wize Israel in an amount of $650,000 shall be due no later than the second anniversary
of the receipt of FDA approval (the &ldquo;Deferred Amount&rdquo;); however, following the Food and Drug Administration (&ldquo;FDA&rdquo;)
approval, if annual royalties due to Resdevco by Wize Israel exceed the Minimum Royalties (as defined in the License Agreement),
an amount equal to 50% of such excess shall be added towards settlement of the Deferred Amount. As to royalty payments, the Resdevco
Amendment provides that Resdevco shall be entitled to the greater of $.60, or a percentage of revenues, not to exceed 10%, from
sales made in the United States and other countries, excluding Israel, China and Ukraine with a minimum of the Minimum Royalties.
The Resdevco Amendment further provides that Resdevco may terminate the License Agreement upon 30-days&rsquo; written notice if
certain regulatory and/or sales milestones are not met within certain specified dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 4, 2020, we,
OcuWize and Resdevco entered into a further amendment to the License Agreement, whereby the parties agreed, among other things,
that if (i) within 3 months after we receive a pre-Investigational New Drug (&ldquo;IND&rdquo;) with respect to the LO2A, or (ii)
in case of proven inability to receive such Pre-IND as a direct result of the COVID-19, in both cases not later than December 31,
2021, we provide Resdevco with a written termination notice, the License Agreement shall be terminated immediately, and to the
extent we exercise such termination right before the end of 2021, no minimum royalty fee shall be due for the year 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has determined not to pursue currently any activities
outside the USA until the Company will obtain from Resdevco satisfactory registration file including DES and at least one more
indication such as CCH or Sj&ouml;gren&rsquo;s. The Company seeks to approve a proposed regulatory strategy acceptable to the Chinese
market based on the regulatory files once provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LO2A</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LO2A is a drug developed
by Prof. Dikstein in the 1990s, initially for the treatment of DES, and later on for other ophthalmological disorders, including
CCH and Sj&ouml;gren&rsquo;s. LO2A is a sterile, preservative-free, single-dose artificial tear preparation containing 0.015% SH
as the drug substance. It has been developed as a substitute for natural tears, in order to lubricate and protect the ocular surface
tissues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SH is a salt of hyaluronic
acid (&ldquo;HA&rdquo;). HA is present in the extracellular matrix (&ldquo;ECM&rdquo;) of all tissues and is particularly abundant
in vitreous humour, skin, cartilage and the synovial fluid of joints. HA&rsquo;s long chain molecules form a filter matrix interspersed
with cellular fluids, which provide visco-elastic properties to the tissues. In the eye, endogenous HA forms a layer over the surface
of the cornea. It serves to protect the corneal cells and reduce cell damage; so it is important in maintaining cell viability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HA is an important
pericellular and cell-surface constituent and is involved in the regulation of cellular activity through its interaction with other
macromolecules. Recently, nonclinical pharmacological experiments have shown that HA promotes the viability of corneal cells and
corneal epithelial wound healing by direct interaction with cell receptors. It acts as a signaling molecule in the ECM and is a
ligand for specific receptor molecules, notably CD44, a cell surface adhesion molecule found on human corneal cells. Increased
expression of CD44 receptors has been shown to be associated with corneal re-epithelialization. Any disruption of corneal integrity,
as may occur with dry eyes, triggers the re-synthesis of HA and increases cell proliferation. These effects have been demonstrated
to be dose-dependent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LO2A eye drops incorporate
a high molecular weight SH (1.5-1.65 million Da), which enables it to be effective in solution at a low concentration. It confers
specific physical properties upon a solution. Its complex molecular structure adsorbs a relatively high volume of water, so that
the solution takes on a gelatinous form. This water is released upon an increase in pressure. The viscosity of high MW SH is affected
by shear rate; at high shear rate the macromolecules change their shape, align in the treatment of flow and its viscosity decreases.
This enables the LO2A solution to flow across the corneal surface immediately after blinking. The physiochemical property of SH
is similar to that of mucin, which constitutes the base layer of the lacrimal film and interacts strongly with the corneo-conjunctival
surface. Molecules of mucin are able to bind water molecules up to 80 times greater in weight than their own. This is due to a
large number of negatively-charged glycoside groups that are attached to the terminal section of the polypeptide skeleton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All excipients included
in LO2A eye drops comply with the relevant monographs of the European Pharmacopoeia. None of the excipients are of animal or human
origin. They are established excipients for pharmaceutical products, including those approved for ocular use. Their functions include
adjusting tonicity and increasing the viscosity of the formulation. This allows the LO2A eye drops to have a lubricating effect
that is compatible with the external ocular environment. The visco-elasticity of LO2A eye drops ensures that they are retained
on the corneal surface for a period of 4-6 hours, as demonstrated in a Phase I clinical pharmacology study conducted with LO2A
in the University Hospital of Antwerp, Belgium in 1992. In this Phase I, randomized, blinded, cross-over study, fluorescence was
used to measure pre-corneal retention time in healthy volunteers following a single instillation of LO2A and placebo (isotonic
phosphate buffered saline) both labeled with fluorescein. The study compared the elimination coefficient and area under fluorescence
decay curve for LO2A versus placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LO2A eye drops do not
contain any preservatives. This is an important feature of the formulation as preservatives have a recognized potential for irritation
and sensitization and can damage the ocular surface and the cornea. This is of particular relevance to patients with symptoms of
DES, in whom the corneal surface is already compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The adverse events
reported both from clinical trials of LO2A and from literature reports of different eye drop formulations containing SH, were minor
ocular events which are expected to occur with any ophthalmic formulation. LO2A eye drops are presented in sterile, unit-dose vials
to minimize the risk of infection and contamination.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
properties of the LO2A formulation described above make it a suitable candidate for use in a variety of dry eye indications including
those with an inflammatory component. LO2A is currently registered and marketed in Germany and Switzerland for the treatment of
DES, in Hungary for the treatment of DES, CCH and Sj&ouml;gren&rsquo;s and in the Netherlands for the treatment of DES and Sj&ouml;gren&rsquo;s.
LO2A is sold under the brand name Hylan<SUP>&reg;</SUP>&nbsp;in Germany and the Netherlands, Lacrycon<SUP>&reg;&nbsp;</SUP>in Switzerland,
and Conheal<SUP>&reg;</SUP>&nbsp;in Hungary (the &ldquo;Approved Territories&rdquo;). LO2A has been sold by Resdevco through local
distributors in these countries for a number of years. In these countries, the drug is sold in a unit dose format, and is manufactured
in Germany and France. We currently intend to market LO2A as a treatment for DES, CCH and Sj&ouml;gren&rsquo;s in the Licensed
Territories, and believe that LO2A for treatment of ophthalmic inflammatory disorders such as CCH and Sj&ouml;gren&rsquo;s presents
a significant market opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to distribute LO2A via local or multi-national
distributors, including by cooperation with a major medical company with means and experience in the end processes of approving
and marketing drugs. In order to register LO2A for the treatment of dry eye patients suffering from CCH and Sj&ouml;gren&rsquo;s,
we estimate that LO2A will be required to undergo additional clinical trials in addition to our completed Phase II and Phase IV
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan, subject to successful studies results, to engage local
or multinational distributors to handle the distribution of LO2A or engage in such other strategic transactions that may monetize
our rights in our LO2A licensed technology. In particular, we intend to (i) engage, subject to obtaining the requisite rights in
LO2A, pharmaceutical companies or distributors around the world with relevant marketing capabilities in the pharmaceutical field,
in order for such pharmaceutical companies to sell LO2A, with us prioritizing those territories where we may expedite the registration
process of LO2A based on existing knowledge and studies previously conducted on LO2A, without requiring additional studies, or
(ii) explore other strategic transactions with pharmaceutical companies or others that will monetize our rights in the LO2A licensed
technology.&nbsp;However, there is no assurance whether we will be able to consummate any such transactions and, even if we did,
what will be the timing or terms thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Clinical Trial</I></B>s</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, we
completed a multi-center trial at five different medical centers in Israel (the &ldquo;Multi-Center Trial&rdquo;). The Multi-Center
Trial was a Phase II randomized, double-blind, placebo-controlled study carried out in parallel groups that evaluated the safety
and efficacy of LO2A for patients suffering from moderate to severe CCH. The primary efficacy endpoint for this study was the change
from baseline in lissamine green conjunctival staining score at 3 months; secondary endpoints include change from baseline in lissamine
green conjunctival staining score at 1 month, change from baseline in LIPCOF score at 1 and 3 months, change from baseline in TFBUT
at 1 and 3 months and change from baseline in OSDI questionnaire score at 1 and 3 months. Safety endpoints include adverse events
recorded throughout the trial, best-corrected visual acuity, slit lamp biomicroscopy findings, undilated fundoscopy findings and
intraocular pressure measurements. We consulted with ophthalmology consultants from the United States in the preparation of the
protocol for the Multi-Center Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2018, we
received the top line results for the Multi-Center Trial which describe analysis of the primary endpoint. The originally planned
primary analysis was based upon recruitment of a sample size of 62 patients. Analysis was performed on the 49 fully evaluable patients
using a mixed model with repeated measures (MMRM) and utilized all post baseline observations, (1-month and 3-month follow-ups)
demonstrating statistical significance between the LO2A group and the placebo group (P=0.0079). The planned primary endpoint analysis
compared average reduction in LGCS score from baseline to three months. This analysis also demonstrated a strong trend towards
significance (P=0.0713) with average reduction in LGCS score between baseline and 3 months of -3.5 and -1.6 in the LO2A and placebo
groups, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2018, we commenced
our Phase IV Study, which is a randomized, double-masked, study of LO2A versus Alcon&rsquo;s Systane<SUP>&reg;</SUP>&nbsp;Ultra
UD, an over-the-counter lubricant eye drop product used to relieve dry and irritated eyes. The Phase IV Study took place in Israel
and evaluated the safety and efficacy of LO2A for symptomatic improvement of DES in 60 adult patients with Sj&ouml;gren&rsquo;s.
In January 2020, we enrolled our last patient to the study. Patients were randomized in a 1:1 ratio to one of two treatment groups,
LO2A or Systane<SUP>&reg;&nbsp;</SUP>Ultra UD. Drops are administered topically to the eye over a three month period. The primary
efficacy endpoint for this study is change from baseline in corneal and conjunctival staining score at 3 months. Secondary efficacy
endpoints include change from baseline in corneal and conjunctival staining score at 1 month, change from baseline in eye dryness
score (visual analogue scale) at 1 and 3 months and change from baseline in OSDI questionnaire score at 1 and 3 months. Safety
will be evaluated by collection of adverse event data throughout the study, best-corrected visual acuity and slit lamp biomicroscopy
findings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Phase IV Study
was designed to support our clinical approval pathway for LO2A for the treatment of DES in patients with Sj&ouml;gren&rsquo;s within
certain markets including the U.S. Data obtained from this study will be included in the clinical data package submitted during
interactions with the FDA. The study is considered necessary as the existing clinical data in this indication is considered of
insufficient quality for submission to the regulatory agencies mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 12, 2020, we announced topline results from the
Phase IV clinical trial. The randomized, double-masked comparative study evaluated LO2A versus Alcon&rsquo;s Systane&reg; Ultra
UD (&ldquo;comparator&rdquo;), an over-the-counter lubricant eye drop product used to relieve dry and irritated eyes in DES patients,
which is also used to treat dry eye in patients with Sj&ouml;gren&rsquo;s syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The study design
included 69 patients (138 eyes) with Sj&ouml;gren&rsquo;s syndrome experiencing DES that were randomized in a 1:1 ratio into two
treatment groups, LO2A or Systane&reg; Ultra UD. Drops were administered topically to the eye over a 3-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary endpoint
of the study was change in corneal staining score, using the National Eye Institute (NEI) Industry Grading System after 3 months
of study treatment. This is an objective measure used to determine the severity of the damage caused by dryness of the eye (referred
to as &ldquo;sign&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Secondary endpoints
included a conjunctival staining score after one month of treatment and changes in quality of life with subjective questionnaires,
including Ocular Surface Disease Index (OSDI) and Visual Analogue Scale (VAS) score after one and three months of treatment (referred
to as &ldquo;symptoms&rdquo;). Clinically significant results were defined as a reduction of 3 points in corneal and conjunctival
staining and an improvement of 30 points in VAS and of 10 points in OSDI measurements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The topline results
consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LOA2 met its primary endpoint of non-inferiority vs. comparator at the 3-month time point in corneal staining with a p value of 0.001.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LO2A continued, as in prior trials, to demonstrate a good safety profile with no major adverse events or side effects reported.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A numeric advantage was evident in both the signs and symptoms of DES for patients using LO2A vs. the comparator in the subgroup of patients with primary Sj&ouml;gren&rsquo;s (11 and 17 patients with primary Sj&ouml;gren&rsquo;s were in the LO2A and Control groups, respectively).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LO2A demonstrated clinically meaningful improvement in both the signs and symptoms of DES in patients suffering from Sj&ouml;gren&rsquo;s - 100% of the patients treated with LO2A showed a clinically significant improvement in at least one of the primary and secondary end point measurements included in the trial at the 3-month time point vs. 90% of patients treated with comparator. In addition, among the LO2A treatment group, 74% of patients showed a clinically significant improvement in both signs and symptoms vs. 59% in the comparator group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the subset of patients with primary Sj&ouml;gren&rsquo;s, average conjunctival staining at the 3-month time point was reduced on average by 4.1 points by LO2A, compared to an average reduction of 2.7 points by the comparator, marking about a 52% difference.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the subset of patients with primary Sj&ouml;gren&rsquo;s, there was an average reduction of 37.4 points in the eye dryness score measured by VAS in the group treated by LO2A, compared to an average reduction of 21.4 points in the comparator group at the 3-month time point, resulting in approximately a 75% difference.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December 31, 2020 were approximately $434,000 compared with approximately $492,000 for the year ended
December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The safety and efficacy
of LO2A has been shown in several clinical trials, conducted by Prof. Dikstein, the inventor of LO2A. The following paragraphs
describe the clinical and non-clinical data upon which approvals were granted in the Approved Territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A pivotal clinical
trial conducted with LO2A eye drops in six centers in France, is summarized below. There are a further seven published clinical
studies on LO2A, which are also summarized. Six of these studies documented the efficacy of LO2A eye drops by both the investigators
and the patients. Adverse events and tolerance parameters were also recorded. The remaining study specifically investigated tolerance
parameters after application of LO2A eye drops. No clinical Pharmacokinetics studies have been conducted for LO2A eye drops. The
PK profile of SH is well established. Extensive safety monitoring in both animal and human studies have shown that, after ocular
application, no clinically meaningful systemic absorption is expected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Phase I study was
performed at the University of Antwerp, Belgium in 1992 to measure the pre-corneal residence time of LO2A eye drops versus placebo
in healthy volunteers (Study EC-914-1B). This was a single blind study in which 6 healthy volunteers received a single administration
of LO2A eye drops to one eye and placebo to the other eye, both labeled with fluorescein. Variance analysis (ANOVA) for the area
under the fluorescence delay curve demonstrated that LO2A was retained on the corneal surface significantly longer than placebo
eye drops (p=0.048; significance level p=0.05). No adverse events were reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Six Phase II studies
were performed. These are described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Randomized Controlled
Trial of High Molecular Weight Hyaluronic Acid (LO2A) in DES</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was performed
in 1992 at the Hospital San Biagio, Domodossola, Italy. The objectives of the study were to evaluate the efficacy of 30-day treatment
with LO2A in reducing the severity of DES, to confirm an optimum dosing schedule for LO2A (3, 4, 6 or 8 drops/day) and to assess
the interference of LO2A with other ocular therapies. One hundred patients with moderate-to-severe DES were randomized 1:1 to treatment
(LO2A) or comparator (Hyalistil containing 0.2% SH and the preservative thimerosal at 0.005%). Statistical analyses were performed
using Wilcoxon, Mann-Whitney U test and Chi square test. The significance level was p=0.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The study demonstrated
significant improvement in composite score from objective parameters including Schirmer test, fluorescein staining, TFBUT and Rose
Bengal staining (p&lt;0.001 for both treatments using Wilcoxon test), but no significant difference between treatment groups in
the reduction in total scores at Day 30 (p=0.998 using Mann-Whitney U test). For LO2A, a dosing schedule of four applications/day
reduced scores at Day 30 significantly more than lower dosing schedules (p=0.02 using Mann-Whitney U test). There was no significant
difference between 4 applications/day and higher dosing schedules. The number of patients rating tolerance as &lsquo;good&rsquo;
or above was significantly higher for LO2A (96%) than the comparator (78%)(p = 0.029 using Chi square test). Adverse events were
experienced by two patients in the LO2A group (both &ldquo;sticky eye&rdquo;) and 11 patients in the comparator group. There were
no serious adverse events (&ldquo;SAEs&rdquo;) or apparent interactions between LO2A and concomitant eye treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Double-Masked, Crossover
Comparison of a New Artificial Tear Preparation containing Hyaluronic Acid (LO2A) and Lacrisol&reg; in DES Treatment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was performed
in 1992 at the University of Florence, Italy. The objectives of the study were to compare the efficacy of LO2A with Lacrisol<SUP>&reg;</SUP>&nbsp;at
reducing the severity of DES and reducing ocular signs and symptoms. Thirty-five patients with moderate-to-severe DES were treated
alternately with LO2A for a 30-day treatment period and then Lacrisol<SUP>&reg;</SUP>&nbsp;for a further 30-day treatment period.
The trial was double-blind and allocation of treatments at Day 0 was randomized. Lacrisol<SUP>&reg;&nbsp;</SUP>is an eye drop product
containing 0.5% Hydroxypropyl Methylcellulose (&ldquo;HPMC&rdquo;). Statistical analyses were performed using Wilcoxon tests. All
analyses were performed using two-sided tests and results were considered to be statistically significant if the p value was less
than or equal to 0.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study demonstrated
a statistically significant improvement in mean, objective dry eye score (based on Schirmer test, fluorescein staining, TFBUT and
Rose Bengal staining) following LO2A treatment compared to the Lacrisol<SUP>&reg;</SUP>&nbsp;group (p&lt;0.001). The severity of
ocular signs and symptoms including redness, burning, foreign body sensation and photophobia was significantly less following LO2A
treatment (p&lt;0.02 for photophobia and p&lt;0.01 for other symptoms). Adverse events were experienced by 4 patients treated with
LO2A (two patients with mild burning, one patient with blurred vision and one patient with &ldquo;thread sensation&rdquo;) and
10 patients treated with Lacrisol<SUP>&reg;</SUP>. There were no SAEs reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Double-Masked Clinical
Trial of an Unpreserved Hyaluronic Acid Based Eye Drops (LO2A) in DES</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was performed
in 1992 at the University of Genoa, Italy. The objective of the study was to compare the efficacy of LO2A with Lacrisol<SUP>&reg;</SUP>&nbsp;in
reducing the severity of DES and ocular symptoms. Twenty-three patients with moderate to severe DES applied LO2A to the first eye
and Lacrisol<SUP>&reg;</SUP>&nbsp;(0.5% HPMC) to the second eye. The trial was double-blind and the treatment regime was five applications/day
for 30 days. The recorded data were statistically analyzed by using the Student&rsquo;s t test and Mann-Whitney U test. The threshold
for clinical significance was p=0.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study demonstrated
that after 30 days of treatment the mean, objective dry eye scores (based on measurement of meniscal thickness, fluorescein staining,
TFBUT and Rose Bengal staining) for LO2A treatment were significantly lower than for Lacrisol<SUP>&reg;&nbsp;</SUP>treatment for
three out of the four tests (p=0.011 for TFBUT [Student t test], p=0.046 for fluorescein staining [Mann-Whitney U test] and p=0.032
for Rose Bengal staining [Mann-Whitney U test]). The thickness of the lacrimal meniscus did not change significantly in any patient;
however, the range of values recorded at Day 0 (0.1-0.2 mm) was not indicative of pathological changes. The severity of the ocular
symptoms (burning, foreign body sensation and photophobia) was also significantly reduced for LO2A treatment compared to Lacrisol<SUP>&reg;</SUP>&nbsp;at
Day 30 (p=0.009 for burning, p=0.006 for foreign body sensation and p=0.025 for photophobia using Mann-Whitney U test). There were
no adverse events associated with LO2A treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Clinical Evaluation
of LO2A Eye Drops versus Reference in Patients suffering from DES</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was performed
in 1992 at the University of Rome &ldquo;Tor Vergata&rdquo;, Italy. The objective of the study was to compare the efficacy of LO2A
with eye drops containing 0.5% HPMC in reducing the severity of DES. Sixteen patients were treated with LO2A or HPMC eye drops.
The study was double blind and assessed the treatment of 5 drops/day for 3-4 weeks. The data were statistically analyzed by comparing
the scores obtained by the Wilcoxon test and adopting a significance threshold of p = 0.05. This study demonstrated that LO2A eye
drops had significantly lower scores than HPMC in the fluorescein (p=0.001), TFBUT (p=0.015) and Rose Bengal test (p=0.007). There
was no difference between treatments in meniscal thickness measurements and Schirmer tests. Adverse events were reported by one
patient treated with LO2A (blurred vision). There were no SAEs reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Assessment of Tolerance
to LO2A Eye Drops</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was performed
at the University of Catania, Italy in 1992. The objective of the study was to assess the ocular tolerance of patients with moderate
to severe DES to the application of LO2A drops compared with eye drops containing 0.5% HPMC. Eighteen patients applied LO2A drops
to the first eye and HPMC in the second eye. The study was double-blind and assessed treatment of 4 drops/day for 20 days. This
study demonstrated that 11 out of 18 patients (61.1%) experienced no discomfort upon application of LO2A compared to 1 out of 18
patients (5.6%)) with HPMC eye drops. This difference was found to be highly significant (p=0.0004) according to chi-squared test
(significance level was p=0.05). The subjective symptoms reported at the time of HPMC instillation included blurred vision (16/18;
89%), foreign body sensation (11/18; 61%), stinging (7/18; 39%), photophobia (2/18; 11%) itching (1/18; 6%) and pain (1/18; 6%).
The subjective symptoms reported at the time of LO2A instillation included foreign body sensation (5/18; 28%), stinging (4/18;
22%), blurred vision (3/18; 17%) and photophobia (2/18; 11%). No SAEs were reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The Effect of a
New Tear Substitute Containing Glycerol and Hyaluronate on Keratoconjunctivitis Sicca</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was performed
in 1998 at Hadassah University Hospital, Jerusalem, Israel. The objective of the study was to evaluate the efficacy of LO2A in
patients suffering from keratoconjunctivitis sicca compared to their current tear substitute. Twenty-five patients with a history
of dry eye symptoms for at least one year who were using a known tear substitute preparation (containing either cellulose derivatives
or polyvinylpyrolidone plus hydroxyethylcellulose) and had positive Rose Bengal staining were included. One eye was randomized
to topical treatment with LO2A and the other &ldquo;control&rdquo; eye to continued treatment with the pre-existing tear substitute
preparation. In the first stage of the study, 15 patients received treatment for one week and in the second stage, 10 patients
received treatment for two weeks. Statistical analysis of the results included the Wilcoxon signed rank test for comparison between
scores for the same eye at different times, and Mann-Whitney test for comparison between scores of study versus control eyes adopting
a significance threshold of p = 0.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The average patient
satisfaction score for LO2A was significantly higher compared to the control preparation at 1 week (p=0.0003) and at 2 weeks (p=0.0232).
A highly significant reduction in Rose Bengal staining was demonstrated following one week of treatment with LO2A (p&lt;0.0001)
and the LO2A-treated eyes had significantly less staining compared to control eyes at both one (p=0.021) and two weeks (p=0.023).
The paper did not report any adverse events associated with LO2A treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pivotal, Phase
III study is described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Acceptability and Efficacy
of LO2A Eye Drops vs Gel-Larmes&reg; in Moderate to Severe DES - Clinical Trial Protocol No. EC-921-3</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was performed
in 1993 at the Hospital H&ocirc;tel-Dieu, Paris, France with additional sites in Brest, Montpellier, Limoges, Lyon and Nice. The
objective of this study was to demonstrate the superiority of LO2A to Gel-Larmes<SUP>&reg;</SUP>&nbsp;(0.3% Carbomer containing
the preservative thimerosal at 0.005%) in improving patient symptoms and to demonstrate equivalence of the study treatments in
reducing the severity of DES. One hundred patients with moderate to severe DES were randomized 1:1 to treatment (LO2A) or Gel-Larmes<SUP>&reg;</SUP>.
The study assessed treatment of four applications/day for 12 weeks. Differences between the study treatment groups were analyzed
statistically using either the Student&rsquo;s t test (means) or Chi squared test (percentages). Equivalence between the treatment
groups was tested by comparison of distributions using the Dunett and Gent&rsquo;s Chi squared test. Probability level was 0.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study demonstrated
that LO2A was significantly superior to Gel-Larmes<SUP>&reg;</SUP>&nbsp;in improving patient symptoms (p=0.024). The severity of
DES was measured using Schirmer test, fluorescein staining, TFBUT and Rose Bengal staining. A reduction in total score of &ge;4,
obtained from these four objective tests, was achieved by 17 patients (left eye) and 23 patients (right eye) in the LO2A group
and by 20 patients (left eye) and 16 patients (right eye) in the Gel-Larmes<SUP>&reg;</SUP>&nbsp;group, demonstrating that LO2A
and Gel-Larmes<SUP>&reg;</SUP>&nbsp;were equivalent in improving signs of DES (probability of equivalence: p=0.039 right eye and
p=0.00002 left eye). The number of patients rating tolerance as &lsquo;good&rsquo; or above was significantly higher in the LO2A
group compared to Gel-Larmes<SUP>&reg;</SUP>&nbsp;at all time points (Days 15 - p=0.031; Day 45 -p=0.00006; Day 90 - p=0.0004).
Adverse events were experienced by 10 patients (21.7%) in the LO2A group and 17 patients (36.2%) in the Gel-Larmes<SUP>&reg;</SUP>&nbsp;group.
The adverse events experienced by patients in the LO2A group included inflammatory reaction (2 patients), burning/itching/stinging
sensation (7 patients) and secretions (1 patient). One unrelated SAE was reported in this study (chest pain) in a patient randomized
to the Gel-Larmes<SUP>&reg;</SUP>&nbsp;group. In conclusion, this study demonstrated that LO2A was significantly better than Gel-Larmes<SUP>&reg;&nbsp;</SUP>in
terms of subjective symptoms and tolerability in treating DES with a treatment regimen of four drops/day for 12 weeks and equivalent
in improving signs of DES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Phase II study was
performed at Semmelweis University, Budapest, Hungary between 2012-2013 to assess the efficacy of LO2A eye drops in patients with
severe CCH. Twenty patients with Grade 2 or 3 CCH (according to LIPCOF score), who had previously failed treatment on a variety
of artificial tear preparations, applied LO2A eye drops to both eyes in a single arm, open label study. Patients applied 4 drops/day
for each eye for 3 months. A mean decrease from baseline of one LIPCOF degree was assumed to be clinically relevant. Statistical
comparisons were performed using a paired t-test (TFBUT) or Wilcoxon Signed Rank Test (LIPCOF degree, Oxford grade and OSDI score)
at a two-sided significance level of 5% (p=0.05).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study demonstrated
that after 3 months, CCH decreased from a mean LIPCOF degree of 2.9&plusmn;0.4 in both eyes to 1.4&plusmn;0.6 on the right (median
decrease of -2 points, 95% confidence interval (&ldquo;<B>CI</B>&rdquo;) from -2.0 to -1.0), and to 1.4&plusmn;0.7 on the left
eye (median decrease of -1 points, 95% CI from -2.0 to -1.0) (p&lt; 0.001 for both sides). The TFBUT increased significantly after
one-month treatment (right eye median increase of 1.1 sec, 95% CI from 0.2 to 1.0 sec; left eye median increase of 0.9 sec, 95%
CI from 0.3 to 1.5 sec)(p=0.02 right eye; p=0.004 left eye). The mean Oxford Scheme grade staining decreased significantly during
the entire period of the examination (right eye median decrease of -1.0 grade, 95% CI from -1.0 to -1.0 grade; left eye median
decrease of -1.0 grade, 95% CI from -1.0 to -1.0 grade after three months)(p&lt;0.001 both sides). The subjective complaints of
the patients measured with the OSDI questionnaire showed a significant improvement after 3 months&rsquo; treatment (median decrease
of -13.1 scores, 95% CI from -25.0 to -8.3 scores)(p&lt;0.001). During the study period, two patients complained of a greasy sensation
on their eyelids, but they did not stop the treatment. No other adverse reactions were reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the results
of this trial, the Hungarian health authorities approved the amendment of the LO2A labeling to include the treatment of DES patients
suffering from CCH, and patents were filed in the United States, Israel and Japan for the use of the active component of the drug
for treating CCH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A further Phase II
study was performed at Semmelweis University, Budapest, Hungary in 2016. This study explored the safety and efficacy of LO2A in
patients with moderate severity dry eye associated with Sj&ouml;gren&rsquo;s where the ocular surface showed Lissamine Green staining
causing marked subjective symptoms using the OSDI questionnaire. Twenty-one patients applied LO2A eye drops to both eyes in a single
arm, open label study. Patients applied 4 drops a day to each eye for 3 months. LIPCOF score, Lissamine Green staining, tear production
and OSDI questionnaire were measured. The study demonstrated a reduction in the LIPCOF score, a decrease in Lissamine Green staining
according to the Oxford scale and mitigation of subjective symptoms of dry eye according to the OSDI questionnaire. However, there
was no change in tear production during the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are evaluating such information and are considering the potential
consequences on our business. In addition, we consider our ability to use the clinical results and approval received in the Netherlands
the treatment of Sj&ouml;gren&rsquo;s to assist our Company in the registration of LO2A as a treatment for Sj&ouml;gren&rsquo;s
in the Licensed Territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Raw Materials and Suppliers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
raw materials that would be required to manufacture LO2A are widely available from numerous suppliers and are generally considered
to be generic industrial chemical supplies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Manufacturing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that LO2A can be manufactured in sufficient commercial quantities, in compliance with regulatory requirements and at an acceptable
cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection with LO2A.
We and our manufacturer must ensure that all of the processes, methods and equipment are compliant with both current Good Manufacturing
Practices (&ldquo;cGMP&rdquo;), as required by the FDA, and current Good Laboratory Practices for drugs on an ongoing basis, as
mandated by the applicable regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers.
We have entered into agreements with a manufacturer in Germany relating to the manufacturing of LO2A. We have completed the production
of LO2A for purposes of our ongoing Phase II clinical trial and expect to begin production for commercial use only after obtaining
the requisite regulatory approvals in Israel to market LO2A and receive orders from the distributors (for more information, see
&ldquo;Item 1. BUISNESS &mdash; Marketing, Sales and Distribution&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Marketing, Sales and Distribution</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to engage local
or multinational distributors to handle the distribution of LO2A. In particular, we intend to enter into agreements with pharmaceutical
companies with relevant marketing capabilities in the field of pharmaceuticals in order to have them distribute and sell LO2A in
the Licensed Territories. The registration process in certain countries, including the United States, requires us to undertake
additional clinical trials, in addition to the completed Phase II and Phase IV clinical trials that we completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to engage
pharmaceutical companies or distributors around the world with relevant marketing capabilities in the pharmaceutical field, in
order for such pharmaceutical companies to sell LO2A, with us prioritizing those countries where we may expedite the registration
process of LO2A based on existing knowledge and studies previously conducted on LO2A, without requiring additional studies. In
this respect, we have been studying the possibility of marketing LO2A for DES treatment only in the United States, but have not
made any determinations regarding the best route that can be used to obtain FDA approval to market LO2A. Currently, we intend to
approach the FDA as part of our preliminary request procedure (Pre-IND) and discuss possible alternatives for approving LO2A for
treating DES in the United States. However, as this FDA process is both time consuming and costly, we do not intend to approach
the FDA on a Pre-IND basis until we are able to secure additional funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical
industry is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research and
development process. Adequate protection of intellectual property, successful product development, adequate funding and retention
of skilled, experienced and professional personnel are among the many factors critical to success in the pharmaceutical industry.
We operate in markets featuring competition between competing manufacturers in the field of DES treatment, while, to our knowledge,
no therapy is currently approved specifically for Sj&ouml;gren&rsquo;s or CCH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global DES market
features three particularly dominant companies, which are responsible for an estimated 82% of all revenues: Novartis/Alcon (through
its Celluvisc&reg;, Hyalein&reg;, Vismed&reg; and Systane&reg; drugs); Allergan (Restasis&reg;, Refresh&reg;) and Santen. In July
2016, the FDA approved an additional medicine, Xiidra&reg;, produced by Shire Plc, for the treatment of DES, and sales began in
August 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, no therapeutic
agent has received approval specifically for Sj&ouml;gren&rsquo;s. Drugs that are used for the symptomatic relief of ocular signs
and symptoms associated with Sj&ouml;gren&rsquo;s include cholinergic agonists e.g. Salagen (pilocarpine) and Evoxac (cevilemine)
and the immunomodulatory agent Restasis (cyclosporine). Systemic Immunomodulary treatments, usually for extra-glandular disease,
which may be used include hydroxychloroquine (mild inflammatory symptoms of joints, muscles and skin), corticosteroids (rare but
serious symptoms: vasculitic rash, interstitial lung disease, interstitial nephritis, glomerulonephritis), immunosuppressive agents
e.g. methotrexate, azathioprine, cyclophosphamide (used to treat serious internal organ manifestations) and biologic agents e.g.
rituximab. Corticosteroids and immunosuppressants lead to broad, non-selective immunosuppression often associated with significant
adverse events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the best of our
knowledge, the pipeline of drugs in development for the indication of Sj&ouml;gren&rsquo;s is relatively small with only one product
in Phase III, Orencia, being developed by Bristol-Myers Squibb. There are a number of drugs in Phase I or II stages of development
including AMG/MEDI5872 developed by Amgen, BIIB063 developed by Biogen, CFZ533 and VAY736 developed by Novartis, GSK618960 developed
by GSK, LY3090106 developed by Eli Lilly, MEDI4920 developed by MedImmune, RG7625 developed by Roche, RSLV developed by Resolve
Therapeutics and Actemra developed by the University Hospital of Strasbourg. In addition, there is an ongoing Phase II combination
study combining Benlysta and Rituxan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that LO2A
has a number of advantages over competing products in the DES and Sj&ouml;gren&rsquo;s markets, including LO2A lacking preservatives,
its ability to be used with any contact lenses, its anti-irritant properties and its non-Newtonian viscosity profile. On the other
hand, other drugs on the market, including new drugs under development, may all be competitive to LO2A. In fact, some of these
drugs are well established and accepted among patients and physicians in their respective markets, can be efficiently produced
and marketed, and are relatively safe. Moreover, other companies of various sizes engage in activities similar to ours. Most, if
not all, of our competitors have substantially greater financial and other resources available to them. Competitors include companies
with marketed products and/or an advanced research and development pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
in part on our ability (directly or through Resdevco) to obtain and maintain proprietary protection for LO2A and its underlying
technology and know-how, and to operate without infringing the proprietary rights of others and to prevent others from infringing
such proprietary rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LO2A composition
and use thereof for treating or alleviating DES was covered by U.S. Patent No. 5,106,615, which has expired. Accordingly, we are
currently focusing our marketing and commercial efforts with respect to CCH and Sj&ouml;gren&rsquo;s rather than DES, as more fully
described elsewhere in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The use of LO2A for
treating or alleviating CCH is protected by the patent family of International Patent Application WO2012150583, filed on April
5, 2012, assigned to Resdevco, entitled EYE DROPS FOR TREATMENT OF CONJUNCTIVOCHALASIS. Corresponding members include U.S. Patent
No. 8,912,166, Israeli Patent No. 212725, Japanese Patent No. 5957517 and European Patent No. 2704747. Patents will expire, without
extension, in 2032.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The use of LO2A for
treating or alleviating irritation of the eye caused non-infectious diseases, such as Sj&ouml;gren&rsquo;s, is covered by the
patent family of International Patent Application WO2018163151, filed on February 19, 2018, assigned to Resdevco, entitled EYE
DROPS FOR TREATMENT OF IRRITATION NOT DUE TO INFECTION. Corresponding patent applications are pending in the USA, Europe, China
and other countries. Patents to issue will expire, without extension, in 2038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the LO2A
License Agreement, Resdevco has contractually agreed to be responsible for the payment of all relevant fees associated with the
maintenance of its intellectual property rights. The patent positions of biopharmaceutical companies, such as Resdevco and us,
are generally uncertain and involve complex legal and factual questions. Resdevco&rsquo;s ability to maintain and solidify its
proprietary position for LO2A will depend on its success in obtaining effective claims and enforcing those claims once granted.
There is no certainty that any of Resdevco&rsquo;s pending patent applications or those pending patent applications that it licenses
will result in the issuance of any patents or that we will obtain rights to any further patents or patent applications. Any issued
patents and those that may issue in the future may be challenged, narrowed, circumvented or found to be invalid or unenforceable,
which could limit our ability to stop competitors from marketing related products or the length of term of patent protection that
we may have for LO2A under the LO2A License Agreement. We cannot be certain that Resdevco was the first to invent the inventions
claimed in its owned or licensed patents or pending patent applications. In addition, our competitors may independently develop
similar technologies or duplicate any technology developed by Resdevco, and the rights granted under any issued patents may not
provide Resdevco or us with any meaningful competitive advantages against these competitors. Please see under &ldquo;RISK FACTORS
&ndash; Risks Related to our Intellectual Property&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Environmental Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our manufacturers,
distributors and other service providers are subject to various environmental, health and safety laws and regulations, including
those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal of hazardous,
radioactive and biological materials and wastes and the cleanup of contaminated sites. We believe that our business, including
those of our service providers, are being operated in compliance in all material respects with applicable environmental and health
and safety laws and regulations. Based on information currently available to us, we do not expect environmental costs and contingencies
to have a material adverse effect on our business. However, significant expenditures may be imposed on those third party service
providers should they be required to comply with new or more stringent environmental or health and safety laws, regulations or
requirements, which may in turn adversely affect us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Government Regulations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in a highly
controlled regulatory environment. Stringent regulations establish requirements relating to analytical, toxicological and clinical
standards and protocols in respect of the testing of pharmaceuticals. Regulations also cover research, development, manufacturing
and reporting procedures, both pre- and post-approval. In many markets, especially in Europe, marketing and pricing strategies
are subject to national legislation or administrative practices that include requirements to demonstrate not only the quality,
safety and efficacy of a new product, but also its cost-effectiveness relating to other treatment options. Failure to comply with
regulations can result in stringent sanctions, including product recalls, withdrawal of approvals, seizure of products and criminal
prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining regulatory
approvals for the commercial sale of LO2A or any of our future product candidates, we must demonstrate through clinical trials
that any of our product candidates are safe and effective. Historically, the results from preclinical studies and early clinical
trials often have not accurately predicted results of later clinical trials. In addition, a number of pharmaceutical products have
shown promising results in clinical trials but subsequently failed to establish sufficient safety and efficacy results to obtain
necessary regulatory approvals. We have incurred and will continue to incur substantial expense for, and devote a significant amount
of time to, clinical trials. Many factors can delay the commencement and rate of completion of clinical trials, including the inability
to recruit patients at the expected rate, the inability to follow patients adequately after treatment, the failure to manufacture
sufficient quantities of materials used for clinical trials, and the emergence of unforeseen safety issues and governmental and
regulatory delays. If a product candidate fails to demonstrate safety and efficacy in clinical trials, this failure may delay development
of other product candidates and hinder our ability to conduct related clinical trials. Additionally, as a result of these failures,
we may also be unable to obtain additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Governmental authorities
in all major markets require that a new pharmaceutical product be approved before it is marketed, and have established high standards
for technical appraisal, which can result in an expensive and lengthy approval process. The time to obtain approval varies by country
and some products are never approved. The lengthy process of conducting clinical trials, seeking approval and the subsequent compliance
with applicable statutes and regulations, if approval is obtained, are very costly and require the expenditure of substantial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the regulatory
processes in countries where we are seeking or will seek regulatory approval follow below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>United States</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the Public Health Services Act and the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated thereunder,
and other federal and state statutes and regulations govern, among other things, the quality, safety and effectiveness standards
for any of our product candidates and the raw materials and components used in the production of, testing, manufacture, labeling,
storage, record keeping, approval, advertising and promotion of our products on a product-by-product basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before the clinical
studies, the FDA requires from the applicants to complete extensive preclinical laboratory tests, drug chemistry, animal (in vivo),
formulation, stability and other studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain preclinical
tests must be conducted in compliance with good laboratory practice (GLP) regulations. Non-compliance with GLP standard can, in
some cases, lead to invalidation of the studies, requiring them to be replicated. After laboratory analysis and preclinical testing,
a sponsor files an IND application, with the FDA to begin human testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of the
preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.
The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises
concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed
to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical
trial can begin. Submission of an IND may result in the FDA not allowing the clinical trials to commence or not allowing the clinical
trials to commence on the terms originally specified in the IND. A separate submission to an existing IND must also be made for
each successive clinical trial conducted during drug development, and the FDA must grant permission, either explicitly or implicitly
by not objecting, before each clinical trial can begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Typically, a manufacturer
conducts a three-phase human clinical testing program which itself is subject to numerous laws and regulatory requirements, including
adequate monitoring, reporting, record keeping and informed consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve
the administration of the investigational drug to human subjects under the supervision of qualified investigators. Clinical trials
are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in
monitoring safety and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as part of the IND. An
independent institutional review board (&ldquo;IRB&rdquo;), for each medical center proposing to conduct a clinical trial must
also review and approve a plan for any clinical trial before it can begin at that center and the IRB must monitor the clinical
trial until it is completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various
grounds. Clinical testing also must satisfy extensive Good Clinical Practice (&ldquo;GCP&rdquo;), requirements, including the requirements
for informed consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All clinical research
performed in the United States in support of a new drug application (&ldquo;NDA&rdquo;) must be authorized in advance by the FDA
under the IND regulations and procedures described above. However, a sponsor who wishes to conduct a clinical trial outside the
United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial
is not conducted under an IND, the sponsor may submit data from the clinical trial to FDA in support of an NDA so long as the clinical
trial is conducted in compliance with an international guideline for the ethical conduct of clinical research known as the Declaration
of Helsinki and/or the laws and regulations of the country or countries in which the clinical trial is performed, whichever provides
the greater protection to the participants in the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Phase I, small
clinical trials are conducted to determine the safety and proper dose ranges of any of our product candidates. In Phase II, clinical
trials are conducted to assess safety and gain preliminary evidence of the efficacy of any of our product candidates. In Phase
III, clinical trials are conducted to provide sufficient data for the statistically valid evidence of safety and efficacy and
these studies include a large number of participants. The time and expense required for us to perform this clinical testing can
vary and is substantial. We cannot be certain that we will successfully complete Phase I, Phase II or Phase III testing of any
of our product candidates within any specific time period, if at all. Furthermore, the FDA, the IRB responsible for approving
and monitoring the clinical trials at a given site, the Data Safety Monitoring Board, where one is used, or we may suspend the
clinical trials at any time on various grounds, including a finding that subjects or patients are exposed to unacceptable health
risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the clinical data
from these clinical trials (Phases I, II and III) is deemed to support the safety and effectiveness of the candidate product for
its intended use, then we may proceed to seek to file with the FDA an NDA seeking approval to market a new drug for one or more
specified intended uses. We cannot ascertain whether the clinical data will support and justify filing an NDA. Nevertheless, if
and when we are able to ascertain that the clinical data supports and justifies filing an NDA, we intend to make such appropriate
filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of an NDA
is to provide the FDA with sufficient information so that it can assess whether it ought to approve the candidate product for marketing
for specific intended uses. The NDA normally contains, among other things, sections describing the chemistry, manufacturing, and
controls, non-clinical pharmacology and toxicology, human pharmacokinetics and bioavailability, microbiology, the results of the
clinical trials, and the proposed labeling which contains, among other things, the intended uses of the candidate product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot take any
action to market any new drug or biologic product in the United States until our appropriate marketing application has been approved
by the FDA. The FDA has substantial discretion over the approval process and may disagree with our interpretation of the data submitted.
The process may be significantly extended by requests for additional information or clarification regarding information already
provided. As part of this review, the FDA may refer the application to an appropriate advisory committee, typically a panel of
clinicians. Satisfaction of these and other regulatory requirements typically takes several years, and the actual time required
may vary substantially based upon the type, complexity and novelty of the product. Government regulation may delay or prevent marketing
of potential products for a considerable period of time and impose costly procedures on our activities. We cannot be certain that
the FDA or other regulatory agencies will approve any of our products on a timely basis, if at all. Success in early stage clinical
trials does not assure success in later-stage clinical trials. Even if a product receives regulatory approval, the approval may
be significantly limited to specific indications or uses and these limitations may adversely affect the commercial viability of
the product. Delays in obtaining, or failures to obtain regulatory approvals, would have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also seek approval
under programs designed to accelerate the FDA&rsquo;s review and approval of NDAs. For instance, a sponsor may seek FDA designation
of a drug candidate as a &ldquo;fast track product.&rdquo; Fast track products are those products intended for the treatment of
a serious or life-threatening disease or condition and which demonstrate the potential to address unmet medical needs for such
disease or condition. If fast track designation is obtained, the FDA may initiate review of sections of an NDA before the application
is complete. This &ldquo;rolling review&rdquo; is available if the applicant provides and the FDA approves a schedule for submission
to the FDA of the remaining information. In some cases, a fast track product may be approved on the basis of either a surrogate
endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical
benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.
Approvals of this kind, referred to as accelerated approvals, typically include requirements for appropriate post-approval Phase
IV clinical trials to validate the surrogate endpoint or otherwise confirm the effect of the clinical endpoint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Food
and Drug Administration Safety and Innovation Act, which was enacted and signed into law in 2012, established a new category of
drugs referred to as &ldquo;breakthrough therapies&rdquo; that may be subject to accelerated approval. A sponsor may seek FDA designation
of a drug candidate as a &ldquo;breakthrough therapy&rdquo; if the drug is intended, alone or in combination with one or more other
drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. Drug candidates may also be eligible for &ldquo;priority review&rdquo;
or review within a six-month timeframe from the date a complete NDA is accepted for filing, if a sponsor shows that its drug candidate
provides a significant improvement compared to marketed drugs. Fast track designation, accelerated approval, breakthrough therapy
designation and priority review do not change the standards for approval, but may expedite the development or approval process.
When appropriate, we intend to seek fast track designation, accelerated approval, breakthrough therapy designation and priority
review, as applicable for our drug candidates. We cannot predict whether any of our drug candidates will obtain such designations
or approvals, or the ultimate impact, if any, of such designations or approvals on the timing or likelihood of FDA approval of
any of its proposed drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even after we obtain
FDA approval, we may be required to conduct further clinical trials and provide additional data on safety and effectiveness. We
are also required to gain separate approval for the use of an approved product as a treatment for indications other than those
initially approved. Before approving an application, the FDA will inspect the facility or the facilities at which the finished
drug product, and sometimes the active drug ingredient, is manufactured, and will not approve the drug unless cGMP compliance is
satisfactory. The FDA may also inspect the sites at which the clinical trials were conducted to assess their compliance, and will
not approve the drug unless compliance with GCP requirements is satisfactory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, as a result of
these inspections, the FDA determines that our facilities do not comply with applicable FDA regulations and conditions of product
approval, the FDA may seek civil, criminal or administrative sanctions and/or remedies against us including the suspension of our
manufacturing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugs may be marketed
only for the FDA approved indications and in accordance with the provisions of the approved labeling. Further, if there are any
modifications to the drug, including changes in indications, labeling, or manufacturing processes or facilities, the applicant
may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require us to develop additional data
or conduct additional preclinical studies and clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have currently received
no approvals to market our products from the FDA or other foreign regulators, besides Israel and the countries where LO2A is already
marketed by Resdevco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Post-Marketing Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following approval
of a new product, a pharmaceutical company generally must engage in numerous specific monitoring and recordkeeping activities and
continue to submit periodic and other reports to the applicable regulatory agencies, including any cases of adverse events and
appropriate quality control records. Modifications or enhancements to the products or labeling or changes of site of manufacture
are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy
review process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prescription drug advertising
is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion, including
direct-to-consumer advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their
first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the U.S. Prescription Drug
Marketing Act, a part of the U.S. Federal Food, Drug, and Cosmetic Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations
require that products be manufactured in specific approved facilities and in accordance with cGMPs, and NDA holders must list their
products and register their manufacturing establishments with the FDA. These regulations also impose certain organizational, procedural
and documentation requirements with respect to manufacturing and quality assurance activities. NDA holders using contract manufacturers,
laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified
suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time,
and the discovery of violative conditions, including failure to conform to cGMPs, could result in enforcement actions that interrupt
the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Healthcare Laws
and Regulations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject
to various federal, state and international laws pertaining to health care &ldquo;fraud and abuse&rdquo; including anti-kickback
laws and false claims laws. The federal Anti-kickback law, which governs federal healthcare programs (e.g., Medicare, Medicaid),
makes it illegal to solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business, including
the purchase or prescription of a particular drug. Many states have similar laws that are not restricted to federal healthcare
programs. Federal and state false claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented
for payment to third party payors (including Medicare and Medicaid), claims for reimbursement, including claims for the sale of
drugs or services, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically
unnecessary items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the government or
other relevant party were to allege that we violated these laws there could be a material adverse effect on our stock price. Even
an unsuccessful challenge could cause adverse publicity and be costly to respond to, which could have a materially adverse effect
on our business, results of operations and financial condition. A finding of liability under these laws can have significant adverse
financial implications for us and can result in payment of large penalties and possible exclusion from federal healthcare programs.
We will consult counsel concerning the potential application of these and other laws to our business and our sales, marketing and
other activities and will make good faith efforts to comply with them. However, given their broad reach and the increasing attention
given by law enforcement authorities, we cannot assure you that some of our activities will not be challenged or deemed to violate
some of these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>European Economic Area</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
have license or right to distribute in countries in the European Union (&ldquo;<B>EU</B>&rdquo;). Although we are not currently
seeking regulatory approval in the EU, we may do so in the future. As such, a summary of the EU regulatory processes follows below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A medicinal product
may only be placed on the market in the European Economic Area (the &ldquo;<B>EEA</B>&rdquo;), composed of the 28 EU member states,
plus Norway, Iceland and Lichtenstein, when a marketing authorization has been issued by the competent authority of a member state
pursuant to Directive 2001/83/EC (as recently amended by Directive 2004/27/EC), or an authorization has been granted under the
centralized procedure in accordance with Regulation (EC) No. 726/2004 or its predecessor, Regulation 2309/93. There are essentially
three community procedures created under prevailing European pharmaceutical legislation that, if successfully completed, allow
an applicant to place a medicinal product on the market in the EEA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Centralized Procedure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulation 726/2004/EC
now governs the centralized procedure when a marketing authorization is granted by the European Commission, acting in its capacity
as the European Licensing Authority on the advice of the EMA. That authorization is valid throughout the entire community and directly
or (as to Norway, Iceland and Liechtenstein) indirectly allows the applicant to place the product on the market in all member states
of the EEA. The EMA is the administrative body responsible for coordinating the existing scientific resources available in the
member states for evaluation, supervision and pharmacovigilance of medicinal products. Certain medicinal products, as described
in the Annex to Regulation 726/2004, must be authorized centrally. These are products that are developed by means of a biotechnological
process in accordance with Paragraph 1 to the Annex to the Regulation. Medicinal products for human use containing a new active
substance for which the therapeutic indication is the treatment of acquired immune deficiency syndrome (&ldquo;<B>AIDS</B>&rdquo;),
cancer, neurodegenerative disorder or diabetes must also be authorized centrally. Starting on May 20, 2008, the mandatory centralized
procedure was extended to autoimmune diseases and other immune dysfunctions and viral diseases. Finally, all medicinal products
that are designated as orphan medicinal products pursuant to Regulation 141/2000 must be authorized under the centralized procedure.
An applicant may also opt for assessment through the centralized procedure if it can show that the medicinal product constitutes
a significant therapeutic, scientific or technical innovation or that the granting of authorization centrally is in the interests
of patients at the community level. For each application submitted to the EMA for scientific assessment, the EMA is required to
ensure that the opinion of the Committee for Medicinal Products for Human Use (&ldquo;<B>CHMP</B>&rdquo;), is given within 210
days after receipt of a valid application. This 210 days period does not include the time that the applicant to answer any questions
raised during the application procedure, the so-called &lsquo;clock stop&rsquo; period. If the opinion is positive, the EMA is
required to send the opinion to the European Commission, which is responsible for preparing the draft decision granting a marketing
authorization. This draft decision may differ from the CHMP opinion, stating reasons for diverging for the CHMP opinion. The draft
decision is sent to the applicant and the member states, after which the European Commission takes a final decision. If the initial
opinion of the CHMP is negative, the applicant is afforded an opportunity to seek a re-examination of the opinion. The CHMP is
required to re-examine its opinion within 60 days following receipt of the request by the applicant. All CHMP refusals and the
reasons for refusal are made public on the EMA website. Without a centralized marketing authorization it is prohibited to place
a medicinal product that must be authorized centrally on the market in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>National Procedure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This procedure is available
for medicinal products that do not fall within the scope of mandatory centralized authorization and are intended for use in only
one EU member state. Specific procedures and timelines differ between member states, but the duration of the procedure is generally
210 days and based on a risk/efficacy assessment by the competent authority of the member state concerned, followed by determination
of Summary of Product Characteristics (&ldquo;<B>SmPC</B>&rdquo;) package leaflet and label text/layout and subsequently grant
of the marketing authorization. Marketing authorizations granted on this basis are not mutually recognized by other member states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The majority of medicines
available in the EU were authorized at national level, either because they were authorized before EMA&rsquo;s creation or they
were not in the scope of the centralized procedure. Each EU Member State has its own national authorization procedures. If a company
wishes to request marketing authorization in several EU Member States for a medicine that is outside the scope of the centralized
procedure, it may use one of the following routes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the mutual-recognition procedure, whereby a marketing authorization granted in one Member State can be recognized in other EU countries; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the decentralized procedure, whereby a medicine that has not yet been authorized in the EU can be simultaneously authorized in several EU Member States.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Mutual Recognition and Decentralized
Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the exception
of products that are authorized centrally, the competent authorities of the member states are responsible for granting marketing
authorizations for medicinal products placed on their national markets. If the applicant for a marketing authorization intends
to market the same medicinal product in more than one member state, the applicant may seek an authorization progressively in the
community under the mutual recognition or decentralized procedure. Mutual recognition is used if the medicinal product has already
been authorized in a member state. In this case, the holder of this marketing authorization requests the member state where the
authorization has been granted to act as reference member state by preparing an updated assessment report that is then used to
facilitate mutual recognition of the existing authorization in the other member states in which approval is sought (the so-called
concerned member state(s)). The reference member state must prepare an updated assessment report within 90 days of receipt of a
valid application. This Annual Report together with the approved SmPC (which sets out the conditions of use of the product), and
a labeling and package leaflet are sent to the concerned member states for their consideration. The concerned member states are
required to approve the assessment report, the SmPC and the labeling and package leaflet within 90 days of receipt of these documents.
The total procedural time is 180 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decentralized procedure
is used in cases where the medicinal product has not received a marketing authorization in the EU at the time of application. The
applicant requests a member state of its choice to act as reference member state to prepare an assessment report that is then used
to facilitate agreement with the concerned member states and the grant of a national marketing authorization in all of these member
states. In this procedure, the reference member state must prepare, for consideration by the concerned member states, the draft
assessment report, a draft SmPC and a draft of the labeling and package leaflet within 120 days after receipt of a valid application.
As in the case of mutual recognition, the concerned member states are required to approve these documents within 90 days of their
receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For both mutual recognition
and decentralized procedures, if a concerned member state objects to the grant of a marketing authorization on the grounds of a
potential serious risk to public health, it may raise a reasoned objection with the reference member state. The points of disagreement
are in the first instance referred to the Co-ordination Group on Mutual Recognition and Decentralized Procedures (&ldquo;<B>CMD</B>&rdquo;),
to reach an agreement within 60 days of the communication of the points of disagreement. If member states fail to reach an agreement,
then the matter is referred to the EMA and CHMP for arbitration. The CHMP is required to deliver a reasoned opinion within 60 days
of the date on which the matter is referred. The scientific opinion adopted by the CHMP forms the basis for a binding European
Commission decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Irrespective of whether
the medicinal product is assessed centrally, de-centrally or through a process of mutual recognition, the medicinal product must
be manufactured in accordance with the principles of good manufacturing practice as set out in Directive 2003/94/EC and Volume
4 of the rules governing medicinal products in the European community. Moreover, community law requires the clinical results in
support of clinical safety and efficacy based upon clinical trials conducted in the European community to be in compliance with
the requirements of Directive 2001/20/EC, which implements GCP in the conduct of clinical trials on medicinal products for human
use. Clinical trials conducted outside the European community and used to support applications for marketing within the EU must
have been conducted in a way consistent with the principles set out in Directive 2001/20/EC. The conduct of a clinical trial in
the EU requires, pursuant to Directive 2001/20/EC, authorization by the relevant national competent authority where a trial takes
place, and an ethics committee to have issued a favorable opinion in relation to the arrangements for the trial. It also requires
that the sponsor of the trial, or a person authorized to act on his behalf in relation to the trial, be established in the community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are various types
of applications for marketing authorizations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Full Applications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A full application
is one that is made under any of the community procedures described above and &ldquo;stands alone&rdquo; in the sense that it contains
all of the particulars and information required by Article 8(3) of Directive 2001/83 (as amended) to allow the competent authority
to assess the quality, safety and efficacy of the product and in particular the balance between benefit and risk. Article 8(3)(l)
in particular refers to the need to present the results of the applicant&rsquo;s research on (i) pharmaceutical (physical-chemical,
biological or microbiological) tests, (ii) preclinical (toxicological and pharmacological) studies and (iii) clinical trials in
humans. The nature of these tests, studies and trials is explained in more detail in Annex I to Directive 2001/83/EC. Full applications
would be required for products containing new active substances not previously approved by the competent authority, but may also
be made for other products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Abridged Applications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Article 10 of Directive
2001/83/EC contains exemptions from the requirement that the applicant provide the results of its own preclinical and clinical
research. There are three regulatory routes for an applicant to seek an exemption from providing such results, namely (i) cross-referral
to an innovator&rsquo;s results without consent of the innovator, (ii) well established use according to published literature and
(iii) consent to refer to an existing dossier of research results filed by a previous applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Cross-referral to
Innovator&rsquo;s Data</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Articles 10(1) and
10(2)(b) of Directive 2001/83/EC provide the legal basis for an applicant to seek a marketing authorization on the basis that its
product is a generic medicinal product (a copy) of a reference medicinal product that has already been authorized, in accordance
with community provisions. A reference product is, in principle, an original product granted an authorization on the basis of a
full dossier of particulars and information. This is the main exemption used by generic manufacturers for obtaining a marketing
authorization for a copy product. The generic applicant is not required to provide the results of preclinical studies and of clinical
trials if its product meets the definition of a generic medicinal product and the applicable regulatory results protection period
for the results submitted by the innovator has expired. A generic medicinal product is defined as a medicinal product:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">having the same qualitative and quantitative composition in active substance as the reference medicinal product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">having the same pharmaceutical form as the reference medicinal product; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Applications in respect
of a generic medicinal product cannot be made before the expiry of the protection period. Where the reference product was granted
a national marketing authorization pursuant to an application made before October 30, 2005, the protection period is either six
years or 10 years, depending upon the election of the particular member state concerned. Where the reference product was granted
a marketing authorization centrally, pursuant to an application made before November 20, 2005, the protection period is 10 years.
For applications made after these dates, Regulation 726/2004 and amendments to Directive 2001/83/EC provide for a harmonized protection
period regardless of the approval route utilized. The harmonized protection period is in total 10 years, including eight years
of research data protection and two years of marketing protection. The effect is that the originator&rsquo;s results can be the
subject of a cross-referral application after eight years, but any resulting authorization cannot be exploited for a further two
years. The rationale of this procedure is not that the competent authority does not have before it relevant tests and trials upon
which to assess the efficacy and safety of the generic product, but that the relevant particulars can, if the research data protection
period has expired, be found on the originator&rsquo;s file and used for assessment of the generic medicinal product. The 10-year
protection period can be extended to 11 years where, in the first eight years post-authorization, the holder of the authorization
obtains approval for a new indication assessed as offering a significant clinical benefit in comparison with existing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the copy product
does not meet the definition of a generic medicinal product or if certain types of changes occur in the active substance(s) or
in the therapeutic indications, strength, pharmaceutical form or route of administration in relation to the reference medicinal
product, Article 10(3) of Directive 2001/83/EC provides that the results of the appropriate preclinical studies or clinical trials
must be provided by the applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Well-established
Medicinal Use</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Article 10a of
Directive 2001/83/EC, an applicant may, in substitution for the results of its own preclinical and clinical research, present detailed
references to published literature demonstrating that the active substance(s) of a product have a well-established medicinal use
within the community with recognized efficacy and an acceptable level of safety. The applicant is entitled to refer to a variety
of different types of literature, including reports of clinical trials with the same active substance(s) and epidemiological studies
that indicate that the constituent or constituents of the product have an acceptable safety/efficacy profile for a particular indication.
However, use of the published literature exemption is restricted by stating that in no circumstances will constituents be treated
as having a well-established use if they have been used for less than 10 years from the first systematic and documented use of
the substance as a medicinal product in the EU. Even after 10 years&rsquo; systematic use, the threshold for well-established medicinal
use might not be met. European pharmaceutical law requires the competent authorities to consider among other factors the period
over which a substance has been used, the amount of patient use of the substance, the degree of scientific interest in the use
of the substance (as reflected in the scientific literature) and the coherence (consistency) of all the scientific assessments
made in the literature. For this reason, different substances may reach the threshold for well-established use after different
periods, but the minimum period is 10 years. If the applicant seeks approval of an entirely new therapeutic use compared with that
to which the published literature refers, additional preclinical and/or clinical results would have to be provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Consent to refer
to an existing dossier info</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Article 10c of
Directive 2001/83/EC, following the grant of a marketing authorization the holder of such authorization may consent to a competent
authority utilizing the pharmaceutical, preclinical and clinical documentation that it submitted to obtain approval for a medicinal
product to assess a subsequent application relating to a medicinal product possessing the same qualitative and quantitative composition
with respect to the active substances and the same pharmaceutical form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Law Relating to
Pediatric Research</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulation (EC) 1901/2006
(as amended by Regulation (EC) 1902/2006) was adopted on December 12, 2006. This Regulation governs the development of medicinal
products for human use in order to meet the specific therapeutic needs of the pediatric population. It requires any application
for marketing authorization made after July 26, 2008 in respect of a product not authorized in the European Community on January
26, 2007 (the time the Regulation entered into force), to include the results of all studies performed and details of all information
collected in compliance with a pediatric investigation plan agreed by the Pediatric Committee of the EMA, unless the product is
subject to an agreed waiver or deferral or unless the product is excluded from the scope of Regulation 1902/2006 (generics, hybrid
medicinal products, biosimilars, homeopathic and traditional (herbal) medicinal products and medicinal products containing one
or more active substances of well-established medicinal use). Waivers can be granted in certain circumstances where pediatric studies
are not required or desirable. Deferrals can be granted in certain circumstances where the initiation or completion of pediatric
studies should be deferred until appropriate studies in adults have been performed. Moreover, this regulation imposes the same
obligation from January 26, 2009 on an applicant seeking approval of a new indication, pharmaceutical form or route of administration
for a product already authorized and still protected by a supplementary protection certificate granted under Regulation EC 469/2009
and its precursor (EEC) 1768/92 or by a patent that qualifies for the granting of such a supplementary protection certificate.
The pediatric Regulation 1901/2006 also provides, subject to certain conditions, a reward for performing such pediatric studies,
regardless of whether the pediatric results provided resulted in the grant of a pediatric indication. This reward comes in the
form of an extension of six months to the supplementary protection certificate granted in respect of the product, unless the product
is subject to orphan drug designation, in which case the 10-year market exclusivity period for such orphan products is extended
to 12 years. If any of the non-centralized procedures for marketing authorization have been used, the six-month extension of the
supplementary protection certificate is only granted if the medicinal product is authorized in all member states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Post-authorization
Obligations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the pre-authorization
phase the applicant must provide a detailed pharmacovigilance plan that it intends to implement post-authorization. An authorization
to market a medicinal product in the EU carries with it an obligation to comply with many post-authorization organizational and
behavioral regulations relating to the marketing and other activities of authorization holders. These include requirements relating
to post-authorization efficacy studies, post-authorization safety studies, adverse event reporting and other pharmacovigilance
requirements, advertising, packaging and labeling, patient package leaflets, distribution and wholesale dealing. The regulations
frequently operate within a criminal law framework and failure to comply with the requirements may not only affect the authorization,
but also can lead to financial and other sanctions levied on the company in question and responsible officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
currently on-going overhaul of EU pharmacovigilance legislation the financial and organizational burden on market authorization
holders will increase significantly, such as the obligation to maintain a pharmacovigilance system master file that applies to
all holders of marketing authorizations granted in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004. Marketing
authorization holders must furthermore collect data on adverse events associated with use of the authorized product outside the
scope of the authorization. Pharmacovigilance for biological products and medicines with a new active substance will be strengthened
by subjecting their authorization to additional monitoring activities. The EU is currently in the process of issuing implementing
regulations for the new pharmacovigilance framework.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any authorization
granted by member state authorities, which within three years of its granting is not followed by the actual placing on the market
of the authorized product in the authorizing member state ceases to be valid. When an authorized product previously placed on
the market in the authorizing member state is no longer actually present on the market for a period of three consecutive years,
the authorization for that product shall cease to be valid. The same two three year periods apply to authorizations granted by
the European Commission based on the centralized procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Other Countries</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States and the EU, we may be subject to a variety of other regulations governing clinical trials and commercial sales
and distribution of drugs in other countries. Whether or not our products receive approval from the FDA or EMA approval of such
products must be obtained by the comparable regulatory authorities of countries other than the United States or EU before we can
commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and
the time may be longer or shorter than that required for FDA or EMA approval. The requirements governing the conduct of clinical
trials and product licensing vary greatly from country to country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirements that
we and our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior to commercialization
of our products in such countries can be rigorous, costly and uncertain. In the European countries, Canada and Australia, regulatory
requirements and approval processes are similar in principle to those in the United States. Additionally, depending on the type
of drug for which approval is sought, there are currently two potential tracks for marketing approval in the European countries:
mutual recognition and the centralized procedure. These review mechanisms may ultimately lead to approval in all EU countries,
but each method grants all participating countries some decision-making authority in product approval. Foreign governments also
have stringent post-approval requirements including those relating to manufacture, labeling, reporting, record keeping and marketing.
Failure to substantially comply with these on-going requirements could lead to government action against the product, us and/or
our representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Related Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time,
legislation is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions governing
the approval, manufacturing and marketing of products regulated by the FDA or EMA and other applicable regulatory bodies to which
we are subject. In addition, regulations and guidance are often revised or reinterpreted by the national agency in ways that may
significantly affect our business and our therapeutic candidates. It is impossible to predict whether such legislative changes
will be enacted, whether FDA or EMA regulations, guidance or interpretations will change, or what the impact of such changes, if
any, may be. We may need to adapt our business and therapeutic candidates and products to changes that occur in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Seasonality</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and operations
are generally not affected by seasonal fluctuations or factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employees </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have
one part time (80%) consultant (our CEO) and two full time employees (our CFO and one other employee who is the daughter of
our CEO). In addition, from time to time, we engage certain outside consultants that are, in general, compensated on an
hourly basis, with compensation taking the form of both cash and share-based payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ITEM
1A. RISK FACTORS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>An investment in
our securities involves a high degree of risk. You should consider carefully the following information about these risks, together
with the other information contained in this Annual Report, including the matters addressed in the section entitled &ldquo;CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS&rdquo; beginning on page iii of this Annual Report, before making an investment decision.
Our business, prospects, financial condition, and results of operations may be materially and adversely affected as a result of
any of the following risks. The value of our securities could decline as a result of any of these risks. You could lose all or
part of your investment in our securities. Some of the statements in &ldquo;RISK FACTORS&rdquo; are forward-looking statements.
The following risk factors are not the only risk factors facing our company. Additional risks and uncertainties not presently known
to us or that we currently deem immaterial may also affect our business, prospects, financial condition, and results of operations
and it is not possible to predict all risk factors, nor can we assess the impact of all factors on us or the extent to which any
factor or combination of factors may cause actual results to differ materially from those contained in or implied by any forward-looking
statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks, including risks that may adversely affect our business, financial condition and results
of operations. These risks are discussed more fully below and include, but are not limited to, risks related to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Cosmos Transaction </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; width: 0.25in; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing, and perceived benefits of, the Cosmos Transaction; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         likelihood of entering into an LO2A Transaction or stockholders obtaining any benefit
                                         from owning a CVR; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         interests some of our officers and directors may have in the Cosmos Transaction; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         stockholder&rsquo;s reduced ownership as a result of the Cosmos Transaction; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         difficulty in valuing Cosmos; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         potential need to raise funds in the future, if the Cosmos Transaction is consummated;
                                         </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact to our business if we are required to register under the Investment Advisors Act
                                         of 1940, as amended; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         fact that we have incurred operating losses and may continue to do so for the foreseeable
                                         future; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         exposure to fluctuations in the market value of our investments; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         we may need to raise additional capital, which may be required to maintain or improve
                                         our licensed technology which may cause dilution to existing stockholders; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         according to management estimates, liquidity resources as of December 31, 2020 may not
                                         be sufficient to maintain our operations for the next twelve months which raises substantial
                                         doubt regarding our ability to continue as a going concern; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Business and Regulatory Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         we may never become profitable and that we may never commercialize LO2A;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         timing and expense of our clinical trials, and the regulatory requirements relating to
                                         LO2A; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         expense of potentially acquiring or licensing additional technologies or product candidates;
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         reliance on third party manufacturers; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         lack of any sales, marketing or distribution capabilities; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">competition
                                         and technological challenges we may face; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         impact of COVID-19; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">growth
                                         challenges we may face; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         need to obtain and keep adequate insurance; </FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         reliance on the LO2A License Agreement and the potential need to expand our rights under
                                         such agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         need to obtain and maintain patents and intellectual property, the costs relating to
                                         maintain such patents and intellectual property, and the cost of enforcing and litigation
                                         such patents and intellectual property; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         reliance on confidentiality agreements; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                         subject to government regulations; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of healthcare reforms on our business and reimbursements; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of our business successes or failure on the value of our Common Stock; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         difficulty stockholders may face as a result of our status as a former &ldquo;shell company&rdquo;
                                         and that are Common Stock may be a &ldquo;penny stock&rdquo;;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         impact of future stock sales on our stock price; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         concentration of stock ownership limiting the ability of stockholders to influence us;
                                         </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         potential lack of liquidity, or volatility, of our common stock and warrants; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         potential failure to maintain effective internal controls over financial reporting; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         existence of anti-takeover provisions in our charter documents and Delaware law; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         we do not intend to pay dividends on our common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Operations in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; width: 0.5in; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; width: 0.25in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         risks relating to the political, economic and military instability that may exist in
                                         Israel;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         potential for operations to be disrupted as a result of obligations of Israeli citizens
                                         to perform military service; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-align: justify; text-indent: 0"></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         difficulty in enforcing judgements against us or certain of our executive officers and
                                         directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Risks Related to the Cosmos Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>The Cosmos Transaction may not be
completed at all or in the anticipated timeframe.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white"><FONT STYLE="background-color: white">The completion of the
Cosmos Transaction is no longer subject to the closing conditions because we declared the Offer unconditional, but we cannot assure
you that the transaction will occur as planned or that it will not be delayed past our expected closing date of March 9, 2021.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not achieve
the perceived benefits of the Cosmos Transaction and the market price of our common stock following the Cosmos Transaction may
decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of
our common stock may decline as a result of the Cosmos Transaction for a number of reasons, including if: investors react negatively
to the prospects of the combined company&rsquo;s business; the effect of the Cosmos Transaction on the combined company&rsquo;s
business and prospects is not consistent with the expectations of our management or of financial or industry analysts; or the combined
company does not achieve the perceived benefits of the transaction as rapidly or to the extent anticipated by our management or
financial or industry analysts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>There can be no assurance that we
will successfully enter into any LO2A Transaction or, if we do, that such LO2A Transaction will ultimately be successful or that
any CVR payments will be made.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are numerous
risks and uncertainties associated with the entitlement to payment under the CVR Agreement. We are currently exploring potential
LO2A Transactions with third parties. If and when such discussions materialize and, thereafter, negotiations are successfully
concluded, we may enter into a transaction for the sale or licensing of the LO2A Technology to such third party. Any proceeds
that we receive in connection with a LO2A Transaction, will be distributed in accordance with the CVR Agreement. If no LO2A Transaction
is entered into within the first two years of the closing of the Cosmos Transaction, then we may continue or terminate the LO2A
program, in our discretion, and are not required to effect any LO2A Transaction. The CVR will terminate automatically upon such
LO2A program termination. There can be no assurance that we will successfully enter into any LO2A Transaction or, if we do, that
such LO2A Transaction will ultimately be successful or that any CVR payments will be made. In addition, the CVRs are not freely
transferable and will not be registered with the SEC or listed on any securities exchange. Also, the tax consequences regarding
the receipt of the CVRs are uncertain.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The Cosmos Transaction
may be completed even though certain events occur prior to the closing that materially and adversely affect Wize or Cosmos.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bid Agreement provides
that either Wize or Cosmos can refuse to complete the transactions contemplated thereunder if there is a material adverse change
affecting the other party between December 30, 2020, the date of the Bid Agreement, and the closing. However, since we have declared
the Offer unconditional and are expecting the closing to occur on or about March 9, 2021, material adverse changes generally do
not permit either party to refuse to complete the transaction.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Some of our officers
and directors have interests in the Cosmos Transaction that are different from those of our stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Certain of our
officers and directors participate in arrangements that provide them with interests in the Cosmos Transaction that are different
from, or in addition to, the interests of our stockholders. These interests include acceleration of&nbsp;vesting of&nbsp;unvested&nbsp;stock
options and RSUs of our directors and executive officers;&nbsp;indemnification and insurance of our directors and executive officers;
change in control provisions of employment and consultation arrangements of our chief executive officer and chief financial officer;
termination of existing consulting and employment agreements with our chief executive officer and chief financial officer, respectively,
and execution of new consulting arrangements with our chief executive officer and chief financial officer; participation of our
chief executive officer and chief financial officer in the Post-Closing Incentive Plan; and participation of our chief executive
officer in the PIPE Agreements. The members of our Board of Directors were aware of these additional&nbsp;interests, and considered
them, when they approved the Bid Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cosmos is not a publicly traded company, making it difficult
to determine the fair market value thereof.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">The
outstanding share capital of Cosmos is not traded on any public market, which makes it difficult to determine the fair market value
of Cosmos. There can be no assurance that the consideration to be issued to Cosmos shareholders will not exceed the actual value
of Cosmos.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our securityholders will have a reduced
ownership and voting interest in, and will exercise less influence over the management of, the combined company following the closing
as compared to their current ownership and voting interest in our company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Cosmos Transaction
is completed, our current securityholders will own a smaller percentage of the combined company than their current ownership in
Wize. Immediately following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos shareholders
are expected to own approximately 87.65% of the outstanding common stock of Wize, while Wize existing stockholders are expected
to remain the owners of approximately 10.75% of the outstanding common stock of Wize, each on a fully diluted basis and including
warrants to be issued to Wize&rsquo;s financial advisor to the transaction. Consequently, our stockholders as a group will have
less influence over the management and policies of the combined company after the Cosmos Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our stockholders may not realize
a benefit from the Cosmos Transaction commensurate with the ownership dilution they will experience in connection with the transaction.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the combined company
is unable to realize the strategic and financial benefits currently anticipated from the Cosmos Transaction, our stockholders will
have experienced substantial dilution of their ownership interests without receiving the expected commensurate benefit, or only
receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the expected strategic
and financial benefits currently anticipated from the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The combined company may need to
raise additional capital by issuing securities or debt or through licensing or other strategic arrangements, which may cause dilution
to the combined company&rsquo;s stockholders or restrict the combined company&rsquo;s operations or impact its proprietary rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The combined company
may be required to raise additional funds sooner than currently planned. If either or both of Wize or Cosmos hold less cash at
the time of the closing than the parties currently expect, the combined company will need to raise additional capital sooner than
expected. Additional financing may not be available to the combined company when it needs it or may not be available on favorable
terms. To the extent that the combined company raises additional capital by issuing equity securities, such an issuance may cause
significant dilution to the combined company&rsquo;s stockholders&rsquo; ownership and the terms of any new equity securities may
have preferences over the combined company&rsquo;s common stock. Any debt financing the combined company enters into may involve
covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific
restrictions on the use of the combined company&rsquo;s assets, as well as prohibitions on its ability to create liens, pay dividends,
redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing, partnering
or other strategic arrangements, it may be necessary to relinquish rights to some of the combined company&rsquo;s technologies
or proprietary rights, or grant licenses on terms that are not favorable to the combined company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>During the pendency of the Cosmos
Transaction, we may not be able to enter into a business combination with another party at a favorable price because of restrictions
in the Bid Agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Covenants in the Bid
Agreement impede our ability to make acquisitions or solicit alternative change of control transactions, subject to certain exceptions.
In addition, while the Bid Agreement is in effect, we are generally prohibited from soliciting, initiating, encouraging or entering
into certain extraordinary transactions, such as a merger, sale of assets, or other business combination with any third-party that
would be inconsistent with the transaction. Any such transactions could be favorable to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Failure to complete
the Cosmos Transaction may result in our having to paying a termination fee to Cosmos and could significantly harm the market price
of our common stock and negatively affect our future business and operations of each company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Cosmos Transaction
is not completed and the Bid Agreement is terminated under certain circumstances, we may be required to pay Cosmos a termination
fee of $150,000. Even if a termination fee is not payable in connection with a termination of the Bid Agreement, we will have incurred
significant fees and expenses, most of which must be paid whether or not the transaction is completed. Further, if the Cosmos Transaction
is not completed, it could significantly harm the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if the
Bid Agreement is terminated and our board of directors determines to seek another business combination, there can be no assurance
that we will be able to find a partner and close an alternative transaction on terms that are as favorable or more favorable than
the terms set forth in the Bid Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our business
and financial condition will be materially adversely affected if we are required to register as an investment company under the
Investment Company Act.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Wize is not, and does not intend to become,
an &ldquo;investment company&rdquo; as defined in the U.S. Investment Company Act of 1940, as amended (the &ldquo;Investment Company
Act&rdquo;). Currently, Wize relies on the exclusion from the definition of &ldquo;investment company&rdquo; afforded by Rule 3a-2
under the Investment Company Act. In this regard, Wize has undertaken measures, including through the sale of the Bonus Shares,
to ensure that it is compliant with the conditions for relying on this rule, within the time period permitted by Rule 3a-2. If
Wize is not able to comply within the time period permitted by Rule 3a-2 and as extended by the staff of the SEC in a few no-action
letters, Wize may be required to register as an &ldquo;investment company&rdquo; under the Investment Company Act or cease operations.
In addition, even if Wize were to successfully comply with the requirements of Rule 3a-2, there is a risk that, following the Closing
Date, Wize (as the combined company that engages, through Cosmos, in the business of developing blockchain infrastructure, including
particularly the hosting and ownership of application-specific integrated circuit (ASIC) hardware, and in activities related to
cryptocurrency mining (mainly bitcoin)), may be required to register as an &ldquo;investment company&rdquo; if the SEC or a court
were to take the position that cryptocurrencies of the types that the combined company may hold are &ldquo;securities,&rdquo; as
defined in the Investment Company Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although the SEC and courts are providing
increasing guidance on the treatment of cryptocurrencies for purposes of federal securities law, this continues to be an evolving
area of law. Therefore, it is possible that the SEC or a court could take a position that may be adverse to the position Wize has
taken, or the combined company intends to take, on these matters. If Wize were required to register as an investment company but
fails to do so, the consequences may be severe. Among the various remedies it may pursue, the SEC may seek an order of a court
to enjoin Wize from continuing to operate as an unregistered investment company. In addition, all contracts that Wize has entered
into in the course of its business, including securities that it has offered and sold to investors, will be rendered unenforceable
except to the extent of any equitable remedies that might apply. An affected investor in such case may pursue the remedy of rescission.
If Wize were to register as an investment company, it may be forced to significantly change its structure and operations in order
to comply with the substantive requirements of the Investment Company Act. In particular, Wize may be forced to change its capital
structure in order to satisfy the limits on leverage and classes of securities imposed by the Investment Company Act, modify the
composition of its board of directors in order to maintain the required number of independent directors and the requirements of
&ldquo;independence&rdquo; set forth in rules under the Investment Company Act, restrict transactions that it may engage in with
affiliated persons, fair value its assets in the manner required by the Investment Company Act, adopt a code of ethics to comply
with restrictions on personal trading by officers and employees of Wize, etc. Compliance with the requirements of the Investment
Company Act applicable to registered investment companies may make it difficult for Wize to continue its current operations or,
following the Closing Date, its operations as a company that is engaged in the business of developing blockchain infrastructure
and in activities related to cryptocurrency mining.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Litigation relating
to the Cosmos Transaction could require us to incur significant costs and suffer management distraction, and could delay or enjoin
the transaction.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We&nbsp;could be subject
to demands or litigation related to the Cosmos Transaction, whether or not it is consummated. Such actions may create uncertainty
relating to the transaction, or delay or enjoin it, result in substantial costs to us and divert management time and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Our business has been primarily dependent
on the success of our in-licensed LO2A. If the Cosmos Transaction is not completed, our business will continue to be dependent
on the LO2A. If, however, the Cosmos Transaction is completed, many of these risks will be (i) primarily related to the likelihood
of our ability to successfully enter into any LO2A Transaction and, if we do, the terms thereof, which will mostly affect the holders
of CVRs, and (ii) immaterial to the operation of the post-closing combined company.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Business Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We have incurred
operating losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable
future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical company currently
focused on the treatment of ophthalmic disorders, including DES. We have in-licensed certain rights to LO2A, a drug developed for
the treatment of DES, and other ophthalmological illnesses, including CCH and Sj&ouml;gren&rsquo;s. Since April 2015, we have been
financing our operations through numerous financing or strategic activities, including from loans from Ridge Valley Corporation
(&ldquo;<B>Ridge</B>&rdquo;) and Rimon Gold Assets Ltd. (&ldquo;<B>Rimon Gold</B>&rdquo;) and from third parties, private placements
(of ordinary shares of Wize Israel and, following the 2017 Merger, our common stock) and, most recently, the Bonus Agreements and
the pending PIPE Agreements. We have historically incurred net losses, including net losses of approximately $10.42 million and
$3.45 million for the years ended December 31, 2020 and 2019, respectively. At December 31, 2020, we had an accumulated deficit
of approximately $39.2 million. We do not know whether or when we will become profitable. To date, we have not commercialized any
products or generated any material revenues from product sales and accordingly we do not have a revenue stream to support our cost
structure. Our losses have resulted principally from costs incurred in development and discovery activities as well as from certain
financial expenses related mainly to convertible loans. We expect to continue to incur losses for the foreseeable future, and these
losses will likely increase as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate and manage pre-clinical development and clinical trials for LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory approvals for LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement internal systems and infrastructures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to license additional technologies to develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay royalties and other payments related to the LO2A License Agreement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire management and other personnel; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">move towards commercialization.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No certainty exists
that we will be able to complete the development of LO2A for CCH, Sj&ouml;gren&rsquo;s or any other ophthalmic disorder, due to
financial, technological or other difficulties. If LO2A fails in clinical trials or does not gain regulatory clearance or approval,
or if LO2A does not achieve market acceptance, we may never become profitable. Even if we do achieve profitability, we may not
be able to sustain or increase profitability on a quarterly or annual basis. Our inability to achieve and then maintain profitability
would negatively affect our business, financial condition, results of operations and cash flows. Moreover, our prospects must be
considered in light of the risks and uncertainties encountered by an early-stage company and in highly regulated and competitive
markets, such as the biopharmaceutical market, where regulatory approval and market acceptance of our products are uncertain. There
can be no assurance that our efforts will ultimately be successful or result in revenues or profits.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"><B><I>We are exposed
to fluctuations in the market value of our investments. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As of December 31, 2020, we owned 18,822,533 Bonus Shares, representing
approximately 2% of the outstanding shares of Bonus. As of such date, the closing sale price of one Bonus Share was NIS 0.484 (equivalent
to $0.151), totaling an amount of $2,833,000. Market values of these investments can be negatively affected by various factors,
including business and financial results, of the issuers of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">We adjust our marketable
securities according to fair value based on Bonus Share market price. All gains and losses on marketable securities, realized and
unrealized, are recognized as financial income (expense), which increases the volatility of our financial income (expense).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">As a result of these
factors, the value or liquidity of our cash equivalents, as well as our marketable securities could decline and result in a material
impairment, which could materially adversely affect our financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may need to
raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to
obtain and will dilute current stockholders&rsquo; ownership interests.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sources of financing at our disposal are estimated by our
management to be currently insufficient (i) to conduct our ongoing business for the next 12 months, (ii) to conduct any future
clinical trials, and (iii) for LO2A&rsquo;s commercial production and marketing. No certainty exists that we will be able to secure
the additional sources of finance we need to perform the advanced and necessary stages of receiving regulatory approvals for marketing
and distributing our products, including the costs derived from performing clinical trials and the requirements of the regulatory
authorities. The lack of satisfactory means of financing may bring our business activity to a halt. As of December 31, 2020, we
had cash and cash equivalents of approximately $0.2 million and marketable securities of approximately $2.8 million. We have expended
and may continue to expend substantial resources for the foreseeable future developing LO2A. These expenditures
will include costs associated with research and development, manufacturing, conducting clinical trials, as well as commercializing
any products approved for sale. Because the outcome of our planned and anticipated clinical trials is highly uncertain, we cannot
reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of LO2A. In addition,
other unanticipated costs may arise. As a result of these and other factors currently unknown to us, we will require additional
funds, through public or private equity or debt financings or other sources, such as strategic partnerships and alliances and licensing
arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if
we believe we have sufficient funds for our current or future operating plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital
requirements will depend on many factors, including the progress and results of our clinical trials, the duration and cost of discovery
and preclinical development, and laboratory testing and clinical trials of LO2A, the timing and outcome of regulatory review of
LO2A, the number and development requirements of other product candidates that we pursue, if any, and the costs of activities,
such as product marketing, sales, and distribution. Because of the numerous risks and uncertainties associated with the development
and commercialization of LO2A, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated
with our anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital
requirements depend on many factors, including:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any payments to be made to Resdevco under the LO2A License Agreement;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure to obtain regulatory approval or achieve commercial success of LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our preclinical studies and clinical trials for any future earlier stage product candidate, and any decisions to initiate clinical trials if supported by the preclinical results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs, timing and outcome of regulatory review of LO2A that progress to clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual property-related claims;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of commercialization activities if any LO2A is approved for sale for a particular indication, including marketing, sales and distribution costs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of manufacturing LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, receipt and amount of sales of, or royalties on, our future products, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to attract and retain skilled personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or other lawsuits related to our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which we acquire or invest in businesses, products or technologies and other strategic relationships; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of financing unanticipated working capital requirements and responding to competitive pressures.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional funds may
not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on
a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other research
and development activities for LO2A or delay, limit, reduce or terminate our establishment of sales and marketing capabilities
or other activities that may be necessary to commercialize LO2A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may incur substantial
costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance
fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection
with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>According to
management estimates, liquidity resources as of December 31, 2020 may not be sufficient to maintain our operations for the next
twelve months which raises substantial doubt regarding our ability to continue as a going concern. If we do not continue as a going
concern, investors could lose their entire investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to management
estimates, liquidity resources as of December 31, 2020, may not be sufficient to maintain our operations for the next 12 months.
Our inability to raise funds to conduct our research and development activities may have a severe negative impact on our ability
to remain a viable company. These conditions raise substantial doubt about our ability to continue as a going concern. As such,
the report of our independent registered public accounting firm on our audited financial statements as of and for the year ended
December 31, 2020 contains an emphasis of matter paragraph regarding substantial doubt about our ability to continue as a going
concern. This emphasis of matter paragraph could materially limit our ability to raise additional funds through the issuance of
debt or equity securities or otherwise. Future reports on our annual financial statements may include an emphasis of matter paragraph
with respect to our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we fail to
obtain necessary funds for our operations, we will be unable to maintain and improve our licensed technology, and we will be unable
to develop and commercialize LO2A.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our present and future
capital requirements depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of research and development investment required to develop LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of obtaining or manufacturing LO2A for research and development and testing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of preclinical and clinical testing, which can be unpredictable in drug development;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in drug development plans needed to address any difficulties that may arise in manufacturing, preclinical activities or clinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability and willingness to enter into new agreements with strategic partners and the terms of these agreements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success rate in preclinical and clinical efforts associated with milestones and royalties;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of investigating patents that might block us from developing potential product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of recruiting and retaining qualified personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the time and costs involved in obtaining regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our revenues, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need or decision to acquire or license complementary technologies or new platform or product candidate targets.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to
obtain the funds necessary for our operations, we will be unable to maintain and improve our licensed technology, and we will be
unable to develop and commercialize our products and technologies, which would materially and adversely affect our business, liquidity
and results of operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Business and Regulatory
Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We have not yet
commercialized LO2A, and may never become profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although LO2A is approved
for sale for certain indications in a limited number of jurisdictions, we have not yet commenced commercialization of LO2A, and
may never be able to do so other than with respect to the entry into of distribution agreements in Israel, which are not expected
to result in material revenues. Our activity is influenced by the policies of regulatory authorities. Changes and developments
in regulatory requirements or our failure to meet such requirements may lead to restrictions or delays in developing LO2A and cause
material expenses for us. We do not know when or if we will complete any of our product development efforts of LO2A, obtain regulatory
approval for any future product candidates incorporating our technologies or successfully commercialize any approved products.
Even if we are successful in developing LO2A that is approved for marketing, we will not be successful unless these products gain
market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance of these products
will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of regulatory approvals in the countries, and for the uses, we seek;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the competitive environment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the establishment and demonstration in the medical community of the safety and clinical efficacy of LO2A and its potential advantages over existing therapeutic products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to enter into strategic agreements with pharmaceutical and biotechnology companies with strong marketing and sales capabilities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the adequacy and success of distribution, sales and marketing efforts; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the pricing and reimbursement policies of government and third-party payors, such as insurance companies, health maintenance organizations and other plan administrators.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians, patients,
thirty-party payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of third-party
payors, cover any of our products or products incorporating our technologies. As a result, we are unable to predict the extent
of future losses or the time required to achieve profitability, if at all. Even if we successfully develop one or more products
that incorporate our technologies, we may not become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our current
pipeline is based on a single compound, LO2A. Failure to develop LO2A will have a material adverse effect on us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LO2A is at various
stages of clinical development and may never be commercialized for the indications in the territories that we presently have rights
under the LO2A License Agreement. The progress and results of any future clinical trials are uncertain, and the failure of LO2A
to receive regulatory approvals will have a material adverse effect on our business, operating results and financial condition
to the extent we are unable to commercialize LO2A. In addition, we face the risks of failure inherent in developing therapeutic
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, LO2A
must satisfy rigorous standards of safety and efficacy before it can be approved by the FDA, and any applicable foreign regulatory
authorities for commercial use. The FDA and foreign regulatory authorities have full discretion over this approval process. We
will need to conduct significant additional research, involving testing in animals and in humans, before we can file applications
for product approval. Typically, in the pharmaceutical industry, there is a high rate of attrition for product candidates in pre-clinical
testing and clinical trials. Also, satisfying regulatory requirements typically takes many years, is dependent upon the type,
complexity and novelty of the product and requires the expenditure of substantial resources. In addition, delays or rejections
may be encountered based upon additional government regulation, including any changes in FDA policy, during the process of product
development, clinical trials and regulatory reviews.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to receive
FDA approval or approval from foreign regulatory authorities to market a product candidate, we must demonstrate through pre-clinical
testing and through human clinical trials that the product candidate is safe and effective for its intended uses (<I>e.g.</I>,
treatment of a specific condition in a specific way subject to contradictions and other limitations). Even if we comply with all
FDA requests, the FDA may ultimately reject one or more of our new drug applications (the &ldquo;<B>NDA</B>&rdquo;) or grant approval
for a narrowly intended use that is not commercially feasible. We might not obtain regulatory approval for LO2A in a timely manner,
if at all. Failure to obtain FDA approval for LO2A in a timely manner or at all will severely undermine our business by reducing
the number of salable products and, therefore, corresponding product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Results of earlier
clinical trials may not be predictive of the results of later-stage clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of preclinical
studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy results despite having progressed
through preclinical studies and initial clinical trials. Many companies in the pharmaceutical industry have suffered significant
setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in
earlier studies. Any delay in, or termination or suspension of, our clinical trials will delay the requisite filings with the
FDA or any applicable foreign regulatory authority and, ultimately, our ability to commercialize LO2A and generate product revenues.
If the clinical trials do not support our product claims, the completion of development of such product candidates may be significantly
delayed or abandoned, which will significantly impair our ability to generate product revenues and will materially adversely affect
our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This drug candidate
development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product
candidates are developed from preclinical through early to late stage clinical trials towards approval and commercialization,
it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered
along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize
the product candidates for late stage clinical trials, approval and commercialization, such changes do carry the risk that they
will not achieve these intended objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in our clinical
trials or future clinical trials could cause LO2A or any future product candidate to perform differently, including causing toxicities,
which could delay completion of our clinical trials, delay approval of our product candidates, and/or jeopardize our ability to
commence product sales and generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We might be
unable to develop LO2A that will achieve commercial success in a timely and cost-effective manner, or ever.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if regulatory
authorities approve LO2A for the indications in the territories that we presently have rights under the LO2A License Agreement,
they may not be commercially successful. LO2A may not be commercially successful because government agencies and other third-party
payors may not cover the product or the coverage may be too limited to be commercially successful; physicians and others may not
use or recommend our products, even following regulatory approval. A product approval, assuming one issues, may limit the uses
for which the product may be distributed thereby adversely affecting the commercial viability of the product. Third parties may
develop superior products or have proprietary rights that preclude us from marketing our products. Patient acceptance of and demand
for LO2A for which we obtain regulatory approval or license will depend largely on many factors, including but not limited to
the extent, if any, of reimbursement of costs by government agencies and other third-party payors, pricing, the effectiveness
of our marketing and distribution efforts, the safety and effectiveness of alternative products, and the prevalence and severity
of side effects associated with our products. If physicians, government agencies and other third-party payors do not accept our
products, we will not be able to generate significant revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Clinical trials
are very expensive, time-consuming and difficult to design and implement, and, as a result, we may suffer delays or suspensions
in future trials which would have a material adverse effect on our ability to generate revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials
are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements.
Regulatory authorities, such as the FDA, may preclude clinical trials from proceeding. Additionally, the clinical trial process
is time-consuming, failure can occur at any stage of the trials, and we may encounter problems that cause us to abandon or repeat
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, in October
2017, we terminated our Single Center Trial. The Single Center Trial was a Phase II, randomized, double-blind, placebo-controlled,
pilot study carried out in parallel groups that was intended to evaluate the safety and efficacy of LO2A for patients suffering
from moderate to severe CCH, with Wize Israel having sole access to the trial data. On October 24, 2017, Wize Israel received
notice from the CRO that manages and supervises Wize Israel&rsquo;s clinical trials, that an inadequate amount of quality information
may be derived from the results collected thus far, given that there is no correlation in the reaction of both eyes to LO2A, in
contrast to professional literature and other trials. In addition, the recruitment rate of patients was less than required and
there was a higher than expected dropout rate. In light of the above, the CRO concluded that the results of the trial would be
of no use even if the trial continued until the end of its term. Based on the CRO&rsquo;s conclusion, Wize Israel determined to
terminate the trial and to save the future costs that would be incurred in connection with such trial. For the avoidance of doubt,
this does not impact the Multi-Center Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commencement and
completion of clinical trials may be delayed by several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    safety issues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determination of
    dosing issues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of effectiveness
    or efficacy during clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of third
    party suppliers to perform final manufacturing steps for the drug substance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower than expected
    rates of patient recruitment and enrollment, especially during the COVID-19 pandemic;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of healthy
    volunteers and patients to conduct trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to monitor
    patients adequately during or after treatment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of third
    party contract research organizations to properly implement or monitor the clinical trial protocols;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of institutional
    review boards to approve our clinical trial protocols;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability or unwillingness
    of medical investigators and institutional review boards to follow our clinical trial protocols; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of sufficient
    funding to finance the clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced
the risks involved with conducting clinical trials, including but not limited to, increased expense and delay and failure to meet
end points of the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we or
regulatory authorities may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable
health risks or if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of these trials.
Any suspension of clinical trials will delay possible regulatory approval, if any, and adversely impact our ability to develop
products and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we acquire
or license additional technology or product candidates, we may incur a number of costs, may have integration difficulties and
may experience other risks that could harm our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may acquire and
license additional product candidates and technologies. Any product candidate or technology we license from others or acquire
will likely require additional development efforts prior to commercial sale, including extensive pre-clinical or clinical testing,
or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks
of failure inherent in pharmaceutical product development, including the possibility that the product candidate or product developed
based on licensed technology will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In
addition, we cannot assure you that any product candidate that we develop based on acquired or licensed technology that is granted
regulatory approval will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace.
Moreover, integrating any newly acquired product candidates could be expensive and time-consuming. If we cannot effectively manage
these aspects of our business strategy, our business may not succeed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If any third
party upon whom we rely to manufacture LO2A is unable to timely manufacture LO2A in compliance with cGMP and other regulations
our business will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
have the ability to manufacture the compounds that we need to conduct our clinical trials and, therefore, rely upon, and intend
to continue to rely upon, a certain contract manufacturer to produce and supply LO2A (including the active pharmaceutical ingredients)
for use in clinical trials and for future sales. If such manufacturer is unable to manufacture the compounds in a timely fashion
or in compliance with current cGMP and other applicable regulations or if there is a strain on the relationship with such manufacturer,
our clinical development programs may be delayed which could have a detrimental effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The manufacture
of LO2A is a chemical synthesis process and if our manufacturer encounters problems manufacturing LO2A, our business could suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulators throughout
the world, including the FDA, require manufacturers to register manufacturing facilities. Such regulators also inspect these facilities
to confirm compliance with requirements that such regulators establish. We have engaged a contract manufacturer to produce and
supply LO2A and such third party manufacturer may face manufacturing or quality control problems causing product production and
shipment delays or a situation where such manufacturer may not be able to maintain compliance with the applicable regulators&rsquo;
requirements necessary to continue manufacturing LO2A. In addition, drug manufacturers may be subject to ongoing periodic unannounced
inspections by regulators to ensure strict compliance with requirements and other regulations and applicable standards. Any failure
to comply with such requirements could adversely affect our clinical research activities and our ability to market and develop
LO2A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We do not currently
have sales, marketing or distribution capabilities or experience, and are unable to effectively sell, market or distribute LO2A
now and do not expect to be able to do so in the future. The failure to enter into agreements with third parties that are capable
of performing these functions would have a material adverse effect on our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently intend to either (i) explore strategic transactions
with pharmaceutical companies or others that will monetize our rights in the LO2A licensed technology, or (ii) enter into agreements
with pharmaceutical companies and distributors with relevant marketing capabilities in the field of pharmaceuticals in order to
use them to sell LO2A in countries around the world where we hold rights to sell LO2A. We do not currently have and do not expect
to develop our own sales, marketing and distribution capabilities. If we are unable to enter into agreements with third parties
to perform these functions, we will not be able to successfully market LO2A. In order to successfully market LO2A, we must make
arrangements with third parties to perform these services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we do not intend
to develop a marketing and sales force with technical expertise and supporting distribution capabilities, we will be unable to
market LO2A directly. To promote any of our potential products through third parties, we will have to locate acceptable third
parties for these functions and enter into agreements with them on acceptable terms, and may not be able to do so. Any third-party
arrangements we are able to enter into may result in lower revenues than we could achieve by directly marketing and selling our
potential products. In addition, to the extent that we depend on third parties for marketing and distribution, any revenues we
receive will depend upon the efforts of such third parties, as well as the terms of our agreements with such third parties, which
cannot be predicted in most cases at this time. As a result, we might not be able to market and sell LO2A in the United States
or overseas, which would have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We face significant
competition and continuous technological change, and developments by competitors may render our products or technologies obsolete
or non-competitive. If we cannot successfully compete with new or existing products, our marketing and sales will suffer and may
not ever be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are active in a
competitive market. The fierce competition in the field and the introduction of new competitors to the field may negatively impact
our monetary results. We will compete against fully integrated pharmaceutical and biotechnology companies and smaller companies
that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private
research organizations. In addition, many of these competitors, either alone or together with their collaborative partners, operate
larger research and development programs than ours, and have substantially greater financial resources, as well as significantly
greater experience in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing drugs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertaking pre-clinical
    testing and human clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining FDA, addressing
    various regulatory matters and other regulatory approvals of drugs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">formulating and
    manufacturing drugs; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching, marketing
    and selling drugs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our competitors
develop and commercialize products faster, or develop and commercialize products that are superior to LO2A, our commercial opportunities
will be reduced or eliminated. The extent to which LO2A achieves market acceptance will depend on competitive factors, many of
which are beyond our control. Competition in the biotechnology and biopharmaceutical industry is intense and has been accentuated
by the rapid pace of technology development. Our competitors include large integrated pharmaceutical companies, biotechnology
companies that currently have drug and target discovery efforts, universities, and public and private research institutions. Almost
all of these entities have substantially greater research and development capabilities and financial, scientific, manufacturing,
marketing and sales resources than us. These organizations also compete with us to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract parties
    for acquisitions, joint ventures or other collaborations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">license proprietary
    technology that is competitive with the technology we are developing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract funding;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and hire
    scientific talent and other qualified personnel.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may
succeed in developing and commercializing products earlier and obtaining regulatory approvals from the FDA and other foreign regulatory
authorities more rapidly. Our competitors may also develop products or technologies that are superior to those we are developing,
and render LO2A or any future product candidate or technology obsolete or non-competitive. If we cannot successfully compete with
new or existing products, our marketing and sales will suffer and may never be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may suffer
losses from product liability claims if LO2A causes harm to patients.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LO2A could cause adverse
events. There is also a risk that certain adverse events may not be observed in clinical trials, but may nonetheless occur in
the future. If any of these adverse events occur, they may render LO2A ineffective or harmful in some patients, and our sales
would suffer, materially adversely affecting our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The clinical trials
we carry out are with an insurance policy that allows the trials to be conducted. Accordingly, it is uncertain whether we will
be able to complete our receipt of the regulatory approvals for marketing the drug. Furthermore, it is uncertain whether indemnification
will be provided by the insurance companies. In addition, potential adverse events caused by LO2A could lead to product liability
lawsuits. If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required
to limit the marketing and commercialization of LO2A. Our business is exposed to potential product liability risks, which are
inherent in the testing, manufacturing, marketing and sale of pharmaceutical products. We may not be able to avoid product liability
claims. Product liability insurance for the pharmaceutical and biotechnology industries is generally expensive, if available at
all. If, at any time, we are unable to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against
potential product liability claims, we may be unable to clinically test, market or commercialize LO2A. A successful product liability
claim brought against us in excess of our insurance coverage, if any, may cause us to incur substantial liabilities, and, as a
result, our business, liquidity and results of operations would be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>LO2A will remain
subject to ongoing regulatory requirements even if it receives marketing approval, and if we fail to comply with these requirements,
we could lose these approvals, and the sales of any approved commercial products could be suspended.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive
regulatory approval to market LO2A, the product will remain subject to extensive regulatory requirements, including requirements
relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.
Even if regulatory approval of a product is granted, the approval may be subject to limitations on the uses for which the product
may be marketed or the conditions of approval, or may contain requirements for costly post-marketing testing and surveillance
to monitor the safety or efficacy of the product, which could negatively impact us or our collaboration partners by reducing revenues
or increasing expenses, and cause the approved product candidate not to be commercially viable. In addition, as clinical experience
with a drug expands after approval, typically because it is used by a greater number and more diverse group of patients after
approval than during clinical trials, side effects and other problems may be observed after approval that were not seen or anticipated
during pre-approval clinical trials or other studies. Any adverse effects observed after the approval and marketing of a product
candidate could result in limitations on the use of or withdrawal of any approved products from the marketplace. Absence of long-term
safety data may also limit the approved uses of our products, if any. If we fail to comply with the regulatory requirements of
the FDA and other applicable U.S. and foreign regulatory authorities, or previously unknown problems with any approved commercial
products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed
sanctions or other setbacks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on
    the products, manufacturers or manufacturing process;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>



<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">warning letters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">civil or criminal
    penalties, fines and injunctions;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizures
    or detentions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">import or export
    bans or restrictions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary or mandatory
    product recalls and related publicity requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal
    of regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">total or partial
    suspension of production; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve
    pending applications for marketing approval of new products or supplements to approved applications.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our collaborators
are slow or unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies,
marketing approval for LO2A may be lost or cease to be achievable, resulting in decreased revenue from milestones, product sales
or royalties, which would have a material adverse effect on our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The COVID-19
pandemic, or any other pandemic, epidemic or outbreak of an infectious disease, may materially and adversely affect our business
and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The outbreak
of COVID-19 originated in Wuhan, China, in December 2019 and has since spread to multiple countries, including the United States,
Israel and many European countries in which we operate. On March 11, 2020, the World Health Organization declared the outbreak
a pandemic. While COVID-19 is still spreading and the final implications of the pandemic are difficult to estimate at this stage,
it is clear that it has affected the lives of a large portion of the global population. At this time, the pandemic has caused
states of emergency to be declared in various countries, travel restrictions imposed globally, quarantines established in certain
jurisdictions and various institutions and companies being closed. We are actively monitoring the pandemic and we are taking any
necessary measures to respond to the situation in cooperation with the various stakeholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on guidelines
provided by the Israeli Government, employers (including us) are also required to prepare and increase as much as possible the
capacity and arrangement for employees to work remotely. We have been deemed an essential business in Israel and our offices remain
open during the pandemic, though some of our workforce works remotely. In addition, COVID-19 infection of our workforce could
result in a temporary disruption in our business activities, including manufacturing, sales and other functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 pandemic
is also affecting the United States, Israel and global economies and has affected, and may continue to affect, the conduct of
our clinical trials and may in the future affect our operations and those of third parties on which we rely, including by causing
disruptions in our raw material supply, though to date we have not experienced any such disruptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the COVID-19
pandemic may affect the operations of the FDA, and other health authorities, which could result in delays of reviews and approvals,
including with respect to our existing clinical trials&nbsp;and may, directly or indirectly impact the pace of enrolment in our
clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians&rsquo; offices unless
due to a health emergency and clinical trial staff can no longer get to the clinic. Additionally, such facilities and offices
have been and may continue to be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19
patients, thereby decreasing availability, in whole or in part, for clinical trial services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, during certain
periods of the COVID-19 pandemic, our stock price fluctuated significantly, and such fluctuation may continue to occur. The ultimate
impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays
or impacts on our business, financing or clinical trial activities, or on healthcare systems or the global economy as a whole.
However, these effects could have a material impact on our liquidity, capital resources, operations and business and those of
the third parties on which we rely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.5pt"><B><I>We rely significantly
on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity
incidents, could harm our ability to operate our business effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage
from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. System failures, accidents or security breaches could cause interruptions in our operations, and could result in a material
disruption of our clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources
to remedy. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase
our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of,
or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur
liability and our research and development programs and the development of LO2A could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may encounter
difficulties in managing our growth. Failure to manage our growth effectively will have a material adverse effect on our business,
results of operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able
to successfully grow and expand. Successful implementation of our business plan will require management of growth, including potentially
rapid and substantial growth, which will result in an increase in the level of responsibility for management personnel and place
a strain on our human and capital resources. To manage growth effectively, we will be required to continue to implement and improve
our operating and financial systems and controls to expand, train and manage our employee base. Our ability to manage our operations
and growth effectively requires us to continue to expend funds to enhance our operational, financial and management controls,
reporting systems and procedures and to attract and retain sufficient numbers of talented personnel. If we are unable to scale
up and implement improvements to our control systems in an efficient or timely manner, or if we encounter deficiencies in existing
systems and controls, then we will not be able to make available the products required to successfully commercialize our technology.
Failure to attract and retain sufficient numbers of talented personnel will further strain our human resources and could impede
our growth or result in ineffective growth. Moreover, the management, systems and controls currently in place or to be implemented
may not be adequate for such growth, and the steps taken to hire personnel and to improve such systems and controls might not
be sufficient. If we are unable to manage our growth effectively, it will have a material adverse effect on our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>If we are unable
to obtain adequate insurance, our financial condition could be adversely affected in the event of uninsured or inadequately insured
loss or damage. Our ability to effectively recruit and retain qualified officers and directors could also be adversely affected
if we experience difficulty in obtaining adequate directors&rsquo; and officers&rsquo; liability insurance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able
to obtain insurance policies on terms affordable that would adequately insure our business and property against damage, loss or
claims by third parties. To the extent our business or property suffers any damages, losses or claims by third parties, which
are not covered or adequately covered by insurance, our financial condition may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to
maintain sufficient insurance as a public company to cover liability claims made against our officers and directors. If we are
unable to adequately insure our officers and directors, we may not be able to retain or recruit qualified officers and directors
to manage our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our ability
to pursue the purchase, marketing, sale and distribution of LO2A depends upon the continuation of the LO2A License Agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not own LO2A.
We have entered into the LO2A License Agreement with Resdevco to license certain rights to LO2A (see &ldquo;Item 1. BUSINESS &mdash;
LO2A License Agreement&rdquo; above). The LO2A License Agreement requires us to, among other things, make certain minimum royalty
payments to Resdevco and meet certain regulatory milestones. If we do not meet our obligations under the LO2A License Agreement
in a timely manner, or if we otherwise breach the terms of the LO2A License Agreement, Resdevco could terminate the LO2A License
Agreement and we would lose the rights to LO2A. From time to time, in the ordinary course of business, we may have disagreements
with Resdevco regarding the terms of the LO2A License Agreement or ownership of proprietary rights, which could lead to delays
in the research, development, collaboration and commercialization of LO2A, or could require or result in litigation or arbitration,
which could be time-consuming and expensive. If the LO2A License Agreement is terminated, it would have a material adverse effect
on our business, prospects and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our inability
to expand our rights under the LO2A License Agreement may have a detrimental effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the LO2A
License Agreement, we have (i) the right to add additional territories in the future, subject to a commitment by us to pay minimum
royalties, (ii) the right to purchase Resdevco&rsquo;s agreements with its existing distributors of LO2A in other jurisdictions,
subject to the payment by us of the amount set forth in the LO2A License Agreement, and (iii) a right of first negotiation with
potential distributors to whom Resdevco may in the future grant distribution rights to LO2A in certain territories, subject to
the payment by us of certain minimum royalties. The LO2A License Agreement historically included an option for us to purchase
from Resdevco all remaining territories for a fixed amount, but such option was cancelled on March 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to exercise
our rights mentioned above and to expand our business is subject to us having sufficient cash resources to make the applicable
payments to Resdevco. If we do not have sufficient cash resources to make such payments, we will not be able to exercise our expansion
rights under the LO2A License Agreement and our business may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The failure
to obtain or maintain patents and other intellectual property could impact our ability to compete effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success, competitive
position, and future revenues, if any, depend in part on our ability to obtain and successfully leverage intellectual property
covering LO2A, know-how, methods, processes, and other technologies, to protect our trade secrets, to prevent others from using
our intellectual property and to operate without infringing the intellectual property rights of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risks and uncertainties
that we face with respect to our intellectual property rights include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">while any patents
    that we license under the LO2A License Agreement have been issued, their scope of protection is limited to the CCH indication
    in the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not obtain
    rights from Resdevco to any further patents or patent applications related to LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we or Resdevco may
    be subject to interference proceedings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we or Resdevco may
    be subject to opposition proceedings in foreign countries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any patent that
    is issued may not provide meaningful protection;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we or Resdevco may
    not be able to develop additional proprietary technologies that are patentable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies
    may challenge patents licensed or issued to us or our customers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies
    may independently develop similar or alternative technologies, or duplicate our technologies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other companies
    may design around technologies we have licensed or developed; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement of patents
    is complex, uncertain and expensive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If patent rights covering
LO2A are not sufficiently broad or expire, they may not provide us with any protection against competitors with similar products
and technologies. For example, a patent covering the composition and use of LO2A for treating or alleviating DES has expired.
Furthermore, if the United States Patent and Trademark Office (the &ldquo;<B>USPTO</B>&rdquo;), or foreign patent offices issue
patents to us or our licensors, others may challenge the patents or design around the patents, or the patent office or the courts
may invalidate the patents. Thus, any patents we own or license from or to third parties may not provide any protection against
our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain
that patents will be issued as a result of any pending applications, and cannot be certain that any of our issued patents, including
those licensed from Resdevco or any other third-party in the future, will give us adequate protection from competing products.
For example, issued patents, including the patents licensed by us, may be circumvented or challenged, declared invalid or unenforceable,
or narrowed in scope.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, since
publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that
we or Resdevco were or will be the first to make our inventions or to file patent applications covering those inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible
that others may obtain issued patents that could prevent us from commercializing LO2A or require us to obtain licenses requiring
the payment of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have licensed,
our rights depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable
to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents
and patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology. We require
our employees, consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure of
confidential information to any other parties. We require our employees and consultants to disclose and assign their ideas, developments,
discoveries and inventions to us. These agreements may not, however, provide adequate protection for our trade secrets, know-how
or other proprietary information in the event of any unauthorized use or disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Costly litigation
may be necessary to protect our or Resdevco&rsquo;s intellectual property rights and we or Resdevco may be subject to claims alleging
the violation of the intellectual property rights of others.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our activity in the
field of life sciences exposes us to the possibility of legal proceedings connected with our business activities. We may face
significant expense and liability as a result of litigation or other proceedings relating to patents and other intellectual property
rights of others. In the event that another party has also filed a patent application or been issued a patent relating to an invention
or technology claimed by us or Resdevco in pending applications, we may be required to participate in an interference proceeding
declared by the USPTO to determine priority of invention, which could result in substantial uncertainties and costs for us, even
if the eventual outcome was favorable to us. We, or our licensors, could be required to participate in interference proceedings
involving issued patents and pending applications of another entity. An adverse outcome in an interference proceeding could require
us to cease using the technology or to license rights from prevailing third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost to us of
any patent litigation or other proceeding relating to our licensed patents or patent applications, even if resolved in our favor,
could be substantial. The ability of us and Resdevco to enforce our patent protection could be limited by our financial resources,
and may be subject to lengthy delays. If we are unable to effectively enforce our or Resdevco&rsquo;s proprietary rights, or if
we are found to infringe the rights of others, we may be in breach of the LO2A License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A third party may
claim that we or Resdevco are using inventions claimed by their patents and may go to court to stop us or Resdevco from engaging
in our normal operations and activities, such as research, development and the sale of any future products. Such lawsuits are
expensive and would consume time and other resources. There is a risk that the court will decide that we or Resdevco are infringing
the third party&rsquo;s patents and will order us or Resdevco to stop the activities claimed by the patents, redesign our products
or processes to avoid infringement or obtain licenses (which may not be available on commercially reasonable terms). In addition,
there is a risk that a court will order us to pay the other party damages for having infringed their patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, there is
no guarantee that any prevailing patent owner would offer us or Resdevco a license so that we or Resdevco could continue to engage
in activities claimed by the patent, or that such a license, if made available, could be acquired on commercially acceptable terms.
In addition, third parties may, in the future, assert other intellectual property infringement claims against us or Resdevco with
respect to its product candidates, technologies or other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We rely on our
and Resdevco&rsquo;s confidentiality agreements that could be breached and may be difficult to enforce, which could result in
third parties using our intellectual property to compete against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe
that we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure
of confidential information to third parties, as well as agreements that purport to require the disclosure and assignment of the
rights to the ideas, developments, discoveries and inventions of our employees and consultants while they are employed by us and
we believe that Resdevco also takes such measures, the agreements can be difficult and costly to enforce. Although we believe
that our licensors seek to obtain these types of agreements from our contractors, consultants, advisors and research collaborators,
to the extent that employees and consultants utilize or independently develop intellectual property in connection with any of
our projects, disputes may arise as to the intellectual property rights associated with our products. If a dispute arises, a court
may determine that the right belongs to a third party. In addition, enforcement of our and Resdevco&rsquo;s rights can be costly
and unpredictable. We and Resdevco also rely on trade secrets and proprietary know-how that we believe that Resdevco seeks to
protect in part by confidentiality agreements with employees, contractors, consultants, advisors or others. Despite the protective
measures we and Resdevco employ, we still face the risk that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">these agreements
    may be breached;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">these agreements
    may not provide adequate remedies for the applicable type of breach;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our and Resdevco&rsquo;s
    trade secrets or proprietary know-how will otherwise become known; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our competitors
    will independently develop similar technology or proprietary information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Patent protection
outside the United States is particularly uncertain, and if we are involved in opposition proceedings outside the United States,
we may have to expend substantial sums and management resources.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent law outside
the United States is different than in the United States. Further, the laws of some foreign countries may not protect our or Resdevco&rsquo;s
intellectual property rights to the same extent as the laws of the United States, if at all. A failure to obtain sufficient intellectual
property protection in any country could materially and adversely affect our business, results of operations and future prospects.
Moreover, we may participate in opposition proceedings to determine the validity of our foreign patents or our competitors&rsquo;
foreign patents, which could result in substantial costs and divert management&rsquo;s resources and attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be
able to enforce employees&rsquo; and consultants covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees or consultants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into
non-competition agreements with our key employees and key consultants, within the framework of their employment agreements or
consultant agreements, respectively. These agreements prohibit such persons, if they cease working for us, from competing directly
with us or working for our competitors for a limited period. Under applicable law, we may be unable to enforce these agreements.
If we cannot enforce our non-competition agreements with such persons, then we may be unable to prevent our competitors from benefiting
from the expertise of our former employees and consultants, which could materially adversely affect our business, results of operations
and ability to capitalize on our proprietary information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and
may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others may be able
    to make compounds that are the same as or similar to LO2A but that are not covered by the claims of the patents that we have
    exclusively licensed;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resdevco or any
    future strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent
    applications that we have exclusively licensed;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resdevco or any
    future strategic partners might not have been the first to file patent applications covering certain of our technology;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others may independently
    develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property
    rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is possible that
    any pending patent applications will not lead to issued patents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued patents that
    we have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable,
    as a result of legal challenges by our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our competitors
    might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive products for sale in our major commercial markets; &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not develop
    additional proprietary technologies that are patentable; and &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patents of others
    may have an adverse effect on our business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may be subject
to claims challenging the inventorship of our patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject
to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property
as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants
or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other
claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an
outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We are subject
to government regulations and we may experience delays in obtaining required regulatory approvals to market LO2A.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various aspects of
our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time.
Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and
attention and, consequently, could adversely affect our business operations and financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in regulatory
approval, limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect on us.
If we experience significant delays in testing or receiving approvals or sign-offs to conduct clinical trials, our product development
costs, or our ability to license LO2A, will increase. If certain country&rsquo;s regulatory authority grants regulatory approval
to market a product, this approval will be limited to those disease states and conditions for which the product has demonstrated,
through clinical trials, to be safe and effective. Any product approvals that we receive in the future could also include significant
restrictions on the use or marketing of our products. Product approvals, if granted, can be withdrawn for failure to comply with
regulatory requirements or upon the occurrence of adverse events following commercial introduction of the products. Failure to
comply with applicable regulatory requirements may result in criminal prosecution, civil penalties, recall or seizure of products,
total or partial suspension of production or injunction, as well as other regulatory action against us or LO2A. If approval is
withdrawn for a product, or if a product were seized or recalled, we would be unable to sell or license that product and our revenues
would suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We expect the
healthcare industry to face increased limitations on reimbursement as a result of healthcare reform, which could adversely affect
third-party coverage of our products and how much or under what circumstances healthcare providers will prescribe or administer
our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In both the United
States and other countries, sales of our products will depend in part upon the availability of reimbursement from third-party
payors, which include governmental authorities, managed care organizations and other private health insurers. Third-party payors
are increasingly challenging the price and examining the cost effectiveness of medical products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increasing expenditures
for healthcare have been the subject of considerable public attention in the United States. Both private and government entities
are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare system
have been introduced or proposed in Congress and in some state legislatures, including reducing reimbursement for prescription
products and reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2010, the United
States Congress enacted the Patient Protection and Affordable Care Act of 2010 or, Affordable Care Act. The Affordable Care Act
seeks to reduce the federal deficit and the rate of growth in health care spending through, among other things, stronger prevention
and wellness measures, increased access to primary care, changes in health care delivery systems and the creation of health insurance
exchanges. Enrollment in the health insurance exchanges began in October 2013. The Affordable Care Act requires the pharmaceutical
industry to share in the costs of reform, by, among other things, increasing Medicaid rebates and expanding Medicaid rebates to
cover Medicaid managed care programs. Other components of healthcare reform include funding of pharmaceutical costs for Medicare
patients in excess of the prescription drug coverage limit and below the catastrophic coverage threshold. Under the Affordable
Care Act, pharmaceutical companies are now obligated to fund 50% of the patient obligation for branded prescription pharmaceuticals
in this gap, or &ldquo;donut hole.&rdquo; Additionally, commencing in 2011, an excise tax was levied against certain branded pharmaceutical
products. The tax is specified by statute to be approximately $3 billion in 2012 through 2016, $3.5 billion in 2017, $4.2 billion
in 2018, and $2.8 billion each year thereafter. The tax is to be apportioned to qualifying pharmaceutical companies based on an
allocation of their governmental programs as a portion of total pharmaceutical government programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we cannot
predict the full effect on our business of the implementation of existing legislation, including the Affordable Care Act or the
enactment of additional legislation, we believe that legislation or regulations that reduce reimbursement for or restrict coverage
of our products could adversely affect how much or under what circumstances healthcare providers will prescribe or administer
our products. This could materially and adversely affect our business by reducing our ability to generate revenue, raise capital,
obtain additional collaborators and market our products. In addition, we believe the increasing emphasis on managed care in the
United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact
product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may be subject
to U.S. and foreign anti-kickback laws and regulations. Our failure to comply with these laws and regulations could have adverse
consequences.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are extensive
U.S. federal and state laws and regulations prohibiting fraud and abuse in the healthcare industry that can result in significant
criminal and civil penalties. These federal laws include: the anti-kickback statute, which prohibits certain business practices
and relationships, including the payment or receipt of remuneration for the referral of patients whose care will be paid by Medicare
or other federal healthcare programs; the physician self-referral prohibition, commonly referred to as the Stark Law; the anti-inducement
law, which prohibits providers from offering anything to a Medicare or Medicaid beneficiary to induce that beneficiary to use
items or services covered by either program; the False Claims Act, which prohibits any person from knowingly presenting or causing
to be presented false or fraudulent claims for payment by the federal government, including the Medicare and Medicaid programs;
and the Civil Monetary Penalties Law, which authorizes the U.S. Department of Health and Human Services to impose civil penalties
administratively for fraudulent or abusive acts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sanctions for violating
these federal laws include criminal and civil penalties that range from punitive sanctions, damage assessments, money penalties,
imprisonment, denial of Medicare and Medicaid payments, or exclusion from the Medicare and Medicaid programs, or both, and debarment.
As federal and state budget pressures continue, federal and state administrative agencies may also continue to escalate investigation
and enforcement efforts to root out waste and to control fraud and abuse in governmental healthcare programs. Private enforcement
of healthcare fraud has also increased, due in large part to amendments to the civil False Claims Act in 1986 that were designed
to encourage private persons to sue on behalf of the government. A violation of any of these federal and state fraud and abuse
laws and regulations or any similar law in a different jurisdiction which is applicable to us could have a material adverse effect
on our liquidity and financial condition. An investigation into the use by physicians of any of our products once commercialized
may dissuade physicians from either purchasing or using them, and could have a material adverse effect on our ability to commercialize
those products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The failure
of our business to succeed may result in the depression in the value of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While LO2A is approved
for sale in certain jurisdictions for the treatment of DES, LO2A is only approved for sale for the treatment of CCH in Hungary
and for the treatment of Sj&ouml;gren&rsquo;s in the Netherlands. LO2A may never be successfully developed and approved for sale
or successfully commercialized for the treatment of CCH or for Sj&ouml;gren&rsquo;s in any other jurisdiction. The failure to
successfully commercialize LO2A for the treatment of CCH and Sj&ouml;gren&rsquo;s may have a material adverse effect on our business
and could depress the value of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our restricted
shares are subject to resale restrictions imposed by Rule 144, including those set forth in Rule 144(i) which applies to a &ldquo;shell
company.&rdquo;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the 2017
Merger, we were a &ldquo;shell company&rdquo; under applicable SEC rules and regulations. Pursuant to Rule 144, promulgated under
the Securities Act, sales of the securities of a shell company, such as ours under that rule are not permitted until at least
12 months have elapsed from the date on which we file with the SEC Form 10 information in a Current Report on Form 8-K, reflecting
our status as a non-shell company (which occurred on November 21, 2017). As a result, some of our stockholders would be forced
to hold their shares of Common Stock for at least that 12-month period before they are eligible to sell those shares, and even
after that 12-month period, sales may not be made under Rule 144 unless we and our relevant stockholders are in compliance with
other requirements of Rule 144. Further, it will be more difficult for us to raise funding to support our operations through the
sale of debt or equity securities, unless we agree to register such securities under the Securities Act, which could cause us
to expend additional time and cash resources. The lack of liquidity of our securities as a result of the inability to sell under
Rule 144 for a longer period of time could cause the market price of our securities to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Because our
Common Stock may be a &ldquo;penny stock&rdquo;, it may be more difficult for investors to sell shares of our Common Stock, and
the market price of our Common Stock may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock may
be a &ldquo;penny stock&rdquo; if, among other things, the stock price is below $5.00 per share, it is not listed on a national
securities exchange or it has not met certain net tangible asset or average revenue requirements. Broker-dealers who sell penny
stocks must provide purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. This document
provides information about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A broker
must also give a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation,
make a written determination that the penny stock is a suitable investment for the purchaser, and obtain the purchaser&rsquo;s
written agreement to the purchase. Broker-dealers must also provide customers that hold penny stock in their accounts with such
broker-dealer a monthly statement containing price and market information relating to the penny stock. If a penny stock is sold
to an investor in violation of the penny stock rules, the investor may be able to cancel its purchase and get its money back.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If applicable, the
penny stock rules may make it difficult for investors to sell our shares of Common Stock. Because of the rules and restrictions
applicable to a penny stock, there is less trading in penny stocks and the market price of our Common Stock may be adversely affected.
Also, many brokers choose not to participate in penny stock transactions. Accordingly, investors may not always be able to resell
their shares of our Common Stock publicly at times and prices that they feel are appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be
able to attract the attention of major brokerage firms, which may limit the liquidity of our Common Stock and may make it more
difficult for us to raise additional capital in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Securities analysts
of major brokerage firms may not provide coverage of our Common Stock because there may be little incentive for brokerage firms
to recommend the purchase of our Common Stock. As a result, our Common Stock may have limited liquidity and investors may have
difficulty selling it. Furthermore, we cannot assure you that brokerage firms will want to conduct any secondary offerings on
our behalf if we seek to raise additional capital in the future. Our inability to raise additional capital may have a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Future sales
of our Common Stock could reduce our stock price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Sales
by stockholders of substantial amounts of our Common Stock, or the perception that these sales may occur in the future, could
materially and adversely affect the market price of our Common Stock. Furthermore, the market price of our Common Stock could
drop significantly if our executive officers, directors, or certain large shareholders sell their shares, or are perceived by
the market as intending to sell them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The concentration
of the capital stock ownership with our insiders will likely limit the ability of our stockholders to influence corporate matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 1,
2021, our executive officers, directors, five percent or greater stockholders, and their respective affiliated entities in the
aggregate beneficially own approximately 53.55% of our Common Stock. As a result of such ownership, despite the fact that each
one of them, to our knowledge, will continue to operate independently from the other with respect to their respective shareholding
of the Company&rsquo;s shares, these stockholders, if acting together, will have control over matters that require approval by
our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might
be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing
a corporate transaction that other stockholders may view as beneficial, including preventing changes in control or in management.
For more information about our current share ownership, please see &ldquo;Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We may not be
able to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the 2017
Merger, Wize Israel was traded on the TASE and was not subject to Section 404 of the Sarbanes-Oxley Act of 2002. The standards
required for a public company under Section 404 of the Sarbanes-Oxley Act of 2002 are different from those required of a public
company whose shares are traded on the TASE. Management may not be able to effectively and timely implement controls and procedures
that adequately respond to the regulatory compliance and reporting requirements that are applicable to us after the 2017 Merger.
If management is not able to implement the additional requirements of Section 404 of the Sarbanes-Oxley Act of 2002 in a timely
manner or with adequate compliance, it may not be able to assess whether its internal control over financial reporting is effective,
which may subject us to adverse regulatory consequences and could harm investor confidence and the market price of our Common
Stock. In addition, as a smaller reporting company we are not subject to the auditor attestation requirements of Section 404 of
such internal control.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>We have not
paid, and do not intend to pay, dividends on our Common Stock and therefore, unless our Common Stock appreciates in value, our
investors may not benefit from holding our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any
cash dividends on our Common Stock since inception and do not anticipate paying any cash dividends on our Common Stock in the
foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Anti-takeover
provisions under our certificate of incorporation could make an acquisition of us, which may be beneficial to our stockholders,
more difficult and may prevent attempts by the stockholders to replace or remove management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of
Incorporation contains provisions, such as blank check preferred stock, advance notice, and stockholder action by written consent
which could make it more difficult for a third party to acquire us. These provisions may have the effect of preventing or hindering
any attempts by our stockholders to replace our Board of Directors (the &ldquo;Board&rdquo;) or management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The public trading
market for our Common Stock is volatile and may result in higher spreads in stock prices, which may limit the ability of our investors
to sell their shares at a profit, if at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock trades
in the over-the-counter market and is quoted on the OTCQB. The over-the-counter market for securities has historically experienced
extreme price and volume fluctuations during certain periods. These broad market fluctuations may adversely affect the market
price of our Common Stock and result in substantial losses to its investors. In addition, the spreads on stock traded through
the over-the-counter market are generally unregulated and higher than on stock exchanges, which mean that the difference between
the price at which shares could be purchased by investors in the over-the-counter market compared to the price at which they could
be subsequently sold would be greater than on these exchanges. Significant spreads between the bid and asked prices of the stock
could continue during any period in which a sufficient volume of trading is unavailable or if the stock is quoted by an insignificant
number of market makers. Historically our trading volume has been insufficient to significantly reduce this spread and has had
a limited number of market makers sufficient to affect this spread. These higher spreads could adversely affect investors who
purchase the shares at the higher price at which the shares are sold, but subsequently sell the shares at the lower bid prices
quoted by the brokers. Unless the bid price for the stock exceeds the price paid for the shares by the investor, plus brokerage
commissions or charges, the investor could lose money on the sale. For higher spreads such as those on over-the-counter stocks,
this is likely a much greater percentage of the price of the stock than for exchange listed stocks. There is no assurance that
at the time an investor in our Common Stock wishes to sell the shares, the bid price will have sufficiently increased to create
a profit on the sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>An active market
for our Common Stock may not develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our Common
Stock trades on the OTCQB, we do not have an active trading market and an active trading market may not develop. If an active
trading market does not develop, or is not sustained, it may be difficult for investors to sell their shares without depressing
the market price for the shares or at all. Further, an inactive market may also impair our ability to raise capital by selling
shares of our Common Stock and may impair our ability to enter into strategic partnerships or acquire companies or products by
using our shares of Common Stock as consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our Common Stock
is thinly traded, so you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money
or otherwise desire to liquidate your shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock has
historically been sporadically traded on the OTCQB, meaning that the number of persons interested in purchasing our shares at
or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors,
including the fact that we are a small company which is relatively unknown to stock analysts, stock brokers, institutional investors
and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such
persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend
the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several
days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large
and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We
cannot give you any assurance that a broader or more active public trading market for our Common Stock will develop or be sustained,
or that current trading levels will be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our Board can,
without stockholder approval, cause preferred stock to be issued on terms that adversely affect common stockholders or which could
be used to resist a potential take-over of us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Certificate
of Incorporation, our Board is authorized to issue up to 1,000,000 shares of preferred stock, 178 of which are issued and outstanding
as of the date of this Annual Report. Also, our Board, without stockholder approval, may determine the price, rights, preferences,
privileges and restrictions, including voting rights, of those shares. If the Board causes shares of preferred stock to be issued,
the rights of the holders of our Common Stock could be adversely affected. The Board&rsquo;s ability to determine the terms of
preferred stock and to cause its issuance, while providing desirable flexibility in connection with possible acquisitions and
other corporate purposes, could have the effect of making it more difficult for a third party to acquire a majority of our outstanding
voting stock. Preferred shares issued by the Board could include voting rights, or even super voting rights, which could shift
the ability to control us to the holders of the preferred stock. Preferred shares could also have conversion rights into shares
of Common Stock at a discount to the market price of the Common Stock which could negatively affect the market for our Common
Stock. In addition, preferred shares would have preference in the event of liquidation of the corporation, which means that the
holders of preferred shares would be entitled to receive the net assets of the corporation distributed in liquidation before the
holders of Common Stock receive any distribution of the liquidated assets. We have no current plans to issue any shares of preferred
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The market price
of our Common Stock may fluctuate significantly, which could result in substantial losses by our investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the first quarter of 2021, the market price of our common stock fluctuated from a high of $1.19
per share to a low of $0.23 per share, and our stock price continues to fluctuate. The market price of our common stock may continue
to fluctuate significantly in response to numerous factors, some of which are beyond its control, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of
    technological innovations, new products or product enhancements by us or others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by
    us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expiration or terminations
    of licenses, research contracts or other collaboration agreements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public concern as
    to the safety of LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">success of research
    and development projects;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">success in clinical
    and preclinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments concerning
    intellectual property rights or regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations in our
    and our competitors&rsquo; results of operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in earnings
    estimates or recommendations by securities analysts, if our Common Stock is covered by analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in government
    regulations or patent decisions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments by
    our licensees;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments in
    the biotechnology industry;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of product
    liability or intellectual property lawsuits;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future issuances
    of Common Stock or other securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the addition or
    departure of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by
    us or our competitors of acquisitions, investments or strategic alliances;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market conditions,
    including the volatility of market prices for shares of biotechnology companies generally, and other factors, including factors
    unrelated to our operating performance; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the other factors
    described in the section entitled &ldquo;RISK FACTORS&rdquo; above and below.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors and
any corresponding price fluctuations may materially and adversely affect the market price of our Common Stock and result in substantial
losses by our investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the stock
market in general, and the market for biotechnology companies in particular, has experienced extreme price and volume fluctuations
in the past. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause
a decline in the value of our Common Stock. Price volatility of our Common Stock might be worse if the trading volume of our Common
Stock is low. In the past, following periods of market volatility, stockholders have often instituted securities class action
litigation. If we are involved in securities litigation, it could have a substantial cost and divert resources and attention of
management from our business, even if successful. Future sales of our Common Stock could also reduce the market price of such
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Operations in
Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Potential political,
economic and military instability in the State of Israel, where our senior management and our head executive office facilities
are located, may adversely affect our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive office
where we conduct initial research and development activities, as well as some of our clinical sites and suppliers are located
in Israel. Our officers and our directors are residents of Israel. Accordingly, political, economic and military conditions in
Israel and the surrounding region may directly affect our business and operations. Since the establishment of the State of Israel
in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors. Any hostilities involving Israel
or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect our
operations and results of operations and could make it more difficult for us to raise capital. During the summer of 2014 and the
winter of 2012 and 2008, Israel was engaged in an armed conflict with Hamas, a militia group and political party operating in
the Gaza Strip, and during the summer of 2006, Israel was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite
militia group and political party. These conflicts involved missile strikes against civilian targets in various parts of Israel,
and negatively affected business conditions in Israel. To date, Israel faces political tension with respect to its relationships
with Turkey, Iran and other Arab neighbor countries. In addition, recent political uprisings and social unrest in various countries
in the Middle East and North Africa are affecting the political stability of those countries. This instability may lead to deterioration
of the political relationships that exist between Israel and these countries, and have raised concerns regarding security in the
region and the potential for armed conflict. Any armed conflicts, terrorist activities or political instability in the region
could adversely affect business conditions and could harm our results of operations. For example, any major escalation in hostilities
in the region could result in a portion of our employees and service providers being called up to perform military duty for an
extended period of time. Parties with whom we do business have sometimes declined to travel to Israel during periods of heightened
unrest or tension, forcing us to make alternative arrangements when necessary. In addition, the political and security situation
in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated
to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. Any future deterioration
in the political and security situation in Israel will negatively impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance
does not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although
the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts
of war, we cannot assure you that this government coverage will be maintained. Any losses or damages incurred by us could have
a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively
affect business conditions and could harm our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, in the past,
the State of Israel and Israeli companies have been subjected to an economic boycott. Several countries still restrict business
with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating
results, financial condition or the expansion of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our operations
may be disrupted as a result of the obligation of Israeli citizens to perform military service.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many Israeli citizens,
including Or Eisenberg, our Chief Financial Officer, Treasurer and Secretary, are obligated to perform one month, and in some
cases more, of annual military reserve duty until they reach the age of 45 (or older, for reservists with certain occupations)
and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there
have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups
in the future. Our operations could be disrupted by such call-ups, which may include the call-up of Or Eisenberg. Such disruption
could materially adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Because a certain
portion of our expenses is incurred in currencies other than the U.S. Dollar, our results of operations may be harmed by currency
fluctuations and inflation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our reporting and
functional currency is the U.S. Dollar, but some portion of our clinical trials and operations expenses are in NIS and Euro. As
a result, we are exposed to some currency fluctuation risks, largely derived from our current and future engagements for financing
and distribution. Fluctuation in the exchange rates of foreign currency has an influence on the cost of goods sold and our financing
revenues and expenses. We may, in the future, decide to enter into currency hedging transactions to decrease the risk of financial
exposure from fluctuations in the exchange rate of the currencies mentioned above in relation to the U.S. Dollar. These measures,
however, may not adequately protect us from adverse effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Investors may
have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal
securities laws against us and our officers and directors or asserting U.S. securities laws claims in Israel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors and
officers are not residents of the United States and our assets are located outside the United States. Service of process upon
our directors and officers and enforcement of judgments obtained in the United States against us, and our directors and officers
may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that it may be difficult
to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability
provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities
laws against our officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition,
even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim.
If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel
addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it
difficult to collect on judgments rendered against us and/or our officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, among other
reasons, including but not limited to, fraud, a lack of due process, a judgment which is at variance with another judgment that
was given in the same matter and if a suit in the same matter between the same parties was pending before a court or tribunal
in Israel, an Israeli court will not enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement
of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or
security of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_004"></A>ITEM 1B. UNRESOLVED STAFF COMMENTS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_005"></A>ITEM 2. PROPERTIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located at 24 Hanagar Street, Hod Hasharon, Israel, 4527708 where we lease approximately 710 square feet of office
space for annual rent of approximately $25,000. Other than such office lease, we do not own or lease any material tangible fixed
assets. We believe that our existing facilities are suitable and adequate to meet our current business requirements. In the event
that we should require additional or alternative facilities, we believe that such facilities can be obtained on short notice at
competitive rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_006"></A>ITEM 3. LEGAL PROCEEDINGS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2018, the Israeli Securities Authority (&ldquo;ISA&rdquo;)
commenced administrative enforcement proceedings against Wize Israel, the Company&rsquo;s former Chairman and the Company&rsquo;s
Chief Financial Officer (who, at the relevant time, served as Wize Israel&rsquo;s chief financial officer) in connection with certain
public reports filed by Wize Israel with the ISA prior to the closing of the 2017 Merger. In August 2019, the ISA&rsquo;s Administrative
Enforcement Committee approved a settlement of the proceedings, whereby, (i) Wize Israel undertook to pay a civil penalty of NIS
200,000 (equivalent to approximately $57,000) to the ISA and (ii) the Company&rsquo;s Chief Financial Officer undertook to pay
a civil penalty of NIS 175,000 (equivalent to approximately $50,000) to the ISA and also agreed that, if he will violate, at any
time until August 2020, certain provisions of Israeli securities laws relating to misleading public reports, he will be barred,
for a nine-month period thereafter, from serving as an officer or director in certain entities supervised by the ISA, including
companies that are publicly traded in Israel (but, for the sake of clarity, not companies traded in the U.S., such as the Company).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as described
above, we are currently not, and have not been in the recent past, a party to any legal proceedings which may have or have had
in the recent past significant effects on our financial position or profitability. However, we have been in the past, and may
be from time to time in the future, named as a defendant in certain routine litigation incidental to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_007"></A>ITEM 4. MINE SAFETY DISCLOSURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_008"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_009"></A>ITEM 5. MARKET FOR REGISTRANT&rsquo;S
COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Price for our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock traded
on the OTCQB under the symbol &ldquo;WIZP&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 1, 2021, there
were approximately 126 stockholders of record holding 23,905,209 shares of our Common Stock. This number does not include an indeterminate
number of stockholders whose shares are held by brokers in street name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid
any cash dividends on our Common Stock and do not anticipate paying any cash dividends on our Common Stock in the foreseeable
future. We intend to retain future earnings to fund ongoing operations and future capital requirements of our business. Any future
determination to pay cash dividends will be at the discretion of our Board and will be dependent upon our financial condition,
results of operations, capital requirements and such other factors as our Board deems relevant. Our ability to pay cash dividends
is subject to limitations imposed by state law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unregistered Sales of Equity Securities
and Use of Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as set
forth elsewhere in this Annual Report or as previously disclosed in our filings with the SEC, we did not sell any equity securities during the year ended
December&nbsp;31,&nbsp;2020 in transactions that were not registered under the Securities Act. The issuance of such securities
were made in transactions exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 and/or Regulation
S promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_010"></A>ITEM 6. SELECTED FINANCIAL DATA.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a &ldquo;smaller
reporting company&rdquo; the information required by this item is not required to be provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_011"></A>ITEM 7. MANAGEMENT&rsquo;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>You should read
the following discussion and analysis of our financial condition and results of operations together with our audited annual consolidated
financial statements as of December 31, 2020 and December 31, 2019 and accompanying notes appearing elsewhere in this Annual Report.
This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The actual
results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including,
but not limited to, those set forth under &ldquo;Risk Factors&rdquo; and elsewhere in this Annual Report. All amounts are in U.S.
dollars and rounded.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage
biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. We have in-licensed LO2A,
a drug developed for the treatment of DES and other ophthalmological illnesses, including CCH and Sj&ouml;gren&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not generated
any material revenues from operations since our inception and we do not currently expect to generate any significant revenues
for the foreseeable future, primarily because LO2A is still in early clinical stage development in the markets and for the indications
we are currently targeting (DES with CCH and/or Sj&ouml;gren&rsquo;s). Our operating expenses have decreased from $3,170,000 in
the year ended December 31, 2019 to $2,442,000 in the year ended December 31, 2020. We may require significant additional capital
and, assuming we will have sufficient liquidity resources, we anticipate we will incur significantly higher costs in the foreseeable
future, in order to finance our current strategic plans, including the conduct of ongoing and future clinical trials as well as
further research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Results of Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Year Ended December
31, 2020 Compared to Year Ended December 31, 2019</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 9pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(434,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(492,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,008,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,678,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total operating costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,442,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,170,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Financial income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,487,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(280,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,929,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,450,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not generate
any revenues from operations during the years ended December 31, 2020 and 2019. We had no revenues primarily because (1) from
the time of the creditors&rsquo; arrangement in February 2015 until May 2015, when we (through Wize Israel and OcuWize) entered
into the LO2A License Agreement, Wize Israel did not conduct any business operations and (2) thereafter, currently, Wize Israel
is engaged primarily in research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Research and development
expenses.</I>&nbsp;Research and development expenses were $434,000 for the year
ended December 31, 2020, compared to $492,000 for the year ended December 31, 2019, a decrease of $58,000 or 11.8%. The decrease
in research and development expenses is primarily related to conducting the Sj&ouml;gren clinical trial in 2019, as compared to
only conducting a partial trial in 2020. For more information with respect to our expenses in connection with entering into the
LO2A License Agreement, please see Note 5 of the audited consolidated financial statements of Wize Israel appearing elsewhere in
this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>General and administrative
expenses.</I>&nbsp;General and administrative expenses were $2,008,000 for the
year ended December 31, 2020, compared to $2,678,000 for the year ended December 31, 2019, a decrease of $670,000 or 25%. The decrease
in general and administrative expenses during these periods is primarily related to decrease in share based payments of $442,000,
a decrease in professional services of $436,000 and in overseas travel expenses of $103,000, which were partially offset by an
increase in payroll and benefits of $364,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Financial income
(expense), Net</I>. Financial expense, net was $2,487,000 for the year ended December
31, 2020 compared to financial expense, net of $280,000 for the year ended December 31, 2019, a change of $2,207,000 or 788.2%.
The increase in financial expense, net during this period is primarily related to the increase in financial loss related to the
Bonus Agreements of $3,642,000, and decrease in gain from amortization of premium related to convertible loans of $1,257,000, which
were partially offset by an increase in gain from change in the fair value of marketable securities and sale of shares of $1,727,000
and decrease in loss from loss from extinguishment of convertible loans of $977,000 that occurred in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Net Loss</I>. As
a result of the foregoing, we incurred a net loss of $4,929,000
for the year ended December 31, 2020 compared to a net loss of $3,450,000 for the year ended December 31, 2019, an increase in
the net loss of $1,479,000 or 42.9%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidity and Capital Resources</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>General</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Liquidity is the
ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise
operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of
accounts receivable and accounts payable and capital expenditures. In the past several years, we financed our operations
primarily through equity and convertible debt financings in private placements, as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Working Capital
and Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020 and December 31, 2019, we had $247,000 and $718,000 in cash and cash equivalents, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020, we had $265,000 in outstanding short
term loans relating to the loan obtained by OcuWize from Bank Hapoalim. As of December 31, 2019, we had no outstanding loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2020 and December 31, 2019, we had $1,317,000
and $506,000 of working capital, respectively. As of December 31, 2020, we had an accumulated deficit of $39,218,000. The increase
in working capital was primarily due to an increase in marketable equity securities related to our acquisition of the Bonus Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
presents the major components of net cash flows (used in) provided by operating, investing and financing activities for the periods
presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,519,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,064,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net cash provided by investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">823,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Net cash provided by (used in) financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">197,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(360,000</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Year Ended December
31, 2020 Compared to Year Ended December 31, 2019</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December 31, 2020 and 2019, net cash used
in operating activities was $1,519,000 and $2,064,000, respectively. The decrease in net cash used in operating activities was
mainly due to (A) (i) a decrease in amortization of premium related to convertible loans of $1,257,000,(ii) an increase in loss
from recognition of mandatorily redeemable Series B Preferred Stock of $3,207,000, (iii) an increase in loss from revaluation of
mandatorily redeemable Series B Preferred Stock $597,000, (iv) an increase in loss from revaluation of a contingent obligation
with respect to future revenues of $435,000, (v) a decrease in other current assets of $251,000 and (vi) an increase in other accounts
payable of $524,000, which were partially offset by (B) (i) an increase in net loss of $1,479,000, (ii) an increase in gain on
marketable equity securities of $1,724,000,(iii) a decrease in stock based compensation of $572,000, (iv) a decrease in loss from
extinguishment of convertible loans of $977,000, (v) recognition of a gain from completion of milestone closing of $847,000 and
(vi) recognition of gain from settlement shares of $100,000 in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December 31, 2020 and 2019, net cash provided
by investing activities was $823,000 and none, respectively. The increase in net cash used in investing activities was mainly due
to an increase in proceeds from the sale of Bonus Shares of $821,000 which did not occur in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">For the years ended December 31, 2020 and 2019, net cash provided
by (used in) financing activities was $197,000 and $(360,000), respectively. The cash provided by financing activities in 2020
was due to a loan received from a bank on July 15, 2020 in an amount of $247,000 and the difference between the funds that were
raised in the Series B Purchase Agreement (as defined below) in the amount of $7,500,000 and the funds that were invested in connection
with the Bonus Agreements, which amounted to $7,400,000, which was partially offset by the payment of license fees to Resdevco
for the 2020 fiscal year in an amount of $150,000. Cash provided in 2019 from proceeds of $550,000 from issuance of shares and
warrants and cash used was from convertible loans repayment in an amount of $760,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Outlook</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to management
estimates, liquidity resources as of December 31, 2020 may not be sufficient to maintain our planned level of operations for the
next 12 months. However, for a long-term solution (for the sake of clarity, if the pending Cosmos Transaction is not consummated
as planned), we will need to seek additional capital for the purpose of implementing our business strategy and managing our business
and developing drug candidates. Conducting clinical trials and commercializing products is expensive and we will need to raise
substantial additional funds to achieve our strategic objectives. We have not yet generated any material revenues from our current
operations, and therefore we are dependent upon external sources for financing our operations. We will require significant additional
financing in the near future. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements
as well as the ability to obtain financing will depend on many factors, including those listed under &ldquo;RISK FACTORS &ndash;
Risks Related to our Business&rdquo; above. As of December 31, 2020, we had an accumulated deficit and a minimal amount of stockholders&rsquo;
equity. In addition, during the years ended December 31, 2019 and 2020, we reported losses and negative cash flows from operating
activities. Our management considered the significance of such conditions in relation to our ability to meet our current and future
obligations and determined that such conditions raise substantial doubt about each our ability to continue as a going concern.
As such, the report of our independent registered public accounting firm on the audited financial statements as of and for the
year ended December 31, 2020 contains an emphasis of matter paragraph regarding substantial doubt about our ability to continue
as a going concern. Substantial doubt about our ability to continue as a going concern could materially limit our ability to raise
additional funds through the issuance of new debt or equity securities or otherwise. Future reports on our financial statements
may also include an emphasis of matter paragraph with respect to our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no agreements, arrangements, or understandings
with any person to obtain funds through bank loans, lines of credit, or any other sources, other than the PIPE Agreements in connection
with the Bid Agreement. Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through
debt or equity financings, or by out-licensing our distribution rights. We cannot be certain that additional funding will be available
to us on acceptable terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate
one or more of our commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are addressing
our liquidity issues by implementing initiatives to raise additional funds as well as other measures that we believe will allow
us to continue as a going concern. Such initiatives may include monetizing of our assets, including the sale of the Bonus Shares
that we currently hold a result of the Bonus Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Notwithstanding
the foregoing, if we consummate the Cosmos Transaction, including the Offer, as currently contemplated to occur on or about March
9, 2021, our business, including outlook, future plans and corporate structure, will be materially impacted. For example, due to
the Cosmos Transaction and the contemplated distribution of CVRs, we expect that, following the Closing Date, we will focus on
the development of Cosmos&rsquo; Bitcoin mining business and that, with respect to our initiatives for the LO2A, we will focus
on achieving an LO2A Transaction as contemplated by the CVR Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Principal Financing
Activities.</I>&nbsp;The following is a summary of the equity and debt financings conducted by us in the past several years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>2019 Loan Amendment.</I>&nbsp;On
March 4, 2019, the Company and Wize Israel entered into an amendment (the &ldquo;2019 Amendment&rdquo;) to convertible loan agreements
that were originally entered into in 2016 and 2017 (the &ldquo;Loan Agreements&rdquo;) with Rimon Gold, Ridge and Fisher (&ldquo;Fisher&rdquo;,
and together with Rimon Gold and Ridge, the &ldquo;2019 Lenders&rdquo;). Pursuant to the 2019 Amendment, the maturity date under
the Loan Agreements was extended to May 31, 2019. The parties also agreed that the 2019 Lenders&rsquo; remaining investment
rights under one of the Loan Agreements to invest up to $512,800, in the aggregate, at $1.308 per share, and the Lender&rsquo;s
remaining investment rights under one of the other Loan Agreements to invest up to $663,400, in the aggregate, at $1.332 per share,
be extended from June 30, 2019 to November 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>April 2019 Purchase
of Existing Convertible Loans by Chief Executive Officer</I>. In April 2019 our Chief Executive Officer&nbsp;purchased directly
from Ridge all of the outstanding convertible loans held by Ridge in the amount of approximately&nbsp;$279,000&nbsp;for a total
of 265,531 shares of common stock issuable upon conversion of the loans and accompanying investment rights to purchase an additional
94,382 shares of common stock at&nbsp;$1.332&nbsp;per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>May 2019 Loan Amendment</I>.
On May 31, 2019, the Company and Wize Israel entered into an amendment to convertible loan agreements (the &ldquo;<B>May 2019
Amendment</B>&rdquo;) with Rimon Gold, Mobigo Inc., an entity owned by our Chief Executive Officer (&ldquo;<B>Mobigo</B>&rdquo;),
and Fisher. Pursuant to the May 2019 Amendment, the maturity dates under the Loan Agreements were extended to November 30, 2019.
The parties also agreed that the lenders&rsquo; investment rights under the Loan Agreements to invest up to $512,809, in the aggregate,
at $1.308 per share, and invest up to $663,446, in the aggregate, at $1.332 per share, be extended to May 31, 2021. As consideration
for extending the maturity date of the loans, the Company issued to the lenders two-year warrants to purchase an aggregate of
868,034 shares of common stock at an exercise price of $1.10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>November 2019 Loan
Amendment</I>. On November 29, 2019, the Company and Wize Israel entered into an amendment to convertible loan agreements with
Rimon Gold, Mobigo and Fisher (together, the &ldquo;Lenders&rdquo;). Pursuant to the Amendment, the Company repaid approximately
$760,000 of the $1,520,000 outstanding under the loans on November 29, 2019 and the Lenders agreed to convert the remaining outstanding
amounts of the loans at a later date. On December 13, 2019, the Company issued to the Lenders an aggregate of 2,816,196 shares
of common stock upon conversion of the loans at a reduced conversion price of $0.27 per share and issued warrants to purchase
an aggregate of 5,632,392 shares of common stock at an exercise price of $0.27. The warrants have a term of five years and will
be exercisable five days following the public announcement of positive clinical data results for LO2A. In addition, the parties
agreed that effective December 13, 2019, the exercise price or conversion price of all other convertible securities previously
issued to the Lenders in connection with the loans (the &ldquo;Existing Convertible Securities&rdquo;) shall be adjusted to $0.27
per share&nbsp;and that the aggregate number of shares of common stock issuable upon exercise or conversion of a Lender&rsquo;s
Existing Convertible Securities shall be reduced in accordance with the percent of such Lender&rsquo;s conversion of its outstanding
loan. In addition, it was agreed that in any case when the exercise price of the October 2018 Warrants is reduced as a result
of dilutive issuance to an exercise price lower than the exercise or conversion price of the Investment Rights granted under the
Loan Agreements, than the exercise or conversion price of the Investment Rights shall be reduced to the new 2018 Warrants exercise
price (&ldquo;New Exercise Price&rdquo;). As of December 31, 2019, the New Exercise Price of such Investment Rights was $0.16.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>December 2019 Private Placement</I>.
On December 20, 2019 the, Company entered into a securities purchase agreement (the &ldquo;<B>December 2019 Purchase Agreement</B>&rdquo;)
with an accredited investor. Pursuant to the December 2019 Purchase Agreement, the Company sold to the investor, in a private
placement, an aggregate of 2,037,037 shares of common stock for a purchase price of $0.27 per share, for aggregate gross proceeds
of $550,000. The Company also agreed to issue to the investor five-year warrants to purchase an aggregate of 4,074,047 shares
of common stock. The warrants will have an exercise price of $0.27 per share and will be exercisable five days following the public
announcement of positive clinical data results for LO2A. The warrants will be exercisable on a cashless basis in the event that,
six months after issuance, there is not an effective registration statement for the resale of the shares underlying the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The Bonus/LO2A
Transaction</I>. On January 9, 2020, the Company entered into (i) an Exchange Agreement (the &ldquo;Bonus Exchange Agreement&rdquo;),
with Bonus BioGroup Ltd. (&ldquo;Bonus&rdquo;), an Israeli company whose ordinary shares are traded on the Tel Aviv Stock Exchange
(&ldquo;TASE&rdquo;), and (ii) a Share Purchase Agreement (the &ldquo;Bonus Purchase Agreement&rdquo;, and together with the Bonus
Exchange Agreement, the &ldquo;Bonus Agreements&rdquo;) with Bonus. Pursuant to the Bonus Agreements, the Company agreed to grant
Bonus, in consideration for the issuance of 62,370,000 ordinary shares of Bonus (the &ldquo;LO2A Shares&rdquo;), the right to
receive 37% of future L02A-based products (&ldquo;LO2A Proceeds&rdquo;) (if any), which, as more fully defined in the Bonus Exchange
Agreement, include proceeds generated by the Company, Wize Israel and OcuWize, as a result of (i) the sale, license or other disposal
of products or other rights underlying the LO2A technology licensed to OcuWize under the License Agreement, as amended; and (ii)
a Sale Transaction, which, as more fully defined in the Bonus Exchange Agreement, includes the sale of shares or assets of Wize
Israel and/or OcuWize. In addition, if the Sale Transaction involves a change of control of the Company, Bonus will be entitled
to elect, to either remain with its right to 37% of the LO2A Proceeds or receive a one-time payment equal to 37% of the value
attributed to Wize Israel out of the total proceeds payable for the Company in such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Bonus
Purchase Agreement, the Company agreed to purchase 51,282,000 ordinary shares of Bonus (the &ldquo;PIPE Shares&rdquo;, and together
with the LO2A Shares, the &ldquo;Bonus Shares&rdquo;), for an aggregate purchase price of $7.4 million, which funds were deposited
into an escrow account (the &ldquo;Bonus Escrow Account&rdquo;), of which (i) $500,000 was to be paid to Bonus as an advance promptly
following execution of the Bonus Purchase Agreement, (ii) $3.2 million was to be released to Bonus concurrently with the closing
of the transactions contemplated by the Bonus Agreements in exchange for 50% of the PIPE Shares and (iii) $3.7 million was to
be released to Bonus upon the Milestone Closing (as defined in the Bonus Purchase Agreement), in exchange for 50% of the PIPE
Shares that were to be issued by Bonus and deposited into the escrow at the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June and July 2020,
we entered into a letter agreement (and amendment thereto) with Bonus, whereby, among other things, we agreed with Bonus on the
manner that a portion of the fees payable to the financial advisor in connection with the Bonus Agreements will be payable by
Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our obligation to
consummate the Milestone Closing was conditioned upon the satisfaction by Bonus of certain conditions, including the listing of
its ordinary shares (or, if an ADR Program is to be implemented by Bonus, the American Depositary Shares representing such ordinary
shares) on the Nasdaq Capital Market (or another superior tier of the Nasdaq market) (the &ldquo;Nasdaq Listing&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 29, 2020,&nbsp;we entered
into an Addendum (the &ldquo;Addendum&rdquo;) with Bonus, whereby, among other things, Bonus agreed to issue to Wize ordinary
shares of Bonus (the &ldquo;Bonus Shares&rdquo;), the total number of which consists of (i) the Milestone Settlement Shares, which,
as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$500,000 expressed in NIS (based on
the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement
Shares, the &ldquo;Settlement Shares&rdquo;), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained
by dividing US$350,000 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50. In consideration for the
Settlement Shares, Wize agreed to make certain amendments to the Bonus Agreements, including the following key modifications:
(i) Wize will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto, conduct the Milestone
Closing, which means that US$3.7 million were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus
Shares held in such escrow (the &ldquo;Nasdaq Milestone Shares&rdquo;) were released to Wize and to its former holders of Series
B Preferred Stock (the &ldquo;Former Series B Holders&rdquo;); (ii) Wize will waive approximately US$120,000 in liquidated damages
that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for Wize to
create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under
the Bonus Exchange Agreement, including certain related negative covenants. The closing occurred on December 29, 2020. It should
be noted that, in accordance with the obligations of Wize to the Former Series B Holders (see below), Wize has transferred 80%
of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of March 1, 2021, we
held 2,845,541 Bonus Shares, which based on the closing sale price of the Bonus Shares on the TASE as of such date, were worth
NIS 3, 656,520 (equivalent to $1,114,793).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Series B Preferred
Stock and Redemption.</I> In order to finance the transactions contemplated by the Bonus Purchase Agreement, on January 9, 2020,
the Company entered into a Securities Purchase Agreement (the &ldquo;Series B Purchase Agreement&rdquo;) with certain accredited
investors. Pursuant to the Series B Purchase Agreement, the Company sold to the investors, and the investors purchased from the
Company, in a private placement, an aggregate of 7,500 shares of newly created Series B Non-Voting Redeemable Preferred Stock,
par value $0.001 per share, of the Company (the &ldquo;Series B Preferred Stock&rdquo;) for a purchase price of $1,000 per share,
for aggregate gross proceeds under the Series B Purchase Agreement of $7.5 million, which funds were deposited into an escrow
account, of which (i) $500,000 was paid to the Bonus Escrow Account and $100,000 was paid to the Company to cover certain of its
transactions expenses, in each case, promptly following the execution of the Series B Purchase Agreement, and (ii) the remaining
$6.9 million were released to the Bonus Escrow Account upon the closing of the transactions contemplated by the Series B Purchase
Agreement (of which, as described above, $3.7 million shall be released upon the earlier of the Milestone Closing or upon written
consent of the holders of at least a majority of the Series B Preferred Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Certificate
of Designations of Series B Non-Voting Redeemable Preferred Stock (the &ldquo;Series B Certificate of Designations&rdquo;), the
Company designated 7,500 shares of preferred stock as Series B Preferred Stock. The Series B Preferred Stock were not convertible
into shares of common stock of the Company and had no voting powers, except as related to certain rights to protect the rights
and preferences of the Series B Preferred Stock and with respect to sales or dispositions of the Series B Preferred Stock at a
price per share below the Price Restriction. The Series B Preferred Stock entitled its holders to (i) 80% of the proceeds received
by the Company through future sales of the Bonus Shares issued to the Company under the Bonus Agreements and (ii) 80% of any cash
dividends received by the Company on such Bonus Shares. Under the Series B Certificate of Designations, the Company has the option
to redeem the Series B Preferred Stock at any time by distributing to holders of the Series B Preferred Stock (i) 80% of the Bonus
Shares then held by the Company and (ii) 80% of all dividends received by the Company but not yet paid to holders of the Series
B Preferred Stock (the &ldquo;Redemption Payment&rdquo;). The Company was required to redeem the Series B Preferred Stock through
payment of the Redemption Payment upon the earlier of (i) 60 days following the Nasdaq Listing, and (ii) December 28, 2020, unless
the Company elected to redeem the Series B Preferred Stock earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 19, 2020,&nbsp;the
Company closed (i) the Series B Purchase Agreement and issued and sold 7,500 shares of Series B Preferred Stock for aggregate
gross proceeds of $7.5 million and (ii) the Bonus Agreements, whereby the Company sold 37% of the LO2A Proceeds to Bonus as described
above and invested $7.4 million in Bonus, of which $3.7 million were released to Bonus at closing in consideration for 85,239,000
Bonus Shares and $3.7 million were deposited into an escrow account, and in consideration for their release upon the Nasdaq Listing,
an additional 28,413,000 Bonus Shares will be released to the Company (and, following the redemption described below, to the other
former holders of Series B Preferred Stock). However, as of September 30, 2020 and as of the date hereof, Bonus has not satisfied
the Nasdaq Listing condition and the Milestone Closing has not occurred. Accordingly, such amount is presented as restricted deposit
(asset) in the balance sheet, as of September 30, 2020 and the same amount is reflected as part of the liability with respect
to the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2020, the
Company elected to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares to
the holders of Series B Preferred Stock, representing 80% of the Bonus Shares then held by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Short Term Loan.
</I>On July 15, 2020, OcuWize entered into a loan agreement with Bank Hapoalim (the &ldquo;Bank&rdquo;), whereby the Bank extended
a loan in the principal amount of NIS 850,000 (approximately $247,000) (the &ldquo;2020 Loan&rdquo;). The 2020 Loan bears interest
at an annual rate of 5.45%, which will be paid in monthly payments. The 2020 Loan has a maturity date of January 15, 2020. In
order to secure its obligations and performance pursuant to the 2020 Loan, OcuWize recorded a pledge in favor of the Bank and
agreed that at any time, the value of all the assets in the bank account will not be less than NIS 1,700,000 (approximately $496,000).
In order to satisfy this requirement, the Company loaned to OcuWize a portion of the Bonus Shares held by it. The 2020 Loan was
fully repaid on January 14, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Warrant Exercises
and Exchanges</I>. On December 8, 2020, we entered into exchange agreements (the &ldquo;Exchange Agreements&rdquo;) with certain
holders of common stock purchase warrants issued by the Company in October 2018 to purchase an aggregate of 3,000,000 shares of
the Company&rsquo;s common stock (the &ldquo;2018 Warrants&rdquo;). Pursuant to the terms of the Exchange Agreements, the holders
of the 2018 Warrants surrendered their 2018 Warrants for cancellation and received, as consideration for such cancellation, an
aggregate of 3,000,000 restricted shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2020,
we entered into an agreement (the &ldquo;2020 Agreement&rdquo;) with certain holders representing a majority of the then outstanding
2018 Warrants. Pursuant to the terms of the 2020 Agreement, we agreed to voluntarily reduce the exercise price of the 2018 Warrants
to $0.001 per share until January 7, 2021, after which such exercise price shall revert back to $0.16 per share. As a result of
the adjustment to the exercise price of the 2018 Warrants, the exercise price of the warrants issued in November 2017 (the &ldquo;2017
Warrants&rdquo;), the placement agent warrants issued in October 2018 (the &ldquo;2018 Placement Agent Warrants&rdquo;), the warrants
issued to certain lenders in May 2019 (the &ldquo;May 2019 Warrants&rdquo;), the warrants issued to certain lenders in November
2019 (the &ldquo;November 2019 Warrants&rdquo;), the warrants issued to certain purchasers from the private placement in December
2019 (the &ldquo;December 2019 Warrants&rdquo;) and certain investment rights issued in January 2017 (the &ldquo;Investment Rights&rdquo;)
were also adjusted to reflect a reduced exercise price of $0.001 per share (collectively, the &ldquo;Warrant Adjustments&rdquo;).
As a result of the Warrant Adjustments, on December 29, 2020 an aggregate of 13,332,657 were issued as a result of the exercise
of such warrants, each on a cashless basis. Such warrant exercises also included warrants beneficially owned by our Chief Executive
Officer, Noam Dannenberg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the foregoing,
as of March 1, 2021, we no longer have any warrants or investment rights outstanding except 26,287 warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Off-Balance Sheet Arrangements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020 and December 31, 2019, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation
S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recently Issued Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information with
respect to recent accounting pronouncements, see Note 2u to our audited consolidated financial statements for the year
ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Critical Accounting Policies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Contingent obligation with respect to future revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company&rsquo;s contingent
obligation to payment of 37% of the future LO2A Proceeds, if any, was accounted for as long-term debt in accordance with the provisions
of Accounting Standards Codification (&ldquo;ASC&rdquo;) 470-10-25, &ldquo;Sales of Future Revenues or Various other Measures of
Income,&rdquo; which relates to cash received in exchange for payments of a specified percentage or amount of revenue or other
measure of income of a particular product line, business segment, trademark, patent, or contractual right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>






<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Such repayment obligations are
contingent upon the receipt by the Company of any future proceeds from LO2A sales, license or other, as described in Note 5 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company elected to measure
the contingent payment obligation in its entirety, at its fair value (the &ldquo;Fair Value Option&rdquo;) in accordance with ASC
825-10, &ldquo;Financial Instruments&rdquo; due to the variable and contingent nature of the repayment provisions of such financial
liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The fair value of such liability
was measured upon its initial recognition at its fair value, based on the difference between the fair value of the marketable securities
received by the Company, less the amount of cash paid by the Company. In subsequent periods, the fair value of the liability for
contingent payment obligation is based on management estimate. As of December 31, 2020, the Company revalued the liability to its
fair value with the assistance of an external valuation specialist, pursuant to the Company&rsquo;s estimations and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company has determined that
the inputs used in measuring the fair value of the contingent payment obligation fall within Level 3 in the fair value hierarchy
which involves significant estimations and assumptions regarding any projected future proceeds from the LO2A, including, among
others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product into the U.S. market
- 12%, the patent expiration date (2038), the operational profit estimated rate - 26%, the probabilities for FDA phases approvals,
and the risk-adjusted rate for discounting future cash flows - 20.3%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company has determined that
the inputs used in measuring the fair value of the contingent payment obligation fall within Level 3 in the fair value hierarchy
which involves significant estimates and assumptions including, among others, any projected future proceeds from the LO2A, the
risk-adjusted rate for discounting future cash flows and other relevant assumptions, see Note 10.&nbsp;&nbsp;Actual results could
differ from the estimates made. Changes in fair value (including the component related to imputed interest), would be included
in the consolidated statements of comprehensive loss as part of financial income (loss) under the heading &ldquo;Changes in fair
value of contingent payment obligation with respect to future revenues.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_012"></A>ITEM 7A. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a smaller reporting
company, we have elected not to provide the disclosure required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_013"></A>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All information required
by this item is included in Item 15 of Part IV of this Annual Report and is incorporated into this item by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_014"></A>ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_015"></A>ITEM 9A. CONTROLS AND PROCEDURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evaluation of Disclosure Controls and
Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with
the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure
controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered
by this Annual Report. Based on such evaluation, our Acting Chief Executive Officer and Chief Financial Officer have concluded
that as of&nbsp;December 31, 2020, our disclosure controls and procedures are designed at a reasonable assurance level and are
effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under
the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of
the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including
our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management&rsquo;s Report on Internal
Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is
responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance
regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles. &nbsp;Internal&nbsp;control over financial reporting includes those policies and
procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions
and dispositions of the assets of our company; (ii) provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of our management and directors; and (iii) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&rsquo;s
assets that could have a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. &nbsp;Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Management assessed
our internal control over financial reporting as of December 31, 2020, the end of our fiscal year. &nbsp;Management based its
assessment on criteria established in&nbsp;<I>Internal Control&mdash;Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO)</I>. &nbsp;Management&rsquo;s assessment included evaluation of such elements
as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and
our overall control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our assessment,
management has concluded that our internal control over financial reporting was effective, as of the end of the fiscal year, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external reporting purposes in accordance with generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Report of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report
does not include an attestation report of the Company&rsquo;s independent registered public accounting firm regarding internal
control over financial reporting. Management&rsquo;s report was not subject to attestation by the Company&rsquo;s independent
registered public accounting firm pursuant to the rules of the SEC, applicable to smaller reporting companies that permit the
Company to provide only management&rsquo;s report in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Internal Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes
in our internal control over financial reporting identified in management&rsquo;s evaluation pursuant to Rules 13a-15(d) or 15d-15(d)
of the Exchange Act during the fourth quarter of 2020 that materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations on Effectiveness of Controls
and Procedures and Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In designing and evaluating
the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls
and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control
objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect
the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible
controls and procedures relative to their costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_016"></A>ITEM 9B. OTHER INFORMATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bid Agreement contains an obligation that Wize will establish
an incentive compensation program with respect to 40,000,000 shares of our common stock, to be granted promptly following the Closing
Date, in the form of performance-based RSUs, performance rights or indeterminate rights based on the performance milestone criteria
and allocation set in the Bid Agreement (the &ldquo;Post-Closing Incentive Plan&rdquo;), 20 million of which are to be granted
to personnel specified by Wize prior to the Closing Date and the remainder to be granted to personnel of Cosmos. In this respect,
it should be noted that our Board of Directors determined to specify to Cosmos that each of Mr. Danenberg and Mr. Eisenberg would
receive, once such Post-Closing Incentive Plan is established, 8,960,000 and 7,240,000 performance-based RSUs (or other rights)
pursuant to the Post-Closing Incentive Plan, respectively, and that Mr. Danenberg will have discretion to direct Cosmos to whom
to award the balance. Under the Bid Agreement, such grants will be made promptly, and in any event, within 90 days, following the
Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_017"></A>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_018"></A>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS
AND CORPORATE GOVERNANCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is
certain information with respect to the individuals who are our directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 61%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Sieczkarek</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the
    Board</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Belkin</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yossi Keret</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Zarzewsky</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Danenberg</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial
    Officer, Treasurer and Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Experience</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a
brief account of the education and business experience during at least the past five years of each director and executive officer,
indicating the principal occupation during that period, and the name and principal business of the organization in which such
occupation and employment were carried out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Mark Sieczkarek
</B>has served as our Chairman since April 23, 2019. Mr. Sieczkarek has served as Chief Executive Officer of Fe3 Medical Inc.,
now Bria Medical, since 2015 and as a director of Orange Twist LLC since 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">From
2015 through 2018, Mr. Sieczkarek served as Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc. He has served
as Chief Executive Officer and Chairman of Solta Medical, Inc. from 2006 until its acquisition by Valeant Pharmaceuticals International,
Inc. in 2014. From 2003 to 2011, Mr. Sieczkarek served as Chief Executive Officer of Conceptus, Inc. prior to its acquisition
by Bayer Pharmaceuticals. From 1995 to 2003, Mr. Sieczkarek held multiple roles of increasing commercial responsibility at Bausch
&amp; Lomb, including President of Europe and the Americas. He has also held senior executive level positions with KOS Pharmaceuticals,
various subsidiaries of Bristol Myers-Squibb, and Sanofi Diagnostics Pasteur. Mr. Sieczkarek earned an MBA in Finance from Canisius
College in Buffalo, New York and a BS in Accounting from the State University of New York at Buffalo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Michael Belkin,
M.A., M.D.</B>&nbsp;Michael Belkin has served on our board since July 1, 2013. Dr.
Belkin is, and has been since 1981, a Professor, and since 2010, a Professor Emeritus, of Ophthalmology at Tel Aviv University
in Tel Aviv, Israel, and the Director of the Ophthalmic Technologies Laboratory at the university&rsquo;s Eye Research Institute
at the Sheba Medical Center since 1997. Since 2006, Dr. Belkin also serves as a Senior Consultant to the Eye Research Institute
at the Singapore National Eye Institute. He was awarded a master&rsquo;s degree in natural sciences by Cambridge University, England,
and received a doctorate in medicine from the Hebrew University of Jerusalem. Dr. Belkin previously served as Director of Research,
Development and Non-Conventional Warfare Medicine in the Israel Defense Forces Medical Corps. He also established and was the first
full-time Director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology
and the President of the Israel Society of Eye and Vision Research, of which he was one of the founders. Dr. Belkin is an author
of over 250 scientific publications and more than 35 patents. He is an internationally recognized eye researcher and has received
various research awards. He is an entrepreneur and advisor of several ophthalmic companies in the fields of lasers, optics, ophthalmic
devices, pharmaceutics and biotechnology. One of hisinventions, the ExPRESS miniature glaucoma shunt, is currently used worldwide.
He established a few more startups based on his inventions such as Belkin laser, NovaSight and SpringVision. He serves as chairman
and member of various international and local scientific and professional committees as well as scientific journals&rsquo; editorial
boards. Dr. Belkin&rsquo;s qualifications to serve on our Board include his expertise in ophthalmic medical research, his medical
experience, and his experience as an advisor to several ophthalmic companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Yossi Keret</B>.
Yossi Keret has served on our board since the closing of the 2017 Merger. Mr. Keret is serving as Chief Executive Officer, and
Director of Nanorobotics LTD as of March 2019. Mr. Keret has served as the Chief Executive Officer, Managing Director and Director
of Weebit-Nano Ltd.&nbsp;(ASX:WBT) from August 2015 to October 2017. From October 1996 to October 2015, Mr. Keret served as the
Chief Financial Officer of numerous public and private companies, including Eric Cohen Books Ltd. &amp; Burlington English Ltd.,
Daimler Financial Services Israel Ltd., Pluristem Life Systems Inc. (NASDAQ:PST), M.L.L. Software and Computers Industries Ltd.
(TASE:MLL), Internet-Zahav Group, Ltd. (NASDAQ:IGLD) and Top Image Systems Ltd. (NASDAQ:TISA). Mr. Keret commenced his career
at Kost Forer Gabbay &amp; Kasierer, registered public accounting firm, a member firm of Ernst &amp; Young Global (&ldquo;<B>EY</B>&rdquo;).&nbsp;
Mr. Keret holds a B.A. from Haifa University in Economics and Accounting and is a Certified Public Accountant in Israel. Mr. Keret&rsquo;s
qualifications to serve on our Board include his expertise in financial matters and his serving as the Chief Financial Officer
in numerous private and public companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Joseph Zarzewsky</B>.
Joseph Zarzewsky has served on our board since the closing of the 2017 Merger. Mr. Zarzewsky has served as the Vice President
of Business Development at the Mitrelli Group (&ldquo;<B>Mitrelli</B>&rdquo;) since June 2010.&nbsp; He has served as the Chairman
of &ldquo;SMAD&rdquo;, a joint venture between Mitrelli and the Harbin Government, China, since June 2011.&nbsp; Mr. Zarzewsky
has also served as the Chairman of the Investment Committee of the Harbin Israel Fund since 2012. He has also previously served
as the Vice President of marketing at Clal Insurance Enterprises Holdings Ltd. (TASE: CLIS) and as the Vice President of Marketing
for the Israel Postal Authority. Mr. Zarzewsky has served as a director of Excellence Underwriter House Ltd. since 2007. In 2008,
he was appointed as the Honorary Economic Advisor of the Harbin Government, China. In addition, in June 2012, he was honored as
an Honorary Citizen of Harbin, China. Mr. Zarzewsky holds an MA in Commercial Law from both the University of Tel Aviv and University
of California, Berkeley.&nbsp; Mr. Zarzewsky&rsquo;s qualifications to serve on our Board include his expertise in financial matters.
Mr. Zarzewsky also serves as a member of the board of directors of Brimag Digital Age Ltd. (TASE: BRMG) and CollPlant Biotechnologies
Ltd. (NASDAQ: CLGN).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>Noam
Danenberg</B>. Noam Danenberg has served as our Chief Executive Officer since
April 23, 2019. He served as our Chairman and director since November 7, 2018 until April 23, 2019. He served as our Chief Operating
Officer from the closing of the 2017 Merger until November 7, 2018. Mr. Danenberg has served as a strategic advisor of Wize Israel
since April 2015. Mr. Danenberg co-founded Panmed Inc. in January 2014, a&nbsp;biomed investment company. Since 2000, Mr. Danenberg
has provided private investment consulting services to numerous private and public companies through his wholly owned company,
N. Danenberg Holding (2000) Ltd. From May 2014 to January 2015, Mr. Danenberg served as a director of Go.D.M. Investments Ltd.
(TASE: GODM). From 2000 to 2012, Mr. Danenberg served as an investment advisor at International Software Consulting Limited and
from 2004 to 2008 he served as the Chairman and CEO of Fitracks Inc. From 2006 to 2012, he also served as the Chairman of the Board
of Hawk Medical Technologies Ltd. Mr. Danenberg holds a B.B.A. from the European University in Antwerp, Belgium and an M.B.A. from
the Boston University Brussels Graduate Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>Or
Eisenberg</B>. Or Eisenberg has served as our Chief Financial Officer, Treasurer and Secretary since the closing of the 2017 Merger.
He served as our Acting Chief Executive officer since November 15, 2017 until April 23, 2019. Mr. Eisenberg has served as the
Chief Financial Officer and Acting Chief Executive Officer of Wize Israel since March 2015. From October 2010 to December 2014,
he served as the controller of the Katzir Fund Group. From March 2013 to December 2014, he served as either an external controller
or Chief Financial Officer of a number of public companies whose shares are listed for trading on the TASE. From October 2007
to October 2010, Mr. Eisenberg was an accountant at Kost Forer Gabbay &amp; Kasierer, a registered public accounting firm, a member
firm of EY. Mr. Eisenberg holds a B.A. from Haifa University in Economics and Accounting and is a Certified Public Accountant
in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Scientific Advisory Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a Scientific
Advisory Board consisting of internationally recognized scientists who advise us on the scientific and technical aspects of our
business. The Scientific Advisory Board reviews and consults with respect to projects and occasionally assesses the value of new
technologies and developments. In addition, individual members of the Scientific Advisory Board meet with us periodically to provide
advice in their particular areas of expertise. The Scientific Advisory Board consists of the following members:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Professor Penny
Asbell, MD</B>. joined our Scientific Advisory Board in July 2018. She is a Key Opinion Leader in the treatment of DES. As a principal
investigator in countless clinical studies sponsored by the National Institute of Health&rsquo;s National Eye Institute and by
industry sponsors, Dr. Asbell has participated in the development of pharmaceuticals that have included pivotal treatments for
ocular conditions including dry eyes. In June 2018, Dr. Asbell was named to her current position as the Barrett G. Haik Endowed
Chair for Ophthalmology in the College of Medicine and Director of the Hamilton Eye Institute at the University of Tennessee Health
Science Center (&ldquo;<B>UTHSC</B>&rdquo;). Dr. Asbell joined UTHSC from the Icahn School of Medicine at Mount Sinai (&ldquo;<B>ISMMS</B>&rdquo;)
in New York, where she is a professor of Ophthalmology and director of the Cornea Service and of the Cornea Clinical and Research
Fellowships, which she initiated. She is the vice chair of the ISMMS Appointment and Promotion Committee, medical director of
the Faculty Practice for Ophthalmology, and system vice chair for Academic Affairs for the Department of Ophthalmology. She established
Mount Sinai&rsquo;s Lowenstein Foundation Sjogren&rsquo;s Center to provide multi-specialty care for patients with dry eyes and
associated systemic problems and founded the Ocular Inflammatory Biomarker Laboratory at Mount Sinai that is actively seeking
validated biomarkers for ocular surface disease. Dr. Asbell has authored and co-authored hundreds of articles, authored 25 book
chapters, and has presented over 200 lectures and courses. In addition, she has been extensively interviewed by the New York Times,
CBS News, Good Morning America, Bloomberg News, CNN, and many other nationally broadcasted events. She is a world-renowned educator
and has lectured throughout the United States, Europe, Japan, India, and South America. Dr. Asbell has served on the board of
directors of the Tear Film and Ocular Surface Society, the Cornea Society, the Eye Bank for Sight Restoration and Program Committee-Cornea
for ARVO. She is currently the Deputy Editor of Eyewiki which is sponsored by the American Academy of Ophthalmology, Editor in
Chief of ECL, the official journal of CLAO, and Section Editor of Cornea for BMC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Dr. Joseph Tauber,
MD.&nbsp;</B>Dr. Tauber joined our Scientific Advisory Board in March 2018. He has been a principal investigator in over 125 research
studies of high-risk corneal transplantation, inflammation and allergic eye diseases, corneal infectious diseases and numerous
studies related to DES. Dr. Tauber has written five book chapters and over 60 articles in ophthalmology medical journals. He has
been awarded the Heed Ophthalmic Foundation Fellowship Award and the National Eye Institute Individual NRSA Award. Dr. Tauber
received his doctorate from Harvard Medical School, his training in internal medicine at Beth Israel Hospital and in ophthalmology
at Tufts-New England Medical Center. He has served as Clinical Professor of Ophthalmology at Kansas University School of Medicine
and University of Missouri-Kansas City School of Medicine. Dr. Tauber specializes in anterior segment surgery, corneal transplantation,
the treatment of corneal and external diseases and laser vision correction procedures. A board-certified ophthalmologist, Dr.
Tauber is the Founder of Tauber Eye Center in Kansas City, Missouri.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family
relationships among our executive officers and directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been no
events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation
of the ability and integrity of any of our directors, executive officers, or control persons during the past ten years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors are appointed
by our Board or elected by our shareholders to hold office until such director&rsquo;s successor is elected and qualified or until
such director&rsquo;s earlier resignation or removal. &nbsp;Annual meetings of the stockholders, for the election of directors
to succeed those whose terms expire, are to be held at such time each year as designated by our Board, which date shall be within
13 months of the last annual meeting of stockholders. &nbsp;Officers are elected by the Board of Directors, which is required to
consider that subject at its first meeting after every annual meeting of stockholders. &nbsp;Each officer holds his office until
his successor is elected and qualified or until his earlier resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not aware of
any legal proceedings in which any of our directors, officers or affiliates, any owner of record or beneficially of more than five
percent of any class of our voting securities, or any associate of any such director, officer, or affiliate of our company, or
security holder is a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;`</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not adopted
a code of ethics that applies to our officers, directors and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our securities are not listed on a national securities exchange
or in an inter-dealer quotation system which has requirements that directors be independent. However, we have adopted the independence
standards of the Nasdaq to determine the independence of our directors and those directors serving on any committee. These standards
provide that a person will be considered an independent director if he or she is not an officer of the company and is, in the view
of the company&rsquo;s board of directors, free of any relationship that would interfere with the exercise of independent judgment.
Our Board has determined that each of Mark Sieczkarek, Dr. Michael Belkin, Yossi Keret and Joseph Zarzewsky are independent as
defined under the rules promulgated by the Nasdaq. Other than Mr. Zarzewsky, none of the independent directors has any relationship
with us besides serving on our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 19, 2017, Wize
Israel entered into a finder&rsquo;s fee agreement with Harbin Israel (Trading) Ltd., an affiliate of Mr. Zarzewsky, pursuant to
which Mr. Zarzewsky will receive a 5% royalty on all of Wize Israel&rsquo;s revenues to the extent such revenues are earned from
relationships initiated by Mr. Zarzewsky and agreed to by Wize Israel. The term of the agreement is for 12 months unless earlier
terminated. Either party may terminate upon twenty-one days&rsquo; notice. Mr. Zarzewsky introduced us to the Chinese Distributor.
See &ldquo;Item 1. BUSINESS &mdash; Marketing, Sales and Distribution&rdquo; above. Our Board considered these relationships and
determined that they would not interfere with Mr. Zarzewsky&rsquo;s exercise of independent judgment in carrying out the responsibilities
of a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined
that each of the directors is qualified to serve as a director of the Company based on a review of the experience, qualifications,
attributes and skills of each director. In reaching this determination, we have considered a variety of criteria, including, among
other things: character and integrity; ability to review critically, evaluate, question and discuss information provided, to exercise
effective business judgment and to interact effectively with the other directors; and willingness and ability to commit the time
necessary to perform the duties of a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined
that each of the directors is qualified to serve as a director of the Company based on a review of the experience, qualifications,
attributes and skills of each director. In reaching this determination, we have considered a variety of criteria, including, among
other things: character and integrity; ability to review critically, evaluate, question and discuss information provided, to exercise
effective business judgment and to interact effectively with the other directors; and willingness and ability to commit the time
necessary to perform the duties of a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Meeting Attendance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2020, our Board held 7 meetings. &nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Audit Committee
and Audit Committee Financial Expert</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our Audit Committee are Yossi Keret and Joseph
Zarzewsky. Our Board has determined that Yossi Keret is an &ldquo;audit committee financial expert&rdquo; as set forth in Item
407(d)(5) of Regulation S-K and that all members of the Audit Committee are &ldquo;independent&rdquo; as defined by the rules of
the SEC and the Nasdaq rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our Compensation Committee are Yossi Keret, Dr.
Michael Belkin and Joseph Zarzewsky. The Board of Directors has determined that all of the members of the Compensation Committee
are &ldquo;independent&rdquo; as defined by the rules of the SEC and the Nasdaq rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other Committees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of our small
size, our Board carries out the duties of the nominating and corporate governance committee. In selecting nominees for directorships,
our Board considers a broad range of characteristics related to qualifications, background and diversity of nominees based on our
current business needs. &nbsp;Our Board has not adopted written guidelines regarding nominees for director. &nbsp;There have been
no material changes to the procedures by which security holders may recommend nominees to our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Leadership Structure and Role
in Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
our Bylaws, our Board appoints our officers, including our Chief Executive Officer, Chief Financial Officer, and such other officers
as our Board may appoint from time to time. Mr. Mark Sieczkarek currently serves as our Chairman of the Board, Mr. Noam Danenberg
currently serves as our Chief Executive Officer and Mr. Or Eisenberg currently serves as our Chief Financial Officer, Treasurer
and Secretary. Our Board periodically considers whether changes to our overall leadership structure are appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chairman is responsible
for chairing meetings of our Board. Our Bylaws provide that if our Chairman is unable to preside at meetings of our Board, our
Chief Executive Officer, if such officer is a director, shall preside at such meetings. Our Chairman is also responsible for chairing
meetings of stockholders. In his absence, our Board may appoint another party to chair the stockholders&rsquo; meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Risk is inherent with
every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including
strategic risks, enterprise risks, financial risks, regulatory risks, and others. Management is responsible for the day-to-day
management of risks the company faces, while our Board, as a whole, has responsibility for the oversight of risk management. In
its risk oversight role, our Board has the responsibility to satisfy itself that the risk management processes designed and implemented
by management are adequate and functioning as designed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board believes
that full and open communication between management and our Board is essential for effective risk management and oversight. Senior
management attends Board of Directors meetings and is available to address any questions or concerns raised by our Board on risk
management-related and any other matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Communications by Stockholders with
Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We encourage stockholder
communications to our Board and/or individual directors. &nbsp;Stockholders who wish to communicate with our Board or an individual
director should send their communications to the care of Secretary, Wize Pharma, Inc., 24 Hanagar Street, Hod Hasharon, Israel
4527708. &nbsp;The Secretary will maintain a log of such communications and will transmit as soon as practicable such communications
to the Chairman of the Board or to the identified individual director(s), although communications that are abusive, in bad taste
or that present safety or security concerns may be handled differently, as determined by the Secretary.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Attendance at Annual Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will make every
effort to schedule our annual meeting of stockholders at a time and date to accommodate attendance by directors taking into account
the directors&rsquo; schedules. &nbsp;While all directors are encouraged to attend our annual meeting of stockholders, there is
no formal policy as to their attendance at annual meetings of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Delinquent Section 16(a) Reports</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 16(a) of the
Exchange Act requires our directors, executive officers and persons who own more than 10% of our Common Stock to file with the
SEC reports of ownership and changes in ownership of our Common Stock. Our directors, executive officers and greater than 10%
beneficial owners of our Common Stock are required by SEC regulation to furnish us with copies of all Section&nbsp;16(a) reports
they file. Based solely upon information furnished to us and contained in reports filed with the SEC, we believe that all Section&nbsp;16(a)
reports of our directors, executive officers and greater than 10% beneficial owners were filed timely for the fiscal year ended
December 31, 2020 except that Rimon Gold filed one late Form 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_019"></A>ITEM 11. EXECUTIVE COMPENSATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth information concerning the annual compensation awarded to, earned by, or paid to the following named executive officers
for all services rendered in all capacities to us for the years ended December 31, 2020 and 2019. The amounts set forth for Mr.
Eisenberg and Mr. Danenberg were originally denominated in NIS and were translated into U.S. Dollars at the average current exchange
rate for each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name And Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<BR> ($) (1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus&nbsp;<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<BR> Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Awards<BR> ($)
    (2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other Compensation ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%; text-align: left; text-indent: -10pt; padding-left: 10pt">Or Eisenberg,</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">228,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;199,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">427,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief&nbsp;Financial
    Officer&nbsp;and former Acting Chief Executive Officer</FONT> (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">295,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam
    Danenberg,<BR> Chief Executive Officer, former Chairman, Chief Operating Officer and Strategic&nbsp;Advisor&nbsp;(5)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">199,000</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">422,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">304,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts shown represent consulting fees earned or paid during the fiscal year.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects the aggregate grant date fair value of option awards granted during the relevant fiscal year calculated in accordance with Financial Accounting Standards Board (&ldquo;FASB&rdquo;) ASC Topic 718.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount represents car allowance.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Eisenberg was appointed as our Acting Chief Executive Officer and Chief Financial Officer on November 16, 2017 in connection with the 2017 Merger. He served as the Acting Chief Executive Officer and Chief Financial Officer of Wize Israel since 2015. Mr. Eisenberg resigned from his position as the Acting Chief Executive Officer in April 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Danenberg was appointed as our Chief Executive Officer in April 2019. He served as our Chairman and director since November 7, 2018 until April 23, 2019. Mr. Danenberg resigned from his position as our Chief Operating Officer, Chairman and Strategic Advisor in November 2018.&nbsp;&nbsp;The services of Mr. Danenberg were provided via N. Danenberg Holdings (2000) Ltd. (&ldquo;Danenberg Holdings&rdquo;), a services company wholly owned by Mr. Danenberg, pursuant to the terms of the services agreement by and between Wize Israel and Danenberg Holdings.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Executive Employment Agreements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth
below, we have not entered into any employment agreements with the named executive officers listed in the table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Employment
Agreement with Or Eisenberg</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Mr.
Eisenberg has served as Wize Israel&rsquo;s Chief Financial Officer and Acting Chief Executive Officer since March 2015 and as
our Financial Officer since the 2017 Merger. Mr. Eisenberg&rsquo;s employment agreement is with Wize Israel. On August 21, 2018,
Wize Israel entered into a restated employment agreement with Mr. Eisenberg, which provides for an initial term of three years,
subject to automatic one year renewals thereafter unless the agreement is terminated in accordance with its terms. Mr. Eisenberg
is entitled to receive an annual base salary of 480,000 NIS ($147,014), subject to adjustment by the Board of Directors of Wize
Israel. The salary shall be increased by 10% upon each of the listing of the Company&rsquo;s securities on a national exchange
and the completion of the Phase IV study randomized, double-masked study of LO2A versus Alcon&rsquo;s Systane<SUP>&reg;&nbsp;</SUP>Ultra
UD. The salary shall also be increased by NIS 10,000 upon&nbsp;<U>each</U>&nbsp;final closing of a financing of the Company or
Wize Israel during the course of Mr. Eisenberg&rsquo;s employment in which the Company receives net proceeds of $4,000,000. Mr.
Eisenberg&rsquo;s salary was so increased following consummation of the Company&rsquo;s October 2018 private placement and the
Series B Purchase Agreement. He is also eligible to receive a transaction bonus in connection with certain material transactions,
subject to the Company&rsquo;s clawback rights, as outlined in the employment agreement. In addition, he is eligible to participate
in all health insurance and benefit plans offered by the Company to its executives and is entitled to the reimbursement of business
expenses and a vehicle allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the event Mr. Eisenberg&rsquo;s employment is terminated by Wize Israel other than for Cause or if he resigns for Good Reason (as
such terms are defined in his employment agreement), he will be entitled to receive severance benefits under Israeli law as well
as his salary for the remainder of the term of the agreement. In the event Mr. Eisenberg is terminated for Cause, he will be not
entitled to receive any payments other than such amounts owing and outstanding prior to the termination of his employment. Mr.
Eisenberg is subject to non-competition and non-solicitation restrictions throughout his employment and for a period of six months
following the termination of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Services
Agreement with Noam Danenberg</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
August 20, 2018, Wize Israel entered into a restated consulting services agreement with N. Danenberg Holdings (2000) Ltd. (the
&ldquo;<B>Consulting Company</B>&rdquo;) and Noam Danenberg, the Chief Operating Officer of the Company at the time and the Company&rsquo;s
current Chief Executive Officer. The Consulting Services Agreement provides that Mr. Danenberg will provide consulting services
including, but not limited to, general strategic consulting services around business development and fund raising for an initial
term of three years. As payment for the consulting services, the Company will pay the Consulting Company 40,000 NIS ($10,921) per
month subject to adjustment by the Board of Wize Israel. In addition, the Consulting Company will be eligible to receive a transaction
bonus in connection with certain material transactions, subject to the Company&rsquo;s clawback right, as outlined in the consulting
services agreement. The consulting fees shall be increased by 10% upon each of the listing of the Company&rsquo;s securities on
a national exchange and the completion of the Phase IV study randomized, double-masked study of LO2A versus Alcon&rsquo;s Systane<SUP>&reg;&nbsp;</SUP>Ultra
UD. The consulting fees shall also be increased by NIS 10,000 upon&nbsp;each&nbsp;final closing of a financing of the Company or
Wize Israel during the course of the services agreement in which the Company receives net proceeds of $4,000,000. The consulting
fees were so increased following consummation of the Company&rsquo;s October 2018 private placement and the Series B Purchase Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the event that the Consulting Company terminates the engagement for Good Reason as defined in the consulting services agreement,
it is entitled to receive the balance of the remaining service fees for the term of the agreement. In the event that Wize Israel
terminates the agreement for Cause as defined in the consulting services agreement, the Consulting Company will not be entitled
to receive any payments other than amounts owing and outstanding prior to the termination of the agreement. Following the initial
three year term, the agreement may be terminated by either party upon 120 days prior written notice. The Consulting Company and
Mr. Danenberg are subject to non-competition and non-solicitation restrictions throughout the engagement and for a period of six-months
following the termination of the consulting services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
November 7, 2018, the consulting agreement was amended in connection with Mr. Danenberg&rsquo;s resignation as Chief Operating
Officer and appointment to the Board and as Chairman of the Board. The material terms of the agreement were not revised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Chairman
Agreement with Mark Sieczkarek</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with Mr. Sieczkarek&rsquo;s appointment, the Company and Mr. Sieczkarek entered into a Chairman Agreement (the &ldquo;Chairman
Agreement&rdquo;) whereby Mr. Sieczkarek shall receive 202,399 restricted stock units and options to purchase 102,222 shares of
the Company&rsquo;s common stock at an exercise price of $2.00 per share (the &ldquo;Chairman Awards&rdquo;). The Chairman Awards
shall vest as follows: one-eight (1/8) on the effective date of the Chairman Agreement and subsequently in seven equal quarterly
installments commencing July 1, 2019. The Chairman Agreement has an initial term of two years and provides that in the event of
a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as of that date.
The Chairman Agreement also contains standard representations and warranties regarding confidential information, non-competition
and non-solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Outstanding Equity Awards at Fiscal
Year-End</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables
provides information regarding all outstanding equity awards for our named executive officers as of December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unexercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR>
 Exercise<BR>
 price ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration<BR> Date</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">Or Eisenberg (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.59</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">4/4/2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Noam Danenberg (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/4/2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Mark Sieczkarek (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,777</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">14/5/2026</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These options were granted on April 1, 2018 and vested as follows: the options vests in twelve (12) consecutive equal installments over a three year period commencing the April 1, 2019.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These options were granted on April 1, 2018 and vested as follows: the options vests in twelve (12) consecutive equal installments over a three year period commencing the April 1, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 5%; text-align: left">(3)</TD><TD STYLE="text-align: justify; width: 95%">These options were granted on May
                                         15, 2019 and vested as follows: eight (8) installments commencing May 15, 2019 and subsequently
                                         in seven equal quarterly installments commencing May 15, 2019.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
provides information regarding the total compensation that we paid or awarded to our directors during the year ended December 31,
2020. Mr. Danenberg&rsquo;s compensation is described under &ldquo;Executive Compensation&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees&nbsp;Earned<BR>
    or Paid<BR>
    in Cash</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock<BR>
    Awards</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
    Awards</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nonqualified<BR>
    Deferred<BR>
    Compensation<BR>
    Earnings</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
    Other<BR>
    Compensation</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)(1)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Sieczkarek (2)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">52,730&nbsp;</FONT></P></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,170</FONT></P></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">59,900</FONT></P></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Michael Belkin
    (3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,400</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,860</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,570</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">54,830</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yossi Keret</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,100</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,860</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,570</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,530</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Franck Amouyal
    (4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">-</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">-</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Zarzewsky</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,100</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,860</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,570</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,530</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects the aggregate grant date fair value of option awards granted during the relevant fiscal year calculated in accordance with FASB ASC Topic 718.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify; width: 97%">On April 23, 2019, we granted to Mark Sieczkarek 202,399 restricted
stock units vesting quarterly over a period of 1.5 years.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">On May 15, 2019, we granted to Mark Sieczkarek options to purchase
102,222 shares of our Common Stock at $2 per share. The options vested as follows: eight (8) installments commencing May 15, 2019</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">On August 11, 2020, we granted to Mark Sieczkarek 150,000 restricted
stock units vesting quarterly over a period of 2 years.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On July 1, 2013, we granted to Dr. Belkin options to purchase 2,176 shares of our Common Stock at $159.12 per share. The options are fully vested and will be expire on the ten year anniversary of the grant date.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Amouyal resigned from the Board on March 8, 2020. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Finder&rsquo;s Fee
Agreement with Joseph Zarzewsky</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 19, 2017,
Wize Israel entered into a finder&rsquo;s fee agreement with Harbin Israel (Trading) Ltd., an affiliate of Mr. Zarzewsky, pursuant
to which Mr. Zarzewsky will receive a 5% royalty on all of Wize Israel&rsquo;s revenues to the extent such revenues are earned
from relationships initiated by Mr. Zarzewsky and agreed to by Wize Israel. The term of the agreement is for 12 months unless
earlier terminated. Either party may terminate upon twenty-one days&rsquo; notice, and it was terminated on February 25, 2021.
Mr. Zarzewsky introduced us to the Chinese Distributor. See &ldquo;Item 1. BUSINESS &mdash;&nbsp;Marketing and Sales&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Consulting Agreement
with Michael Belkin.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2019,
we entered into a consulting agreement with Michael Belkin, pursuant to which we agreed to pay him a monthly retainer of NIS 5,000
(approximately $1,450) and options exercisable into 5,000 shares of common stock per month. The agreement expired on September
30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Compensation of
Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2019, our
board approved annual cash fees of $15,000 in addition to $1,400 per in person meeting, $500 per signed unanimous consent and $700
per telephonic meeting, with respect to meetings and/or signed resolutions, as applicable, of the Board of Directors or a committee
of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board also approved
the following equity grants in the past two years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2019, our
    Board approved the following equity grants (i) 100,000 restricted stock units vesting quarterly over a period of two years to
    each director, (ii) 140,000 restricted stock units vesting quarterly over a period of two years to Mr. Danenberg as
    compensation for his services as the then Chairman, and (iii) 140,000 restricted stock units vesting quarterly over a period
    of two years to our Chief Financial Officer; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, our Board approved the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each of the other three non-executive directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also purchased Directors and Officers insurance to cover
the potential liability of our directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_020"></A>ITEM 12. SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following table sets forth information as of March 1, 2021 regarding the beneficial ownership of our Common Stock by (i)
those persons who are known to us to be the beneficial owner(s) of more than 5% of our Common Stock, (ii) each of our directors
and named executive officers, and (iii) all of our directors and executive officers as a group. Except as otherwise indicated,
the beneficial owners listed in the table below possess the sole voting and dispositive power in regard to such shares and have
an address of c/o Wize Pharma, Inc., 24 Hanagar Street, Hod Hasharon, Israel 4527708. As of March 1, 2021, there were 33,052,951
shares of our Common Stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership
is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
&nbsp;Shares of our Common Stock subject to options, warrants, notes or other conversion privileges currently exercisable or convertible,
or exercisable within 60 days of the date of this table, are deemed outstanding for computing the percentage of the person holding
such option, warrant, note, or other convertible instrument but are not deemed outstanding for computing the percentage of any
other person. Where more than one person has a beneficial ownership interest in the same shares, the sharing of beneficial ownership
of these shares is designated in the footnotes to this table. &nbsp;Unless otherwise indicated in the footnotes to this table,
we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated
as beneficially owned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount and<BR> Nature of<BR>
    Beneficial<BR> Ownership</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of Class</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">5% and Greater Shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon
    Gold Assets Ltd.&nbsp;(1)</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,927,866</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">20.96</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ridge Valley Corporation&nbsp;(2)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,040,760</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.15</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan Rubini&nbsp;(3)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,100,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21.48</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Named Executive Officers and Directors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Sieczkarek
    (4)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">360,871</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.09</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Michael Belkin&nbsp;(5)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">194,676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yossi Keret&nbsp;(6)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Zarzewsky&nbsp;(7)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg&nbsp;(8)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Danenberg&nbsp;(9)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,945,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.9</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officers
    and Directors as a Group (7 Persons)&nbsp;(11)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,879,354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.6</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents ownership of less than 1%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon Gold is an
    Israeli private company wholly owned by the Goldfinger Trust (the &ldquo;<B>Trust</B>&rdquo;), whose trustee is Abir Raveh
    (the &ldquo;<B>Trustee</B>&rdquo;) and whose beneficiary is Yair Goldfinger. The Trust directs the management of Rimon Gold,
    its investment and voting decisions and the Trustee directs the management of the Trust, its investment and voting decisions.
    The address of Rimon Gold, the Trust and the Trustee is 32 Habarzel, Tel Aviv, Israel. Mr. Goldfinger does not direct the
    management of Rimon Gold, the Trust or the Trustee, its investment or voting decisions and disclaims beneficial ownership
    of the shares reported in this table.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ridge is a Seychelles
    corporation, whose address is Room 206, Premier Building, P.O Box 332, Victoria, Mahe, Seychelles. Priscilla Julie is the
    sole director of Ridge and holds the voting and dispositive power of the shares of Common Stock beneficially owned by Ridge.
    Noam Danenberg, our Chairman, is married to Tali Danenberg Harpaz, who owns 49% of Ridge.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes 178,000 shares of Common Stock issuable upon conversion of Series A Preferred Stock within 61 days following provision of notice to the Company. The address for Mr. Rubini is 2655 Marston Drive, Anchorage, Alaska 99517.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 215,499 shares of Common Stock, (ii) 44,050 shares of Common Stock issuable upon the vesting of RSUs within 60 days of March 1, 2021, (iii) 102,222 shares of Common Stock issuable upon the exercise of stock options currently exercisable or exercisable within 60 days of March 1, 2021. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 112,500 shares of Common Stock, (ii) 44,050 shares
of Common Stock issuable upon the vesting of RSUs within 60 days of March 1, 2021, (iii) 57,176 shares of Common Stock issuable
upon the exercise of stock options currently exercisable or exercisable within 60 days of March 1, 2021.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 112,500 shares of Common Stock, (ii) 25,000 shares
of Common Stock issuable upon the vesting of RSUs within 60 days of March 1, 2021, (iii) 25,000 shares of Common Stock issuable
upon the exercise of stock options currently exercisable or exercisable within 60 days of March 1, 2021.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 112,500 shares of Common Stock, (ii) 25,000 shares
of Common Stock issuable upon the vesting of RSUs within 60 days of March 1, 2021, (iii) 25,000 shares of Common Stock issuable
upon the exercise of stock options currently exercisable or exercisable within 60 days of March 1, 2021.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 162,600 shares of Common Stock, (ii) 17,500 shares
of Common Stock issuable upon the vesting of RSUs within 60 days of March 1, 2021, (iii) 36,000 shares of Common Stock issuable
upon the exercise of stock options currently exercisable or exercisable within 60 days of March 1, 2021.</font></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i)
    162,600 shares of Common Stock which were issued to N. Danenberg Holdings, a services company wholly owned by Mr. Danenberg
    (&ldquo;NDH&rdquo;), (ii) 2,480,069 shares of Common Stock which were issued to Mobigo Inc, a services company wholly owned
    by Mr. Danenberg, (iii) 17,500 shares of Common Stock issuable upon the vesting of RSUs which were issued to NDH, and (iv)
    36,000 shares of Common Stock issuable upon the exercise of stock options currently exercisable or exercisable within 60 days
    of March 1, 2021 which were issued to NDH. Excludes the shares beneficially owned by Ridge (see footnote 2).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="vertical-align: baseline">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; vertical-align: baseline">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 3,493,906 shares of Common Stock, (ii) 129,050 shares of Common Stock issuable upon the vesting of RSUs within 60 days of March 1, 2021, and (iii) 256,398 shares of Common Stock issuable upon the exercise of stock options currently exercisable or exercisable within 60 days of March 1, 2021.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Option Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><B><I>2012 Stock
Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 6, 2012,
our Board and stockholders adopted the 2012 Stock Incentive Plan (the &ldquo;2012 Plan&rdquo;). The purpose of the 2102 Plan is
to advance the interests of our stockholders by enhancing the Company&rsquo;s ability to attract, retain and motivate persons who
are expected to make important contributions to us and by providing such persons with equity ownership opportunities and performance-based
incentives that are intended to better align the interests of such persons with those of our stockholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each stock option granted
shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement,
provided that no option will be granted with a term in excess of 10 years. Upon the adoption of the 2012 Plan, we reserved for
issuance 45,370 shares of Common Stock. There are 45,370 shares of Common Stock authorized for non-statutory and incentive stock
options, restricted stock units, and stock grants under the 2012 Plan, which are subject to adjustment in the event of stock splits,
stock dividends, and other situations. As of December 31, 2020, we had 40,474 shares of Common Stock available for future grant
under the 2012 Plan. During the years ended December 31, 2020 and 2019, we did not grant any new stock options under the 2012 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2012 Plan is administered
by our Board. The persons eligible to participate in the 2012 Plan are as follows: all of our employees, officers and directors,
as well as consultants and advisors to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2012 Plan will
continue in effect until all of the stock available for grant or issuance has been acquired through exercise of options or grants
of shares, or until February 6, 2022, whichever is earlier. The 2012 Plan may also be terminated in the event of certain corporate
transactions such as a merger or consolidation or the sale, transfer or other disposition of all or substantially all of our assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 29, 2013,
our Board conditionally approved the adoption of an annex (the &ldquo;<B>Annex</B>&rdquo;) to the 2012 Plan. Approval of the Annex
by our Board was contingent upon the following: 1) 30 days elapsing since approval of the Annex by the Board of Directors, and
2) filing with Israeli income tax authorities (the &ldquo;<B>Tax Authorities</B>&rdquo;). On February 7, 2013, the Annex was filed
with the Tax Authorities and on March&nbsp;8, 2013, the Annex became effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Annex applies only
to grantees who are residents of the State of Israel at the date of grant or those who are deemed to be residents of the State
of Israel for the payment of tax at the date of grant. U.S. tax rules and regulations will not apply to any grants to a grantee
who is a resident of the State of Israel at the date of grant or those who are deemed to be residents of the State of Israel for
the payment of tax at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the
approval and adoption of the Annex is to harmonize the terms and conditions of the 2012 Plan with applicable Israeli law and provide
specific provisions regarding optionees who are subject to Section 102(a) of the Israeli Income Tax Ordinance (New Version), 5721-1961
(the &ldquo;<B>Ordinance</B>&rdquo;). The Annex is intended to promote our interests by providing present and future officers,
other employees (including directors who are also our employees) and consultants with an incentive to enter into and continue in
our employ and to acquire a proprietary interest in our long-term success. Our Board shall have the authority to determine additional
persons which will be granted rights under the Annex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Annex,
our Board is authorized to grant stock options to persons subject to the Ordinance. Our Board may grant to employees, officers,
and directors options under Section 102 of the Ordinance, or 102 Options, and to consultants and other service providers options
under Section 3(i) of the Ordinance, or 3(i) Options. Our Board may designate 102 Options as &ldquo;Approved 102 Options&rdquo;
for which the options and shares upon exercise must be held in trust and granted through a trustee, and as &ldquo;Unapproved 102
Options&rdquo; for which the options and shares upon exercise do not have to be held in trust. As described further below, the
type of option and duration of time the option and shares upon exercise are held in trust will determine the tax consequences to
the participant. Of the Approved 102 Options, our Board may grant options as &ldquo;Work Income Options&rdquo; for which the options
and shares upon exercise must be held in trust for 12 months from the date of grant, or as &ldquo;Capital Gain Options&rdquo; for
which the options and shares upon exercise must be held in trust for 24 months from the date of grant. If the requirements of the
Approved 102 Options are not met, the options are regarded as Unapproved 102 Options. 3(i) Options and the shares upon exercise
may be held in trust as well, depending upon the agreement between our Board, optionee, and the trustee of the trust. Approved
102 Options which have been granted as &ldquo;Capital Gains Options&rdquo; enable the optionee to pay capital gains tax on such
option provided the terms of the grant and Section 102 of the Ordinance have been met whilst all other option grants under the
Annex are treated as regular income and are subject to the taxation applicable thereto. The trustee appointed under the Annex is
required to qualify as a trustee under Section 102 of the Ordinance and shall hold any options granted under the Annex in trust
for the respective holding periods as designated under the Annex and Section 102 of the Ordinance. The grant of options under the
Annex requires the delivery of a grant notification letter to each optionee in which all the relevant terms and conditions of such
grant are set out. The grant notification letter may include additional matters relating to the vesting of the options, exercise
periods, events of termination of employment, etc. The Annex sets out that for as long as options or shares purchased pursuant
to thereto are held by the trustee on behalf of the optionee, all rights of the optionee over the shares are personal, cannot be
transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution. The Annex shall be governed
by and construed and enforced in accordance with the laws of the State of Delaware.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
summarizes information as of the close of business on December 31, 2020 concerning the 2012 Plan and other options outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Plan&nbsp;category</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of securities to be<BR> issued&nbsp;upon exercise of<BR> outstanding options, warrants and rights<BR> (a)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-average exercise price&nbsp;of outstanding options, warrants and rights<BR> (b)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))(c)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,352</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">81.81</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">40,474</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Equity compensation plans not approved by security holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,352</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,474</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><B><I>2018 Stock
Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 22, 2018,
the Board approved the adoption of the 2018 Stock Incentive Plan (the &ldquo;<B>2018 Plan</B>&rdquo;), including an Israeli annex
to comply with Israeli law, in particular the provisions of section 102 of the Israeli Income Tax Ordinance. Under the 2018 Plan,
we may grant our employees, directors, consultants and/or contractors stock options, shares of Common Stock, restricted stock and
restricted stock units of our company. The Board is currently serving as the administrator of the 2018 Plan, although the 2018
Plan allows for the administrator to be a committee of the Board appointed by the Board for the purpose of the administration of
the 2018 Plan. Each stock option granted is exercisable, unless otherwise determined by the administrator, in twelve equal installments
over the three year period from the date of grant. Unless otherwise determined by the administrator, the term of each award will
be seven years. The exercise price per share subject to each option will be determined by the administrator, subject to applicable
laws and to guidelines adopted by the Board from time to time. In the event the exercise price is not determined by the administrator,
the exercise price of an option will be equal to the closing stock price of the Common Stock on the last trading day prior to the
date of grant. Upon the adoption of the 2018 Plan, the Board reserved for issuance 435,053 shares of Common Stock. On August 15,
2018, the Company amended the 2018 Plan to increase the number of shares issuable under the Plan to 2,500,000 shares, and on the
first day of each fiscal year beginning with the 2019 fiscal year, by an amount equal to the lesser of (i) 1,000,000 shares or
(ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
summarizes information as of the close of business on December 31, 2020 concerning the 2018 Plan and other options outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan&nbsp;category</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number&nbsp;of securities to be<BR>
issued&nbsp;upon exercise of<BR>
outstanding options, warrants and rights<BR>
(a)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted-average exercise price&nbsp;of outstanding options, warrants and rights<BR>
(b)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))(c)</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 67%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by security holders</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">290,222</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">2.64</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,184,813</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by security holders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">290,222</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2.64</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,184,813</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_021"></A>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, DIRECTOR INDEPENDENCE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Described
below are the transactions and series of similar transactions since January 1, 2020 to which we were a party in which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amounts involved exceeded the lesser of $120,000 or one percent of our total assets at year end for the last two completed fiscal years; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -31.5pt; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any of the directors, executive officers, holders of more than 5% of our share capital, or any member of their respective immediate family had or will have a direct or indirect material interest.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information,
please see &ldquo;Item 7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Agreements
with Executive Officers and Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Mr. Noam Danenberg, our chief executive officer is also the
husband of Tali Harpaz, who owns 49% of Ridge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Series B Purchase Agreement, Mr. Danenberg, through Mobigo, has purchased 300 shares of Series B Preferred Stock in the
aggregate amount of $300,000, and Mr. Sieczkarek has purchased 50 shares of Series B Preferred Stock in the aggregate amount of
$50,000.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
a result of the Warrant Adjustments, on December 29, 2020 an aggregate of 13,332,657 were issued as a result of the exercise of
such warrants, each on a cashless basis. Such warrant exercises also included warrants beneficially owned by our Chief Executive
Officer, Noam Dannenberg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Wize
Israel has entered into employment, services and other agreements with certain of its directors and executive officers. For more
information regarding these other agreements entered into by Wize Israel with certain of its directors and executive officers,
please see &ldquo;Item 11. EXECUTIVE COMPENSATION &mdash; Executive Compensation &ndash; Executive Employment Agreements&rdquo;
and &ldquo;Item 11. EXECUTIVE COMPENSATION &mdash; Compensation of Directors&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">See
also the PIPE Agreement entered into by Mr. Danenberg. For more information regarding this agreement, please see &ldquo;Item 1.
BUSINESS &ndash; Overview &ndash; The Cosmos Transaction.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Item 10 &ndash;
&ldquo;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE &ndash;Director Independence&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Procedures for Approval of Related Party
Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board is charged
with reviewing and approving all potential related party transactions.&nbsp;&nbsp;All such related party transactions must then
be reported under applicable SEC rules. We have not adopted other procedures for review, or standards for approval, of such transactions,
but instead review them on a case-by-case basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_022"></A>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND
SERVICES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 15, 2018,
the Company dismissed Kost Forer Gabbay &amp; Kasierer, a member of EY as the Company&rsquo;s independent registered public accounting
firm and engaged Fahn Kanne &amp; Co. Grant Thornton Israel (&ldquo;<B>Grant Thornton</B>&rdquo;) as its new independent registered
public accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the two most
recent fiscal years and the interim periods preceding the engagement of Grant Thornton, neither the Company nor anyone on its behalf
had previously consulted with Grant Thornton regarding either (a) the application of accounting principles to a specified transaction,
either completed or proposed; or the type of audit opinion that might be rendered on the Company&rsquo;s financial statements,
and neither a written report was provided nor oral advice was provided to the Company that concluded was an important factor considered
by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (b) any matter that was either
the subject of a disagreement (as defined in paragraph 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or
a reportable event (as described in paragraph 304(a)(1)(v)) of Regulation S-K).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Audit Fee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
shows the fees paid or accrued by us for the audit and other services provided by Grant Thornton for 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Audit Fees (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">75,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">75,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Audit Related Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Tax Fees (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">All other Fees (3)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total Fees</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">75,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">80,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of fees billed for the audit of our annual financial statements and the review of financial statements included in our 10-Q, 8-K reports and services normally provided by the accountant in connection with statutory and regulatory filings or engagements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate fees billed in each of the last two fiscal years for professional services rendered by the named accountant for tax compliance, tax advice, and tax planning.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate fees billed in each of the last two fiscal years for products and services provided by the named accountant, other than the services reported above.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee Pre-approval Policies
and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until February 22,
2018, we did not have an audit committee and as a result our Board performed the duties of an audit committee. &nbsp;Our audit
committee evaluates and approves in advance, the scope and cost of the engagement of an auditor before the auditor renders audit
and non-audit services. &nbsp;We do not rely on pre-approval policies and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_023"></A>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_024"></A>ITEM 15. EXHIBITS, FINANCIAL STATEMENT
SCHEDULES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(a) Index to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following consolidated
financial statements are filed as part of this Annual Report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WIZE PHARMA, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS OF DECEMBER 31, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S. DOLLARS IN THOUSANDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-weight: bold; text-align: left"><A HREF="#fin_001">Report of Independent Registered Public Accounting Firm</A></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><A HREF="#fin_002">Consolidated Balance Sheets</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-4</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><A HREF="#fin_003">Consolidated Statements of Comprehensive Loss</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><A HREF="#fin_004">Consolidated Statements of Changes in Stockholders&rsquo; Equity (Deficit)</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-6</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><A HREF="#fin_005">Consolidated Statements of Cash Flows</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-8</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><A HREF="#fin_006">Notes to Consolidated Financial Statements</A></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-9</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="fin_001"></A>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 66px; width: 270px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 75%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fahn Kanne &amp; Co.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Head Office</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>32 Hamasger Street<BR>
 Tel-Aviv 6721118, ISRAEL<BR>
 PO Box 36172, 6136101</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">T +972 3 7106666</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F +972 3 7106660</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">www.gtfk.co.il</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Wize Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the financial statements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Wize Pharma, Inc. (a Delaware corporation) and its subsidiaries (the &ldquo;<B>Company</B>&rdquo;) as of December
31, 2020 and 2019, the related consolidated statements of comprehensive loss, changes in stockholders&rsquo; equity (deficit),
and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to
as the &ldquo;<B>Financial Statements</B>&rdquo;). In our opinion, the Financial Statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for
each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the
United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Going concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying Financial Statements have been prepared assuming
that the Company will continue as a going concern.&nbsp;&nbsp;As discussed in Note&nbsp;1b to the Financial Statements, the Company
has incurred net losses and negative cash flows from operations since its inception, and has not yet generated any material revenues.
As of December&nbsp;31, 2020, there is an accumulated deficit of $39,218 thousand and a stockholders&rsquo; deficit of $4,148 thousand.&nbsp;These
conditions, along with other matters as set forth in Note 1b, raise substantial doubt about the Company&rsquo;s ability to continue
as a going concern. Management&rsquo;s plans in regards to these matters are also described in Note 1b. The Financial Statements
do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These Financial Statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s Financial Statements based
on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;<B>PCAOB</B>&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the Financial Statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the Financial Statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the Financial Statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the Financial Statements. We believe that our audits provide a
reasonable basis for our opinion.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical audit matter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">critical audit matter communicated below
is a matter arising from the current period audit of the Financial Statements that was communicated or required to be communicated
to the audit committee and that: (1) relates to accounts or disclosures that are material to the Financial Statements and (2) involved
our especially challenging, subjective, or complex judgments. The communication of this critical audit matter does not alter in
any way our opinion on the Financial Statements, taken as a whole, and we are not, by communicating the critical audit matter below,
providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described further in Note 1a, Note 2v
and in Note 10a to the Financial Statements, the Company granted to a third party the right to receive a percentage of the Company&rsquo;s
future proceeds, as defined, from specified products, in exchange for the issuance to the Company of a fixed number of the third
party&rsquo;s shares. The Company has elected to measure the contingent obligation with respect to future revenues at fair value
on a recurring basis, with changes in fair value recognized in earnings. The determination of the fair value of the contingent
obligation requires management to make significant estimates and assumptions related to the forecast of future revenues, estimated
maximum penetration rate into the U.S market, estimated operational profit rate, probability of regulatory approvals, and risk-adjusted
rate for estimating future cash flows. These assumptions could have a significant impact on the determination of the fair value
of the contingent obligation with respect to future revenues. We identified the remeasurement of the fair value of this contingent
obligation as of December 31, 2020 as a critical audit matter principal consideration for our determination that the remeasurement
of the fair value of the contingent obligation with respect to future revenues as of December 31, 2020 is a critical audit matter
is the high degree of management subjective judgement necessary in determining the inputs and assumptions utilized in the analysis.
The assumptions included the forecast of future revenues, estimated maximum penetration into the U.S. market, estimated operational
profit rate, probability of regulatory approvals, and risk-adjusted rate for estimating future cash flows, which contribute significantly
to the fair value of this contingent obligation as of December 31, 2020. Given the subjective nature and judgement applied by management,
including management-employed specialists, auditing these estimates required a high degree of auditor judgement and an increased
extent of effort including the use of auditor-employed specialists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit procedures related to the remeasurement
of the contingent obligation with respect to future revenues as of December 31, 2020, included the following, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We evaluated the qualifications of the
management-employed specialists, and obtained the reports prepared by the specialists.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We evaluated the reasonableness of management&rsquo;s
assumptions related to the forecast of future revenues, estimated maximum penetration into the U.S. market, estimated operational
profit rate, probability of regulatory approvals, and risk-adjusted rate for estimating future cash flows by comparing these estimates
to historical operating results, third-party industry and other data related to the regulatory environment and the market for the
specified products, and discussions with management, along with sensitivity analyses around the estimates.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We utilized an auditor-employed valuation
specialist to assess the appropriateness of the valuation methodology used and to assist us with testing key inputs and assumptions
in the valuation model.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ FAHN KANNE &amp; CO. GRANT THORNTON ISRAEL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel-Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="fin_002"></A>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands (except share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">247</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">718</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Restricted cash deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Marketable equity securities (Notes 3,10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other current assets (Note 4)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">378</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,160</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,147</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">NON-CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right of use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total non-current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,189</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,176</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Accounts payable (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">369</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease obligation - current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Current portion of license purchase obligation (Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Short term loan payable (Note 9)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">265</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,843</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">641</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">NON-CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Contingent obligation with respect to future revenues (Note 10)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,494</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Total&nbsp;non-current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,494</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">COMMITMENTS AND CONTINGENCIES (Note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">STOCKHOLDERS&rsquo; EQUITY (DEFICIT) (Note 13):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock A, with $0.001 par value per share (&ldquo;<B>Series A Preferred Stock</B>&rdquo;)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Authorized: 1,000,000 shares at December 31, 2020 and 2019; Issued and outstanding: 178 shares at December 31, 2020 and 2019.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">C<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ommon
stock, with $0.001 par value per share (&ldquo;<B>Common Stock</B>&rdquo;) </FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">500,000,000 shares authorized at December 31, 2020 and 2019; 32,783,495 and 15,873,128 shares issued and outstanding at December 31, 2020 and 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,491</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(39,218</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(33,899</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">535</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">TOTAL LIABILITIES AND
    STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,189</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,176</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than 1 thousand.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of the consolidated
Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="fin_003"></A>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>CONSOLIDATED STATEMENTS
OF COMPREHENSIVE LOSS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands (except share and per share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">434</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">492</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative expenses (Note 14a)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,008</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,678</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,442</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,170</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Financial expense, net (Note 14b)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(280</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,929</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,450</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Addition to net loss (for EPS purpose)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Deemed dividend with respect to the repurchase of right for future investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(185</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(267</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deemed dividend due to exercise price adjustment of warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(390</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss applicable to stockholders of Common Stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,319</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,902</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,929</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,450</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Basic and diluted net loss per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.36</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Weighted average number of shares of Common Stock used in computing basic and diluted net loss per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">16,669,628</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,519,682</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of the consolidated
Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.35pt; text-indent: -8.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="fin_004"></A>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>CONSOLIDATED STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY (DEFICIT</B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands (except share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Series A <BR>
Preferred Stock</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional paid-in</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated other comprehensive<BR>
income</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Total stockholders&rsquo;<BR>
</B> <B>equity</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> (loss)</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(deficit)</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Balance as of December 31, 2018</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">910</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">8,957,550</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD>
    <TD STYLE="text-align: right">30,272</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(73</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD>
    <TD STYLE="text-align: right">(29,997</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD>
    <TD STYLE="text-align: right">212</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 32%; text-align: left">Amounts allocated to repurchase of existing right for future investment related to the 2016 Loan and the 2017 Loan (See Note&nbsp;8)</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">-</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">-</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">-</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">-</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">(633</TD>
    <TD STYLE="width: 0.5%; text-align: left">)</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">-</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">-</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.5%">&nbsp;</TD>
    <TD STYLE="width: 0.5%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">(633</TD>
    <TD STYLE="width: 0.5%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Amounts that were allocated to recognition of the
    right for future investment and warrants &ndash; 2016 Loan (See Note 8)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">637</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">637</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Amounts that were allocated to recognition of the right for future investment and warrants &ndash; 2017 Loan (See Note 8)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">962</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">962</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deemed dividends with respect to the repurchase of&nbsp;&nbsp;right for future investment (See Note 8)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(185</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(185</TD>
    <TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of Common Stock and warrants for cash (Note 13n)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,037,037</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">548</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">550</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of Common Stock and warrants due to 2016 Loan and 2017 Loan repayment (Note 13e)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,816,196</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">991</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">994</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Terms modification and cancellation of existing financial instruments due to 2016 and 2017 loan repayment (Note 8e)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(135</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(135</TD>
    <TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of Common Stock (Note 13b)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">900,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">764</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">765</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion of Preferred stock into Common Stock (Note 13c)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(732</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">732,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants (Note 13)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">267</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(267</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Stock-based compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">430,345</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">818</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">818</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,450</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,450</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Balance as of December 31, 2019</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">178</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">15,873,128</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">16</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">34,491</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">(73</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">(33,899</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">535</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representing
amount less than $1</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of the consolidated
Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>CONSOLIDATED STATEMENTS
OF CHANGES IN STOCKHOLDERS&rsquo; EQUITY (DEFICIT</B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands (except share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Series A<BR> Preferred Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Additional paid-in</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated other comprehensive</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> stockholder&rsquo;s<BR> equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">loss</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(deficit)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; text-indent: -9pt; padding-left: 9pt">Balance as of December 31, 2019</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">178</TD><TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">*</TD><TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">15,873,128</TD><TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">16</TD><TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">34,491</TD><TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(73</TD><TD STYLE="width: 0.25%; text-align: left">)</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">(33,899</TD><TD STYLE="width: 0.25%; text-align: left">)</TD><TD STYLE="width: 0.25%">&nbsp;</TD>
    <TD STYLE="width: 0.25%; text-align: left">$</TD><TD STYLE="width: 5%; text-align: right">535</TD><TD STYLE="width: 0.25%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Deemed dividend due to exercise price adjustment of
    warrants (Notes 13p, 13q)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of shares with respect to exercise of warrants
    (Notes 13p, 13q)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,332,654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">577,713</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,929</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,929</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance as of December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">178</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">32,783,495</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">35,110</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(73</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(39,218</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(4,148</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representing amount less than $1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of the consolidated
Financial Statements.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="fin_005"></A>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>CONSOLIDATED STATEMENTS
OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended <BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Cash flows from operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,929</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,450</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">818</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income (loss) from marketable equity securities sale and revaluation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,197</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">527</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of premium related to convertible loans (Notes 8 and 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,257</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued interest on convertible loans (Notes 8 and 13b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from extinguishment of convertible loans (Notes 8 and 13b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">977</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gain from completion of milestone closing (Note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(847</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gain from settlement shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from recognition of mandatorily redeemable Series B Preferred Stock (Note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change from revaluation of mandatorily redeemable Series B Preferred Stock (Note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">597</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change from revaluation of contingent obligation with respect to future revenues (Note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Increase in license purchase obligation (Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financial expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">313</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accounts payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">587</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">63</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,519</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,064</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Proceeds from sale of marketable equity securities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">824</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from issuance of shares and warrants (Note 13n)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net proceeds from issuance of mandatorily redeemable Series B Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Loan received</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">247</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible loan repayment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(760</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Repayment of license purchase obligation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(150</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(150</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">197</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(360</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate change on cash, cash equivalents and restricted cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in cash, cash equivalents and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(499</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,424</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash at the beginning of the year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">759</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,183</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Cash, cash equivalents and restricted cash at the end of the year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">260</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">759</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Supplemental disclosure of non-cash investing and financing
    activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Ordinary shares issued through receipt of marketable securities (Note 13b)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">765</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amount allocated to the&nbsp;repurchase right for existing right for future investment related to the 2016 Loan and the 2017 Loan &ndash; March 2019 Loan Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(481</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amounts that were allocated to the recognition of right for future investment - 2016 Loan &ndash; March 2019 Loan Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">256</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amounts that were allocated to the recognition of right for future investment - 2017 Loan &ndash; March 2019 Loan Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">386</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Deemed dividends with respect to the repurchase of&nbsp;&nbsp;right for future investment &ndash; March 2019 Loan Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">104</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amount allocated to the&nbsp;repurchase right for existing right to future investment related to the 2016 Loan and the 2017 Loan &ndash; May 2019 Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(152</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amounts that were allocated to the right for future investment and warrants - 2016 Loan &ndash; May 2019 Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">381</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amounts that were allocated to the right for future investment and warrants - 2017 Loan &ndash; May 2019 Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">576</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Deemed dividends with respect to the repurchase of right for future investment &ndash; May 2019 Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">81</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amount allocated to the 2016 Loan - March 2019 Loan Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">729</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amount allocated to the 2017 Loan - March 2019 Loan Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,037</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amount allocated to the 2016 Loan - May 2019 Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">634</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amount allocated to the 2017 Loan - May 2019 Amendment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">922</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Repayment of convertible loans through Common Stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">760</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">267</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Sell of Cannabics&rsquo;s shares through a broker</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">260</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Amounts transferred from Series B
    Preferred Stock proceeds  to restricted deposit held in escrow</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,700</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Investment in marketable securities -
    Bonus Shares</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,851</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Recognition of contingent obligation with respect to future revenues</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Issuance of mandatorily redeemable Series B Preferred Stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,400</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Settlement of mandatorily redeemable series B Preferred Stock through distribution of Bonus Shares</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,604</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Deemed dividend due to exercise price adjustment of warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">390</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Issuance of shares with respect to exercise of warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Transaction costs liability, see note 10</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">350</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Release of escrow account &ndash; Bonus Shares</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,700</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representing amount less than $1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying notes are an integral part of the consolidated
Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="fin_006"></A>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 1:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENERAL</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wize Pharma, Inc. (the &ldquo;<B>Company</B>&rdquo; or &ldquo;<B>Wize</B>&rdquo;) was incorporated in the State of Delaware.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Wize, through its wholly-owned Delaware subsidiary, Wize NC
Inc. (&ldquo;<B>Wize NC</B>&rdquo;), and the wholly-owned subsidiary of Wize NC, OcuWize Ltd. (&ldquo;<B>OcuWize</B>&rdquo;), is
a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome
(&ldquo;<B>DES</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Commencing August 30, 2016, Wize Pharma Ltd., a wholly owned
subsidiary of the Company (&ldquo;<B>Wize Israel</B>&rdquo;) manages most of its activity through OcuWize Ltd. (&ldquo;<B>OcuWize</B>&rdquo;),
a wholly owned Israeli subsidiary of Wize Israel, which manages and develops most of the Company&rsquo;s activity under an existing
license agreement. In May 2015, Wize Israel entered into an Exclusive Distribution and Licensing Agreement (as amended, the &ldquo;<B>License
Agreement</B>&rdquo;), with Resdevco Research and Development Company Ltd. (&ldquo;<B>Resdevco</B>&rdquo;). Pursuant to the License
Agreement, Resdevco granted to Wize Israel (and thereafter, to OcuWize) an exclusive license to develop in the United States, under
the LO2A licensed technology, products in the field of ophthalmic disorders, to mutually agree upon a manufacturer and to purchase,
market, sell and distribute LO2A in finished product form in the licensed territories in the field of ophthalmic disorders, see
also note 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For discussion regarding the issuance
of the Series B Preferred Stock (as described in Note 10 below) as a partial financing, concurrently with the recognition of an
obligation with respect to 37% of future revenues of LO2A-based products (&ldquo;<B>LO2A Proceeds</B>&rdquo;) (if any) and the
purchase of shares of Bonus BioGroup Ltd. (&ldquo;<B>Bonus</B>&rdquo;), classified as marketable equity securities that was completed
in February 2020, see also Note 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On December 30, 2020, the Company entered into a Bid Implementation
Agreement (as amended, the &ldquo;Bid Agreement&rdquo;) with Cosmos Capital Limited, a digital infrastructure provider based in
Sydney, Australia (&ldquo;Cosmos&rdquo;). Pursuant to the Bid Agreement, the Company commenced an off-market takeover offer under applicable
Australian laws (the &ldquo;Offer&rdquo;), whereby it offers 61.11 shares of  common stock in exchange for each one outstanding
share of Cosmos. Immediately following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos
shareholders are expected to own approximately 87.65% of the outstanding common stock of Wize, while Wize existing stockholders
are expected to remain the owners of approximately 10.75% of the outstanding common stock of Wize, each on a fully diluted basis
and including warrants to be issued to Wize&rsquo;s financial advisor to the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Pursuant to the Bid Agreement, prior to the Closing
Date, Wize will enter into a Contingent Value Rights Agreement (the &ldquo;CVR Agreement&rdquo;) with  certain of Wize&rsquo;s
subsidiaries (the &ldquo;Wize Subsidiaries&rdquo;), a person designated by Wize prior to the Closing Date as the Holders&rsquo;
Representative (as defined herein), and the Rights Agent (as defined therein). Pursuant to the CVR Agreement, at the Closing Date,
each Wize pre-Closing securityholder will receive one non-transferable CVR for each outstanding share of common stock of Wize and
for each share of common stock of Wize underlying other convertible securities and warrants, held as of 4:01 p.m. Eastern Time
on the day immediately before the Effective Time (as defined in the CVR Agreement). See also note 10c.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going concern uncertainty and management plans:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has not yet generated any material revenues from
its current operations, and therefore is dependent upon external sources for financing its operations. As of December 31, 2020,
the Company has an accumulated deficit of $39,218 and a total stockholders&rsquo; deficit of $4,148.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, in each of the years
ended December 31, 2020 and 2019, the Company reported losses and negative cash flows from operating activities.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management considered the significance
of such conditions in relation to the Company&rsquo;s ability to meet its current and future obligations and determined that such
conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 1:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENERAL (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The accompanying financial statements
do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the
amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Until such time as the
Company generates sufficient revenue to fund its operations (if ever), the Company plans to finance its operations through
the sale of Bonus Shares (as hereinafter defined), and, to the extent available, short-term and long-term loans as well as
equity financings. There can be no assurance that the Company will succeed in obtaining the necessary financing to continue
its operations as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding the issuance, and subsequent
redemption, of the Series B Preferred Stock concurrently with the transaction with Bonus in February 2020, see also Note 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding the transaction with
Cosmos on December 30, 2020, see note 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company had an accumulated deficit
of $39,218 and a total stockholders&rsquo; deficit of $4,148. The Company has historically incurred net losses and is not able
to determine whether or when it will become profitable, if ever. To date, the Company has not commercialized any products or generated
any material revenues from product sales and accordingly it does not have a revenue stream to support its cost structure. The Company&rsquo;s
losses (other than financing related income and expenses) have resulted principally from costs incurred in development and discovery
activities and general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company expects to continue
to incur losses for the foreseeable future, and these losses will likely increase as it:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiates and manages further development and clinical trials for LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeks regulatory approvals for LO2A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implements internal systems and infrastructures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seeks to license additional technologies to develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pays royalties related to the License Agreement and in connection with the obligation with respect to future revenues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hires management and other personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">moves
    towards commercialization; and</FONT></TD></TR>
</TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks related to the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic, including on our clinical trials, the demand for our products, our ability to operate and on overall economic conditions.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">No certainty exists that the Company
will be able to complete the development of LO2A for Conjunctivochalasis (&ldquo;<B>CCH</B>&rdquo;), Sj&ouml;gren&rsquo;s syndrome
(&ldquo;<B>Sj&ouml;gren&rsquo;s</B>&rdquo;) or any other ophthalmic disorder, due to financial, technological or other difficulties.
If LO2A fails in clinical trials or does not gain regulatory clearance or approval, or if LO2A does not achieve market acceptance,
the Company may never become profitable. In addition, while the Company explores license and other strategic transactions in an
attempt to monetize the LO2A, there is no assurance that the Company will be successful in doing so and, even if is able to do
so, what the timing or terms thereof may be of such licenses or strategic transactions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&rsquo;s inability to
achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash
flows. Moreover, the Company&rsquo;s prospects must be considered in light of the risks and uncertainties encountered by an early-stage
company and in a highly regulated and competitive market, such as the biopharmaceutical market, where regulatory approval and market
acceptance of its products are uncertain, and the other risks set forth in the Company&rsquo;s filings with the U.S. Securities
and Exchange Commission (&ldquo;<B>SEC</B>&rdquo;), including risks and uncertainties relating to the outbreak of the COVID-19
pandemic. There can be no assurance that the Company&rsquo;s efforts will ultimately be successful or result in revenues or profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In light of the pending transaction
with Bonus (see note 10), there are also risks relating to, among other things, the timing and anticipated completion of such
transaction and whether the expected benefits of and potential value created by the transaction will materialize.</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated Financial Statements
have been prepared in accordance with accounting principles generally accepted in the United States (&ldquo;<B>U.S. GAAP</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates in preparation of Financial Statements:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company&rsquo;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time
they are made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As applicable to the consolidated Financial Statements, the
most significant estimates and assumptions relate to the going concern assumptions, determining the fair value of embedded and
freestanding financial instruments related to convertible loans and rights to future investment as part of modification or the
settlement of the convertible loans determining the fair value of the contingent obligation with respect to future revenues and
whether modification of terms of financial instruments is considered substantial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated Financial Statements
include the accounts of the Company and its wholly owned subsidiaries. Inter-company balances and transactions have been eliminated
upon consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company aims to direct
its main operations in the United States market. In addition, the convertible loans were denominated in U.S. dollars.
Similarly, the Company issued warrants eligible for exercise for the Company&rsquo;s shares of Common Stock at an exercise
price denominated in U.S. dollars and during January 2020 the Company completed the issuance of 7,500 Series B Non-Voting
Redeemable Preferred Stock for a purchase price of $1 per share for total gross proceeds of $7,500. Also, the management
believes the Company will raise funds through private investment rounds and / or from issuance of equity in dollar amounts by
approaching the market in the United States. As a result, it was determined that the U.S dollar is the currency of the
primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.
Thus, the functional currency of the Company is the U.S. dollar. The Company maintains its books and records in local
currency, which is NIS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Balances denominated in, or linked
to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date.&nbsp;&nbsp;For foreign
currency transactions included in the consolidated statement of comprehensive loss, the exchange rates applicable on the relevant
transaction dates are used.&nbsp;&nbsp;Transaction gains or losses arising from changes in the exchange rates used in the translation
of such balances are carried to financing income or expenses as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The following table presents data
regarding the dollar exchange rate of relevant currencies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">USD 1 = NIS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.456</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.9</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7.8</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cash equivalents are short-term
highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For presentation of statement of
cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total
amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right">December&nbsp;31</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">247</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">718</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Restricted cash deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">41</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">260</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">759</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted bank deposit:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Restricted bank deposit is a deposit
with maturities of more than three months and up to one year. The restricted bank deposit was presented at its cost, including
accrued interest and represents cash which is used as collateral for Wize Israel&rsquo;s credit card used for certain corporate
business expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&rsquo;s investment in marketable equity securities
which is based on equity securities with readily determinable fair values was classified as financial instruments at fair value
with any changes in fair value recognized periodically in earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives
of the assets at the following rates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Computers and electronic equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Furniture and office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&rsquo;s long-lived assets are reviewed for impairment
in accordance with Accounting Standards Codification (&ldquo;<B>ASC</B>&rdquo;) 360, &ldquo;Property, Plant and Equipment&rdquo;,
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds its fair value. Assets to be disposed of are reported at the lower
of the carrying amount or fair value less costs to sell. During the years ended December 31, 2020 and 2019, no impairment losses
have been identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Research and development expenses
are charged to the statement of comprehensive loss as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In-Process Research and Development
assets, acquired in an asset acquisition (<I>i.e.</I>, assets acquired outside a business combination transactions) that are to
be used in a research and development project which are determined not to have an alternative future use are charged to expense
at the acquisition date in accordance with ASC 730, &ldquo;Research and Development&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">j.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Severance pay:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Wize Israel has two employee as
of December 31, 2020 and 2019. Wize Israel&rsquo;s liability for severance pay is subject to Section 14 of Israel&rsquo;s the Severance
Compensation Act, 1963 (&ldquo;<B>Section 14</B>&rdquo;), pursuant to which all Wize Israel&rsquo;s employees are included under
Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee&rsquo;s
name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release Wize Israel from any
future severance payments in respect of those employees. Wize Israel has made all of the required payments as of December 31, 2020
and 2019.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fund is made available to the
employee at the time the employer-employee relationship is terminated, regardless of cause of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The severance pay liabilities and
deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably
transferred to the severance funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Severance expenses for the years
ended December&nbsp;31, 2020 and 2019 amounted to $16 and $17, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for income
taxes in accordance with ASC 740, &ldquo;Income Taxes&rdquo;. This topic prescribes the use of the liability method whereby deferred
tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets
to amounts more likely than not to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company implements a two-step
approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to
be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on
an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized tax positions
has been recognized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentrations of credit risk:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and restricted
bank deposits. Cash and cash equivalents and restricted bank deposits are invested in banks in Israel and the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management believes that the financial
institutions that hold the Company&rsquo;s investments are financially sound and, accordingly, minimal credit risk exists with
respect to these investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has no off-balance-sheet
concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible loans: &nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Allocation of proceeds:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The proceeds received upon the
original issuance of the 2016 Loan (as defined below) together with a freestanding derivative financial instrument (derivative
liability for right to future investment) were allocated to the financial instruments issued based on the residual value method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The detachable derivative financial
instrument related to the 2016 Loan was recognized based on its fair value and the remaining amount of the proceeds was allocated
to the 2016 Loan component.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2017 Loan (as defined below)
was not issued with any detachable instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Beneficial Conversion Features
(&ldquo;BCFs&rdquo;):</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 125px">&nbsp;</TD>
    <TD STYLE="width: 29px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial recognition, the Company has considered the provisions of ASC 815-40, &ldquo;Derivatives and Hedging &ndash; Contracts in Entity&rsquo;s Own Equity&rdquo; (&ldquo;<B>ASC 815-40</B>&rdquo;), and determined that the embedded conversion feature of the 2016 Loan should not be separated from the host instrument because it qualifies for equity classification. Furthermore, the Company applied ASC 470-20, &ldquo;Debt &ndash; Debt with Conversion and Other Options&rdquo; (&ldquo;<B>ASC 470-20</B>) which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios, and has applied the BCFs guidance to determine whether the conversion feature is beneficial to the investor.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">The BCFs was calculated by allocating
the proceeds received in financing transactions to the 2016 Loan and to any detachable freestanding financial instrument (derivative
liability for future investment) included in the transaction, and by measuring the intrinsic value of the conversion option based
on the effective conversion price as a result of the allocated proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">The intrinsic value of the conversion
option with respect to the 2016 Loan was recorded as a discount on the 2016 Loan with a corresponding amount credited directly
to equity as additional paid-in capital. After the initial recognition, the discount on the 2016 Loan was amortized as interest
expense over the contractual term of the 2016 Loan (before its modification) by using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 125px">&nbsp;</TD>
    <TD STYLE="width: 29px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial recognition, the Company has considered the provisions of ASC 815-15,&nbsp;&ldquo;Derivatives and Hedging - Embedded Derivatives&rdquo;, and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, did not meet the definition of a derivative in accordance with the provisions of ASC 815-10, &ldquo;Derivatives and Hedging&rdquo;&nbsp;&nbsp;since its terms did not require or permit net settlement. Thus, it was determined that the conversion feature does not meet the characteristic of being readily convertible to cash.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Furthermore, the Company applied
ASC 470-20 which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Pursuant to ASC 470-20-30, the
amount of the BCFs with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion
price (<I>i.e.</I>, the entire proceeds received for the 2017 Loan) and the aggregate fair value of the Common Stock and other
securities (which consist of the future Investment Rights) into which the 2017 Loan was convertible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">As such difference was determined
to be greater than the amount of the entire proceeds originally received for the 2017 Loan, the amount of the discount assigned
to the BCFs was limited to the amount of the entire proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 125px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 29px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following modifications or exchanges of convertible loans that were accounted for as an extinguishment (see below), upon each additional recognition of the convertible loans based on their modified terms, the Company applied ASC 470-20, &ldquo;Debt &ndash; Debt with conversion and other options&rdquo; to determine whether the conversion feature is considered beneficial to the investors. However, due to the fact that following each of the extinguishments of the convertible loans, such modified convertible loans were recognized based on their fair value as of the modification date, the conversion terms were not considered beneficial to the investors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 125px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 29px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Modifications or Exchanges</U>:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Modifications to, or exchanges
of, financial instruments such as convertible loans, are accounted for as a modification or an extinguishment, following to provisions
of ASC 470-50, &ldquo;Debt- Modification and Extinguishments&rdquo; (&ldquo;<B>ASC 470-50</B>&rdquo;). Such an assessment done
by management either qualitatively or quantitatively based on the facts and circumstances of each transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Under ASC 470-50, modifications
or exchanges are generally considered extinguishments with gains or losses recognized in current earnings if the terms of the new
debt and original instrument are substantially different. The instruments are considered &ldquo;substantially different&rdquo;
when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present
value of the remaining cash flows under the terms of the original instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">If the terms of a debt instrument
are changed or modified and the present value of the cash flows under the terms of the new debt instrument is less than 10%, the
debt instruments are not considered to be substantially different, except in the following two circumstances (i)&nbsp;&nbsp;The
transaction significantly affects the terms of an embedded conversion option, such that the change in the fair value of the embedded
conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and
after the modification or exchange) is at least 10% of the carrying amount of the original debt instrument immediately before the
modification or exchange or (ii)&nbsp;&nbsp;The transaction adds a substantive conversion option or eliminates a conversion option
that was substantive at the date of the modification or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If the original and new debt
instruments are considered as &ldquo;substantially different&rdquo;, the original debt is derecognized and the new debt is initially
recorded at fair value, with the difference recognized as an extinguishment gain or loss under financial expense or income as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If a convertible debt instrument
with a beneficial conversion option that was separately accounted for in equity, is extinguished prior to its conversion or stated
maturity date, a portion of the reacquisition price is allocated to the repurchase of the beneficial conversion option. The amount
of the reacquisition price allocated to the beneficial conversion option is measured using the intrinsic value of that conversion
option at the extinguishment date. The residual amount, if any, is allocated to the convertible debt instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">The gain or loss on the extinguishment
of the convertible debt instrument is determined based on the difference between the carrying amount and the fair value of the
allocated reacquisition price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Modifications to, or exchanges
of equity financial instruments such as right to future investment, are accounted for as a modification or an extinguishment in
a similar manner as described above. Such an assessment is done by management either qualitatively or quantitatively based on the
facts and circumstances of each transaction. Among others, management considers whether, the fair value of the financial instruments
before and after the modification or exchange are substantially different.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If the original and new equity
instruments are considered as &ldquo;substantially different&rdquo;, the excess fair value of the allocated reacquisition price
over the fair value of the modified financial instrument before the modification, is recognized directly to retained earnings as
a deemed dividend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"><U>Issuance costs of convertible
loan:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 125px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2016 Loan (or costs allocated to such component in a package issuance) were presented as a direct deduction from the amount of the 2016 Loan and in subsequent periods such costs (together with the discount created by BCFs if applicable) expensed as financing expenses over the contractual term of the 2016 Loan by using the effective interest method. Any such costs that were allocated to the derivative component were expensed as incurred.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 125px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2017 Loan (or costs allocated to such component in a package issuance) were presented as a deferred asset since the 2017 Loan was completely discounted at the initial recognition. In subsequent periods, such expenses were amortized ratably over the original term of the 2017 Loan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"><U>Extinguishment of convertible
loans:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Upon the final extinguishment
of the convertible loans upon their maturity, the difference between the reacquisition price which consist of the cash paid, the
fair value of instruments issued (shares and warrants) and the modification of loans and cancellation of existing financial instruments)
and the carrying amounts of the convertible loans being extinguished was recognized as a gain or loss in the period of extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of financial instruments:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">ASC 820, &ldquo;Fair Value Measurements
and Disclosures&rdquo; (&ldquo;<B>ASC 820</B>&rdquo;), defines fair value as the price that would be received to sell an asset
or paid to transfer a liability (<I>i.e.</I>, the &ldquo;exit price&rdquo;) in an orderly transaction between market participants
at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In determining fair value, the
Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used
when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based
on market data obtained from sources independent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Unobservable inputs are inputs
that reflect the Company&rsquo;s assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The hierarchy is broken down into
three levels based on the inputs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;1&nbsp;</FONT></TD>
    <TD STYLE="width: 19px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;2&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;3&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The availability of observable
inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of
investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based
on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment
and the investments are categorized as Level&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The carrying amounts of cash and
cash equivalents, short-term bank deposits, other accounts receivable, trade payables and other accounts payable approximate their
fair value due to the short-term maturities of such instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Fair value of the marketable equity
securities is determined based on a Level 1 input.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450 &ldquo;Contingencies&rdquo;. A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed
and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information
and events pertaining to a particular matter. As of December&nbsp;31, 2020, the Company is not a party to any litigation that could
have a material adverse effect on the Company&rsquo;s business, financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Legal costs incurred in connection
with loss contingencies are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Effective January 1, 2019, the Company accounts for its leases
under ASC 842, &ldquo;Leases&rdquo;. Under this guidance, arrangements meeting the definition of a lease are classified as operating
or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated
by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&rsquo;s incremental borrowing
rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results
in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In calculating the right of use
asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases
having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on
a straight-line basis over the lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recognized&nbsp;$42
of operating lease right of use assets and operating lease liabilities at January 1, 2019. As of December 31, 2020 and 2019, total
of right-of-use assets related to the Company&rsquo;s operating leases and operating lease liabilities was $22.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recorded an amortization
of $20 in right of use assets and operating lease liabilities for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A Warrants and December 2019 Warrants with Down-Round Protection:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Commencing January 1, 2018 and
following the early adoption of Accounting Standard Update (&ldquo;<B>ASU</B>&rdquo;) No. 2017-11, &ldquo;I. Accounting for certain
financial instruments with Down Round Features&rdquo; (ASU 2017-11), the Company disregards certain down-round features when assessing
whether a financial instrument is indexed to its own stock, for purposes of determining liability or equity classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Based on its evaluation,
management has determined that the Series A Warrants and warrants that were issued in October 2018 (the &ldquo;<B>October
2018 Warrants</B>&rdquo;) and in December 2019 (the &ldquo;<B>December 2019 Warrants</B>&rdquo;), as part of a private
placement, as described in Note&nbsp;13n, respectively, which include a down-round protection that would adjust the exercise
price of the Series A Warrants based on the price at which the Company subsequently issues shares or other equity-linked
financial instruments, if that price is less than the original exercise price of the Series A Warrants, are eligible for
equity classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In accordance with the provisions
of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (<I>i.e.</I>, when the exercise price of
the Series A Warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend
and as a reduction of income available (increase of loss applicable) to common shareholders for purposes of basic earnings per
share (EPS) calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding a triggering event that required down-round adjustment
of the exercise price of the warrants during 2020 and 2019, see Note 13p and 13q, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Modifications to the terms of warrants that are classified
as equity and remains to be classified in equity after the modification, are accounted for in a similar manner to share-based compensation
guidance with respect to modifications. Accordingly, the incremental fair value from the modification (the change in the fair value
of the warrant before and after the modification) is recognized in retained earnings as a deemed dividend (e.g., dividends to a
particular class of equity holders).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted loss per share:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Basic loss per share is computed
by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares of Common Stock
outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Series
A Preferred Stock) are considered in the computation of basic income (loss) per share using the two-class method. In periods of
net loss, such participating securities are included in the computation, since the holders of such securities have a contractual
obligation to share the losses of the Company (as the convertible Series A Preferred Stock do not have a right to receive any mandatory
redemption amount and as they are entitled only to dividends on an as-converted basis together with the common shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In computing diluted loss per share,
basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of options, warrants and
rights for future investment issued or granted using the &ldquo;treasury stock method&rdquo; and upon the conversion of 2017 Loan
and 2016 Loan using the &ldquo;if-converted method&rdquo;, if the effect of each of such financial instruments is dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For the year ended
December&nbsp;31, 2020 and 2019, all outstanding warrants, stock options and other convertible instruments have been excluded
from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    2:-</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING
    POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The loss and the weighted average
number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2020 and 2019, is as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Numerator:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,929</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,450</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Add: Loss attributed to preferred stock (*)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">136</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to right for future investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(185</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend due to down round adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(267</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to stockholders of Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,266</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,766</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Shares of Common Stock used in computing basic and diluted net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,669,628</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,519,682</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss per share of Common Stock, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.32</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.36</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                         the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase
                                         Agreement (as defined below). These shares of preferred stock are participating securities. During
                                         the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>Year
                                         ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December
                                         31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Number of shares:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Common shares used
    in computing basic and diluted loss per share</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">16,669,628</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">10,519,682</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Preferred Stock and options excluded
    from the calculations of diluted loss per share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">614,763</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">16,931,097</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive loss</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The components of accumulated
other comprehensive loss which resulted from foreign currency translation adjustment as of December&nbsp;31, 2020 and 2019 were
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <BR> accumulated <BR>
    other <BR> comprehensive <BR> income (loss)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2020</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(73</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(73</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font-size: 6pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Stock-based compensation to employees
is accounted for in accordance with ASC 718, &ldquo;Compensation - Stock Compensation&rdquo; (&ldquo;<B>ASC 718</B>&rdquo;), which
requires estimation of the fair value of equity - based payment awards on the date of grant using an option pricing model. The
value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Stock-based compensation expense
is recognized for the value of awards granted based on the accelerated method over the requisite service period of each of the
awards, net of estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates.</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fair value of stock options
granted to Wize Israel employees was estimated using the Black- Scholes option pricing model, which requires a number of assumptions,
of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated
based upon historical volatilities of the Company on a weekly basis since the marketability of Wize Israel is less than the expected
option term. The expected option term represents the period that Wize Israel&rsquo;s stock options are expected to be outstanding
and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The expected dividend yield assumption
is based on Wize Israel&rsquo;s historical experience and expectation of no future dividend payouts. Wize Israel has historically
not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Following the adoption of ASU 2018-07 in January 2018, all equity-classified
nonemployee share-based payment are accounted for in accordance with the provisions of ASC 718 and accordingly, awards granted
during 2019 and 2020 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent Accounting Pronouncements not adopted
    yet</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">ASU 2016-13, &ldquo;Financial Instruments &ndash; Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&rdquo; (&ldquo;ASU 2016-13&rdquo;)</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On June 2016, the FASB issued ASU Update 2016-13,
&ldquo;Financial Instruments &ndash; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&rdquo; (&ldquo;ASU
2016-13&rdquo;) ASU Update 2016-13 revised the criteria for the measurement, recognition, and reporting of credit losses on financial
instruments to be recognized when expected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On November 2019, the FASB issued
ASU 2019-10, &ldquo;Financial Instruments&mdash;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic
842) &ndash; Effective Dates,&rdquo; which, among other provisions, the effective date of ASU 2016-13 was amended as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">1. Public
business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (SRCs)
as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">2. All
other entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">As the Company is eligible to be considered as smaller reporting
company, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal
years, with early adoption permitted.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is in the process
of evaluating the effect that ASU 2016-13 will have on the results of operations and financial statements, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt"></FONT></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;<FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">ASU 2020-06&mdash;Debt&mdash;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&mdash;Contracts in Entity&rsquo;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts
in an Entity&rsquo;s Own Equity</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In August 2020, the FASB issued
ASU 2020-06&mdash;Debt&mdash;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&mdash;Contracts
in Entity&rsquo;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&rsquo;s Own Equity
(ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts in an entity&rsquo;s own equity. Among other changes, ASU 2020-06 removes from
GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and beneficial conversion
feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for
such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life
of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument
contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt
instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to
calculate the impact of convertible instruments on diluted earnings per share (EPS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The amendments in ASU 2020-06
are effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding
entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021,
including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning
after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">ASU 2020-06 can be adopted
on either a fully retrospective or modified retrospective basis. The adoption of this standard is not expected to result in a
material impact to the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent obligation with respect to future
    revenues</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company&rsquo;s contingent
obligation to payment of 37% of the future LO2A Proceeds, if any, was accounted for as long-term debt in accordance with the provisions
of Accounting Standards Codification (&ldquo;ASC&rdquo;) 470-10-25, &ldquo;Sales of Future Revenues or Various other Measures
of Income,&rdquo; which relates to cash received in exchange for payments of a specified percentage or amount of revenue or other
measure of income of a particular product line, business segment, trademark, patent, or contractual right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Such repayment obligations are
contingent upon the receipt by the Company of any future proceeds from LO2A sales, license or other, as described in Note 5 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company elected to measure
the contingent payment obligation in its entirety, at its fair value (the &ldquo;Fair Value Option&rdquo;) in accordance with
ASC 825-10, &ldquo;Financial Instruments&rdquo; due to the variable and contingent nature of the repayment provisions of such
financial liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fair value of such
liability was measured upon its initial recognition at its fair value, based on the difference between the fair value of the
marketable securities received by the Company, less the amount of cash paid by the Company. In subsequent periods, the fair
value of the liability for contingent payment obligation is based on management estimate. As of December 31, 2020, the
Company revalued the liability to its fair value with the assistance of an external valuation specialist, pursuant to the
Company&rsquo;s estimations and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 2:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined
that the inputs used in measuring the fair value of the contingent payment obligation fall within Level 3 in the fair value
hierarchy which involves significant estimations and assumptions regarding any projected future proceeds from the LO2A,
including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product
into the U.S. market - 12%, the patent expiration date (2038), the operational profit estimated rate - 26%, the probabilities
for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined that the inputs used in measuring
the fair value of the contingent payment obligation fall within Level 3 in the fair value hierarchy which involves significant
estimates and assumptions including, among others, any projected future proceeds from the LO2A, the risk-adjusted rate for discounting
future cash flows and other relevant assumptions, see Note 10.&nbsp;&nbsp;Actual results could differ from the estimates made.
Changes in fair value (including the component related to imputed interest), would be included in the consolidated statements of
comprehensive loss as part of financial income (loss) under the heading &ldquo;Changes in fair value of contingent payment obligation
with respect to future revenues.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">w.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mandatorily Redeemable Series B Preferred
    Stock</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company classified its formerly
outstanding Series B Preferred Stock as a liability, as their terms embody an unconditional obligation of the Company to redeem
the shares by transferring cash or other assets that equal (i) 80% of the proceeds received by the Company through future sales
of the Bonus Shares issued to the Company under the Bonus Agreements (as hereinafter defined) and (ii) 80% of any cash dividends
received by the Company on such Bonus Shares) at a specified or determinable date or dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company elected to measure
this liability in its entirety, at its fair value (the &ldquo;Fair Value Option&rdquo;) in accordance with ASC 825-10, &ldquo;Financial
Instruments&rdquo; due to the variable and contingent nature of the redemption price of such financial liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Upon initial recognition and in
subsequent periods, the Company measured the&nbsp;fair value of the liability related to the Series B Preferred Stock based on
the value of the Bonus Shares and the cash amount that the Company was required to transfer to the Series B investors upon the
redemption of the Series B Preferred Stock. The difference between the amount received by the Company upon the issuance of the
Series B Preferred Stock and their fair value as of that date was carried immediately to the consolidated statements of comprehensive
loss as part of financial income (loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The issuance costs of the Series
B Preferred Stock were recognized immediately as an expense during the three months ended March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On July 8, 2020, the Company elected
to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares to the (now former)
holders of Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 29, 2020, Wize entered into an Addendum (the &ldquo;Addendum&rdquo;)
with Bonus, whereby, among other things, Bonus agreed to issue to the Company additional ordinary shares of Bonus (the &ldquo;Bonus
Shares&rdquo;, the total number of which consists of (i) the Milestone Settlement Shares, which, as defined in the Addendum, means
Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum)
by NIS 0.50, and (ii) the HCW Settlement Shares, as defined in note 10a (together with the Milestone Settlement Shares, the &ldquo;Settlement
Shares&rdquo;), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed
in NIS (based on the exchange rate set in the Addendum) by NIS 0.50. In consideration for the Settlement Shares, the Company agreed
to make certain amendments to the Bonus Agreements, including the following key modifications: (i) the Company will waive the requirement
that Bonus will affect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing, which means that US$3.7 million
were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the &ldquo;Nasdaq
Milestone Shares&rdquo;) were released to the Company and to its former holders of Series B Preferred Stock (the &ldquo;Former
Series B Holders&rdquo;); (ii) the Company will waive approximately US$120 in liquidated damages that accrued as a result of the
delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli
subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under the Bonus Exchange Agreement,
including certain related negative covenants. The closing occurred on December 29, 2020. It should be noted that, in accordance
with the obligations of the Company to the Former Series B Holders (see below), the Company has transferred 80% of the Milestone
Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the entire
balance of the Series B preferred stock was extinguished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 3:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MARKETABLE EQUITY SECURITIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owned 52,249 ordinary shares of Can-Fite representing
approximately 0.04% of Can-Fite&rsquo;s issued and outstanding share capital as of December 31, 2019. As of December 31, 2019,
the investment amounted to $6. During the year ended December 31, 2019 the Company recorded a loss of $26. During 2020 the Company
sold all of its Can-Fite ordinary shares for net proceeds of approximately $3. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2019 the Company held 25,000 ordinary shares
of Cannabics Pharmaceuticals, Inc. (&ldquo;<B>Cannabics</B>&rdquo;) representing less than 1% of its issued and outstanding share
capital as of that day. As of December 31, 2019, the investment amounted to $3. During 2020 the Company sold all of its Cannabics
ordinary shares for net proceeds of approximately $260.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2019, the Company sold 2,238,944 shares
of Cannabics through a broker at the amount of $260 (see also Note 4) which were received as of the date of Financial Statements.
The Company made a payment of $1 to the broker as a deposit for the Broker&rsquo;s activity. During 2019 the Company recorded a
loss of $501.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns 18,822,533 ordinary shares of Bonus representing
approximately 1.9% of Bonus&rsquo;s issued and outstanding share capital as of December 31, 2020. As of December 31, 2020, the
fair value of the investment, based on the quoted market price on TASE, amounts to $2,834 and is presented as Marketable equity
securities in the accompanying consolidated balance sheet. During 2020 the Company recorded an income from sale of shares and revaluation
of $1,197 with respect to this investment, see also Note 10.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 4:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER CURRENT ASSETS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Prepaid expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">92</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Governmental authorities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other receivable (Note 3c)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">260</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">66</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">378</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B></B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 5:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSE AGREEMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In May 2015, Wize Israel
entered into an Exclusive Distribution and Licensing Agreement (as amended, the &ldquo;<B>License Agreement</B>&rdquo;) with
Resdevco Ltd. (&ldquo;<B>Resdevco</B>&rdquo;), whereby Resdevco granted to Wize Israel (and thereafter, to OcuWize) an
exclusive license to purchase, market, sell and distribute a formula known as LO2A (&ldquo;<B>LO2A</B>&rdquo;) in the United
States and China as well as a contingent right to do the same in other countries. LO2A is a drug developed for the treatment
of DES, and other ophthalmological illnesses, including CCH and Sj&ouml;gren&rsquo;s. Pursuant to the LO2A License Agreement,
Wize Israel is required to pay Resdevco royalties for sales in the licensed territories, payable on a semi-annual basis,
subject to making certain minimum royalty payments as set forth in the LO2A License Agreement. In January 2020 and January
2021, the Company paid Resdevco royalties in the amount of $150.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the License Agreement,
the minimum royalties payable by Wize Israel to Resdevco shall be $150 per year through 2021. A one-time payment to Resdevco by
Wize Israel in an amount of $650 shall be due no later than the second anniversary of the receipt of Food and Drug Administration
(&ldquo;<B>FDA</B>&rdquo;) approval (the &ldquo;<B>Deferred Amount</B>&rdquo;); however, following FDA approval, if annual royalties
due to Resdevco by Wize Israel exceed the Minimum Royalties (as defined in the License Agreement), an amount equal to 50% of such
excess shall be added towards settlement of the Deferred Amount. As to royalty payments, Resdevco shall be entitled to the greater
of $0.60 per unit sold, or a percentage of revenues, not to exceed 10%, from sales made in the United States and other countries,
excluding Israel, China and Ukraine, but not less than the Minimum Royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined not
to pursue currently any activities outside the USA until the Company will obtain from Resdevco satisfactory registration file
including DES and at least one more indication such as CCH or Sj&ouml;gren&rsquo;s. The Company seeks to approve a proposed regulatory
strategy acceptable to the Chinese market based on the regulatory files provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 5:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSE AGREEMENT (Cont.)</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The LO2A License Agreement has
an initial term of seven years that expires in May 2022, and, unless Wize Israel provides prior notice of at least twelve (12)
months terminating the agreement, the LO2A License Agreement renews automatically each year. Wize Israel may terminate the LO2A
License Agreement prior to May 2022, subject to certain conditions, including, a 180 days prior notice to Resdevco, and penalty
payment of $100,000, depending on the timing of termination. The LO2A License Agreement may also be terminated by either party
upon the occurrence of certain other customary termination triggers, including material breaches of the LO2A License Agreement
by either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On May 4, 2020, the Company and
Resdevco entered into a further amendment to the License Agreement, whereby the parties agreed, among other things, that if (i)
within 3 months after we receive a pre-Investigational New Drug (&ldquo;IND&rdquo;) with respect to the LO2A, or (ii) in case of
proven inability to receive such Pre-IND as a direct result of the COVID-19, in both cases not later than December 31, 2021, we
provide Resdevco with a written termination notice, the License Agreement shall be terminated immediately, and to the extent we
exercise such termination right before the end of 2021, no minimum royalty fee shall be due for the year 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of the date of these Financial
Statements, the Company had not received FDA approval for LO2A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">See Note 10 below regarding the Company&rsquo;s contingent obligation
for the payment of 37% of the future Lo2A proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2020, the Company has recognized a liability
of $250, representing the minimum commitment to pay royalties to Resdevco based on the upcoming January 2021 payment in an amount
of $150 and an amount of $100 which represents a termination fee payable to Resdevco if the Company exercises its right to terminate
the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2020 and 2019, the current liability to pay
future royalties amounts to $250 (for additional information and minimum royalties see also Note 6).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 6:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSE PURCHASE OBLIGATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2017, Wize
    Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 were reduced to $150
    for 2018 and 2019. In addition, If Wize Israel would have obtained an FDA marketing license during 2019, the Company was also
    required to pay Resdevco the remainder of the payment of 2019, however, such approval was not achieved in 2019. Consequently,
    during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the
    2018 minimum commitment, which was paid during the third quarter of 2018. In addition, during the third quarter of 2018 and
    2019, the Company has recognized an amount of $150 as a liability in respect to the 2019 and 2020, respectively, minimum commitment.
    Such amount was reflected as an expense under research and development expenses in 2018 and 2019 as applicable. In February
    2019, the Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through
    2021, and thereafter annual payments of $475,000 per year, and shall pay Resdevco $650,000 within two years after receipt
    of FDA approval for eye drops utilizing the licensed technology.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table
    details the repayment dates of the remaining Minimal Commitment on the financial liability and the balance in the consolidated
    Financial Statements:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Repayment dates:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 9pt">January 1, 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">January 1, 2021 (see to Note 5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Remaining balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Current liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-current liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 7:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACCOUNTS PAYABLE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Employees and payroll accruals</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">475</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">87</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Liability to HCW, see Note 10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">278</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Trade payables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,306</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">369</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 8:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE LOANS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On March 20, 2016, Wize Israel
entered into an agreement (as amended, the &ldquo;<B>2016 Loan Agreement</B>&rdquo;) pursuant to which Rimon Gold Assets Ltd.
(&ldquo;<B>Rimon Gold</B>&rdquo;) extended a loan in the principal amount of up to NIS 2 million (approximately $531 according
to an exchange rate at 2016 loan originate date), which bears interest at an annual rate of 4% (the &ldquo;<B>2016 Loan</B>&rdquo;).
Pursuant to the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as
defined below), the 2016 Loan had a maturity date of December 31, 2018. Regarding the modifications of the maturity date of the
2016 Loan on October 2018, March 2019 and May 2019, see also Note 8a, 8b, 8c and 8d. Regarding loan extinguishment, refer to Note
8e.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the 2016 Loan Agreement,
Rimon Gold had the right, at its sole discretion, to convert any outstanding portion of the 2016 Loan, but not less than NIS 100,000
(approximately $26 according to an exchange rate at 2016 loan origination date), into Wize Israel ordinary shares at a conversion
price of NIS 15.2592 per share (approximately $3.84), subject to adjustments for stock splits and similar events set forth in
the 2016 Loan Agreement. As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016
Loan was adjusted to NIS 3.6 (approximately $0.96). As a result of the 2017 Loan Amendment, the aggregate principal amount of
the 2016 Loan was adjusted to $531 and the conversion price per share for the 2016 Loan was adjusted to $0.9768.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, under the 2016
Loan Agreement, as modified by the 2017 Loan Agreement and the 2017 Loan Amendment, Rimon Gold had the right (the &ldquo;<B>2016
Investment Right</B>&rdquo;), until June 30, 2019, to invest up to $797, in the aggregate, at an agreed price per share, which
was adjusted based on the Exchange Ratio (as defined in the Agreement and Plan of Merger with Bufiduck Ltd., a company formed
under the laws of the State of Israel and our wholly owned subsidiary and Wize Israel) from NIS 20.4 (approximately $6.00) to
NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment, from NIS 5.04 to $1.308 (subject to adjustments in case of
stock splits or similar events).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Rimon Gold was entitled, under
certain circumstances, to demand repayment of the 2016 Loan subject to certain conditions. However, as described in note 8e below
the convertible loan was extinguished in November 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On January 15, 2017, Wize Israel
entered into the loan agreement (the &ldquo;<B>2017 Loan Agreement</B>&rdquo;, and together with the 2016 Loan Agreement the &ldquo;<B>Loan
Agreements</B>&rdquo;) with Ridge Valley Corporation (&ldquo;<B>Ridge</B>&rdquo;), and, by way of entering into assignments and
assumption agreements following such date, also with Rimon Gold and Shimshon Fisher (&ldquo;<B>Fisher</B>&rdquo;, and together
with Ridge and Rimon Gold, the &ldquo;<B>2017 Lenders</B>&rdquo;), whereby each of the 2017 Lenders extended a loan in the principal
amount of up to NIS 1 million (approximately $274 according to an exchange rate at 2017 loan originate date) and in the aggregate
principal amount of up to NIS 3 million (approximately $822 according to an exchange rate at 2017 loan originate date), which
bears interest at an annual rate of 4% (the &ldquo;<B>2017 Loan</B>&rdquo;, and together with the 2016 Loan, the &ldquo;<B>Loans</B>&rdquo;).
Pursuant to the 2017 Loan Agreement and the 2017 Loan Amendment, the 2017 Loan had a maturity date of December 31, 2018. Regarding
the modification of the maturity date of the 2017 loan in October 2018, March 2019 and May 2019, see also Note 8b, 8c and 8d.
Regarding loan extinguishment, refer to Note 8e.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 8:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE LOANS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the 2017 Loan
Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017
Loan, but no less than NIS 100,000 (approximately $28 according to an exchange rate at 2017 loan originate date), that the
lender provided to Wize Israel (each such portion converted into Wize Israel ordinary shares at a conversion price per share
equal to the lower of (1) NIS 24 (approximately $6.72) and (2) the lowest price per share of Wize Israel in any offering made
by Wize Israel following the date of the 2017 Loan Agreement and through the date of such requested conversion, subject to
adjustments for stock splits and similar events set forth in the 2017 Loan Agreement (the &ldquo;<B>2017 Loan Conversion
Price</B>&rdquo;). As a result of the private placement agreement, dated June 23, 2017 between Wize Israel, and certain
investors (see also Note 12b to the 2018 consolidated Financial Statements), the 2017 Loan Conversion Price for Rimon Gold,
Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion
Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately
$1.15).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As a result of the 2017 Loan
Amendment, the aggregate principal amount of the 2017 Loan was adjusted to $822 and the 2017 Loan Conversion Price was adjusted
to $1.1112. See &ldquo;2017 Loan Amendment&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, under the 2017
Loan Agreement, as modified by the 2017 Loan Amendment, the 2017 Lenders had the right (the &ldquo;<B>2017 Investment Right</B>&rdquo;,
and together with the 2016 Investment Right the &ldquo;<B>Investment Rights</B>&rdquo;), until June 30, 2019, to invest up to
$1,233, in the aggregate, at an agreed price per share equal to 120% of the applicable 2017 Loan Conversion Price, which was adjusted
in December 2017, based on the 2017 Loan Amendment, to a fixed exercise price of $1.332 (subject to adjustments in case of stock
splits or similar events).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Ridge was entitled, under certain
circumstances, to demand repayment of the 2017 Loan subject to certain conditions. However, as described in note 8e below, the
convertible loan was extinguished on November 2019. On April 21, 2019, Ridge transferred the loan and the 2017 Investment Right
to Mobigo Inc, a company wholly owned by the Company&rsquo;s CEO, Noam Danenberg (&ldquo;<B>Mobigo</B>&rdquo;). Mr. Danenberg
waived a debt owed to him directly by Ridge (that did not involve the Company) as consideration for these derivative securities.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2017 Loan Amendment</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On December 21, 2017, the Company
entered into an amendment (the &ldquo;<B>2017 Loan Amendment</B>&rdquo;) to the 2016 Loan Agreement and the 2017 Loan Agreement.
Pursuant to&nbsp;the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31,
2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise
period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June
30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017 Loan</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016 Loan</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt">Aggregate principal amount</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">822</TD><TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 4pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(*)</P></TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">531</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Conversion price per Company&rsquo;s share</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.1112</TD><TD STYLE="white-space: nowrap; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.9768</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Aggregate maximum of Right to Future Investment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,233</TD><TD STYLE="white-space: nowrap; padding-bottom: 4pt; text-align: left"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">(**)</P></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">797</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Exercise price per Company&rsquo;s share of Right to Future Investment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.332</TD><TD STYLE="white-space: nowrap; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.308</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal loan amount
    of $274 for each of the three 2017 Lenders.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(**)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum of Right
    to Future Investment of $411 for each of the three 2017 Lenders.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Accordingly, each of the modified
financial instruments was initially recorded at fair value. Then, the total fair value of the modified financial instruments related
to the 2017 Loan and 2016 Loan (the &ldquo;<B>Reacquisition Price</B>&rdquo;) was allocated to the original financial instruments
included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial instruments as of the
date of the extinguishment. As a result, an aggregate amount of $2,104 was allocated to the 2016 Loan and an aggregate amount
of $2,985 was allocated to the 2017 Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2017 Loan amendment was accounted
for as an extinguishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 8:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE LOANS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2018 Loan Amendment</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In connection with the Purchase
Agreement (as defined below), on October 19, 2018, the Company and Wize Israel entered into an amendment to the convertible loans
outstanding as of that date (the &ldquo;<B>2018 Loan Amendment</B>&rdquo;). Pursuant to the 2018 Loan Amendment, the maturity
date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following
the date that the registration statement the Company will file under the registration rights agreement dated October 22, 2018
(the &ldquo;<B>Registration Rights Agreement</B>&rdquo;) covering the resale of all Common Stock, issued pursuant to the Purchase
Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Series A Warrants, are registered
for resale for investors who are not a party to the 2018 Loan Amendment, (b) 90 days following the date on which all securities
issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement,
and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the 2018 Loan Amendment, the expiration
date of the Investment Rights under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan
Agreements maturity date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2018 Loan Amendment was accounted
for as an extinguishment on October 19, 2018.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to ASC 470-50, each
of the modified financial instruments were measured at fair value. Then, the Reacquisition Price was allocated to the original
financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial
instruments as of the date of the extinguishment. As a result, an aggregate amount of $2,314 was allocated to the 2016 Loan and
its related right to future investment and an aggregate amount of $3,286 was allocated to the 2017 Loan and its related right
to future investment.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the Reacquisition
Price that was allocated to the Right to Future Investment amounting to $874 which was included in the 2016 Loan and its fair
value as of that date amounting to $764 was recorded directly to additional paid in capital (as a deemed dividend in an amount
of $110). In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $1,336 which
was included in the 2017 Loan and its fair value as of that date amounting to $1,154, was recorded directly to additional paid-in
capital (as a deemed dividend in an amount of $182). The difference between reacquisition price that was allocated to the 2017
Loan and to the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as a loss
on extinguishment amounting to $1,709 of the 2017 Loan and 2016 Loan.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2018 Loan Amendment became
effective in the fourth quarter of 2018 and all of the accounting effects were recognized in the fourth quarter of 2018.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 8:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE LOANS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;<B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>March 2019 Loan
    Amendment</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On March 4, 2019, the Company
and Wize Israel entered into another amendment to convertible loan agreements (the &ldquo;<B>March 2019 Amendment</B>&rdquo;)
with Rimon Gold, Ridge and Fisher. Pursuant to the March 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement,
and (ii) 2017 Loan Agreement were extended to May 31, 2019 from March 4, 2019. The parties also agreed that Rimon Gold&rsquo;s,
Ridge&rsquo;s and Fisher&rsquo;s remaining 2016 Investment Rights (as of that date) under the 2016 Loan Agreement to invest up
to $512.8, in the aggregate, at $1.308 per share, and the expiration date of Rimon Gold&rsquo;s, Ridge&rsquo;s and Fisher&rsquo;s
remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at
$1.332 per share, be extended from June 30, 2019 to November 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The March 2019 Amendment was accounted
for as an extinguishment on March 4, 2019. Until that date, the 2017 Loan and the 2016 Loan were being accounted for under the
terms of the 2018 Loan Amendment discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to ASC 470-50, each
of the modified financial instruments were measured at fair value on the extinguishment date. Then, the Reacquisition Price was
allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative
fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $986 was allocated
to the 2016 Loan and its related right to future investment and an aggregate amount of $1,423 was allocated to the 2017 Loan and
its right to future investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the Reacquisition
Price that was allocated to the Right to Future Investment amounting to $237 which was included in the 2016 Loan and its fair
value as of that date amounting to $192 was recorded directly to additional paid-in capital (as a deemed dividend in an amount
of $45). In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $348 which was
included in the 2017 Loan and its fair value as of that date amounting to $289, was recorded directly to additional paid-in capital
(as a deemed dividend in an amount of $59). The difference between reacquisition price that was allocated to the 2017 Loan and
to the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as gain on extinguishment
amounting to $48 of the 2017 Loan and 2016 Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>May 2019 Amendment</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On May 31, 2019, the Company and Wize Israel entered into an
additional extension to convertible loan agreements (the &ldquo;<B>May 2019 Amendment</B>&rdquo;) with Rimon Gold, Noam Danenberg
and Fisher. Pursuant to the May 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement
was extended to November 30, 2019 from May 31, 2019 (as previously described under the March 2019 Amendment). The parties also
agreed that the expiration date of Rimon Gold&rsquo;s, Mr. Danenberg&rsquo;s and Fisher&rsquo;s remaining 2016 Investment Rights
(as of that date) under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and Rimon Gold&rsquo;s,
Mr. Danenberg&rsquo;s and Fisher&rsquo;s remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest
up to $663.4, in the aggregate, at $1.332 per share, be extended from November 30, 2019 to May 31, 2021. As consideration for extending
the maturity date of the loans, the Company issued to Rimon Gold, Mr. Danenberg (through Mobigo, his wholly owned company), and
Fisher two-year warrants to purchase an aggregate of 868,034 shares of Common Stock at a fixed price of $1.10 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The May 2019 Amendment was accounted
for as an extinguishment on May 31, 2019. Until that date, the 2017 Loan and the 2016 Loan were being accounted for under the
terms of the March 2019 Loan Amendment discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to ASC 470-50, each
of the modified financial instruments were measured at fair value on the extinguishment date. Then, the Reacquisition Price was
allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative
fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $1,015 was
allocated to the 2016 Loan and an aggregate amount of $1,498 was allocated to the 2017 Loan and its related right to future investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the Reacquisition
Price that was allocated to the Right to Future Investment amounting to $94 which was included in the 2016 Loan and its fair value
as of that date amounting to $61 was recorded directly to additional paid-in capital (as a deemed dividend in an amount of $33).
In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $139 which was included
in the 2017 Loan and its fair value as of that date amounting to $91, was recorded directly to additional paid-in capital (as
a deemed dividend in an amount of $48). The difference between reacquisition price that was allocated to the 2017 Loan and to
the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as loss on extinguishment
amounting to $926 of the 2017 Loan and 2016 Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 8:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE LOANS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>November 2019
    Amendment</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Effective November 29, 2019, the
Company and Wize Israel entered into an amendment to convertible loan agreements (the &ldquo;<B>November 2019 Amendment</B>&rdquo;)
with Rimon Gold, Mobigo and Fisher.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the November 2019
Amendment, the Company repaid in cash approximately $760 of the $1,520 ($1,353 of principal and $167 accrued interest) outstanding
under the loans on November 29, 2019 and Rimon Gold, Mobigo, and Fisher agreed to convert the remaining outstanding amounts of
the loans at a later date. On December 13, 2019, the Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196
shares of Common Stock upon conversion of the loans at a reduced conversion price of $0.27 per share and issued the December 2019
Warrants to purchase an aggregate of 5,632,392 shares of Common Stock at an exercise price of $0.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The December 2019 Warrants have a term of five years and will
be exercisable five days following the public announcement of positive clinical data results for LO2A. In addition, the parties
agreed that effective December 13, 2019, the exercise price or conversion price of all other convertible securities (rights for
future investment) previously issued to Rimon Gold, Mobigo, and Fisher in connection with the loans (the &ldquo;<B>Existing Convertible
Securities</B>&rdquo;) shall be adjusted to $0.27 per share&nbsp;and that the aggregate number of shares of Common Stock issuable
upon exercise or conversion of a lender&rsquo;s Existing Convertible Securities shall be reduced in accordance with the percent
of such lender&rsquo;s conversion of its outstanding loan. In addition, it was agreed that in any case when the exercise price
of the October 2018 Warrants is reduced as a result of dilutive issuance to an exercise price lower than the exercise or conversion
price of the Investment Rights granted under the Loan Agreements, than the exercise or conversion price of the Investment Rights
shall be reduced to the new October 2018 Warrants exercise price (&ldquo;<B>New Exercise Price</B>&rdquo;). As of December 31,
2019, the New Exercise Price of such Investment Rights was $0.16. See Note 13n regarding the modification of the exercise price
of such warrants and their exercise into ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the aggregate
reacquisition price of the loans (<I>i.e</I>, the cash, the fair value of the shares and the December 2019 Warrants and the incremental
fair value related to the existing convertible loans) approximate $1,619 and the carrying amount of the convertible loans (principal
and accrued interest) was recognized as a loss from extinguishment in an amount of $99 as part of financial income (expense)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management considered the provisions
of ASC 815-40 and has determined that the December 2019 Warrants are considered indexed to the Company&rsquo;s stock and that
all other relevant criteria required for equity classifications are met. Accordingly, it was determined that the December 2019
Warrants are eligible for equity classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 8:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONVERTIBLE LOANS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>November 2019
    Amendment</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The below table describes the roll forward of 2017 Loan and
2016 Loan for the year ended December 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Opening balance (including accrued interest)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,635</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of premium related to convertible loans prior to 2018 modification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of premium related to convertible loans following 2018 modification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(641</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &ndash; March 2019 modification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,873</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued interest on 2017 Loan and 2016 Loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Amount allocated to 2016 Loan and 2017 Loan based on modified terms &ndash; March 2019 modification</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,767</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amortization of premium related to convertible loans following March 2019 modifications</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(413</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &ndash; May 2019 extension</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,353</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Amount allocated to 2016 Loan and 2017 Loan based on modified terms &ndash; May 2019 extension</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,556</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of premium related to convertible loans &ndash; May 2019 extension</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(203</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">November 2019 repayment in cash and Common Stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,520</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 9:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHORT TERM LOAN PAYABLE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 15, 2020, OcuWize entered into a loan agreement with
Bank Hapoalim (the &ldquo;Bank&rdquo;), whereby the Bank extended a loan in the principal amount of NIS 850 (approximately $247)
(the &ldquo;2020 Loan&rdquo;), which is presented as a short term loan payable in the consolidated balance sheet. The 2020 Loan
bears interest at an annual rate of 5.45%, which is paid in monthly payments. The 2020 Loan has a maturity date of January 15,
2021. In order to secure its obligations and performance pursuant to the 2020 Loan, OcuWize recorded a pledge in favor of the Bank
and agreed that at all times, the value of all the assets in the OcuWize bank account will not be less than NIS 1,700 (approximately
$496). In order to satisfy this requirement, the Company loaned to OcuWize a portion of the Bonus Shares held by it. The 2020 Loan
including interest was fully paid on January 14, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 10:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT TRANSACTIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Bonus/LO2A
    Transaction</B>:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On January 9, 2020, the Company
entered into (i) an Exchange Agreement (the &ldquo;Bonus Exchange Agreement&rdquo;), with Bonus and (ii) a Share Purchase Agreement
(the &ldquo;Bonus Purchase Agreement&rdquo; and, together with the Bonus Exchange Agreement, the &ldquo;Bonus Agreements&rdquo;)
with Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the Bonus Agreements,
the Company agreed to grant Bonus, in consideration for the issuance of 62,370,000 ordinary shares of Bonus to the Company (the
&ldquo;LO2A Shares&rdquo;), the right to receive 37% of future LO2A Proceeds (if any), which, as more fully defined in the Bonus
Exchange Agreement, include proceeds generated by the Company, Wize Israel and OcuWize, as a result of (i) the sale, license or
other disposal of products or other rights underlying the LO2A technology licensed to OcuWize under the License Agreement; and
(ii) a Sale Transaction, which, as more fully defined in the Bonus Exchange Agreement, includes the sale of shares or assets of
Wize Israel and/or OcuWize. In addition, if the Sale Transaction involves a change of control of the Company, Bonus will be entitled
to elect, to either remain with its right to 37% of the LO2A Proceeds or receive a one-time payment equal to 37% of the value
attributed to Wize Israel out of the total proceeds payable for the Company in such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, pursuant to the Bonus
Purchase Agreement, the Company agreed to purchase 51,282,000 ordinary shares of Bonus (the &ldquo;PIPE Shares&rdquo;, and together
with the LO2A Shares, the &ldquo;Bonus Shares&rdquo;), for an aggregate purchase price of $7,400 in cash, which funds were deposited
directly into an escrow account (the &ldquo;Bonus Escrow Account&rdquo;), of which (i) $500 was paid to Bonus as an advance promptly
following execution of the Bonus Purchase Agreement, (ii) $3,200 was released to Bonus concurrently with the closing of the transactions
contemplated by the Bonus Agreements in exchange for 50% of the PIPE Shares and (iii) $3,700 was released to Bonus upon the Milestone
Closing (as defined in the Bonus Purchase Agreement), in exchange for the remaining 50% of the PIPE Shares that were issued by
Bonus and deposited into the escrow at the closing. The Company&rsquo;s obligation to consummate the Milestone Closing is conditioned
upon the satisfaction by Bonus of certain conditions, including the listing of its ordinary shares (or, if an ADR Program is to
be implemented by Bonus, the American Depositary Shares representing such ordinary shares) on the Nasdaq Capital Market (or another
superior tier of the Nasdaq market) (the &ldquo;Nasdaq Listing&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, pursuant to the Bonus
Agreements (as amended as of June 24, 2020), Bonus agreed to cover nearly 50% of the Company&rsquo;s fees and expenses payable
by the Company in cash, Bonus shares and/or a combination thereof to H.C. Wainwright &amp; Co., LLC (&ldquo;HCW&rdquo;) in connection
with the transactions contemplated by the Bonus Agreements and the Series B Purchase Agreement (as defined below). In particular,
Bonus agreed to reimburse the Company or pay HCW directly $350 in cash, Bonus shares and/or a combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding the release of the remaining escrow amount of $3,700
to the Series B investors upon settlement agreement between the parties, see below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to the Bonus Agreements,
as amended, the total number of Bonus Shares issuable to the Company (including the shares to be released at the Milestone Closing)
was computed as the number of ordinary shares of Bonus equal to the quotient obtained by dividing (A) $16,400 expressed in NIS
(based on the exchange rate between NIS and the dollar as of January 8, 2020) by (B) NIS 0.50. As of January 9, 2020, such total
number of Bonus Shares represented (on a post-issuance basis) approximately 12% of the outstanding share capital of Bonus. The
fair value of Bonus shares based on a quote of the share price on January 9, 2020, the date of signing the Bonus Agreements, was
$0.12 per share and, as of the date of the closing was $0.11 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 10:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNIFICANT TRANSACTIONS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Bonus/LO2A
Transaction</B>:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The transactions contemplated
by the Bonus Agreements were completed on February 19, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of the date of closing of the
Bonus Agreements, the Company received 85,239,000 of Bonus Shares. Pursuant to the Bonus Agreements, an additional 28,413,000
Bonus Shares were to be released to the Company upon the Nasdaq Listing and concurrently with the release of the $3,700 from the
escrow account to Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As the Bonus Shares represent marketable securities with readily
determinable fair value, Bonus shares issued to the Company were recognized upon initial recognition based on their quoted price
(less applicable non-marketability discount) as of the date of the completion of the Bonus Agreements at an aggregate amount of
$8,759. The difference between the fair value of Bonus shares and the amount of cash that was transferred directly to Bonus from
an escrow account was recognized as financial liability, representing the Company&rsquo;s obligation to Bonus with respect to the
LO2A Proceeds in an amount of $5,059 (see Note 2v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 29, 2020, the
Company entered into an Addendum (the &ldquo;Addendum&rdquo;) with Bonus, whereby the parties agreed to amend certain
provisions of the Bonus Agreements. Under the Addendum, at the Closing, Bonus will issue to the Company ordinary shares of
Bonus (the &ldquo;Bonus Shares&rdquo;), the total number of which consists of (i) the Milestone Settlement Shares, which, as
defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing $500 expressed in NIS (based on the
exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement
Shares, the &ldquo;Settlement Shares&rdquo;), which, as defined in the Addendum, means Bonus Shares equal to the quotient
obtained by dividing $350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In consideration for the
Settlement Shares, the Company agreed to make certain amendments to the Bonus Agreements, including the following key
modifications: (i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto,
conduct the Milestone Closing (as defined in the Bonus Agreements), which means that, at the Closing, $3.7 million will be
released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the &ldquo;Nasdaq
Milestone Shares&rdquo;) will be released to the Company (20% of the shares) and to the Company&rsquo;s former holders of
Series B Preferred Stock (the &ldquo;Former Series B Holders&rdquo;); (ii) the Company will waive approximately $120 in
liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend
the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of
Bonus to secure the Company&rsquo;s obligations under the Bonus Exchange Agreement, including certain related negative
covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Closing was subject to customary conditions, including obtaining
the approval of the Tel-Aviv Stock Exchange (&ldquo;TASE&rdquo;), and occurred on December 30, 2020. It should be noted that, in
accordance with the Securities Purchase Agreement, dated January 9, 2020 (as amended), by and among the Company and the Former
Series B Holders, the Company was required to transfer 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares
to such investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, during the period
from completion of the Bonus Agreements (February 19, 2020) and through December 31, 2020, the Company recognized financial income
from both sales of Bonus marketable securities and revaluation of its remaining investment in Bonus marketable securities as of
December 31, 2020, in an amount of $1,197 due to the change in the quoted market price of these shares on TASE. Such amount was
presented as part of financial expenses, net.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">During the year ended December 31, 2020, the Company received
cash proceeds of $821 from sales of 5,871,260 of Bonus Shares, which are marketable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 10:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNIFICANT TRANSACTIONS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Mandatorily
    Redeemable Series B Investment</B>:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In order to finance the transactions
contemplated by the Bonus Purchase Agreement, on January 9, 2020, the Company entered into a Securities Purchase Agreement (the
&ldquo;Series B Purchase Agreement&rdquo;) with certain accredited investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the Series B Purchase
Agreement, the Company agreed to sell to the investors, and the investors agreed to purchase from the Company, in a private placement,
an aggregate of 7,500 shares of newly created Series B Non-Voting Redeemable Preferred Stock, par value $0.001 per share, of the
Company (&ldquo;Series B Preferred Stock&rdquo;) for a purchase price of $1.00 per share, for aggregate gross proceeds under the
Series B Purchase Agreement of $7,500, which funds were deposited into an escrow account, of which (i) $500 was to be paid to
the Bonus Escrow Account and $100 was paid directly to the Company to cover certain of its transactions expenses, in each case,
promptly following the execution of the Series B Purchase Agreement, and (ii) the remaining $6,900 was to be released to the Bonus
Escrow Account upon the closing of the transactions contemplated by the Series B Purchase Agreement (of which, as described above,
$3,200 was to be released upon the earlier of the Milestone Closing or upon written consent of the holders of at least a majority
of the Series B Preferred Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Series B Purchase Agreement
contained customary covenants, representations and warranties of the parties thereto, including, among others, (i) a covenant
by the investors not to transfer the Series B Preferred Stock without the approval of the Company; (ii) a covenant by the Company,
for as long as any Series B Preferred Stock remain outstanding, not to sell any Bonus Shares for a price per share equal to less
than NIS 0.40 (the &ldquo;Price Restriction&rdquo;); and (iii) a covenant by the Company, simultaneously with, or promptly after,
the redemption of the Series B Preferred Stock, to assign certain rights under the Bonus Purchase Agreement, such as the right
to liquidated damages in the event of delayed Nasdaq Listing, and under the Bonus Registration Rights Agreement, to the investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In connection with the Series
B Purchase Agreement, the Company agreed to file, at the closing, a Certificate of Designations of Series B Non-Voting Redeemable
Preferred Stock with the Secretary of State of Delaware (the &ldquo;Series B Certificate of Designations&rdquo;). Pursuant to
the Series B Certificate of Designations, the Company designated 7,500 shares of preferred stock as Series B Preferred Stock.
The Series B Preferred Stock were not convertible into shares of Common Stock of the Company and have no voting powers, except
as related to certain rights to protect the rights and preferences of the Series B Preferred Stock and with respect to sales or
dispositions of the Series B Preferred Stock at a price per share below the Price Restriction. The Series B Preferred Stock entitled
its holders to (i) 80% of the proceeds received by the Company through future sales of the Bonus Shares issued to the Company
under the Bonus Agreements and (ii) 80% of any cash dividends received by the Company on such Bonus Shares. Under the Series B
Certificate of Designations, the Company had the option to redeem the Series B Preferred Stock at any time by distributing to
holders of the Series B Preferred Stock (i) 80% of the Bonus Shares then held by the Company and (ii) 80% of all dividends received
by the Company but not yet paid to holders of the Series B Preferred Stock (the &ldquo;Redemption Payment&rdquo;). The Company
was required to redeem the Series B Preferred Stock through payment of the Redemption Payment upon the earlier of (i) 60 days
following the Nasdaq Listing of the Bonus Shares, and (ii) December 28, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">However, until the completion of the Nasdaq Listing, an amount
of $3,700 was required to remain in an escrow account and, upon the failure of such listing by Bonus by the Milestone End Date,
such amount shall be required to be released in its entirety to the Series B investors. This escrow account of $3,700 was presented
as restricted deposit in the Company&rsquo; consolidated balance sheet commencing upon the closing of the transaction and until
December 29, 2020, following the Addendum with Bonus described in Note 10a above, and the same amount was reflected as part of
the liability with respect to the mandatorily redeemable series B preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of the completion date (February 19, 2020), the Company recognized
a liability in light of its obligation to redeem the Series B Preferred Stock at its fair value in an amount of $10,707, representing
the sum of the remaining escrow amount of $3,700 (which, in case the Milestone Closing will not be met, will be paid to the Series
B investors) and 80% of the Company&rsquo;s investment in Bonus marketable shares, see Note 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 10:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNIFICANT TRANSACTIONS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the amount
of the liability recognized with respect to the Series B Preferred Stock ($10,707) and the cash amount actually invested by such
preferred stock investors ($7,500), amounting to $3,207 was recognized immediately as financial expense, net upon the completion
of the Bonus agreement and the Series B Purchase Agreement, within financial income (loss), net.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, from the date of
the completion of the Bonus agreements and until the redemption, the Company recognized a loss in an amount of $597, net due to
the revaluation of the mandatorily redeemable Series B Preferred Stock liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On July 8, 2020, the Company elected to redeem all of the Series
B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares representing an amount of $6,597 to the holders
of Series B Preferred Stock representing 80% of the Bonus shares then held by the Company. As a result of such distribution, as
of the date of these financial statements, the Company owns the remaining 18,822,533 Bonus Shares, representing approximately 1.61%
of the outstanding shares of Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As discussed above, on November
29, 2020, the Company entered into an Addendum (the &ldquo;Addendum&rdquo;) with Bonus, whereby, among other things, Bonus agreed
to issue to the Company&rsquo;s ordinary shares of Bonus (the &ldquo;Bonus Shares&rdquo;), the total number of which consists of
(i) the Milestone Settlement Shares, which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing
US$500 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together
with the Milestone Settlement Shares, the &ldquo;Settlement Shares&rdquo;), which, as defined in the Addendum, means Bonus Shares
equal to the quotient obtained by dividing US$350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.
In consideration for the Settlement Shares, the Company agreed to make certain amendments to the Bonus Agreements, including the
following key modifications: (i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation
thereto, conduct the Milestone Closing, which means that US$3.7 million were released from an existing escrow account to Bonus,
whereas the 28,413,000 Bonus Shares held in such escrow (the &ldquo;Nasdaq Milestone Shares&rdquo;) were released to the Company
and to its former holders of Series B Preferred Stock (the &ldquo;Former Series B Holders&rdquo;); (ii) the Company will waive
approximately US$120 in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus
agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens
in favor of Bonus to secure obligations under the Bonus Exchange Agreement, including certain related negative covenants. The closing
occurred on December 29, 2020. It should be noted that, in accordance with the obligations of the Company to the Former Series
B Holders (see below), the Company has transferred 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares
to such investors. As a result of the transactions above, the Company redeemed all of the outstanding shares of Series B Preferred
Stock, and had satisfied its obligation under the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As a result of the Bonus transaction,
the company received an aggregate amount of 119,294,300 Bonus shares, out of which a total number of 93,576,800 Bonus shares were
distributes to the holders of Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The below table describes the
roll forward of Mandatorily Redeemable Series B liability for the year ended December 31, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Opening balance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left">Series B Preferred Stock issued</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(7,500</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from initial recognition of mandatorily redeemable Series B Preferred Stock at fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,207</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Revaluation of mandatorily redeemable Series B Preferred
    Stock </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(597</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Redemption of mandatorily redeemable Series B Preferred Stock with Bonus Shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,604</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Extinguishment of mandatorily redeemable Series B Preferred Stock by release of escrow account</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,700</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Cosmos Transaction</B>:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On December 30, 2020, the Company
or &ldquo;Wize&rdquo;, entered into a Bid Implementation Agreement (the &ldquo;Bid Agreement&rdquo;) with Cosmos Capital Limited,
a digital infrastructure provider based in Sydney, Australia (&ldquo;Cosmos&rdquo;), whereby the parties agreed that the Company
would commence an off-market takeover offer under applicable Australian laws (the &ldquo;Offer&rdquo;) to acquire all of the outstanding
shares of Cosmos in exchange for common shares of the Company. For more information, about the Cosmos transaction, CVR agreement
and PIPE Agreements, see Note 16 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 11:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAXES ON INCOME </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to the Company:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On December 22, 2017, the Tax
Cuts and Jobs Act was enacted and made key changes to US tax law which include (i) establish a flat corporate income tax rate
of 21% to replace previous rates that ranged from 15% to 39% and eliminates the corporate alternative minimum tax; (ii) create
a territorial tax system rather than a worldwide system, which will generally allow companies to repatriate future foreign source
earnings without incurring additional US taxes by providing a 100% exemption for the foreign source portion of dividends from
certain foreign subsidiaries; (iii) subject certain foreign earnings on which US income tax is currently deferred to a one-time
transition tax; (iv) create a &ldquo;minimum tax&rdquo; on certain foreign earnings and a new base erosion anti-abuse tax that
subjects certain payments made by a US company to a related foreign company to additional taxes; (v) create an incentive for US
companies to sell, lease or license goods and services abroad by effectively taxing them at a reduced rate; (vi) reduce the maximum
deduction for Net Operating Loss (&ldquo;<B>NOL</B>&rdquo;) carryforwards arising in tax years beginning after 2017 to a percentage
of the taxpayer&rsquo;s taxable income, allows any NOLs generated in tax years beginning after December 31, 2017 to be carried
forward indefinitely and generally repeals carrybacks;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(vii) elimination of foreign tax
credits or deductions for taxes (including withholding taxes) paid or accrued with respect to any dividend to which the new exemption
applies, but foreign tax credits will continue to be allowed to offset tax on foreign income taxed to the US shareholder subject
to limitations; (viii) limit the deduction for net interest expense incurred by US corporations, (ix) allow businesses to immediately
write off (or expense) the cost of new investments in certain qualified depreciable assets made after September 27, 2017 (but
would be phased down starting in 2023); (x) may require certain changes in tax accounting methods for revenue recognition; (xi)
repeal the Section 199 domestic production deductions beginning in 2018; (xii) eliminate or reduce certain deductions, exclusions
and credits, and adds other provisions that broaden the tax base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has calculated an
estimate of the impact of the Tax Act in our year-end income tax provision in accordance with our understanding of the Tax Act
and guidance available as of December 31, 2020. The provisional amount related to the re-measurement of the Company&rsquo;s net
U.S. deferred tax asset, based on the rate at which they are now expected to reverse in the future, considered immaterial, but
which was fully and equally offset by a corresponding reduction in the Company&rsquo;s valuation allowance. The effect of the
change in federal corporate tax rate from 39% to 21% is subject to change based on resolution of estimates used in determining
the amounts of deferred tax assets and liabilities that were re-measured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to Wize Israel and OcuWize:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In December 2016, the Israeli
Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018
Budget Years), a reduction of the corporate tax rate in 2017 from 25% to 24%, and in 2018 and thereafter from 24% to 23%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Accordingly, taxable income of
the Israeli Subsidiary is subject to the Israeli Corporate tax rate,which was 23% in 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carry forward:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company has NOL carry forwards
for federal income tax purposes of approximately $7,570.&nbsp; The application of the NOL carry forwards is limited due to IRC
section 382 limitation. The annual NOL carry forward (pre-merger, approximately $4,784) is limited to $10.965 per year.&nbsp;The
balance as of December 31, 2020 of the NOL carry forwards of approximately $4,786 is available in full.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December&nbsp;31, 2020, the Company&rsquo;s subsidiaries,
Wize Israel and OcuWize have accumulated losses for tax purposes in the amount of approximately $5,476 and $5,366 respectively,
which may be carried forward and offset against taxable income in the future for an indefinite period in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d.</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020, Wize Israel&rsquo;s
    2011 tax assessment was considered final. OcuWize has not received final tax assessment since its inception.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 11:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAXES ON INCOME (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before taxes on income consists of the
    following:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: -10pt; padding-left: 10pt">Domestic</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,318</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,709</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign (*)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,842</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,613</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(12,160</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(11,322</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relates to Wize Israel and OcuWize.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: 0.7in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Deferred income taxes reflect
the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and the amounts used for income tax purposes. Significant components of the Company&rsquo;s deferred tax assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Operating loss carry forwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,899</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,974</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Reserves and allowances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">261</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">128</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net deferred tax asset before valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,165</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,108</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net deferred tax asset</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In assessing the realization of
deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets
will not be realized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The ultimate realization of the
deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences
are deductible and NOLs are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance
at December&nbsp;31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below is the reconciliation
    between the &ldquo;theoretical&rdquo; income tax expense or benefit, assuming that all the income was taxed at the regular
    tax rate applicable to companies in Israel and the taxes recorded in the statements of comprehensive loss in the reporting
    year:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before taxes on income, as reported in the statements of comprehensive loss</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">(4,929</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">(3,450</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Theoretical tax benefit on this loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">725</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses not deductible for tax purposes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(983</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(639</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Tax benefit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 12:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMITMENTS AND CONTINGENCIES </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Agreements</U>:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting November
    22, 2020, the Company rents its offices from a third party for a rental monthly fee of $2. The rent period is for a period
    of 12 months.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Company&rsquo;s
    engagement in a License Agreement to market a drug and amendment to such an agreement, see also Notes 5 and 6 above.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 19, 2017 (the &ldquo;<B>Effective
        Date</B>&rdquo;), Wize Israel entered into a finder&rsquo;s fee agreement with a service provider (through his wholly
        owned company), who is also a director of the Company (the &ldquo;<B>Vendor</B>&rdquo;), pursuant to which the Vendor
        is entitle to receive a royalty rate of 5% on all of Wize Israel&rsquo;s revenues to the extent such revenues are earned
        from relationships initiated by the Vendor and agreed to by Wize Israel. The term of the agreement is for 12 months unless
        earlier terminated. Either party may terminate upon 21 days&rsquo; notice. The service provider will be entitled to the
        finder fee of 5% even if the agreement will be terminated.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Vendor introduced Wize Israel
        and the Company to the Chinese Distributor (see also Note 5). During the period commencing the Effective Date and ending
        December 31, 2019 and 2020, the Vendor has not earned any royalties, and the Company has no obligation to pay any royalties.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For discussion regarding Bonus transaction, see Note 10 above.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; EQUITY </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Common Stock
    confers upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in
    the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; EQUITY </B></FONT> <B>(Cont.)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 71px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2019, the Company entered
        into a joint venture agreement with Cannabics traded on the Over-The-Counter (OTC) markets in the United States.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement, the parties
        agreed to form a new joint venture company for the purpose of researching, developing and administering cannabinoid formulations
        to treat ophthalmic conditions. The new company will initially be owned 50% each by the Company and Cannabics.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2019, the Company&rsquo;s joint
        venture agreement with Cannabics became effective. Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000
        shares of its Common Stock and Cannabics issued to the Company 2,263,944 shares of Cannabics&rsquo; common stock, which represented
        a holding percentage less than 5 percent of Cannabic&rsquo;s then outstanding share capital. The joint venture currently has no
        assets or liabilities and has not started conducting any of its planned operations.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the foregoing, the Company
        relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions
        not involving a public offering.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the share issuance, the
        Company recorded an amount of $765 as an increase to Common Stock (at par value) and additional paid-in capital with a corresponding
        amount of $765 as an investment in marketable securities. Such amount was based on the fair value of Cannabics&rsquo; shares as
        of the date at which the agreement became effective. The investment in marketable securities was remeasured in subsequent periods
        at fair value with changes carried to profit or loss. During the year ended December 31, 2019 the Company recognized loss of $501
        due to the change in fair value from March 1, 2019 to December 31, 2019.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2019, the Company determined
        to terminate all activities under the joint venture until such time as the parties jointly determine that no uncertainty remains
        with respect to U.S. federal enforcement of the cannabis industry.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2019, the Company issued 60,000 shares of Common Stock to certain investors in exchange for conversion of 60 shares of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 71px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt">In April 29,
        2019, the Company issued 336,000 shares of Common Stock to certain investors in exchange for conversion of 336 shares
        of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt">In May 7,
        2019, the Company issued 336,000 shares of Common Stock to certain investors in exchange for conversion of 336 shares
        of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 23, 2019, the Company&rsquo;s Board appointed Mark Sieczkarek as the Company&rsquo;s Chairman of the Board (the &ldquo;<B>Chairman
    Appointment</B>&rdquo;).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    July 18, 2019, the Company issued to a consultant, 6,945 shares of Common Stock in exchange for its services provided in the
    three months ended September 30, 2019. The Company recognized an amount of $3 in the year ended December 31, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 20, 2019, the Company issued to a consultant, 45,000 shares of Common Stock in exchange for its services provided in
    2019. The Company recognized an amount of $18 in the year ended December 31, 2019.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; EQUITY (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection
        with Mr. Sieczkarek&rsquo;s appointment, the Company and Mr. Sieczkarek entered into a Chairman Agreement (the &ldquo;<B>Chairman
        Agreement</B>&rdquo;) whereby Mr. Sieczkarek shall receive 202,399 restricted stock units (&ldquo;<B>RSUs</B>&rdquo;) and options
        to purchase 102,222 shares of the Company&rsquo;s Common Stock at an exercise price of $2.00 per share (the &ldquo;Chairman Awards&rdquo;).
        The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and subsequently in seven equal quarterly installments
        commencing July 1, 2019. The Chairman Agreement has an initial term of two years (the &ldquo;Term&rdquo;) and provides that in
        the event of a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as
        of that date. The Chairman Agreement also contains standard representations and warranties regarding confidential information,
        non-competition and non-solicitation.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Total value of
        the options granted is $29, which is recorded quarterly over the vesting period. The total value of the share based expense related
        to the RSU is $185, which is being recognized ratably over the vesting period.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 11, 2020, the Company&rsquo;s Board of Directors approved
the equity grant of 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of
Directors of the Company, see also note 13p below.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On January 6,
        2020, April 15, 2020, July 1, 2020 and October 1, 2020 the Company issued 25,300, 25,300, 25,300 and 44,050, respectively, shares
        to the Chairman pursuant to the agreement above following the vesting of certain portions of the RSUs.&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company
recognized $46 during the year ended December 31, 2020 as a share-based expense in connection to the RSU&rsquo;s and options granted.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    April 2019, Mr. Danenberg purchased directly from Ridge all Ridge&rsquo;s rights under the second convertible loan agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2019, the Company issued
        to a consultant, 135,000 shares of restricted Common Stock which is due and issuable according to the following schedule:
        25% as of May 1, 2019 and additional 25% every quarter following May 1, 2019. The aggregate fair value of these shares
        of RSUs at grant date issued was $106, and is being recognized over a period of 1 year following May 1, 2019.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recognized $104 and $2 during the years ended December
31, 2019 and 2020, respectively as a share-based expense in connection to the RSU&rsquo;s.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    May 15, 2019, the Company granted to a consultant, 10,000 fully vested RSUs. The Company determined the fair value of the
    RSUs to be the quoted market price of the Company&rsquo;s Common Stock on the date of issuance. The aggregate fair value of
    these RSUs issued at grant date was $5, and was recognized during the year ended December 31, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; EQUITY (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 19, 2019,
    the Company granted to one of its directors certain options exercisable into 30,000 shares of Common Stock with an exercise
    price of $0.58 per share. The options will vest monthly over a period of six (6) months. The Company recognized $13 of
    share-based compensation expense during year ended December 31, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 13,
    2019, the Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196 shares of Common Stock as part of the
    extinguishment of the loans, see also Note 8e.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2019, the Company
        entered into a securities purchase agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with an accredited investor.
        Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase
        from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27
        per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to
        the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock.
        The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public
        announcement of positive clinical data results for LO2A.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The December 2019 Warrants will
        be exercisable on a cashless basis in the event that, six months after issuance, there is not an effective registration
        statement for the resale of the shares underlying the December 2019 Warrants.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management considered the provisions
        of ASC 815-40, and has determined that the December 2019 Warrants are considered indexed to the Company&rsquo;s stock
        and that all other relevant criteria required for equity classification are met. Accordingly, it was determined that the
        December 2019 Warrants are eligible for equity classification.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2019, the December 2019 Warrants exercise price
was reduced to $0.16 due to the triggering of certain down-round anti-dilution protection or price protection features included
in the original terms of these warrants. The difference between the fair value of the warrants and the incremental fair value resulting
from the triggering of the above mentioned features was recognized as a deemed dividend and as an increase of the loss applicable
to common stockholders in an amount of $15. See also note 13p and 13q below.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 11, 2020, the Company&rsquo;s Board of Directors approved
the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of
the Board of Directors of the Company and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each
of the other three non-executive directors. The aggregate fair value of these shares of RSUs at grant date issued was $73, and
is being recognized over a period of 2 years following August 11, 2020. The Company recognized $34 during the year ended December
31, 2020, as a share-based expense in connection to the RSU&rsquo;s.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STOCKHOLDERS&rsquo; EQUITY (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 8, 2020, the Company
        entered into exchange agreements (the &ldquo;Exchange Agreements&rdquo;) with certain holders (the &ldquo;Series A
        Holders&rdquo;) of 3,000,000 Series A Warrants.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exchange
        Agreements, the Holders agreed to surrender their Warrants for cancellation and received, as consideration for such cancellation,
        an aggregate of 3,000,000 shares of common stock. The securities issued pursuant to the foregoing are exempt
        from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), pursuant
        to Section 3(a)(9) and/or Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder
        because, among other things, the transaction did not involve a public offering and the warrant holders are accredited
        investors. The difference between the fair value of the warrants before the exchange and the fair value of the shares
        was recognized as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $63.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 24, 2020, the Company entered into an agreement (the
&ldquo;Agreement&rdquo;) with certain holders (the &ldquo;Series A Holders&rdquo;) representing a majority of the Series A Warrants.
Pursuant to the terms of the Agreement, the Company and Series A Holders mutually agreed that the Company would voluntarily reduce
the exercise price of the Warrants to $0.001 per share until January 7, 2021, after which such exercise price shall revert back
to $0.16 per share.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the adjustment
        to the exercise price of the Series A Warrants, the exercise price of the warrants issued in November 2017 (the &ldquo;2017
        Warrants&rdquo;), the placement agent warrants issued in October 2018 (the &ldquo;2018 Placement Agent Warrants&rdquo;),
        the warrants issued to certain lenders in May 2019 (the &ldquo;May 2019 Warrants&rdquo;), the warrants issued to certain
        lenders in November 2019 (the &ldquo;November 2019 Warrants&rdquo;), the warrants issued to certain purchasers from the
        private placement in December 2019 (the &ldquo;December 2019 Warrants&rdquo;) and certain investment rights issued on
        January 2017 (the &ldquo;Investment Rights&rdquo;) were also adjusted to reflect a reduced exercise price of $0.001 per
        share (collectively, the &ldquo;Warrant Adjustments&rdquo;). As a result of the Warrant Adjustments, on December 29, 2020
        an aggregate of 13,332,654 shares of common stock were issued as a result of the exercise of such warrants, each on a
        cashless basis. Among others, such warrant exercises also included warrants beneficially owned by our Chief Executive
        Officer, Noam Dannenberg. The difference between the fair value of the warrants before and after the adjustment was recognized
        as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $327.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</FONT></TD>
    <TD>Stock based-compensation:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>The 2012 Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In 2012, the Company&rsquo;s Board
approved the adoption of the 2012 Stock Incentive Plan (the &ldquo;<B>2012 Plan</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">An Israeli annex was subsequently
adopted in 2013 to comply with the requirements set by the Israeli law in general and in particular with the provisions of section
102 of the Israeli tax ordinance. Under the 2012 Plan and Israeli annex, the Company may grant its officers, directors, employees
and consultants, stock options, restricted stocks and RSUs of the Company. Each Stock option granted shall be exercisable at such
times and terms and conditions as the Company&rsquo;s Board may specify in the applicable option agreement, provided that no option
will be granted with a term in excess of 10 years. Upon the adoption of the 2012 Plan, the Company reserved for issuance 45,370
shares of Common Stock, $0.001 par value each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company
has 40,474 shares of Common Stock available for future grant under the 2012 Plan. As of December 31, 2020, under the 2012 Plan,
the Company had options exercisable into 4,896 shares of Common Stock outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>The 2018 Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 22, 2018, the Company&rsquo;s
Board approved the adoption of the 2018 Stock Incentive Plan (the &ldquo;<B>2018 Plan</B>&rdquo;), including an Israeli annex
to comply with Israeli law, in particular the provisions of section 102 of the Israeli Income Tax Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the 2018 Plan, the Company
may grant its employees, directors, consultants and/or contractors&rsquo; stock options, shares of Common Stock, restricted stock
and RSUs of the Company. The Compensation Committee of the Board is currently serving as the administrator of the 2018 Plan. Each
stock option granted is exercisable, unless otherwise determined by the administrator, in twelve equal installments over the three
- year period from the date of grant. Unless otherwise determined by the administrator, the term of each award will be seven years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The exercise price per share subject
to each option will be determined by the administrator, subject to applicable laws and to guidelines adopted by the Board from
time to time. In the event the exercise price is not determined by the administrator, the exercise price of an option will be
equal to the closing stock price of the Common Stock on the last trading day prior to the date of grant.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; EQUITY (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Upon the adoption of the 2018
Plan, the Board reserved for issuance 435,053 shares of Common Stock. On August 15, 2018, the Company amended the 2018 Plan to
increase the number of shares issuable under the Plan to 2,500,000 shares of Common Stock. In addition, the Board approved to
increase the number of shares issuable under the Plan on the first day of each fiscal year beginning with the 2019 fiscal year,
by an amount equal to the lesser of (i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately
preceding fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company
has 2,184,813 shares of Common Stock available for future grant under the 2018 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Through December 31, 2020, 290,222
options to directors, officers and consultants are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><U>Grants under the 2018 Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2018,
    the Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with
    an exercise price of $3.59 per share. The options will vest quarterly over a period of 36 months. The Company recognized $51
    and $154 during the year ended December 31, 2020 and 2019, respectively.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2019, the Company&rsquo;s
        Board approved the following:</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 120px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To grant to each
    of Company&rsquo;s four directors 100,000 RSUs. The RSUs will vest quarterly over a period of 24 months.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 120px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To grant to each
    its officers (Company&rsquo;s Chief executive officer and to Company&rsquo;s Chief financial officer)&nbsp;140,000 RSU&rsquo;s.
    The RSU&rsquo;s will vest quarterly over a period of 24 months.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company determined the fair
value of the RSUs to be the quoted market price of the Company&rsquo;s Common Stock on the date of grant. The aggregate fair value
of these RSUs issued was $476. The Company is recognizing this amount ratably over the vesting period of 24 months following March
31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In connections with the above,
on July 25, 2019 (the initial quarterly vesting date) the Company issued 85,000 Common shares to its officers and directors.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recognized $132 and
$337 during the year ended December 31, 2020 and 2019 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; EQUITY (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 18, 2019,
    the Company granted to its employee, 21,600 options exercisable into 21,600 shares of Common Stock at an exercise price of
    $0.75 per share of Common Stock. The options began vesting quarterly over a period of 36 months commencing April 18, 2019.
    The Company recognized $2 during the year ended December 31, 2019 as a share-based expense. The total value of the share based
    expense is $10, which is recorded quarterly over the vesting period. Since the Company has terminated its employment agreement
    in December 2019, as of December 31, 2020, all of the options were forfeited. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions related to the grant of options to employees and
directors under the 2012 Plan during the year ended December&nbsp;31, 2020 and 2019, were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <BR> of options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> exercise <BR> price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> remaining <BR> contractual <BR> life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,896</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">190.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.86</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(544</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">216</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options outstanding and exercisable at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,352</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">81.81</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3.32</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <BR> of options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> exercise <BR> price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> remaining <BR> contractual <BR> life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,896</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">190.7</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.86</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Granted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options outstanding and exercisable at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,896</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">190.7</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.86</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 13:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCKHOLDERS&rsquo; EQUITY (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions related to the grant
of options to employees and directors under the 2018 Plan during the year ended December&nbsp;31, 2020 and 2019, were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <BR> of options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> exercise <BR> price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> remaining <BR> contractual <BR> life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Options outstanding as of December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">352,072</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.91</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.72</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(61,850</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.97</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Options outstanding as of December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">290,222</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.64</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.84</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Options exercisable as of December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">255,459</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.56</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.82</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number <BR> of options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> exercise <BR> price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> average <BR> remaining <BR> contractual <BR> life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Options outstanding as of December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">255,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.68</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.55</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,822</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(56,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.69</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Options outstanding as of December 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">352,072</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.91</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.72</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Options exercisable as of December 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">181,799</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.75</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.72</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">At December 31, 2020, there was
$3 of total unrecognized compensation cost related to non-vested option grants that is expected to be recognized over a weighted-average
period of 0.5 years. The intrinsic value of options outstanding and exercisable at December 31, 2020 was not significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company uses the Black-Scholes
option-pricing model to estimate fair value of grants of stock options. With respect to grants of options, the risk-free rate
of interest was based on the U.S. Treasury rates appropriate for the contractual term of the grant, expected volatility was calculated
based on average volatility of the Company and five representative companies and expected term of stock-based grants of 7 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 14:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELECTED STATEMENTS OF OPERATIONS DATA</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>Year ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Overseas travel</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">103</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">688</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Rent and office maintenance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Payroll and benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">834</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Professional services and consultation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">953</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Taxes and tolls</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Director salary and insurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">116</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">208</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,008</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,678</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial expense, net:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>Year ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financial income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left">Income from sale and revaluation of marketable securities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,197</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Exchange rate gains, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Gain from completion of milestone closing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">847</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Gain from settlement shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Amortization of premium related to convertible loans</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,257</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total financial income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,144</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,272</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Financial expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued interest on convertible loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued interest on loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from recognition of mandatorily redeemable Series B Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,207</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from revaluation of contingent obligation with respect to future revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(435</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Revaluation of mandatorily redeemable Series B Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(597</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Bonus transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(350</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Change in the fair value of marketable securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(527</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Bank commissions and exchange rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from extinguishment of convertible loans (Note 8c, 8d, 8e)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(977</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total financial expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,631</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,552</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total financial expense, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,487</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(280</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;<B>&nbsp;</B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 15:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED PARTIES BALANCES AND TRANSACTIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances with interested and related parties:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt">Other receivables</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">52</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Accounts payable</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">439</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">104</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Convertible Loans</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with interested and related parties:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Amounts charged to:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 4pt">General and administrative expenses*</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">1,212</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">1,140</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Finance expenses, net (income)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(625</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in">* Including an amount of $76 with respect to stock-based compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE 16:-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT EVENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Cosmos Transaction</B>:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On
December 30, 2020, the Company entered into the Bid Agreement with Cosmos, which was subsequently amended on January 18, 2021 for
the primary purpose of simplifying the Offer structure. Under the Bid Agreement (as amended), the parties agreed that the Company
would commence the Offer, an off-market takeover offer under applicable Australian laws, to acquire all of the Cosmos Shares in
exchange for 61.11 Company's shares of common stock for each Cosmos Share, being the Offer Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under
the Bid Agreement, 22.33 Company shares of common stock out of the Offer Consideration will be &ldquo;Restricted Stock&rdquo; subject
to a Stock Restriction Agreement to be entered into at the Closing Date and 38.78 Company shares of common stock will be &ldquo;Covered
Securities&rdquo;. A Cosmos shareholder who accepts the Offer (an &ldquo;Accepting Shareholder&rdquo;) will not be permitted to
sell or encumber their Restricted Stock until December 31, 2021 (the &ldquo;Milestone Date&rdquo;). In addition, an Accepting Shareholders
may not exercise voting rights in respect of Restricted Stock from the date of issuance of the Offer Consideration until the Milestone
Date. An Accepting Shareholder is entitled to sell or encumber its Covered Securities. However, if (subject to certain limited
exceptions) an Accepting Shareholder sells or encumbers any of its Covered Securities before the Milestone Date, the Company has
an option to repurchase a pro rata proportion of the Restricted Stock for the lower of $0.0001 and the fair market value of the
Restricted Stock. The Restricted Stock (and any dividends thereon) will be held by the Company in escrow for the Accepting Shareholder&rsquo;s
benefit until such time as the Restricted Stock is repurchased by Wize or all restrictions thereon lapse. If any Restricted Stock
is repurchased under the Company&rsquo;s repurchase option, a pro rata proportion of the dividend on the Restricted Stock shall
be retained by the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Immediately
following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos shareholders are expected
to own approximately 87.65% of the outstanding common stock of the Company, while the Company's existing stockholders are expected
to remain the owners of approximately 10.75% of the outstanding common stock of the Company, each on a fully diluted basis and
including warrants to be issued to the Company's financial advisor to the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the Bid Agreement,
prior to the Closing Date, the Company will enter into a Contingent Value Rights Agreement (the &ldquo;CVR Agreement&rdquo;) with
Cosmos, certain of the Company&rsquo;s subsidiaries (the &ldquo;Wize Subsidiaries&rdquo;), a person designated by the Company
prior to the Closing Date as the Holders&rsquo; Representative (as defined herein), and the Rights Agent (as defined therein).
Pursuant to the CVR Agreement, at the Closing Date, each Wize pre-Closing security holder will receive one non-transferable CVR
for each outstanding share of common stock of the Company and for each share of common stock of the Company underlying other convertible
securities and warrants, held as of 4:01&nbsp;p.m. Eastern Time on the day immediately&nbsp;<FONT STYLE="background-color: white">before
the Effective Time (as defined in the CVR Agreement). Each CVR will represent the right to receive a pro rata share of any consideration
that may be received by the Company or the Company Subsidiaries in connection with the Company&rsquo;s existing LO2A business.
In particular, CVR holders will be entitled to any consideration (whether cash, stock, assets or otherwise) that the Company or
the Company Subsidiaries (or any of its Affiliates or shareholders) receives in connection with an LO2A Transaction, which,
as defined in the CVR Agreement, includes (i) a sale of any of the Company Subsidiaries to a third party and/or (ii) the partnering,
licensing, sublicensing, distribution, reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third
party, less transaction expenses and customary deductions as detailed in the CVR agreement, including a deduction of up to $300,000
that the Company Subsidiaries undertook to incur in the development of the LO2A Technology at the request of the Holders&rsquo;
Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>WIZE PHARMA INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. dollars in thousands, except share and per share data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE 16:-</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SUBSEQUENT EVENTS (Cont.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="background-color: white">The
Bid Agreement also contains certain covenants to be performed at or following the Closing Date, including, among others, (i) agreement
that the Board of Directors of the Company immediately following the Closing Date will consist, subject to certain exceptions,
of three members to be designated by Cosmos and one member to be designated by the Company; (ii) covenants that the Company will
seek, following the Closing Date, stockholder approval to be renamed Cosmos Capital, Inc. (or similar name), and to effect a reverse
share split of the Company&rsquo;s common stock; (iii) covenants that the Company will establish an incentive compensation program
with respect to 40,000,000 shares of its common stock, to be granted promptly following the Closing Date, in the form of performance-based
RSUs, performance rights or indeterminate rights based on the performance milestone criteria and allocation set in the Bid Agreement
(the &ldquo;Post-Closing Incentive Plan&rdquo;), 50% of which are to be granted to personnel specified by the Company prior to
the Closing Date and the remainder to be granted to personnel of Cosmos (see also Item 9B below); (iv) an obligation by the Company
to terminate or procure the termination of each of the current employment or consulting agreements of the Company with Mr. Mark
Sieczkarek, the Chairman of the Company Board of Directors, Mr. Noam Danenberg, the Chief Executive Officer of the Company, Mr.
Or Eisenberg, the Chief Financial Officer of the Company, and another part-time employee related to Mr. Danenberg; and (v) an
obligation by the Company to use its reasonable commercial efforts to enter into new, part time, consulting agreements with Mr.
Danenberg and Mr. Eisenberg in a form to be agreed between the Company and Cosmos.&nbsp;In this respect, it should be noted that
the Company, Cosmos and each of Mr. Danenberg and Mr. Eisenberg agreed on the form of such consulting agreements, whereby Mr.
Danenberg and Mr. Eisenberg will provide part time consulting services to the Company following the Closing Date for monthly compensation
of US$10,000 and US$7,500, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="background-color: white">Concurrently
with the execution of the Bid Agreement, the Company entered into Securities Purchase Agreements (the &ldquo;PIPE Agreements&rdquo;) with
certain accredited investors (the &ldquo;PIPE Investors&rdquo;), including Mr. Noam Danenberg, our CEO. Pursuant to the PIPE Agreements,
we agreed to sell to the PIPE Investors, and the PIPE Investors agreed to purchase from us, in a private placement, an aggregate
of 25,000,000 shares of common stock for a purchase price of $0.12 per share, or aggregate gross proceeds of $3.0 million, which,
in the case of Mr. Danenberg, may be satisfied by waiving outstanding amounts owed by the Company or its subsidiaries to Mr. Danenberg
pursuant to his consulting agreement with our subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 1, 2021, we lodged
a Bidder&rsquo;s Statement with the Australian Securities and Investments Commission to commence the Offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 15, 2021, Cosmos informed the Company that
Cosmos completed the issuance of convertible notes (the &ldquo;Cosmos Convertible Notes&rdquo;) with an aggregate principal amount
of approximately US$21 million to several non-U.S. sophisticated or professional investors (the &ldquo;Purchasers&rdquo;). The
Cosmos Convertible Notes are unsecured and shall initially be convertible into shares of Cosmos at a conversion price of AU$23.58
per share (equivalent to US$18.16), reflecting a pre-money valuation of Cosmos of approximately US$185 million. The Cosmos Convertible
Notes will automatically convert to shares six months after the date of issuance. Cosmos is obligated to pay interest to the Purchasers
on the outstanding principal amount of the Cosmos Convertible Notes at the rate of 8% per annum, payable on the conversion date,
in cash or, at Cosmos&rsquo; option, in shares of Cosmos. Redemption of the Cosmos Convertible Notes occurs only if an insolvency
event occurs in respect of Cosmos.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Cosmos Convertible Notes also provide that, subject
to, among other things, the consummation of the Offer before May 31, 2021, Cosmos will cause the Company to assume the Cosmos Convertible
Notes by way of entering into an amended and restate convertible note on substantially the same terms as the Cosmos Convertible
Note (the &ldquo;Wize Convertible Notes&rdquo;), except that, at such time, they shall be convertible, upon the earlier of six
(6) months from the issuance of the Cosmos Convertible Notes and an uplisting of the common stock of the Company to Nasdaq, into
shares of common stock of the Company at a conversion price of US$0.339 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cosmos plans to use the proceeds
of the Cosmos Convertible Notes for the purchase of additional application-specific integrated circuit (ASIC) mining hardware,
modular data centers, associated infrastructure and capital raising costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">February
16, 2021, we announced that the Offer became unconditional and that we plan to consummate the transactions contemplated by the
Bid Agreement and the Offer on or about March 9, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<FONT STYLE="background-color: white">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><B>Exhibit<BR>
</B> <B>Number</B></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017005592/f8k052117ex2i_ophthalixinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Merger, dated as of May 21, 2017, by and among the Company, Bufiduck Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on May 22, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017011161/f8k103117ex2-1_ophthalix.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to Agreement and Plan of Merger, dated as of October 31, 2017, by and among the Company, Bufiduck Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 1, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878212000959/f8k040512_ex3z1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 5, 2012)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213001371/f8k071813_ex3z1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment to Certificate of Incorporation (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on July 18, 2013)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex3-3_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment to Certificate of Incorporation dated November 15, 2017 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 21, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002556/f8k030118ex3-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment to Certificate of Incorporation dated March 1, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 5, 2018)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213000919/f8k051013_ex3z1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on May 10, 2013)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018001336/fs12018ex4-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Specimen Common Stock Certificate (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on February 6, 2018)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2#</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2020ex4-2_wizepharma.htm">Description of Securities</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1+</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878212000335/f8k020812_ex4z1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2012 Stock Incentive Plan (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on February 9, 2012)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2+</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000107878213000416/f8k030813_ex99z1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2012 Stock Incentive Plan, Annex A (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 8, 2013)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390019007317/f8k042319ex10-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman Agreement between the Company and&nbsp;Mark Sieczkarek&nbsp;dated as of April 23, 2019 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 29, 2019)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-09_ophthalix.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exclusive Distribution and Licensing Agreement dated May 1, 2015 between Resdevco Ltd. and Wize Pharma Ltd. (formerly Star Night Technologies Ltd.) (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-10_ophthalix.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Licensing Agreement dated November 22, 2015 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-11_ophthalix.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 2 to Licensing Agreement dated March 20, 2016 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-12_ophthalix.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to Licensing Agreement &ndash; Israeli Market dated May 31, 2016 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-13_ophthalixinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No. 2 to Licensing Agreement &ndash; Ukraine Market dated May 31, 2016 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-15_ophthalixinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Addition to Amendment to Licensing Agreement dated January 6, 2017 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-16_ophthalixinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Second Addition to Amendment to Licensing Agreement dated March 30, 2017 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 133; Options: NewSection; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-17_ophthalixinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Correction to Licensing Agreement dated June 16, 2017 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-18_ophthalix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appendix F to Exclusive Distribution and Licensing Agreement between Resdevco Ltd. and Wize Pharma Ltd. signed on May 1, 2015 dated July 20, 2017 (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-19_ophthalix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appendix G to Exclusive Distribution and Licensing Agreement between Resdevco Ltd. and Wize Pharma Ltd. signed on May 1, 2015 dated July 20, 2017 (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; font-size: 10pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font-size: 10pt; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-20_ophthalixinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumption Agreement dated August 30, 2016 between Resdevco Ltd. and OcuWize Ltd (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15+</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-38_ophthalix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated September 30, 2015 between Wize Pharma Ltd. and Or Eisenberg (unofficial English translation from Hebrew) (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16+</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017007985/fs42017ex10-39_ophthalix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement for Provision of Services Agreement dated September 30, 2015 between Wize Pharma Ltd. and N Danenberg Holdings (2000) Ltd. (unofficial English translation from Hebrew) (Incorporated by reference to Company&rsquo;s Registration Statement on Form S-4 filed with the SEC on July 27, 2017)</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex10-41_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter dated September 6, 2017 from Resdevco Ltd. (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 21, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390017012449/f8k111517ex10-42_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement dated September 25, 2017 between Resdevco Ltd. and Wize Pharma Ltd. (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 21, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018003682/f10k2017ex10-43_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to Exclusive Distribution and Licensing Agreement by and between Wize Pharma Ltd. and Resdevco Research and Development Company Ltd., dated December 26, 2017 (Incorporated by reference to Company&rsquo;s Annual Report on Form 10-K filed with the SEC on March 29, 2018)</FONT></A></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018007232/f10k2017a1ex10-44_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum of Understanding by and between Wize Pharma Ltd. and Resdevco Research and Development Company Ltd., dated January 8, 2018 (Incorporated by reference to Amendment No. 1 to Company&rsquo;s Annual Report on Form 10-K filed with the SEC on June 5, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21+</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018002393/f8k022218ex10-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018 Equity Incentive Plan (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on February 28, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018007235/f8k053118ex10-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive Distribution Agreement between Wize Pharma Ltd. and HPGC Medical Co., Ltd. dated May 31, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed on June 5, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23+</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018011512/f8k0818ex10-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to 2018 Equity Incentive Plan (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 21, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24+</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018011573/f8k082018ex10-1_wize.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated August 21, 2018, between Wize Pharma Ltd. and Or Eisenberg (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 22, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25+</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018011573/f8k082018ex10-2_wize.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Services Agreement, dated August 20, 2018, between Wize Pharma Ltd., N. Danenberg Holdings (2000) Ltd. and Noam Danenberg (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 22, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018014254/f8k102218ex10-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Purchase Agreement dated October 22, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on October 23, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018014254/f8k102218ex10-3_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement dated October 22, 2018&nbsp;&nbsp;(Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on October 23, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018014254/f8k102218ex10-5_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agency Agreement dated October 22, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on October 23, 2018)</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 134; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.29</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018014254/f8k102218ex10-4_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Convertible Loan Amendment dated October 19, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on October 23, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.30</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018015780/f8k110718ex10-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment No.1 to Consulting Services Agreement dated November 7, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 14, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.31+</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390018015780/f8k110718ex10-2_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated November 7, 2018 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 14, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.32*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020008074/f10k2019ex10-55_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Memorandum of Understanding between Wize Pharma Ltd. and Resdevco, Research and Development Ltd. dated February 24, 2019 (Incorporated by reference to Company&rsquo;s Annual Report on Form 10-K filed with the SEC on March 30, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.33</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390019003492/f8k030419ex10-1_wize.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Convertible Loans Agreements dated March 4, 2019 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on March 4, 2019)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.34</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390019010026/f8k053119ex10-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Convertible Loans Agreements dated May 31, 2019 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 4, 2019)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.35</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020005525/ea119347ex8rimon_wize.htm">Amendment to Convertible Loans Agreements dated November 29, 2019 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on December 5, 2019)</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.36</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020001099/f8k010920ex10-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exchange Agreement by and between Bonus BioGroup Ltd. and Wize Pharma Inc., dated January 9, 2020 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 15, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.37</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020001099/f8k010920ex10-2_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Share Purchase Agreement by and between Bonus BioGroup Ltd. and Wize Pharma Inc., dated January 9, 2020 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 15, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.38</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020001099/f8k010920ex3-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Registration Rights Agreement (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 15, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.39</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020001099/f8k010920ex10-4_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series B Purchase Agreement by and between Wize Pharma Inc. and various investors, dated January 9, 2020 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 15, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.40#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10k2020ex10-40_wizepharma.htm">Amendment to Exclusive Distribution and Licensing Agreement by and between Wize Pharma Ltd., OcuWize Ltd. and Resdevco Research and Development Company Ltd., dated May 4, 2020</A>
    &nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.41</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020022287/f10q0620ex10-1_wize.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Letter Agreement (SPA), dated June 24, 2020, by and between the Company and Bonus BioGroup Ltd. (Incorporated by reference to Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.42</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020022287/f10q0620ex10-2_wize.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Letter Agreement (SPA), dated July 1, 2020, by and between the Company and Bonus BioGroup Ltd. (Incorporated by reference to Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on August 14, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.43</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020037331/f10q0920ex10-1_wizepha.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Amendment No. 1, dated as of October 28, 2020, to the Securities Purchase Agreement of October 22, 2018, by and among the Company and the investors signatory thereto (Incorporated by reference to Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 16, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.44</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390020039814/ea130705ex10-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Addendum Agreement, between Wize Pharma, Inc. and Bonus BioGroup Ltd., dated November 29, 2020 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 30, 2020)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.45</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390021000427/ea132523ex10-3_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Securities Purchase Agreement, between Wize Pharma, Inc. and various Purchasers, dated December 30, 2020 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 5, 2021)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.46</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390021000427/ea132523ex10-4_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Securities Purchase Agreement, between Wize Pharma, Inc. and Noam Danenberg, dated December 30, 2020 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 5, 2021)</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 135; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.47&dagger;</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390021002841/ea133377ex2-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deed of Amendment, dated January 18, 2021, of the Bid Implementation Agreement between Wize Pharma, Inc. and Cosmos Capital Limited, dated December 30, 2020 (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 19, 2021)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.48</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390021002841/ea133377ex10-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Stock Restriction Agreement (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 19, 2021)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.49&dagger;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1218683/000121390021002841/ea133377ex10-2_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Contingent Value Rights Agreement (Incorporated by reference to Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 19, 2021)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.1#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10k2020ex21-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subsidiaries of the Company </FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10k2020ex23-1_wizepharma.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of Independent Registered Public Accounting Firm</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1#</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify"><A HREF="f10k2020ex31-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer pursuant to Sec. 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10k2020ex31-2_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Sec. 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2020ex32-1_wizepharma.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. SECTION 1350</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2020ex32-2_wizepharma.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. SECTION 1350</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101#</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following materials
    from Wize, Inc.&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2020 are formatted in XBRL (eXtensible
    Business Reporting Language):&nbsp;&nbsp;(i) the Balance Sheets, (ii) the Statements of Comprehensive Loss, (iii) Statement
    of Changes in Shareholders&rsquo; Equity (Deficiency), (iv) the Statements of Cash Flow, and (iv) Notes to Financial Statements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits and schedules
    to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. We will furnish the omitted exhibits and schedules
    to the Securities and Exchange Commission upon request by the Securities and Exchange Commission.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management compensatory
    plan.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential treatment
    was requested with respect to certain portions of this exhibit pursuant to 17.C.F.R. &sect;240.24b-2. Omitted portions were
    filed separately with the SEC.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_026"></A>ITEM 16. FORM 10-K SUMMARY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 136; Value: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_025"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed
on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Wize Pharma, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 1, 2021</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Or Eisenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>Or Eisenberg<BR>
 Chief Financial Officer, Treasurer and Secretary (Principal Executive Officer, Principal Financial and Accounting Officer)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NAME</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TITLE</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATE</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Or Eisenberg</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, Treasurer and Secretary</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 1, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD ROWSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and&nbsp;Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Noam Danenberg</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 43%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Chief Executive Officer</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 1, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Danenberg</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark Sieczkarek</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 1, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Sieczkarek</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Yossi Keret</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Director</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 1, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yossi Keret</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph Zarzewsky</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Director</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 1, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Zarzewsky</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael Belkin</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Director</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 1, 2021</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Belkin</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">84</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>f10k2020ex4-2_wizepharma.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S
SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of February 26,
2021, Wize Pharma, Inc. (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our&rdquo;) has one class of securities
registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), Common Stock,
par value $0.001 per share (the &ldquo;Common Stock&rdquo;). The Common Stock are quoted on the OTCQB under the symbol &ldquo;WIZP&rdquo;.
The following is a summary of some of the terms of the Company&rsquo;s Common Stock, This summary is not complete and is subject
to and qualified in its entirety by reference to the Company&rsquo;s Restated Certificate of Incorporation (the &ldquo;Articles&rdquo;)
and Amended and Restated Bylaws (the &ldquo;Bylaws&rdquo;). The terms of the Common Stock are also subject to and qualified by
the applicable Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles,
we are authorized to issue up to five hundred million (500,000,000) shares of Common Stock, and one million (1,000,000) shares
of preferred stock, par value $.001 per share(the &ldquo;Preferred Stock&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our Common
Stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our Common
Stock have no cumulative voting rights. Further, holders of our Common Stock have no preemptive or conversion rights or other subscription
rights. Upon our liquidation, dissolution or winding-up, holders of our Common Stock are entitled to share in all assets remaining
after payment of all liabilities and the liquidation preferences of any of our outstanding shares of preferred stock. Subject to
preferences that may be applicable to any outstanding shares of preferred stock, holders of our Common Stock are entitled to receive
dividends, if any, as may be declared from time to time by our Board of Directors (the &ldquo;<B>Board</B>&rdquo;) out of our assets
which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of shares
of our Common Stock that are entitled to cast at least 33&frac13; of the total votes entitled to be cast by the holders of all
of our outstanding capital stock, present in person or by proxy, are necessary to constitute a quorum at any meeting. If a quorum
is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action
exceeds the number of votes cast in opposition to the action, with the exception of the election of directors, which requires a
plurality of the votes cast, represented in person or by proxy, necessary to constitute a quorum for the transaction of business
at any meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes
cast in favor of the action exceeds the number of votes cast in opposition to the action, with the exception of the election of
directors, which requires a plurality of the votes cast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Preferred Stock
may be issued without stockholder approval, from time to time in one or more series, each series to be appropriately designated
by a distinguishing letter or title prior to the issuance of any shares thereof, as determined by our Board. Our Articles expressly
authorizes (subject to the rights of the holders of any series of preferred stock pursuant to the terms of our Articles or any
resolution or resolutions providing for the issuance of such series of stock adopted by the Board) the increase or decrease (but
not below the number of shares of such series then outstanding) of the number of shares of any series subsequent to the issuance
of shares of that series by the affirmative vote of the holders of a majority of the Common Stock irrespective of the provisions
of Section 242(b)(2) of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board may authorize
the issuance of Preferred Stock with voting or conversion rights that could harm the voting power or other rights of the holders
of the Common Stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and
other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of
us and might harm the market price of our Common Stock and the voting and other rights of the holders of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Series A Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 22, 2018,
the Company filed a Certificate of Designations of Series A Preferred Stock (the &ldquo;<B>Series A Certificate of Designations</B>&rdquo;)
with the Secretary of State of Delaware. Pursuant to the Series A Certificate of Designations, the Company designated 1,350 shares
of preferred stock as Series A Preferred Stock. The Series A Preferred Stock has a stated value of $1,000 per share and is convertible
into shares of Common Stock in an amount determined by dividing the stated value of $1,000 by the conversion price of $1.00, such
that each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock. The Series A Preferred Stock may
not be converted into Common Stock to the extent such conversion would cause the holder to beneficially own more than 4.99% (or
9.99%, at the election of the investor) of the Company&rsquo;s outstanding Common Stock. The Series A Preferred Stock is entitled
to dividends on an as-converted basis with the Common Stock. The Series A Preferred Stock votes with the Common Stock on an as-converted
basis, subject to the beneficial ownership limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Series B Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 18, 2020,
the Company filed a Certificate of Designations of Series B Non-Voting Redeemable Preferred Stock (the &ldquo;<B>Series B Certificate
of Designations</B>&rdquo;) with the Secretary of State of Delaware. Pursuant to the Series B Certificate of Designations, the
Company designated 7,500 shares of preferred stock as Series B Preferred Stock. The Series B Preferred Stock are not convertible
into shares of common stock of the Company and have no voting powers, except as related to certain rights to protect the rights
and preferences of the Series B Preferred Stock and with respect to sales or dispositions of the Series B Preferred Stock at a
price per share below the Price Restriction. The Series B Preferred Stock entitles its holders to (i) 80% of the proceeds received
by the Company through future sales of the Bonus Shares issued to the Company under the Bonus Agreements and (ii) 80% of any cash
dividends received by the Company on such Bonus Shares. Under the Series B Certificate of Designations, the Company has the option
to redeem the Series B Preferred Stock at any time by distributing to holders of the Series B Preferred Stock (i) 80% of the Bonus
Shares then held by the Company and (ii) 80% of all dividends received by the Company but not yet paid to holders of the Series
B Preferred Stock (the &ldquo;<B>Redemption Payment</B>&rdquo;). The Company is required to redeem the Series B Preferred Stock
through payment of the Redemption Payment upon the earlier of (i) 60 days following the Nasdaq Listing, and (ii) December 28, 2020.
On July 8, 2020, the Company elected to redeem all of the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Provisions of Delaware Law, Our Articles and
Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of Delaware
law, our Articles and our Bylaws could discourage or make it more difficult to accomplish a proxy contest or other change in our
management or the acquisition of control by a holder of a substantial amount of our voting stock. It is possible that these provisions
could make it more difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to be in their
best interests or in our best interests. These provisions are intended to enhance the likelihood of continuity and stability in
the composition of our Board and in the policies formulated by our Board and to discourage certain types of transactions that may
involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited
acquisition proposal and to discourage certain tactics that may be used in proxy fights. Such provisions also may have the effect
of preventing changes in our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Delaware Statutory Business Combinations
Provision</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 203 of the
DGCL prohibits a publicly-held Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested
stockholder&rdquo; for a period of three (3) years after the date of the transaction in which the person became an interested stockholder,
unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a
prescribed manner or another prescribed exception applies. For purposes of Section 203, a &ldquo;business combination&rdquo; is
defined broadly to include a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder,
and, subject to certain exceptions, an &ldquo;interested stockholder&rdquo; is a person who, together with his or her affiliates
and associates, owns, or within three (3) years prior, did own, 15% or more of the corporation&rsquo;s voting stock. However, we
elected to opt out of the provisions of Section 203.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Advance Notice Provisions for Stockholder
Proposals and Stockholder Nominations of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws provide
that, for nominations to our Board or for other business to be properly brought by a stockholder before a meeting of stockholders,
the stockholder must first have given timely notice of the proposal in writing to our secretary at our principal offices. For an
annual meeting, a stockholder&rsquo;s notice generally must be delivered not less than 45 days nor more than 75 days prior to the
one-year anniversary of the date on which we first mailed our proxy materials for the preceding year&rsquo;s annual meeting of
stockholders. For an annual meeting, the notice must generally be delivered not later than the close of business on the later of
the 90<SUP>th</SUP>&nbsp;day prior to such annual meeting or the 10<SUP>th</SUP>&nbsp;day following the day on which public announcement
is first made. Detailed requirements as to the form of the notice and information required in the notice are specified in our Bylaws.
If it is determined that business was not properly brought before a meeting in accordance with our Bylaws, such business will not
be conducted at the meeting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Special Meetings of Stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special meetings of
the stockholders may be called only by either (i) the chairman of our Board, chief executive officer, or the president, (ii) by
our Board pursuant to a resolution adopted by a majority of the total number of directors which we would have if there were no
vacancies, or (iii) by the holders of 20% of the total votes entitled to be cast by the holders of all our outstanding capital
stock entitled to vote generally in an election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Stockholder Action by Written Consent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of our Articles and our Bylaws permit
our stockholders to act by written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Super Majority Stockholder Vote Required
for Certain Actions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The DGCL generally
provides that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&rsquo;s
certificate of incorporation or bylaws, unless the corporation&rsquo;s certificate of incorporation or bylaws, as the case may
be, requires a greater percentage. Our Articles requires the affirmative vote of the holders of at least 66&frac13; of our outstanding
voting stock to amend or repeal any provision of the our Bylaws or any amend or repeal any provision of our Articles relating to
limitation of director liability, indemnification and advancement of expenses or amendments to our Articles or our Bylaws. All
other provisions of our Articles may be amended or repealed by a simple majority vote of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The transfer agent and registrar for our
Common Stock is VStock Transfer LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">-3-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>3
<FILENAME>f10k2020ex10-40_wizepharma.htm
<DESCRIPTION>AMENDMENT TO EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT BY AND BETWEEN WIZE PHARMA LTD., OCUWIZE LTD. AND RESDEVCO RESEARCH AND DEVELOPMENT COMPANY LTD., DATED MAY 4, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.40</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>AMENDMENT
TO LICENSE AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
agreement (the &ldquo;<B>Amendment</B>&rdquo;) is entered into on May 4, 2020 (the &ldquo;<B>Effective Date</B>&rdquo;), by and
between Resdevco Research and Development Company Ltd., reg. no. 510422223 (the &ldquo;<B>Licensor</B>&rdquo;) and Wize Pharma Ltd.,
reg. no. 520033259 and/or OcuWize Ltd. reg.no. 515241511, the former name of which is Star Night Technologies Ltd. (the &ldquo;<B>Licensee</B>&rdquo;)
(the Licensor and the Licensee shall be collectively referred to hereinafter as the &ldquo;<B>Parties</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Licensor and the Licensee have entered into that certain Exclusive Distribution and Licensing Agreement dated May 1, 2015
and to subsequent amendments thereto (collectively referred to hereunder as the &ldquo;<B>License Agreement</B>&rdquo;), setting
forth the terms and conditions of the license and distribution rights granted by the Licensor to the Licensee in the territory
of the United States of America (the &ldquo;<B>Territory</B>&rdquo;); and</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Parties wish to amend and update certain obligations and time frames which were previously agreed in the License Agreement.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE, </B>the Parties hereby declare and agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Immediate
                                         Termination</U>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary in the License Agreement, if (i) within 3 months after the receipt by Licensee of the Pre-IND, or (ii)
in case of proven inability to receive Pre-IND as a direct result of COVID-19 epidemic, in both cases not later than December
31, 2020, Licensee provides the Licensor with a written notice of Licensee&rsquo;s decision to terminate the License Agreement for any
reason, the License Agreement shall be terminated immediately upon the receipt of such notice by Licensor without any additional
written notice (the &ldquo;<B>Termination Right</B>&rdquo;). For the sake of clarity, to the extent the Termination Right is exercised
as aforesaid before the end of 2020 no minimum royalty fee shall be due from the Licensee for the year 2021.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         Licensee does not exercise the Termination Right by December 31<SUP>st</SUP>, 2020, then,
                                         subject to Licensee&rsquo;s obligations under the License Agreement (as amended among
                                         others on November 8, 2019), the Termination Rights (including the foregoing limitation
                                         of 3 months) shall apply until December 31, 2021 (the &ldquo;<B>Extended Termination
                                         Right</B>&rdquo;). For the sake of clarity, to the extent the Extended Termination Right
                                         is exercised as aforesaid before the end of 2021 no minimum royalty fee shall be due
                                         from the Licensee for the year 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Pre-IND</B>&rdquo;
means pre-IND consultation with FDA and receiving the FDA feedback.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Survival
                                         of Terms</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the avoidance of doubt, the provisions of the License Agreement which by their nature are intended to survive termination or expiration
of the License Agreement shall survive the termination pursuant to Section 1 of this Amendment, including without limitation Article
16.18 to the License Agreement and all Articles indicated therein (the &ldquo;<B>Surviving Obligations</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination
                                         Conditions.</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
derogating from the said in Section 2 above, and as a condition of Licensor&rsquo;s consent to waive its right for 180 days&rsquo; prior termination
notice, it is expressly agreed that immediately upon termination of the License Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
will strictly comply with the provisions of the License Agreement regarding revert of all rights and transfer of all proprietary,
confidential and other information related to the business conducted under the License Agreement from Licensee to Licensor pursuant
to Article 11.3 of the License Agreement, as well as any and all registration files, drug files, authorizations, technical data,
preclinical and clinical data, toxicological and pharmacological data, scientific data, and any other information, documentation
or results obtained or possessed by Licensee, relating to any business conducted by Licensee in connection with the License Agreement
and/or any registration proceedings conducted in the Territory.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee
                                         will use its best efforts to assist Licensor in finding a third-party willing to take
                                         Licensee&rsquo;s place and comply to the greatest extent with the provisions of the License
                                         Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                         the avoidance of doubt, the provisions of penalty payments under Article 12.3 of the
                                         License Agreement shall expressly apply with respect to the termination of the License
                                         Agreement pursuant to Section 1 of this Amendment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensor
                                         shall be free and have full power and discretion to engage with any person and to enter
                                         into any agreement for the grant of any right and interest previously granted under the
                                         License Agreement, explicitly or implicitly, and Licensee will have no claims in this
                                         regard.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without
                                         derogating from the Licensee&rsquo;s Surviving Obligations, Licensee forever waives, releases
                                         and discharges Licensor from any and all claims, causes of action, demands, liabilities,
                                         damages, obligations and debts, of every kind and nature, whether known or unknown, suspected
                                         or unsuspected, that Licensee had in past, currently has or will have in future in connection
                                         with the License Agreement or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                         Amendment constitutes the entire understanding and agreement between the Parties with
                                         regard to the subject matter hereof and supersedes any and all prior discussions, agreements
                                         and correspondence with regard to the subject matter hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                         as explicitly provided in this Amendment, this Amendment shall not derogate from or amend
                                         the provisions of the License Agreement, and it shall remain in full force and effect
                                         throughout their terms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                         amendment of this Amendment and any waiver of any of the terms or conditions thereof
                                         may be made only in in written agreement executed by both Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF, </B>the Parties have entered into this Amendment as of the date written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">/s/ Prof.
    S. Dikstein</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Noam
    Danenberg</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resdevco
    Research and Development</B> &nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wize
    Pharma Ltd.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
    Ltd.</B> &nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OcuWize
    Ltd.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; width: 35%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; width: 20%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; width: 35%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof.
    Shabtay Dikstein</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam
    Danenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">CEO</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>f10k2020ex21-1_wizepharma.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries of Wize Pharma, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Subsidiary</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.5pt solid; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of Incorporation or Organization</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wize NC Inc.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wize Pharma Ltd.</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OcuWize Ltd. (wholly owned by Wize NC Inc.)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>f10k2020ex23-1_wizepharma.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"><B>EXHIBIT 23.1</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"><B>Fahn Kanne &amp; Co.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">Head Office</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">32 Hamasger Street</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">Tel-Aviv 6721118, ISRAEL</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">PO Box 36172, 6136101</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">T +972 3 7106666</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">F +972 3 7106660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">www.gtfk.co.il</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white">We have
issued our report dated March 1, 2021, with respect to the consolidated financial statements included in the Annual Report of
Wize Pharma, Inc. on Form 10-K for the year ended December 31, 2020. We consent to the incorporation by reference of said
report in the Registration Statement of Wize Pharma, Inc. on Form S-8 (File No. 333-224146).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"><B>/s/ FAHN KANNE &amp; CO. GRANT THORNTON ISRAEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.5in; text-align: left; text-indent: -0.5in">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">March 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left"><B>Certified Public Accountants</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: left">Fahn Kanne &amp; Co. is the Israeli member firm
        of Grant Thornton International Ltd.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 0pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>f10k2020ex31-1_wizepharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-bottom: 0pt; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="margin-bottom: 0pt; text-align: center"><B>Certification</B></P>

<P STYLE="margin-bottom: 0pt">I, Noam Danenberg, certify that:</P>

<P STYLE="margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">1.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 97%">I have reviewed this Annual Report on Form 10-K of Wize Pharma, Inc. for the year
ended December 31, 2020;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">2.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 97%">Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">3.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 97%">Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">4.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 97%">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(a)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 95%">Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including
its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this
report is being prepared;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(b)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 95%">Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(c)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 95%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(d)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 95%">Disclosed in this report any change in the registrant&rsquo;s internal control over
financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal
quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">5.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 97%">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(a)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 95%">All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record,
process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(b)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify; width: 95%">Any frausd, whether or not material, that involves management or other employees who
have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0pt">Date:&nbsp;March 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: left;   unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Noam Danenberg</FONT></TD>
    <TD STYLE="width: 68%; text-align: justify;   unicode-bidi: embed; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left;   unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noam Danenberg,<BR>
Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify;   unicode-bidi: embed; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"></P>

<P STYLE="margin-top: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 0pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>f10k2020ex31-2_wizepharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="text-align: center"><B>Certification</B></P>

<P>I, Or Eisenberg, certify that:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%; margin-left: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">1.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">I have reviewed this Annual Report on Form 10-K of Wize Pharma, Inc. for the year
ended December 31, 2020;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">2.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">3.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">4.</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%; margin-left: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 7pt; text-align: left">(a)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including
its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this
report is being prepared;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(b)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(c)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(d)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over
financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal
quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">5.</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(a)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record,
process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 2%; text-align: left">(b)</TD><TD STYLE="width: 1%"></TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date:&nbsp;March 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 100%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Or Eisenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Or Eisenberg,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Chief Financial Officer &nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>(Principal Financial and Accounting Officer) &nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>f10k2020ex32-1_wizepharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
annual report of Wize Pharma, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2020, as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned principal executive officer
of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002 (&ldquo;SOX&rdquo;), that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: left;  font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify;  font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify;  font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;); and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This certification accompanies
this Annual Report on Form 10-K pursuant to Section 906 of SOX and shall not, except to the extent required by such Act, be deemed
filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by
reference into any filling under the Securities Act of 1993, as amended, or the Exchange Act, except to the extent that the Company
specifically incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A signed original of this
written statement required by Rule 13a-14(b) or 15d-14(b) of the Exchange Act and Section 906 of SOX has been provided by the Company
and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: March 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; text-align: left;  font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Noam Danenberg</FONT></TD>
    <TD STYLE="width: 60%; text-align: justify;  font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Noam Danenberg,<BR>
        Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>f10k2020ex32-2_wizepharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION
1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In connection with the
annual report of Wize Pharma, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2020, as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned principal financial and accounting
officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 (&ldquo;SOX&rdquo;), that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: left;  font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify;  font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify;  font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;); and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: left; ">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This certification accompanies
this Annual Report on Form 10-K pursuant to Section 906 of SOX and shall not, except to the extent required by such Act, be deemed
filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by
reference into any filling under the Securities Act of 1993, as amended, or the Exchange Act, except to the extent that the Company
specifically incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A signed original of this
written statement required by Rule 13a-14(b) or 15d-14(b) of the Exchange Act and Section 906 of SOX has been provided by the Company
and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: March 1, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; text-align: left; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Or Eisenberg</FONT></TD>
    <TD STYLE="width: 60%; text-align: justify; ">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg,<BR>
Chief Financial Officer</FONT></TD>
    <TD STYLE="text-align: justify; ">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; "><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="text-align: justify; ">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" 0X# 2(  A$! Q$!_\0
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M%'?^7"S./JG_ (+2?\%-OVJ_@_\ M<_L<?\ !-+]@_3OAUH7[2W[65U!?/\
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MLGB#P_XBET^SFO-*B\/?:0+Q+34;;3K))#:NS1W)Q(H09]9_X-J#M_X(Q?\
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MMY+<"S<RZSIGBZ6#RL@LMU*@PSD@'T7^RO\ \'!G_!3[_@HU\,]>\/?L*?\
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MDJE*/N5+TVFK)*SNW"5GY/2ZZVRO@Q\#O@YX>O(-9TSP!X?.IQ,KP7NH6_\
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M'1H/!C0>(?$FOBTMKNUFDDU'+^(I+7?*D0\JUB;;O9V/[,44 ?D[_P %:O\
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M:WK$\<<5M%:Z9'?32:9HUJL=E;O)<2MYD]S-,WZG44 ?EA_P2/\ ^"9>D_\
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>11
<FILENAME>wizp-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: wizp%2D20201231.xfr; Date: 2021%2D03%2D01T18:25:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020020 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:wizp="http://ophthalic.com/20201231">
    <link:schemaRef xlink:href="wizp-20201231.xsd" xlink:type="simple" />
    <xbrli:context id="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-01to2019-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneEightPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwoZeroOneEightPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneEightPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_TwoZeroOneEightPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneEightPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_DebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleDebtOneMember_us-gaap_DebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_CannabicsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:CannabicsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-03to2020-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-03</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementGeographicalAxis_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_IL_RangeAxis_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_IL_RangeAxis_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_country_IL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OcuwizeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:OcuwizeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_WizeIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:WizeIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_DirectorSalaryAndInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:DirectorSalaryAndInsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_TaxesAndTollsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:TaxesAndTollsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_ProfessionalServicesAndConsultationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:ProfessionalServicesAndConsultationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_PayrollAndBenefitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:PayrollAndBenefitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_RentAndOfficeMaintenanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:RentAndOfficeMaintenanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_ShareBasedPaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:ShareBasedPaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_OverseasTravelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:OverseasTravelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_OtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:OtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_OverseasTravelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:OverseasTravelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ShareBasedPaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:ShareBasedPaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_RentAndOfficeMaintenanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:RentAndOfficeMaintenanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_PayrollAndBenefitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:PayrollAndBenefitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_ProfessionalServicesAndConsultationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:ProfessionalServicesAndConsultationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_TaxesAndTollsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:TaxesAndTollsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_DirectorSalaryAndInsuranceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:DirectorSalaryAndInsuranceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_OtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">wizp:OtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneEightPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_TwoZeroOneEightPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneEightPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_TwoZeroOneTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwoZeroOneTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_TwoZeroOneTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwoZeroOneTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwoThousandTwelvePlanMemberrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wizp:TwoThousandTwelvePlanMemberrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeeStockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wizp:EmployeeStockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_EmployeeStockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wizp:EmployeeStockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-02to2020-12-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-02</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CannabicsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:CannabicsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_CannabicsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:CannabicsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-03to2021-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-03</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-03to2021-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-03</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2017-07-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">wizp:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-05to2020-01-09_custom_BonusExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-05</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-05to2020-01-09_custom_BonusExchangeAgreementMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-05</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-02to2020-02-19_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-02</xbrli:startDate>
        <xbrli:endDate>2020-02-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-19_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-05to2020-01-09_custom_BonusAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-05</xbrli:startDate>
        <xbrli:endDate>2020-01-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09_custom_BonusAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-09_custom_BonusAgreementsMember_custom_IsraeliShekelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:IsraeliShekelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-01to2020-11-29_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_SeriesBPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:SeriesBPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-29_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-02to2020-07-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-02</xbrli:startDate>
        <xbrli:endDate>2020-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-01to2020-11-29_us-gaap_SeriesBPreferredStockMember_custom_BonusAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BonusAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-01to2020-11-29_us-gaap_SeriesBPreferredStockMember_custom_SettlementSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:SettlementSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-12to2020-11-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-12</xbrli:startDate>
        <xbrli:endDate>2020-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-06-04to2017-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-06-04</xbrli:startDate>
        <xbrli:endDate>2017-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-02to2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:OcuwizeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroTwoZeroLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-02</xbrli:startDate>
        <xbrli:endDate>2020-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:OcuwizeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroTwoZeroLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember_custom_ILSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:OcuwizeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroTwoZeroLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:ILSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-01to2017-12-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-01</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_country_IL_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_country_IL_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-30_custom_BidAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:BidAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_PIPEAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:PIPEAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PIPEAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:PIPEAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-12to2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:WizeIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-12</xbrli:startDate>
        <xbrli:endDate>2017-01-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-12to2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:LendersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-12</xbrli:startDate>
        <xbrli:endDate>2017-01-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-03-17to2016-03-20_custom_ConvertibleDebtOneMember_custom_RimonGoldMember_custom_NisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:NisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-03-17</xbrli:startDate>
        <xbrli:endDate>2016-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-03-17to2016-03-20_custom_ConvertibleDebtOneMember_custom_RimonGoldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-03-17</xbrli:startDate>
        <xbrli:endDate>2016-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-03-17to2016-03-20_us-gaap_ConvertibleDebtMember_custom_RimonGoldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-03-17</xbrli:startDate>
        <xbrli:endDate>2016-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-03-17to2016-03-20_custom_ConvertibleDebtOneMember_custom_WizeIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:WizeIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-03-17</xbrli:startDate>
        <xbrli:endDate>2016-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-14to2017-12-21_custom_TwoZeroOneSevenLoanAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroOneSevenLoanAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-14</xbrli:startDate>
        <xbrli:endDate>2017-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-19to2019-03-04_custom_TwoZeroOneNineLoanAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroOneNineLoanAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-19</xbrli:startDate>
        <xbrli:endDate>2019-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-19to2019-03-04_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-19</xbrli:startDate>
        <xbrli:endDate>2019-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-19to2019-03-04_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-19</xbrli:startDate>
        <xbrli:endDate>2019-03-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-03to2018-10-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-03</xbrli:startDate>
        <xbrli:endDate>2018-10-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_LendersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:LendersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-04_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-04_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_RimonGoldAndFisherMember_custom_NisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldAndFisherMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:NisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:LendersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:WizeIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember_custom_NisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:WizeIsraelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:NisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember_custom_NisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:LendersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:NisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-20_custom_ConvertibleDebtOneMember_custom_WizeIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:WizeIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-20_custom_ConvertibleDebtOneMember_custom_RimonGoldMember_custom_NisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:NisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-20_custom_ConvertibleDebtOneMember_custom_WizeIsraelMember_custom_NisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wizp:WizeIsraelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="wizp:TypesOfCurrencyAxis">wizp:NisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-20_us-gaap_ConvertibleDebtMember_custom_RimonGoldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-02to2019-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-02</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-02to2019-05-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-02</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-02to2019-05-31_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-02</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-01to2019-11-29_custom_TwoZeroOneNineLoanAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroOneNineLoanAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-01</xbrli:startDate>
        <xbrli:endDate>2019-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-29_custom_TwoZeroOneNineLoanAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroOneNineLoanAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-01to2019-12-13_custom_TwoZeroOneNineLoanAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroOneNineLoanAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-13_custom_TwoZeroOneNineLoanAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:TwoZeroOneNineLoanAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_WarrantMember722117906">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwentyTwelveStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwentyTwelveStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_TwentyTwelveStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wizp:TwentyTwelveStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-24_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wizp:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-08_custom_SeriesAWarrantsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wizp:SeriesAWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-08_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wizp:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-01to2020-08-11_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-01</xbrli:startDate>
        <xbrli:endDate>2020-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-01to2020-08-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-01</xbrli:startDate>
        <xbrli:endDate>2020-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-15to2019-03-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-15</xbrli:startDate>
        <xbrli:endDate>2019-03-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-25to2019-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-25</xbrli:startDate>
        <xbrli:endDate>2019-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-13to2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-13</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-04-29_us-gaap_PreferredClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-04-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-07_us-gaap_PreferredClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-09to2019-07-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-09</xbrli:startDate>
        <xbrli:endDate>2019-07-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-01to2019-08-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-01</xbrli:startDate>
        <xbrli:endDate>2019-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-14_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-01to2019-05-15_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-01to2019-12-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-01to2019-12-31_custom_EmployeeStockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wizp:EmployeeStockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-08-15_custom_EmployeeStockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wizp:EmployeeStockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-08-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-25to2018-04-04_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-25</xbrli:startDate>
        <xbrli:endDate>2018-04-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-09to2019-03-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-09</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-04-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-15_custom_EmployeeStockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wizp:EmployeeStockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-13_custom_RimonGoldAndFisherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldAndFisherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-17to2019-05-19_custom_RimonGoldAndFisherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldAndFisherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-17</xbrli:startDate>
        <xbrli:endDate>2019-05-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-06_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-15_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-01_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-01_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-01to2020-11-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2021-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">wizp:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">wizp:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleDebtOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:ConvertibleDebtOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-02to2019-05-31_custom_MayTwoThousandNineteenAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">wizp:MayTwoThousandNineteenAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-02</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_RimonGoldAndFisherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">wizp:RimonGoldAndFisherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-13to2019-03-31_us-gaap_PreferredClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-13</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_SeriesAWarrantsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">wizp:SeriesAWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-30_custom_StockRestrictionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:StockRestrictionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-30_custom_CVRAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="wizp:TypeOfAgreementAxis">wizp:CVRAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-01to2020-12-31_custom_CosmosConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">wizp:CosmosConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CosmosConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001218683</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">wizp:CosmosConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD_per_Share">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="ILS_per_Share">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:ILS</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="ILS">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">35110000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">34491000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-03-01" unitRef="USD" decimals="-3">765000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="shares" decimals="INF">178</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="shares" decimals="INF">178</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31_custom_TwentyTwelveStockIncentivePlanMember" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-24_custom_SeriesAWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="shares" decimals="INF">32783495</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="shares" decimals="INF">15873128</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31_custom_EmployeeStockOptionTwoMember" unitRef="shares" decimals="INF">435053</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31_custom_TwentyTwelveStockIncentivePlanMember" unitRef="shares" decimals="INF">45370</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-08-15_custom_EmployeeStockOptionTwoMember" unitRef="shares" decimals="INF">2500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-13_custom_RimonGoldAndFisherMember" unitRef="shares" decimals="INF">2816196</us-gaap:CommonStockSharesIssued>
    <us-gaap:InvestmentIncomeDividend contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">390000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2020-01-01to2020-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">246000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">246000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">818000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">818000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-4929000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-4929000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-3450000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-3450000</us-gaap:ProfitLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">1709000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-977000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-02-19to2019-03-04_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">48000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-02-19to2019-03-04_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">48000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-01-01to2019-12-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">1709000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-05-02to2019-05-31_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">926000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-05-02to2019-05-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">926000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember722117906" unitRef="USD" decimals="-3">99000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebt contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConvertibleDebt contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ConvertibleDebt contextRef="AsOf2020-12-31_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">2985000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2019-12-31_custom_LendersMember" unitRef="USD" decimals="-3">274000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_RimonGoldAndFisherMember_custom_NisMember" unitRef="ILS" decimals="-3">1000000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember" unitRef="USD" decimals="-3">822000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember" unitRef="USD" decimals="-3">822000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember_custom_NisMember" unitRef="ILS" decimals="-3">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2016-03-20_custom_ConvertibleDebtOneMember_custom_WizeIsraelMember" unitRef="USD" decimals="-3">531000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2016-03-20_custom_ConvertibleDebtOneMember_custom_WizeIsraelMember_custom_NisMember" unitRef="ILS" decimals="-3">2000000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2016-03-20_us-gaap_ConvertibleDebtMember_custom_RimonGoldMember" unitRef="USD" decimals="-3">531000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2019-11-29_custom_TwoZeroOneNineLoanAmendmentMember" unitRef="USD" decimals="-3">1353000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2020-12-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">2104000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_RimonGoldAndFisherMember" unitRef="USD" decimals="-3">274000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-07-02to2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember">2021-01-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2017-01-12to2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember">2018-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2016-03-17to2016-03-20_custom_ConvertibleDebtOneMember_custom_WizeIsraelMember">2018-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2020-12-31_custom_PIPEAgreementsMember" unitRef="USD_per_Share" decimals="INF">0.12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember" unitRef="USD_per_Share" decimals="INF">1.332</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">764000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">765000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-05to2020-01-09_custom_BonusAgreementsMember" unitRef="USD" decimals="-3">16400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="-3">15000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-02-25to2019-03-01" unitRef="USD" decimals="-3">765000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockOptionTwoMember" unitRef="shares" decimals="INF">290222</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember" unitRef="shares" decimals="INF">85239000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-03-13to2019-03-31" unitRef="shares" decimals="INF">60000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-04-01to2019-04-29" unitRef="shares" decimals="INF">336000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-05-01to2019-05-07" unitRef="shares" decimals="INF">336000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-12-31">Wize Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-12-31">0001218683</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2020-01-01to2020-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-12-31">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <wizp:LicensePurchaseObligationCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">250000</wizp:LicensePurchaseObligationCurrent>
    <wizp:LicensePurchaseObligationCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">250000</wizp:LicensePurchaseObligationCurrent>
    <us-gaap:RestrictedInvestmentsCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">13000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:RestrictedInvestmentsCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">41000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">-73000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">-73000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31_custom_OcuwizeMember" unitRef="USD" decimals="-3">5366000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31_custom_WizeIsraelMember" unitRef="USD" decimals="-3">5476000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">-39218000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">-33899000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-12-31">000-52545</dei:EntityFileNumber>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityShellCompany>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="From2020-01-01to2020-12-31_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">577713</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">430345</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">2008000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">2678000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_DirectorSalaryAndInsuranceMember" unitRef="USD" decimals="-3">183000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_TaxesAndTollsMember" unitRef="USD" decimals="-3">24000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_ProfessionalServicesAndConsultationMember" unitRef="USD" decimals="-3">953000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_PayrollAndBenefitsMember" unitRef="USD" decimals="-3">470000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_RentAndOfficeMaintenanceMember" unitRef="USD" decimals="-3">49000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_ShareBasedPaymentMember" unitRef="USD" decimals="-3">688000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_OverseasTravelMember" unitRef="USD" decimals="-3">103000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_IncomeStatementLocationAxis_OtherExpensesMember" unitRef="USD" decimals="-3">208000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_OverseasTravelMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_ShareBasedPaymentMember" unitRef="USD" decimals="-3">246000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_RentAndOfficeMaintenanceMember" unitRef="USD" decimals="-3">51000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_PayrollAndBenefitsMember" unitRef="USD" decimals="-3">834000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_ProfessionalServicesAndConsultationMember" unitRef="USD" decimals="-3">517000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_TaxesAndTollsMember" unitRef="USD" decimals="-3">67000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_DirectorSalaryAndInsuranceMember" unitRef="USD" decimals="-3">177000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-12-31_custom_OtherExpensesMember" unitRef="USD" decimals="-3">116000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">247000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">718000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PaymentsForRoyalties contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">250000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">250000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="From2020-01-03to2020-01-31" unitRef="USD" decimals="-3">150000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="From2021-01-03to2021-01-31" unitRef="USD" decimals="-3">150000</us-gaap:PaymentsForRoyalties>
    <us-gaap:DeferredCostsAndOtherAssets contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">650000</us-gaap:DeferredCostsAndOtherAssets>
    <wizp:LicenseAgreementDescription contextRef="From2020-01-01to2020-12-31">A one-time payment to Resdevco by Wize Israel in an amount of $650 shall be due no later than the second anniversary of the receipt of Food and Drug Administration (&#8220;FDA&#8221;) approval (the &#8220;Deferred Amount&#8221;); however, following FDA approval, if annual royalties due to Resdevco by Wize Israel exceed the Minimum Royalties (as defined in the License Agreement), an amount equal to 50% of such excess shall be added towards settlement of the Deferred Amount. As to royalty payments, Resdevco shall be entitled to the greater of $0.60 per unit sold, or a percentage of revenues, not to exceed 10%, from sales made in the United States and other countries, excluding Israel, China and Ukraine, but not less than the Minimum Royalties.</wizp:LicenseAgreementDescription>
    <wizp:LicenseAgreementDescription contextRef="From2021-01-03to2021-01-31_us-gaap_SubsequentEventMember">Representing the minimum commitment to pay royalties based on the upcoming January 2021 payment in an amount of $150 and an amount of $100 which represents a termination fee payable to Resdevco if the Company exercises its right to terminate the License Agreement.</wizp:LicenseAgreementDescription>
    <wizp:RecognizedLeaseLiability contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">250000</wizp:RecognizedLeaseLiability>
    <wizp:PercentageOfDiscountRate contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.10</wizp:PercentageOfDiscountRate>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">250000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">250000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PurchaseObligation contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">250000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligation contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">250000</us-gaap:PurchaseObligation>
    <wizp:LicensePurchaseObligationNet contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <wizp:LicensePurchaseObligationNet contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <wizp:ReducedAnnualRoyaltiesDescription contextRef="From2019-02-01to2019-02-28">The Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through 2021, and thereafter annual payments of $475,000 per year, and shall pay Resdevco $650,000 within two years after receipt of FDA approval for eye drops utilizing the licensed technology.</wizp:ReducedAnnualRoyaltiesDescription>
    <wizp:ReducedAnnualRoyaltiesDescription contextRef="From2017-07-01to2017-07-31_custom_LicenseAgreementMember">Wize Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 were reduced to $150 for 2018 and 2019. In addition, If Wize Israel would have obtained an FDA marketing license during 2019, the Company was also required to pay Resdevco the remainder of the payment of 2019, however, such approval was not achieved in 2019. Consequently, during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the 2018 minimum commitment</wizp:ReducedAnnualRoyaltiesDescription>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">439000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">104000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty contextRef="From2020-01-01to2020-12-31" unitRef="USD" id="Foot-00-0" decimals="-3">1212000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty contextRef="From2019-01-01to2019-12-31" unitRef="USD" id="Foot-00-1" decimals="-3">1140000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <wizp:FinanceIncomeNet contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:FinanceIncomeNet contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-625000</wizp:FinanceIncomeNet>
    <us-gaap:OtherReceivables contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherReceivables contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">52000</us-gaap:OtherReceivables>
    <wizp:ForeignCurrencyExchangeRateTranslation contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="ILS_per_Share" decimals="INF">3.215</wizp:ForeignCurrencyExchangeRateTranslation>
    <wizp:ForeignCurrencyExchangeRateTranslation contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="ILS_per_Share" decimals="INF">3.456</wizp:ForeignCurrencyExchangeRateTranslation>
    <wizp:CurrencyExchangeRatePercentage contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="pure" decimals="INF">-0.069</wizp:CurrencyExchangeRatePercentage>
    <wizp:CurrencyExchangeRatePercentage contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="pure" decimals="INF">-0.078</wizp:CurrencyExchangeRatePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember" unitRef="pure" decimals="INF">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="AsOf2020-12-31_us-gaap_OfficeEquipmentMember" unitRef="pure" decimals="INF">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:DescriptionOfLessorLeasingArrangementsOperatingLeases contextRef="From2020-11-12to2020-11-22">The Company rents its offices from a third party for a rental monthly fee of $2. The rent period is for a period of 12 months.</us-gaap:DescriptionOfLessorLeasingArrangementsOperatingLeases>
    <wizp:FindersFeeAgreementDescription contextRef="From2017-06-04to2017-06-19">The service provider will be entitled to the finder fee of 5% even if the agreement will be terminated.</wizp:FindersFeeAgreementDescription>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-06-04to2017-06-19" unitRef="pure" decimals="INF">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SharesIssued contextRef="AsOf2020-12-31_custom_TwoThousandTwelvePlanMemberrMember" unitRef="shares" decimals="INF">4896</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-01-31" unitRef="shares" decimals="INF">7500</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-12-08_custom_SeriesAWarrantsMember" unitRef="shares" decimals="INF">3000000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-01-06_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF">25300</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-04-15_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF">25300</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-07-01_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF">25300</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2020-10-01_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF">44050</us-gaap:SharesIssued>
    <wizp:DepositPercentage contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.0833</wizp:DepositPercentage>
    <us-gaap:SeveranceCosts1 contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">16000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">17000</us-gaap:SeveranceCosts1>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2020-01-01to2020-12-31">The tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.</us-gaap:IncomeTaxExaminationDescription>
    <wizp:AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">20000</wizp:AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities>
    <wizp:NetIncomeAttributedToPreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" id="Foot-01-0" decimals="-3">53000</wizp:NetIncomeAttributedToPreferredStock>
    <wizp:NetIncomeAttributedToPreferredStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" id="Foot-01-1" decimals="-3">136000</wizp:NetIncomeAttributedToPreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-5266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-3766000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <wizp:NetLossPerShareOfCommonStockBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="USD_per_Share" decimals="INF">-0.32</wizp:NetLossPerShareOfCommonStockBasicAndDiluted>
    <wizp:NetLossPerShareOfCommonStockBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USD_per_Share" decimals="INF">-0.36</wizp:NetLossPerShareOfCommonStockBasicAndDiluted>
    <wizp:PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare contextRef="From2020-01-01to2020-12-31" unitRef="shares" decimals="INF">614763</wizp:PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare>
    <wizp:PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare contextRef="From2019-01-01to2019-12-31" unitRef="shares" decimals="INF">16931097</wizp:PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2020-12-30" unitRef="pure" decimals="INF">0.8765</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2019-02-07" unitRef="pure" decimals="INF">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">22000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">22000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="shares" decimals="INF">16669628</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="shares" decimals="INF">10519682</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-4929000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-3450000</us-gaap:NetIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-2487000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-280000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">760000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2019-11-01to2019-11-29_custom_TwoZeroOneNineLoanAmendmentMember" unitRef="USD" decimals="-3">760000</us-gaap:RepaymentsOfConvertibleDebt>
    <wizp:SecuritiesPurchaseAgreementDescription contextRef="From2020-01-05to2020-01-09_custom_BonusExchangeAgreementMember">The Company agreed to purchase 51,282,000 ordinary shares of Bonus (the "PIPE Shares", and together with the LO2A Shares, the "Bonus Shares"), for an aggregate purchase price of $7,400 in cash, which funds were deposited directly into an escrow account (the "Bonus Escrow Account"), of which (i) $500 was paid to Bonus as an advance promptly following execution of the Bonus Purchase Agreement, (ii) $3,200 was released to Bonus concurrently with the closing of the transactions contemplated by the Bonus Agreements in exchange for 50% of the PIPE Shares and (iii) $3,700 was released to Bonus upon the Milestone Closing (as defined in the Bonus Purchase Agreement), in exchange for the remaining 50% of the PIPE Shares that were issued by Bonus and deposited into the escrow at the closing. The Company's obligation to consummate the Milestone Closing is conditioned upon the satisfaction by Bonus of certain conditions, including the listing of its ordinary shares (or, if an ADR Program is to be implemented by Bonus, the American Depositary Shares representing such ordinary shares) on the Nasdaq Capital Market (or another superior tier of the Nasdaq market) (the "Nasdaq Listing").</wizp:SecuritiesPurchaseAgreementDescription>
    <wizp:SecuritiesPurchaseAgreementDescription contextRef="From2020-01-05to2020-01-09_custom_BonusAgreementsMember">Pursuant to the Bonus Agreements, the Company agreed to grant Bonus, in consideration for the issuance of 62,370,000 ordinary shares of Bonus to the Company (the "LO2A Shares"), the right to receive 37% of future LO2A Proceeds (if any), which, as more fully defined in the Bonus Exchange Agreement, include proceeds generated by the Company, Wize Israel and OcuWize, as a result of (i) the sale, license or other disposal of products or other rights underlying the LO2A technology licensed to OcuWize under the License Agreement; and (ii) a Sale Transaction, which, as more fully defined in the Bonus Exchange Agreement, includes the sale of shares or assets of Wize Israel and/or OcuWize. In addition, if the Sale Transaction involves a change of control of the Company, Bonus will be entitled to elect, to either remain with its right to 37% of the LO2A Proceeds or receive a one-time payment equal to 37% of the value attributed to Wize Israel out of the total proceeds payable for the Company in such transaction.</wizp:SecuritiesPurchaseAgreementDescription>
    <wizp:SecuritiesPurchaseAgreementDescription contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember_us-gaap_SeriesBPreferredStockMember">Pursuant to the Bonus Agreements (as amended as of June 24, 2020), Bonus agreed to cover nearly 50% of the Company's fees and expenses payable by the Company in cash, Bonus shares and/or a combination thereof to H.C. Wainwright &amp; Co., LLC ("HCW") in connection with the transactions contemplated by the Bonus Agreements and the Series B Purchase Agreement (as defined below). In particular, Bonus agreed to reimburse the Company or pay HCW directly $350 in cash, Bonus shares and/or a combination thereof.</wizp:SecuritiesPurchaseAgreementDescription>
    <wizp:SecuritiesPurchaseAgreementDescription contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember">The Company agreed to sell to the investors, and the investors agreed to purchase from the Company, in a private placement, an aggregate of 7,500 shares of newly created Series B Non-Voting Redeemable Preferred Stock, par value $0.001 per share, of the Company ("Series B Preferred Stock") for a purchase price of $1.00 per share, for aggregate gross proceeds under the Series B Purchase Agreement of $7,500, which funds were deposited into an escrow account, of which (i) $500 was to be paid to the Bonus Escrow Account and $100 was paid directly to the Company to cover certain of its transactions expenses, in each case, promptly following the execution of the Series B Purchase Agreement, and (ii) the remaining $6,900 was to be released to the Bonus Escrow Account upon the closing of the transactions contemplated by the Series B Purchase Agreement (of which, as described above, $3,200 was to be released upon the earlier of the Milestone Closing or upon written consent of the holders of at least a majority of the Series B Preferred Stock).</wizp:SecuritiesPurchaseAgreementDescription>
    <wizp:SecuritiesPurchaseAgreementDescription contextRef="From2020-01-01to2020-12-31_custom_SeriesBPurchaseAgreementMember">Pursuant to the Series B Certificate of Designations, the Company designated 7,500 shares of preferred stock as Series B Preferred Stock. The Series B Preferred Stock were not convertible into shares of Common Stock of the Company and have no voting powers, except as related to certain rights to protect the rights and preferences of the Series B Preferred Stock and with respect to sales or dispositions of the Series B Preferred Stock at a price per share below the Price Restriction. The Series B Preferred Stock entitled its holders to (i) 80% of the proceeds received by the Company through future sales of the Bonus Shares issued to the Company under the Bonus Agreements and (ii) 80% of any cash dividends received by the Company on such Bonus Shares. Under the Series B Certificate of Designations, the Company had the option to redeem the Series B Preferred Stock at any time by distributing to holders of the Series B Preferred Stock (i) 80% of the Bonus Shares then held by the Company and (ii) 80% of all dividends received by the Company but not yet paid to holders of the Series B Preferred Stock (the "Redemption Payment"). The Company was required to redeem the Series B Preferred Stock through payment of the Redemption Payment upon the earlier of (i) 60 days following the Nasdaq Listing of the Bonus Shares, and (ii) December 28, 2020.</wizp:SecuritiesPurchaseAgreementDescription>
    <wizp:SecuritiesPurchaseAgreementDescription contextRef="From2019-12-01to2019-12-20">The Company entered into a securities purchase agreement (the "2019 Purchase Agreement") with an accredited investor. Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27 per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock. The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public announcement of positive clinical data results for LO2A.</wizp:SecuritiesPurchaseAgreementDescription>
    <us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">8957550</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">15873128</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">178</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF">178</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">32783495</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF">910</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">-4148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">30272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-29997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">34491000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-33899000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" id="Foot-02-0" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" unitRef="USD" id="Foot-02-1" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">35110000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-39218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockholdersEquity>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2020-01-01to2020-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <wizp:PurchasePricePerShare contextRef="AsOf2020-01-31" unitRef="USD_per_Share" decimals="INF">1</wizp:PurchasePricePerShare>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="shares" decimals="INF">18822533</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="shares" decimals="INF">52249</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares contextRef="AsOf2019-12-31_custom_CannabicsMember" unitRef="shares" decimals="INF">25000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">2834000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">6000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="AsOf2019-12-31_custom_CannabicsMember" unitRef="USD" decimals="-3">3000</us-gaap:MarketableSecuritiesNoncurrent>
    <dei:EntityVoluntaryFilers contextRef="From2020-01-01to2020-12-31">No</dei:EntityVoluntaryFilers>
    <wizp:DeemedDividendDueToDownRoundAdjustment contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToDownRoundAdjustment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-267000</wizp:DeemedDividendDueToDownRoundAdjustment>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <wizp:ExchangeOfCommonStock contextRef="From2020-12-02to2020-12-30" unitRef="shares" decimals="INF">61.11</wizp:ExchangeOfCommonStock>
    <wizp:ReminingOutstandingOwnersPercentage contextRef="AsOf2020-12-30" unitRef="pure" decimals="INF">0.1075</wizp:ReminingOutstandingOwnersPercentage>
    <wizp:DeemedDividendWithRespectToRightForFutureInvestment contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendWithRespectToRightForFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-185000</wizp:DeemedDividendWithRespectToRightForFutureInvestment>
    <wizp:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare contextRef="From2020-01-01to2020-12-31" unitRef="shares" decimals="INF">16669628</wizp:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare>
    <wizp:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare contextRef="From2019-01-01to2019-12-31" unitRef="shares" decimals="INF">10519682</wizp:WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.10</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <wizp:PercentageOfContingentObligation contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="pure" decimals="INF">0.37</wizp:PercentageOfContingentObligation>
    <wizp:DescriptionOfContingentObligation contextRef="From2020-01-01to2020-12-31">Including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product into the U.S. market - 12%, the patent expiration date (2038), the operational profit rate - 26%, the probabilities for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.</wizp:DescriptionOfContingentObligation>
    <wizp:PercentageOfBonueAgreement contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.80</wizp:PercentageOfBonueAgreement>
    <us-gaap:PolicyholderDividendsRateOnPolicyEarnings contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.80</us-gaap:PolicyholderDividendsRateOnPolicyEarnings>
    <wizp:NumberOfBonusSharesDistributedByCompany contextRef="AsOf2020-07-08_us-gaap_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">68191200</wizp:NumberOfBonusSharesDistributedByCompany>
    <wizp:RedeemAllOfSeriesBPreferredStockDescription contextRef="From2020-11-01to2020-11-29_us-gaap_SeriesBPreferredStockMember">(i) the Milestone Settlement Shares, which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement Shares, the &#8220;Settlement Shares&#8221;), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.</wizp:RedeemAllOfSeriesBPreferredStockDescription>
    <wizp:DescriptionOfBonusAgreements contextRef="From2020-11-01to2020-11-29_us-gaap_SeriesBPreferredStockMember_custom_SettlementSharesMember">(i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing, which means that US$3.7 million were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the &#8220;Nasdaq Milestone Shares&#8221;) were released to the Company and to its former holders of Series B Preferred Stock (the &#8220;Former Series B Holders&#8221;); (ii) the Company will waive approximately US$120 in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under the Bonus Exchange Agreement, including certain related negative covenants. The closing occurred on December 29, 2020. It should be noted that, in accordance with the obligations of the Company to the Former Series B Holders (see below), the Company has transferred 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.</wizp:DescriptionOfBonusAgreements>
    <wizp:DescriptionOfBonusAgreements contextRef="From2020-11-01to2020-11-29">(i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing (as defined in the Bonus Agreements), which means that, at the Closing, $3.7 million will be released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq Milestone Shares") will be released to the Company (20% of the shares) and to the Company's former holders of Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive approximately $120in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of Bonus to secure the Company's obligations under the Bonus Exchange Agreement, including certain related negative covenants. The Closing was subject to customary conditions, including obtaining the approval of the TASE, and occurred on December 30, 2020. It should be noted that, in accordance with the Securities Purchase Agreement, dated January 9, 2020 (as amended), by and among the Company and the Former Series B Holders, the Company was required to transfer 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.</wizp:DescriptionOfBonusAgreements>
    <wizp:InvestmentOwnershipPercentage contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.019</wizp:InvestmentOwnershipPercentage>
    <wizp:InvestmentOwnershipPercentage contextRef="From2019-01-01to2019-12-31" unitRef="pure" decimals="INF">0.0004</wizp:InvestmentOwnershipPercentage>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">26000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <wizp:MinimumPercentageOfIssuedAndOutstandingShareCapital contextRef="From2019-01-01to2019-12-31_custom_CannabicsMember">Less than 1%</wizp:MinimumPercentageOfIssuedAndOutstandingShareCapital>
    <wizp:IncomeFromChangeInFairValue contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1197000</wizp:IncomeFromChangeInFairValue>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">15000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">92000</us-gaap:OtherPrepaidExpenseCurrent>
    <wizp:OtherGovernmentalAuthoritiesCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">41000</wizp:OtherGovernmentalAuthoritiesCurrent>
    <wizp:OtherGovernmentalAuthoritiesCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">26000</wizp:OtherGovernmentalAuthoritiesCurrent>
    <wizp:OtherReceivable contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">10000</wizp:OtherReceivable>
    <wizp:OtherReceivable contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">260000</wizp:OtherReceivable>
    <us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">66000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">378000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Principles of consolidation:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The consolidated Financial Statements&#13;include the accounts of the Company and its wholly owned subsidiaries. Inter-company balances and transactions have been eliminated&#13;upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Functional currency:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company aims to direct&#13;its main operations in the United States market. In addition, the convertible loans were denominated in U.S. dollars.&#13;Similarly, the Company issued warrants eligible for exercise for the Company's shares of Common Stock at an exercise&#13;price denominated in U.S. dollars and during January 2020 the Company completed the issuance of 7,500 Series B Non-Voting&#13;Redeemable Preferred Stock for a purchase price of $1 per share for total gross proceeds of $7,500. Also, the management&#13;believes the Company will raise funds through private investment rounds and / or from issuance of equity in dollar amounts by&#13;approaching the market in the United States. As a result, it was determined that the U.S dollar is the currency of the&#13;primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.&#13;Thus, the functional currency of the Company is the U.S. dollar. The Company maintains its books and records in local&#13;currency, which is NIS.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Balances denominated in, or linked&#13;to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date.&amp;#160;&amp;#160;For foreign&#13;currency transactions included in the consolidated statement of comprehensive loss, the exchange rates applicable on the relevant&#13;transaction dates are used.&amp;#160;&amp;#160;Transaction gains or losses arising from changes in the exchange rates used in the translation&#13;of such balances are carried to financing income or expenses as applicable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The following table presents data&#13;regarding the dollar exchange rate of relevant currencies:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;% of change&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 52%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;USD 1 = NIS&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.215&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.456&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash and cash equivalents:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Cash equivalents are short-term&#13;highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;For presentation of statement of&#13;cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total&#13;amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&amp;#160;31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;December&amp;#160;31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;718&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash deposit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;260&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <wizp:RestrictedBankDepositPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted bank deposit:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Restricted bank deposit is a deposit&#13;with maturities of more than three months and up to one year. The restricted bank deposit was presented at its cost, including&#13;accrued interest and represents cash which is used as collateral for Wize Israel's credit card used for certain corporate&#13;business expenses.&lt;/p&gt;</wizp:RestrictedBankDepositPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;i.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development expenses:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Research and development expenses&#13;are charged to the statement of comprehensive loss as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In-Process Research and Development&#13;assets, acquired in an asset acquisition (&lt;i&gt;i.e.&lt;/i&gt;, assets acquired outside a business combination transactions) that are to&#13;be used in a research and development project which are determined not to have an alternative future use are charged to expense&#13;at the acquisition date in accordance with ASC 730, "Research and Development".&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;k.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income taxes:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company accounts for income&#13;taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred&#13;tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets&#13;and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected&#13;to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets&#13;to amounts more likely than not to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company implements a two-step&#13;approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to&#13;be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on&#13;an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals&#13;or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative&#13;basis) likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized tax positions&#13;has been recognized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LoanCommitmentsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;m.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible loans: &amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;u&gt;Allocation of proceeds:&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The proceeds received upon the&#13;original issuance of the 2016 Loan (as defined below) together with a freestanding derivative financial instrument (derivative&#13;liability for right to future investment) were allocated to the financial instruments issued based on the residual value method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The detachable derivative financial&#13;instrument related to the 2016 Loan was recognized based on its fair value and the remaining amount of the proceeds was allocated&#13;to the 2016 Loan component.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The 2017 Loan (as defined below)&#13;was not issued with any detachable instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;u&gt;Beneficial Conversion Features&#13;("BCFs"):&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, the Company has considered the provisions of ASC 815-40, "Derivatives and Hedging &amp;#8211; Contracts in Entity's Own Equity" ("&lt;b&gt;ASC 815-40&lt;/b&gt;"), and determined that the embedded conversion feature of the 2016 Loan should not be separated from the host instrument because it qualifies for equity classification. Furthermore, the Company applied ASC 470-20, "Debt &amp;#8211; Debt with Conversion and Other Options" ("&lt;b&gt;ASC 470-20&lt;/b&gt;) which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios, and has applied the BCFs guidance to determine whether the conversion feature is beneficial to the investor.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;The BCFs was calculated by allocating&#13;the proceeds received in financing transactions to the 2016 Loan and to any detachable freestanding financial instrument (derivative&#13;liability for future investment) included in the transaction, and by measuring the intrinsic value of the conversion option based&#13;on the effective conversion price as a result of the allocated proceeds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;The intrinsic value of the conversion&#13;option with respect to the 2016 Loan was recorded as a discount on the 2016 Loan with a corresponding amount credited directly&#13;to equity as additional paid-in capital. After the initial recognition, the discount on the 2016 Loan was amortized as interest&#13;expense over the contractual term of the 2016 Loan (before its modification) by using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, the Company has considered the provisions of ASC 815-15,&amp;#160;"Derivatives and Hedging - Embedded Derivatives", and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, did not meet the definition of a derivative in accordance with the provisions of ASC 815-10, "Derivatives and Hedging"&amp;#160;&amp;#160;since its terms did not require or permit net settlement. Thus, it was determined that the conversion feature does not meet the characteristic of being readily convertible to cash.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Furthermore, the Company applied&#13;ASC 470-20 which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Pursuant to ASC 470-20-30, the&#13;amount of the BCFs with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion&#13;price (&lt;i&gt;i.e.&lt;/i&gt;, the entire proceeds received for the 2017 Loan) and the aggregate fair value of the Common Stock and other&#13;securities (which consist of the future Investment Rights) into which the 2017 Loan was convertible.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;As such difference was determined&#13;to be greater than the amount of the entire proceeds originally received for the 2017 Loan, the amount of the discount assigned&#13;to the BCFs was limited to the amount of the entire proceeds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Following modifications or exchanges of convertible loans that were accounted for as an extinguishment (see below), upon each additional recognition of the convertible loans based on their modified terms, the Company applied ASC 470-20, "Debt &amp;#8211; Debt with conversion and other options" to determine whether the conversion feature is considered beneficial to the investors. However, due to the fact that following each of the extinguishments of the convertible loans, such modified convertible loans were recognized based on their fair value as of the modification date, the conversion terms were not considered beneficial to the investors.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Modifications or Exchanges&lt;/u&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Modifications to, or exchanges&#13;of, financial instruments such as convertible loans, are accounted for as a modification or an extinguishment, following to provisions&#13;of ASC 470-50, "Debt- Modification and Extinguishments" ("&lt;b&gt;ASC 470-50&lt;/b&gt;"). Such an assessment done&#13;by management either qualitatively or quantitatively based on the facts and circumstances of each transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Under ASC 470-50, modifications&#13;or exchanges are generally considered extinguishments with gains or losses recognized in current earnings if the terms of the new&#13;debt and original instrument are substantially different. The instruments are considered "substantially different"&#13;when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present&#13;value of the remaining cash flows under the terms of the original instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;If the terms of a debt instrument&#13;are changed or modified and the present value of the cash flows under the terms of the new debt instrument is less than 10%, the&#13;debt instruments are not considered to be substantially different, except in the following two circumstances (i)&amp;#160;&amp;#160;The&#13;transaction significantly affects the terms of an embedded conversion option, such that the change in the fair value of the embedded&#13;conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and&#13;after the modification or exchange) is at least 10% of the carrying amount of the original debt instrument immediately before the&#13;modification or exchange or (ii)&amp;#160;&amp;#160;The transaction adds a substantive conversion option or eliminates a conversion option&#13;that was substantive at the date of the modification or exchange.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;If the original and new debt&#13;instruments are considered as "substantially different", the original debt is derecognized and the new debt is initially&#13;recorded at fair value, with the difference recognized as an extinguishment gain or loss under financial expense or income as applicable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;If a convertible debt instrument&#13;with a beneficial conversion option that was separately accounted for in equity, is extinguished prior to its conversion or stated&#13;maturity date, a portion of the reacquisition price is allocated to the repurchase of the beneficial conversion option. The amount&#13;of the reacquisition price allocated to the beneficial conversion option is measured using the intrinsic value of that conversion&#13;option at the extinguishment date. The residual amount, if any, is allocated to the convertible debt instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;The gain or loss on the extinguishment&#13;of the convertible debt instrument is determined based on the difference between the carrying amount and the fair value of the&#13;allocated reacquisition price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;Modifications to, or exchanges&#13;of equity financial instruments such as right to future investment, are accounted for as a modification or an extinguishment in&#13;a similar manner as described above. Such an assessment is done by management either qualitatively or quantitatively based on the&#13;facts and circumstances of each transaction. Among others, management considers whether, the fair value of the financial instruments&#13;before and after the modification or exchange are substantially different.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;If the original and new equity&#13;instruments are considered as "substantially different", the excess fair value of the allocated reacquisition price&#13;over the fair value of the modified financial instrument before the modification, is recognized directly to retained earnings as&#13;a deemed dividend.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;&lt;u&gt;Issuance costs of convertible&#13;loan:&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2016 Loan (or costs allocated to such component in a package issuance) were presented as a direct deduction from the amount of the 2016 Loan and in subsequent periods such costs (together with the discount created by BCFs if applicable) expensed as financing expenses over the contractual term of the 2016 Loan by using the effective interest method. Any such costs that were allocated to the derivative component were expensed as incurred.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2017 Loan (or costs allocated to such component in a package issuance) were presented as a deferred asset since the 2017 Loan was completely discounted at the initial recognition. In subsequent periods, such expenses were amortized ratably over the original term of the 2017 Loan.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;&lt;u&gt;Extinguishment of convertible&#13;loans:&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;Upon the final extinguishment&#13;of the convertible loans upon their maturity, the difference between the reacquisition price which consist of the cash paid, the&#13;fair value of instruments issued (shares and warrants) and the modification of loans and cancellation of existing financial instruments)&#13;and the carrying amounts of the convertible loans being extinguished was recognized as a gain or loss in the period of extinguishment.&lt;/p&gt;</us-gaap:LoanCommitmentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value of financial instruments:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;ASC 820, "Fair Value Measurements&#13;and Disclosures" ("&lt;b&gt;ASC 820&lt;/b&gt;"), defines fair value as the price that would be received to sell an asset&#13;or paid to transfer a liability (&lt;i&gt;i.e.&lt;/i&gt;, the "exit price") in an orderly transaction between market participants&#13;at the measurement date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In determining fair value, the&#13;Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes&#13;the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used&#13;when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based&#13;on market data obtained from sources independent of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Unobservable inputs are inputs&#13;that reflect the Company's assumptions about the assumptions market participants would use in pricing the asset or liability&#13;developed based on the best information available in the circumstances.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The hierarchy is broken down into&#13;three levels based on the inputs as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&amp;#160;1&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&amp;#160;2&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&amp;#160;3&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The availability of observable&#13;inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of&#13;investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based&#13;on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment&#13;and the investments are categorized as Level&amp;#160;3.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The carrying amounts of cash and&#13;cash equivalents, short-term bank deposits, other accounts receivable, trade payables and other accounts payable approximate their&#13;fair value due to the short-term maturities of such instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Fair value of the marketable equity&#13;securities is determined based on a Level 1 input.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <wizp:LegalAndOtherContingenciesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;o.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Legal and other contingencies:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company accounts for its contingent&#13;liabilities in accordance with ASC 450 "Contingencies". A provision is recorded when it is both probable that a liability&#13;has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed&#13;and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information&#13;and events pertaining to a particular matter. As of December&amp;#160;31, 2020, the Company is not a party to any litigation that could&#13;have a material adverse effect on the Company's business, financial position, results of operations or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Legal costs incurred in connection&#13;with loss contingencies are expensed as incurred.&lt;/p&gt;</wizp:LegalAndOtherContingenciesPolicyTextBlock>
    <wizp:MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;w.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Mandatorily Redeemable Series B Preferred&#13;    Stock&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company classified its formerly&#13;outstanding Series B Preferred Stock as a liability, as their terms embody an unconditional obligation of the Company to redeem&#13;the shares by transferring cash or other assets that equal (i) 80% of the proceeds received by the Company through future sales&#13;of the Bonus Shares issued to the Company under the Bonus Agreements (as hereinafter defined) and (ii) 80% of any cash dividends&#13;received by the Company on such Bonus Shares) at a specified or determinable date or dates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company elected to measure&#13;this liability in its entirety, at its fair value (the "Fair Value Option") in accordance with ASC 825-10, "Financial&#13;Instruments" due to the variable and contingent nature of the redemption price of such financial liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Upon initial recognition and in&#13;subsequent periods, the Company measured the&amp;#160;fair value of the liability related to the Series B Preferred Stock based on&#13;the value of the Bonus Shares and the cash amount that the Company was required to transfer to the Series B investors upon the&#13;redemption of the Series B Preferred Stock. The difference between the amount received by the Company upon the issuance of the&#13;Series B Preferred Stock and their fair value as of that date was carried immediately to the consolidated statements of comprehensive&#13;loss as part of financial income (loss).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The issuance costs of the Series&#13;B Preferred Stock were recognized immediately as an expense during the three months ended March 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On July 8, 2020, the Company elected&#13;to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares to the (now former)&#13;holders of Series B Preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On November 29, 2020, Wize entered into an Addendum (the "Addendum")&#13;with Bonus, whereby, among other things, Bonus agreed to issue to the Company additional ordinary shares of Bonus (the "Bonus&#13;Shares", the total number of which consists of (i) the Milestone Settlement Shares, which, as defined in the Addendum, means&#13;Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum)&#13;by NIS 0.50, and (ii) the HCW Settlement Shares, as defined in note 10a (together with the Milestone Settlement Shares, the "Settlement&#13;Shares"), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed&#13;in NIS (based on the exchange rate set in the Addendum) by NIS 0.50. In consideration for the Settlement Shares, the Company agreed&#13;to make certain amendments to the Bonus Agreements, including the following key modifications: (i) the Company will waive the requirement&#13;that Bonus will affect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing, which means that US$3.7 million&#13;were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq&#13;Milestone Shares") were released to the Company and to its former holders of Series B Preferred Stock (the "Former&#13;Series B Holders"); (ii) the Company will waive approximately US$120 in liquidated damages that accrued as a result of the&#13;delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli&#13;subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under the Bonus Exchange Agreement,&#13;including certain related negative covenants. The closing occurred on December 29, 2020. It should be noted that, in accordance&#13;with the obligations of the Company to the Former Series B Holders (see below), the Company has transferred 80% of the Milestone&#13;Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2020, the entire&#13;balance of the Series B preferred stock was extinguished.&lt;/p&gt;</wizp:MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock>
    <wizp:ScheduleOfXchangeRateOfRelevantCurrencies contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;% of change&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 52%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;USD 1 = NIS&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.215&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.456&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:ScheduleOfXchangeRateOfRelevantCurrencies>
    <wizp:ScheduleOfCashAndCashEquivalents contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&amp;#160;31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;December&amp;#160;31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;718&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash deposit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;260&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:ScheduleOfCashAndCashEquivalents>
    <wizp:ScheduleOfEstimatedUsefulLivesOfAssets contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:ScheduleOfEstimatedUsefulLivesOfAssets>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Add: Loss attributed to preferred stock (*)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;136&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend with respect to right for future investment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend due to down round adjustment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(267&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss applicable to stockholders of Common Stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,266&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,766&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares of Common Stock used in computing basic and diluted net loss per share&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,669,628&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,519,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss per share of Common Stock, basic and diluted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;                                         the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase&#13;                                         Agreement (as defined below). These preferred stock are participating securities. During&#13;                                         the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year&#13;                                         ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#13;                                         31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Number of shares:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Common shares used&#13;    in computing basic and diluted loss per share&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;16,669,628&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;10,519,682&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Preferred Stock and options excluded&#13;    from the calculations of diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;614,763&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,931,097&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total &lt;br /&gt; accumulated &lt;br /&gt;&#13;    other &lt;br /&gt; comprehensive &lt;br /&gt; income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(73&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(73&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 3:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;MARKETABLE EQUITY SECURITIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company owned 52,249 ordinary shares of Can-Fite representing&#13;approximately 0.04% of Can-Fite&amp;#8217;s issued and outstanding share capital as of December 31, 2019. As of December 31, 2019,&#13;the investment amounted to $6. During the year ended December 31, 2019 the Company recorded a loss of $26. During 2020 the Company&#13;sold all of its Can-Fite ordinary shares for net proceeds of approximately $3. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of December 31, 2019 the Company held 25,000 ordinary shares&#13;of Cannabics Pharmaceuticals, Inc. (&amp;#8220;&lt;b&gt;Cannabics&lt;/b&gt;&amp;#8221;) representing less than 1% of its issued and outstanding share&#13;capital as of that day. As of December 31, 2019, the investment amounted to $3. During 2020 the Company sold all of its Cannabics&#13;ordinary shares for net proceeds of approximately $260.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During the fourth quarter of 2019, the Company sold 2,238,944 shares&#13;of Cannabics through a broker at the amount of $260 (see also Note 4) which were received as of the date of Financial Statements.&#13;The Company made a payment of $1 to the broker as a deposit for the Broker&amp;#8217;s activity. During 2019 the Company recorded a&#13;loss of $501.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company owns 18,822,533 ordinary shares of Bonus representing&#13;approximately 1.9% of Bonus&amp;#8217;s issued and outstanding share capital as of December 31, 2020. As of December 31, 2020, the&#13;fair value of the investment, based on the quoted market price on TASE, amounts to $2,834 and is presented as Marketable equity&#13;securities in the accompanying consolidated balance sheet. During 2020 the Company recorded an income from sale of shares and revaluation&#13;of $1,197 with respect to this investment, see also Note 10.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 4:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;OTHER CURRENT ASSETS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Governmental authorities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivable (Note 3c)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;260&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;378&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Governmental authorities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivable (Note 3c)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;260&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;378&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <wizp:LicenseAgreementTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 5:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;LICENSE AGREEMENT&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In May 2015, Wize Israel&#13;entered into an Exclusive Distribution and Licensing Agreement (as amended, the &amp;#8220;&lt;b&gt;License Agreement&lt;/b&gt;&amp;#8221;) with&#13;Resdevco Ltd. (&amp;#8220;&lt;b&gt;Resdevco&lt;/b&gt;&amp;#8221;), whereby Resdevco granted to Wize Israel (and thereafter, to OcuWize) an&#13;exclusive license to purchase, market, sell and distribute a formula known as LO2A (&amp;#8220;&lt;b&gt;LO2A&lt;/b&gt;&amp;#8221;) in the United&#13;States and China as well as a contingent right to do the same in other countries. LO2A is a drug developed for the treatment&#13;of DES, and other ophthalmological illnesses, including CCH and Sj&amp;#246;gren&amp;#8217;s. Pursuant to the LO2A License Agreement,&#13;Wize Israel is required to pay Resdevco royalties for sales in the licensed territories, payable on a semi-annual basis,&#13;subject to making certain minimum royalty payments as set forth in the LO2A License Agreement. In January 2020 and January&#13;2021, the Company paid Resdevco royalties in the amount of $150.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pursuant to the License Agreement,&#13;the minimum royalties payable by Wize Israel to Resdevco shall be $150 per year through 2021. A one-time payment to Resdevco by&#13;Wize Israel in an amount of $650 shall be due no later than the second anniversary of the receipt of Food and Drug Administration&#13;(&amp;#8220;&lt;b&gt;FDA&lt;/b&gt;&amp;#8221;) approval (the &amp;#8220;&lt;b&gt;Deferred Amount&lt;/b&gt;&amp;#8221;); however, following FDA approval, if annual royalties&#13;due to Resdevco by Wize Israel exceed the Minimum Royalties (as defined in the License Agreement), an amount equal to 50% of such&#13;excess shall be added towards settlement of the Deferred Amount. As to royalty payments, Resdevco shall be entitled to the greater&#13;of $0.60 per unit sold, or a percentage of revenues, not to exceed 10%, from sales made in the United States and other countries,&#13;excluding Israel, China and Ukraine, but not less than the Minimum Royalties.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has determined not&#13;to pursue currently any activities outside the USA until the Company will obtain from Resdevco satisfactory registration file&#13;including DES and at least one more indication such as CCH or Sj&amp;#246;gren&amp;#8217;s. The Company seeks to approve a proposed regulatory&#13;strategy acceptable to the Chinese market based on the regulatory files provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The LO2A License Agreement has&#13;an initial term of seven years that expires in May 2022, and, unless Wize Israel provides prior notice of at least twelve (12)&#13;months terminating the agreement, the LO2A License Agreement renews automatically each year. Wize Israel may terminate the LO2A&#13;License Agreement prior to May 2022, subject to certain conditions, including, a 180 days prior notice to Resdevco, and penalty&#13;payment of $100,000, depending on the timing of termination. The LO2A License Agreement may also be terminated by either party&#13;upon the occurrence of certain other customary termination triggers, including material breaches of the LO2A License Agreement&#13;by either party.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On May 4, 2020, the Company and&#13;Resdevco entered into a further amendment to the License Agreement, whereby the parties agreed, among other things, that if (i)&#13;within 3 months after we receive a pre-Investigational New Drug (&amp;#8220;IND&amp;#8221;) with respect to the LO2A, or (ii) in case of&#13;proven inability to receive such Pre-IND as a direct result of the COVID-19, in both cases not later than December 31, 2021, we&#13;provide Resdevco with a written termination notice, the License Agreement shall be terminated immediately, and to the extent we&#13;exercise such termination right before the end of 2021, no minimum royalty fee shall be due for the year 2022.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of the date of these Financial&#13;Statements, the Company had not received FDA approval for LO2A.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;See Note 10 below regarding the Company&amp;#8217;s contingent obligation&#13;for the payment of 37% of the future Lo2A proceeds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2020, the Company has recognized a liability&#13;of $250, representing the minimum commitment to pay royalties to Resdevco based on the upcoming January 2021 payment in an amount&#13;of $150 and an amount of $100 which represents a termination fee payable to Resdevco if the Company exercises its right to terminate&#13;the License Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2020 and 2019, the current liability to pay&#13;future royalties amounts to $250 (for additional information and minimum royalties see also Note 6).&lt;/p&gt;</wizp:LicenseAgreementTextBlock>
    <wizp:ScheduleOfOtherAccountsPayableTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Liability to HCW, see Note 10&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;700&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;278&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Trade payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;369&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</wizp:ScheduleOfOtherAccountsPayableTableTextBlock>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">475000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">87000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
    <wizp:LiabilityValue contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">700000</wizp:LiabilityValue>
    <wizp:LiabilityValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">131000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">278000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <wizp:TradePayables contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <wizp:TradePayables contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">4000</wizp:TradePayables>
    <us-gaap:AccountsPayableOtherCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">1306000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">369000</us-gaap:AccountsPayableOtherCurrent>
    <wizp:EscrowAmount contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">3700000</wizp:EscrowAmount>
    <wizp:EscrowAmount contextRef="From2020-01-05to2020-01-09_custom_BonusExchangeAgreementMember_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="-3">3700000</wizp:EscrowAmount>
    <wizp:EscrowAmount contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember" unitRef="USD" decimals="-3">3700000</wizp:EscrowAmount>
    <wizp:EscrowAmount contextRef="From2020-02-02to2020-02-19_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="-3">3700000</wizp:EscrowAmount>
    <wizp:EscrowAmount contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="-3">3700000</wizp:EscrowAmount>
    <wizp:EscrowAmount contextRef="From2020-12-01to2020-12-29_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="-3">3700000</wizp:EscrowAmount>
    <us-gaap:SharePrice contextRef="AsOf2020-01-09_custom_BonusAgreementsMember_custom_IsraeliShekelMember" unitRef="ILS_per_Share" decimals="INF">0.50</us-gaap:SharePrice>
    <wizp:PricePerShareAtDateOfAgreement contextRef="AsOf2020-01-09_custom_BonusAgreementsMember" unitRef="USD_per_Share" decimals="INF">0.12</wizp:PricePerShareAtDateOfAgreement>
    <wizp:PricePerShareAtClosingDate contextRef="AsOf2020-01-09_custom_BonusAgreementsMember" unitRef="USD_per_Share" decimals="INF">0.11</wizp:PricePerShareAtClosingDate>
    <wizp:OutstandingShareCapitalPercentage contextRef="From2020-01-05to2020-01-09_custom_BonusAgreementsMember" unitRef="pure" decimals="INF">0.12</wizp:OutstandingShareCapitalPercentage>
    <wizp:AdditionalOrdinaryShares contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember" unitRef="shares" decimals="INF">28413000</wizp:AdditionalOrdinaryShares>
    <wizp:InvestmentInMarketableSecuritiesBonusShares contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">13851000</wizp:InvestmentInMarketableSecuritiesBonusShares>
    <wizp:InvestmentInMarketableSecuritiesBonusShares contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:InvestmentInMarketableSecuritiesBonusShares contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember" unitRef="USD" decimals="-3">5871260000</wizp:InvestmentInMarketableSecuritiesBonusShares>
    <wizp:RedeemableFairValue contextRef="AsOf2020-02-19_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="-3">10707000</wizp:RedeemableFairValue>
    <wizp:RedeemableFairValue contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="-3">10707000</wizp:RedeemableFairValue>
    <wizp:FinanceExpenses contextRef="From2020-01-01to2020-12-31_us-gaap_SeriesBPreferredStockMember" unitRef="USD" decimals="-3">3207000</wizp:FinanceExpenses>
    <wizp:InvestmentOfMarketableSecuritiesPercentage contextRef="From2020-02-02to2020-02-19_us-gaap_SeriesBPreferredStockMember" unitRef="pure" decimals="INF">0.80</wizp:InvestmentOfMarketableSecuritiesPercentage>
    <wizp:CashOfInvestment contextRef="From2020-01-01to2020-12-31_custom_SeriesBPurchaseAgreementMember" unitRef="USD" decimals="-3">7500000</wizp:CashOfInvestment>
    <us-gaap:RestrictedCash contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">3700000</us-gaap:RestrictedCash>
    <wizp:FairValueOfBonusSharesAndAmount contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember" unitRef="USD" decimals="-3">8759000</wizp:FairValueOfBonusSharesAndAmount>
    <wizp:ReceivedCashProceeds contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">821000</wizp:ReceivedCashProceeds>
    <wizp:ReceivedCashProceeds contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember" unitRef="USD" decimals="-3">5059000</wizp:ReceivedCashProceeds>
    <us-gaap:MarketableSecurities contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">1197000</us-gaap:MarketableSecurities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 12:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;COMMITMENTS AND CONTINGENCIES &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Agreements&lt;/u&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Starting November&#13;    22, 2020, the Company rents its offices from a third party for a rental monthly fee of $2. The rent period is for a period&#13;    of 12 months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the Company&amp;#8217;s&#13;    engagement in a License Agreement to market a drug and amendment to such an agreement, see also Notes 5 and 6 above.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 19, 2017 (the &amp;#8220;&lt;b&gt;Effective&#13;        Date&lt;/b&gt;&amp;#8221;), Wize Israel entered into a finder&amp;#8217;s fee agreement with a service provider (through his wholly&#13;        owned company), who is also a director of the Company (the &amp;#8220;&lt;b&gt;Vendor&lt;/b&gt;&amp;#8221;), pursuant to which the Vendor&#13;        is entitle to receive a royalty rate of 5% on all of Wize Israel&amp;#8217;s revenues to the extent such revenues are earned&#13;        from relationships initiated by the Vendor and agreed to by Wize Israel. The term of the agreement is for 12 months unless&#13;        earlier terminated. Either party may terminate upon 21 days&amp;#8217; notice. The service provider will be entitled to the&#13;        finder fee of 5% even if the agreement will be terminated.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Vendor introduced Wize Israel&#13;        and the Company to the Chinese Distributor (see also Note 5). During the period commencing the Effective Date and ending&#13;        December 31, 2019 and 2020, the Vendor has not earned any royalties, and the Company has no obligation to pay any royalties.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For discussion regarding Bonus transaction, see Note 10 above.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 15:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;RELATED PARTIES BALANCES AND TRANSACTIONS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balances with interested and related parties:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;439&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Convertible Loans&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Transactions with interested and related parties:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Amounts charged to:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;General and administrative expenses*&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,212&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,140&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Finance expenses, net (income)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(625&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;* Including an amount of $76 with respect to stock-based compensation&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <wizp:BalancesWithInterestedAndRelatedPartiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;52&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Accounts payable&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;439&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Convertible Loans&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</wizp:BalancesWithInterestedAndRelatedPartiesTableTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Amounts charged to:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;General and administrative expenses*&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,212&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;1,140&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Finance expenses, net (income)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(625&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;* Including an amount of $76 with respect to stock-based compensation&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">637000</wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment>
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">637000</wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment>
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">962000</wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne>
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">962000</wizp:AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne>
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11uShares contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11uShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">2037037</wizp:IssuanceOfCommonStockAndWarrantsForCashNote11uShares>
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">2000</wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u>
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">548000</wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u>
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">550000</wizp:IssuanceOfCommonStockAndWarrantsForCashNote11u>
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">2816196</wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares>
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">3000</wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t>
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">991000</wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t>
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">994000</wizp:IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t>
    <wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-135000</wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment>
    <wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-135000</wizp:TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">267000</wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-267000</wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">390000</wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-390000</wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares contextRef="From2020-01-01to2020-12-31_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">16332654</wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares>
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">17000</wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote>
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-17000</wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote>
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrantsNote contextRef="From2020-01-01to2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:IncreaseDecreaseInLicensePurchaseObligation contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">150000</wizp:IncreaseDecreaseInLicensePurchaseObligation>
    <wizp:IncreaseDecreaseInLicensePurchaseObligation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">150000</wizp:IncreaseDecreaseInLicensePurchaseObligation>
    <wizp:AccruedInterestOnConvertibleLoans contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AccruedInterestOnConvertibleLoans contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">45000</wizp:AccruedInterestOnConvertibleLoans>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-1257000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:MarketableSecuritiesGainLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1197000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:MarketableSecuritiesGainLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-527000</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">246000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">818000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">1000</us-gaap:Depreciation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-1519000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-2064000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">587000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">63000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-313000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-62000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">823000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" id="Foot-02-2" xsi:nil="true" />
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">824000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">260000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">759000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">3183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">197000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-360000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <wizp:ProceedsFromRepaymentOfLicensePurchaseObligation contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-150000</wizp:ProceedsFromRepaymentOfLicensePurchaseObligation>
    <wizp:ProceedsFromRepaymentOfLicensePurchaseObligation contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-150000</wizp:ProceedsFromRepaymentOfLicensePurchaseObligation>
    <wizp:ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-100000</wizp:ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment>
    <wizp:ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:ProceedsFromIssuanceOfSharesAndWarrants contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:ProceedsFromIssuanceOfSharesAndWarrants contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">550000</wizp:ProceedsFromIssuanceOfSharesAndWarrants>
    <wizp:ReleaseOfEscrowAccountBonusShares contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">3700000</wizp:ReleaseOfEscrowAccountBonusShares>
    <wizp:ReleaseOfEscrowAccountBonusShares contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:LiabilityToHcw contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">350000</wizp:LiabilityToHcw>
    <wizp:LiabilityToHcw contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrants contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">17000</wizp:IssuanceOfSharesWithRespectToExerciseOfWarrants>
    <wizp:IssuanceOfSharesWithRespectToExerciseOfWarrants contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrants contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">390000</wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrants>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrants contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">7604000</wizp:SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares>
    <wizp:SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:IssuanceOfMandatorilyRedeemableSeriesBPreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">7400000</wizp:IssuanceOfMandatorilyRedeemableSeriesBPreferredStock>
    <wizp:IssuanceOfMandatorilyRedeemableSeriesBPreferredStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:RecognitionOfContingentObligationWithRespectToFutureRevenues contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">5059000</wizp:RecognitionOfContingentObligationWithRespectToFutureRevenues>
    <wizp:RecognitionOfContingentObligationWithRespectToFutureRevenues contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">3700000</wizp:AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow>
    <wizp:AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:SELLOFCANNABICSSHARETHROUGHABROKER contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:SELLOFCANNABICSSHARETHROUGHABROKER contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">260000</wizp:SELLOFCANNABICSSHARETHROUGHABROKER>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">267000</wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants>
    <wizp:RepaymentOfConvertibleLoansThroughCommonStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:RepaymentOfConvertibleLoansThroughCommonStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">760000</wizp:RepaymentOfConvertibleLoansThroughCommonStock>
    <wizp:AmountAllocatedToLoanExtensionOne contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountAllocatedToLoanExtensionOne contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">922000</wizp:AmountAllocatedToLoanExtensionOne>
    <wizp:AmountAllocatedToLoanExtension contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountAllocatedToLoanExtension contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">634000</wizp:AmountAllocatedToLoanExtension>
    <wizp:AmountAllocatedToLoanAmendmentOne contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountAllocatedToLoanAmendmentOne contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">1037000</wizp:AmountAllocatedToLoanAmendmentOne>
    <wizp:AmountAllocatedToLoanAmendment contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountAllocatedToLoanAmendment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">729000</wizp:AmountAllocatedToLoanAmendment>
    <wizp:DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">81000</wizp:DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne>
    <wizp:AmountThatWasAllocatedToRightForFutureInvestmentTwo contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountThatWasAllocatedToRightForFutureInvestmentTwo contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">576000</wizp:AmountThatWasAllocatedToRightForFutureInvestmentTwo>
    <wizp:AmountThatWasAllocatedToRightForFutureInvestmentOne contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountThatWasAllocatedToRightForFutureInvestmentOne contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">381000</wizp:AmountThatWasAllocatedToRightForFutureInvestmentOne>
    <wizp:AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-152000</wizp:AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment>
    <wizp:DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">104000</wizp:DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan>
    <wizp:AmountsAllocatedToTheRecognitionOfRightForFutureInvestment contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountsAllocatedToTheRecognitionOfRightForFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">386000</wizp:AmountsAllocatedToTheRecognitionOfRightForFutureInvestment>
    <wizp:AmountThatWasAllocatedToRightForFutureInvestment contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountThatWasAllocatedToRightForFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">256000</wizp:AmountThatWasAllocatedToRightForFutureInvestment>
    <wizp:AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-481000</wizp:AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment>
    <wizp:OrdinarySharesIssuedThroughReceiptOfMarketableSecurities contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:OrdinarySharesIssuedThroughReceiptOfMarketableSecurities contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">765000</wizp:OrdinarySharesIssuedThroughReceiptOfMarketableSecurities>
    <wizp:GainFromCompletionOfMilestoneClosingNote10 contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">847000</wizp:GainFromCompletionOfMilestoneClosingNote10>
    <wizp:GainFromCompletionOfMilestoneClosingNote10 contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">100000</us-gaap:GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet>
    <us-gaap:GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10 contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-3207000</wizp:LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10>
    <wizp:LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10 contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10 contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-597000</wizp:ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10>
    <wizp:ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10 contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10 contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-435000</wizp:ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10>
    <wizp:ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10 contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:LoanReceived contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-247000</wizp:LoanReceived>
    <wizp:LoanReceived contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:MarketableSecuritiesEquitySecuritieCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">2834000</wizp:MarketableSecuritiesEquitySecuritieCurrent>
    <wizp:MarketableSecuritiesEquitySecuritieCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">10000</wizp:MarketableSecuritiesEquitySecuritieCurrent>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">3160000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">1147000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">29000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">29000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">3189000</us-gaap:Assets>
    <us-gaap:Assets contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">1176000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">1306000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">369000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">22000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">22000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">265000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">1843000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">641000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">5494000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">5494000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" id="Foot-03-0" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" id="Foot-03-1" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">33000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">16000</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">3189000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">1176000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="shares" decimals="INF">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="shares" decimals="INF">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="shares" decimals="INF">178</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="shares" decimals="INF">178</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="shares" decimals="INF">32783495</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="shares" decimals="INF">15873128</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">185000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">267000</wizp:DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">390000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-5319000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-3902000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-4929000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-3450000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-01-01to2020-12-31" unitRef="USD_per_Share" decimals="INF">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-01-01to2019-12-31" unitRef="USD_per_Share" decimals="INF">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ShortTermDebtTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 9:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;SHORT TERM LOAN PAYABLE&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On July 15, 2020, OcuWize entered into a loan agreement with&#13;Bank Hapoalim (the &amp;#8220;Bank&amp;#8221;), whereby the Bank extended a loan in the principal amount of NIS 850 (approximately $247)&#13;(the &amp;#8220;2020 Loan&amp;#8221;), which is presented as a short term loan payable in the consolidated balance sheet. The 2020 Loan&#13;bears interest at an annual rate of 5.45%, which is paid in monthly payments. The 2020 Loan has a maturity date of January 15,&#13;2021. In order to secure its obligations and performance pursuant to the 2020 Loan, OcuWize recorded a pledge in favor of the Bank&#13;and agreed that at all times, the value of all the assets in the OcuWize bank account will not be less than NIS 1,700 (approximately&#13;$496). In order to satisfy this requirement, the Company loaned to OcuWize a portion of the Bonus Shares held by it. The 2020 Loan&#13;including interest was fully paid on January 14, 2021.&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember" unitRef="USD" decimals="-3">247000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember_custom_ILSMember" unitRef="ILS" decimals="-3">850000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeFixedInterestRate contextRef="AsOf2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember" unitRef="pure" decimals="INF">0.0545</us-gaap:DerivativeFixedInterestRate>
    <wizp:BankAccount contextRef="AsOf2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember" unitRef="USD" decimals="-3">496000</wizp:BankAccount>
    <wizp:BankAccount contextRef="AsOf2020-07-15_custom_OcuwizeMember_custom_TwoZeroTwoZeroLoanMember_custom_ILSMember" unitRef="ILS" decimals="-3">1700000</wizp:BankAccount>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Foreign (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(12,160&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11,322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Relates to Wize Israel and OcuWize.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Reserves and allowances&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Net deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,108&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,165&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,108&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss before taxes on income, as reported in the statements of comprehensive loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(4,929&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(3,450&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Theoretical tax benefit on this loss&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;725&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses not deductible for tax purposes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(52&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(86&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(639&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-1318000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-1709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="From2020-01-01to2020-12-31" unitRef="USD" id="Foot-04-0" decimals="-3">-10842000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="From2019-01-01to2019-12-31" unitRef="USD" id="Foot-04-1" decimals="-3">-9613000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-12160000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-11322000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">2899000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">2974000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <wizp:DeferredTaxAssetsReservesAndAllowances contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">5000</wizp:DeferredTaxAssetsReservesAndAllowances>
    <wizp:DeferredTaxAssetsReservesAndAllowances contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">6000</wizp:DeferredTaxAssetsReservesAndAllowances>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">261000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">128000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">3165000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">3108000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-4929000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-3450000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1035000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">725000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <wizp:ExpensesNotDeductibleForTaxPurposes contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-52000</wizp:ExpensesNotDeductibleForTaxPurposes>
    <wizp:ExpensesNotDeductibleForTaxPurposes contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-86000</wizp:ExpensesNotDeductibleForTaxPurposes>
    <wizp:IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-983000</wizp:IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized>
    <wizp:IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-639000</wizp:IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:CorporateTaxRate contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_StatementGeographicalAxis_IL" unitRef="pure" decimals="INF">0.23</wizp:CorporateTaxRate>
    <wizp:CorporateTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_IL_RangeAxis_MinimumMember" unitRef="pure" decimals="INF">0.23</wizp:CorporateTaxRate>
    <wizp:CorporateTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_IL_RangeAxis_MaximumMember" unitRef="pure" decimals="INF">0.24</wizp:CorporateTaxRate>
    <wizp:CorporateTaxRate contextRef="From2020-01-01to2020-12-31_country_IL" unitRef="pure" decimals="INF">0.23</wizp:CorporateTaxRate>
    <wizp:CorporateTaxRate contextRef="From2017-01-01to2017-12-31_country_IL_srt_MaximumMember" unitRef="pure" decimals="INF">0.25</wizp:CorporateTaxRate>
    <wizp:CorporateTaxRate contextRef="From2017-01-01to2017-12-31_country_IL_srt_MinimumMember" unitRef="pure" decimals="INF">0.24</wizp:CorporateTaxRate>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">7570000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <wizp:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Overseas travel&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;246&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;688&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Rent and office maintenance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Payroll and benefits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;834&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;470&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Professional services and consultation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;953&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Taxes and tolls&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Director salary and insurance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,008&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,678&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</wizp:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <wizp:ChangeInFairValueOfMarketableSecurities contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1197000</wizp:ChangeInFairValueOfMarketableSecurities>
    <wizp:ChangeInFairValueOfMarketableSecurities contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:ExchangeRateGainsNet contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:ExchangeRateGainsNet contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">15000</wizp:ExchangeRateGainsNet>
    <wizp:GainFromCompletionOfMilestoneClosing contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">847000</wizp:GainFromCompletionOfMilestoneClosing>
    <wizp:GainFromCompletionOfMilestoneClosing contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:GainFromSettlementShares contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">100000</wizp:GainFromSettlementShares>
    <wizp:GainFromSettlementShares contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNonoperatingIncome contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">2144000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">1272000</us-gaap:OtherNonoperatingIncome>
    <wizp:AccruedInterestOnLoans contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-6000</wizp:AccruedInterestOnLoans>
    <wizp:AccruedInterestOnLoans contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:LossFromRecognitionOfMandatorilyRedeemablePreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-3207000</wizp:LossFromRecognitionOfMandatorilyRedeemablePreferredStock>
    <wizp:LossFromRecognitionOfMandatorilyRedeemablePreferredStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-435000</wizp:LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues>
    <wizp:LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:RevaluationOfMandatorilyRedeemablePreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-597000</wizp:RevaluationOfMandatorilyRedeemablePreferredStock>
    <wizp:RevaluationOfMandatorilyRedeemablePreferredStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2020-01-01to2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ExtinguishmentOfDebtAmount contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">977000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:OtherNonoperatingExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">4631000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">1552000</us-gaap:OtherNonoperatingExpense>
    <wizp:CosmosTransactionDescription contextRef="From2020-12-01to2020-12-30_custom_BidAgreementMember">Under the Bid Agreement (as amended), the parties agreed that the Company would commence the Offer, an off-market takeover offer under applicable Australian laws, to acquire all of the Cosmos Shares in exchange for 61.11 Company's shares of common stock for each Cosmos Share, being the Offer Consideration.</wizp:CosmosTransactionDescription>
    <wizp:CosmosTransactionDescription contextRef="From2020-12-01to2020-12-30">(i) agreement that the Board of Directors of The Company immediately following the Closing Date will consist, subject to certain exceptions, of three members to be designated by Cosmos and one member to be designated by The Company; (ii) covenants that The Company will seek, following the Closing Date, stockholder approval to be renamed Cosmos Capital, Inc. (or similar name), and to effect a reverse share split of The Company&#8217;s common stock; (iii) covenants that The Company will establish an incentive compensation program with respect to 40,000,000 shares of its common stock, to be granted promptly following the Closing Date, in the form of performance-based RSUs, performance rights or indeterminate rights based on the performance milestone criteria and allocation set in the Bid Agreement (the &#8220;Post-Closing Incentive Plan&#8221;), 50% of which are to be granted to personnel specified by The Company prior to the Closing Date and the remainder to be granted to personnel of Cosmos (see also Item 9B below); (iv) an obligation by The Company to terminate or procure the termination of each of the current employment or consulting agreements of The Company with Mr. Mark Sieczkarek, the Chairman of The Company Board of Directors, Mr. Noam Danenberg, the Chief Executive Officer of The Company, Mr. Or Eisenberg, the Chief Financial Officer of The Company, and another part-time employee related to Mr. Danenberg; and (v) an obligation by The Company to use its reasonable commercial efforts to enter into new,</wizp:CosmosTransactionDescription>
    <wizp:CosmosTransactionDescription contextRef="From2020-12-01to2020-12-30_custom_CVRAgreementMember">Pursuant to the Bid Agreement, prior to the Closing Date, the Company will enter into a Contingent Value Rights Agreement (the "CVR Agreement") with Cosmos, certain of the Company's subsidiaries (the "Wize Subsidiaries"), a person designated by the Company prior to the Closing Date as the Holders' Representative (as defined herein), and the Rights Agent (as defined therein). Pursuant to the CVR Agreement, at the Closing Date, each Wize pre-Closing security holder will receive one non-transferable CVR for each outstanding share of common stock of the Company and for each share of common stock of the Company underlying other convertible securities and warrants, held as of 4:01 p.m. Eastern Time on the day immediately before the Effective Time (as defined in the CVR Agreement). Each CVR will represent the right to receive a pro rata share of any consideration that may be received by the Company or the Company Subsidiaries in connection with the Company's existing LO2A business. In particular, CVR holders will be entitled to any consideration (whether cash, stock, assets or otherwise) that the Company or the Company Subsidiaries (or any of its Affiliates or shareholders) receives in connection with an LO2A Transaction, which, as defined in the CVR Agreement, includes (i) a sale of any of the Company Subsidiaries to a third party and/or (ii) the partnering, licensing, sublicensing, distribution, reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third party, less transaction expenses and customary deductions as detailed in the CVR agreement, including a deduction of up to $300,000 that the Company Subsidiaries undertook to incur in the development of the LO2A Technology at the request of the Holders' Representative.</wizp:CosmosTransactionDescription>
    <wizp:CosmosTransactionDescription contextRef="From2020-01-01to2020-12-31_custom_CosmosConvertibleNotesMember">On February 15, 2021, Cosmos informed the Company that Cosmos completed the issuance of convertible notes (the "Cosmos Convertible Notes") with an aggregate principal amount of approximately US$21 million to several non-U.S. sophisticated or professional investors (the "Purchasers"). The Cosmos Convertible Notes are unsecured and shall initially be convertible into shares of Cosmos at a conversion price of AU$23.58 per share (equivalent to US$18.16), reflecting a pre-money valuation of Cosmos of approximately US$185 million. The Cosmos Convertible Notes will automatically convert to shares six months after the date of issuance. Cosmos is obligated to pay interest to the Purchasers on the outstanding principal amount of the Cosmos Convertible Notes at the rate of 8% per annum, payable on the conversion date, in cash or, at Cosmos' option, in shares of Cosmos. Redemption of the Cosmos Convertible Notes occurs only if an insolvency event occurs in respect of Cosmos.</wizp:CosmosTransactionDescription>
    <us-gaap:CompensationAndBenefitsTrust contextRef="AsOf2020-12-31_srt_MinimumMember" unitRef="USD" decimals="-3">7500000</us-gaap:CompensationAndBenefitsTrust>
    <us-gaap:CompensationAndBenefitsTrust contextRef="AsOf2020-12-31_srt_MaximumMember" unitRef="USD" decimals="-3">10000000</us-gaap:CompensationAndBenefitsTrust>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2020-01-01to2020-12-31_custom_PIPEAgreementsMember" unitRef="shares" decimals="INF">25000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:DebtInstrumentFeeAmount contextRef="AsOf2020-12-31_custom_PIPEAgreementsMember" unitRef="USD" decimals="-3">3000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2017 Loan&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2016 Loan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Aggregate principal amount&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;822&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;531&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Conversion price per Company's share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1.1112&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.9768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Aggregate maximum of Right to Future Investment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,233&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(**)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;797&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercise price per Company's share of Right to Future Investment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1.332&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1.308&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Principal loan amount&#13;    of $274 for each of the three 2017 Lenders.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(**)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Maximum of Right&#13;    to Future Investment of $411 for each of the three 2017 Lenders.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Opening balance (including accrued interest)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans prior to 2018 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans following 2018 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(641&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &amp;#8211; March 2019 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,873&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued interest on 2017 Loan and 2016 Loan&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amount allocated to 2016 Loan and 2017 Loan based on modified terms &amp;#8211; March 2019 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans following March 2019 modifications&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(413&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &amp;#8211; May 2019 extension&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,353&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Amount allocated to 2016 Loan and 2017 Loan based on modified terms &amp;#8211; May 2019 extension&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans &amp;#8211; May 2019 extension&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(203&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;November 2019 repayment in cash and Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%"&gt;Options outstanding as of December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;352,072&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(61,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options outstanding as of December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;290,222&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.64&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options exercisable as of December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;255,459&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.82&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%"&gt;Options outstanding as of December 31, 2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;255,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;153,822&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(56,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options outstanding as of December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;352,072&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.72&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options exercisable as of December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;181,799&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.75&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.72&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;190.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;216&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding and exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,352&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;81.81&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.32&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;190.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding and exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;190.7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.86&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <wizp:AggregatePrincipalAmount contextRef="AsOf2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_DebtMember" unitRef="USD" id="Foot-05-0" decimals="-3">822000</wizp:AggregatePrincipalAmount>
    <wizp:AggregatePrincipalAmount contextRef="AsOf2020-12-31_custom_ConvertibleDebtOneMember_us-gaap_DebtMember" unitRef="USD" decimals="-3">531000</wizp:AggregatePrincipalAmount>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_DebtMember" unitRef="ILS_per_Share" decimals="INF">1.1112</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2020-12-31_custom_ConvertibleDebtOneMember_us-gaap_DebtMember" unitRef="ILS_per_Share" decimals="INF">0.9768</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember" unitRef="USD_per_Share" decimals="INF">6.72</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember_custom_NisMember" unitRef="ILS_per_Share" decimals="INF">24</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2016-03-20_custom_ConvertibleDebtOneMember_custom_RimonGoldMember_custom_NisMember" unitRef="ILS_per_Share" decimals="INF">15.2592</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2016-03-20_us-gaap_ConvertibleDebtMember_custom_RimonGoldMember" unitRef="USD_per_Share" decimals="INF">0.9768</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2019-12-13_custom_TwoZeroOneNineLoanAmendmentMember" unitRef="USD_per_Share" decimals="INF">0.27</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2020-12-24_custom_SeriesAWarrantsMember" unitRef="USD_per_Share" decimals="INF">0.16</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <wizp:AggregateMaximumOfRightToFutureInvestment contextRef="AsOf2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_DebtMember" unitRef="USD" id="Foot-06-0" decimals="-3">1233000</wizp:AggregateMaximumOfRightToFutureInvestment>
    <wizp:AggregateMaximumOfRightToFutureInvestment contextRef="AsOf2020-12-31_custom_ConvertibleDebtOneMember_us-gaap_DebtMember" unitRef="USD" decimals="-3">797000</wizp:AggregateMaximumOfRightToFutureInvestment>
    <wizp:ExercisePriceOfRightToFutureInvestment contextRef="AsOf2020-12-31_us-gaap_ConvertibleDebtMember_us-gaap_DebtMember" unitRef="ILS_per_Share" decimals="INF">1.332</wizp:ExercisePriceOfRightToFutureInvestment>
    <wizp:ExercisePriceOfRightToFutureInvestment contextRef="AsOf2020-12-31_custom_ConvertibleDebtOneMember_us-gaap_DebtMember" unitRef="ILS_per_Share" decimals="INF">1.308</wizp:ExercisePriceOfRightToFutureInvestment>
    <us-gaap:DebtCurrent contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">2635000</us-gaap:DebtCurrent>
    <wizp:AmortizationOfPremiumRelatedToConvertibleLoans contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" xsi:nil="true" />
    <wizp:AmortizationOfPremiumRelatedToConvertibleLoan contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">-641000</wizp:AmortizationOfPremiumRelatedToConvertibleLoan>
    <wizp:DerecognitionLoanUponExtinguishment contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">-1873000</wizp:DerecognitionLoanUponExtinguishment>
    <wizp:AccruedInterestOnLoan contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">45000</wizp:AccruedInterestOnLoan>
    <wizp:AccruedInterestOnLoan contextRef="From2019-11-01to2019-11-29_custom_TwoZeroOneNineLoanAmendmentMember" unitRef="USD" decimals="-3">167000</wizp:AccruedInterestOnLoan>
    <wizp:AmountAllocatedToLoan contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">1767000</wizp:AmountAllocatedToLoan>
    <wizp:AmortizationOfPremiumRelatedToConvertibleLoansOne contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">-413000</wizp:AmortizationOfPremiumRelatedToConvertibleLoansOne>
    <wizp:DerecognitionLoanUponExtinguishmentOne contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">-1353000</wizp:DerecognitionLoanUponExtinguishmentOne>
    <wizp:AmountAllocatedToLoanOne contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">1556000</wizp:AmountAllocatedToLoanOne>
    <wizp:AmortizationOfPremiumRelatedToConvertibleLoansTwo contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">-203000</wizp:AmortizationOfPremiumRelatedToConvertibleLoansTwo>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">1520000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="From2019-11-01to2019-11-29_custom_TwoZeroOneNineLoanAmendmentMember" unitRef="USD" decimals="-3">1520000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember" unitRef="pure" decimals="INF">1.20</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember" unitRef="pure" decimals="INF">0.04</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2016-03-20_custom_ConvertibleDebtOneMember_custom_WizeIsraelMember" unitRef="pure" decimals="INF">0.04</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2017-01-12to2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember" unitRef="ILS" decimals="-3">1000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2016-03-17to2016-03-20_custom_ConvertibleDebtOneMember_custom_RimonGoldMember_custom_NisMember" unitRef="ILS" decimals="-3">100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2016-03-17to2016-03-20_custom_ConvertibleDebtOneMember_custom_RimonGoldMember" unitRef="USD" decimals="-3">26000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember722117906" unitRef="USD" decimals="-3">1619000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">1336000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2019-12-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">874000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2019-12-31_custom_LendersMember" unitRef="USD" decimals="-3">411000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2019-03-04_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">348000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2019-03-04_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">237000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember" unitRef="USD" decimals="-3">1233000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2016-03-20_us-gaap_ConvertibleDebtMember_custom_RimonGoldMember" unitRef="USD" decimals="-3">797000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2019-05-31_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">139000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount contextRef="AsOf2019-05-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">94000</us-gaap:InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="From2017-01-12to2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember">The 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15).</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="From2016-03-17to2016-03-20_custom_ConvertibleDebtOneMember_custom_RimonGoldMember">As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.6 (approximately $0.96).</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentRedemptionDescription contextRef="From2016-03-17to2016-03-20_us-gaap_ConvertibleDebtMember_custom_RimonGoldMember">The Exchange Ratio (as defined in the Agreement and Plan of Merger with Bufiduck Ltd., a company formed under the laws of the State of Israel and our wholly owned subsidiary and Wize Israel) from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment, from NIS 5.04 to $1.308 (subject to adjustments in case of stock splits or similar events).</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2017-01-12to2017-01-15_us-gaap_ConvertibleDebtMember_custom_WizeIsraelMember">Under the 2017 Loan Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017 Loan, but no less than NIS 100,000 (approximately $28 according to an exchange rate at 2017 loan originate date).</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2017-01-12to2017-01-15_us-gaap_ConvertibleDebtMember_custom_LendersMember">The 2017 Loan Conversion Price was adjusted to $1.1112.</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription contextRef="From2019-12-01to2019-12-13_custom_TwoZeroOneNineLoanAmendmentMember">The Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196 shares of Common Stock upon conversion of the loans at a reduced conversion price of $0.27 per share and issued the December 2019 Warrants to purchase an aggregate of 5,632,392 shares of Common Stock at an exercise price of $0.27.</us-gaap:DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription>
    <wizp:LoanAmendmentDescription contextRef="From2017-12-14to2017-12-21_custom_TwoZeroOneSevenLoanAmendmentMember">The Company entered into an amendment (the "2017 Loan Amendment") to the 2016 Loan Agreement and the 2017 Loan Agreement. Pursuant to the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31, 2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June 30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS.</wizp:LoanAmendmentDescription>
    <wizp:LoanAmendmentDescription contextRef="From2019-02-19to2019-03-04_custom_TwoZeroOneNineLoanAmendmentMember">The parties also agreed that Rimon Gold's, Ridge's and Fisher's remaining 2016 Investment Rights (as of that date) under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and the expiration date of Rimon Gold's, Ridge's and Fisher's remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at $1.332 per share, be extended from June 30, 2019 to November 30, 2019.</wizp:LoanAmendmentDescription>
    <wizp:LoanAmendmentDescription contextRef="From2018-10-03to2018-10-19">Pursuant to the 2018 Loan Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the registration rights agreement dated October 22, 2018 (the "Registration Rights Agreement") covering the resale of all Common Stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Series A Warrants, are registered for resale for investors who are not a party to the 2018 Loan Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the 2018 Loan Amendment, the expiration date of the Investment Rights under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements maturity date.</wizp:LoanAmendmentDescription>
    <wizp:LoanAmendmentDescription contextRef="From2019-05-02to2019-05-31">Pursuant to the May 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement was extended to November 30, 2019 from May 31, 2019 (as previously described under the March 2019 Amendment).</wizp:LoanAmendmentDescription>
    <wizp:LoanAmendmentDescription contextRef="From2019-05-02to2019-05-31_us-gaap_ConvertibleDebtMember">As a result, an aggregate amount of $1,015 was allocated to the 2016 Loan and an aggregate amount of $1,498 was allocated to the 2017 Loan and its related right to future investment.</wizp:LoanAmendmentDescription>
    <wizp:LoanAmendmentDescription contextRef="From2019-05-02to2019-05-31_custom_ConvertibleDebtOneMember">As a result, an aggregate amount of $1,015 was allocated to the 2016 Loan and an aggregate amount of $1,498 was allocated to the 2017 Loan and its related right to future investment.</wizp:LoanAmendmentDescription>
    <wizp:LoanAmendmentDescription contextRef="From2019-05-02to2019-05-31_custom_MayTwoThousandNineteenAmendmentMember">The parties also agreed that the expiration date of Rimon Gold's, Mr. Danenberg's and Fisher's remaining 2016 Investment Rights (as of that date) under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and Rimon Gold's, Mr. Danenberg's and Fisher's remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at $1.332 per share, be extended from November 30, 2019 to May 31, 2021. As consideration for extending the maturity date of the loans, the Company issued to Rimon Gold, Mr. Danenberg (through Mobigo, his wholly owned company), and Fisher two-year warrants to purchase an aggregate of 868,034 shares of Common Stock at a fixed price of $1.10 per share.</wizp:LoanAmendmentDescription>
    <us-gaap:ProceedsFromLoanOriginations1 contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">3286000</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:ProceedsFromLoanOriginations1 contextRef="From2019-02-19to2019-03-04_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">986000</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:ProceedsFromLoanOriginations1 contextRef="From2019-02-19to2019-03-04_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">1423000</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:ProceedsFromLoanOriginations1 contextRef="From2019-01-01to2019-12-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">2314000</us-gaap:ProceedsFromLoanOriginations1>
    <us-gaap:DebtInstrumentFairValue contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">1154000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2019-12-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">764000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2019-03-04_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">289000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2019-03-04_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">192000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2019-05-31_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">91000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2019-05-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">61000</us-gaap:DebtInstrumentFairValue>
    <wizp:DeemedDividend contextRef="Context_FYE_01_Jan_2018T00_00_00_TO_31_Dec_2018T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="-3">182000</wizp:DeemedDividend>
    <wizp:DeemedDividend contextRef="From2019-02-19to2019-03-04_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">45000</wizp:DeemedDividend>
    <wizp:DeemedDividend contextRef="From2019-02-19to2019-03-04_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">59000</wizp:DeemedDividend>
    <wizp:DeemedDividend contextRef="From2019-01-01to2019-12-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">110000</wizp:DeemedDividend>
    <wizp:DeemedDividend contextRef="From2019-05-02to2019-05-31_us-gaap_ConvertibleDebtMember" unitRef="USD" decimals="-3">48000</wizp:DeemedDividend>
    <wizp:DeemedDividend contextRef="From2019-05-02to2019-05-31_custom_ConvertibleDebtOneMember" unitRef="USD" decimals="-3">33000</wizp:DeemedDividend>
    <wizp:InvestmentOptionExercisePrice contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember722117906" unitRef="USD_per_Share" decimals="INF">0.16</wizp:InvestmentOptionExercisePrice>
    <us-gaap:DebtInstrumentTerm contextRef="From2019-01-01to2019-12-31_us-gaap_WarrantMember722117906">P5Y0M0D</us-gaap:DebtInstrumentTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">290222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">352072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="shares" decimals="INF">4896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="shares" decimals="INF">4896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">153822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">61850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="shares" decimals="INF">544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">56750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">255459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="shares" decimals="INF">181799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2019-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="shares" decimals="INF">4896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="shares" decimals="INF">4352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">2.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">2.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">3.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="USD_per_Share" decimals="INF">190.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="USD_per_Share" decimals="INF">190.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">1.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">2.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="USD_per_Share" decimals="INF">216</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">2.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_TwoZeroOneEightPlanMember" unitRef="USD_per_Share" decimals="INF">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="USD_per_Share" decimals="INF">190.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_TwoZeroOneTwoPlanMember" unitRef="USD_per_Share" decimals="INF">81.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember">P5Y10M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember">P3Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember">P5Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneTwoPlanMember">P3Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember">P5Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneTwoPlanMember">P3Y3M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember">P5Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneTwoPlanMember">P2Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <wizp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31_custom_TwoZeroOneEightPlanMember">P5Y8M19D</wizp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <wizp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember">P5Y6M18D</wizp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <wizp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="From2019-01-01to2019-12-31_custom_TwoZeroOneEightPlanMember">P7Y0M0D</wizp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-04-01to2019-04-29_us-gaap_PreferredClassAMember" unitRef="shares" decimals="INF">336</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-05-01to2019-05-07_us-gaap_PreferredClassAMember" unitRef="shares" decimals="INF">336</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-03-13to2019-03-31_us-gaap_PreferredClassAMember" unitRef="shares" decimals="INF">60</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-12-01to2020-12-08_custom_SeriesAWarrantsMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF">3000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-12-31_custom_TwoThousandTwelvePlanMemberrMember" unitRef="shares" decimals="INF">40474</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-12-31_custom_EmployeeStockOptionTwoMember" unitRef="shares" decimals="INF">2184813</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-07-09to2019-07-18" unitRef="USD" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2019-08-01to2019-08-20" unitRef="USD" decimals="-3">18000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2019-07-09to2019-07-18" unitRef="shares" decimals="INF">6945</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2019-08-01to2019-08-20" unitRef="shares" decimals="INF">45000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2020-12-31_custom_EmployeeStockOptionTwoMember" unitRef="USD" decimals="-3">3000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:WarrantExercisePriceIncrease contextRef="From2019-01-01to2019-12-31" unitRef="USD_per_Share" decimals="INF">0.16</us-gaap:WarrantExercisePriceIncrease>
    <wizp:JointVentureAgreementDescription contextRef="From2019-02-15to2019-03-02">Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000 shares of its Common Stock and Cannabics issued to the Company 2,263,944 shares of Cannabics' common stock, which represented a holding percentage less than 5 percent of Cannabic's then outstanding share capital. The joint venture currently has no assets or liabilities and has not started conducting any of its planned operations.</wizp:JointVentureAgreementDescription>
    <wizp:ChairmanAppointmentAgreementDescription contextRef="From2019-08-01to2019-08-20">The Company and Mr. Sieczkarek entered into a Chairman Agreement (the "Chairman Agreement") whereby Mr. Sieczkarek shall receive 202,399 restricted stock units ("RSUs") and options to purchase 102,222 shares of the Company's Common Stock at an exercise price of $2.00 per share (the "Chairman Awards"). The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and subsequently in seven equal quarterly installments commencing July 1, 2019. The Chairman Agreement has an initial term of two years (the "Term") and provides that in the event of a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as of that date. The Chairman Agreement also contains standard representations and warranties regarding confidential information, non-competition and non-solicitation.</wizp:ChairmanAppointmentAgreementDescription>
    <wizp:StockOptionsGrantedDuringVestingPeriod contextRef="From2019-08-01to2019-08-20" unitRef="USD" decimals="-3">29000</wizp:StockOptionsGrantedDuringVestingPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="-3">2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockOptionTwoMember" unitRef="USD" decimals="-3">132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="-3">104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-08-01to2019-08-20" unitRef="USD" decimals="-3">185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2019-01-01to2019-12-31_custom_EmployeeStockOptionTwoMember" unitRef="USD" decimals="-3">337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <wizp:StockIssuanceToConsultantRelatedDescription contextRef="From2019-05-01to2019-05-14_us-gaap_RestrictedStockUnitsRSUMember">The Company issued to a consultant, 135,000 shares of restricted Common Stock which is due and issuable according to the following schedule: 25% as of May 1, 2019 and additional 25% every quarter following May 1, 2019. The aggregate fair value of these shares of RSUs at grant date issued was $106, and is being recognized over a period of 1 year following May 1, 2019.</wizp:StockIssuanceToConsultantRelatedDescription>
    <wizp:StockIssuanceToConsultantRelatedDescription contextRef="From2019-05-01to2019-05-15_us-gaap_RestrictedStockUnitsRSUMember">The Company granted to a consultant, 10,000 fully vested RSUs. The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of issuance. The aggregate fair value of these RSUs issued at grant date was $5, and was recognized during the year ended December 31, 2019.</wizp:StockIssuanceToConsultantRelatedDescription>
    <wizp:StockIssuanceToConsultantRelatedDescription contextRef="From2019-03-09to2019-03-31_us-gaap_RestrictedStockUnitsRSUMember">The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of grant. The aggregate fair value of these RSUs issued was $476. The Company is recognizing this amount ratably over the vesting period of 24 months following March 31, 2019. In connections with the above, on July 25, 2019 (the initial quarterly vesting date) the Company issued 85,000 Common shares to its officers and directors. The Company recognized $132 and $337 during the year ended December 31, 2020 and 2019 respectively.</wizp:StockIssuanceToConsultantRelatedDescription>
    <wizp:StockIssuanceToConsultantRelatedDescription contextRef="From2019-05-17to2019-05-19_custom_RimonGoldAndFisherMember">The Company granted to one of its directors certain options exercisable into 30,000 shares of Common Stock with an exercise price of $0.58 per share. The options will vest monthly over a period of six (6) months. The Company recognized $13 of share-based compensation expense during year ended December 31, 2019.</wizp:StockIssuanceToConsultantRelatedDescription>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="From2018-08-01to2018-08-15_custom_EmployeeStockOptionTwoMember">(i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year.</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <wizp:StockIssuanceToEmployeesRelatedDescription contextRef="From2020-08-01to2020-08-11_us-gaap_RestrictedStockUnitsRSUMember">The Company's Board of Directors approved the equity grant of 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors of the Company.</wizp:StockIssuanceToEmployeesRelatedDescription>
    <wizp:StockIssuanceToEmployeesRelatedDescription contextRef="From2020-08-01to2020-08-11">The Company's Board of Directors approved the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors of the Company and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each of the other three non-executive directors. The aggregate fair value of these shares of RSUs at grant date issued was $73, and is being recognized over a period of 2 years following August 11, 2020. The Company recognized $34 during the year ended December 31, 2020, as a share-based expense in connection to the RSU's.</wizp:StockIssuanceToEmployeesRelatedDescription>
    <wizp:StockIssuanceToEmployeesRelatedDescription contextRef="From2018-03-25to2018-04-04_us-gaap_CommonStockMember">The Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with an exercise price of $3.59 per share. The options will vest quarterly over a period of 36 months. The Company recognized $51 and $154 during the year ended December 31, 2020 and 2019, respectively.</wizp:StockIssuanceToEmployeesRelatedDescription>
    <wizp:StockIssuanceToEmployeesRelatedDescription contextRef="From2019-03-09to2019-03-31_us-gaap_RestrictedStockUnitsRSUMember">1. To grant to each of Company's four directors 100,000 RSUs. The RSUs will vest quarterly over a period of 24 months. 2. To grant to each its officers (Company's Chief executive officer and to Company's Chief financial officer)&#160;140,000 RSU's. The RSU's will vest quarterly over a period of 24 months.</wizp:StockIssuanceToEmployeesRelatedDescription>
    <wizp:StockIssuanceToEmployeesRelatedDescription contextRef="From2019-04-01to2019-04-18">The Company granted to its employee, 21,600 options exercisable into 21,600 shares of Common Stock at an exercise price of $0.75 per share of Common Stock. The options began vesting quarterly over a period of 36 months commencing April 18, 2019. The Company recognized $2 during the year ended December 31, 2019 as a share-based expense. The total value of the share based expense is $10, which is recorded quarterly over the vesting period. Since the Company has terminated its employment agreement in December 2019, as of December 31, 2020, all of the options were forfeited.</wizp:StockIssuanceToEmployeesRelatedDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-01to2020-12-31_custom_TwentyTwelveStockIncentivePlanMember">P10Y0M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="From2019-01-01to2019-12-31">The Company and five representative companies and expected term of stock-based grants of 7 years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <wizp:LossOfChangeInFairValue contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">501000</wizp:LossOfChangeInFairValue>
    <wizp:LossOfChangeInFairValue contextRef="From2020-12-01to2020-12-08_custom_SeriesAWarrantsMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="-3">63000</wizp:LossOfChangeInFairValue>
    <wizp:WeightedaveragePeriod contextRef="From2020-01-01to2020-12-31">P0Y6M0D</wizp:WeightedaveragePeriod>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-499000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-2424000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <wizp:LicensePurchaseObligationLiabilities contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">250000</wizp:LicensePurchaseObligationLiabilities>
    <wizp:LicensePurchaseObligationLiabilities contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">250000</wizp:LicensePurchaseObligationLiabilities>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">36000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">3000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="pure" decimals="INF">0.37</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-01-02" unitRef="USD" decimals="-3">42000</us-gaap:OperatingLeaseLiability>
    <wizp:GrossProceeds contextRef="From2020-01-01to2021-01-31" unitRef="USD" decimals="-3">7500000</wizp:GrossProceeds>
    <wizp:PresentValueOfDebtInstrumentPercentage contextRef="AsOf2020-12-31_srt_MinimumMember" unitRef="pure" decimals="INF">0.10</wizp:PresentValueOfDebtInstrumentPercentage>
    <wizp:LeastPercentageOfCarryingAmount contextRef="From2020-01-01to2020-12-31" unitRef="pure" decimals="INF">0.10</wizp:LeastPercentageOfCarryingAmount>
    <wizp:MinimumCommitmentAmount contextRef="AsOf2019-12-31_custom_LicenseAgreementMember" unitRef="USD" decimals="-3">150000</wizp:MinimumCommitmentAmount>
    <wizp:MinimumCommitmentAmount contextRef="AsOf2020-12-31_custom_LicenseAgreementMember" unitRef="USD" decimals="-3">150000</wizp:MinimumCommitmentAmount>
    <wizp:LossDueToRevaluation contextRef="From2020-01-01to2020-12-31_custom_BonusExchangeAgreementMember" unitRef="USD" decimals="-3">597000</wizp:LossDueToRevaluation>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="From2020-01-01to2020-12-31">The annual NOL carry forward (pre-merger, approximately $4,784) is limited to $10.965 per year.</us-gaap:TaxCreditCarryforwardDescription>
    <wizp:WarrantTermDescription contextRef="From2020-01-01to2020-12-31_custom_SeriesAWarrantsMember_us-gaap_RestrictedStockUnitsRSUMember">The warrants issued to certain purchasers from the private placement in December 2019 (the "December 2019 Warrants") and certain investment rights issued on January 2017 (the "Investment Rights") were also adjusted to reflect a reduced exercise price of $0.001 per share (collectively, the "Warrant Adjustments"). As a result of the Warrant Adjustments, on December 29, 2020 an aggregate of 13,332,654 shares of common stock were issued as a result of the exercise of such warrants, each on a cashless basis. Among others, such warrant exercises also included warrants beneficially owned by our Chief Executive Officer, Noam Dannenberg. The difference between the fair value of the warrants before and after the adjustment was recognized as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $327.</wizp:WarrantTermDescription>
    <wizp:OfferDescription contextRef="From2020-12-01to2020-12-30">Immediately following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos shareholders are expected to own approximately 87.65% of the outstanding common stock of the Company, while the Company's existing stockholders are expected to remain the owners of approximately 10.75% of the outstanding common stock of the Company, each on a fully diluted basis and including warrants to be issued to the Company's financial advisor to the transaction.</wizp:OfferDescription>
    <wizp:OfferDescription contextRef="From2020-12-01to2020-12-30_custom_StockRestrictionAgreementMember">Under the Bid Agreement, 22.33 Company shares of common stock out of the Offer Consideration will be &#8220;Restricted Stock&#8221; subject to a Stock Restriction Agreement to be entered into at the Closing Date and 38.78 Company shares of common stock will be &#8220;Covered Securities&#8221;. A Cosmos shareholder who accepts the Offer (an &#8220;Accepting Shareholder&#8221;) will not be permitted to sell or encumber their Restricted Stock until December 31, 2021 (the &#8220;Milestone Date&#8221;). In addition, an Accepting Shareholders may not exercise voting rights in respect of Restricted Stock from the date of issuance of the Offer Consideration until the Milestone Date. An Accepting Shareholder is entitled to sell or encumber its Covered Securities. However, if (subject to certain limited exceptions) an Accepting Shareholder sells or encumbers any of its Covered Securities before the Milestone Date, the Company has an option to repurchase a pro rata proportion of the Restricted Stock for the lower of $0.0001 and the fair market value of the Restricted Stock. The Restricted Stock (and any dividends thereon) will be held by the Company in escrow for the Accepting Shareholder&#8217;s benefit until such time as the Restricted Stock is repurchased by Wize or all restrictions thereon lapse. If any Restricted Stock is repurchased under the Company&#8217;s repurchase option, a pro rata proportion of the dividend on the Restricted Stock shall be retained by the Company.</wizp:OfferDescription>
    <wizp:PurchaseOfPropertyAndEquipment contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">1000</wizp:PurchaseOfPropertyAndEquipment>
    <wizp:PurchaseOfPropertyAndEquipment contextRef="From2019-01-01to2019-12-31" unitRef="USD" id="Foot-02-3" xsi:nil="true" />
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">434000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">492000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-2442000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-3170000</us-gaap:OperatingIncomeLoss>
    <wizp:FinancialExpenses contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">17000</wizp:FinancialExpenses>
    <wizp:FinancialExpenses contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 1:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;GENERAL&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Wize Pharma, Inc. (the "&lt;b&gt;Company&lt;/b&gt;" or "&lt;b&gt;Wize&lt;/b&gt;") was incorporated in the State of Delaware.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Wize, through its wholly-owned Delaware subsidiary, Wize NC&#13;Inc. ("&lt;b&gt;Wize NC&lt;/b&gt;"), and the wholly-owned subsidiary of Wize NC, OcuWize Ltd. ("&lt;b&gt;OcuWize&lt;/b&gt;"), is&#13;a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome&#13;("&lt;b&gt;DES&lt;/b&gt;").&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Commencing August 30, 2016, Wize Pharma Ltd., a wholly owned&#13;subsidiary of the Company ("&lt;b&gt;Wize Israel&lt;/b&gt;") manages most of its activity through OcuWize Ltd. ("&lt;b&gt;OcuWize&lt;/b&gt;"),&#13;a wholly owned Israeli subsidiary of Wize Israel, which manages and develops most of the Company's activity under an existing&#13;license agreement. In May 2015, Wize Israel entered into an Exclusive Distribution and Licensing Agreement (as amended, the "&lt;b&gt;License&#13;Agreement&lt;/b&gt;"), with Resdevco Research and Development Company Ltd. ("&lt;b&gt;Resdevco&lt;/b&gt;"). Pursuant to the License&#13;Agreement, Resdevco granted to Wize Israel (and thereafter, to OcuWize) an exclusive license to develop in the United States, under&#13;the LO2A licensed technology, products in the field of ophthalmic disorders, to mutually agree upon a manufacturer and to purchase,&#13;market, sell and distribute LO2A in finished product form in the licensed territories in the field of ophthalmic disorders, see&#13;also note 5.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;For discussion regarding the issuance&#13;of the Series B Preferred Stock (as described in Note 10 below) as a partial financing, concurrently with the recognition of an&#13;obligation with respect to 37% of future revenues of LO2A-based products ("&lt;b&gt;LO2A Proceeds&lt;/b&gt;") (if any) and the&#13;purchase of shares of Bonus BioGroup Ltd. ("&lt;b&gt;Bonus&lt;/b&gt;"), classified as marketable equity securities that was completed&#13;in February 2020, see also Note 10.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On December 30, 2020, the Company entered into a Bid Implementation&#13;Agreement (as amended, the "Bid Agreement") with Cosmos Capital Limited, a digital infrastructure provider based in&#13;Sydney, Australia ("Cosmos"). Pursuant to the Bid Agreement, the Company commenced an off-market takeover offer under applicable&#13;Australian laws (the "Offer"), whereby it offers 61.11 shares of  common stock in exchange for each one outstanding&#13;share of Cosmos. Immediately following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos&#13;shareholders are expected to own approximately 87.65% of the outstanding common stock of Wize, while Wize existing stockholders&#13;are expected to remain the owners of approximately 10.75% of the outstanding common stock of Wize, each on a fully diluted basis&#13;and including warrants to be issued to Wize's financial advisor to the transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pursuant to the Bid Agreement, prior to the Closing&#13;Date, Wize will enter into a Contingent Value Rights Agreement (the "CVR Agreement") with  certain of Wize's&#13;subsidiaries (the "Wize Subsidiaries"), a person designated by Wize prior to the Closing Date as the Holders'&#13;Representative (as defined herein), and the Rights Agent (as defined therein). Pursuant to the CVR Agreement, at the Closing Date,&#13;each Wize pre-Closing securityholder will receive one non-transferable CVR for each outstanding share of common stock of Wize and&#13;for each share of common stock of Wize underlying other convertible securities and warrants, held as of 4:01 p.m. Eastern Time&#13;on the day immediately before the Effective Time (as defined in the CVR Agreement). See also note 10c.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Going concern uncertainty and management plans:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has not yet generated any material revenues from&#13;its current operations, and therefore is dependent upon external sources for financing its operations. As of December 31, 2020,&#13;the Company has an accumulated deficit of $39,218 and a total stockholders' deficit of $4,148.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In addition, in each of the years&#13;ended December 31, 2020 and 2019, the Company reported losses and negative cash flows from operating activities.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Management considered the significance&#13;of such conditions in relation to the Company's ability to meet its current and future obligations and determined that such&#13;conditions raise substantial doubt about the Company's ability to continue as a going concern.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The accompanying financial statements&#13;do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the&#13;amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Until such time as the&#13;Company generates sufficient revenue to fund its operations (if ever), the Company plans to finance its operations through&#13;the sale of Bonus Shares (as hereinafter defined), and, to the extent available, short-term and long-term loans as well as&#13;equity financings. There can be no assurance that the Company will succeed in obtaining the necessary financing to continue&#13;its operations as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Regarding the issuance, and subsequent&#13;redemption, of the Series B Preferred Stock concurrently with the transaction with Bonus in February 2020, see also Note 10.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Regarding the transaction with&#13;Cosmos on December 30, 2020, see note 10.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk factors:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2020, the Company had an accumulated deficit&#13;of $39,218 and a total stockholders' deficit of $4,148. The Company has historically incurred net losses and is not able&#13;to determine whether or when it will become profitable, if ever. To date, the Company has not commercialized any products or generated&#13;any material revenues from product sales and accordingly it does not have a revenue stream to support its cost structure. The Company's&#13;losses (other than financing related income and expenses) have resulted principally from costs incurred in development and discovery&#13;activities and general and administrative expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company expects to continue&#13;to incur losses for the foreseeable future, and these losses will likely increase as it:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;initiates and manages further development and clinical trials for LO2A;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;seeks regulatory approvals for LO2A;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;implements internal systems and infrastructures;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;seeks to license additional technologies to develop;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;pays royalties related to the License Agreement and in connection with the obligation with respect to future revenues;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;hires management and other personnel;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;moves&#13;    towards commercialization; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risks related to the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic, including on our clinical trials, the demand for our products, our ability to operate and on overall economic conditions.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;No certainty exists that the Company&#13;will be able to complete the development of LO2A for Conjunctivochalasis ("&lt;b&gt;CCH&lt;/b&gt;"), Sj&amp;#246;gren's syndrome&#13;("&lt;b&gt;Sj&amp;#246;gren's&lt;/b&gt;") or any other ophthalmic disorder, due to financial, technological or other difficulties.&#13;If LO2A fails in clinical trials or does not gain regulatory clearance or approval, or if LO2A does not achieve market acceptance,&#13;the Company may never become profitable. In addition, while the Company explores license and other strategic transactions in an&#13;attempt to monetize the LO2A, there is no assurance that the Company will be successful in doing so and, even if is able to do&#13;so, what the timing or terms thereof may be of such licenses or strategic transactions.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company's inability to&#13;achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash&#13;flows. Moreover, the Company's prospects must be considered in light of the risks and uncertainties encountered by an early-stage&#13;company and in a highly regulated and competitive market, such as the biopharmaceutical market, where regulatory approval and market&#13;acceptance of its products are uncertain, and the other risks set forth in the Company's filings with the U.S. Securities&#13;and Exchange Commission ("&lt;b&gt;SEC&lt;/b&gt;"), including risks and uncertainties relating to the outbreak of the COVID-19&#13;pandemic. There can be no assurance that the Company's efforts will ultimately be successful or result in revenues or profits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In light of the pending transaction&#13;with Bonus (see note 10), there are also risks relating to, among other things, the timing and anticipated completion of such&#13;transaction and whether the expected benefits of and potential value created by the transaction will materialize.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Use of estimates in preparation of Financial Statements:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The preparation of the financial&#13;statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts&#13;reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company's&#13;management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time&#13;they are made.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;These estimates, judgments and&#13;assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the&#13;dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results&#13;could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As applicable to the consolidated Financial Statements, the&#13;most significant estimates and assumptions relate to the going concern assumptions, determining the fair value of embedded and&#13;freestanding financial instruments related to convertible loans and rights to future investment as part of modification or the&#13;settlement of the convertible loans determining the fair value of the contingent obligation with respect to future revenues and&#13;whether modification of terms of financial instruments is considered substantial.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;f.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Marketable equity securities:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company's investment in marketable equity securities&#13;which is based on equity securities with readily determinable fair values was classified as financial instruments at fair value&#13;with any changes in fair value recognized periodically in earnings.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;g.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment, net:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Property and equipment are stated&#13;at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives&#13;of the assets at the following rates:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;h.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Impairment of long-lived assets:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company's long-lived assets are reviewed for impairment&#13;in accordance with Accounting Standards Codification ("&lt;b&gt;ASC&lt;/b&gt;") 360, "Property, Plant and Equipment",&#13;whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability&#13;of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows&#13;expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured&#13;by the amount by which the carrying amount of the asset exceeds its fair value. Assets to be disposed of are reported at the lower&#13;of the carrying amount or fair value less costs to sell. During the years ended December 31, 2020 and 2019, no impairment losses&#13;have been identified.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <wizp:SeverancePayPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;j.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Severance pay:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Wize Israel has two employee as&#13;of December 31, 2020 and 2019. Wize Israel's liability for severance pay is subject to Section 14 of Israel's the Severance&#13;Compensation Act, 1963 ("&lt;b&gt;Section 14&lt;/b&gt;"), pursuant to which all Wize Israel's employees are included under&#13;Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee's&#13;name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release Wize Israel from any&#13;future severance payments in respect of those employees. Wize Israel has made all of the required payments as of December 31, 2020&#13;and 2019.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The fund is made available to the&#13;employee at the time the employer-employee relationship is terminated, regardless of cause of termination.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The severance pay liabilities and&#13;deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably&#13;transferred to the severance funds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Severance expenses for the years&#13;ended December&amp;#160;31, 2020 and 2019 amounted to $16 and $17, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</wizp:SeverancePayPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;l.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Concentrations of credit risk:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Financial instruments that potentially&#13;subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and restricted&#13;bank deposits. Cash and cash equivalents and restricted bank deposits are invested in banks in Israel and the U.S.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Management believes that the financial&#13;institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with&#13;respect to these investments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has no off-balance-sheet&#13;concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px; font-size: 10pt"&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;s.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other comprehensive loss&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The components of accumulated&#13;other comprehensive loss which resulted from foreign currency translation adjustment as of December&amp;#160;31, 2020 and 2019 were&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total &lt;br /&gt; accumulated &lt;br /&gt;&#13;    other &lt;br /&gt; comprehensive &lt;br /&gt; income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(73&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(73&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">3000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2020-01-01to2020-12-31_custom_CannabicsMember" unitRef="USD" decimals="-3">260000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <wizp:PenaltyPayment contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">100000000</wizp:PenaltyPayment>
    <us-gaap:PreferredStockParticipationRights contextRef="From2020-07-02to2020-07-08"> The Company elected to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares representing an amount of $6,597 to the holders of Series B Preferred Stock representing 80% of the Bonus shares then held by the Company. As a result of such distribution, as of the date of these financial statements, the Company owns the remaining 18,822,533 Bonus Shares, representing approximately 1.61% of the outstanding shares of Bonus.</us-gaap:PreferredStockParticipationRights>
    <wizp:BonusTransaction contextRef="From2020-11-01to2020-11-29_us-gaap_SeriesBPreferredStockMember_custom_BonusAgreementsMember" unitRef="shares" decimals="INF">119294300</wizp:BonusTransaction>
    <wizp:BonusSharesOfSeriesBPreferredStock. contextRef="From2020-11-01to2020-11-29_us-gaap_SeriesBPreferredStockMember_custom_BonusAgreementsMember" unitRef="shares" decimals="INF">93576800</wizp:BonusSharesOfSeriesBPreferredStock.>
    <wizp:ScheduleOfMandatorilyRedeemableSeriesBLiability contextRef="From2020-01-01to2020-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Opening balance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Series B Preferred Stock issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Loss from initial recognition of mandatorily redeemable Series B Preferred Stock at fair value&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revaluation of mandatorily redeemable Series B Preferred&#13;    Stock &lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(597&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Redemption of mandatorily redeemable Series B Preferred Stock with Bonus Shares&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,604&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Extinguishment of mandatorily redeemable Series B Preferred Stock by release of escrow account&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</wizp:ScheduleOfMandatorilyRedeemableSeriesBLiability>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="From2020-01-01to2020-12-31">NOL carry forwards of approximately $4,786 is available in full.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <wizp:BonusTransactionCosts contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-350000</wizp:BonusTransactionCosts>
    <wizp:BonusTransactionCosts contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:MarketableEquityDescription contextRef="From2019-01-01to2019-12-31">The Company sold 2,238,944 shares of Cannabics through a broker at the amount of $260 (see also Note 4) which were received as of the date of Financial Statements. The Company made a payment of $1 to the broker as a deposit for the Broker&#8217;s activity. During 2019 the Company recorded a loss of $501.</wizp:MarketableEquityDescription>
    <wizp:ConversionOfPreferredStockIntoCommonStockShares contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="shares" decimals="INF">-732</wizp:ConversionOfPreferredStockIntoCommonStockShares>
    <wizp:ConversionOfPreferredStockIntoCommonStockShares contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">732000</wizp:ConversionOfPreferredStockIntoCommonStockShares>
    <wizp:ConversionOfPreferredStockIntoCommonStock contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" decimals="-3">-1000</wizp:ConversionOfPreferredStockIntoCommonStock>
    <wizp:ConversionOfPreferredStockIntoCommonStock contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">1000</wizp:ConversionOfPreferredStockIntoCommonStock>
    <wizp:ConversionOfPreferredStockIntoCommonStock contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <wizp:ConversionOfPreferredStockIntoCommonStock contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:ConversionOfPreferredStockIntoCommonStock contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <wizp:ConversionOfPreferredStockIntoCommonStock contextRef="From2019-01-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true" />
    <wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-185000</wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment>
    <wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment contextRef="From2019-01-01to2019-12-31" unitRef="USD" decimals="-3">-185000</wizp:StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;p.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leases:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Effective January 1, 2019, the Company accounts for its leases&#13;under ASC 842, "Leases". Under this guidance, arrangements meeting the definition of a lease are classified as operating&#13;or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated&#13;by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing&#13;rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized&#13;over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results&#13;in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In calculating the right of use&#13;asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases&#13;having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on&#13;a straight-line basis over the lease term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company recognized&amp;#160;$42&#13;of operating lease right of use assets and operating lease liabilities at January 1, 2019. As of December 31, 2020 and 2019, total&#13;of right-of-use assets related to the Company's operating leases and operating lease liabilities was $22.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company recorded an amortization&#13;of $20 in right of use assets and operating lease liabilities for the year ended December 31, 2020.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <wizp:MandatorilyRedeemableSeriesBLiability contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" xsi:nil="true" />
    <wizp:MandatorilyRedeemableSeriesBLiability contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <wizp:SeriesBPreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">-7500000</wizp:SeriesBPreferredStock>
    <wizp:RedemptionOfMandatorilyRedeemableSeriesBPreferredStock contextRef="From2020-01-01to2020-12-31" unitRef="USD" decimals="-3">7604000</wizp:RedemptionOfMandatorilyRedeemableSeriesBPreferredStock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-03-01" unitRef="shares" decimals="INF">33052951</dei:EntityCommonStockSharesOutstanding>
    <wizp:SignificantTransactionsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 10:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;SIGNIFICANT TRANSACTIONS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;The Bonus/LO2A&#13;    Transaction&lt;/b&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On January 9, 2020, the Company&#13;entered into (i) an Exchange Agreement (the "Bonus Exchange Agreement"), with Bonus and (ii) a Share Purchase Agreement&#13;(the "Bonus Purchase Agreement" and, together with the Bonus Exchange Agreement, the "Bonus Agreements")&#13;with Bonus.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pursuant to the Bonus Agreements,&#13;the Company agreed to grant Bonus, in consideration for the issuance of 62,370,000 ordinary shares of Bonus to the Company (the&#13;"LO2A Shares"), the right to receive 37% of future LO2A Proceeds (if any), which, as more fully defined in the Bonus&#13;Exchange Agreement, include proceeds generated by the Company, Wize Israel and OcuWize, as a result of (i) the sale, license or&#13;other disposal of products or other rights underlying the LO2A technology licensed to OcuWize under the License Agreement; and&#13;(ii) a Sale Transaction, which, as more fully defined in the Bonus Exchange Agreement, includes the sale of shares or assets of&#13;Wize Israel and/or OcuWize. In addition, if the Sale Transaction involves a change of control of the Company, Bonus will be entitled&#13;to elect, to either remain with its right to 37% of the LO2A Proceeds or receive a one-time payment equal to 37% of the value&#13;attributed to Wize Israel out of the total proceeds payable for the Company in such transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In addition, pursuant to the Bonus&#13;Purchase Agreement, the Company agreed to purchase 51,282,000 ordinary shares of Bonus (the "PIPE Shares", and together&#13;with the LO2A Shares, the "Bonus Shares"), for an aggregate purchase price of $7,400 in cash, which funds were deposited&#13;directly into an escrow account (the "Bonus Escrow Account"), of which (i) $500 was paid to Bonus as an advance promptly&#13;following execution of the Bonus Purchase Agreement, (ii) $3,200 was released to Bonus concurrently with the closing of the transactions&#13;contemplated by the Bonus Agreements in exchange for 50% of the PIPE Shares and (iii) $3,700 was released to Bonus upon the Milestone&#13;Closing (as defined in the Bonus Purchase Agreement), in exchange for the remaining 50% of the PIPE Shares that were issued by&#13;Bonus and deposited into the escrow at the closing. The Company's obligation to consummate the Milestone Closing is conditioned&#13;upon the satisfaction by Bonus of certain conditions, including the listing of its ordinary shares (or, if an ADR Program is to&#13;be implemented by Bonus, the American Depositary Shares representing such ordinary shares) on the Nasdaq Capital Market (or another&#13;superior tier of the Nasdaq market) (the "Nasdaq Listing").&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In addition, pursuant to the Bonus&#13;Agreements (as amended as of June 24, 2020), Bonus agreed to cover nearly 50% of the Company's fees and expenses payable&#13;by the Company in cash, Bonus shares and/or a combination thereof to H.C. Wainwright &amp;#38; Co., LLC ("HCW") in connection&#13;with the transactions contemplated by the Bonus Agreements and the Series B Purchase Agreement (as defined below). In particular,&#13;Bonus agreed to reimburse the Company or pay HCW directly $350 in cash, Bonus shares and/or a combination thereof.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Regarding the release of the remaining escrow amount of $3,700&#13;to the Series B investors upon settlement agreement between the parties, see below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;According to the Bonus Agreements,&#13;as amended, the total number of Bonus Shares issuable to the Company (including the shares to be released at the Milestone Closing)&#13;was computed as the number of ordinary shares of Bonus equal to the quotient obtained by dividing (A) $16,400 expressed in NIS&#13;(based on the exchange rate between NIS and the dollar as of January 8, 2020) by (B) NIS 0.50. As of January 9, 2020, such total&#13;number of Bonus Shares represented (on a post-issuance basis) approximately 12% of the outstanding share capital of Bonus. The&#13;fair value of Bonus shares based on a quote of the share price on January 9, 2020, the date of signing the Bonus Agreements, was&#13;$0.12 per share and, as of the date of the closing was $0.11 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;The Bonus/LO2A&#13;Transaction&lt;/b&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The transactions contemplated&#13;by the Bonus Agreements were completed on February 19, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of the date of closing of the&#13;Bonus Agreements, the Company received 85,239,000 of Bonus Shares. Pursuant to the Bonus Agreements, an additional 28,413,000&#13;Bonus Shares were to be released to the Company upon the Nasdaq Listing and concurrently with the release of the $3,700 from the&#13;escrow account to Bonus.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As the Bonus Shares represent marketable securities with readily&#13;determinable fair value, Bonus shares issued to the Company were recognized upon initial recognition based on their quoted price&#13;(less applicable non-marketability discount) as of the date of the completion of the Bonus Agreements at an aggregate amount of&#13;$8,759. The difference between the fair value of Bonus shares and the amount of cash that was transferred directly to Bonus from&#13;an escrow account was recognized as financial liability, representing the Company's obligation to Bonus with respect to the&#13;LO2A Proceeds in an amount of $5,059 (see Note 2v).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On November 29, 2020, the&#13;Company entered into an Addendum (the "Addendum") with Bonus, whereby the parties agreed to amend certain&#13;provisions of the Bonus Agreements. Under the Addendum, at the Closing, Bonus will issue to the Company ordinary shares of&#13;Bonus (the "Bonus Shares"), the total number of which consists of (i) the Milestone Settlement Shares, which, as&#13;defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing $500 expressed in NIS (based on the&#13;exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement&#13;Shares, the "Settlement Shares"), which, as defined in the Addendum, means Bonus Shares equal to the quotient&#13;obtained by dividing $350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In consideration for the&#13;Settlement Shares, the Company agreed to make certain amendments to the Bonus Agreements, including the following key&#13;modifications: (i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto,&#13;conduct the Milestone Closing (as defined in the Bonus Agreements), which means that, at the Closing, $3.7 million will be&#13;released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq&#13;Milestone Shares") will be released to the Company (20% of the shares) and to the Company's former holders of&#13;Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive approximately $120 in&#13;liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend&#13;the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of&#13;Bonus to secure the Company's obligations under the Bonus Exchange Agreement, including certain related negative&#13;covenants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Closing was subject to customary conditions, including obtaining&#13;the approval of the Tel-Aviv Stock Exchange ("TASE"), and occurred on December 30, 2020. It should be noted that, in&#13;accordance with the Securities Purchase Agreement, dated January 9, 2020 (as amended), by and among the Company and the Former&#13;Series B Holders, the Company was required to transfer 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares&#13;to such investors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In addition, during the period&#13;from completion of the Bonus Agreements (February 19, 2020) and through December 31, 2020, the Company recognized financial income&#13;from both sales of Bonus marketable securities and revaluation of its remaining investment in Bonus marketable securities as of&#13;December 31, 2020, in an amount of $1,197 due to the change in the quoted market price of these shares on TASE. Such amount was&#13;presented as part of financial expenses, net.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;During the year ended December 31, 2020, the Company received&#13;cash proceeds of $821 from sales of 5,871,260 of Bonus Shares, which are marketable securities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;The Mandatorily&#13;    Redeemable Series B Investment&lt;/b&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In order to finance the transactions&#13;contemplated by the Bonus Purchase Agreement, on January 9, 2020, the Company entered into a Securities Purchase Agreement (the&#13;"Series B Purchase Agreement") with certain accredited investors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pursuant to the Series B Purchase&#13;Agreement, the Company agreed to sell to the investors, and the investors agreed to purchase from the Company, in a private placement,&#13;an aggregate of 7,500 shares of newly created Series B Non-Voting Redeemable Preferred Stock, par value $0.001 per share, of the&#13;Company ("Series B Preferred Stock") for a purchase price of $1.00 per share, for aggregate gross proceeds under the&#13;Series B Purchase Agreement of $7,500, which funds were deposited into an escrow account, of which (i) $500 was to be paid to&#13;the Bonus Escrow Account and $100 was paid directly to the Company to cover certain of its transactions expenses, in each case,&#13;promptly following the execution of the Series B Purchase Agreement, and (ii) the remaining $6,900 was to be released to the Bonus&#13;Escrow Account upon the closing of the transactions contemplated by the Series B Purchase Agreement (of which, as described above,&#13;$3,200 was to be released upon the earlier of the Milestone Closing or upon written consent of the holders of at least a majority&#13;of the Series B Preferred Stock).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Series B Purchase Agreement&#13;contained customary covenants, representations and warranties of the parties thereto, including, among others, (i) a covenant&#13;by the investors not to transfer the Series B Preferred Stock without the approval of the Company; (ii) a covenant by the Company,&#13;for as long as any Series B Preferred Stock remain outstanding, not to sell any Bonus Shares for a price per share equal to less&#13;than NIS 0.40 (the "Price Restriction"); and (iii) a covenant by the Company, simultaneously with, or promptly after,&#13;the redemption of the Series B Preferred Stock, to assign certain rights under the Bonus Purchase Agreement, such as the right&#13;to liquidated damages in the event of delayed Nasdaq Listing, and under the Bonus Registration Rights Agreement, to the investors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In connection with the Series&#13;B Purchase Agreement, the Company agreed to file, at the closing, a Certificate of Designations of Series B Non-Voting Redeemable&#13;Preferred Stock with the Secretary of State of Delaware (the "Series B Certificate of Designations"). Pursuant to&#13;the Series B Certificate of Designations, the Company designated 7,500 shares of preferred stock as Series B Preferred Stock.&#13;The Series B Preferred Stock were not convertible into shares of Common Stock of the Company and have no voting powers, except&#13;as related to certain rights to protect the rights and preferences of the Series B Preferred Stock and with respect to sales or&#13;dispositions of the Series B Preferred Stock at a price per share below the Price Restriction. The Series B Preferred Stock entitled&#13;its holders to (i) 80% of the proceeds received by the Company through future sales of the Bonus Shares issued to the Company&#13;under the Bonus Agreements and (ii) 80% of any cash dividends received by the Company on such Bonus Shares. Under the Series B&#13;Certificate of Designations, the Company had the option to redeem the Series B Preferred Stock at any time by distributing to&#13;holders of the Series B Preferred Stock (i) 80% of the Bonus Shares then held by the Company and (ii) 80% of all dividends received&#13;by the Company but not yet paid to holders of the Series B Preferred Stock (the "Redemption Payment"). The Company&#13;was required to redeem the Series B Preferred Stock through payment of the Redemption Payment upon the earlier of (i) 60 days&#13;following the Nasdaq Listing of the Bonus Shares, and (ii) December 28, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;However, until the completion of the Nasdaq Listing, an amount&#13;of $3,700 was required to remain in an escrow account and, upon the failure of such listing by Bonus by the Milestone End Date,&#13;such amount shall be required to be released in its entirety to the Series B investors. This escrow account of $3,700 was presented&#13;as restricted deposit in the Company' consolidated balance sheet commencing upon the closing of the transaction and until&#13;December 29, 2020, following the Addendum with Bonus described in Note 10a above, and the same amount was reflected as part of&#13;the liability with respect to the mandatorily redeemable series B preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of the completion date (February 19, 2020), the Company recognized&#13;a liability in light of its obligation to redeem the Series B Preferred Stock at its fair value in an amount of $10,707, representing&#13;the sum of the remaining escrow amount of $3,700 (which, in case the Milestone Closing will not be met, will be paid to the Series&#13;B investors) and 80% of the Company's investment in Bonus marketable shares, see Note 3.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The difference between the amount&#13;of the liability recognized with respect to the Series B Preferred Stock ($10,707) and the cash amount actually invested by such&#13;preferred stock investors ($7,500), amounting to $3,207 was recognized immediately as financial expense, net upon the completion&#13;of the Bonus agreement and the Series B Purchase Agreement, within financial income (loss), net.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In addition, from the date of&#13;the completion of the Bonus agreements and until the redemption, the Company recognized a loss in an amount of $597, net due to&#13;the revaluation of the mandatorily redeemable Series B Preferred Stock liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On July 8, 2020, the Company elected to redeem all of the Series&#13;B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares representing an amount of $6,597 to the holders&#13;of Series B Preferred Stock representing 80% of the Bonus shares then held by the Company. As a result of such distribution, as&#13;of the date of these financial statements, the Company owns the remaining 18,822,533 Bonus Shares, representing approximately 1.61%&#13;of the outstanding shares of Bonus.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As discussed above, on November&#13;29, 2020, the Company entered into an Addendum (the "Addendum") with Bonus, whereby, among other things, Bonus agreed&#13;to issue to the Company's ordinary shares of Bonus (the "Bonus Shares"), the total number of which consists of&#13;(i) the Milestone Settlement Shares, which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing&#13;US$500 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together&#13;with the Milestone Settlement Shares, the "Settlement Shares"), which, as defined in the Addendum, means Bonus Shares&#13;equal to the quotient obtained by dividing US$350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.&#13;In consideration for the Settlement Shares, the Company agreed to make certain amendments to the Bonus Agreements, including the&#13;following key modifications: (i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation&#13;thereto, conduct the Milestone Closing, which means that US$3.7 million were released from an existing escrow account to Bonus,&#13;whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq Milestone Shares") were released to the Company&#13;and to its former holders of Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive&#13;approximately US$120 in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus&#13;agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens&#13;in favor of Bonus to secure obligations under the Bonus Exchange Agreement, including certain related negative covenants. The closing&#13;occurred on December 29, 2020. It should be noted that, in accordance with the obligations of the Company to the Former Series&#13;B Holders (see below), the Company has transferred 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares&#13;to such investors. As a result of the transactions above, the Company redeemed all of the outstanding shares of Series B Preferred&#13;Stock, and had satisfied its obligation under the Series B Preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As a result of the Bonus transaction,&#13;the company received an aggregate amount of 119,294,300 Bonus shares, out of which a total number of 93,576,800 Bonus shares were&#13;distributes to the holders of Series B Preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The below table describes the&#13;roll forward of Mandatorily Redeemable Series B liability for the year ended December 31, 2020:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Opening balance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Series B Preferred Stock issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Loss from initial recognition of mandatorily redeemable Series B Preferred Stock at fair value&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revaluation of mandatorily redeemable Series B Preferred&#13;    Stock &lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(597&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Redemption of mandatorily redeemable Series B Preferred Stock with Bonus Shares&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,604&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Extinguishment of mandatorily redeemable Series B Preferred Stock by release of escrow account&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;The Cosmos Transaction&lt;/b&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On December 30, 2020, the Company&#13;or "Wize", entered into a Bid Implementation Agreement (the "Bid Agreement") with Cosmos Capital Limited,&#13;a digital infrastructure provider based in Sydney, Australia ("Cosmos"), whereby the parties agreed that the Company&#13;would commence an off-market takeover offer under applicable Australian laws (the "Offer") to acquire all of the outstanding&#13;shares of Cosmos in exchange for common shares of the Company. For more information, about the Cosmos transaction, CVR agreement&#13;and PIPE Agreements, see Note 16 below.&lt;/p&gt;</wizp:SignificantTransactionsTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 2:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The consolidated Financial Statements&#13;have been prepared in accordance with accounting principles generally accepted in the United States ("&lt;b&gt;U.S. GAAP&lt;/b&gt;").&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Use of estimates in preparation of Financial Statements:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The preparation of the financial&#13;statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts&#13;reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company's&#13;management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time&#13;they are made.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;These estimates, judgments and&#13;assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the&#13;dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results&#13;could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As applicable to the consolidated Financial Statements, the&#13;most significant estimates and assumptions relate to the going concern assumptions, determining the fair value of embedded and&#13;freestanding financial instruments related to convertible loans and rights to future investment as part of modification or the&#13;settlement of the convertible loans determining the fair value of the contingent obligation with respect to future revenues and&#13;whether modification of terms of financial instruments is considered substantial.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Principles of consolidation:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The consolidated Financial Statements&#13;include the accounts of the Company and its wholly owned subsidiaries. Inter-company balances and transactions have been eliminated&#13;upon consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Functional currency:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company aims to direct&#13;its main operations in the United States market. In addition, the convertible loans were denominated in U.S. dollars.&#13;Similarly, the Company issued warrants eligible for exercise for the Company's shares of Common Stock at an exercise&#13;price denominated in U.S. dollars and during January 2020 the Company completed the issuance of 7,500 Series B Non-Voting&#13;Redeemable Preferred Stock for a purchase price of $1 per share for total gross proceeds of $7,500. Also, the management&#13;believes the Company will raise funds through private investment rounds and / or from issuance of equity in dollar amounts by&#13;approaching the market in the United States. As a result, it was determined that the U.S dollar is the currency of the&#13;primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.&#13;Thus, the functional currency of the Company is the U.S. dollar. The Company maintains its books and records in local&#13;currency, which is NIS.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Balances denominated in, or linked&#13;to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date.&amp;#160;&amp;#160;For foreign&#13;currency transactions included in the consolidated statement of comprehensive loss, the exchange rates applicable on the relevant&#13;transaction dates are used.&amp;#160;&amp;#160;Transaction gains or losses arising from changes in the exchange rates used in the translation&#13;of such balances are carried to financing income or expenses as applicable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The following table presents data&#13;regarding the dollar exchange rate of relevant currencies:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;% of change&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 52%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;USD 1 = NIS&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.215&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.456&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6.9&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash and cash equivalents:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Cash equivalents are short-term&#13;highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;For presentation of statement of&#13;cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total&#13;amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&amp;#160;31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: right"&gt;December&amp;#160;31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;718&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted cash deposit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;260&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;759&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted bank deposit:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Restricted bank deposit is a deposit&#13;with maturities of more than three months and up to one year. The restricted bank deposit was presented at its cost, including&#13;accrued interest and represents cash which is used as collateral for Wize Israel's credit card used for certain corporate&#13;business expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;f.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Marketable equity securities:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company's investment in marketable equity securities&#13;which is based on equity securities with readily determinable fair values was classified as financial instruments at fair value&#13;with any changes in fair value recognized periodically in earnings.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;g.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment, net:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Property and equipment are stated&#13;at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives&#13;of the assets at the following rates:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;h.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Impairment of long-lived assets:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company's long-lived assets are reviewed for impairment&#13;in accordance with Accounting Standards Codification ("&lt;b&gt;ASC&lt;/b&gt;") 360, "Property, Plant and Equipment",&#13;whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability&#13;of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows&#13;expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured&#13;by the amount by which the carrying amount of the asset exceeds its fair value. Assets to be disposed of are reported at the lower&#13;of the carrying amount or fair value less costs to sell. During the years ended December 31, 2020 and 2019, no impairment losses&#13;have been identified.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;i.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development expenses:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Research and development expenses&#13;are charged to the statement of comprehensive loss as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In-Process Research and Development&#13;assets, acquired in an asset acquisition (&lt;i&gt;i.e.&lt;/i&gt;, assets acquired outside a business combination transactions) that are to&#13;be used in a research and development project which are determined not to have an alternative future use are charged to expense&#13;at the acquisition date in accordance with ASC 730, "Research and Development".&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;j.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Severance pay:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Wize Israel has two employee as&#13;of December 31, 2020 and 2019. Wize Israel's liability for severance pay is subject to Section 14 of Israel's the Severance&#13;Compensation Act, 1963 ("&lt;b&gt;Section 14&lt;/b&gt;"), pursuant to which all Wize Israel's employees are included under&#13;Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee's&#13;name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release Wize Israel from any&#13;future severance payments in respect of those employees. Wize Israel has made all of the required payments as of December 31, 2020&#13;and 2019.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The fund is made available to the&#13;employee at the time the employer-employee relationship is terminated, regardless of cause of termination.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The severance pay liabilities and&#13;deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably&#13;transferred to the severance funds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Severance expenses for the years&#13;ended December&amp;#160;31, 2020 and 2019 amounted to $16 and $17, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;k.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income taxes:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company accounts for income&#13;taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred&#13;tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets&#13;and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected&#13;to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets&#13;to amounts more likely than not to be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company implements a two-step&#13;approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to&#13;be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on&#13;an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals&#13;or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative&#13;basis) likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized tax positions&#13;has been recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;l.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Concentrations of credit risk:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Financial instruments that potentially&#13;subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and restricted&#13;bank deposits. Cash and cash equivalents and restricted bank deposits are invested in banks in Israel and the U.S.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Management believes that the financial&#13;institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with&#13;respect to these investments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has no off-balance-sheet&#13;concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;m.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Convertible loans: &amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;u&gt;Allocation of proceeds:&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The proceeds received upon the&#13;original issuance of the 2016 Loan (as defined below) together with a freestanding derivative financial instrument (derivative&#13;liability for right to future investment) were allocated to the financial instruments issued based on the residual value method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The detachable derivative financial&#13;instrument related to the 2016 Loan was recognized based on its fair value and the remaining amount of the proceeds was allocated&#13;to the 2016 Loan component.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The 2017 Loan (as defined below)&#13;was not issued with any detachable instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;u&gt;Beneficial Conversion Features&#13;("BCFs"):&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, the Company has considered the provisions of ASC 815-40, "Derivatives and Hedging &amp;#8211; Contracts in Entity's Own Equity" ("&lt;b&gt;ASC 815-40&lt;/b&gt;"), and determined that the embedded conversion feature of the 2016 Loan should not be separated from the host instrument because it qualifies for equity classification. Furthermore, the Company applied ASC 470-20, "Debt &amp;#8211; Debt with Conversion and Other Options" ("&lt;b&gt;ASC 470-20&lt;/b&gt;) which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios, and has applied the BCFs guidance to determine whether the conversion feature is beneficial to the investor.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;The BCFs was calculated by allocating&#13;the proceeds received in financing transactions to the 2016 Loan and to any detachable freestanding financial instrument (derivative&#13;liability for future investment) included in the transaction, and by measuring the intrinsic value of the conversion option based&#13;on the effective conversion price as a result of the allocated proceeds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;The intrinsic value of the conversion&#13;option with respect to the 2016 Loan was recorded as a discount on the 2016 Loan with a corresponding amount credited directly&#13;to equity as additional paid-in capital. After the initial recognition, the discount on the 2016 Loan was amortized as interest&#13;expense over the contractual term of the 2016 Loan (before its modification) by using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, the Company has considered the provisions of ASC 815-15,&amp;#160;"Derivatives and Hedging - Embedded Derivatives", and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, did not meet the definition of a derivative in accordance with the provisions of ASC 815-10, "Derivatives and Hedging"&amp;#160;&amp;#160;since its terms did not require or permit net settlement. Thus, it was determined that the conversion feature does not meet the characteristic of being readily convertible to cash.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Furthermore, the Company applied&#13;ASC 470-20 which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Pursuant to ASC 470-20-30, the&#13;amount of the BCFs with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion&#13;price (&lt;i&gt;i.e.&lt;/i&gt;, the entire proceeds received for the 2017 Loan) and the aggregate fair value of the Common Stock and other&#13;securities (which consist of the future Investment Rights) into which the 2017 Loan was convertible.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;As such difference was determined&#13;to be greater than the amount of the entire proceeds originally received for the 2017 Loan, the amount of the discount assigned&#13;to the BCFs was limited to the amount of the entire proceeds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Following modifications or exchanges of convertible loans that were accounted for as an extinguishment (see below), upon each additional recognition of the convertible loans based on their modified terms, the Company applied ASC 470-20, "Debt &amp;#8211; Debt with conversion and other options" to determine whether the conversion feature is considered beneficial to the investors. However, due to the fact that following each of the extinguishments of the convertible loans, such modified convertible loans were recognized based on their fair value as of the modification date, the conversion terms were not considered beneficial to the investors.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 29px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Modifications or Exchanges&lt;/u&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Modifications to, or exchanges&#13;of, financial instruments such as convertible loans, are accounted for as a modification or an extinguishment, following to provisions&#13;of ASC 470-50, "Debt- Modification and Extinguishments" ("&lt;b&gt;ASC 470-50&lt;/b&gt;"). Such an assessment done&#13;by management either qualitatively or quantitatively based on the facts and circumstances of each transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;Under ASC 470-50, modifications&#13;or exchanges are generally considered extinguishments with gains or losses recognized in current earnings if the terms of the new&#13;debt and original instrument are substantially different. The instruments are considered "substantially different"&#13;when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present&#13;value of the remaining cash flows under the terms of the original instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;If the terms of a debt instrument&#13;are changed or modified and the present value of the cash flows under the terms of the new debt instrument is less than 10%, the&#13;debt instruments are not considered to be substantially different, except in the following two circumstances (i)&amp;#160;&amp;#160;The&#13;transaction significantly affects the terms of an embedded conversion option, such that the change in the fair value of the embedded&#13;conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and&#13;after the modification or exchange) is at least 10% of the carrying amount of the original debt instrument immediately before the&#13;modification or exchange or (ii)&amp;#160;&amp;#160;The transaction adds a substantive conversion option or eliminates a conversion option&#13;that was substantive at the date of the modification or exchange.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;If the original and new debt&#13;instruments are considered as "substantially different", the original debt is derecognized and the new debt is initially&#13;recorded at fair value, with the difference recognized as an extinguishment gain or loss under financial expense or income as applicable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;If a convertible debt instrument&#13;with a beneficial conversion option that was separately accounted for in equity, is extinguished prior to its conversion or stated&#13;maturity date, a portion of the reacquisition price is allocated to the repurchase of the beneficial conversion option. The amount&#13;of the reacquisition price allocated to the beneficial conversion option is measured using the intrinsic value of that conversion&#13;option at the extinguishment date. The residual amount, if any, is allocated to the convertible debt instrument.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;The gain or loss on the extinguishment&#13;of the convertible debt instrument is determined based on the difference between the carrying amount and the fair value of the&#13;allocated reacquisition price.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;Modifications to, or exchanges&#13;of equity financial instruments such as right to future investment, are accounted for as a modification or an extinguishment in&#13;a similar manner as described above. Such an assessment is done by management either qualitatively or quantitatively based on the&#13;facts and circumstances of each transaction. Among others, management considers whether, the fair value of the financial instruments&#13;before and after the modification or exchange are substantially different.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;If the original and new equity&#13;instruments are considered as "substantially different", the excess fair value of the allocated reacquisition price&#13;over the fair value of the modified financial instrument before the modification, is recognized directly to retained earnings as&#13;a deemed dividend.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;&lt;u&gt;Issuance costs of convertible&#13;loan:&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2016 Loan (or costs allocated to such component in a package issuance) were presented as a direct deduction from the amount of the 2016 Loan and in subsequent periods such costs (together with the discount created by BCFs if applicable) expensed as financing expenses over the contractual term of the 2016 Loan by using the effective interest method. Any such costs that were allocated to the derivative component were expensed as incurred.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 125px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2017 Loan (or costs allocated to such component in a package issuance) were presented as a deferred asset since the 2017 Loan was completely discounted at the initial recognition. In subsequent periods, such expenses were amortized ratably over the original term of the 2017 Loan.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;&lt;u&gt;Extinguishment of convertible&#13;loans:&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"&gt;Upon the final extinguishment&#13;of the convertible loans upon their maturity, the difference between the reacquisition price which consist of the cash paid, the&#13;fair value of instruments issued (shares and warrants) and the modification of loans and cancellation of existing financial instruments)&#13;and the carrying amounts of the convertible loans being extinguished was recognized as a gain or loss in the period of extinguishment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair value of financial instruments:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;ASC 820, "Fair Value Measurements&#13;and Disclosures" ("&lt;b&gt;ASC 820&lt;/b&gt;"), defines fair value as the price that would be received to sell an asset&#13;or paid to transfer a liability (&lt;i&gt;i.e.&lt;/i&gt;, the "exit price") in an orderly transaction between market participants&#13;at the measurement date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In determining fair value, the&#13;Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes&#13;the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used&#13;when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based&#13;on market data obtained from sources independent of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Unobservable inputs are inputs&#13;that reflect the Company's assumptions about the assumptions market participants would use in pricing the asset or liability&#13;developed based on the best information available in the circumstances.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The hierarchy is broken down into&#13;three levels based on the inputs as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 96px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&amp;#160;1&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 19px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&amp;#160;2&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level&amp;#160;3&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The availability of observable&#13;inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of&#13;investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based&#13;on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment&#13;and the investments are categorized as Level&amp;#160;3.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The carrying amounts of cash and&#13;cash equivalents, short-term bank deposits, other accounts receivable, trade payables and other accounts payable approximate their&#13;fair value due to the short-term maturities of such instruments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Fair value of the marketable equity&#13;securities is determined based on a Level 1 input.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;o.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Legal and other contingencies:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company accounts for its contingent&#13;liabilities in accordance with ASC 450 "Contingencies". A provision is recorded when it is both probable that a liability&#13;has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed&#13;and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information&#13;and events pertaining to a particular matter. As of December&amp;#160;31, 2020, the Company is not a party to any litigation that could&#13;have a material adverse effect on the Company's business, financial position, results of operations or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Legal costs incurred in connection&#13;with loss contingencies are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;p.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leases:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Effective January 1, 2019, the Company accounts for its leases&#13;under ASC 842, "Leases". Under this guidance, arrangements meeting the definition of a lease are classified as operating&#13;or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated&#13;by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing&#13;rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized&#13;over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results&#13;in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In calculating the right of use&#13;asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases&#13;having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on&#13;a straight-line basis over the lease term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company recognized&amp;#160;$42&#13;of operating lease right of use assets and operating lease liabilities at January 1, 2019. As of December 31, 2020 and 2019, total&#13;of right-of-use assets related to the Company's operating leases and operating lease liabilities was $22.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company recorded an amortization&#13;of $20 in right of use assets and operating lease liabilities for the year ended December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;q.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A Warrants and December 2019 Warrants with Down-Round Protection:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Commencing January 1, 2018 and&#13;following the early adoption of Accounting Standard Update ("&lt;b&gt;ASU&lt;/b&gt;") No. 2017-11, "I. Accounting for certain&#13;financial instruments with Down Round Features" (ASU 2017-11), the Company disregards certain down-round features when assessing&#13;whether a financial instrument is indexed to its own stock, for purposes of determining liability or equity classification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Based on its evaluation,&#13;management has determined that the Series A Warrants and warrants that were issued in October 2018 (the "&lt;b&gt;October&#13;2018 Warrants&lt;/b&gt;") and in December 2019 (the "&lt;b&gt;December 2019 Warrants&lt;/b&gt;"), as part of a private&#13;placement, as described in Note&amp;#160;13n, respectively, which include a down-round protection that would adjust the exercise&#13;price of the Series A Warrants based on the price at which the Company subsequently issues shares or other equity-linked&#13;financial instruments, if that price is less than the original exercise price of the Series A Warrants, are eligible for&#13;equity classification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In accordance with the provisions&#13;of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (&lt;i&gt;i.e.&lt;/i&gt;, when the exercise price of&#13;the Series A Warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend&#13;and as a reduction of income available (increase of loss applicable) to common shareholders for purposes of basic earnings per&#13;share (EPS) calculation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Regarding a triggering event that required down-round adjustment&#13;of the exercise price of the warrants during 2020 and 2019, see Note 13p and 13q, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Modifications to the terms of warrants that are classified&#13;as equity and remains to be classified in equity after the modification, are accounted for in a similar manner to share-based compensation&#13;guidance with respect to modifications. Accordingly, the incremental fair value from the modification (the change in the fair value&#13;of the warrant before and after the modification) is recognized in retained earnings as a deemed dividend (e.g., dividends to a&#13;particular class of equity holders).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;r.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic and diluted loss per share:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Basic loss per share is computed&#13;by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares of Common Stock&#13;outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Series&#13;A Preferred Stock) are considered in the computation of basic income (loss) per share using the two-class method. In periods of&#13;net loss, such participating securities are included in the computation, since the holders of such securities have a contractual&#13;obligation to share the losses of the Company (as the convertible Series A Preferred Stock do not have a right to receive any mandatory&#13;redemption amount and as they are entitled only to dividends on an as-converted basis together with the common shares).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In computing diluted loss per share,&#13;basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of options, warrants and&#13;rights for future investment issued or granted using the "treasury stock method" and upon the conversion of 2017 Loan&#13;and 2016 Loan using the "if-converted method", if the effect of each of such financial instruments is dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;For the year ended&#13;December&amp;#160;31, 2020 and 2019, all outstanding warrants, stock options and other convertible instruments have been excluded&#13;from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The loss and the weighted average&#13;number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2020 and 2019, is as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Add: Loss attributed to preferred stock (*)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;136&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend with respect to right for future investment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend due to down round adjustment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(267&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss applicable to stockholders of Common Stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,266&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,766&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares of Common Stock used in computing basic and diluted net loss per share&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,669,628&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,519,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss per share of Common Stock, basic and diluted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;                                         the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase&#13;                                         Agreement (as defined below). These shares of preferred stock are participating securities. During&#13;                                         the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year&#13;                                         ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#13;                                         31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Number of shares:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Common shares used&#13;    in computing basic and diluted loss per share&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;16,669,628&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;10,519,682&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Preferred Stock and options excluded&#13;    from the calculations of diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;614,763&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,931,097&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;s.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other comprehensive loss&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The components of accumulated&#13;other comprehensive loss which resulted from foreign currency translation adjustment as of December&amp;#160;31, 2020 and 2019 were&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total &lt;br /&gt; accumulated &lt;br /&gt;&#13;    other &lt;br /&gt; comprehensive &lt;br /&gt; income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(73&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(73&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;font style="font-size: 6pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;t.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based compensation:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&lt;font style="font-size: 6pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Stock-based compensation to employees&#13;is accounted for in accordance with ASC 718, "Compensation - Stock Compensation" ("&lt;b&gt;ASC 718&lt;/b&gt;"), which&#13;requires estimation of the fair value of equity - based payment awards on the date of grant using an option pricing model. The&#13;value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="font-size: 6pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Stock-based compensation expense&#13;is recognized for the value of awards granted based on the accelerated method over the requisite service period of each of the&#13;awards, net of estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent&#13;periods if actual forfeitures differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The fair value of stock options&#13;granted to Wize Israel employees was estimated using the Black- Scholes option pricing model, which requires a number of assumptions,&#13;of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated&#13;based upon historical volatilities of the Company on a weekly basis since the marketability of Wize Israel is less than the expected&#13;option term. The expected option term represents the period that Wize Israel's stock options are expected to be outstanding&#13;and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions.&#13;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The expected dividend yield assumption&#13;is based on Wize Israel's historical experience and expectation of no future dividend payouts. Wize Israel has historically&#13;not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Following the adoption of ASU 2018-07 in January 2018, all equity-classified&#13;nonemployee share-based payment are accounted for in accordance with the provisions of ASC 718 and accordingly, awards granted&#13;during 2019 and 2020 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;u.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Recent Accounting Pronouncements not adopted&#13;    yet&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 1.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;ASU 2016-13, "Financial Instruments &amp;#8211; Credit&#13;Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13")&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On June 2016, the FASB issued ASU Update 2016-13,&#13;"Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU&#13;2016-13") ASU Update 2016-13 revised the criteria for the measurement, recognition, and reporting of credit losses on financial&#13;instruments to be recognized when expected.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On November 2019, the FASB issued&#13;ASU 2019-10, "Financial Instruments&amp;#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic&#13;842) &amp;#8211; Effective Dates," which, among other provisions, the effective date of ASU 2016-13 was amended as follows&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;1. Public&#13;business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (SRCs)&#13;as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;2. All&#13;other entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;As the Company is eligible to be considered as smaller reporting&#13;company, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal&#13;years, with early adoption permitted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is in the process&#13;of evaluating the effect that ASU 2016-13 will have on the results of operations and financial statements, if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;ASU 2020-06&amp;#8212;Debt&amp;#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives&#13;and Hedging&amp;#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts&#13;in an Entity's Own Equity&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In August 2020, the FASB issued&#13;ASU 2020-06&amp;#8212;Debt&amp;#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#8212;Contracts&#13;in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&#13;(ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,&#13;including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes from&#13;GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and beneficial conversion&#13;feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for&#13;such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life&#13;of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument&#13;contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt&#13;instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to&#13;calculate the impact of convertible instruments on diluted earnings per share (EPS).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The amendments in ASU 2020-06&#13;are effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding&#13;entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021,&#13;including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning&#13;after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than&#13;fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;ASU 2020-06 can be adopted&#13;on either a fully retrospective or modified retrospective basis. The adoption of this standard is not expected to result in a&#13;material impact to the Company's financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;v.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent obligation with respect to future&#13;    revenues&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company's contingent&#13;obligation to payment of 37% of the future LO2A Proceeds, if any, was accounted for as long-term debt in accordance with the provisions&#13;of Accounting Standards Codification ("ASC") 470-10-25, "Sales of Future Revenues or Various other Measures&#13;of Income," which relates to cash received in exchange for payments of a specified percentage or amount of revenue or other&#13;measure of income of a particular product line, business segment, trademark, patent, or contractual right.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Such repayment obligations are&#13;contingent upon the receipt by the Company of any future proceeds from LO2A sales, license or other, as described in Note 5 below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company elected to measure&#13;the contingent payment obligation in its entirety, at its fair value (the "Fair Value Option") in accordance with&#13;ASC 825-10, "Financial Instruments" due to the variable and contingent nature of the repayment provisions of such&#13;financial liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The fair value of such&#13;liability was measured upon its initial recognition at its fair value, based on the difference between the fair value of the&#13;marketable securities received by the Company, less the amount of cash paid by the Company. In subsequent periods, the fair&#13;value of the liability for contingent payment obligation is based on management estimate. As of December 31, 2020, the&#13;Company revalued the liability to its fair value with the assistance of an external valuation specialist, pursuant to the&#13;Company's estimations and assumptions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has determined&#13;that the inputs used in measuring the fair value of the contingent payment obligation fall within Level 3 in the fair value&#13;hierarchy which involves significant estimations and assumptions regarding any projected future proceeds from the LO2A,&#13;including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product&#13;into the U.S. market - 12%, the patent expiration date (2038), the operational profit estimated rate - 26%, the probabilities&#13;for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has determined that the inputs used in measuring&#13;the fair value of the contingent payment obligation fall within Level 3 in the fair value hierarchy which involves significant&#13;estimates and assumptions including, among others, any projected future proceeds from the LO2A, the risk-adjusted rate for discounting&#13;future cash flows and other relevant assumptions, see Note 10.&amp;#160;&amp;#160;Actual results could differ from the estimates made.&#13;Changes in fair value (including the component related to imputed interest), would be included in the consolidated statements of&#13;comprehensive loss as part of financial income (loss) under the heading "Changes in fair value of contingent payment obligation&#13;with respect to future revenues."&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;w.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Mandatorily Redeemable Series B Preferred&#13;    Stock&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company classified its formerly&#13;outstanding Series B Preferred Stock as a liability, as their terms embody an unconditional obligation of the Company to redeem&#13;the shares by transferring cash or other assets that equal (i) 80% of the proceeds received by the Company through future sales&#13;of the Bonus Shares issued to the Company under the Bonus Agreements (as hereinafter defined) and (ii) 80% of any cash dividends&#13;received by the Company on such Bonus Shares) at a specified or determinable date or dates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company elected to measure&#13;this liability in its entirety, at its fair value (the "Fair Value Option") in accordance with ASC 825-10, "Financial&#13;Instruments" due to the variable and contingent nature of the redemption price of such financial liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Upon initial recognition and in&#13;subsequent periods, the Company measured the&amp;#160;fair value of the liability related to the Series B Preferred Stock based on&#13;the value of the Bonus Shares and the cash amount that the Company was required to transfer to the Series B investors upon the&#13;redemption of the Series B Preferred Stock. The difference between the amount received by the Company upon the issuance of the&#13;Series B Preferred Stock and their fair value as of that date was carried immediately to the consolidated statements of comprehensive&#13;loss as part of financial income (loss).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The issuance costs of the Series&#13;B Preferred Stock were recognized immediately as an expense during the three months ended March 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On July 8, 2020, the Company elected&#13;to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares to the (now former)&#13;holders of Series B Preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On November 29, 2020, Wize entered into an Addendum (the "Addendum")&#13;with Bonus, whereby, among other things, Bonus agreed to issue to the Company additional ordinary shares of Bonus (the "Bonus&#13;Shares", the total number of which consists of (i) the Milestone Settlement Shares, which, as defined in the Addendum, means&#13;Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum)&#13;by NIS 0.50, and (ii) the HCW Settlement Shares, as defined in note 10a (together with the Milestone Settlement Shares, the "Settlement&#13;Shares"), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed&#13;in NIS (based on the exchange rate set in the Addendum) by NIS 0.50. In consideration for the Settlement Shares, the Company agreed&#13;to make certain amendments to the Bonus Agreements, including the following key modifications: (i) the Company will waive the requirement&#13;that Bonus will affect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing, which means that US$3.7 million&#13;were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq&#13;Milestone Shares") were released to the Company and to its former holders of Series B Preferred Stock (the "Former&#13;Series B Holders"); (ii) the Company will waive approximately US$120 in liquidated damages that accrued as a result of the&#13;delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli&#13;subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under the Bonus Exchange Agreement,&#13;including certain related negative covenants. The closing occurred on December 29, 2020. It should be noted that, in accordance&#13;with the obligations of the Company to the Former Series B Holders (see below), the Company has transferred 80% of the Milestone&#13;Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2020, the entire&#13;balance of the Series B preferred stock was extinguished.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <wizp:SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;q.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A Warrants and December 2019 Warrants with Down-Round Protection:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Commencing January 1, 2018 and&#13;following the early adoption of Accounting Standard Update ("&lt;b&gt;ASU&lt;/b&gt;") No. 2017-11, "I. Accounting for certain&#13;financial instruments with Down Round Features" (ASU 2017-11), the Company disregards certain down-round features when assessing&#13;whether a financial instrument is indexed to its own stock, for purposes of determining liability or equity classification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Based on its evaluation,&#13;management has determined that the Series A Warrants and warrants that were issued in October 2018 (the "&lt;b&gt;October&#13;2018 Warrants&lt;/b&gt;") and in December 2019 (the "&lt;b&gt;December 2019 Warrants&lt;/b&gt;"), as part of a private&#13;placement, as described in Note&amp;#160;13n, respectively, which include a down-round protection that would adjust the exercise&#13;price of the Series A Warrants based on the price at which the Company subsequently issues shares or other equity-linked&#13;financial instruments, if that price is less than the original exercise price of the Series A Warrants, are eligible for&#13;equity classification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In accordance with the provisions&#13;of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (&lt;i&gt;i.e.&lt;/i&gt;, when the exercise price of&#13;the Series A Warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend&#13;and as a reduction of income available (increase of loss applicable) to common shareholders for purposes of basic earnings per&#13;share (EPS) calculation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Regarding a triggering event that required down-round adjustment&#13;of the exercise price of the warrants during 2020 and 2019, see Note 13p and 13q, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Modifications to the terms of warrants that are classified&#13;as equity and remains to be classified in equity after the modification, are accounted for in a similar manner to share-based compensation&#13;guidance with respect to modifications. Accordingly, the incremental fair value from the modification (the change in the fair value&#13;of the warrant before and after the modification) is recognized in retained earnings as a deemed dividend (e.g., dividends to a&#13;particular class of equity holders).&lt;/p&gt;</wizp:SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;r.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Basic and diluted loss per share:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Basic loss per share is computed&#13;by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares of Common Stock&#13;outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Series&#13;A Preferred Stock) are considered in the computation of basic income (loss) per share using the two-class method. In periods of&#13;net loss, such participating securities are included in the computation, since the holders of such securities have a contractual&#13;obligation to share the losses of the Company (as the convertible Series A Preferred Stock do not have a right to receive any mandatory&#13;redemption amount and as they are entitled only to dividends on an as-converted basis together with the common shares).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In computing diluted loss per share,&#13;basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of options, warrants and&#13;rights for future investment issued or granted using the "treasury stock method" and upon the conversion of 2017 Loan&#13;and 2016 Loan using the "if-converted method", if the effect of each of such financial instruments is dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;For the year ended&#13;December&amp;#160;31, 2020 and 2019, all outstanding warrants, stock options and other convertible instruments have been excluded&#13;from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The loss and the weighted average&#13;number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2020 and 2019, is as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br /&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,450&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Add: Loss attributed to preferred stock (*)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;136&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend with respect to right for future investment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"&gt;Less: Deemed dividend due to down round adjustment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(267&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss applicable to stockholders of Common Stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,266&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,766&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Shares of Common Stock used in computing basic and diluted net loss per share&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,669,628&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,519,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net loss per share of Common Stock, basic and diluted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.32&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;During&#13;                                         the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase&#13;                                         Agreement (as defined below). These shares of preferred stock are participating securities. During&#13;                                         the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year&#13;                                         ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#13;                                         31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Number of shares:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Common shares used&#13;    in computing basic and diluted loss per share&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;16,669,628&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;10,519,682&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Preferred Stock and options excluded&#13;    from the calculations of diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;614,763&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,931,097&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;s.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other comprehensive loss&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The components of accumulated&#13;other comprehensive loss which resulted from foreign currency translation adjustment as of December&amp;#160;31, 2020 and 2019 were&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total &lt;br /&gt; accumulated &lt;br /&gt;&#13;    other &lt;br /&gt; comprehensive &lt;br /&gt; income (loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(73&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(73&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;t.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based compensation:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&lt;font style="font-size: 6pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Stock-based compensation to employees&#13;is accounted for in accordance with ASC 718, "Compensation - Stock Compensation" ("&lt;b&gt;ASC 718&lt;/b&gt;"), which&#13;requires estimation of the fair value of equity - based payment awards on the date of grant using an option pricing model. The&#13;value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;font style="font-size: 6pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Stock-based compensation expense&#13;is recognized for the value of awards granted based on the accelerated method over the requisite service period of each of the&#13;awards, net of estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent&#13;periods if actual forfeitures differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The fair value of stock options&#13;granted to Wize Israel employees was estimated using the Black- Scholes option pricing model, which requires a number of assumptions,&#13;of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated&#13;based upon historical volatilities of the Company on a weekly basis since the marketability of Wize Israel is less than the expected&#13;option term. The expected option term represents the period that Wize Israel's stock options are expected to be outstanding&#13;and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions.&#13;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The expected dividend yield assumption&#13;is based on Wize Israel's historical experience and expectation of no future dividend payouts. Wize Israel has historically&#13;not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Following the adoption of ASU 2018-07 in January 2018, all equity-classified&#13;nonemployee share-based payment are accounted for in accordance with the provisions of ASC 718 and accordingly, awards granted&#13;during 2019 and 2020 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;u.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Recent Accounting Pronouncements not adopted&#13;    yet&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 1.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;ASU 2016-13, "Financial Instruments &amp;#8211; Credit&#13;Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13")&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On June 2016, the FASB issued ASU Update 2016-13,&#13;"Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU&#13;2016-13") ASU Update 2016-13 revised the criteria for the measurement, recognition, and reporting of credit losses on financial&#13;instruments to be recognized when expected.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;On November 2019, the FASB issued&#13;ASU 2019-10, "Financial Instruments&amp;#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic&#13;842) &amp;#8211; Effective Dates," which, among other provisions, the effective date of ASU 2016-13 was amended as follows&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;1. Public&#13;business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (SRCs)&#13;as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;2. All&#13;other entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;As the Company is eligible to be considered as smaller reporting&#13;company, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal&#13;years, with early adoption permitted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The Company is in the process&#13;of evaluating the effect that ASU 2016-13 will have on the results of operations and financial statements, if any.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 1.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;ASU 2020-06&amp;#8212;Debt&amp;#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives&#13;and Hedging&amp;#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts&#13;in an Entity's Own Equity&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;In August 2020, the FASB issued&#13;ASU 2020-06&amp;#8212;Debt&amp;#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#8212;Contracts&#13;in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&#13;(ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,&#13;including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes from&#13;GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and beneficial conversion&#13;feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for&#13;such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life&#13;of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument&#13;contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt&#13;instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to&#13;calculate the impact of convertible instruments on diluted earnings per share (EPS).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;The amendments in ASU 2020-06&#13;are effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding&#13;entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021,&#13;including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning&#13;after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than&#13;fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify"&gt;ASU 2020-06 can be adopted&#13;on either a fully retrospective or modified retrospective basis. The adoption of this standard is not expected to result in a&#13;material impact to the Company's financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <wizp:ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;v.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent obligation with respect to future&#13;    revenues&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company's contingent&#13;obligation to payment of 37% of the future LO2A Proceeds, if any, was accounted for as long-term debt in accordance with the provisions&#13;of Accounting Standards Codification ("ASC") 470-10-25, "Sales of Future Revenues or Various other Measures&#13;of Income," which relates to cash received in exchange for payments of a specified percentage or amount of revenue or other&#13;measure of income of a particular product line, business segment, trademark, patent, or contractual right.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Such repayment obligations are&#13;contingent upon the receipt by the Company of any future proceeds from LO2A sales, license or other, as described in Note 5 below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company elected to measure&#13;the contingent payment obligation in its entirety, at its fair value (the "Fair Value Option") in accordance with&#13;ASC 825-10, "Financial Instruments" due to the variable and contingent nature of the repayment provisions of such&#13;financial liability.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="font-size: 7pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The fair value of such&#13;liability was measured upon its initial recognition at its fair value, based on the difference between the fair value of the&#13;marketable securities received by the Company, less the amount of cash paid by the Company. In subsequent periods, the fair&#13;value of the liability for contingent payment obligation is based on management estimate. As of December 31, 2020, the&#13;Company revalued the liability to its fair value with the assistance of an external valuation specialist, pursuant to the&#13;Company's estimations and assumptions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has determined&#13;that the inputs used in measuring the fair value of the contingent payment obligation fall within Level 3 in the fair value&#13;hierarchy which involves significant estimations and assumptions regarding any projected future proceeds from the LO2A,&#13;including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product&#13;into the U.S. market - 12%, the patent expiration date (2038), the operational profit estimated rate - 26%, the probabilities&#13;for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has determined that the inputs used in measuring&#13;the fair value of the contingent payment obligation fall within Level 3 in the fair value hierarchy which involves significant&#13;estimates and assumptions including, among others, any projected future proceeds from the LO2A, the risk-adjusted rate for discounting&#13;future cash flows and other relevant assumptions, see Note 10.&amp;#160;&amp;#160;Actual results could differ from the estimates made.&#13;Changes in fair value (including the component related to imputed interest), would be included in the consolidated statements of&#13;comprehensive loss as part of financial income (loss) under the heading "Changes in fair value of contingent payment obligation&#13;with respect to future revenues."&lt;/p&gt;</wizp:ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock>
    <wizp:LicensePurchaseObligationTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;LICENSE PURCHASE OBLIGATION&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In July 2017, Wize&#13;    Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 were reduced to $150&#13;    for 2018 and 2019. In addition, If Wize Israel would have obtained an FDA marketing license during 2019, the Company was also&#13;    required to pay Resdevco the remainder of the payment of 2019, however, such approval was not achieved in 2019. Consequently,&#13;    during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the&#13;    2018 minimum commitment, which was paid during the third quarter of 2018. In addition, during the third quarter of 2018 and&#13;    2019, the Company has recognized an amount of $150 as a liability in respect to the 2019 and 2020, respectively, minimum commitment.&#13;    Such amount was reflected as an expense under research and development expenses in 2018 and 2019 as applicable. In February&#13;    2019, the Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through&#13;    2021, and thereafter annual payments of $475,000 per year, and shall pay Resdevco $650,000 within two years after receipt&#13;    of FDA approval for eye drops utilizing the licensed technology.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following table&#13;    details the repayment dates of the remaining Minimal Commitment on the financial liability and the balance in the consolidated&#13;    Financial Statements:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold"&gt;Repayment dates:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; padding-left: 9pt"&gt;January 1, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;January 1, 2021 (see to Note 5)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Remaining balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt"&gt;Current liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Non-current liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:LicensePurchaseObligationTextBlock>
    <wizp:ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold"&gt;Repayment dates:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; padding-left: 9pt"&gt;January 1, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;January 1, 2021 (see to Note 5)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Remaining balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt"&gt;Current liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Non-current liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock>
    <wizp:OtherAccountsPayableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 7:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;ACCOUNTS PAYABLE&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;475&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Liability to HCW, see Note 10&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;700&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;131&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;278&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Trade payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;369&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:OtherAccountsPayableTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 8:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;CONVERTIBLE LOANS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On March 20, 2016, Wize Israel&#13;entered into an agreement (as amended, the "&lt;b&gt;2016 Loan Agreement&lt;/b&gt;") pursuant to which Rimon Gold Assets Ltd.&#13;("&lt;b&gt;Rimon Gold&lt;/b&gt;") extended a loan in the principal amount of up to NIS 2 million (approximately $531 according&#13;to an exchange rate at 2016 loan originate date), which bears interest at an annual rate of 4% (the "&lt;b&gt;2016 Loan&lt;/b&gt;").&#13;Pursuant to the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as&#13;defined below), the 2016 Loan had a maturity date of December 31, 2018. Regarding the modifications of the maturity date of the&#13;2016 Loan on October 2018, March 2019 and May 2019, see also Note 8a, 8b, 8c and 8d. Regarding loan extinguishment, refer to Note&#13;8e.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Under the 2016 Loan Agreement,&#13;Rimon Gold had the right, at its sole discretion, to convert any outstanding portion of the 2016 Loan, but not less than NIS 100,000&#13;(approximately $26 according to an exchange rate at 2016 loan origination date), into Wize Israel ordinary shares at a conversion&#13;price of NIS 15.2592 per share (approximately $3.84), subject to adjustments for stock splits and similar events set forth in&#13;the 2016 Loan Agreement. As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016&#13;Loan was adjusted to NIS 3.6 (approximately $0.96). As a result of the 2017 Loan Amendment, the aggregate principal amount of&#13;the 2016 Loan was adjusted to $531 and the conversion price per share for the 2016 Loan was adjusted to $0.9768.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In addition, under the 2016&#13;Loan Agreement, as modified by the 2017 Loan Agreement and the 2017 Loan Amendment, Rimon Gold had the right (the "&lt;b&gt;2016&#13;Investment Right&lt;/b&gt;"), until June 30, 2019, to invest up to $797, in the aggregate, at an agreed price per share, which&#13;was adjusted based on the Exchange Ratio (as defined in the Agreement and Plan of Merger with Bufiduck Ltd., a company formed&#13;under the laws of the State of Israel and our wholly owned subsidiary and Wize Israel) from NIS 20.4 (approximately $6.00) to&#13;NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment, from NIS 5.04 to $1.308 (subject to adjustments in case of&#13;stock splits or similar events).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Rimon Gold was entitled, under&#13;certain circumstances, to demand repayment of the 2016 Loan subject to certain conditions. However, as described in note 8e below&#13;the convertible loan was extinguished in November 2019.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On January 15, 2017, Wize Israel&#13;entered into the loan agreement (the "&lt;b&gt;2017 Loan Agreement&lt;/b&gt;", and together with the 2016 Loan Agreement the "&lt;b&gt;Loan&#13;Agreements&lt;/b&gt;") with Ridge Valley Corporation ("&lt;b&gt;Ridge&lt;/b&gt;"), and, by way of entering into assignments and&#13;assumption agreements following such date, also with Rimon Gold and Shimshon Fisher ("&lt;b&gt;Fisher&lt;/b&gt;", and together&#13;with Ridge and Rimon Gold, the "&lt;b&gt;2017 Lenders&lt;/b&gt;"), whereby each of the 2017 Lenders extended a loan in the principal&#13;amount of up to NIS 1 million (approximately $274 according to an exchange rate at 2017 loan originate date) and in the aggregate&#13;principal amount of up to NIS 3 million (approximately $822 according to an exchange rate at 2017 loan originate date), which&#13;bears interest at an annual rate of 4% (the "&lt;b&gt;2017 Loan&lt;/b&gt;", and together with the 2016 Loan, the "&lt;b&gt;Loans&lt;/b&gt;").&#13;Pursuant to the 2017 Loan Agreement and the 2017 Loan Amendment, the 2017 Loan had a maturity date of December 31, 2018. Regarding&#13;the modification of the maturity date of the 2017 loan in October 2018, March 2019 and May 2019, see also Note 8b, 8c and 8d.&#13;Regarding loan extinguishment, refer to Note 8e.&lt;/p&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Under the 2017 Loan&#13;Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017&#13;Loan, but no less than NIS 100,000 (approximately $28 according to an exchange rate at 2017 loan originate date), that the&#13;lender provided to Wize Israel (each such portion converted into Wize Israel ordinary shares at a conversion price per share&#13;equal to the lower of (1) NIS 24 (approximately $6.72) and (2) the lowest price per share of Wize Israel in any offering made&#13;by Wize Israel following the date of the 2017 Loan Agreement and through the date of such requested conversion, subject to&#13;adjustments for stock splits and similar events set forth in the 2017 Loan Agreement (the "&lt;b&gt;2017 Loan Conversion&#13;Price&lt;/b&gt;"). As a result of the private placement agreement, dated June 23, 2017 between Wize Israel, and certain&#13;investors (see also Note 12b to the 2018 consolidated Financial Statements), the 2017 Loan Conversion Price for Rimon Gold,&#13;Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion&#13;Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately&#13;$1.15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As a result of the 2017 Loan&#13;Amendment, the aggregate principal amount of the 2017 Loan was adjusted to $822 and the 2017 Loan Conversion Price was adjusted&#13;to $1.1112. See "2017 Loan Amendment" below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In addition, under the 2017&#13;Loan Agreement, as modified by the 2017 Loan Amendment, the 2017 Lenders had the right (the "&lt;b&gt;2017 Investment Right&lt;/b&gt;",&#13;and together with the 2016 Investment Right the "&lt;b&gt;Investment Rights&lt;/b&gt;"), until June 30, 2019, to invest up to&#13;$1,233, in the aggregate, at an agreed price per share equal to 120% of the applicable 2017 Loan Conversion Price, which was adjusted&#13;in December 2017, based on the 2017 Loan Amendment, to a fixed exercise price of $1.332 (subject to adjustments in case of stock&#13;splits or similar events).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Ridge was entitled, under certain&#13;circumstances, to demand repayment of the 2017 Loan subject to certain conditions. However, as described in note 8e below, the&#13;convertible loan was extinguished on November 2019. On April 21, 2019, Ridge transferred the loan and the 2017 Investment Right&#13;to Mobigo Inc, a company wholly owned by the Company's CEO, Noam Danenberg ("&lt;b&gt;Mobigo&lt;/b&gt;"). Mr. Danenberg&#13;waived a debt owed to him directly by Ridge (that did not involve the Company) as consideration for these derivative securities.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2017 Loan Amendment&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On December 21, 2017, the Company&#13;entered into an amendment (the "&lt;b&gt;2017 Loan Amendment&lt;/b&gt;") to the 2016 Loan Agreement and the 2017 Loan Agreement.&#13;Pursuant to&amp;#160;the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31,&#13;2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise&#13;period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June&#13;30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2017 Loan&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2016 Loan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Aggregate principal amount&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;822&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;531&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Conversion price per Company's share&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1.1112&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.9768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Aggregate maximum of Right to Future Investment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,233&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(**)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;797&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Exercise price per Company's share of Right to Future Investment&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1.332&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1.308&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Principal loan amount&#13;    of $274 for each of the three 2017 Lenders.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(**)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Maximum of Right&#13;    to Future Investment of $411 for each of the three 2017 Lenders.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Accordingly, each of the modified&#13;financial instruments was initially recorded at fair value. Then, the total fair value of the modified financial instruments related&#13;to the 2017 Loan and 2016 Loan (the "&lt;b&gt;Reacquisition Price&lt;/b&gt;") was allocated to the original financial instruments&#13;included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial instruments as of the&#13;date of the extinguishment. As a result, an aggregate amount of $2,104 was allocated to the 2016 Loan and an aggregate amount&#13;of $2,985 was allocated to the 2017 Loan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The 2017 Loan amendment was accounted&#13;for as an extinguishment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;2018 Loan Amendment&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In connection with the Purchase&#13;Agreement (as defined below), on October 19, 2018, the Company and Wize Israel entered into an amendment to the convertible loans&#13;outstanding as of that date (the "&lt;b&gt;2018 Loan Amendment&lt;/b&gt;"). Pursuant to the 2018 Loan Amendment, the maturity&#13;date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following&#13;the date that the registration statement the Company will file under the registration rights agreement dated October 22, 2018&#13;(the "&lt;b&gt;Registration Rights Agreement&lt;/b&gt;") covering the resale of all Common Stock, issued pursuant to the Purchase&#13;Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Series A Warrants, are registered&#13;for resale for investors who are not a party to the 2018 Loan Amendment, (b) 90 days following the date on which all securities&#13;issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement,&#13;and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the 2018 Loan Amendment, the expiration&#13;date of the Investment Rights under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan&#13;Agreements maturity date.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The 2018 Loan Amendment was accounted&#13;for as an extinguishment on October 19, 2018.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;According to ASC 470-50, each&#13;of the modified financial instruments were measured at fair value. Then, the Reacquisition Price was allocated to the original&#13;financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial&#13;instruments as of the date of the extinguishment. As a result, an aggregate amount of $2,314 was allocated to the 2016 Loan and&#13;its related right to future investment and an aggregate amount of $3,286 was allocated to the 2017 Loan and its related right&#13;to future investment.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The difference between the Reacquisition&#13;Price that was allocated to the Right to Future Investment amounting to $874 which was included in the 2016 Loan and its fair&#13;value as of that date amounting to $764 was recorded directly to additional paid in capital (as a deemed dividend in an amount&#13;of $110). In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $1,336 which&#13;was included in the 2017 Loan and its fair value as of that date amounting to $1,154, was recorded directly to additional paid-in&#13;capital (as a deemed dividend in an amount of $182). The difference between reacquisition price that was allocated to the 2017&#13;Loan and to the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as a loss&#13;on extinguishment amounting to $1,709 of the 2017 Loan and 2016 Loan.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The 2018 Loan Amendment became&#13;effective in the fourth quarter of 2018 and all of the accounting effects were recognized in the fourth quarter of 2018.&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;March 2019 Loan&#13;    Amendment&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On March 4, 2019, the Company&#13;and Wize Israel entered into another amendment to convertible loan agreements (the "&lt;b&gt;March 2019 Amendment&lt;/b&gt;")&#13;with Rimon Gold, Ridge and Fisher. Pursuant to the March 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement,&#13;and (ii) 2017 Loan Agreement were extended to May 31, 2019 from March 4, 2019. The parties also agreed that Rimon Gold's,&#13;Ridge's and Fisher's remaining 2016 Investment Rights (as of that date) under the 2016 Loan Agreement to invest up&#13;to $512.8, in the aggregate, at $1.308 per share, and the expiration date of Rimon Gold's, Ridge's and Fisher's&#13;remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at&#13;$1.332 per share, be extended from June 30, 2019 to November 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The March 2019 Amendment was accounted&#13;for as an extinguishment on March 4, 2019. Until that date, the 2017 Loan and the 2016 Loan were being accounted for under the&#13;terms of the 2018 Loan Amendment discussed above.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;According to ASC 470-50, each&#13;of the modified financial instruments were measured at fair value on the extinguishment date. Then, the Reacquisition Price was&#13;allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative&#13;fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $986 was allocated&#13;to the 2016 Loan and its related right to future investment and an aggregate amount of $1,423 was allocated to the 2017 Loan and&#13;its right to future investment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The difference between the Reacquisition&#13;Price that was allocated to the Right to Future Investment amounting to $237 which was included in the 2016 Loan and its fair&#13;value as of that date amounting to $192 was recorded directly to additional paid-in capital (as a deemed dividend in an amount&#13;of $45). In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $348 which was&#13;included in the 2017 Loan and its fair value as of that date amounting to $289, was recorded directly to additional paid-in capital&#13;(as a deemed dividend in an amount of $59). The difference between reacquisition price that was allocated to the 2017 Loan and&#13;to the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as gain on extinguishment&#13;amounting to $48 of the 2017 Loan and 2016 Loan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;May 2019 Amendment&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On May 31, 2019, the Company and Wize Israel entered into an&#13;additional extension to convertible loan agreements (the "&lt;b&gt;May 2019 Amendment&lt;/b&gt;") with Rimon Gold, Noam Danenberg&#13;and Fisher. Pursuant to the May 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement&#13;was extended to November 30, 2019 from May 31, 2019 (as previously described under the March 2019 Amendment). The parties also&#13;agreed that the expiration date of Rimon Gold's, Mr. Danenberg's and Fisher's remaining 2016 Investment Rights&#13;(as of that date) under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and Rimon Gold's,&#13;Mr. Danenberg's and Fisher's remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest&#13;up to $663.4, in the aggregate, at $1.332 per share, be extended from November 30, 2019 to May 31, 2021. As consideration for extending&#13;the maturity date of the loans, the Company issued to Rimon Gold, Mr. Danenberg (through Mobigo, his wholly owned company), and&#13;Fisher two-year warrants to purchase an aggregate of 868,034 shares of Common Stock at a fixed price of $1.10 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The May 2019 Amendment was accounted&#13;for as an extinguishment on May 31, 2019. Until that date, the 2017 Loan and the 2016 Loan were being accounted for under the&#13;terms of the March 2019 Loan Amendment discussed above.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;According to ASC 470-50, each&#13;of the modified financial instruments were measured at fair value on the extinguishment date. Then, the Reacquisition Price was&#13;allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative&#13;fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $1,015 was&#13;allocated to the 2016 Loan and an aggregate amount of $1,498 was allocated to the 2017 Loan and its related right to future investment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The difference between the Reacquisition&#13;Price that was allocated to the Right to Future Investment amounting to $94 which was included in the 2016 Loan and its fair value&#13;as of that date amounting to $61 was recorded directly to additional paid-in capital (as a deemed dividend in an amount of $33).&#13;In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $139 which was included&#13;in the 2017 Loan and its fair value as of that date amounting to $91, was recorded directly to additional paid-in capital (as&#13;a deemed dividend in an amount of $48). The difference between reacquisition price that was allocated to the 2017 Loan and to&#13;the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as loss on extinguishment&#13;amounting to $926 of the 2017 Loan and 2016 Loan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;November 2019&#13;    Amendment&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Effective November 29, 2019, the&#13;Company and Wize Israel entered into an amendment to convertible loan agreements (the "&lt;b&gt;November 2019 Amendment&lt;/b&gt;")&#13;with Rimon Gold, Mobigo and Fisher.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pursuant to the November 2019&#13;Amendment, the Company repaid in cash approximately $760 of the $1,520 ($1,353 of principal and $167 accrued interest) outstanding&#13;under the loans on November 29, 2019 and Rimon Gold, Mobigo, and Fisher agreed to convert the remaining outstanding amounts of&#13;the loans at a later date. On December 13, 2019, the Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196&#13;shares of Common Stock upon conversion of the loans at a reduced conversion price of $0.27 per share and issued the December 2019&#13;Warrants to purchase an aggregate of 5,632,392 shares of Common Stock at an exercise price of $0.27.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The December 2019 Warrants have a term of five years and will&#13;be exercisable five days following the public announcement of positive clinical data results for LO2A. In addition, the parties&#13;agreed that effective December 13, 2019, the exercise price or conversion price of all other convertible securities (rights for&#13;future investment) previously issued to Rimon Gold, Mobigo, and Fisher in connection with the loans (the "&lt;b&gt;Existing Convertible&#13;Securities&lt;/b&gt;") shall be adjusted to $0.27 per share&amp;#160;and that the aggregate number of shares of Common Stock issuable&#13;upon exercise or conversion of a lender's Existing Convertible Securities shall be reduced in accordance with the percent&#13;of such lender's conversion of its outstanding loan. In addition, it was agreed that in any case when the exercise price&#13;of the October 2018 Warrants is reduced as a result of dilutive issuance to an exercise price lower than the exercise or conversion&#13;price of the Investment Rights granted under the Loan Agreements, than the exercise or conversion price of the Investment Rights&#13;shall be reduced to the new October 2018 Warrants exercise price ("&lt;b&gt;New Exercise Price&lt;/b&gt;"). As of December 31,&#13;2019, the New Exercise Price of such Investment Rights was $0.16. See Note 13n regarding the modification of the exercise price&#13;of such warrants and their exercise into ordinary shares.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The difference between the aggregate&#13;reacquisition price of the loans (&lt;i&gt;i.e&lt;/i&gt;, the cash, the fair value of the shares and the December 2019 Warrants and the incremental&#13;fair value related to the existing convertible loans) approximate $1,619 and the carrying amount of the convertible loans (principal&#13;and accrued interest) was recognized as a loss from extinguishment in an amount of $99 as part of financial income (expense)&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Management considered the provisions&#13;of ASC 815-40 and has determined that the December 2019 Warrants are considered indexed to the Company's stock and that&#13;all other relevant criteria required for equity classifications are met. Accordingly, it was determined that the December 2019&#13;Warrants are eligible for equity classification.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The below table describes the roll forward of 2017 Loan and&#13;2016 Loan for the year ended December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 88%; text-align: left"&gt;Opening balance (including accrued interest)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans prior to 2018 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans following 2018 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(641&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &amp;#8211; March 2019 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,873&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Accrued interest on 2017 Loan and 2016 Loan&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amount allocated to 2016 Loan and 2017 Loan based on modified terms &amp;#8211; March 2019 modification&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans following March 2019 modifications&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(413&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &amp;#8211; May 2019 extension&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,353&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Amount allocated to 2016 Loan and 2017 Loan based on modified terms &amp;#8211; May 2019 extension&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Amortization of premium related to convertible loans &amp;#8211; May 2019 extension&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(203&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;November 2019 repayment in cash and Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,520&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 11:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;TAXES ON INCOME &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax rates applicable to the Company:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On December 22, 2017, the Tax&#13;Cuts and Jobs Act was enacted and made key changes to US tax law which include (i) establish a flat corporate income tax rate&#13;of 21% to replace previous rates that ranged from 15% to 39% and eliminates the corporate alternative minimum tax; (ii) create&#13;a territorial tax system rather than a worldwide system, which will generally allow companies to repatriate future foreign source&#13;earnings without incurring additional US taxes by providing a 100% exemption for the foreign source portion of dividends from&#13;certain foreign subsidiaries; (iii) subject certain foreign earnings on which US income tax is currently deferred to a one-time&#13;transition tax; (iv) create a "minimum tax" on certain foreign earnings and a new base erosion anti-abuse tax that&#13;subjects certain payments made by a US company to a related foreign company to additional taxes; (v) create an incentive for US&#13;companies to sell, lease or license goods and services abroad by effectively taxing them at a reduced rate; (vi) reduce the maximum&#13;deduction for Net Operating Loss ("&lt;b&gt;NOL&lt;/b&gt;") carryforwards arising in tax years beginning after 2017 to a percentage&#13;of the taxpayer's taxable income, allows any NOLs generated in tax years beginning after December 31, 2017 to be carried&#13;forward indefinitely and generally repeals carrybacks;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;(vii) elimination of foreign tax&#13;credits or deductions for taxes (including withholding taxes) paid or accrued with respect to any dividend to which the new exemption&#13;applies, but foreign tax credits will continue to be allowed to offset tax on foreign income taxed to the US shareholder subject&#13;to limitations; (viii) limit the deduction for net interest expense incurred by US corporations, (ix) allow businesses to immediately&#13;write off (or expense) the cost of new investments in certain qualified depreciable assets made after September 27, 2017 (but&#13;would be phased down starting in 2023); (x) may require certain changes in tax accounting methods for revenue recognition; (xi)&#13;repeal the Section 199 domestic production deductions beginning in 2018; (xii) eliminate or reduce certain deductions, exclusions&#13;and credits, and adds other provisions that broaden the tax base.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company has calculated an&#13;estimate of the impact of the Tax Act in our year-end income tax provision in accordance with our understanding of the Tax Act&#13;and guidance available as of December 31, 2020. The provisional amount related to the re-measurement of the Company's net&#13;U.S. deferred tax asset, based on the rate at which they are now expected to reverse in the future, considered immaterial, but&#13;which was fully and equally offset by a corresponding reduction in the Company's valuation allowance. The effect of the&#13;change in federal corporate tax rate from 39% to 21% is subject to change based on resolution of estimates used in determining&#13;the amounts of deferred tax assets and liabilities that were re-measured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tax rates applicable to Wize Israel and OcuWize:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In December 2016, the Israeli&#13;Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018&#13;Budget Years), a reduction of the corporate tax rate in 2017 from 25% to 24%, and in 2018 and thereafter from 24% to 23%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Accordingly, taxable income of&#13;the Israeli Subsidiary is subject to the Israeli Corporate tax rate,which was 23% in 2020 and 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net operating loss carry forward:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2020, the Company has NOL carry forwards&#13;for federal income tax purposes of approximately $7,570.&amp;#160; The application of the NOL carry forwards is limited due to IRC&#13;section 382 limitation. The annual NOL carry forward (pre-merger, approximately $4,784) is limited to $10.965 per year.&amp;#160;The&#13;balance as of December 31, 2020 of the NOL carry forwards of approximately $4,786 is available in full.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December&amp;#160;31, 2020, the Company's subsidiaries,&#13;Wize Israel and OcuWize have accumulated losses for tax purposes in the amount of approximately $5,476 and $5,366 respectively,&#13;which may be carried forward and offset against taxable income in the future for an indefinite period in Israel.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of December 31, 2020, Wize Israel's&#13;    2011 tax assessment was considered final. OcuWize has not received final tax assessment since its inception.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Loss before taxes on income consists of the&#13;    following:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-indent: -10pt; padding-left: 10pt"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,318&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Foreign (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(12,160&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11,322&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Relates to Wize Israel and OcuWize.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: 0.7in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;f.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred income taxes:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Deferred income taxes reflect&#13;the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes&#13;and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Reserves and allowances&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Net deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,165&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,108&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,165&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,108&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In assessing the realization of&#13;deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets&#13;will not be realized.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The ultimate realization of the&#13;deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences&#13;are deductible and NOLs are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance&#13;at December&amp;#160;31, 2020 and 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;g.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Below is the reconciliation&#13;    between the "theoretical" income tax expense or benefit, assuming that all the income was taxed at the regular&#13;    tax rate applicable to companies in Israel and the taxes recorded in the statements of comprehensive loss in the reporting&#13;    year:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss before taxes on income, as reported in the statements of comprehensive loss&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(4,929&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(3,450&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Theoretical tax benefit on this loss&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;725&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Expenses not deductible for tax purposes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(52&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(86&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(639&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <wizp:IncomeTaxRatePercentageDescription contextRef="From2017-12-01to2017-12-22">(i) establish a flat corporate income tax rate of 21% to replace previous rates that ranged from 15% to 39% and eliminates the corporate alternative minimum tax; (ii) create a territorial tax system rather than a worldwide system, which will generally allow companies to repatriate future foreign source earnings without incurring additional US taxes by providing a 100% exemption for the foreign source portion of dividends from certain foreign subsidiaries; (iii) subject certain foreign earnings on which US income tax is currently deferred to a one-time transition tax; (iv) create a "minimum tax" on certain foreign earnings and a new base erosion anti-abuse tax that subjects certain payments made by a US company to a related foreign company to additional taxes; (v) create an incentive for US companies to sell, lease or license goods and services abroad by effectively taxing them at a reduced rate; (vi) reduce the maximum deduction for Net Operating Loss ("NOL") carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer's taxable income, allows any NOLs generated in tax years beginning after December 31, 2017 to be carried forward indefinitely and generally repeals carrybacks; (vii) elimination of foreign tax credits or deductions for taxes (including withholding taxes) paid or accrued with respect to any dividend to which the new exemption applies, but foreign tax credits will continue to be allowed to offset tax on foreign income taxed to the US shareholder subject to limitations; (viii) limit the deduction for net interest expense incurred by US corporations, (ix) allow businesses to immediately write off (or expense) the cost of new investments in certain qualified depreciable assets made after September 27, 2017 (but would be phased down starting in 2023); (x) may require certain changes in tax accounting methods for revenue recognition; (xi) repeal the Section 199 domestic production deductions beginning in 2018; (xii) eliminate or reduce certain deductions, exclusions and credits, and adds other provisions that broaden the tax base.</wizp:IncomeTaxRatePercentageDescription>
    <wizp:CorporateAndDeferredTaxDescription contextRef="From2020-01-01to2020-12-31"> The provisional amount related to the re-measurement of the Company's net U.S. deferred tax asset, based on the rate at which they are now expected to reverse in the future, considered immaterial, but which was fully and equally offset by a corresponding reduction in the Company's valuation allowance. The effect of the change in federal corporate tax rate from 39% to 21% is subject to change based on resolution of estimates used in determining the amounts of deferred tax assets and liabilities that were re-measured.</wizp:CorporateAndDeferredTaxDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 13:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;STOCKHOLDERS' EQUITY &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Common Stock&#13;    confers upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in&#13;    the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 71px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 7, 2019, the Company entered&#13;        into a joint venture agreement with Cannabics traded on the Over-The-Counter (OTC) markets in the United States.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the agreement, the parties&#13;        agreed to form a new joint venture company for the purpose of researching, developing and administering cannabinoid formulations&#13;        to treat ophthalmic conditions. The new company will initially be owned 50% each by the Company and Cannabics.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 1, 2019, the Company's joint&#13;        venture agreement with Cannabics became effective. Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000&#13;        shares of its Common Stock and Cannabics issued to the Company 2,263,944 shares of Cannabics' common stock, which represented&#13;        a holding percentage less than 5 percent of Cannabic's then outstanding share capital. The joint venture currently has no&#13;        assets or liabilities and has not started conducting any of its planned operations.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the foregoing, the Company&#13;        relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions&#13;        not involving a public offering.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the share issuance, the&#13;        Company recorded an amount of $765 as an increase to Common Stock (at par value) and additional paid-in capital with a corresponding&#13;        amount of $765 as an investment in marketable securities. Such amount was based on the fair value of Cannabics' shares as&#13;        of the date at which the agreement became effective. The investment in marketable securities was remeasured in subsequent periods&#13;        at fair value with changes carried to profit or loss. During the year ended December 31, 2019 the Company recognized loss of $501&#13;        due to the change in fair value from March 1, 2019 to December 31, 2019.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 13, 2019, the Company determined&#13;        to terminate all activities under the joint venture until such time as the parties jointly determine that no uncertainty remains&#13;        with respect to U.S. federal enforcement of the cannabis industry.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;c.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In March 2019, the Company issued 60,000 shares of Common Stock to certain investors in exchange for conversion of 60 shares of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 71px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;d.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt"&gt;In April 29,&#13;        2019, the Company issued 336,000 shares of Common Stock to certain investors in exchange for conversion of 336 shares&#13;        of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt"&gt;In May 7,&#13;        2019, the Company issued 336,000 shares of Common Stock to certain investors in exchange for conversion of 336 shares&#13;        of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; text-indent: 0.9pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;e.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; text-indent: 0.9pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;    April 23, 2019, the Company's Board appointed Mark Sieczkarek as the Company's Chairman of the Board (the "&lt;b&gt;Chairman&#13;    Appointment&lt;/b&gt;").&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; text-indent: 0.9pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;f.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; text-indent: 0.9pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;    July 18, 2019, the Company issued to a consultant, 6,945 shares of Common Stock in exchange for its services provided in the&#13;    three months ended September 30, 2019. The Company recognized an amount of $3 in the year ended December 31, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;g.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; text-indent: 0.9pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;    August 20, 2019, the Company issued to a consultant, 45,000 shares of Common Stock in exchange for its services provided in&#13;    2019. The Company recognized an amount of $18 in the year ended December 31, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;h.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection&#13;        with Mr. Sieczkarek's appointment, the Company and Mr. Sieczkarek entered into a Chairman Agreement (the "&lt;b&gt;Chairman&#13;        Agreement&lt;/b&gt;") whereby Mr. Sieczkarek shall receive 202,399 restricted stock units ("&lt;b&gt;RSUs&lt;/b&gt;") and options&#13;        to purchase 102,222 shares of the Company's Common Stock at an exercise price of $2.00 per share (the "Chairman Awards").&#13;        The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and subsequently in seven equal quarterly installments&#13;        commencing July 1, 2019. The Chairman Agreement has an initial term of two years (the "Term") and provides that in&#13;        the event of a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as&#13;        of that date. The Chairman Agreement also contains standard representations and warranties regarding confidential information,&#13;        non-competition and non-solicitation.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Total value of&#13;        the options granted is $29, which is recorded quarterly over the vesting period. The total value of the share based expense related&#13;        to the RSU is $185, which is being recognized ratably over the vesting period.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On August 11, 2020, the Company's Board of Directors approved&#13;the equity grant of 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of&#13;Directors of the Company, see also note 13p below.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On January 6,&#13;        2020, April 15, 2020, July 1, 2020 and October 1, 2020 the Company issued 25,300, 25,300, 25,300 and 44,050, respectively, shares&#13;        to the Chairman pursuant to the agreement above following the vesting of certain portions of the RSUs.&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company&#13;recognized $46 during the year ended December 31, 2020 as a share-based expense in connection to the RSU's and options granted.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;i.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; text-indent: 0.9pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;    April 2019, Mr. Danenberg purchased directly from Ridge all Ridge's rights under the second convertible loan agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;j.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 14, 2019, the Company issued&#13;        to a consultant, 135,000 shares of restricted Common Stock which is due and issuable according to the following schedule:&#13;        25% as of May 1, 2019 and additional 25% every quarter following May 1, 2019. The aggregate fair value of these shares&#13;        of RSUs at grant date issued was $106, and is being recognized over a period of 1 year following May 1, 2019.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company recognized $104 and $2 during the years ended December&#13;31, 2019 and 2020, respectively as a share-based expense in connection to the RSU's.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;k.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; text-indent: 0.9pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On&#13;    May 15, 2019, the Company granted to a consultant, 10,000 fully vested RSUs. The Company determined the fair value of the&#13;    RSUs to be the quoted market price of the Company's Common Stock on the date of issuance. The aggregate fair value of&#13;    these RSUs issued at grant date was $5, and was recognized during the year ended December 31, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;l.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On May 19, 2019,&#13;    the Company granted to one of its directors certain options exercisable into 30,000 shares of Common Stock with an exercise&#13;    price of $0.58 per share. The options will vest monthly over a period of six (6) months. The Company recognized $13 of&#13;    share-based compensation expense during year ended December 31, 2019.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;m.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On December 13,&#13;    2019, the Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196 shares of Common Stock as part of the&#13;    extinguishment of the loans, see also Note 8e.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2019, the Company&#13;        entered into a securities purchase agreement (the "2019 Purchase Agreement") with an accredited investor.&#13;        Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase&#13;        from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27&#13;        per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to&#13;        the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock.&#13;        The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public&#13;        announcement of positive clinical data results for LO2A.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The December 2019 Warrants will&#13;        be exercisable on a cashless basis in the event that, six months after issuance, there is not an effective registration&#13;        statement for the resale of the shares underlying the December 2019 Warrants.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management considered the provisions&#13;        of ASC 815-40, and has determined that the December 2019 Warrants are considered indexed to the Company's stock&#13;        and that all other relevant criteria required for equity classification are met. Accordingly, it was determined that the&#13;        December 2019 Warrants are eligible for equity classification.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 2019, the December 2019 Warrants exercise price&#13;was reduced to $0.16 due to the triggering of certain down-round anti-dilution protection or price protection features included&#13;in the original terms of these warrants. The difference between the fair value of the warrants and the incremental fair value resulting&#13;from the triggering of the above mentioned features was recognized as a deemed dividend and as an increase of the loss applicable&#13;to common stockholders in an amount of $15. See also note 13p and 13q below.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;o.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On August 11, 2020, the Company's Board of Directors approved&#13;the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of&#13;the Board of Directors of the Company and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each&#13;of the other three non-executive directors. The aggregate fair value of these shares of RSUs at grant date issued was $73, and&#13;is being recognized over a period of 2 years following August 11, 2020. The Company recognized $34 during the year ended December&#13;31, 2020, as a share-based expense in connection to the RSU's.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;p.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 8, 2020, the Company&#13;        entered into exchange agreements (the "Exchange Agreements") with certain holders (the "Series A&#13;        Holders") of 3,000,000 Series A Warrants.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the Exchange&#13;        Agreements, the Holders agreed to surrender their Warrants for cancellation and received, as consideration for such cancellation,&#13;        an aggregate of 3,000,000 shares of common stock. The securities issued pursuant to the foregoing are exempt&#13;        from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant&#13;        to Section 3(a)(9) and/or Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder&#13;        because, among other things, the transaction did not involve a public offering and the warrant holders are accredited&#13;        investors. The difference between the fair value of the warrants before the exchange and the fair value of the shares&#13;        was recognized as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $63.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;q.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 24, 2020, the Company entered into an agreement (the&#13;"Agreement") with certain holders (the "Series A Holders") representing a majority of the Series A Warrants.&#13;Pursuant to the terms of the Agreement, the Company and Series A Holders mutually agreed that the Company would voluntarily reduce&#13;the exercise price of the Warrants to $0.001 per share until January 7, 2021, after which such exercise price shall revert back&#13;to $0.16 per share.&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the adjustment&#13;        to the exercise price of the Series A Warrants, the exercise price of the warrants issued in November 2017 (the "2017&#13;        Warrants"), the placement agent warrants issued in October 2018 (the "2018 Placement Agent Warrants"),&#13;        the warrants issued to certain lenders in May 2019 (the "May 2019 Warrants"), the warrants issued to certain&#13;        lenders in November 2019 (the "November 2019 Warrants"), the warrants issued to certain purchasers from the&#13;        private placement in December 2019 (the "December 2019 Warrants") and certain investment rights issued on&#13;        January 2017 (the "Investment Rights") were also adjusted to reflect a reduced exercise price of $0.001 per&#13;        share (collectively, the "Warrant Adjustments"). As a result of the Warrant Adjustments, on December 29, 2020&#13;        an aggregate of 13,332,654 shares of common stock were issued as a result of the exercise of such warrants, each on a&#13;        cashless basis. Among others, such warrant exercises also included warrants beneficially owned by our Chief Executive&#13;        Officer, Noam Dannenberg. The difference between the fair value of the warrants before and after the adjustment was recognized&#13;        as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $327.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;r.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;Stock based-compensation:&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;u&gt;The 2012 Plan&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In 2012, the Company's Board&#13;approved the adoption of the 2012 Stock Incentive Plan (the "&lt;b&gt;2012 Plan&lt;/b&gt;").&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;An Israeli annex was subsequently&#13;adopted in 2013 to comply with the requirements set by the Israeli law in general and in particular with the provisions of section&#13;102 of the Israeli tax ordinance. Under the 2012 Plan and Israeli annex, the Company may grant its officers, directors, employees&#13;and consultants, stock options, restricted stocks and RSUs of the Company. Each Stock option granted shall be exercisable at such&#13;times and terms and conditions as the Company's Board may specify in the applicable option agreement, provided that no option&#13;will be granted with a term in excess of 10 years. Upon the adoption of the 2012 Plan, the Company reserved for issuance 45,370&#13;shares of Common Stock, $0.001 par value each.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2020, the Company&#13;has 40,474 shares of Common Stock available for future grant under the 2012 Plan. As of December 31, 2020, under the 2012 Plan,&#13;the Company had options exercisable into 4,896 shares of Common Stock outstanding and exercisable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;u&gt;The 2018 Plan&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On February 22, 2018, the Company's&#13;Board approved the adoption of the 2018 Stock Incentive Plan (the "&lt;b&gt;2018 Plan&lt;/b&gt;"), including an Israeli annex&#13;to comply with Israeli law, in particular the provisions of section 102 of the Israeli Income Tax Ordinance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the 2018 Plan, the Company&#13;may grant its employees, directors, consultants and/or contractors' stock options, shares of Common Stock, restricted stock&#13;and RSUs of the Company. The Compensation Committee of the Board is currently serving as the administrator of the 2018 Plan. Each&#13;stock option granted is exercisable, unless otherwise determined by the administrator, in twelve equal installments over the three&#13;- year period from the date of grant. Unless otherwise determined by the administrator, the term of each award will be seven years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The exercise price per share subject&#13;to each option will be determined by the administrator, subject to applicable laws and to guidelines adopted by the Board from&#13;time to time. In the event the exercise price is not determined by the administrator, the exercise price of an option will be&#13;equal to the closing stock price of the Common Stock on the last trading day prior to the date of grant.&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Upon the adoption of the 2018&#13;Plan, the Board reserved for issuance 435,053 shares of Common Stock. On August 15, 2018, the Company amended the 2018 Plan to&#13;increase the number of shares issuable under the Plan to 2,500,000 shares of Common Stock. In addition, the Board approved to&#13;increase the number of shares issuable under the Plan on the first day of each fiscal year beginning with the 2019 fiscal year,&#13;by an amount equal to the lesser of (i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately&#13;preceding fiscal year.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2020, the Company&#13;has 2,184,813 shares of Common Stock available for future grant under the 2018 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Through December 31, 2020, 290,222&#13;options to directors, officers and consultants are outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;u&gt;Grants under the 2018 Plan&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On April 4, 2018,&#13;    the Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with&#13;    an exercise price of $3.59 per share. The options will vest quarterly over a period of 36 months. The Company recognized $51&#13;    and $154 during the year ended December 31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock-based compensation:&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 31, 2019, the Company's&#13;        Board approved the following:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 120px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;To grant to each&#13;    of Company's four directors 100,000 RSUs. The RSUs will vest quarterly over a period of 24 months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 120px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;To grant to each&#13;    its officers (Company's Chief executive officer and to Company's Chief financial officer)&amp;#160;140,000 RSU's.&#13;    The RSU's will vest quarterly over a period of 24 months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company determined the fair&#13;value of the RSUs to be the quoted market price of the Company's Common Stock on the date of grant. The aggregate fair value&#13;of these RSUs issued was $476. The Company is recognizing this amount ratably over the vesting period of 24 months following March&#13;31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In connections with the above,&#13;on July 25, 2019 (the initial quarterly vesting date) the Company issued 85,000 Common shares to its officers and directors.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company recognized $132 and&#13;$337 during the year ended December 31, 2020 and 2019 respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;On April 18, 2019,&#13;    the Company granted to its employee, 21,600 options exercisable into 21,600 shares of Common Stock at an exercise price of&#13;    $0.75 per share of Common Stock. The options began vesting quarterly over a period of 36 months commencing April 18, 2019.&#13;    The Company recognized $2 during the year ended December 31, 2019 as a share-based expense. The total value of the share based&#13;    expense is $10, which is recorded quarterly over the vesting period. Since the Company has terminated its employment agreement&#13;    in December 2019, as of December 31, 2020, all of the options were forfeited. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions related to the grant of options to employees and&#13;directors under the 2012 Plan during the year ended December&amp;#160;31, 2020 and 2019, were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;190.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;216&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding and exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,352&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;81.81&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.32&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;190.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Options outstanding and exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,896&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;190.7&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.86&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions related to the grant&#13;of options to employees and directors under the 2018 Plan during the year ended December&amp;#160;31, 2020 and 2019, were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%"&gt;Options outstanding as of December 31, 2019&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;352,072&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(61,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options outstanding as of December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;290,222&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.64&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options exercisable as of December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;255,459&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.82&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number &lt;br /&gt; of options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise &lt;br /&gt; price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; remaining &lt;br /&gt; contractual &lt;br /&gt; life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%"&gt;Options outstanding as of December 31, 2018&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;255,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;153,822&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(56,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options outstanding as of December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;352,072&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.91&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.72&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;Options exercisable as of December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;181,799&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.75&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.72&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;At December 31, 2020, there was&#13;$3 of total unrecognized compensation cost related to non-vested option grants that is expected to be recognized over a weighted-average&#13;period of 0.5 years. The intrinsic value of options outstanding and exercisable at December 31, 2020 was not significant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company uses the Black-Scholes&#13;option-pricing model to estimate fair value of grants of stock options. With respect to grants of options, the risk-free rate&#13;of interest was based on the U.S. Treasury rates appropriate for the contractual term of the grant, expected volatility was calculated&#13;based on average volatility of the Company and five representative companies and expected term of stock-based grants of 7 years.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <wizp:SelectedStatementsOfOperationsDataTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 14:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;SELECTED STATEMENTS OF OPERATIONS DATA&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;a.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;General and administrative expenses:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Overseas travel&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;103&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;246&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;688&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Rent and office maintenance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Payroll and benefits&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;834&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;470&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Professional services and consultation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;517&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;953&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Taxes and tolls&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Director salary and insurance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;208&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,008&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,678&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;b.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Financial expense, net:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Financial income:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Income from sale and revaluation of marketable securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Exchange rate gains, net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Gain from completion of milestone closing&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;847&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Gain from settlement shares&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Amortization of premium related to convertible loans&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,257&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total financial income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Financial expense:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued interest on convertible loans&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued interest on loans&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss from recognition of mandatorily redeemable Series B Preferred Stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss from revaluation of contingent obligation with respect to future revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revaluation of mandatorily redeemable Series B Preferred Stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(597&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Bonus transaction costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(350&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Change in the fair value of marketable securities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Bank commissions and exchange rates&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss from extinguishment of convertible loans (Note 8c, 8d, 8e)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(977&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,552&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total financial expense, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,487&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(280&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:SelectedStatementsOfOperationsDataTextBlock>
    <wizp:ScheduleOfFinancingExpensesNetTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;Year ended &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Financial income:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 76%; text-align: left"&gt;Income from sale and revaluation of marketable securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Exchange rate gains, net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Gain from completion of milestone closing&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;847&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Gain from settlement shares&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Amortization of premium related to convertible loans&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,257&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total financial income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Financial expense:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued interest on convertible loans&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued interest on loans&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss from recognition of mandatorily redeemable Series B Preferred Stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss from revaluation of contingent obligation with respect to future revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Revaluation of mandatorily redeemable Series B Preferred Stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(597&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Bonus transaction costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(350&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Change in the fair value of marketable securities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Bank commissions and exchange rates&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss from extinguishment of convertible loans (Note 8c, 8d, 8e)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(977&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,631&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,552&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total financial expense, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,487&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(280&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</wizp:ScheduleOfFinancingExpensesNetTableTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 16:-&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;The Cosmos Transaction&lt;/b&gt;:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On&#13;December 30, 2020, the Company entered into the Bid Agreement with Cosmos, which was subsequently amended on January 18, 2021 for&#13;the primary purpose of simplifying the Offer structure. Under the Bid Agreement (as amended), the parties agreed that the Company&#13;would commence the Offer, an off-market takeover offer under applicable Australian laws, to acquire all of the Cosmos Shares in&#13;exchange for 61.11 Company's shares of common stock for each Cosmos Share, being the Offer Consideration.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under&#13;the Bid Agreement, 22.33 Company shares of common stock out of the Offer Consideration will be "Restricted Stock" subject&#13;to a Stock Restriction Agreement to be entered into at the Closing Date and 38.78 Company shares of common stock will be "Covered&#13;Securities". A Cosmos shareholder who accepts the Offer (an "Accepting Shareholder") will not be permitted to&#13;sell or encumber their Restricted Stock until December 31, 2021 (the "Milestone Date"). In addition, an Accepting Shareholders&#13;may not exercise voting rights in respect of Restricted Stock from the date of issuance of the Offer Consideration until the Milestone&#13;Date. An Accepting Shareholder is entitled to sell or encumber its Covered Securities. However, if (subject to certain limited&#13;exceptions) an Accepting Shareholder sells or encumbers any of its Covered Securities before the Milestone Date, the Company has&#13;an option to repurchase a pro rata proportion of the Restricted Stock for the lower of $0.0001 and the fair market value of the&#13;Restricted Stock. The Restricted Stock (and any dividends thereon) will be held by the Company in escrow for the Accepting Shareholder's&#13;benefit until such time as the Restricted Stock is repurchased by Wize or all restrictions thereon lapse. If any Restricted Stock&#13;is repurchased under the Company's repurchase option, a pro rata proportion of the dividend on the Restricted Stock shall&#13;be retained by the Company.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Immediately&#13;following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos shareholders are expected&#13;to own approximately 87.65% of the outstanding common stock of the Company, while the Company's existing stockholders are expected&#13;to remain the owners of approximately 10.75% of the outstanding common stock of the Company, each on a fully diluted basis and&#13;including warrants to be issued to the Company's financial advisor to the transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Pursuant to the Bid Agreement,&#13;prior to the Closing Date, the Company will enter into a Contingent Value Rights Agreement (the "CVR Agreement") with&#13;Cosmos, certain of the Company's subsidiaries (the "Wize Subsidiaries"), a person designated by the Company&#13;prior to the Closing Date as the Holders' Representative (as defined herein), and the Rights Agent (as defined therein).&#13;Pursuant to the CVR Agreement, at the Closing Date, each Wize pre-Closing security holder will receive one non-transferable CVR&#13;for each outstanding share of common stock of the Company and for each share of common stock of the Company underlying other convertible&#13;securities and warrants, held as of 4:01&amp;#160;p.m. Eastern Time on the day immediately&amp;#160;&lt;font style="background-color: white"&gt;before&#13;the Effective Time (as defined in the CVR Agreement). Each CVR will represent the right to receive a pro rata share of any consideration&#13;that may be received by the Company or the Company Subsidiaries in connection with the Company's existing LO2A business.&#13;In particular, CVR holders will be entitled to any consideration (whether cash, stock, assets or otherwise) that the Company or&#13;the Company Subsidiaries (or any of its Affiliates or shareholders) receives in connection with an LO2A Transaction, which,&#13;as defined in the CVR Agreement, includes (i) a sale of any of the Company Subsidiaries to a third party and/or (ii) the partnering,&#13;licensing, sublicensing, distribution, reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third&#13;party, less transaction expenses and customary deductions as detailed in the CVR agreement, including a deduction of up to $300,000&#13;that the Company Subsidiaries undertook to incur in the development of the LO2A Technology at the request of the Holders'&#13;Representative.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="background-color: white"&gt;The&#13;Bid Agreement also contains certain covenants to be performed at or following the Closing Date, including, among others, (i) agreement&#13;that the Board of Directors of the Company immediately following the Closing Date will consist, subject to certain exceptions,&#13;of three members to be designated by Cosmos and one member to be designated by the Company; (ii) covenants that the Company will&#13;seek, following the Closing Date, stockholder approval to be renamed Cosmos Capital, Inc. (or similar name), and to effect a reverse&#13;share split of the Company's common stock; (iii) covenants that the Company will establish an incentive compensation program&#13;with respect to 40,000,000 shares of its common stock, to be granted promptly following the Closing Date, in the form of performance-based&#13;RSUs, performance rights or indeterminate rights based on the performance milestone criteria and allocation set in the Bid Agreement&#13;(the "Post-Closing Incentive Plan"), 50% of which are to be granted to personnel specified by the Company prior to&#13;the Closing Date and the remainder to be granted to personnel of Cosmos (see also Item 9B below); (iv) an obligation by the Company&#13;to terminate or procure the termination of each of the current employment or consulting agreements of the Company with Mr. Mark&#13;Sieczkarek, the Chairman of the Company Board of Directors, Mr. Noam Danenberg, the Chief Executive Officer of the Company, Mr.&#13;Or Eisenberg, the Chief Financial Officer of the Company, and another part-time employee related to Mr. Danenberg; and (v) an&#13;obligation by the Company to use its reasonable commercial efforts to enter into new, part time, consulting agreements with Mr.&#13;Danenberg and Mr. Eisenberg in a form to be agreed between the Company and Cosmos.&amp;#160;In this respect, it should be noted that&#13;the Company, Cosmos and each of Mr. Danenberg and Mr. Eisenberg agreed on the form of such consulting agreements, whereby Mr.&#13;Danenberg and Mr. Eisenberg will provide part time consulting services to the Company following the Closing Date for monthly compensation&#13;of US$10,000 and US$7,500, respectively.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Concurrently&#13;with the execution of the Bid Agreement, the Company entered into Securities Purchase Agreements (the "PIPE Agreements") with&#13;certain accredited investors (the "PIPE Investors"), including Mr. Noam Danenberg, our CEO. Pursuant to the PIPE Agreements,&#13;we agreed to sell to the PIPE Investors, and the PIPE Investors agreed to purchase from us, in a private placement, an aggregate&#13;of 25,000,000 shares of common stock for a purchase price of $0.12 per share, or aggregate gross proceeds of $3.0 million, which,&#13;in the case of Mr. Danenberg, may be satisfied by waiving outstanding amounts owed by the Company or its subsidiaries to Mr. Danenberg&#13;pursuant to his consulting agreement with our subsidiary.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On February 1, 2021, we lodged&#13;a Bidder's Statement with the Australian Securities and Investments Commission to commence the Offer.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On February 15, 2021, Cosmos informed the Company that&#13;Cosmos completed the issuance of convertible notes (the "Cosmos Convertible Notes") with an aggregate principal amount&#13;of approximately US$21 million to several non-U.S. sophisticated or professional investors (the "Purchasers"). The&#13;Cosmos Convertible Notes are unsecured and shall initially be convertible into shares of Cosmos at a conversion price of AU$23.58&#13;per share (equivalent to US$18.16), reflecting a pre-money valuation of Cosmos of approximately US$185 million. The Cosmos Convertible&#13;Notes will automatically convert to shares six months after the date of issuance. Cosmos is obligated to pay interest to the Purchasers&#13;on the outstanding principal amount of the Cosmos Convertible Notes at the rate of 8% per annum, payable on the conversion date,&#13;in cash or, at Cosmos' option, in shares of Cosmos. Redemption of the Cosmos Convertible Notes occurs only if an insolvency&#13;event occurs in respect of Cosmos.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Cosmos Convertible Notes also provide that, subject&#13;to, among other things, the consummation of the Offer before May 31, 2021, Cosmos will cause the Company to assume the Cosmos Convertible&#13;Notes by way of entering into an amended and restate convertible note on substantially the same terms as the Cosmos Convertible&#13;Note (the "Wize Convertible Notes"), except that, at such time, they shall be convertible, upon the earlier of six&#13;(6) months from the issuance of the Cosmos Convertible Notes and an uplisting of the common stock of the Company to Nasdaq, into&#13;shares of common stock of the Company at a conversion price of US$0.339 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Cosmos plans to use the proceeds&#13;of the Cosmos Convertible Notes for the purchase of additional application-specific integrated circuit (ASIC) mining hardware,&#13;modular data centers, associated infrastructure and capital raising costs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;February&#13;16, 2021, we announced that the Offer became unconditional and that we plan to consummate the transactions contemplated by the&#13;Bid Agreement and the Offer on or about March 9, 2021.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2020-12-31_custom_CosmosConvertibleNotesMember" unitRef="ILS_per_Share" decimals="INF">0.339</us-gaap:SaleOfStockPricePerShare>
    <dei:EntityPublicFloat contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">1961169</dei:EntityPublicFloat>
    <wizp:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Mar_2019T00_00_00_TO_31_Mar_2019T00_00_00" unitRef="USD" decimals="-3">260000</wizp:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents>
    <wizp:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Dec_2018T00_00_00_TO_31_Dec_2018T00_00_00" unitRef="USD" decimals="-3">759000</wizp:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-07" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-06" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-0" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-1" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-2" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-3" xlink:label="Foot-02_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-02_loc" xlink:to="Footnote-03" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-0" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-1" xlink:label="Foot-03_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-03_loc" xlink:to="Footnote-05" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-0" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-1" xlink:label="Foot-04_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-04_loc" xlink:to="Footnote-04" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-0" xlink:label="Foot-05_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-05_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-06-0" xlink:label="Foot-06_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-06_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Maximum of Right to Future Investment of $411 for each of the three 2017 Lenders.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">Principal loan amount of $274 for each of the three 2017 Lenders.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">Representing amount less than $1</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">Relates to Wize Israel  and OcuWize.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-05" xml:lang="en-US">Less than 1 thousand.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-06" xml:lang="en-US">During the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase Agreement (as defined below). These preferred stock are participating securities. During the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-07" xml:lang="en-US">Including an amount of $76 with respect to stock-based compensation</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>wizp-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: wizp%2D20201231.xfr; Date: 2021%2D03%2D01T18:25:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020020 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9Kopw7xRiXhun8uMZn9cOayIabOdxZRxCekxvWB0bRmKHy0uposL5ivlA9RWsb4A -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:wizp="http://ophthalic.com/20201231" elementFormDefault="qualified" targetNamespace="http://ophthalic.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://ophthalic.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit" id="StatementsOfChangesInShareholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/General" id="General">
	  <link:definition>00000007 - Disclosure - General</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/MarketableEquitySecurities" id="MarketableEquitySecurities">
	  <link:definition>00000009 - Disclosure - Marketable Equity Securities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - Other Current Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/LicenseAgreement" id="LicenseAgreement">
	  <link:definition>00000011 - Disclosure - License Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/LicensePurchaseObligation" id="LicensePurchaseObligation">
	  <link:definition>00000012 - Disclosure - License Purchase Obligation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/AccountsPayable" id="AccountsPayable">
	  <link:definition>00000013 - Disclosure - Accounts Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/ConvertibleLoans" id="ConvertibleLoans">
	  <link:definition>00000014 - Disclosure - Convertible Loans</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/ShortTermLoanPayable" id="ShortTermLoanPayable">
	  <link:definition>00000015 - Disclosure - Short Term Loan Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantTransactions" id="SignificantTransactions">
	  <link:definition>00000016 - Disclosure - Significant Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/TaxesOnIncome" id="TaxesOnIncome">
	  <link:definition>00000017 - Disclosure - Taxes on Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000019 - Disclosure - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsData" id="SelectedStatementsOfOperationsData">
	  <link:definition>00000020 - Disclosure - Selected Statements of Operations Data</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions" id="RelatedPartiesBalancesAndTransactions">
	  <link:definition>00000021 - Disclosure - Related Parties Balances and Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000025 - Disclosure - Other Current Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/LicensePurchaseObligationTables" id="LicensePurchaseObligationTables">
	  <link:definition>00000026 - Disclosure - License Purchase Obligation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/AccountsPayableTables" id="AccountsPayableTables">
	  <link:definition>00000027 - Disclosure - Accounts Payable (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/ConvertibleLoansTables" id="ConvertibleLoansTables">
	  <link:definition>00000028 - Disclosure - Convertible Loans (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantTransactionsTables" id="SignificantTransactionsTables">
	  <link:definition>00000029 - Disclosure - Significant Transactions (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/TaxesOnIncomeTables" id="TaxesOnIncomeTables">
	  <link:definition>00000030 - Disclosure - Taxes on Income (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000031 - Disclosure - Stockholders' Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables" id="SelectedStatementsOfOperationsDataTables">
	  <link:definition>00000032 - Disclosure - Selected Statements of Operations Data (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables" id="RelatedPartiesBalancesAndTransactionsTables">
	  <link:definition>00000033 - Disclosure - Related Parties Balances and Transactions (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/GeneralDetails" id="GeneralDetails">
	  <link:definition>00000034 - Disclosure - General (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
	  <link:definition>00000035 - Disclosure - Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails1" id="SignificantAccountingPoliciesDetails1">
	  <link:definition>00000036 - Disclosure - Significant Accounting Policies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails2" id="SignificantAccountingPoliciesDetails2">
	  <link:definition>00000037 - Disclosure - Significant Accounting Policies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails3" id="SignificantAccountingPoliciesDetails3">
	  <link:definition>00000038 - Disclosure - Significant Accounting Policies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails4" id="SignificantAccountingPoliciesDetails4">
	  <link:definition>00000039 - Disclosure - Significant Accounting Policies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails5" id="SignificantAccountingPoliciesDetails5">
	  <link:definition>00000040 - Disclosure - Significant Accounting Policies (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual" id="SignificantAccountingPoliciesDetailsTextual">
	  <link:definition>00000041 - Disclosure - Significant Accounting Policies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/MarketableEquitySecuritiesDetails" id="MarketableEquitySecuritiesDetails">
	  <link:definition>00000042 - Disclosure - Marketable Equity Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000043 - Disclosure - Other Current Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/LicenseAgreementDetails" id="LicenseAgreementDetails">
	  <link:definition>00000044 - Disclosure - License Agreement (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetails" id="LicensePurchaseObligationDetails">
	  <link:definition>00000045 - Disclosure - License Purchase Obligation (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual" id="LicensePurchaseObligationDetailsTextual">
	  <link:definition>00000046 - Disclosure - License Purchase Obligation (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/AccountsPayableDetails" id="AccountsPayableDetails">
	  <link:definition>00000047 - Disclosure - Accounts Payable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/ConvertibleLoansDetails" id="ConvertibleLoansDetails">
	  <link:definition>00000048 - Disclosure - Convertible Loans (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/ConvertibleLoansDetails1" id="ConvertibleLoansDetails1">
	  <link:definition>00000049 - Disclosure - Convertible Loans (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/ConvertibleLoansDetailsTextual" id="ConvertibleLoansDetailsTextual">
	  <link:definition>00000050 - Disclosure - Convertible Loans (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/ShortTermLoanPayableDetails" id="ShortTermLoanPayableDetails">
	  <link:definition>00000051 - Disclosure - Short Term Loan Payable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantTransactionsDetails" id="SignificantTransactionsDetails">
	  <link:definition>00000052 - Disclosure - Significant Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SignificantTransactionsDetailsTextual" id="SignificantTransactionsDetailsTextual">
	  <link:definition>00000053 - Disclosure - Significant Transactions (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails" id="TaxesOnIncomeDetails">
	  <link:definition>00000054 - Disclosure - Taxes on Income (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails1" id="TaxesOnIncomeDetails1">
	  <link:definition>00000055 - Disclosure - Taxes on Income (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails2" id="TaxesOnIncomeDetails2">
	  <link:definition>00000056 - Disclosure - Taxes on Income (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/TaxesOnIncomeDetailsTextual" id="TaxesOnIncomeDetailsTextual">
	  <link:definition>00000057 - Disclosure - Taxes on Income (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000058 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000059 - Disclosure - Stockholders' Equity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000060 - Disclosure - Stockholders' Equity (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
	  <link:definition>00000061 - Disclosure - Stockholders' Equity (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails" id="SelectedStatementsOfOperationsDataDetails">
	  <link:definition>00000062 - Disclosure - Selected Statements of Operations Data (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1" id="SelectedStatementsOfOperationsDataDetails1">
	  <link:definition>00000063 - Disclosure - Selected Statements of Operations Data (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails" id="RelatedPartiesBalancesAndTransactionsDetails">
	  <link:definition>00000064 - Disclosure - Related Parties Balances and Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1" id="RelatedPartiesBalancesAndTransactionsDetails1">
	  <link:definition>00000065 - Disclosure - Related Parties Balances and Transactions (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual" id="RelatedPartiesBalancesAndTransactionsDetailsTextual">
	  <link:definition>00000066 - Disclosure - Related Parties Balances and Transactions (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://ophthalic.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
	  <link:definition>00000067 - Disclosure - Subsequent Events (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="wizp-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="wizp-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="wizp-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="wizp-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="wizp_LicensePurchaseObligationCurrent" name="LicensePurchaseObligationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicenseAgreementDescription" name="LicenseAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RecognizedLeaseLiability" name="RecognizedLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PercentageOfDiscountRate" name="PercentageOfDiscountRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicensePurchaseObligationNet" name="LicensePurchaseObligationNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ReducedAnnualRoyaltiesDescription" name="ReducedAnnualRoyaltiesDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_FinanceIncomeNet" name="FinanceIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ForeignCurrencyExchangeRateTranslation" name="ForeignCurrencyExchangeRateTranslation" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CurrencyExchangeRatePercentage" name="CurrencyExchangeRatePercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_FindersFeeAgreementDescription" name="FindersFeeAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DepositPercentage" name="DepositPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" name="AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_NetIncomeAttributedToPreferredStock" name="NetIncomeAttributedToPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_NetLossPerShareOfCommonStockBasicAndDiluted" name="NetLossPerShareOfCommonStockBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" name="PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SecuritiesPurchaseAgreementDescription" name="SecuritiesPurchaseAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PurchasePricePerShare" name="PurchasePricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendDueToDownRoundAdjustment" name="DeemedDividendDueToDownRoundAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ExchangeOfCommonStock" name="ExchangeOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ReminingOutstandingOwnersPercentage" name="ReminingOutstandingOwnersPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendWithRespectToRightForFutureInvestment" name="DeemedDividendWithRespectToRightForFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" name="WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PercentageOfContingentObligation" name="PercentageOfContingentObligation" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DescriptionOfContingentObligation" name="DescriptionOfContingentObligation" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PercentageOfBonueAgreement" name="PercentageOfBonueAgreement" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_NumberOfBonusSharesDistributedByCompany" name="NumberOfBonusSharesDistributedByCompany" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RedeemAllOfSeriesBPreferredStockDescription" name="RedeemAllOfSeriesBPreferredStockDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DescriptionOfBonusAgreements" name="DescriptionOfBonusAgreements" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_InvestmentOwnershipPercentage" name="InvestmentOwnershipPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital" name="MinimumPercentageOfIssuedAndOutstandingShareCapital" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IncomeFromChangeInFairValue" name="IncomeFromChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OtherGovernmentalAuthoritiesCurrent" name="OtherGovernmentalAuthoritiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OtherReceivable" name="OtherReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RestrictedBankDepositPolicyTextBlock" name="RestrictedBankDepositPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LegalAndOtherContingenciesPolicyTextBlock" name="LegalAndOtherContingenciesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" name="MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfXchangeRateOfRelevantCurrencies" name="ScheduleOfXchangeRateOfRelevantCurrencies" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfCashAndCashEquivalents" name="ScheduleOfCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfEstimatedUsefulLivesOfAssets" name="ScheduleOfEstimatedUsefulLivesOfAssets" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicenseAgreementTextBlock" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfOtherAccountsPayableTableTextBlock" name="ScheduleOfOtherAccountsPayableTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LiabilityValue" name="LiabilityValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TradePayables" name="TradePayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_EscrowAmount" name="EscrowAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PricePerShareAtDateOfAgreement" name="PricePerShareAtDateOfAgreement" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PricePerShareAtClosingDate" name="PricePerShareAtClosingDate" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OutstandingShareCapitalPercentage" name="OutstandingShareCapitalPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AdditionalOrdinaryShares" name="AdditionalOrdinaryShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_InvestmentInMarketableSecuritiesBonusShares" name="InvestmentInMarketableSecuritiesBonusShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RedeemableFairValue" name="RedeemableFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_FinanceExpenses" name="FinanceExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_InvestmentOfMarketableSecuritiesPercentage" name="InvestmentOfMarketableSecuritiesPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CashOfInvestment" name="CashOfInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_FairValueOfBonusSharesAndAmount" name="FairValueOfBonusSharesAndAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ReceivedCashProceeds" name="ReceivedCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock" name="BalancesWithInterestedAndRelatedPartiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" name="AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" name="AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares" name="IssuanceOfCommonStockAndWarrantsForCashNote11uShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u" name="IssuanceOfCommonStockAndWarrantsForCashNote11u" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" name="IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" name="IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" name="TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" name="DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" name="DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" name="IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" name="IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IncreaseDecreaseInLicensePurchaseObligation" name="IncreaseDecreaseInLicensePurchaseObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AccruedInterestOnConvertibleLoans" name="AccruedInterestOnConvertibleLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ProceedsFromRepaymentOfLicensePurchaseObligation" name="ProceedsFromRepaymentOfLicensePurchaseObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" name="ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ProceedsFromIssuanceOfSharesAndWarrants" name="ProceedsFromIssuanceOfSharesAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ReleaseOfEscrowAccountBonusShares" name="ReleaseOfEscrowAccountBonusShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LiabilityToHcw" name="LiabilityToHcw" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants" name="IssuanceOfSharesWithRespectToExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants" name="DeemedDividendDueToExercisePriceAdjustmentOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" name="SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock" name="IssuanceOfMandatorilyRedeemableSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues" name="RecognitionOfContingentObligationWithRespectToFutureRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" name="AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SELLOFCANNABICSSHARETHROUGHABROKER" name="SELLOFCANNABICSSHARETHROUGHABROKER" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" name="DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RepaymentOfConvertibleLoansThroughCommonStock" name="RepaymentOfConvertibleLoansThroughCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToLoanExtensionOne" name="AmountAllocatedToLoanExtensionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToLoanExtension" name="AmountAllocatedToLoanExtension" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToLoanAmendmentOne" name="AmountAllocatedToLoanAmendmentOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToLoanAmendment" name="AmountAllocatedToLoanAmendment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" name="DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo" name="AmountThatWasAllocatedToRightForFutureInvestmentTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne" name="AmountThatWasAllocatedToRightForFutureInvestmentOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" name="AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" name="DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment" name="AmountsAllocatedToTheRecognitionOfRightForFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountThatWasAllocatedToRightForFutureInvestment" name="AmountThatWasAllocatedToRightForFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" name="AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities" name="OrdinarySharesIssuedThroughReceiptOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_GainFromCompletionOfMilestoneClosingNote10" name="GainFromCompletionOfMilestoneClosingNote10" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" name="LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" name="ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" name="ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LoanReceived" name="LoanReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MarketableSecuritiesEquitySecuritieCurrent" name="MarketableSecuritiesEquitySecuritieCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" name="DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BankAccount" name="BankAccount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeferredTaxAssetsReservesAndAllowances" name="DeferredTaxAssetsReservesAndAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ExpensesNotDeductibleForTaxPurposes" name="ExpensesNotDeductibleForTaxPurposes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" name="IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CorporateTaxRate" name="CorporateTaxRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ChangeInFairValueOfMarketableSecurities" name="ChangeInFairValueOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ExchangeRateGainsNet" name="ExchangeRateGainsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_GainFromCompletionOfMilestoneClosing" name="GainFromCompletionOfMilestoneClosing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_GainFromSettlementShares" name="GainFromSettlementShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AccruedInterestOnLoans" name="AccruedInterestOnLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock" name="LossFromRecognitionOfMandatorilyRedeemablePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" name="LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RevaluationOfMandatorilyRedeemablePreferredStock" name="RevaluationOfMandatorilyRedeemablePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CosmosTransactionDescription" name="CosmosTransactionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AggregatePrincipalAmount" name="AggregatePrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AggregateMaximumOfRightToFutureInvestment" name="AggregateMaximumOfRightToFutureInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ExercisePriceOfRightToFutureInvestment" name="ExercisePriceOfRightToFutureInvestment" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmortizationOfPremiumRelatedToConvertibleLoans" name="AmortizationOfPremiumRelatedToConvertibleLoans" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmortizationOfPremiumRelatedToConvertibleLoan" name="AmortizationOfPremiumRelatedToConvertibleLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DerecognitionLoanUponExtinguishment" name="DerecognitionLoanUponExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AccruedInterestOnLoan" name="AccruedInterestOnLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToLoan" name="AmountAllocatedToLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne" name="AmortizationOfPremiumRelatedToConvertibleLoansOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DerecognitionLoanUponExtinguishmentOne" name="DerecognitionLoanUponExtinguishmentOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToLoanOne" name="AmountAllocatedToLoanOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo" name="AmortizationOfPremiumRelatedToConvertibleLoansTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LoanAmendmentDescription" name="LoanAmendmentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_InvestmentOptionExercisePrice" name="InvestmentOptionExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_JointVentureAgreementDescription" name="JointVentureAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ChairmanAppointmentAgreementDescription" name="ChairmanAppointmentAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockOptionsGrantedDuringVestingPeriod" name="StockOptionsGrantedDuringVestingPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockIssuanceToConsultantRelatedDescription" name="StockIssuanceToConsultantRelatedDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockIssuanceToEmployeesRelatedDescription" name="StockIssuanceToEmployeesRelatedDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LossOfChangeInFairValue" name="LossOfChangeInFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_WeightedaveragePeriod" name="WeightedaveragePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicensePurchaseObligationLiabilities" name="LicensePurchaseObligationLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_GrossProceeds" name="GrossProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PresentValueOfDebtInstrumentPercentage" name="PresentValueOfDebtInstrumentPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LeastPercentageOfCarryingAmount" name="LeastPercentageOfCarryingAmount" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MinimumCommitmentAmount" name="MinimumCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LossDueToRevaluation" name="LossDueToRevaluation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_WarrantTermDescription" name="WarrantTermDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OfferDescription" name="OfferDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PurchaseOfPropertyAndEquipment" name="PurchaseOfPropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_FinancialExpenses" name="FinancialExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeverancePayPolicyTextBlock" name="SeverancePayPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PenaltyPayment" name="PenaltyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusTransaction" name="BonusTransaction" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusSharesOfSeriesBPreferredStock." name="BonusSharesOfSeriesBPreferredStock." nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability" name="ScheduleOfMandatorilyRedeemableSeriesBLiability" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusTransactionCosts" name="BonusTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MarketableEquityDescription" name="MarketableEquityDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ConversionOfPreferredStockIntoCommonStockShares" name="ConversionOfPreferredStockIntoCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ConversionOfPreferredStockIntoCommonStock" name="ConversionOfPreferredStockIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" name="StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MandatorilyRedeemableSeriesBLiability" name="MandatorilyRedeemableSeriesBLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeriesBPreferredStock" name="SeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock" name="RedemptionOfMandatorilyRedeemableSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SignificantTransactionsTextBlock" name="SignificantTransactionsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" name="SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" name="ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicensePurchaseObligationTextBlock" name="LicensePurchaseObligationTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" name="ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OtherAccountsPayableTextBlock" name="OtherAccountsPayableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IncomeTaxRatePercentageDescription" name="IncomeTaxRatePercentageDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CorporateAndDeferredTaxDescription" name="CorporateAndDeferredTaxDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SelectedStatementsOfOperationsDataTextBlock" name="SelectedStatementsOfOperationsDataTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ScheduleOfFinancingExpensesNetTableTextBlock" name="ScheduleOfFinancingExpensesNetTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" name="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ConvertibleDebtOneMember" name="ConvertibleDebtOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RimonGoldMember" name="RimonGoldMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LendersMember" name="LendersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_NisMember" name="NisMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_WizeIsraelMember" name="WizeIsraelMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RimonGoldAndFisherMember" name="RimonGoldAndFisherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwoZeroOneSevenLoanAmendmentMember" name="TwoZeroOneSevenLoanAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwoZeroOneSixLoanAmendmentMember" name="TwoZeroOneSixLoanAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwoZeroOneEightPlanMember" name="TwoZeroOneEightPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ReceiptOnAccountOfStockToBeIssuedMember" name="ReceiptOnAccountOfStockToBeIssuedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SieczkarekMember" name="SieczkarekMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CannabicsMember" name="CannabicsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OcuwizeMember" name="OcuwizeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DirectorSalaryAndInsuranceMember" name="DirectorSalaryAndInsuranceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TaxesAndTollsMember" name="TaxesAndTollsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ProfessionalServicesAndConsultationMember" name="ProfessionalServicesAndConsultationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PayrollAndBenefitsMember" name="PayrollAndBenefitsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RentAndOfficeMaintenanceMember" name="RentAndOfficeMaintenanceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ShareBasedPaymentMember" name="ShareBasedPaymentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OverseasTravelMember" name="OverseasTravelMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OtherExpensesMember" name="OtherExpensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_VendorMember" name="VendorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwoZeroOneTwoPlanMember" name="TwoZeroOneTwoPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusPurchaseAgreementsMember" name="BonusPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeriesBNonVotingRedeemablePreferredStockMember" name="SeriesBNonVotingRedeemablePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeriesBCertificateOfDesignationsMember" name="SeriesBCertificateOfDesignationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwoZeroOneNineLoanAmendmentMember" name="TwoZeroOneNineLoanAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeriesCertificateOfDesignationsMember" name="SeriesCertificateOfDesignationsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MesodiConsultationInvestmentsLtdMember" name="MesodiConsultationInvestmentsLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwoThousandTwelvePlanMemberrMember" name="TwoThousandTwelvePlanMemberrMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_EmployeeStockOptionTwoMember" name="EmployeeStockOptionTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusExchangeAgreementMember" name="BonusExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeriesBPurchaseAgreementMember" name="SeriesBPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusAgreementsMember" name="BonusAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IsraeliShekelMember" name="IsraeliShekelMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusLoanMember" name="BonusLoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusPurchaseAgreementMember" name="BonusPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SettlementSharesMember" name="SettlementSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusPurchaseAgreementOneMember" name="BonusPurchaseAgreementOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwoZeroTwoZeroLoanMember" name="TwoZeroTwoZeroLoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ILSMember" name="ILSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusTransactionCostsMember" name="BonusTransactionCostsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BidAgreementMember" name="BidAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockRestrictionAgreementMember" name="StockRestrictionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CVRAgreementMember" name="CVRAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PIPEAgreementsMember" name="PIPEAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TwentyTwelveStockIncentivePlanMember" name="TwentyTwelveStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MayTwoThousandNineteenAmendmentMember" name="MayTwoThousandNineteenAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CosmosConvertibleNotesMember" name="CosmosConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AdditionToNetLossAbstract" name="AdditionToNetLossAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_CumulativeEffectAdjustmentFromTransition" name="CumulativeEffectAdjustmentFromTransition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" name="IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" name="IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" name="IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" name="AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" name="AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ConvertibleLoanExtinguishment" name="ConvertibleLoanExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ConvertibleLoanExtinguishmentAndWarrantsModification" name="ConvertibleLoanExtinguishmentAndWarrantsModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicenseAgreementAbstract" name="LicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicensePurchaseObligationAbstract" name="LicensePurchaseObligationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OtherAccountsPayableAbstract" name="OtherAccountsPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SignificantTransactionsAbstract" name="SignificantTransactionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SelectedStatementsOfOperationsDataAbstract" name="SelectedStatementsOfOperationsDataAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_GeneralTextualAbstract" name="GeneralTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_NumeratorAbstract" name="NumeratorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_DenominatorAbstract" name="DenominatorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SignificantAccountingPoliciesTextualAbstract" name="SignificantAccountingPoliciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_MarketableEquitySecuritiesTextualAbstract" name="MarketableEquitySecuritiesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicenseAgreementTextualAbstract" name="LicenseAgreementTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LicensePurchaseObligationTextualAbstract" name="LicensePurchaseObligationTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LoanRollForwardAbstract" name="LoanRollForwardAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TypesOfCurrencyAxis" name="TypesOfCurrencyAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="wizp_TypesOfCurrencyDomain" name="TypesOfCurrencyDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ConvertibleLoansTextualAbstract" name="ConvertibleLoansTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ShortTermLoanPayableTextual" name="ShortTermLoanPayableTextual" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TypeOfAgreementAxis" name="TypeOfAgreementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="wizp_TypeOfAgreementDomain" name="TypeOfAgreementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SignificantTransactionsTextualAbstract" name="SignificantTransactionsTextualAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusSharesHeldInEscrow" name="BonusSharesHeldInEscrow" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RedeemablePreferredStockLiability" name="RedeemablePreferredStockLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_FinancialIncome" name="FinancialIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TaxesOnIncomeTextualAbstract" name="TaxesOnIncomeTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockholdersEquityTextualAbstract" name="StockholdersEquityTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RegistrationStatementDescription" name="RegistrationStatementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_FinanceExpense" name="FinanceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PreferredStockDesignated" name="PreferredStockDesignated" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PreferredStockDesignatedStock" name="PreferredStockDesignatedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_LiquidatedDamagesToInvestorsDescription" name="LiquidatedDamagesToInvestorsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PlacementAgencyAgreementDescription" name="PlacementAgencyAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_PlacementAgentWarrantsDescription" name="PlacementAgentWarrantsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ExtinguishmentOfLoansDescription" name="ExtinguishmentOfLoansDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockOutstandingRelatedDescription" name="StockOutstandingRelatedDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BalancesWithRelatedPartiesAbstract" name="BalancesWithRelatedPartiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_AmountsChargedAbstract" name="AmountsChargedAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract" name="RelatedPartiesBalancesAndTransactionsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_SubsequentEventsTextualAbstract" name="SubsequentEventsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_BonusPurchaseAgreements" name="BonusPurchaseAgreements" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_OrdinarySharesOfBonus" name="OrdinarySharesOfBonus" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_TotalProceedsPayable" name="TotalProceedsPayable" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" name="StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_RestrictedStockUnitsVestTerm" name="RestrictedStockUnitsVestTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="wizp_ExpressedBonusAmount" name="ExpressedBonusAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>wizp-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: wizp%2D20201231.xfr; Date: 2021%2D03%2D01T18:25:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020020 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ophthalic.com/role/DocumentAndEntityInformation" xlink:href="wizp-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/BalanceSheets" xlink:href="wizp-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/BalanceSheetsParenthetical" xlink:href="wizp-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfComprehensiveLoss" xlink:href="wizp-20201231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:href="wizp-20201231.xsd#StatementsOfChangesInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfCashFlows" xlink:href="wizp-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/General" xlink:href="wizp-20201231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPolicies" xlink:href="wizp-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/MarketableEquitySecurities" xlink:href="wizp-20201231.xsd#MarketableEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssets" xlink:href="wizp-20201231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicenseAgreement" xlink:href="wizp-20201231.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligation" xlink:href="wizp-20201231.xsd#LicensePurchaseObligation" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayable" xlink:href="wizp-20201231.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoans" xlink:href="wizp-20201231.xsd#ConvertibleLoans" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ShortTermLoanPayable" xlink:href="wizp-20201231.xsd#ShortTermLoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactions" xlink:href="wizp-20201231.xsd#SignificantTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncome" xlink:href="wizp-20201231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/CommitmentsAndContingencies" xlink:href="wizp-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquity" xlink:href="wizp-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsData" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsData" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SubsequentEvents" xlink:href="wizp-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesPolicies" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesTables" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssetsTables" xlink:href="wizp-20201231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationTables" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayableTables" xlink:href="wizp-20201231.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansTables" xlink:href="wizp-20201231.xsd#ConvertibleLoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsTables" xlink:href="wizp-20201231.xsd#SignificantTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeTables" xlink:href="wizp-20201231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityTables" xlink:href="wizp-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/GeneralDetails" xlink:href="wizp-20201231.xsd#GeneralDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails1" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails2" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails3" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails4" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails5" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/MarketableEquitySecuritiesDetails" xlink:href="wizp-20201231.xsd#MarketableEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssetsDetails" xlink:href="wizp-20201231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicenseAgreementDetails" xlink:href="wizp-20201231.xsd#LicenseAgreementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetails" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayableDetails" xlink:href="wizp-20201231.xsd#AccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetails" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetails1" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetailsTextual" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ShortTermLoanPayableDetails" xlink:href="wizp-20201231.xsd#ShortTermLoanPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsDetails" xlink:href="wizp-20201231.xsd#SignificantTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsDetailsTextual" xlink:href="wizp-20201231.xsd#SignificantTransactionsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails1" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails2" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetailsTextual" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/CommitmentsAndContingenciesDetails" xlink:href="wizp-20201231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetails" xlink:href="wizp-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetails1" xlink:href="wizp-20201231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetailsTextual" xlink:href="wizp-20201231.xsd#StockholdersEquityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SubsequentEventsDetails" xlink:href="wizp-20201231.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaapRestrictedInvestmentsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedInvestmentsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableSecuritiesEquitySecuritieCurrent" xlink:label="loc_wizpMarketableSecuritiesEquitySecuritieCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_wizpMarketableSecuritiesEquitySecuritieCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationCurrent" xlink:label="loc_wizpLicensePurchaseObligationCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_wizpLicensePurchaseObligationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnConvertibleLoans" xlink:label="loc_wizpAccruedInterestOnConvertibleLoans" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_wizpAccruedInterestOnConvertibleLoans" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GainFromCompletionOfMilestoneClosingNote10" xlink:label="loc_wizpGainFromCompletionOfMilestoneClosingNote10" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_wizpGainFromCompletionOfMilestoneClosingNote10" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="loc_wizpLossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_wizpLossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="loc_wizpChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_wizpChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:label="loc_wizpChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_wizpChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncreaseDecreaseInLicensePurchaseObligation" xlink:label="loc_wizpIncreaseDecreaseInLicensePurchaseObligation" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_wizpIncreaseDecreaseInLicensePurchaseObligation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinancialExpenses" xlink:label="loc_wizpFinancialExpenses" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_wizpFinancialExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PurchaseOfPropertyAndEquipment" xlink:label="loc_wizpPurchaseOfPropertyAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_wizpPurchaseOfPropertyAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromIssuanceOfSharesAndWarrants" xlink:label="loc_wizpProceedsFromIssuanceOfSharesAndWarrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_wizpProceedsFromIssuanceOfSharesAndWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:label="loc_wizpProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_wizpProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanReceived" xlink:label="loc_wizpLoanReceived" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_wizpLoanReceived" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromRepaymentOfLicensePurchaseObligation" xlink:label="loc_wizpProceedsFromRepaymentOfLicensePurchaseObligation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_wizpProceedsFromRepaymentOfLicensePurchaseObligation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/General" xlink:title="00000007 - Disclosure - General" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/MarketableEquitySecurities" xlink:title="00000009 - Disclosure - Marketable Equity Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicenseAgreement" xlink:title="00000011 - Disclosure - License Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligation" xlink:title="00000012 - Disclosure - License Purchase Obligation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayable" xlink:title="00000013 - Disclosure - Accounts Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoans" xlink:title="00000014 - Disclosure - Convertible Loans" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ShortTermLoanPayable" xlink:title="00000015 - Disclosure - Short Term Loan Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactions" xlink:title="00000016 - Disclosure - Significant Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncome" xlink:title="00000017 - Disclosure - Taxes on Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsData" xlink:title="00000020 - Disclosure - Selected Statements of Operations Data" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions" xlink:title="00000021 - Disclosure - Related Parties Balances and Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationTables" xlink:title="00000026 - Disclosure - License Purchase Obligation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayableTables" xlink:title="00000027 - Disclosure - Accounts Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansTables" xlink:title="00000028 - Disclosure - Convertible Loans (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsTables" xlink:title="00000029 - Disclosure - Significant Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeTables" xlink:title="00000030 - Disclosure - Taxes on Income (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - Stockholders&apos; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables" xlink:title="00000032 - Disclosure - Selected Statements of Operations Data (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables" xlink:title="00000033 - Disclosure - Related Parties Balances and Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/GeneralDetails" xlink:title="00000034 - Disclosure - General (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails1" xlink:title="00000036 - Disclosure - Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_wizpCashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wizpCashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaapRestrictedInvestmentsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wizpCashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedInvestmentsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails2" xlink:title="00000037 - Disclosure - Significant Accounting Policies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails3" xlink:title="00000038 - Disclosure - Significant Accounting Policies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails4" xlink:title="00000039 - Disclosure - Significant Accounting Policies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails5" xlink:title="00000040 - Disclosure - Significant Accounting Policies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:title="00000041 - Disclosure - Significant Accounting Policies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/MarketableEquitySecuritiesDetails" xlink:title="00000042 - Disclosure - Marketable Equity Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssetsDetails" xlink:title="00000043 - Disclosure - Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherGovernmentalAuthoritiesCurrent" xlink:label="loc_wizpOtherGovernmentalAuthoritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_wizpOtherGovernmentalAuthoritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherReceivable" xlink:label="loc_wizpOtherReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_wizpOtherReceivable" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicenseAgreementDetails" xlink:title="00000044 - Disclosure - License Agreement (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationDetails" xlink:title="00000045 - Disclosure - License Purchase Obligation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual" xlink:title="00000046 - Disclosure - License Purchase Obligation (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayableDetails" xlink:title="00000047 - Disclosure - Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableOtherCurrent" xlink:to="loc_us-gaapOtherEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiabilityValue" xlink:label="loc_wizpLiabilityValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableOtherCurrent" xlink:to="loc_wizpLiabilityValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableOtherCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TradePayables" xlink:label="loc_wizpTradePayables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableOtherCurrent" xlink:to="loc_wizpTradePayables" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetails" xlink:title="00000048 - Disclosure - Convertible Loans (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetails1" xlink:title="00000049 - Disclosure - Convertible Loans (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetailsTextual" xlink:title="00000050 - Disclosure - Convertible Loans (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ShortTermLoanPayableDetails" xlink:title="00000051 - Disclosure - Short Term Loan Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsDetails" xlink:title="00000052 - Disclosure - Significant Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsDetailsTextual" xlink:title="00000053 - Disclosure - Significant Transactions (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails" xlink:title="00000054 - Disclosure - Taxes on Income (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails1" xlink:title="00000055 - Disclosure - Taxes on Income (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails2" xlink:title="00000056 - Disclosure - Taxes on Income (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetailsTextual" xlink:title="00000057 - Disclosure - Taxes on Income (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000058 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetails" xlink:title="00000059 - Disclosure - Stockholders&apos; Equity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetails1" xlink:title="00000060 - Disclosure - Stockholders&apos; Equity (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetailsTextual" xlink:title="00000061 - Disclosure - Stockholders&apos; Equity (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails" xlink:title="00000062 - Disclosure - Selected Statements of Operations Data (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1" xlink:title="00000063 - Disclosure - Selected Statements of Operations Data (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails" xlink:title="00000064 - Disclosure - Related Parties Balances and Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1" xlink:title="00000065 - Disclosure - Related Parties Balances and Transactions (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:title="00000066 - Disclosure - Related Parties Balances and Transactions (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SubsequentEventsDetails" xlink:title="00000067 - Disclosure - Subsequent Events (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>wizp-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: wizp%2D20201231.xfr; Date: 2021%2D03%2D01T18:25:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020020 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ophthalic.com/role/DocumentAndEntityInformation" xlink:href="wizp-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/BalanceSheets" xlink:href="wizp-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/BalanceSheetsParenthetical" xlink:href="wizp-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfComprehensiveLoss" xlink:href="wizp-20201231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:href="wizp-20201231.xsd#StatementsOfChangesInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfCashFlows" xlink:href="wizp-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/General" xlink:href="wizp-20201231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPolicies" xlink:href="wizp-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/MarketableEquitySecurities" xlink:href="wizp-20201231.xsd#MarketableEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssets" xlink:href="wizp-20201231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicenseAgreement" xlink:href="wizp-20201231.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligation" xlink:href="wizp-20201231.xsd#LicensePurchaseObligation" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayable" xlink:href="wizp-20201231.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoans" xlink:href="wizp-20201231.xsd#ConvertibleLoans" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ShortTermLoanPayable" xlink:href="wizp-20201231.xsd#ShortTermLoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactions" xlink:href="wizp-20201231.xsd#SignificantTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncome" xlink:href="wizp-20201231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/CommitmentsAndContingencies" xlink:href="wizp-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquity" xlink:href="wizp-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsData" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsData" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SubsequentEvents" xlink:href="wizp-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesPolicies" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesTables" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssetsTables" xlink:href="wizp-20201231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationTables" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayableTables" xlink:href="wizp-20201231.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansTables" xlink:href="wizp-20201231.xsd#ConvertibleLoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsTables" xlink:href="wizp-20201231.xsd#SignificantTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeTables" xlink:href="wizp-20201231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityTables" xlink:href="wizp-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/GeneralDetails" xlink:href="wizp-20201231.xsd#GeneralDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails1" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails2" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails3" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails4" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails5" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/MarketableEquitySecuritiesDetails" xlink:href="wizp-20201231.xsd#MarketableEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssetsDetails" xlink:href="wizp-20201231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicenseAgreementDetails" xlink:href="wizp-20201231.xsd#LicenseAgreementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetails" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayableDetails" xlink:href="wizp-20201231.xsd#AccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetails" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetails1" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetailsTextual" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ShortTermLoanPayableDetails" xlink:href="wizp-20201231.xsd#ShortTermLoanPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsDetails" xlink:href="wizp-20201231.xsd#SignificantTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsDetailsTextual" xlink:href="wizp-20201231.xsd#SignificantTransactionsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails1" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails2" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetailsTextual" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/CommitmentsAndContingenciesDetails" xlink:href="wizp-20201231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetails" xlink:href="wizp-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetails1" xlink:href="wizp-20201231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetailsTextual" xlink:href="wizp-20201231.xsd#StockholdersEquityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SubsequentEventsDetails" xlink:href="wizp-20201231.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" xlink:label="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" xlink:label="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11u_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11u_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11uShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11uShares_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CumulativeEffectAdjustmentFromTransition" xlink:label="loc_wizpCumulativeEffectAdjustmentFromTransition_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpCumulativeEffectAdjustmentFromTransition_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" xlink:label="loc_wizpIssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" xlink:label="loc_wizpAmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" xlink:label="loc_wizpAmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" xlink:label="loc_wizpTermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpTermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoanExtinguishment" xlink:label="loc_wizpConvertibleLoanExtinguishment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConvertibleLoanExtinguishment_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNote_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNote_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConversionOfPreferredStockIntoCommonStock" xlink:label="loc_wizpConversionOfPreferredStockIntoCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConversionOfPreferredStockIntoCommonStock_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConversionOfPreferredStockIntoCommonStockShares" xlink:label="loc_wizpConversionOfPreferredStockIntoCommonStockShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConversionOfPreferredStockIntoCommonStockShares_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoanExtinguishmentAndWarrantsModification" xlink:label="loc_wizpConvertibleLoanExtinguishmentAndWarrantsModification_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConvertibleLoanExtinguishmentAndWarrantsModification_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" xlink:label="loc_wizpStockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpStockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/General" xlink:title="00000007 - Disclosure - General" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/MarketableEquitySecurities" xlink:title="00000009 - Disclosure - Marketable Equity Securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicenseAgreement" xlink:title="00000011 - Disclosure - License Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligation" xlink:title="00000012 - Disclosure - License Purchase Obligation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayable" xlink:title="00000013 - Disclosure - Accounts Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoans" xlink:title="00000014 - Disclosure - Convertible Loans" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ShortTermLoanPayable" xlink:title="00000015 - Disclosure - Short Term Loan Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactions" xlink:title="00000016 - Disclosure - Significant Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncome" xlink:title="00000017 - Disclosure - Taxes on Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&apos; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsData" xlink:title="00000020 - Disclosure - Selected Statements of Operations Data" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions" xlink:title="00000021 - Disclosure - Related Parties Balances and Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationTables" xlink:title="00000026 - Disclosure - License Purchase Obligation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayableTables" xlink:title="00000027 - Disclosure - Accounts Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansTables" xlink:title="00000028 - Disclosure - Convertible Loans (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsTables" xlink:title="00000029 - Disclosure - Significant Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeTables" xlink:title="00000030 - Disclosure - Taxes on Income (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - Stockholders&apos; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneEightPlanMember" xlink:label="loc_wizpTwoZeroOneEightPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneEightPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneTwoPlanMember" xlink:label="loc_wizpTwoZeroOneTwoPlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneTwoPlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables" xlink:title="00000032 - Disclosure - Selected Statements of Operations Data (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables" xlink:title="00000033 - Disclosure - Related Parties Balances and Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/GeneralDetails" xlink:title="00000034 - Disclosure - General (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails1" xlink:title="00000036 - Disclosure - Significant Accounting Policies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails2" xlink:title="00000037 - Disclosure - Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails3" xlink:title="00000038 - Disclosure - Significant Accounting Policies (Details 3)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails4" xlink:title="00000039 - Disclosure - Significant Accounting Policies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails5" xlink:title="00000040 - Disclosure - Significant Accounting Policies (Details 5)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:title="00000041 - Disclosure - Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantAccountingPoliciesTextualAbstract" xlink:label="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_us-gaapOperatingLeaseLiability_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DepositPercentage" xlink:label="loc_wizpDepositPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpDepositPercentage_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_us-gaapSeveranceCosts1_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_wizpAmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpAmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_us-gaapSharesIssued_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PurchasePricePerShare" xlink:label="loc_wizpPurchasePricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpPurchasePricePerShare_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LeastPercentageOfCarryingAmount" xlink:label="loc_wizpLeastPercentageOfCarryingAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpLeastPercentageOfCarryingAmount_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfContingentObligation" xlink:label="loc_wizpPercentageOfContingentObligation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpPercentageOfContingentObligation_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfContingentObligation" xlink:label="loc_wizpDescriptionOfContingentObligation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpDescriptionOfContingentObligation_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfBonueAgreement" xlink:label="loc_wizpPercentageOfBonueAgreement_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpPercentageOfBonueAgreement_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:label="loc_us-gaapPolicyholderDividendsRateOnPolicyEarnings_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_us-gaapPolicyholderDividendsRateOnPolicyEarnings_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NumberOfBonusSharesDistributedByCompany" xlink:label="loc_wizpNumberOfBonusSharesDistributedByCompany_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpNumberOfBonusSharesDistributedByCompany_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemAllOfSeriesBPreferredStockDescription" xlink:label="loc_wizpRedeemAllOfSeriesBPreferredStockDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpRedeemAllOfSeriesBPreferredStockDescription_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfBonusAgreements" xlink:label="loc_wizpDescriptionOfBonusAgreements_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpDescriptionOfBonusAgreements_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GrossProceeds" xlink:label="loc_wizpGrossProceeds_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpGrossProceeds_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PresentValueOfDebtInstrumentPercentage" xlink:label="loc_wizpPresentValueOfDebtInstrumentPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract_110" xlink:to="loc_wizpPresentValueOfDebtInstrumentPercentage_110" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/MarketableEquitySecuritiesDetails" xlink:title="00000042 - Disclosure - Marketable Equity Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CannabicsMember" xlink:label="loc_wizpCannabicsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpCannabicsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableEquitySecuritiesTextualAbstract" xlink:label="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOwnershipPercentage" xlink:label="loc_wizpInvestmentOwnershipPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_wizpInvestmentOwnershipPercentage_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital" xlink:label="loc_wizpMinimumPercentageOfIssuedAndOutstandingShareCapital_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_wizpMinimumPercentageOfIssuedAndOutstandingShareCapital_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaapMarketableSecuritiesNoncurrent_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_us-gaapMarketableSecuritiesNoncurrent_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableEquityDescription" xlink:label="loc_wizpMarketableEquityDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_wizpMarketableEquityDescription_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncomeFromChangeInFairValue" xlink:label="loc_wizpIncomeFromChangeInFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_wizpIncomeFromChangeInFairValue_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract_80" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_80" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssetsDetails" xlink:title="00000043 - Disclosure - Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicenseAgreementDetails" xlink:title="00000044 - Disclosure - License Agreement (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementTextualAbstract" xlink:label="loc_wizpLicenseAgreementTextualAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpLicenseAgreementTextualAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfDiscountRate" xlink:label="loc_wizpPercentageOfDiscountRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicenseAgreementTextualAbstract_70" xlink:to="loc_wizpPercentageOfDiscountRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicenseAgreementTextualAbstract_70" xlink:to="loc_us-gaapPaymentsForRoyalties_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsAndOtherAssets" xlink:label="loc_us-gaapDeferredCostsAndOtherAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicenseAgreementTextualAbstract_70" xlink:to="loc_us-gaapDeferredCostsAndOtherAssets_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementDescription" xlink:label="loc_wizpLicenseAgreementDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicenseAgreementTextualAbstract_70" xlink:to="loc_wizpLicenseAgreementDescription_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RecognizedLeaseLiability" xlink:label="loc_wizpRecognizedLeaseLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicenseAgreementTextualAbstract_70" xlink:to="loc_wizpRecognizedLeaseLiability_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfContingentObligation" xlink:label="loc_wizpPercentageOfContingentObligation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicenseAgreementTextualAbstract_70" xlink:to="loc_wizpPercentageOfContingentObligation_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PenaltyPayment" xlink:label="loc_wizpPenaltyPayment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicenseAgreementTextualAbstract_70" xlink:to="loc_wizpPenaltyPayment_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationDetails" xlink:title="00000045 - Disclosure - License Purchase Obligation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual" xlink:title="00000046 - Disclosure - License Purchase Obligation (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecuritiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementMember" xlink:label="loc_wizpLicenseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_wizpLicenseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationTextualAbstract" xlink:label="loc_wizpLicensePurchaseObligationTextualAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_wizpLicensePurchaseObligationTextualAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MinimumCommitmentAmount" xlink:label="loc_wizpMinimumCommitmentAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicensePurchaseObligationTextualAbstract_70" xlink:to="loc_wizpMinimumCommitmentAmount_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReducedAnnualRoyaltiesDescription" xlink:label="loc_wizpReducedAnnualRoyaltiesDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLicensePurchaseObligationTextualAbstract_70" xlink:to="loc_wizpReducedAnnualRoyaltiesDescription_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayableDetails" xlink:title="00000047 - Disclosure - Accounts Payable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetails" xlink:title="00000048 - Disclosure - Convertible Loans (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleDebtOneMember" xlink:label="loc_wizpConvertibleDebtOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpConvertibleDebtOneMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtMember" xlink:label="loc_us-gaapDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDebtMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AggregatePrincipalAmount" xlink:label="loc_wizpAggregatePrincipalAmount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpAggregatePrincipalAmount_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AggregateMaximumOfRightToFutureInvestment" xlink:label="loc_wizpAggregateMaximumOfRightToFutureInvestment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpAggregateMaximumOfRightToFutureInvestment_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExercisePriceOfRightToFutureInvestment" xlink:label="loc_wizpExercisePriceOfRightToFutureInvestment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpExercisePriceOfRightToFutureInvestment_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetails1" xlink:title="00000049 - Disclosure - Convertible Loans (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanRollForwardAbstract" xlink:label="loc_wizpLoanRollForwardAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpLoanRollForwardAbstract_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_us-gaapDebtCurrent_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoans" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoans_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoans_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoan" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoan_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoan_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DerecognitionLoanUponExtinguishment" xlink:label="loc_wizpDerecognitionLoanUponExtinguishment_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpDerecognitionLoanUponExtinguishment_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnLoan" xlink:label="loc_wizpAccruedInterestOnLoan_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpAccruedInterestOnLoan_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoan" xlink:label="loc_wizpAmountAllocatedToLoan_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpAmountAllocatedToLoan_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansOne_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansOne_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DerecognitionLoanUponExtinguishmentOne" xlink:label="loc_wizpDerecognitionLoanUponExtinguishmentOne_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpDerecognitionLoanUponExtinguishmentOne_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanOne" xlink:label="loc_wizpAmountAllocatedToLoanOne_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpAmountAllocatedToLoanOne_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansTwo_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansTwo_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpLoanRollForwardAbstract_20" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_20" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetailsTextual" xlink:title="00000050 - Disclosure - Convertible Loans (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleDebtOneMember" xlink:label="loc_wizpConvertibleDebtOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpConvertibleDebtOneMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneSevenLoanAmendmentMember" xlink:label="loc_wizpTwoZeroOneSevenLoanAmendmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroOneSevenLoanAmendmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneNineLoanAmendmentMember" xlink:label="loc_wizpTwoZeroOneNineLoanAmendmentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroOneNineLoanAmendmentMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneSixLoanAmendmentMember" xlink:label="loc_wizpTwoZeroOneSixLoanAmendmentMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroOneSixLoanAmendmentMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MayTwoThousandNineteenAmendmentMember" xlink:label="loc_wizpMayTwoThousandNineteenAmendmentMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpMayTwoThousandNineteenAmendmentMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WizeIsraelMember" xlink:label="loc_wizpWizeIsraelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpWizeIsraelMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LendersMember" xlink:label="loc_wizpLendersMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpLendersMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldMember" xlink:label="loc_wizpRimonGoldMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpRimonGoldMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldAndFisherMember" xlink:label="loc_wizpRimonGoldAndFisherMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpRimonGoldAndFisherMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyAxis" xlink:label="loc_wizpTypesOfCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_wizpTypesOfCurrencyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NisMember" xlink:label="loc_wizpNisMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypesOfCurrencyDomain" xlink:to="loc_wizpNisMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtMember" xlink:label="loc_us-gaapDebtMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDebtMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoansTextualAbstract" xlink:label="loc_wizpConvertibleLoansTextualAbstract_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpConvertibleLoansTextualAbstract_470" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapConvertibleDebt_470" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_470" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_470" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_470" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_470" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount" xlink:label="loc_us-gaapInvestmentCompanyFinancialCommitmentToInvesteeFutureAmount_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapInvestmentCompanyFinancialCommitmentToInvesteeFutureAmount_470" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription_470" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription" xlink:label="loc_us-gaapDebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription_470" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapSharesIssuedPricePerShare_470" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_470" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaapDeferredCostsCurrentAndNoncurrent_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDeferredCostsCurrentAndNoncurrent_470" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanAmendmentDescription" xlink:label="loc_wizpLoanAmendmentDescription_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_wizpLoanAmendmentDescription_470" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="loc_us-gaapProceedsFromLoanOriginations1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapProceedsFromLoanOriginations1_470" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentFairValue_470" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividend" xlink:label="loc_wizpDeemedDividend_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_wizpDeemedDividend_470" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_470" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_470" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_470" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnLoan" xlink:label="loc_wizpAccruedInterestOnLoan_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_wizpAccruedInterestOnLoan_470" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOptionExercisePrice" xlink:label="loc_wizpInvestmentOptionExercisePrice_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_wizpInvestmentOptionExercisePrice_470" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpConvertibleLoansTextualAbstract_470" xlink:to="loc_us-gaapDebtInstrumentTerm_470" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ShortTermLoanPayableDetails" xlink:title="00000051 - Disclosure - Short Term Loan Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OcuwizeMember" xlink:label="loc_wizpOcuwizeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpOcuwizeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroTwoZeroLoanMember" xlink:label="loc_wizpTwoZeroTwoZeroLoanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroTwoZeroLoanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyAxis" xlink:label="loc_wizpTypesOfCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_wizpTypesOfCurrencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ILSMember" xlink:label="loc_wizpILSMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypesOfCurrencyDomain" xlink:to="loc_wizpILSMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ShortTermLoanPayableTextual" xlink:label="loc_wizpShortTermLoanPayableTextual_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpShortTermLoanPayableTextual_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BankAccount" xlink:label="loc_wizpBankAccount_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpBankAccount_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsDetails" xlink:title="00000052 - Disclosure - Significant Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsDetailsTextual" xlink:title="00000053 - Disclosure - Significant Transactions (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementAxis" xlink:label="loc_wizpTypeOfAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_wizpTypeOfAgreementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementDomain" xlink:label="loc_wizpTypeOfAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_wizpTypeOfAgreementAxis" xlink:to="loc_wizpTypeOfAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementDomain" xlink:label="loc_wizpTypeOfAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_wizpTypeOfAgreementAxis" xlink:to="loc_wizpTypeOfAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusExchangeAgreementMember" xlink:label="loc_wizpBonusExchangeAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpBonusExchangeAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusAgreementsMember" xlink:label="loc_wizpBonusAgreementsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpBonusAgreementsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesBPurchaseAgreementMember" xlink:label="loc_wizpSeriesBPurchaseAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpSeriesBPurchaseAgreementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SettlementSharesMember" xlink:label="loc_wizpSettlementSharesMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpSettlementSharesMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyAxis" xlink:label="loc_wizpTypesOfCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_wizpTypesOfCurrencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IsraeliShekelMember" xlink:label="loc_wizpIsraeliShekelMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypesOfCurrencyDomain" xlink:to="loc_wizpIsraeliShekelMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsTextualAbstract" xlink:label="loc_wizpSignificantTransactionsTextualAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SecuritiesPurchaseAgreementDescription" xlink:label="loc_wizpSecuritiesPurchaseAgreementDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpSecuritiesPurchaseAgreementDescription_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WarrantTermDescription" xlink:label="loc_wizpWarrantTermDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpWarrantTermDescription_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_EscrowAmount" xlink:label="loc_wizpEscrowAmount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpEscrowAmount_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapSharePrice_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PricePerShareAtDateOfAgreement" xlink:label="loc_wizpPricePerShareAtDateOfAgreement_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpPricePerShareAtDateOfAgreement_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PricePerShareAtClosingDate" xlink:label="loc_wizpPricePerShareAtClosingDate_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpPricePerShareAtClosingDate_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OutstandingShareCapitalPercentage" xlink:label="loc_wizpOutstandingShareCapitalPercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpOutstandingShareCapitalPercentage_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdditionalOrdinaryShares" xlink:label="loc_wizpAdditionalOrdinaryShares_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpAdditionalOrdinaryShares_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusSharesHeldInEscrow" xlink:label="loc_wizpBonusSharesHeldInEscrow_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpBonusSharesHeldInEscrow_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapMarketableSecurities_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentInMarketableSecuritiesBonusShares" xlink:label="loc_wizpInvestmentInMarketableSecuritiesBonusShares_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpInvestmentInMarketableSecuritiesBonusShares_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemableFairValue" xlink:label="loc_wizpRedeemableFairValue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpRedeemableFairValue_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemablePreferredStockLiability" xlink:label="loc_wizpRedeemablePreferredStockLiability_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpRedeemablePreferredStockLiability_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceExpenses" xlink:label="loc_wizpFinanceExpenses_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpFinanceExpenses_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOfMarketableSecuritiesPercentage" xlink:label="loc_wizpInvestmentOfMarketableSecuritiesPercentage_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpInvestmentOfMarketableSecuritiesPercentage_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CashOfInvestment" xlink:label="loc_wizpCashOfInvestment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpCashOfInvestment_220" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinancialIncome" xlink:label="loc_wizpFinancialIncome_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpFinancialIncome_220" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapRestrictedCash_220" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossDueToRevaluation" xlink:label="loc_wizpLossDueToRevaluation_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpLossDueToRevaluation_220" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParticipationRights" xlink:label="loc_us-gaapPreferredStockParticipationRights_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_us-gaapPreferredStockParticipationRights_220" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FairValueOfBonusSharesAndAmount" xlink:label="loc_wizpFairValueOfBonusSharesAndAmount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpFairValueOfBonusSharesAndAmount_220" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReceivedCashProceeds" xlink:label="loc_wizpReceivedCashProceeds_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpReceivedCashProceeds_220" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemAllOfSeriesBPreferredStockDescription" xlink:label="loc_wizpRedeemAllOfSeriesBPreferredStockDescription_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpRedeemAllOfSeriesBPreferredStockDescription_220" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfBonusAgreements" xlink:label="loc_wizpDescriptionOfBonusAgreements_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpDescriptionOfBonusAgreements_220" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransaction" xlink:label="loc_wizpBonusTransaction_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpBonusTransaction_220" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusSharesOfSeriesBPreferredStock." xlink:label="loc_wizpBonusSharesOfSeriesBPreferredStock._220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSignificantTransactionsTextualAbstract_220" xlink:to="loc_wizpBonusSharesOfSeriesBPreferredStock._220" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails" xlink:title="00000054 - Disclosure - Taxes on Income (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails1" xlink:title="00000055 - Disclosure - Taxes on Income (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails2" xlink:title="00000056 - Disclosure - Taxes on Income (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetailsTextual" xlink:title="00000057 - Disclosure - Taxes on Income (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OcuwizeMember" xlink:label="loc_wizpOcuwizeMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpOcuwizeMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WizeIsraelMember" xlink:label="loc_wizpWizeIsraelMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpWizeIsraelMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TaxesOnIncomeTextualAbstract" xlink:label="loc_wizpTaxesOnIncomeTextualAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncomeTaxRatePercentageDescription" xlink:label="loc_wizpIncomeTaxRatePercentageDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_wizpIncomeTaxRatePercentageDescription_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CorporateAndDeferredTaxDescription" xlink:label="loc_wizpCorporateAndDeferredTaxDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_wizpCorporateAndDeferredTaxDescription_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CorporateTaxRate" xlink:label="loc_wizpCorporateTaxRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_wizpCorporateTaxRate_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_us-gaapOperatingLossCarryforwards_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract_110" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_110" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000058 - Disclosure - Commitments and Contingencies (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetails" xlink:title="00000059 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneTwoPlanMember" xlink:label="loc_wizpTwoZeroOneTwoPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneTwoPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetails1" xlink:title="00000060 - Disclosure - Stockholders&apos; Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneEightPlanMember" xlink:label="loc_wizpTwoZeroOneEightPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneEightPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:to="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:to="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_50" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetailsTextual" xlink:title="00000061 - Disclosure - Stockholders&apos; Equity (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwentyTwelveStockIncentivePlanMember" xlink:label="loc_wizpTwentyTwelveStockIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwentyTwelveStockIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesAWarrantsMember" xlink:label="loc_wizpSeriesAWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_wizpSeriesAWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaapPreferredClassAMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredClassAMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoThousandTwelvePlanMemberrMember" xlink:label="loc_wizpTwoThousandTwelvePlanMemberrMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_wizpTwoThousandTwelvePlanMemberrMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_EmployeeStockOptionTwoMember" xlink:label="loc_wizpEmployeeStockOptionTwoMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_wizpEmployeeStockOptionTwoMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldAndFisherMember" xlink:label="loc_wizpRimonGoldAndFisherMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpRimonGoldAndFisherMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockholdersEquityTextualAbstract" xlink:label="loc_wizpStockholdersEquityTextualAbstract_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpStockholdersEquityTextualAbstract_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapCommonStockSharesIssued_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_450" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapInvestments_450" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_450" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapSharesIssuedPricePerShare_450" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_450" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_450" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RegistrationStatementDescription" xlink:label="loc_wizpRegistrationStatementDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpRegistrationStatementDescription_450" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SecuritiesPurchaseAgreementDescription" xlink:label="loc_wizpSecuritiesPurchaseAgreementDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpSecuritiesPurchaseAgreementDescription_450" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WarrantTermDescription" xlink:label="loc_wizpWarrantTermDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpWarrantTermDescription_450" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_450" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfTradingActivitiesAndManagementOfRelatedRisks" xlink:label="loc_us-gaapDescriptionOfTradingActivitiesAndManagementOfRelatedRisks_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapDescriptionOfTradingActivitiesAndManagementOfRelatedRisks_450" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_450" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceExpense" xlink:label="loc_wizpFinanceExpense_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpFinanceExpense_450" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_450" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockDesignated" xlink:label="loc_wizpPreferredStockDesignated_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpPreferredStockDesignated_450" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockDesignatedStock" xlink:label="loc_wizpPreferredStockDesignatedStock_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpPreferredStockDesignatedStock_450" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapDividendsCommonStockStock_450" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_450" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiquidatedDamagesToInvestorsDescription" xlink:label="loc_wizpLiquidatedDamagesToInvestorsDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpLiquidatedDamagesToInvestorsDescription_450" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PlacementAgencyAgreementDescription" xlink:label="loc_wizpPlacementAgencyAgreementDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpPlacementAgencyAgreementDescription_450" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PlacementAgentWarrantsDescription" xlink:label="loc_wizpPlacementAgentWarrantsDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpPlacementAgentWarrantsDescription_450" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_JointVentureAgreementDescription" xlink:label="loc_wizpJointVentureAgreementDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpJointVentureAgreementDescription_450" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_450" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapAdditionalPaidInCapital_450" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaapChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_450" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChairmanAppointmentAgreementDescription" xlink:label="loc_wizpChairmanAppointmentAgreementDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpChairmanAppointmentAgreementDescription_450" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockOptionsGrantedDuringVestingPeriod" xlink:label="loc_wizpStockOptionsGrantedDuringVestingPeriod_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpStockOptionsGrantedDuringVestingPeriod_450" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_450" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapSharesIssued_450" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuanceToConsultantRelatedDescription" xlink:label="loc_wizpStockIssuanceToConsultantRelatedDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpStockIssuanceToConsultantRelatedDescription_450" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExtinguishmentOfLoansDescription" xlink:label="loc_wizpExtinguishmentOfLoansDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpExtinguishmentOfLoansDescription_450" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities_450" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockOutstandingRelatedDescription" xlink:label="loc_wizpStockOutstandingRelatedDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpStockOutstandingRelatedDescription_450" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_450" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuanceToEmployeesRelatedDescription" xlink:label="loc_wizpStockIssuanceToEmployeesRelatedDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpStockIssuanceToEmployeesRelatedDescription_450" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_450" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_450" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_450" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossOfChangeInFairValue" xlink:label="loc_wizpLossOfChangeInFairValue_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpLossOfChangeInFairValue_450" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WeightedaveragePeriod" xlink:label="loc_wizpWeightedaveragePeriod_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpStockholdersEquityTextualAbstract_450" xlink:to="loc_wizpWeightedaveragePeriod_450" xlink:type="arc" order="46" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails" xlink:title="00000062 - Disclosure - Selected Statements of Operations Data (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:label="loc_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OverseasTravelMember" xlink:label="loc_wizpOverseasTravelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpOverseasTravelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ShareBasedPaymentMember" xlink:label="loc_wizpShareBasedPaymentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpShareBasedPaymentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RentAndOfficeMaintenanceMember" xlink:label="loc_wizpRentAndOfficeMaintenanceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpRentAndOfficeMaintenanceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PayrollAndBenefitsMember" xlink:label="loc_wizpPayrollAndBenefitsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpPayrollAndBenefitsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProfessionalServicesAndConsultationMember" xlink:label="loc_wizpProfessionalServicesAndConsultationMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpProfessionalServicesAndConsultationMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransactionCostsMember" xlink:label="loc_wizpBonusTransactionCostsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpBonusTransactionCostsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TaxesAndTollsMember" xlink:label="loc_wizpTaxesAndTollsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpTaxesAndTollsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DirectorSalaryAndInsuranceMember" xlink:label="loc_wizpDirectorSalaryAndInsuranceMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpDirectorSalaryAndInsuranceMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherExpensesMember" xlink:label="loc_wizpOtherExpensesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpOtherExpensesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_210" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1" xlink:title="00000063 - Disclosure - Selected Statements of Operations Data (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails" xlink:title="00000064 - Disclosure - Related Parties Balances and Transactions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1" xlink:title="00000065 - Disclosure - Related Parties Balances and Transactions (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:title="00000066 - Disclosure - Related Parties Balances and Transactions (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SubsequentEventsDetails" xlink:title="00000067 - Disclosure - Subsequent Events (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementAxis" xlink:label="loc_wizpTypeOfAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_wizpTypeOfAgreementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementDomain" xlink:label="loc_wizpTypeOfAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_wizpTypeOfAgreementAxis" xlink:to="loc_wizpTypeOfAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementDomain" xlink:label="loc_wizpTypeOfAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_wizpTypeOfAgreementAxis" xlink:to="loc_wizpTypeOfAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BidAgreementMember" xlink:label="loc_wizpBidAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpBidAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PIPEAgreementsMember" xlink:label="loc_wizpPIPEAgreementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpPIPEAgreementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockRestrictionAgreementMember" xlink:label="loc_wizpStockRestrictionAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpStockRestrictionAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CVRAgreementMember" xlink:label="loc_wizpCVRAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpCVRAgreementMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CosmosConvertibleNotesMember" xlink:label="loc_wizpCosmosConvertibleNotesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_wizpCosmosConvertibleNotesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SubsequentEventsTextualAbstract" xlink:label="loc_wizpSubsequentEventsTextualAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_wizpSubsequentEventsTextualAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CosmosTransactionDescription" xlink:label="loc_wizpCosmosTransactionDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpCosmosTransactionDescription_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OfferDescription" xlink:label="loc_wizpOfferDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpOfferDescription_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndBenefitsTrust" xlink:label="loc_us-gaapCompensationAndBenefitsTrust_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapCompensationAndBenefitsTrust_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusPurchaseAgreements" xlink:label="loc_wizpBonusPurchaseAgreements_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpBonusPurchaseAgreements_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OrdinarySharesOfBonus" xlink:label="loc_wizpOrdinarySharesOfBonus_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpOrdinarySharesOfBonus_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TotalProceedsPayable" xlink:label="loc_wizpTotalProceedsPayable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpTotalProceedsPayable_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleTermsOfConversionFeature_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapDebtInstrumentConvertibleTermsOfConversionFeature_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapSharesIssuedPricePerShare_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" xlink:label="loc_wizpStockIssuedDuringPeriodSharesRestrictedStockAwardGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpStockIssuedDuringPeriodSharesRestrictedStockAwardGrant_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RestrictedStockUnitsVestTerm" xlink:label="loc_wizpRestrictedStockUnitsVestTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpRestrictedStockUnitsVestTerm_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExpressedBonusAmount" xlink:label="loc_wizpExpressedBonusAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_wizpExpressedBonusAmount_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapSharesIssued_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapPreferredStockSharesIssued_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wizpSubsequentEventsTextualAbstract_110" xlink:to="loc_us-gaapSaleOfStockPricePerShare_110" xlink:type="arc" order="18" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>wizp-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: wizp%2D20201231.xfr; Date: 2021%2D03%2D01T18:25:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020020 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">2017 Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneEightPlanMember" xlink:label="wizp_TwoZeroOneEightPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroOneEightPlanMember" xlink:to="wizp_TwoZeroOneEightPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwoZeroOneEightPlanMember_lbl" xml:lang="en-US">2018 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtMember" xlink:to="us-gaap_DebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtMember_lbl" xml:lang="en-US">2017 loan amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleDebtOneMember" xlink:label="wizp_ConvertibleDebtOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ConvertibleDebtOneMember" xlink:to="wizp_ConvertibleDebtOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ConvertibleDebtOneMember_lbl" xml:lang="en-US">2016 Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CannabicsMember" xlink:label="wizp_CannabicsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CannabicsMember" xlink:to="wizp_CannabicsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CannabicsMember_lbl" xml:lang="en-US">Cannabics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="country_IL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US">ISRAEL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OcuwizeMember" xlink:label="wizp_OcuwizeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OcuwizeMember" xlink:to="wizp_OcuwizeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OcuwizeMember_lbl" xml:lang="en-US">OcuWize [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WizeIsraelMember" xlink:label="wizp_WizeIsraelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_WizeIsraelMember" xlink:to="wizp_WizeIsraelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_WizeIsraelMember_lbl" xml:lang="en-US">Wize Israel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DirectorSalaryAndInsuranceMember" xlink:label="wizp_DirectorSalaryAndInsuranceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DirectorSalaryAndInsuranceMember" xlink:to="wizp_DirectorSalaryAndInsuranceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DirectorSalaryAndInsuranceMember_lbl" xml:lang="en-US">Director Salary And Insurance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TaxesAndTollsMember" xlink:label="wizp_TaxesAndTollsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TaxesAndTollsMember" xlink:to="wizp_TaxesAndTollsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TaxesAndTollsMember_lbl" xml:lang="en-US">Taxes And Tolls [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProfessionalServicesAndConsultationMember" xlink:label="wizp_ProfessionalServicesAndConsultationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProfessionalServicesAndConsultationMember" xlink:to="wizp_ProfessionalServicesAndConsultationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ProfessionalServicesAndConsultationMember_lbl" xml:lang="en-US">Professional Services And Consultation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PayrollAndBenefitsMember" xlink:label="wizp_PayrollAndBenefitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PayrollAndBenefitsMember" xlink:to="wizp_PayrollAndBenefitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PayrollAndBenefitsMember_lbl" xml:lang="en-US">Payroll And Benefits [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RentAndOfficeMaintenanceMember" xlink:label="wizp_RentAndOfficeMaintenanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RentAndOfficeMaintenanceMember" xlink:to="wizp_RentAndOfficeMaintenanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RentAndOfficeMaintenanceMember_lbl" xml:lang="en-US">Rent And Office Maintenance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ShareBasedPaymentMember" xlink:label="wizp_ShareBasedPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ShareBasedPaymentMember" xlink:to="wizp_ShareBasedPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ShareBasedPaymentMember_lbl" xml:lang="en-US">Share Based Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OverseasTravelMember" xlink:label="wizp_OverseasTravelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OverseasTravelMember" xlink:to="wizp_OverseasTravelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OverseasTravelMember_lbl" xml:lang="en-US">Overseas Travel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherExpensesMember" xlink:label="wizp_OtherExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherExpensesMember" xlink:to="wizp_OtherExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OtherExpensesMember_lbl" xml:lang="en-US">Other Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and electronic equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and office equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneTwoPlanMember" xlink:label="wizp_TwoZeroOneTwoPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroOneTwoPlanMember" xlink:to="wizp_TwoZeroOneTwoPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwoZeroOneTwoPlanMember_lbl" xml:lang="en-US">2012 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoThousandTwelvePlanMemberrMember" xlink:label="wizp_TwoThousandTwelvePlanMemberrMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoThousandTwelvePlanMemberrMember" xlink:to="wizp_TwoThousandTwelvePlanMemberrMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwoThousandTwelvePlanMemberrMember_lbl" xml:lang="en-US">2012 Plan [Member</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_EmployeeStockOptionTwoMember" xlink:label="wizp_EmployeeStockOptionTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_EmployeeStockOptionTwoMember" xlink:to="wizp_EmployeeStockOptionTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_EmployeeStockOptionTwoMember_lbl" xml:lang="en-US">2018 Plan [Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementMember" xlink:label="wizp_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicenseAgreementMember" xlink:to="wizp_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementAxis" xlink:label="wizp_TypeOfAgreementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TypeOfAgreementAxis" xlink:to="wizp_TypeOfAgreementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TypeOfAgreementAxis_lbl" xml:lang="en-US">Type Of Agreement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusExchangeAgreementMember" xlink:label="wizp_BonusExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusExchangeAgreementMember" xlink:to="wizp_BonusExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusExchangeAgreementMember_lbl" xml:lang="en-US">Bonus Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusAgreementsMember" xlink:label="wizp_BonusAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusAgreementsMember" xlink:to="wizp_BonusAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusAgreementsMember_lbl" xml:lang="en-US">Bonus Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyAxis" xlink:label="wizp_TypesOfCurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TypesOfCurrencyAxis" xlink:to="wizp_TypesOfCurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TypesOfCurrencyAxis_lbl" xml:lang="en-US">Types Of Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IsraeliShekelMember" xlink:label="wizp_IsraeliShekelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IsraeliShekelMember" xlink:to="wizp_IsraeliShekelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IsraeliShekelMember_lbl" xml:lang="en-US">Israeli Shekel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesBPurchaseAgreementMember" xlink:label="wizp_SeriesBPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SeriesBPurchaseAgreementMember" xlink:to="wizp_SeriesBPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SeriesBPurchaseAgreementMember_lbl" xml:lang="en-US">Series B Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SettlementSharesMember" xlink:label="wizp_SettlementSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SettlementSharesMember" xlink:to="wizp_SettlementSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SettlementSharesMember_lbl" xml:lang="en-US">Settlement Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroTwoZeroLoanMember" xlink:label="wizp_TwoZeroTwoZeroLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroTwoZeroLoanMember" xlink:to="wizp_TwoZeroTwoZeroLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwoZeroTwoZeroLoanMember_lbl" xml:lang="en-US">2020 Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ILSMember" xlink:label="wizp_ILSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ILSMember" xlink:to="wizp_ILSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ILSMember_lbl" xml:lang="en-US">NIS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_RangeAxis_2_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TypeOfAgreementAxis" xlink:to="wizp_TypeOfAgreementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_TypeOfAgreementAxis_2_lbl" xml:lang="en-US">Type of Agreement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BidAgreementMember" xlink:label="wizp_BidAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BidAgreementMember" xlink:to="wizp_BidAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BidAgreementMember_lbl" xml:lang="en-US">Bid Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PIPEAgreementsMember" xlink:label="wizp_PIPEAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PIPEAgreementsMember" xlink:to="wizp_PIPEAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PIPEAgreementsMember_lbl" xml:lang="en-US">PIPE Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LendersMember" xlink:label="wizp_LendersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LendersMember" xlink:to="wizp_LendersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LendersMember_lbl" xml:lang="en-US">Lenders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldMember" xlink:label="wizp_RimonGoldMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RimonGoldMember" xlink:to="wizp_RimonGoldMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RimonGoldMember_lbl" xml:lang="en-US">Rimon Gold [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NisMember" xlink:label="wizp_NisMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_NisMember" xlink:to="wizp_NisMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_NisMember_lbl" xml:lang="en-US">NIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneSevenLoanAmendmentMember" xlink:label="wizp_TwoZeroOneSevenLoanAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroOneSevenLoanAmendmentMember" xlink:to="wizp_TwoZeroOneSevenLoanAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwoZeroOneSevenLoanAmendmentMember_lbl" xml:lang="en-US">Two Zero One Seven Loan Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneNineLoanAmendmentMember" xlink:label="wizp_TwoZeroOneNineLoanAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroOneNineLoanAmendmentMember" xlink:to="wizp_TwoZeroOneNineLoanAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwoZeroOneNineLoanAmendmentMember_lbl" xml:lang="en-US">Two Zero One Nine Loan Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldAndFisherMember" xlink:label="wizp_RimonGoldAndFisherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RimonGoldAndFisherMember" xlink:to="wizp_RimonGoldAndFisherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RimonGoldAndFisherMember_lbl" xml:lang="en-US">Rimon Gold And Fisher [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwentyTwelveStockIncentivePlanMember" xlink:label="wizp_TwentyTwelveStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwentyTwelveStockIncentivePlanMember" xlink:to="wizp_TwentyTwelveStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwentyTwelveStockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesAWarrantsMember" xlink:label="wizp_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SeriesAWarrantsMember" xlink:to="wizp_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassAMember_lbl" xml:lang="en-US">Preferred Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MayTwoThousandNineteenAmendmentMember" xlink:label="wizp_MayTwoThousandNineteenAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MayTwoThousandNineteenAmendmentMember" xlink:to="wizp_MayTwoThousandNineteenAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MayTwoThousandNineteenAmendmentMember_lbl" xml:lang="en-US">May 2019 Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockRestrictionAgreementMember" xlink:label="wizp_StockRestrictionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockRestrictionAgreementMember" xlink:to="wizp_StockRestrictionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockRestrictionAgreementMember_lbl" xml:lang="en-US">Stock Restriction Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CVRAgreementMember" xlink:label="wizp_CVRAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CVRAgreementMember" xlink:to="wizp_CVRAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CVRAgreementMember_lbl" xml:lang="en-US">CVR Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CosmosConvertibleNotesMember" xlink:label="wizp_CosmosConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CosmosConvertibleNotesMember" xlink:to="wizp_CosmosConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CosmosConvertibleNotesMember_lbl" xml:lang="en-US">Cosmos Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DocumentAndEntityInformationAbstract" xlink:label="wizp_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DocumentAndEntityInformationAbstract" xlink:to="wizp_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="us-gaap_RestrictedInvestmentsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsCurrent" xlink:to="us-gaap_RestrictedInvestmentsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsCurrent_lbl" xml:lang="en-US">Restricted cash deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableSecuritiesEquitySecuritieCurrent" xlink:label="wizp_MarketableSecuritiesEquitySecuritieCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MarketableSecuritiesEquitySecuritieCurrent" xlink:to="wizp_MarketableSecuritiesEquitySecuritieCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MarketableSecuritiesEquitySecuritieCurrent_lbl" xml:lang="en-US">Marketable equity securities (Notes 3,10)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Account payable (Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligation - current</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationCurrent" xlink:label="wizp_LicensePurchaseObligationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationCurrent" xlink:to="wizp_LicensePurchaseObligationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicensePurchaseObligationCurrent_lbl" xml:lang="en-US">Current portion of license purchase obligation (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short term loan payable (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US">Contingent obligation with respect to future revenues (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT) (Note 13):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock A, with $0.001 par value per share ("Series A Preferred Stock") Authorized: 1,000,000 shares at December 31, 2020 and 2019; Issued and outstanding: 178 shares at December 31, 2020 and 2019.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, with $0.001 par value per share ("Common Stock") 500,000,000 shares authorized at December 31, 2020 and 2019; 32,783,495 and 15,873,128 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock A, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock A, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock A, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock A, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses (Note 14a)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial expense, net (Note 14b)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdditionToNetLossAbstract" xlink:label="wizp_AdditionToNetLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AdditionToNetLossAbstract" xlink:to="wizp_AdditionToNetLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AdditionToNetLossAbstract_lbl" xml:lang="en-US">Addition to net loss (for EPS purpose)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xml:lang="en-US">Deemed dividend with respect to the repurchase of right for future investment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants_lbl" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss applicable to stockholders of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares of common stock used in computing basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_2_lbl" xml:lang="en-US">Series A Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_2_lbl" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Amounts allocated to repurchase of existing right for future investment related to the 2016 Loan and the 2017 Loan (See Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" xlink:label="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" xlink:to="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment_lbl" xml:lang="en-US">Amounts that were allocated to recognition of the right for future investment and warrants - 2016 Loan (See Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" xlink:label="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" xlink:to="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne_lbl" xml:lang="en-US">Amounts that were allocated to recognition of the right for future investment and warrants - 2017 Loan (See Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u" xlink:to="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u_lbl" xml:lang="en-US">Issuance of Common Stock and warrants for cash (Note 13n)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares" xlink:to="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares_lbl" xml:lang="en-US">Issuance of Common Stock and warrants for cash (Note 13n), Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" xlink:to="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t_lbl" xml:lang="en-US">Issuance of Common Stock and warrants due to 2016 Loan and 2017 Loan repayment (Note 13e)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" xlink:to="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares_lbl" xml:lang="en-US">Issuance of Common Stock and warrants due to 2016 Loan and 2017 Loan repayment (Note 13e), Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CumulativeEffectAdjustmentFromTransition" xlink:label="wizp_CumulativeEffectAdjustmentFromTransition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CumulativeEffectAdjustmentFromTransition" xlink:to="wizp_CumulativeEffectAdjustmentFromTransition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CumulativeEffectAdjustmentFromTransition_lbl" xml:lang="en-US">Cumulative effect adjustment from transition to ASU 2016-01</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment_lbl" xml:lang="en-US">Issuance of shares with respect to exercise of PIPE Warrants and right for future investment (Note 11d)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares_lbl" xml:lang="en-US">Issuance of shares with respect to exercise of PIPE Warrants and right for future investment (Note 11d), shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" xlink:label="wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" xlink:to="wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of units consisting of Common Stock, Series A Preferred Stock and detachable warrants net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" xlink:label="wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" xlink:to="wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment_lbl" xml:lang="en-US">Amount allocated to the right for future investment - 2016 Loan upon 2018 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" xlink:label="wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" xlink:to="wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment_lbl" xml:lang="en-US">Amount allocated to the right for future investment - 2017 Loan upon 2018 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" xlink:label="wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" xlink:to="wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment_lbl" xml:lang="en-US">Terms modification and cancellation of existing financial instruments due to 2016 and 2017 loan repayment (Note 8e)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoanExtinguishment" xlink:label="wizp_ConvertibleLoanExtinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ConvertibleLoanExtinguishment" xlink:to="wizp_ConvertibleLoanExtinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ConvertibleLoanExtinguishment_lbl" xml:lang="en-US">Convertible loan extinguishment (Note 8e)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote_lbl" xml:lang="en-US">Issuance of shares with respect to exercise of warrants (Notes 13p, 13q)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares_lbl" xml:lang="en-US">Issuance of shares with respect to exercise of warrants (Notes 13p, 13q), Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock (Note 13b)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock (Note 13b), Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConversionOfPreferredStockIntoCommonStock" xlink:label="wizp_ConversionOfPreferredStockIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ConversionOfPreferredStockIntoCommonStock" xlink:to="wizp_ConversionOfPreferredStockIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ConversionOfPreferredStockIntoCommonStock_lbl" xml:lang="en-US">Conversion of Preferred stock into Common Stock (Note 13c)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConversionOfPreferredStockIntoCommonStockShares" xlink:label="wizp_ConversionOfPreferredStockIntoCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ConversionOfPreferredStockIntoCommonStockShares" xlink:to="wizp_ConversionOfPreferredStockIntoCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ConversionOfPreferredStockIntoCommonStockShares_lbl" xml:lang="en-US">Conversion of Preferred stock into Common Stock (Note 13c), Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoanExtinguishmentAndWarrantsModification" xlink:label="wizp_ConvertibleLoanExtinguishmentAndWarrantsModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ConvertibleLoanExtinguishmentAndWarrantsModification" xlink:to="wizp_ConvertibleLoanExtinguishmentAndWarrantsModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ConvertibleLoanExtinguishmentAndWarrantsModification_lbl" xml:lang="en-US">Convertible loan extinguishment and warrants modification (Note 11h)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants_lbl" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" xlink:label="wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" xlink:to="wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment_lbl" xml:lang="en-US">Deemed dividends with respect to the repurchase of right for future investment (See Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote_lbl" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants (Notes 13p, 13q)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xml:lang="en-US">Income (loss) from marketable equity securities sale and revaluation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premium related to convertible loans (Notes 8 and 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnConvertibleLoans" xlink:label="wizp_AccruedInterestOnConvertibleLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnConvertibleLoans" xlink:to="wizp_AccruedInterestOnConvertibleLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AccruedInterestOnConvertibleLoans_lbl" xml:lang="en-US">Accrued interest on convertible loans (Notes 8 and 13b)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss from extinguishment of convertible loans (Notes 8 and 13b)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GainFromCompletionOfMilestoneClosingNote10" xlink:label="wizp_GainFromCompletionOfMilestoneClosingNote10" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GainFromCompletionOfMilestoneClosingNote10" xlink:to="wizp_GainFromCompletionOfMilestoneClosingNote10_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_GainFromCompletionOfMilestoneClosingNote10_lbl" xml:lang="en-US">Gain from completion of milestone closing (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet_lbl" xml:lang="en-US">Gain from settlement shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:to="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10_lbl" xml:lang="en-US">Loss from recognition of mandatorily redeemable Series B Preferred Stock (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:to="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_lbl" xml:lang="en-US">Change from revaluation of mandatorily redeemable Series B Preferred Stock (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:label="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:to="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10_lbl" xml:lang="en-US">Change from revaluation of contingent obligation with respect to future revenues (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncreaseDecreaseInLicensePurchaseObligation" xlink:label="wizp_IncreaseDecreaseInLicensePurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IncreaseDecreaseInLicensePurchaseObligation" xlink:to="wizp_IncreaseDecreaseInLicensePurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IncreaseDecreaseInLicensePurchaseObligation_lbl" xml:lang="en-US">Increase in license purchase obligation (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinancialExpenses" xlink:label="wizp_FinancialExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinancialExpenses" xlink:to="wizp_FinancialExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_FinancialExpenses_lbl" xml:lang="en-US">Financial expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PurchaseOfPropertyAndEquipment" xlink:label="wizp_PurchaseOfPropertyAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PurchaseOfPropertyAndEquipment" xlink:to="wizp_PurchaseOfPropertyAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_PurchaseOfPropertyAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from sale of marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromIssuanceOfSharesAndWarrants" xlink:label="wizp_ProceedsFromIssuanceOfSharesAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProceedsFromIssuanceOfSharesAndWarrants" xlink:to="wizp_ProceedsFromIssuanceOfSharesAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ProceedsFromIssuanceOfSharesAndWarrants_lbl" xml:lang="en-US">Proceeds from issuance of shares and warrants (Note 13n)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:label="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:to="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment_lbl" xml:lang="en-US">Net proceeds from issuance of mandatorily redeemable Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanReceived" xlink:label="wizp_LoanReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LoanReceived" xlink:to="wizp_LoanReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="wizp_LoanReceived_lbl" xml:lang="en-US">Loan received</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Convertible loan repayment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromRepaymentOfLicensePurchaseObligation" xlink:label="wizp_ProceedsFromRepaymentOfLicensePurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProceedsFromRepaymentOfLicensePurchaseObligation" xlink:to="wizp_ProceedsFromRepaymentOfLicensePurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ProceedsFromRepaymentOfLicensePurchaseObligation_lbl" xml:lang="en-US">Repayment of license purchase obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate change on cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities" xlink:label="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities" xlink:to="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities_lbl" xml:lang="en-US">Ordinary shares issued through receipt of marketable securities (Note 13b)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:label="wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:to="wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment_lbl" xml:lang="en-US">Amount allocated to the&#160;repurchase right for existing right for future investment related to the 2016 Loan and the 2017 Loan - March 2019 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountThatWasAllocatedToRightForFutureInvestment" xlink:label="wizp_AmountThatWasAllocatedToRightForFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountThatWasAllocatedToRightForFutureInvestment" xlink:to="wizp_AmountThatWasAllocatedToRightForFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountThatWasAllocatedToRightForFutureInvestment_lbl" xml:lang="en-US">Amounts that were allocated to the recognition of right for future investment - 2016 Loan - March 2019 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment" xlink:label="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment" xlink:to="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment_lbl" xml:lang="en-US">Amounts that were allocated to the recognition of right for future investment - 2017 Loan - March 2019 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" xlink:label="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" xlink:to="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan_lbl" xml:lang="en-US">Deemed dividends with respect to the repurchase of&#160;right for future investment - March 2019 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:label="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:to="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment_lbl" xml:lang="en-US">Amount allocated to the&#160;repurchase right for existing right to future investment related to the 2016 Loan and the 2017 Loan - May 2019 Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne" xlink:label="wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne" xlink:to="wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne_lbl" xml:lang="en-US">Amounts that were allocated to the right for future investment and warrants - 2016 Loan - May 2019 Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo" xlink:label="wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo" xlink:to="wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo_lbl" xml:lang="en-US">Amounts that were allocated to the right for future investment and warrants - 2017 Loan - May 2019 Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" xlink:label="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" xlink:to="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne_lbl" xml:lang="en-US">Deemed dividends with respect to the repurchase of&#160;right for future investment - May 2019 Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanAmendment" xlink:label="wizp_AmountAllocatedToLoanAmendment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToLoanAmendment" xlink:to="wizp_AmountAllocatedToLoanAmendment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToLoanAmendment_lbl" xml:lang="en-US">Amount allocated to the 2016 Loan - March 2019 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanAmendmentOne" xlink:label="wizp_AmountAllocatedToLoanAmendmentOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToLoanAmendmentOne" xlink:to="wizp_AmountAllocatedToLoanAmendmentOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToLoanAmendmentOne_lbl" xml:lang="en-US">Amount allocated to the 2017 Loan - March 2019 Loan Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanExtension" xlink:label="wizp_AmountAllocatedToLoanExtension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToLoanExtension" xlink:to="wizp_AmountAllocatedToLoanExtension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToLoanExtension_lbl" xml:lang="en-US">Amount allocated to the 2016 Loan - May 2019 Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanExtensionOne" xlink:label="wizp_AmountAllocatedToLoanExtensionOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToLoanExtensionOne" xlink:to="wizp_AmountAllocatedToLoanExtensionOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToLoanExtensionOne_lbl" xml:lang="en-US">Amount allocated to the 2017 Loan - May 2019 Amendment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RepaymentOfConvertibleLoansThroughCommonStock" xlink:label="wizp_RepaymentOfConvertibleLoansThroughCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RepaymentOfConvertibleLoansThroughCommonStock" xlink:to="wizp_RepaymentOfConvertibleLoansThroughCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RepaymentOfConvertibleLoansThroughCommonStock_lbl" xml:lang="en-US">Repayment of convertible loans through Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants_lbl" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SELLOFCANNABICSSHARETHROUGHABROKER" xlink:label="wizp_SELLOFCANNABICSSHARETHROUGHABROKER" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SELLOFCANNABICSSHARETHROUGHABROKER" xlink:to="wizp_SELLOFCANNABICSSHARETHROUGHABROKER_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SELLOFCANNABICSSHARETHROUGHABROKER_lbl" xml:lang="en-US">Sell of Cannabics's shares through a broker</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" xlink:label="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" xlink:to="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow_lbl" xml:lang="en-US">Amounts transferred from Series B Preferred Stock proceeds to restricted deposit held in escrow</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentInMarketableSecuritiesBonusShares" xlink:label="wizp_InvestmentInMarketableSecuritiesBonusShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_InvestmentInMarketableSecuritiesBonusShares" xlink:to="wizp_InvestmentInMarketableSecuritiesBonusShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_InvestmentInMarketableSecuritiesBonusShares_lbl" xml:lang="en-US">Investment in marketable securities - Bonus Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues" xlink:label="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues" xlink:to="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues_lbl" xml:lang="en-US">Recognition of contingent obligation with respect to future revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock" xlink:label="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock" xlink:to="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock_lbl" xml:lang="en-US">Issuance of mandatorily redeemable Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" xlink:label="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" xlink:to="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares_lbl" xml:lang="en-US">Settlement of mandatorily redeemable series B Preferred Stock through distribution of Bonus Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants_lbl" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of shares with respect to exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiabilityToHcw" xlink:label="wizp_LiabilityToHcw" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LiabilityToHcw" xlink:to="wizp_LiabilityToHcw_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LiabilityToHcw_lbl" xml:lang="en-US">Transaction costs liability, see note 10</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReleaseOfEscrowAccountBonusShares" xlink:label="wizp_ReleaseOfEscrowAccountBonusShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReleaseOfEscrowAccountBonusShares" xlink:to="wizp_ReleaseOfEscrowAccountBonusShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ReleaseOfEscrowAccountBonusShares_lbl" xml:lang="en-US">Release of escrow account &#8211; Bonus Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">MARKETABLE EQUITY SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementAbstract" xlink:label="wizp_LicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicenseAgreementAbstract" xlink:to="wizp_LicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicenseAgreementAbstract_lbl" xml:lang="en-US">License Agreement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementTextBlock" xlink:label="wizp_LicenseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicenseAgreementTextBlock" xlink:to="wizp_LicenseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicenseAgreementTextBlock_lbl" xml:lang="en-US">LICENSE AGREEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationAbstract" xlink:label="wizp_LicensePurchaseObligationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationAbstract" xlink:to="wizp_LicensePurchaseObligationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicensePurchaseObligationAbstract_lbl" xml:lang="en-US">License Purchase Obligation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationTextBlock" xlink:label="wizp_LicensePurchaseObligationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationTextBlock" xlink:to="wizp_LicensePurchaseObligationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicensePurchaseObligationTextBlock_lbl" xml:lang="en-US">LICENSE PURCHASE OBLIGATION</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherAccountsPayableAbstract" xlink:label="wizp_OtherAccountsPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherAccountsPayableAbstract" xlink:to="wizp_OtherAccountsPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OtherAccountsPayableAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherAccountsPayableTextBlock" xlink:label="wizp_OtherAccountsPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherAccountsPayableTextBlock" xlink:to="wizp_OtherAccountsPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OtherAccountsPayableTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE LOANS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT TERM LOAN PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsAbstract" xlink:label="wizp_SignificantTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SignificantTransactionsAbstract" xlink:to="wizp_SignificantTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsTextBlock" xlink:label="wizp_SignificantTransactionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SignificantTransactionsTextBlock" xlink:to="wizp_SignificantTransactionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">SIGNIFICANT TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SelectedStatementsOfOperationsDataAbstract" xlink:label="wizp_SelectedStatementsOfOperationsDataAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SelectedStatementsOfOperationsDataAbstract" xlink:to="wizp_SelectedStatementsOfOperationsDataAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SelectedStatementsOfOperationsDataAbstract_lbl" xml:lang="en-US">Selected Statements of Operations Data [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SelectedStatementsOfOperationsDataTextBlock" xlink:label="wizp_SelectedStatementsOfOperationsDataTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SelectedStatementsOfOperationsDataTextBlock" xlink:to="wizp_SelectedStatementsOfOperationsDataTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SelectedStatementsOfOperationsDataTextBlock_lbl" xml:lang="en-US">SELECTED STATEMENTS OF OPERATIONS DATA</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES BALANCES AND TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in preparation of Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RestrictedBankDepositPolicyTextBlock" xlink:label="wizp_RestrictedBankDepositPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RestrictedBankDepositPolicyTextBlock" xlink:to="wizp_RestrictedBankDepositPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RestrictedBankDepositPolicyTextBlock_lbl" xml:lang="en-US">Restricted bank deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeverancePayPolicyTextBlock" xlink:label="wizp_SeverancePayPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SeverancePayPolicyTextBlock" xlink:to="wizp_SeverancePayPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of credit risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoanCommitmentsPolicy" xlink:label="us-gaap_LoanCommitmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanCommitmentsPolicy" xlink:to="us-gaap_LoanCommitmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoanCommitmentsPolicy_lbl" xml:lang="en-US">Convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LegalAndOtherContingenciesPolicyTextBlock" xlink:label="wizp_LegalAndOtherContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LegalAndOtherContingenciesPolicyTextBlock" xlink:to="wizp_LegalAndOtherContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LegalAndOtherContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Legal and other contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" xlink:label="wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" xlink:to="wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock_lbl" xml:lang="en-US">Series A Warrants and December 2019 Warrants with Down-Round Protection</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="us-gaap_FiscalPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiscalPeriod" xlink:to="us-gaap_FiscalPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiscalPeriod_lbl" xml:lang="en-US">Disclosure of new accounting standards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements not adopted yet</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" xlink:label="wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" xlink:to="wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock_lbl" xml:lang="en-US">Contingent obligation with respect to future revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" xlink:label="wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" xlink:to="wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Mandatorily Redeemable Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfXchangeRateOfRelevantCurrencies" xlink:label="wizp_ScheduleOfXchangeRateOfRelevantCurrencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfXchangeRateOfRelevantCurrencies" xlink:to="wizp_ScheduleOfXchangeRateOfRelevantCurrencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfXchangeRateOfRelevantCurrencies_lbl" xml:lang="en-US">Schedule of exchange rate of relevant currencies</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfCashAndCashEquivalents" xlink:label="wizp_ScheduleOfCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfCashAndCashEquivalents" xlink:to="wizp_ScheduleOfCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfCashAndCashEquivalents_lbl" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfEstimatedUsefulLivesOfAssets" xlink:label="wizp_ScheduleOfEstimatedUsefulLivesOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfEstimatedUsefulLivesOfAssets" xlink:to="wizp_ScheduleOfEstimatedUsefulLivesOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfEstimatedUsefulLivesOfAssets_lbl" xml:lang="en-US">Schedule of estimated useful lives of the assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" xlink:label="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" xlink:to="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of repayment dates of the remaining minimal commitment on the financial liability</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfOtherAccountsPayableTableTextBlock" xlink:label="wizp_ScheduleOfOtherAccountsPayableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfOtherAccountsPayableTableTextBlock" xlink:to="wizp_ScheduleOfOtherAccountsPayableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfOtherAccountsPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:label="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:to="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock_lbl" xml:lang="en-US">Schedule of 2017 loan and 2016 loan that were amended to be denominated in U.S. dollars instead of NIS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of roll forward of 2017 loan and 2016 loan</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability" xlink:label="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability" xlink:to="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability_lbl" xml:lang="en-US">Schedule of mandatorily redeemable series B liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of loss before taxes on income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax expense or benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of grant of options to employees and directors</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfFinancingExpensesNetTableTextBlock" xlink:label="wizp_ScheduleOfFinancingExpensesNetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfFinancingExpensesNetTableTextBlock" xlink:to="wizp_ScheduleOfFinancingExpensesNetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ScheduleOfFinancingExpensesNetTableTextBlock_lbl" xml:lang="en-US">Schedule of financing expenses net</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock" xlink:label="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock" xlink:to="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of interested and related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of transactions with interested and related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GeneralTextualAbstract" xlink:label="wizp_GeneralTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GeneralTextualAbstract" xlink:to="wizp_GeneralTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_GeneralTextualAbstract_lbl" xml:lang="en-US">General (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Percentage of future revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExchangeOfCommonStock" xlink:label="wizp_ExchangeOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExchangeOfCommonStock" xlink:to="wizp_ExchangeOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ExchangeOfCommonStock_lbl" xml:lang="en-US">Exchange of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Shareholders outstanding percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReminingOutstandingOwnersPercentage" xlink:label="wizp_ReminingOutstandingOwnersPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReminingOutstandingOwnersPercentage" xlink:to="wizp_ReminingOutstandingOwnersPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ReminingOutstandingOwnersPercentage_lbl" xml:lang="en-US">Percentage of expected ownership remains</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Total stockholders' deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ForeignCurrencyExchangeRateTranslation" xlink:label="wizp_ForeignCurrencyExchangeRateTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ForeignCurrencyExchangeRateTranslation" xlink:to="wizp_ForeignCurrencyExchangeRateTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ForeignCurrencyExchangeRateTranslation_lbl" xml:lang="en-US">Currencies</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CurrencyExchangeRatePercentage" xlink:label="wizp_CurrencyExchangeRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CurrencyExchangeRatePercentage" xlink:to="wizp_CurrencyExchangeRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CurrencyExchangeRatePercentage_lbl" xml:lang="en-US">Currencies percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:label="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:to="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NumeratorAbstract" xlink:label="wizp_NumeratorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_NumeratorAbstract" xlink:to="wizp_NumeratorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NetIncomeAttributedToPreferredStock" xlink:label="wizp_NetIncomeAttributedToPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_NetIncomeAttributedToPreferredStock" xlink:to="wizp_NetIncomeAttributedToPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_NetIncomeAttributedToPreferredStock_lbl" xml:lang="en-US">Add: Loss attributed to preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="us-gaap_InvestmentIncomeDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeDividend" xlink:to="us-gaap_InvestmentIncomeDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeDividend_lbl" xml:lang="en-US">Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendWithRespectToRightForFutureInvestment" xlink:label="wizp_DeemedDividendWithRespectToRightForFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendWithRespectToRightForFutureInvestment" xlink:to="wizp_DeemedDividendWithRespectToRightForFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendWithRespectToRightForFutureInvestment_lbl" xml:lang="en-US">Less: Deemed dividend with respect to right for future investment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToDownRoundAdjustment" xlink:label="wizp_DeemedDividendDueToDownRoundAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToDownRoundAdjustment" xlink:to="wizp_DeemedDividendDueToDownRoundAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendDueToDownRoundAdjustment_lbl" xml:lang="en-US">Less: Deemed dividend due to down round adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss applicable to stockholders of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DenominatorAbstract" xlink:label="wizp_DenominatorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DenominatorAbstract" xlink:to="wizp_DenominatorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Shares of Common Stock used in computing basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NetLossPerShareOfCommonStockBasicAndDiluted" xlink:label="wizp_NetLossPerShareOfCommonStockBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_NetLossPerShareOfCommonStockBasicAndDiluted" xlink:to="wizp_NetLossPerShareOfCommonStockBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_NetLossPerShareOfCommonStockBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share of Common Stock, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Number of shares:</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" xlink:label="wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" xlink:to="wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare_lbl" xml:lang="en-US">Common shares used in computing basic and diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" xlink:label="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" xlink:to="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare_lbl" xml:lang="en-US">Preferred Stock and options excluded from the calculations of diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Total accumulated other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantAccountingPoliciesTextualAbstract" xlink:label="wizp_SignificantAccountingPoliciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SignificantAccountingPoliciesTextualAbstract" xlink:to="wizp_SignificantAccountingPoliciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SignificantAccountingPoliciesTextualAbstract_lbl" xml:lang="en-US">Significant Accounting Policies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets and operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DepositPercentage" xlink:label="wizp_DepositPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DepositPercentage" xlink:to="wizp_DepositPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DepositPercentage_lbl" xml:lang="en-US">Percentage of deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax benefit, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xml:lang="en-US">Amortization of right use assets and operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Aggregate purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PurchasePricePerShare" xlink:label="wizp_PurchasePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PurchasePricePerShare" xlink:to="wizp_PurchasePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LeastPercentageOfCarryingAmount" xlink:label="wizp_LeastPercentageOfCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LeastPercentageOfCarryingAmount" xlink:to="wizp_LeastPercentageOfCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LeastPercentageOfCarryingAmount_lbl" xml:lang="en-US">Least percentage of carrying amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:to="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xml:lang="en-US">Percentage of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfContingentObligation" xlink:label="wizp_PercentageOfContingentObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PercentageOfContingentObligation" xlink:to="wizp_PercentageOfContingentObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PercentageOfContingentObligation_lbl" xml:lang="en-US">Percentage of contingent obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfContingentObligation" xlink:label="wizp_DescriptionOfContingentObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DescriptionOfContingentObligation" xlink:to="wizp_DescriptionOfContingentObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DescriptionOfContingentObligation_lbl" xml:lang="en-US">Description of contingent obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfBonueAgreement" xlink:label="wizp_PercentageOfBonueAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PercentageOfBonueAgreement" xlink:to="wizp_PercentageOfBonueAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PercentageOfBonueAgreement_lbl" xml:lang="en-US">Bonus agreements percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:label="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:to="us-gaap_PolicyholderDividendsRateOnPolicyEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PolicyholderDividendsRateOnPolicyEarnings_lbl" xml:lang="en-US">Cash dividends received, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NumberOfBonusSharesDistributedByCompany" xlink:label="wizp_NumberOfBonusSharesDistributedByCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_NumberOfBonusSharesDistributedByCompany" xlink:to="wizp_NumberOfBonusSharesDistributedByCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_NumberOfBonusSharesDistributedByCompany_lbl" xml:lang="en-US">Number of bonus shares distributed by company</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemAllOfSeriesBPreferredStockDescription" xlink:label="wizp_RedeemAllOfSeriesBPreferredStockDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RedeemAllOfSeriesBPreferredStockDescription" xlink:to="wizp_RedeemAllOfSeriesBPreferredStockDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RedeemAllOfSeriesBPreferredStockDescription_lbl" xml:lang="en-US">Redeem Series B Preferred Stock, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfBonusAgreements" xlink:label="wizp_DescriptionOfBonusAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DescriptionOfBonusAgreements" xlink:to="wizp_DescriptionOfBonusAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DescriptionOfBonusAgreements_lbl" xml:lang="en-US">Description of bonus agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GrossProceeds" xlink:label="wizp_GrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GrossProceeds" xlink:to="wizp_GrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PresentValueOfDebtInstrumentPercentage" xlink:label="wizp_PresentValueOfDebtInstrumentPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PresentValueOfDebtInstrumentPercentage" xlink:to="wizp_PresentValueOfDebtInstrumentPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PresentValueOfDebtInstrumentPercentage_lbl" xml:lang="en-US">Present value of debt instrument percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableEquitySecuritiesTextualAbstract" xlink:label="wizp_MarketableEquitySecuritiesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MarketableEquitySecuritiesTextualAbstract" xlink:to="wizp_MarketableEquitySecuritiesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MarketableEquitySecuritiesTextualAbstract_lbl" xml:lang="en-US">Marketable Equity Securities (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Ordinary shares investment holding</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOwnershipPercentage" xlink:label="wizp_InvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_InvestmentOwnershipPercentage" xlink:to="wizp_InvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_InvestmentOwnershipPercentage_lbl" xml:lang="en-US">Percentage of issued and outstanding share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital" xlink:label="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital" xlink:to="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital_lbl" xml:lang="en-US">Minimum percentage of issued and outstanding share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable investment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Marketable securities loss</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableEquityDescription" xlink:label="wizp_MarketableEquityDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MarketableEquityDescription" xlink:to="wizp_MarketableEquityDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MarketableEquityDescription_lbl" xml:lang="en-US">Marketable equity, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncomeFromChangeInFairValue" xlink:label="wizp_IncomeFromChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IncomeFromChangeInFairValue" xlink:to="wizp_IncomeFromChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IncomeFromChangeInFairValue_lbl" xml:lang="en-US">Income from sale of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherGovernmentalAuthoritiesCurrent" xlink:label="wizp_OtherGovernmentalAuthoritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherGovernmentalAuthoritiesCurrent" xlink:to="wizp_OtherGovernmentalAuthoritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OtherGovernmentalAuthoritiesCurrent_lbl" xml:lang="en-US">Governmental authorities</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherReceivable" xlink:label="wizp_OtherReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherReceivable" xlink:to="wizp_OtherReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OtherReceivable_lbl" xml:lang="en-US">Other receivable (Note 3c)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_2_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementTextualAbstract" xlink:label="wizp_LicenseAgreementTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicenseAgreementTextualAbstract" xlink:to="wizp_LicenseAgreementTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicenseAgreementTextualAbstract_lbl" xml:lang="en-US">License Agreement (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfDiscountRate" xlink:label="wizp_PercentageOfDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PercentageOfDiscountRate" xlink:to="wizp_PercentageOfDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PercentageOfDiscountRate_lbl" xml:lang="en-US">Percentage of discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payments for future royalties amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsAndOtherAssets" xlink:label="us-gaap_DeferredCostsAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsAndOtherAssets" xlink:to="us-gaap_DeferredCostsAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsAndOtherAssets_lbl" xml:lang="en-US">Deferred Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementDescription" xlink:label="wizp_LicenseAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicenseAgreementDescription" xlink:to="wizp_LicenseAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicenseAgreementDescription_lbl" xml:lang="en-US">License agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RecognizedLeaseLiability" xlink:label="wizp_RecognizedLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RecognizedLeaseLiability" xlink:to="wizp_RecognizedLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RecognizedLeaseLiability_lbl" xml:lang="en-US">Recognized liability</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PenaltyPayment" xlink:label="wizp_PenaltyPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PenaltyPayment" xlink:to="wizp_PenaltyPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PenaltyPayment_lbl" xml:lang="en-US">Penalty payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationFiscalYearMaturityAbstract_lbl" xml:lang="en-US">Repayment dates:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">January 1, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xml:lang="en-US">January 1, 2021 (see to Note 5)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Remaining balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationCurrent" xlink:to="wizp_LicensePurchaseObligationCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_LicensePurchaseObligationCurrent_2_lbl" xml:lang="en-US">Current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationNet" xlink:label="wizp_LicensePurchaseObligationNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationNet" xlink:to="wizp_LicensePurchaseObligationNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicensePurchaseObligationNet_lbl" xml:lang="en-US">Non-current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationLiabilities" xlink:label="wizp_LicensePurchaseObligationLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationLiabilities" xlink:to="wizp_LicensePurchaseObligationLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicensePurchaseObligationLiabilities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationTextualAbstract" xlink:label="wizp_LicensePurchaseObligationTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationTextualAbstract" xlink:to="wizp_LicensePurchaseObligationTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LicensePurchaseObligationTextualAbstract_lbl" xml:lang="en-US">License Purchase Obligation (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MinimumCommitmentAmount" xlink:label="wizp_MinimumCommitmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MinimumCommitmentAmount" xlink:to="wizp_MinimumCommitmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MinimumCommitmentAmount_lbl" xml:lang="en-US">Minimum commitment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReducedAnnualRoyaltiesDescription" xlink:label="wizp_ReducedAnnualRoyaltiesDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReducedAnnualRoyaltiesDescription" xlink:to="wizp_ReducedAnnualRoyaltiesDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ReducedAnnualRoyaltiesDescription_lbl" xml:lang="en-US">Reduced annual royalties description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and payroll accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiabilityValue" xlink:label="wizp_LiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LiabilityValue" xlink:to="wizp_LiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LiabilityValue_lbl" xml:lang="en-US">Liability to HCW, see Note 10</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TradePayables" xlink:label="wizp_TradePayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TradePayables" xlink:to="wizp_TradePayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TradePayables_lbl" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Total accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AggregatePrincipalAmount" xlink:label="wizp_AggregatePrincipalAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AggregatePrincipalAmount" xlink:to="wizp_AggregatePrincipalAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AggregatePrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per Company's share</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AggregateMaximumOfRightToFutureInvestment" xlink:label="wizp_AggregateMaximumOfRightToFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AggregateMaximumOfRightToFutureInvestment" xlink:to="wizp_AggregateMaximumOfRightToFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AggregateMaximumOfRightToFutureInvestment_lbl" xml:lang="en-US">Aggregate maximum of Right to Future Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExercisePriceOfRightToFutureInvestment" xlink:label="wizp_ExercisePriceOfRightToFutureInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExercisePriceOfRightToFutureInvestment" xlink:to="wizp_ExercisePriceOfRightToFutureInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ExercisePriceOfRightToFutureInvestment_lbl" xml:lang="en-US">Exercise price per Company's share of Right to Future Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanRollForwardAbstract" xlink:label="wizp_LoanRollForwardAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LoanRollForwardAbstract" xlink:to="wizp_LoanRollForwardAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LoanRollForwardAbstract_lbl" xml:lang="en-US">Roll forward of 2017 Loan and 2016 Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US">Opening balance (including accrued interest)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoans" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfPremiumRelatedToConvertibleLoans" xlink:to="wizp_AmortizationOfPremiumRelatedToConvertibleLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoans_lbl" xml:lang="en-US">Amortization of premium related to convertible loans prior to 2018 modification</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoan" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfPremiumRelatedToConvertibleLoan" xlink:to="wizp_AmortizationOfPremiumRelatedToConvertibleLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoan_lbl" xml:lang="en-US">Amortization of premium related to convertible loans following 2018 modification</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DerecognitionLoanUponExtinguishment" xlink:label="wizp_DerecognitionLoanUponExtinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DerecognitionLoanUponExtinguishment" xlink:to="wizp_DerecognitionLoanUponExtinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DerecognitionLoanUponExtinguishment_lbl" xml:lang="en-US">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments - March 2019 modification</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnLoan" xlink:label="wizp_AccruedInterestOnLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnLoan" xlink:to="wizp_AccruedInterestOnLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AccruedInterestOnLoan_lbl" xml:lang="en-US">Accrued interest on 2017 Loan and 2016 Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoan" xlink:label="wizp_AmountAllocatedToLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToLoan" xlink:to="wizp_AmountAllocatedToLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToLoan_lbl" xml:lang="en-US">Amount allocated to 2016 Loan and 2017 Loan based on modified terms - March 2019 modification</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne" xlink:to="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne_lbl" xml:lang="en-US">Amortization of premium related to convertible loans following March 2019 modifications</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DerecognitionLoanUponExtinguishmentOne" xlink:label="wizp_DerecognitionLoanUponExtinguishmentOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DerecognitionLoanUponExtinguishmentOne" xlink:to="wizp_DerecognitionLoanUponExtinguishmentOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DerecognitionLoanUponExtinguishmentOne_lbl" xml:lang="en-US">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments - May 2019 extension</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanOne" xlink:label="wizp_AmountAllocatedToLoanOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToLoanOne" xlink:to="wizp_AmountAllocatedToLoanOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountAllocatedToLoanOne_lbl" xml:lang="en-US">Amount allocated to 2016 Loan and 2017 Loan based on modified terms - May 2019 extension</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo" xlink:to="wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo_lbl" xml:lang="en-US">Amortization of premium related to convertible loans - May 2019 extension</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">November 2019 repayment in cash and Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DebtCurrent_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroOneSevenLoanAmendmentMember" xlink:to="wizp_TwoZeroOneSevenLoanAmendmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_TwoZeroOneSevenLoanAmendmentMember_2_lbl" xml:lang="en-US">2017 Loan Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroOneNineLoanAmendmentMember" xlink:to="wizp_TwoZeroOneNineLoanAmendmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_TwoZeroOneNineLoanAmendmentMember_2_lbl" xml:lang="en-US">2019 Loan Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneSixLoanAmendmentMember" xlink:label="wizp_TwoZeroOneSixLoanAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TwoZeroOneSixLoanAmendmentMember" xlink:to="wizp_TwoZeroOneSixLoanAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TwoZeroOneSixLoanAmendmentMember_lbl" xml:lang="en-US">2016 Loan Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RimonGoldAndFisherMember" xlink:to="wizp_RimonGoldAndFisherMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_RimonGoldAndFisherMember_2_lbl" xml:lang="en-US">Rimon Gold and Shimshon Fisher [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoansTextualAbstract" xlink:label="wizp_ConvertibleLoansTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ConvertibleLoansTextualAbstract" xlink:to="wizp_ConvertibleLoansTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ConvertibleLoansTextualAbstract_lbl" xml:lang="en-US">Convertible Loans (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Converted instrument, amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount" xlink:label="us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount" xlink:to="us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount_lbl" xml:lang="en-US">Right future investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionDescription" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US">Exchange ratio, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription" xlink:label="us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription" xlink:to="us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription_lbl" xml:lang="en-US">Converted debt, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Fixed exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Average exchange rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US">Initial recognition amount</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanAmendmentDescription" xlink:label="wizp_LoanAmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LoanAmendmentDescription" xlink:to="wizp_LoanAmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LoanAmendmentDescription_lbl" xml:lang="en-US">Loan amendment, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="us-gaap_ProceedsFromLoanOriginations1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xml:lang="en-US">Aggregate amount of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividend" xlink:label="wizp_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividend" xlink:to="wizp_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Repayment in cash and common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayment of convertible loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnLoan" xlink:to="wizp_AccruedInterestOnLoan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_AccruedInterestOnLoan_2_lbl" xml:lang="en-US">Accrued interest on loan</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOptionExercisePrice" xlink:label="wizp_InvestmentOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_InvestmentOptionExercisePrice" xlink:to="wizp_InvestmentOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_InvestmentOptionExercisePrice_lbl" xml:lang="en-US">New exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ShortTermLoanPayableTextual" xlink:label="wizp_ShortTermLoanPayableTextual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ShortTermLoanPayableTextual" xlink:to="wizp_ShortTermLoanPayableTextual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ShortTermLoanPayableTextual_lbl" xml:lang="en-US">Short Term Loan Payable (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="us-gaap_DerivativeFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Annual rate</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BankAccount" xlink:label="wizp_BankAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BankAccount" xlink:to="wizp_BankAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BankAccount_lbl" xml:lang="en-US">Bank account</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MandatorilyRedeemableSeriesBLiability" xlink:label="wizp_MandatorilyRedeemableSeriesBLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MandatorilyRedeemableSeriesBLiability" xlink:to="wizp_MandatorilyRedeemableSeriesBLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="wizp_MandatorilyRedeemableSeriesBLiability_lbl" xml:lang="en-US">Opening balance</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesBPreferredStock" xlink:label="wizp_SeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SeriesBPreferredStock" xlink:to="wizp_SeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SeriesBPreferredStock_lbl" xml:lang="en-US">Series B Preferred Stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:to="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10_2_lbl" xml:lang="en-US">Loss from initial recognition of mandatorily redeemable Series B Preferred Stock at fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:to="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_2_lbl" xml:lang="en-US">Revaluation of mandatorily redeemable Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock" xlink:label="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock" xlink:to="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock_lbl" xml:lang="en-US">Redemption of mandatorily redeemable Series B Preferred Stock with Bonus Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_EscrowAmount" xlink:label="wizp_EscrowAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_EscrowAmount" xlink:to="wizp_EscrowAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_EscrowAmount_lbl" xml:lang="en-US">Extinguishment of mandatorily redeemable Series B Preferred Stock by release of escrow account</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MandatorilyRedeemableSeriesBLiability" xlink:to="wizp_MandatorilyRedeemableSeriesBLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="wizp_MandatorilyRedeemableSeriesBLiability_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TypeOfAgreementAxis" xlink:to="wizp_TypeOfAgreementAxis_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="wizp_TypeOfAgreementAxis_3_lbl" xml:lang="en-US">TypeOfAgreementAxis [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IsraeliShekelMember" xlink:to="wizp_IsraeliShekelMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_IsraeliShekelMember_2_lbl" xml:lang="en-US">NIS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsTextualAbstract" xlink:label="wizp_SignificantTransactionsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SignificantTransactionsTextualAbstract" xlink:to="wizp_SignificantTransactionsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SignificantTransactionsTextualAbstract_lbl" xml:lang="en-US">Significant Transactions (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SecuritiesPurchaseAgreementDescription" xlink:label="wizp_SecuritiesPurchaseAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SecuritiesPurchaseAgreementDescription" xlink:to="wizp_SecuritiesPurchaseAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SecuritiesPurchaseAgreementDescription_lbl" xml:lang="en-US">Purchase agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WarrantTermDescription" xlink:label="wizp_WarrantTermDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_WarrantTermDescription" xlink:to="wizp_WarrantTermDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_WarrantTermDescription_lbl" xml:lang="en-US">Warrant term, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_EscrowAmount" xlink:to="wizp_EscrowAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_EscrowAmount_2_lbl" xml:lang="en-US">Escrow amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PricePerShareAtDateOfAgreement" xlink:label="wizp_PricePerShareAtDateOfAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PricePerShareAtDateOfAgreement" xlink:to="wizp_PricePerShareAtDateOfAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PricePerShareAtDateOfAgreement_lbl" xml:lang="en-US">Price per share at the date of agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PricePerShareAtClosingDate" xlink:label="wizp_PricePerShareAtClosingDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PricePerShareAtClosingDate" xlink:to="wizp_PricePerShareAtClosingDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PricePerShareAtClosingDate_lbl" xml:lang="en-US">Price per share at the closing date</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OutstandingShareCapitalPercentage" xlink:label="wizp_OutstandingShareCapitalPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OutstandingShareCapitalPercentage" xlink:to="wizp_OutstandingShareCapitalPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OutstandingShareCapitalPercentage_lbl" xml:lang="en-US">Outstanding share capital percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of ordinary shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Amount of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdditionalOrdinaryShares" xlink:label="wizp_AdditionalOrdinaryShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AdditionalOrdinaryShares" xlink:to="wizp_AdditionalOrdinaryShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AdditionalOrdinaryShares_lbl" xml:lang="en-US">Additional ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusSharesHeldInEscrow" xlink:label="wizp_BonusSharesHeldInEscrow" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusSharesHeldInEscrow" xlink:to="wizp_BonusSharesHeldInEscrow_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusSharesHeldInEscrow_lbl" xml:lang="en-US">Bonus Shares held in escrow</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLoss_2_lbl" xml:lang="en-US">Company recognized a loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Contingent obligation with respect to future revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_InvestmentInMarketableSecuritiesBonusShares" xlink:to="wizp_InvestmentInMarketableSecuritiesBonusShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_InvestmentInMarketableSecuritiesBonusShares_2_lbl" xml:lang="en-US">Investment in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemableFairValue" xlink:label="wizp_RedeemableFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RedeemableFairValue" xlink:to="wizp_RedeemableFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_RedeemableFairValue_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemablePreferredStockLiability" xlink:label="wizp_RedeemablePreferredStockLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RedeemablePreferredStockLiability" xlink:to="wizp_RedeemablePreferredStockLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RedeemablePreferredStockLiability_lbl" xml:lang="en-US">Redeemable preferred stock liability</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceExpenses" xlink:label="wizp_FinanceExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinanceExpenses" xlink:to="wizp_FinanceExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_FinanceExpenses_lbl" xml:lang="en-US">Finance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOfMarketableSecuritiesPercentage" xlink:label="wizp_InvestmentOfMarketableSecuritiesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_InvestmentOfMarketableSecuritiesPercentage" xlink:to="wizp_InvestmentOfMarketableSecuritiesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_InvestmentOfMarketableSecuritiesPercentage_lbl" xml:lang="en-US">Investment of marketable securities percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CashOfInvestment" xlink:label="wizp_CashOfInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CashOfInvestment" xlink:to="wizp_CashOfInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CashOfInvestment_lbl" xml:lang="en-US">Cash of investment</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinancialIncome" xlink:label="wizp_FinancialIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinancialIncome" xlink:to="wizp_FinancialIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_FinancialIncome_lbl" xml:lang="en-US">Financial income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossDueToRevaluation" xlink:label="wizp_LossDueToRevaluation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossDueToRevaluation" xlink:to="wizp_LossDueToRevaluation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LossDueToRevaluation_lbl" xml:lang="en-US">Loss due to revaluation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParticipationRights" xlink:label="us-gaap_PreferredStockParticipationRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParticipationRights" xlink:to="us-gaap_PreferredStockParticipationRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParticipationRights_lbl" xml:lang="en-US">Preferred stock description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FairValueOfBonusSharesAndAmount" xlink:label="wizp_FairValueOfBonusSharesAndAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FairValueOfBonusSharesAndAmount" xlink:to="wizp_FairValueOfBonusSharesAndAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_FairValueOfBonusSharesAndAmount_lbl" xml:lang="en-US">Fair value of bonus shares and amount</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReceivedCashProceeds" xlink:label="wizp_ReceivedCashProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReceivedCashProceeds" xlink:to="wizp_ReceivedCashProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ReceivedCashProceeds_lbl" xml:lang="en-US">Received cash proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransaction" xlink:label="wizp_BonusTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusTransaction" xlink:to="wizp_BonusTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusTransaction_lbl" xml:lang="en-US">Bonus transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusSharesOfSeriesBPreferredStock." xlink:label="wizp_BonusSharesOfSeriesBPreferredStock." />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusSharesOfSeriesBPreferredStock." xlink:to="wizp_BonusSharesOfSeriesBPreferredStock._lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusSharesOfSeriesBPreferredStock._lbl" xml:lang="en-US">Bonus shares series B Preferred stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeferredTaxAssetsReservesAndAllowances" xlink:label="wizp_DeferredTaxAssetsReservesAndAllowances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeferredTaxAssetsReservesAndAllowances" xlink:to="wizp_DeferredTaxAssetsReservesAndAllowances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeferredTaxAssetsReservesAndAllowances_lbl" xml:lang="en-US">Reserves and allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Net deferred tax asset before valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xml:lang="en-US">Loss before taxes on income, as reported in the statements of comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xml:lang="en-US">Theoretical tax benefit on this loss</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExpensesNotDeductibleForTaxPurposes" xlink:label="wizp_ExpensesNotDeductibleForTaxPurposes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExpensesNotDeductibleForTaxPurposes" xlink:to="wizp_ExpensesNotDeductibleForTaxPurposes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ExpensesNotDeductibleForTaxPurposes_lbl" xml:lang="en-US">Expenses not deductible for tax purposes</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" xlink:label="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" xlink:to="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized_lbl" xml:lang="en-US">Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TaxesOnIncomeTextualAbstract" xlink:label="wizp_TaxesOnIncomeTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TaxesOnIncomeTextualAbstract" xlink:to="wizp_TaxesOnIncomeTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TaxesOnIncomeTextualAbstract_lbl" xml:lang="en-US">Taxes on Income (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncomeTaxRatePercentageDescription" xlink:label="wizp_IncomeTaxRatePercentageDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IncomeTaxRatePercentageDescription" xlink:to="wizp_IncomeTaxRatePercentageDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_IncomeTaxRatePercentageDescription_lbl" xml:lang="en-US">Percentage of income tax, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CorporateAndDeferredTaxDescription" xlink:label="wizp_CorporateAndDeferredTaxDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CorporateAndDeferredTaxDescription" xlink:to="wizp_CorporateAndDeferredTaxDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CorporateAndDeferredTaxDescription_lbl" xml:lang="en-US">Corporate and deferred tax, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CorporateTaxRate" xlink:label="wizp_CorporateTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CorporateTaxRate" xlink:to="wizp_CorporateTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CorporateTaxRate_lbl" xml:lang="en-US">Corporate tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Net operating loss carryforwards for federal income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Tax credit carryforward, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Operating loss carryforwards, limitations on use</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3_lbl" xml:lang="en-US">Accumulated losses for tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases" xlink:label="us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases" xlink:to="us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases_lbl" xml:lang="en-US">Rent agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FindersFeeAgreementDescription" xlink:label="wizp_FindersFeeAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FindersFeeAgreementDescription" xlink:to="wizp_FindersFeeAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_FindersFeeAgreementDescription_lbl" xml:lang="en-US">Finder's fee agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Percentage of royalty rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options outstanding and exercisable at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options outstanding and exercisable at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding at beginning of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options outstanding and exercisable at end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Number of options, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of options, Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted average remaining contractual life, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted average remaining contractual life, Options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted average remaining contractual life, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockholdersEquityTextualAbstract" xlink:label="wizp_StockholdersEquityTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockholdersEquityTextualAbstract" xlink:to="wizp_StockholdersEquityTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockholdersEquityTextualAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants remain outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Aggregate exercise price of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Issued shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted instrument shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Warrants exercised shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Future investment exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock available for future grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Shares of common stock, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock value issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RegistrationStatementDescription" xlink:label="wizp_RegistrationStatementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RegistrationStatementDescription" xlink:to="wizp_RegistrationStatementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RegistrationStatementDescription_lbl" xml:lang="en-US">Registration statement, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_WarrantTermDescription" xlink:to="wizp_WarrantTermDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_WarrantTermDescription_2_lbl" xml:lang="en-US">Warrant, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfTradingActivitiesAndManagementOfRelatedRisks" xlink:label="us-gaap_DescriptionOfTradingActivitiesAndManagementOfRelatedRisks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfTradingActivitiesAndManagementOfRelatedRisks" xlink:to="us-gaap_DescriptionOfTradingActivitiesAndManagementOfRelatedRisks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfTradingActivitiesAndManagementOfRelatedRisks_lbl" xml:lang="en-US">Trading activities, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceExpense" xlink:label="wizp_FinanceExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinanceExpense" xlink:to="wizp_FinanceExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_FinanceExpense_lbl" xml:lang="en-US">Finance expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Ownership, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockDesignated" xlink:label="wizp_PreferredStockDesignated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PreferredStockDesignated" xlink:to="wizp_PreferredStockDesignated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PreferredStockDesignated_lbl" xml:lang="en-US">Preferred stock, designated</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockDesignatedStock" xlink:label="wizp_PreferredStockDesignatedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PreferredStockDesignatedStock" xlink:to="wizp_PreferredStockDesignatedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PreferredStockDesignatedStock_lbl" xml:lang="en-US">Preferred stock designated stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="us-gaap_DividendsCommonStockStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockStock" xlink:to="us-gaap_DividendsCommonStockStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockStock_lbl" xml:lang="en-US">Shares of common stock, dividing</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiquidatedDamagesToInvestorsDescription" xlink:label="wizp_LiquidatedDamagesToInvestorsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LiquidatedDamagesToInvestorsDescription" xlink:to="wizp_LiquidatedDamagesToInvestorsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LiquidatedDamagesToInvestorsDescription_lbl" xml:lang="en-US">Liquidated damages to investors, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PlacementAgencyAgreementDescription" xlink:label="wizp_PlacementAgencyAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PlacementAgencyAgreementDescription" xlink:to="wizp_PlacementAgencyAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PlacementAgencyAgreementDescription_lbl" xml:lang="en-US">Placement ageny agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PlacementAgentWarrantsDescription" xlink:label="wizp_PlacementAgentWarrantsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PlacementAgentWarrantsDescription" xlink:to="wizp_PlacementAgentWarrantsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PlacementAgentWarrantsDescription_lbl" xml:lang="en-US">Placement agent warrants, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_JointVentureAgreementDescription" xlink:label="wizp_JointVentureAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_JointVentureAgreementDescription" xlink:to="wizp_JointVentureAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_JointVentureAgreementDescription_lbl" xml:lang="en-US">Joint venture agreement, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChairmanAppointmentAgreementDescription" xlink:label="wizp_ChairmanAppointmentAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChairmanAppointmentAgreementDescription" xlink:to="wizp_ChairmanAppointmentAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ChairmanAppointmentAgreementDescription_lbl" xml:lang="en-US">Chairman appointment agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockOptionsGrantedDuringVestingPeriod" xlink:label="wizp_StockOptionsGrantedDuringVestingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockOptionsGrantedDuringVestingPeriod" xlink:to="wizp_StockOptionsGrantedDuringVestingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockOptionsGrantedDuringVestingPeriod_lbl" xml:lang="en-US">Stock options granted during the vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based expense related to RSU's</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuanceToConsultantRelatedDescription" xlink:label="wizp_StockIssuanceToConsultantRelatedDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockIssuanceToConsultantRelatedDescription" xlink:to="wizp_StockIssuanceToConsultantRelatedDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockIssuanceToConsultantRelatedDescription_lbl" xml:lang="en-US">Stock issuance to consultant related, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExtinguishmentOfLoansDescription" xlink:label="wizp_ExtinguishmentOfLoansDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExtinguishmentOfLoansDescription" xlink:to="wizp_ExtinguishmentOfLoansDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ExtinguishmentOfLoansDescription_lbl" xml:lang="en-US">Extinguishment of the loans, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xml:lang="en-US">Description of investments</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockOutstandingRelatedDescription" xlink:label="wizp_StockOutstandingRelatedDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockOutstandingRelatedDescription" xlink:to="wizp_StockOutstandingRelatedDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockOutstandingRelatedDescription_lbl" xml:lang="en-US">Stock outstanding related, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3_lbl" xml:lang="en-US">Common stock outstanding and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuanceToEmployeesRelatedDescription" xlink:label="wizp_StockIssuanceToEmployeesRelatedDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockIssuanceToEmployeesRelatedDescription" xlink:to="wizp_StockIssuanceToEmployeesRelatedDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockIssuanceToEmployeesRelatedDescription_lbl" xml:lang="en-US">Company stock grants to its employee related, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable, term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Contractual term of stock-based grants, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Common stockholders amount</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossOfChangeInFairValue" xlink:label="wizp_LossOfChangeInFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossOfChangeInFairValue" xlink:to="wizp_LossOfChangeInFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LossOfChangeInFairValue_lbl" xml:lang="en-US">Loss of change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WeightedaveragePeriod" xlink:label="wizp_WeightedaveragePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_WeightedaveragePeriod" xlink:to="wizp_WeightedaveragePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_WeightedaveragePeriod_lbl" xml:lang="en-US">Weighted average period for non vested optons</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable_lbl" xml:lang="en-US">Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems_lbl" xml:lang="en-US">Research and Development Assets Acquired Other than Through Business Combination [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OverseasTravelMember" xlink:to="wizp_OverseasTravelMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_OverseasTravelMember_2_lbl" xml:lang="en-US">Overseas travel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ShareBasedPaymentMember" xlink:to="wizp_ShareBasedPaymentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_ShareBasedPaymentMember_2_lbl" xml:lang="en-US">Stock-based compensation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RentAndOfficeMaintenanceMember" xlink:to="wizp_RentAndOfficeMaintenanceMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_RentAndOfficeMaintenanceMember_2_lbl" xml:lang="en-US">Rent and office maintenance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PayrollAndBenefitsMember" xlink:to="wizp_PayrollAndBenefitsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_PayrollAndBenefitsMember_2_lbl" xml:lang="en-US">Payroll and benefits [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProfessionalServicesAndConsultationMember" xlink:to="wizp_ProfessionalServicesAndConsultationMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_ProfessionalServicesAndConsultationMember_2_lbl" xml:lang="en-US">Professional services and consultation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransactionCostsMember" xlink:label="wizp_BonusTransactionCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusTransactionCostsMember" xlink:to="wizp_BonusTransactionCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusTransactionCostsMember_lbl" xml:lang="en-US">Bonus transaction costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TaxesAndTollsMember" xlink:to="wizp_TaxesAndTollsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_TaxesAndTollsMember_2_lbl" xml:lang="en-US">Taxes and tolls [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DirectorSalaryAndInsuranceMember" xlink:to="wizp_DirectorSalaryAndInsuranceMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_DirectorSalaryAndInsuranceMember_2_lbl" xml:lang="en-US">Director salary and insurance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherExpensesMember" xlink:to="wizp_OtherExpensesMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_OtherExpensesMember_2_lbl" xml:lang="en-US">Others [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl" xml:lang="en-US">Financial income:</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeInFairValueOfMarketableSecurities" xlink:label="wizp_ChangeInFairValueOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeInFairValueOfMarketableSecurities" xlink:to="wizp_ChangeInFairValueOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ChangeInFairValueOfMarketableSecurities_lbl" xml:lang="en-US">Income from sale and revaluation of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExchangeRateGainsNet" xlink:label="wizp_ExchangeRateGainsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExchangeRateGainsNet" xlink:to="wizp_ExchangeRateGainsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ExchangeRateGainsNet_lbl" xml:lang="en-US">Exchange rate gains, net</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GainFromCompletionOfMilestoneClosing" xlink:label="wizp_GainFromCompletionOfMilestoneClosing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GainFromCompletionOfMilestoneClosing" xlink:to="wizp_GainFromCompletionOfMilestoneClosing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_GainFromCompletionOfMilestoneClosing_lbl" xml:lang="en-US">Gain from completion of milestone closing</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GainFromSettlementShares" xlink:label="wizp_GainFromSettlementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GainFromSettlementShares" xlink:to="wizp_GainFromSettlementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_GainFromSettlementShares_lbl" xml:lang="en-US">Gain from settlement shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of premium related to convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Total financial income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:label="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherExpenseDisclosureNonoperatingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenseDisclosureNonoperatingAbstract_lbl" xml:lang="en-US">Financial expense:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnConvertibleLoans" xlink:to="wizp_AccruedInterestOnConvertibleLoans_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="wizp_AccruedInterestOnConvertibleLoans_2_lbl" xml:lang="en-US">Accrued interest on convertible loans</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnLoans" xlink:label="wizp_AccruedInterestOnLoans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnLoans" xlink:to="wizp_AccruedInterestOnLoans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AccruedInterestOnLoans_lbl" xml:lang="en-US">Accrued interest on loans</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock" xlink:label="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock" xlink:to="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock_lbl" xml:lang="en-US">Loss from recognition of mandatorily redeemable Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" xlink:label="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" xlink:to="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues_lbl" xml:lang="en-US">Loss from revaluation of contingent obligation with respect to future revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RevaluationOfMandatorilyRedeemablePreferredStock" xlink:label="wizp_RevaluationOfMandatorilyRedeemablePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RevaluationOfMandatorilyRedeemablePreferredStock" xlink:to="wizp_RevaluationOfMandatorilyRedeemablePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RevaluationOfMandatorilyRedeemablePreferredStock_lbl" xml:lang="en-US">Revaluation of mandatorily redeemable Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransactionCosts" xlink:label="wizp_BonusTransactionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusTransactionCosts" xlink:to="wizp_BonusTransactionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusTransactionCosts_lbl" xml:lang="en-US">Bonus transaction costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesGainLoss_3_lbl" xml:lang="en-US">Change in the fair value of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Bank commissions and exchange rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US">Loss from extinguishment of convertible loans (Note 8c,8d,8e)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Total financial expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Total financial expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BalancesWithRelatedPartiesAbstract" xlink:label="wizp_BalancesWithRelatedPartiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BalancesWithRelatedPartiesAbstract" xlink:to="wizp_BalancesWithRelatedPartiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BalancesWithRelatedPartiesAbstract_lbl" xml:lang="en-US">Balances with interested and related parties:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Convertible Loans</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountsChargedAbstract" xlink:label="wizp_AmountsChargedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountsChargedAbstract" xlink:to="wizp_AmountsChargedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_AmountsChargedAbstract_lbl" xml:lang="en-US">Amounts charged to:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceIncomeNet" xlink:label="wizp_FinanceIncomeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinanceIncomeNet" xlink:to="wizp_FinanceIncomeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_FinanceIncomeNet_lbl" xml:lang="en-US">Finance expenses, net (income)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract" xlink:label="wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract" xlink:to="wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract_lbl" xml:lang="en-US">Related Parties Balances and Transactions (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SubsequentEventsTextualAbstract" xlink:label="wizp_SubsequentEventsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SubsequentEventsTextualAbstract" xlink:to="wizp_SubsequentEventsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_SubsequentEventsTextualAbstract_lbl" xml:lang="en-US">Subsequent Events (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CosmosTransactionDescription" xlink:label="wizp_CosmosTransactionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CosmosTransactionDescription" xlink:to="wizp_CosmosTransactionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CosmosTransactionDescription_lbl" xml:lang="en-US">Cosmos transaction, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OfferDescription" xlink:label="wizp_OfferDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OfferDescription" xlink:to="wizp_OfferDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OfferDescription_lbl" xml:lang="en-US">Offer, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndBenefitsTrust" xlink:label="us-gaap_CompensationAndBenefitsTrust" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndBenefitsTrust" xlink:to="us-gaap_CompensationAndBenefitsTrust_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndBenefitsTrust_lbl" xml:lang="en-US">Monthly compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusPurchaseAgreements" xlink:label="wizp_BonusPurchaseAgreements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusPurchaseAgreements" xlink:to="wizp_BonusPurchaseAgreements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_BonusPurchaseAgreements_lbl" xml:lang="en-US">Bonus Agreements, description</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OrdinarySharesOfBonus" xlink:label="wizp_OrdinarySharesOfBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OrdinarySharesOfBonus" xlink:to="wizp_OrdinarySharesOfBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_OrdinarySharesOfBonus_lbl" xml:lang="en-US">Ordinary shares of Bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TotalProceedsPayable" xlink:label="wizp_TotalProceedsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TotalProceedsPayable" xlink:to="wizp_TotalProceedsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_TotalProceedsPayable_lbl" xml:lang="en-US">Total proceeds payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl" xml:lang="en-US">Convertible loan agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_3_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" xlink:label="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" xlink:to="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant_lbl" xml:lang="en-US">Restricted stock units grant shares</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RestrictedStockUnitsVestTerm" xlink:label="wizp_RestrictedStockUnitsVestTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RestrictedStockUnitsVestTerm" xlink:to="wizp_RestrictedStockUnitsVestTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RestrictedStockUnitsVestTerm_lbl" xml:lang="en-US">Restricted stock units vest term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Aggregate gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExpressedBonusAmount" xlink:label="wizp_ExpressedBonusAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExpressedBonusAmount" xlink:to="wizp_ExpressedBonusAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ExpressedBonusAmount_lbl" xml:lang="en-US">Expressed bonus amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_SharesIssued_3_lbl" xml:lang="en-US">Aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnConvertibleLoans" xlink:to="wizp_AccruedInterestOnConvertibleLoans_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AccruedInterestOnConvertibleLoans_doc" xml:lang="en-US">Accrued interest on convertible loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnLoan" xlink:to="wizp_AccruedInterestOnLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AccruedInterestOnLoan_doc" xml:lang="en-US">Accrued interest on loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" xlink:to="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment_doc" xml:lang="en-US">Amount of increase (decrease) to additional paid in capital Amount that was allocated to the right for future investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" xlink:to="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne_doc" xml:lang="en-US">Amount of increase (decrease) to additional paid in capital Amount that was allocated to the right for future investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AggregateMaximumOfRightToFutureInvestment" xlink:to="wizp_AggregateMaximumOfRightToFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AggregateMaximumOfRightToFutureInvestment_doc" xml:lang="en-US">Aggregate maximum of right to future investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfPremiumRelatedToConvertibleLoan" xlink:to="wizp_AmortizationOfPremiumRelatedToConvertibleLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoan_doc" xml:lang="en-US">Amortization of premium related to convertible loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfPremiumRelatedToConvertibleLoans" xlink:to="wizp_AmortizationOfPremiumRelatedToConvertibleLoans_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoans_doc" xml:lang="en-US">Amortization of premium related to convertible loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne" xlink:to="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne_doc" xml:lang="en-US">Amortization of premium related to convertible loans following 2019 modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToLoan" xlink:to="wizp_AmountAllocatedToLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmountAllocatedToLoan_doc" xml:lang="en-US">Amount allocated to loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:to="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment_doc" xml:lang="en-US">Amount allocated to the repurchase right to existing right to future investment related to 2016 and 2017 loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountThatWasAllocatedToRightForFutureInvestment" xlink:to="wizp_AmountThatWasAllocatedToRightForFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmountThatWasAllocatedToRightForFutureInvestment_doc" xml:lang="en-US">Amount that was allocated to the right for future investment - loan 2016.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment" xlink:to="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment_doc" xml:lang="en-US">Amounts that were allocated to the recognition of right for future investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock" xlink:to="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock_doc" xml:lang="en-US">Balances with interested and related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CorporateAndDeferredTaxDescription" xlink:to="wizp_CorporateAndDeferredTaxDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_CorporateAndDeferredTaxDescription_doc" xml:lang="en-US">The description related to deferred and corporate tax.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CorporateTaxRate" xlink:to="wizp_CorporateTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_CorporateTaxRate_doc" xml:lang="en-US">Corporate tax rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CumulativeEffectAdjustmentFromTransition" xlink:to="wizp_CumulativeEffectAdjustmentFromTransition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_CumulativeEffectAdjustmentFromTransition_doc" xml:lang="en-US">Cumulative effect adjustment from transition to ASU 2016-01.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividend" xlink:to="wizp_DeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_DeemedDividend_doc" xml:lang="en-US">Amount of deemed dividend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeferredTaxAssetsReservesAndAllowances" xlink:to="wizp_DeferredTaxAssetsReservesAndAllowances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_DeferredTaxAssetsReservesAndAllowances_doc" xml:lang="en-US">Deferred tax assets reserves and allowances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DerecognitionLoanUponExtinguishment" xlink:to="wizp_DerecognitionLoanUponExtinguishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_DerecognitionLoanUponExtinguishment_doc" xml:lang="en-US">The derecognition of carrying amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExchangeRateGainsNet" xlink:to="wizp_ExchangeRateGainsNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ExchangeRateGainsNet_doc" xml:lang="en-US">Exchange rate gains, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExercisePriceOfRightToFutureInvestment" xlink:to="wizp_ExercisePriceOfRightToFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ExercisePriceOfRightToFutureInvestment_doc" xml:lang="en-US">Exercise price of right to future investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ExpensesNotDeductibleForTaxPurposes" xlink:to="wizp_ExpensesNotDeductibleForTaxPurposes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ExpensesNotDeductibleForTaxPurposes_doc" xml:lang="en-US">Expenses not deductible for tax purposes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinanceExpense" xlink:to="wizp_FinanceExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_FinanceExpense_doc" xml:lang="en-US">Financial expens.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinanceIncomeNet" xlink:to="wizp_FinanceIncomeNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_FinanceIncomeNet_doc" xml:lang="en-US">Finance income net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GeneralTextualAbstract" xlink:to="wizp_GeneralTextualAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_GeneralTextualAbstract_doc" xml:lang="en-US">General Textual.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IncomeTaxRatePercentageDescription" xlink:to="wizp_IncomeTaxRatePercentageDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IncomeTaxRatePercentageDescription_doc" xml:lang="en-US">Information about income tax rate percentage description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IncreaseDecreaseInLicensePurchaseObligation" xlink:to="wizp_IncreaseDecreaseInLicensePurchaseObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IncreaseDecreaseInLicensePurchaseObligation_doc" xml:lang="en-US">Amount of increase (decrease) in license purchase obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" xlink:to="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized_doc" xml:lang="en-US">ncrease in taxes resulting mainly from taxable losses in the reported year for which no deferred tax assets were recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_InvestmentOwnershipPercentage" xlink:to="wizp_InvestmentOwnershipPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_InvestmentOwnershipPercentage_doc" xml:lang="en-US">Investment, ownership percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment_doc" xml:lang="en-US">Amount of issuance of shares with respect to exercise of warrants and right for future investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares_doc" xml:lang="en-US">Issuance of shares with respect to exercise of warrants and right for future investment one shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LegalAndOtherContingenciesPolicyTextBlock" xlink:to="wizp_LegalAndOtherContingenciesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LegalAndOtherContingenciesPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for legal and other contingencies.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicenseAgreementDescription" xlink:to="wizp_LicenseAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LicenseAgreementDescription_doc" xml:lang="en-US">License Agreement, Description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicenseAgreementTextBlock" xlink:to="wizp_LicenseAgreementTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LicenseAgreementTextBlock_doc" xml:lang="en-US">The entire disclosure for License agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationCurrent" xlink:to="wizp_LicensePurchaseObligationCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LicensePurchaseObligationCurrent_doc" xml:lang="en-US">The amount of license purchase obligation current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationNet" xlink:to="wizp_LicensePurchaseObligationNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LicensePurchaseObligationNet_doc" xml:lang="en-US">The amount of license purchase obligation net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LicensePurchaseObligationTextBlock" xlink:to="wizp_LicensePurchaseObligationTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LicensePurchaseObligationTextBlock_doc" xml:lang="en-US">Disclosure of license purchase obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LiquidatedDamagesToInvestorsDescription" xlink:to="wizp_LiquidatedDamagesToInvestorsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LiquidatedDamagesToInvestorsDescription_doc" xml:lang="en-US">Liquidated damages to investors, description,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LoanAmendmentDescription" xlink:to="wizp_LoanAmendmentDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LoanAmendmentDescription_doc" xml:lang="en-US">Information about loan amendment description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MarketableSecuritiesEquitySecuritieCurrent" xlink:to="wizp_MarketableSecuritiesEquitySecuritieCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_MarketableSecuritiesEquitySecuritieCurrent_doc" xml:lang="en-US">Amount of investments in equity securities and other forms of securities that provide ownership interests expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital" xlink:to="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital_doc" xml:lang="en-US">Minimum percentage of issued and outstanding share capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_NetLossPerShareOfCommonStockBasicAndDiluted" xlink:to="wizp_NetLossPerShareOfCommonStockBasicAndDiluted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_NetLossPerShareOfCommonStockBasicAndDiluted_doc" xml:lang="en-US">Net loss per share of Common stock, basic and diluted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities" xlink:to="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities_doc" xml:lang="en-US">Amount of ordinary shares issued through receipt of marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherAccountsPayableTextBlock" xlink:to="wizp_OtherAccountsPayableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_OtherAccountsPayableTextBlock_doc" xml:lang="en-US">Disclosure of Other Accounts Payable text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherGovernmentalAuthoritiesCurrent" xlink:to="wizp_OtherGovernmentalAuthoritiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_OtherGovernmentalAuthoritiesCurrent_doc" xml:lang="en-US">Amount related to government authorities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OtherReceivable" xlink:to="wizp_OtherReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_OtherReceivable_doc" xml:lang="en-US">Other receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PercentageOfDiscountRate" xlink:to="wizp_PercentageOfDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PercentageOfDiscountRate_doc" xml:lang="en-US">Percentage of discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PlacementAgentWarrantsDescription" xlink:to="wizp_PlacementAgentWarrantsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PlacementAgentWarrantsDescription_doc" xml:lang="en-US">Placement agent warrants, description,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PreferredStockDesignated" xlink:to="wizp_PreferredStockDesignated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PreferredStockDesignated_doc" xml:lang="en-US">Number of preferrred stock designated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PreferredStockDesignatedStock" xlink:to="wizp_PreferredStockDesignatedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PreferredStockDesignatedStock_doc" xml:lang="en-US">Amount of designated stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" xlink:to="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare_doc" xml:lang="en-US">Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProceedsFromIssuanceOfSharesAndWarrants" xlink:to="wizp_ProceedsFromIssuanceOfSharesAndWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ProceedsFromIssuanceOfSharesAndWarrants_doc" xml:lang="en-US">The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:to="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment_doc" xml:lang="en-US">Proceeds from issuance of shares with respect to exercise of PIPE warrants and right for future investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RecognizedLeaseLiability" xlink:to="wizp_RecognizedLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_RecognizedLeaseLiability_doc" xml:lang="en-US">Recognized liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReducedAnnualRoyaltiesDescription" xlink:to="wizp_ReducedAnnualRoyaltiesDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ReducedAnnualRoyaltiesDescription_doc" xml:lang="en-US">Reduced annual royalties description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RepaymentOfConvertibleLoansThroughCommonStock" xlink:to="wizp_RepaymentOfConvertibleLoansThroughCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_RepaymentOfConvertibleLoansThroughCommonStock_doc" xml:lang="en-US">Repayment of convertible loans through Common Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RestrictedStockUnitsVestTerm" xlink:to="wizp_RestrictedStockUnitsVestTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_RestrictedStockUnitsVestTerm_doc" xml:lang="en-US">Restricted stock units vest term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfFinancingExpensesNetTableTextBlock" xlink:to="wizp_ScheduleOfFinancingExpensesNetTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ScheduleOfFinancingExpensesNetTableTextBlock_doc" xml:lang="en-US">Schedule of financing expenses net..</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_doc" xml:lang="en-US">Schedule of general and administrative expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfOtherAccountsPayableTableTextBlock" xlink:to="wizp_ScheduleOfOtherAccountsPayableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ScheduleOfOtherAccountsPayableTableTextBlock_doc" xml:lang="en-US">Schedule of other accounts payable table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" xlink:to="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock_doc" xml:lang="en-US">Schedule of repayment dates of remaining Minimal Commitment on the financial liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SecuritiesPurchaseAgreementDescription" xlink:to="wizp_SecuritiesPurchaseAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_SecuritiesPurchaseAgreementDescription_doc" xml:lang="en-US">Purchase agreement, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SelectedStatementsOfOperationsDataTextBlock" xlink:to="wizp_SelectedStatementsOfOperationsDataTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_SelectedStatementsOfOperationsDataTextBlock_doc" xml:lang="en-US">The entire disclosure of Selected Statements Of Operations Data.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SeverancePayPolicyTextBlock" xlink:to="wizp_SeverancePayPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_SeverancePayPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for severance pay.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" xlink:to="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant_doc" xml:lang="en-US">Stock issued during period shares restricted stock award grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_TradePayables" xlink:to="wizp_TradePayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_TradePayables_doc" xml:lang="en-US">Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_WarrantTermDescription" xlink:to="wizp_WarrantTermDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_WarrantTermDescription_doc" xml:lang="en-US">Warrant term, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReminingOutstandingOwnersPercentage" xlink:to="wizp_ReminingOutstandingOwnersPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ReminingOutstandingOwnersPercentage_doc" xml:lang="en-US">Remining outstanding owners percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DescriptionOfBonusAgreements" xlink:to="wizp_DescriptionOfBonusAgreements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_DescriptionOfBonusAgreements_doc" xml:lang="en-US">Description of bonus agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RedeemAllOfSeriesBPreferredStockDescription" xlink:to="wizp_RedeemAllOfSeriesBPreferredStockDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_RedeemAllOfSeriesBPreferredStockDescription_doc" xml:lang="en-US">Redeem all of the Series B Preferred Stock, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PricePerShareAtDateOfAgreement" xlink:to="wizp_PricePerShareAtDateOfAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PricePerShareAtDateOfAgreement_doc" xml:lang="en-US">Price per share at the date of agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PricePerShareAtClosingDate" xlink:to="wizp_PricePerShareAtClosingDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PricePerShareAtClosingDate_doc" xml:lang="en-US">Price per share at the closing date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusSharesHeldInEscrow" xlink:to="wizp_BonusSharesHeldInEscrow_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_BonusSharesHeldInEscrow_doc" xml:lang="en-US">Bonus Shares held in escrow.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_InvestmentInMarketableSecuritiesBonusShares" xlink:to="wizp_InvestmentInMarketableSecuritiesBonusShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_InvestmentInMarketableSecuritiesBonusShares_doc" xml:lang="en-US">Amount of Investment in marketable securities (Bonus shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FairValueOfBonusSharesAndAmount" xlink:to="wizp_FairValueOfBonusSharesAndAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_FairValueOfBonusSharesAndAmount_doc" xml:lang="en-US">Fair value of bonus shares and amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReceivedCashProceeds" xlink:to="wizp_ReceivedCashProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ReceivedCashProceeds_doc" xml:lang="en-US">Received cash proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote_doc" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote_doc" xml:lang="en-US">Issuance of shares with respect to exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares_doc" xml:lang="en-US">Issuance of shares with respect to exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:to="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_doc" xml:lang="en-US">Change from revaluation of mandatorily redeemable Series B Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:to="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10_doc" xml:lang="en-US">Change from revaluation of contingent obligation with respect to future revenues.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GainFromCompletionOfMilestoneClosingNote10" xlink:to="wizp_GainFromCompletionOfMilestoneClosingNote10_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_GainFromCompletionOfMilestoneClosingNote10_doc" xml:lang="en-US">Gain from completion of milestone closing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:to="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10_doc" xml:lang="en-US">Loss from recognition of mandatorily redeemable Series B Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LoanReceived" xlink:to="wizp_LoanReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LoanReceived_doc" xml:lang="en-US">Loan received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" xlink:to="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow_doc" xml:lang="en-US">Amounts transferred from Series B Preferred Stock investment to restricted deposit held in escrow.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues" xlink:to="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues_doc" xml:lang="en-US">Recognition of contingent obligation with respect to future revenues.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock" xlink:to="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock_doc" xml:lang="en-US">Issuance of mandatorily redeemable Series B Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" xlink:to="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares_doc" xml:lang="en-US">Settlement of mandatorily redeemable series B Preferred Stock through distribution of Bonus shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants_doc" xml:lang="en-US">Deemed dividend due to exercise price adjustment of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants" xlink:to="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants_doc" xml:lang="en-US">Issuance of shares with respect to exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LiabilityToHcw" xlink:to="wizp_LiabilityToHcw_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LiabilityToHcw_doc" xml:lang="en-US">Liability to HCW.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ReleaseOfEscrowAccountBonusShares" xlink:to="wizp_ReleaseOfEscrowAccountBonusShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ReleaseOfEscrowAccountBonusShares_doc" xml:lang="en-US">Release of escrow account Bonus shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeInFairValueOfMarketableSecurities" xlink:to="wizp_ChangeInFairValueOfMarketableSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ChangeInFairValueOfMarketableSecurities_doc" xml:lang="en-US">Change in the fair value of marketable securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GainFromCompletionOfMilestoneClosing" xlink:to="wizp_GainFromCompletionOfMilestoneClosing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_GainFromCompletionOfMilestoneClosing_doc" xml:lang="en-US">Gain from completion of milestone closing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GainFromSettlementShares" xlink:to="wizp_GainFromSettlementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_GainFromSettlementShares_doc" xml:lang="en-US">Gain from settlement shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_AccruedInterestOnLoans" xlink:to="wizp_AccruedInterestOnLoans_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_AccruedInterestOnLoans_doc" xml:lang="en-US">Accrued interest on loans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock" xlink:to="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock_doc" xml:lang="en-US">Loss from recognition of mandatorily redeemable Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" xlink:to="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues_doc" xml:lang="en-US">Loss from revaluation of contingent obligation with respect to future revenues.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RevaluationOfMandatorilyRedeemablePreferredStock" xlink:to="wizp_RevaluationOfMandatorilyRedeemablePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_RevaluationOfMandatorilyRedeemablePreferredStock_doc" xml:lang="en-US">Revaluation of mandatorily redeemable Series B Preferred Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CosmosTransactionDescription" xlink:to="wizp_CosmosTransactionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_CosmosTransactionDescription_doc" xml:lang="en-US">Cosmos transaction, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_OfferDescription" xlink:to="wizp_OfferDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_OfferDescription_doc" xml:lang="en-US">Offer, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PresentValueOfDebtInstrumentPercentage" xlink:to="wizp_PresentValueOfDebtInstrumentPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_PresentValueOfDebtInstrumentPercentage_doc" xml:lang="en-US">Present value of debt instrument percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LeastPercentageOfCarryingAmount" xlink:to="wizp_LeastPercentageOfCarryingAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LeastPercentageOfCarryingAmount_doc" xml:lang="en-US">Least percentage of carrying amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MinimumCommitmentAmount" xlink:to="wizp_MinimumCommitmentAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_MinimumCommitmentAmount_doc" xml:lang="en-US">Amount of minimum commitment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LossDueToRevaluation" xlink:to="wizp_LossDueToRevaluation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_LossDueToRevaluation_doc" xml:lang="en-US">Amount of loss due to revaluation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_FinancialExpenses" xlink:to="wizp_FinancialExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_FinancialExpenses_doc" xml:lang="en-US">Financial expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusTransaction" xlink:to="wizp_BonusTransaction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_BonusTransaction_doc" xml:lang="en-US">Bonus transaction by shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusSharesOfSeriesBPreferredStock." xlink:to="wizp_BonusSharesOfSeriesBPreferredStock._doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_BonusSharesOfSeriesBPreferredStock._doc" xml:lang="en-US">Bonus shares series B Preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability" xlink:to="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability_doc" xml:lang="en-US">Schedule of mandatorily redeemable series B liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_SeriesBPreferredStock" xlink:to="wizp_SeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_SeriesBPreferredStock_doc" xml:lang="en-US">Series B preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock" xlink:to="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock_doc" xml:lang="en-US">Changes from redemption of mandatorily redeemable series B preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_BonusTransactionCosts" xlink:to="wizp_BonusTransactionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_BonusTransactionCosts_doc" xml:lang="en-US">Bonus transaction costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ConversionOfPreferredStockIntoCommonStock" xlink:to="wizp_ConversionOfPreferredStockIntoCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="wizp_ConversionOfPreferredStockIntoCommonStock_doc" xml:lang="en-US">Conversion of preferred stock into common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_NisMember" xlink:to="wizp_NisMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_NisMember_2_lbl" xml:lang="en-US">NIS [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_2_lbl" xml:lang="en-US">Other Preferred Stock Dividends and Adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" xlink:to="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants_2_lbl" xml:lang="en-US">DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_2_lbl" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_GainFromCompletionOfMilestoneClosingNote10" xlink:to="wizp_GainFromCompletionOfMilestoneClosingNote10_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_GainFromCompletionOfMilestoneClosingNote10_3_lbl" xml:lang="en-US">GainFromCompletionOfMilestoneClosingNote10</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet_2_lbl" xml:lang="en-US">Gain (Loss) on Derivative Instruments Held for Trading Purposes, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:to="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10_4_lbl" xml:lang="en-US">ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:to="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10_3_lbl" xml:lang="en-US">ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_PurchaseOfPropertyAndEquipment" xlink:to="wizp_PurchaseOfPropertyAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_PurchaseOfPropertyAndEquipment_2_lbl" xml:lang="en-US">PurchaseOfPropertyAndEquipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:to="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment_3_lbl" xml:lang="en-US">Proceeds From Issuance Of Shares Respect To Exercise Of Pipe Warrants And Right For Future Investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_LoanReceived" xlink:to="wizp_LoanReceived_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_LoanReceived_3_lbl" xml:lang="en-US">LoanReceived</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:to="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeDividend" xlink:to="us-gaap_InvestmentIncomeDividend_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeDividend_2_lbl" xml:lang="en-US">Investment Income, Dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_2_lbl" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_3_lbl" xml:lang="en-US">Debt, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_MandatorilyRedeemableSeriesBLiability" xlink:to="wizp_MandatorilyRedeemableSeriesBLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_MandatorilyRedeemableSeriesBLiability_3_lbl" xml:lang="en-US">MandatorilyRedeemableSeriesBLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="wizp_RedeemableFairValue" xlink:to="wizp_RedeemableFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="wizp_RedeemableFairValue_2_lbl" xml:lang="en-US">RedeemableFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_2_lbl" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>wizp-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: wizp%2D20201231.xfr; Date: 2021%2D03%2D01T18:25:18Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020020 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://ophthalic.com/role/DocumentAndEntityInformation" xlink:href="wizp-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/BalanceSheets" xlink:href="wizp-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/BalanceSheetsParenthetical" xlink:href="wizp-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfComprehensiveLoss" xlink:href="wizp-20201231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:href="wizp-20201231.xsd#StatementsOfChangesInShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StatementsOfCashFlows" xlink:href="wizp-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/General" xlink:href="wizp-20201231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPolicies" xlink:href="wizp-20201231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/MarketableEquitySecurities" xlink:href="wizp-20201231.xsd#MarketableEquitySecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssets" xlink:href="wizp-20201231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicenseAgreement" xlink:href="wizp-20201231.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligation" xlink:href="wizp-20201231.xsd#LicensePurchaseObligation" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayable" xlink:href="wizp-20201231.xsd#AccountsPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoans" xlink:href="wizp-20201231.xsd#ConvertibleLoans" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ShortTermLoanPayable" xlink:href="wizp-20201231.xsd#ShortTermLoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactions" xlink:href="wizp-20201231.xsd#SignificantTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncome" xlink:href="wizp-20201231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/CommitmentsAndContingencies" xlink:href="wizp-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquity" xlink:href="wizp-20201231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsData" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsData" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SubsequentEvents" xlink:href="wizp-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesPolicies" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesTables" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssetsTables" xlink:href="wizp-20201231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationTables" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayableTables" xlink:href="wizp-20201231.xsd#AccountsPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansTables" xlink:href="wizp-20201231.xsd#ConvertibleLoansTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsTables" xlink:href="wizp-20201231.xsd#SignificantTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeTables" xlink:href="wizp-20201231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityTables" xlink:href="wizp-20201231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/GeneralDetails" xlink:href="wizp-20201231.xsd#GeneralDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails1" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails2" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails3" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails4" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetails5" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:href="wizp-20201231.xsd#SignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/MarketableEquitySecuritiesDetails" xlink:href="wizp-20201231.xsd#MarketableEquitySecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/OtherCurrentAssetsDetails" xlink:href="wizp-20201231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicenseAgreementDetails" xlink:href="wizp-20201231.xsd#LicenseAgreementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetails" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual" xlink:href="wizp-20201231.xsd#LicensePurchaseObligationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/AccountsPayableDetails" xlink:href="wizp-20201231.xsd#AccountsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetails" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetails1" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ConvertibleLoansDetailsTextual" xlink:href="wizp-20201231.xsd#ConvertibleLoansDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/ShortTermLoanPayableDetails" xlink:href="wizp-20201231.xsd#ShortTermLoanPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsDetails" xlink:href="wizp-20201231.xsd#SignificantTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SignificantTransactionsDetailsTextual" xlink:href="wizp-20201231.xsd#SignificantTransactionsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails1" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetails2" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/TaxesOnIncomeDetailsTextual" xlink:href="wizp-20201231.xsd#TaxesOnIncomeDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/CommitmentsAndContingenciesDetails" xlink:href="wizp-20201231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetails" xlink:href="wizp-20201231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetails1" xlink:href="wizp-20201231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/StockholdersEquityDetailsTextual" xlink:href="wizp-20201231.xsd#StockholdersEquityDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1" xlink:href="wizp-20201231.xsd#SelectedStatementsOfOperationsDataDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:href="wizp-20201231.xsd#RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://ophthalic.com/role/SubsequentEventsDetails" xlink:href="wizp-20201231.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DocumentAndEntityInformationAbstract" xlink:label="loc_wizpDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaapRestrictedInvestmentsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedInvestmentsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableSecuritiesEquitySecuritieCurrent" xlink:label="loc_wizpMarketableSecuritiesEquitySecuritieCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_wizpMarketableSecuritiesEquitySecuritieCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationCurrent" xlink:label="loc_wizpLicensePurchaseObligationCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_wizpLicensePurchaseObligationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdditionToNetLossAbstract" xlink:label="loc_wizpAdditionToNetLossAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_wizpAdditionToNetLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpAdditionToNetLossAbstract" xlink:to="loc_us-gaapOtherPreferredStockDividendsAndAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpAdditionToNetLossAbstract" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpAdditionToNetLossAbstract" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpAdditionToNetLossAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" xlink:label="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" xlink:label="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11u" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11u" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11uShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsForCashNote11uShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" xlink:label="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CumulativeEffectAdjustmentFromTransition" xlink:label="loc_wizpCumulativeEffectAdjustmentFromTransition" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpCumulativeEffectAdjustmentFromTransition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsAndRightForFutureInvestmentOneShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" xlink:label="loc_wizpIssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfUnitsConsistingOfCommonStockSeriesPreferredStockAndDetachableWarrantsNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" xlink:label="loc_wizpAmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAmountAllocatedToRightForFutureInvestment2016LoanUpon2018LoanAmendment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" xlink:label="loc_wizpAmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpAmountAllocatedToRightForFutureInvestment2017LoanUpon2018LoanAmendment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" xlink:label="loc_wizpTermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpTermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoanExtinguishment" xlink:label="loc_wizpConvertibleLoanExtinguishment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConvertibleLoanExtinguishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNote" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConversionOfPreferredStockIntoCommonStock" xlink:label="loc_wizpConversionOfPreferredStockIntoCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConversionOfPreferredStockIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConversionOfPreferredStockIntoCommonStockShares" xlink:label="loc_wizpConversionOfPreferredStockIntoCommonStockShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConversionOfPreferredStockIntoCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoanExtinguishmentAndWarrantsModification" xlink:label="loc_wizpConvertibleLoanExtinguishmentAndWarrantsModification" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpConvertibleLoanExtinguishmentAndWarrantsModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" xlink:label="loc_wizpStockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpStockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnConvertibleLoans" xlink:label="loc_wizpAccruedInterestOnConvertibleLoans" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_wizpAccruedInterestOnConvertibleLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GainFromCompletionOfMilestoneClosingNote10" xlink:label="loc_wizpGainFromCompletionOfMilestoneClosingNote10" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_wizpGainFromCompletionOfMilestoneClosingNote10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsHeldForTradingPurposesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="loc_wizpLossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_wizpLossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="loc_wizpChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_wizpChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:label="loc_wizpChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_wizpChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncreaseDecreaseInLicensePurchaseObligation" xlink:label="loc_wizpIncreaseDecreaseInLicensePurchaseObligation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_wizpIncreaseDecreaseInLicensePurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinancialExpenses" xlink:label="loc_wizpFinancialExpenses" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_wizpFinancialExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PurchaseOfPropertyAndEquipment" xlink:label="loc_wizpPurchaseOfPropertyAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_wizpPurchaseOfPropertyAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecurities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromIssuanceOfSharesAndWarrants" xlink:label="loc_wizpProceedsFromIssuanceOfSharesAndWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_wizpProceedsFromIssuanceOfSharesAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:label="loc_wizpProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_wizpProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanReceived" xlink:label="loc_wizpLoanReceived" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_wizpLoanReceived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProceedsFromRepaymentOfLicensePurchaseObligation" xlink:label="loc_wizpProceedsFromRepaymentOfLicensePurchaseObligation" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_wizpProceedsFromRepaymentOfLicensePurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities" xlink:label="loc_wizpOrdinarySharesIssuedThroughReceiptOfMarketableSecurities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpOrdinarySharesIssuedThroughReceiptOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:label="loc_wizpAmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountThatWasAllocatedToRightForFutureInvestment" xlink:label="loc_wizpAmountThatWasAllocatedToRightForFutureInvestment" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountThatWasAllocatedToRightForFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment" xlink:label="loc_wizpAmountsAllocatedToTheRecognitionOfRightForFutureInvestment" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountsAllocatedToTheRecognitionOfRightForFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" xlink:label="loc_wizpDeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpDeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:label="loc_wizpAmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne" xlink:label="loc_wizpAmountThatWasAllocatedToRightForFutureInvestmentOne" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountThatWasAllocatedToRightForFutureInvestmentOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo" xlink:label="loc_wizpAmountThatWasAllocatedToRightForFutureInvestmentTwo" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountThatWasAllocatedToRightForFutureInvestmentTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" xlink:label="loc_wizpDeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpDeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanAmendment" xlink:label="loc_wizpAmountAllocatedToLoanAmendment" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountAllocatedToLoanAmendment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanAmendmentOne" xlink:label="loc_wizpAmountAllocatedToLoanAmendmentOne" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountAllocatedToLoanAmendmentOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanExtension" xlink:label="loc_wizpAmountAllocatedToLoanExtension" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountAllocatedToLoanExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanExtensionOne" xlink:label="loc_wizpAmountAllocatedToLoanExtensionOne" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountAllocatedToLoanExtensionOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RepaymentOfConvertibleLoansThroughCommonStock" xlink:label="loc_wizpRepaymentOfConvertibleLoansThroughCommonStock" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpRepaymentOfConvertibleLoansThroughCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SELLOFCANNABICSSHARETHROUGHABROKER" xlink:label="loc_wizpSELLOFCANNABICSSHARETHROUGHABROKER" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpSELLOFCANNABICSSHARETHROUGHABROKER" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" xlink:label="loc_wizpAmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpAmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentInMarketableSecuritiesBonusShares" xlink:label="loc_wizpInvestmentInMarketableSecuritiesBonusShares" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpInvestmentInMarketableSecuritiesBonusShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues" xlink:label="loc_wizpRecognitionOfContingentObligationWithRespectToFutureRevenues" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpRecognitionOfContingentObligationWithRespectToFutureRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock" xlink:label="loc_wizpIssuanceOfMandatorilyRedeemableSeriesBPreferredStock" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpIssuanceOfMandatorilyRedeemableSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" xlink:label="loc_wizpSettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpSettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants" xlink:label="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrants" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpDeemedDividendDueToExercisePriceAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants" xlink:label="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrants" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpIssuanceOfSharesWithRespectToExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiabilityToHcw" xlink:label="loc_wizpLiabilityToHcw" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpLiabilityToHcw" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReleaseOfEscrowAccountBonusShares" xlink:label="loc_wizpReleaseOfEscrowAccountBonusShares" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_wizpReleaseOfEscrowAccountBonusShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/General" xlink:title="00000007 - Disclosure - General">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/MarketableEquitySecurities" xlink:title="00000009 - Disclosure - Marketable Equity Securities">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicenseAgreement" xlink:title="00000011 - Disclosure - License Agreement">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementAbstract" xlink:label="loc_wizpLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementTextBlock" xlink:label="loc_wizpLicenseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementAbstract" xlink:to="loc_wizpLicenseAgreementTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligation" xlink:title="00000012 - Disclosure - License Purchase Obligation">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationAbstract" xlink:label="loc_wizpLicensePurchaseObligationAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationTextBlock" xlink:label="loc_wizpLicensePurchaseObligationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicensePurchaseObligationAbstract" xlink:to="loc_wizpLicensePurchaseObligationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayable" xlink:title="00000013 - Disclosure - Accounts Payable">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherAccountsPayableAbstract" xlink:label="loc_wizpOtherAccountsPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherAccountsPayableTextBlock" xlink:label="loc_wizpOtherAccountsPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpOtherAccountsPayableAbstract" xlink:to="loc_wizpOtherAccountsPayableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoans" xlink:title="00000014 - Disclosure - Convertible Loans">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ShortTermLoanPayable" xlink:title="00000015 - Disclosure - Short Term Loan Payable">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaapShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactions" xlink:title="00000016 - Disclosure - Significant Transactions">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsAbstract" xlink:label="loc_wizpSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsTextBlock" xlink:label="loc_wizpSignificantTransactionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpSignificantTransactionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncome" xlink:title="00000017 - Disclosure - Taxes on Income">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/CommitmentsAndContingencies" xlink:title="00000018 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquity" xlink:title="00000019 - Disclosure - Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsData" xlink:title="00000020 - Disclosure - Selected Statements of Operations Data">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SelectedStatementsOfOperationsDataAbstract" xlink:label="loc_wizpSelectedStatementsOfOperationsDataAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SelectedStatementsOfOperationsDataTextBlock" xlink:label="loc_wizpSelectedStatementsOfOperationsDataTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSelectedStatementsOfOperationsDataAbstract" xlink:to="loc_wizpSelectedStatementsOfOperationsDataTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions" xlink:title="00000021 - Disclosure - Related Parties Balances and Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RestrictedBankDepositPolicyTextBlock" xlink:label="loc_wizpRestrictedBankDepositPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpRestrictedBankDepositPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeverancePayPolicyTextBlock" xlink:label="loc_wizpSeverancePayPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpSeverancePayPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoanCommitmentsPolicy" xlink:label="loc_us-gaapLoanCommitmentsPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLoanCommitmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LegalAndOtherContingenciesPolicyTextBlock" xlink:label="loc_wizpLegalAndOtherContingenciesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpLegalAndOtherContingenciesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" xlink:label="loc_wizpSeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpSeriesAWarrantsWithDownRoundProtectionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaapFiscalPeriod" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiscalPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" xlink:label="loc_wizpContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpContingentObligationWithRespectToFutureRevenuesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" xlink:label="loc_wizpMandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpMandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfXchangeRateOfRelevantCurrencies" xlink:label="loc_wizpScheduleOfXchangeRateOfRelevantCurrencies" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpScheduleOfXchangeRateOfRelevantCurrencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfCashAndCashEquivalents" xlink:label="loc_wizpScheduleOfCashAndCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpScheduleOfCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfEstimatedUsefulLivesOfAssets" xlink:label="loc_wizpScheduleOfEstimatedUsefulLivesOfAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpScheduleOfEstimatedUsefulLivesOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationTables" xlink:title="00000026 - Disclosure - License Purchase Obligation (Tables)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationAbstract" xlink:label="loc_wizpLicensePurchaseObligationAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" xlink:label="loc_wizpScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicensePurchaseObligationAbstract" xlink:to="loc_wizpScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayableTables" xlink:title="00000027 - Disclosure - Accounts Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherAccountsPayableAbstract" xlink:label="loc_wizpOtherAccountsPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfOtherAccountsPayableTableTextBlock" xlink:label="loc_wizpScheduleOfOtherAccountsPayableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpOtherAccountsPayableAbstract" xlink:to="loc_wizpScheduleOfOtherAccountsPayableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansTables" xlink:title="00000028 - Disclosure - Convertible Loans (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:label="loc_us-gaapScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsTables" xlink:title="00000029 - Disclosure - Significant Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsAbstract" xlink:label="loc_wizpSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability" xlink:label="loc_wizpScheduleOfMandatorilyRedeemableSeriesBLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpScheduleOfMandatorilyRedeemableSeriesBLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeTables" xlink:title="00000030 - Disclosure - Taxes on Income (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - Stockholders&apos; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneEightPlanMember" xlink:label="loc_wizpTwoZeroOneEightPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneEightPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneTwoPlanMember" xlink:label="loc_wizpTwoZeroOneTwoPlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneTwoPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables" xlink:title="00000032 - Disclosure - Selected Statements of Operations Data (Tables)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SelectedStatementsOfOperationsDataAbstract" xlink:label="loc_wizpSelectedStatementsOfOperationsDataAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:label="loc_wizpScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSelectedStatementsOfOperationsDataAbstract" xlink:to="loc_wizpScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ScheduleOfFinancingExpensesNetTableTextBlock" xlink:label="loc_wizpScheduleOfFinancingExpensesNetTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSelectedStatementsOfOperationsDataAbstract" xlink:to="loc_wizpScheduleOfFinancingExpensesNetTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables" xlink:title="00000033 - Disclosure - Related Parties Balances and Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock" xlink:label="loc_wizpBalancesWithInterestedAndRelatedPartiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_wizpBalancesWithInterestedAndRelatedPartiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/GeneralDetails" xlink:title="00000034 - Disclosure - General (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GeneralTextualAbstract" xlink:label="loc_wizpGeneralTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_wizpGeneralTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="loc_us-gaapRevenueRemainingPerformanceObligationPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRevenueRemainingPerformanceObligationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExchangeOfCommonStock" xlink:label="loc_wizpExchangeOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_wizpExchangeOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReminingOutstandingOwnersPercentage" xlink:label="loc_wizpReminingOutstandingOwnersPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_wizpReminingOutstandingOwnersPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ForeignCurrencyExchangeRateTranslation" xlink:label="loc_wizpForeignCurrencyExchangeRateTranslation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpForeignCurrencyExchangeRateTranslation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CurrencyExchangeRatePercentage" xlink:label="loc_wizpCurrencyExchangeRatePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpCurrencyExchangeRatePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails1" xlink:title="00000036 - Disclosure - Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaapRestrictedInvestmentsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedInvestmentsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_wizpCashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpCashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails2" xlink:title="00000037 - Disclosure - Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails3" xlink:title="00000038 - Disclosure - Significant Accounting Policies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NumeratorAbstract" xlink:label="loc_wizpNumeratorAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpNumeratorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpNumeratorAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NetIncomeAttributedToPreferredStock" xlink:label="loc_wizpNetIncomeAttributedToPreferredStock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpNumeratorAbstract" xlink:to="loc_wizpNetIncomeAttributedToPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaapInvestmentIncomeDividend" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpNumeratorAbstract" xlink:to="loc_us-gaapInvestmentIncomeDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendWithRespectToRightForFutureInvestment" xlink:label="loc_wizpDeemedDividendWithRespectToRightForFutureInvestment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpNumeratorAbstract" xlink:to="loc_wizpDeemedDividendWithRespectToRightForFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividendDueToDownRoundAdjustment" xlink:label="loc_wizpDeemedDividendDueToDownRoundAdjustment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpNumeratorAbstract" xlink:to="loc_wizpDeemedDividendDueToDownRoundAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpNumeratorAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DenominatorAbstract" xlink:label="loc_wizpDenominatorAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_wizpDenominatorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDenominatorAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NetLossPerShareOfCommonStockBasicAndDiluted" xlink:label="loc_wizpNetLossPerShareOfCommonStockBasicAndDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpDenominatorAbstract" xlink:to="loc_wizpNetLossPerShareOfCommonStockBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails4" xlink:title="00000039 - Disclosure - Significant Accounting Policies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" xlink:label="loc_wizpWeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_wizpWeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" xlink:label="loc_wizpPreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAbstract" xlink:to="loc_wizpPreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetails5" xlink:title="00000040 - Disclosure - Significant Accounting Policies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:title="00000041 - Disclosure - Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantAccountingPoliciesTextualAbstract" xlink:label="loc_wizpSignificantAccountingPoliciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DepositPercentage" xlink:label="loc_wizpDepositPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpDepositPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="loc_wizpAmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpAmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PurchasePricePerShare" xlink:label="loc_wizpPurchasePricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpPurchasePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LeastPercentageOfCarryingAmount" xlink:label="loc_wizpLeastPercentageOfCarryingAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpLeastPercentageOfCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfContingentObligation" xlink:label="loc_wizpPercentageOfContingentObligation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpPercentageOfContingentObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfContingentObligation" xlink:label="loc_wizpDescriptionOfContingentObligation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpDescriptionOfContingentObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfBonueAgreement" xlink:label="loc_wizpPercentageOfBonueAgreement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpPercentageOfBonueAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyholderDividendsRateOnPolicyEarnings" xlink:label="loc_us-gaapPolicyholderDividendsRateOnPolicyEarnings" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_us-gaapPolicyholderDividendsRateOnPolicyEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NumberOfBonusSharesDistributedByCompany" xlink:label="loc_wizpNumberOfBonusSharesDistributedByCompany" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpNumberOfBonusSharesDistributedByCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemAllOfSeriesBPreferredStockDescription" xlink:label="loc_wizpRedeemAllOfSeriesBPreferredStockDescription" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpRedeemAllOfSeriesBPreferredStockDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfBonusAgreements" xlink:label="loc_wizpDescriptionOfBonusAgreements" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpDescriptionOfBonusAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GrossProceeds" xlink:label="loc_wizpGrossProceeds" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PresentValueOfDebtInstrumentPercentage" xlink:label="loc_wizpPresentValueOfDebtInstrumentPercentage" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantAccountingPoliciesTextualAbstract" xlink:to="loc_wizpPresentValueOfDebtInstrumentPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/MarketableEquitySecuritiesDetails" xlink:title="00000042 - Disclosure - Marketable Equity Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CannabicsMember" xlink:label="loc_wizpCannabicsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpCannabicsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableEquitySecuritiesTextualAbstract" xlink:label="loc_wizpMarketableEquitySecuritiesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOwnershipPercentage" xlink:label="loc_wizpInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_wizpInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital" xlink:label="loc_wizpMinimumPercentageOfIssuedAndOutstandingShareCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_wizpMinimumPercentageOfIssuedAndOutstandingShareCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaapMarketableSecuritiesNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_us-gaapMarketableSecuritiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MarketableEquityDescription" xlink:label="loc_wizpMarketableEquityDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_wizpMarketableEquityDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncomeFromChangeInFairValue" xlink:label="loc_wizpIncomeFromChangeInFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_wizpIncomeFromChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpMarketableEquitySecuritiesTextualAbstract" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/OtherCurrentAssetsDetails" xlink:title="00000043 - Disclosure - Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherGovernmentalAuthoritiesCurrent" xlink:label="loc_wizpOtherGovernmentalAuthoritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_wizpOtherGovernmentalAuthoritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherReceivable" xlink:label="loc_wizpOtherReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_wizpOtherReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicenseAgreementDetails" xlink:title="00000044 - Disclosure - License Agreement (Details)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementAbstract" xlink:label="loc_wizpLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementTextualAbstract" xlink:label="loc_wizpLicenseAgreementTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpLicenseAgreementTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfDiscountRate" xlink:label="loc_wizpPercentageOfDiscountRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementTextualAbstract" xlink:to="loc_wizpPercentageOfDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementTextualAbstract" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsAndOtherAssets" xlink:label="loc_us-gaapDeferredCostsAndOtherAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementTextualAbstract" xlink:to="loc_us-gaapDeferredCostsAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementDescription" xlink:label="loc_wizpLicenseAgreementDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementTextualAbstract" xlink:to="loc_wizpLicenseAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RecognizedLeaseLiability" xlink:label="loc_wizpRecognizedLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementTextualAbstract" xlink:to="loc_wizpRecognizedLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PercentageOfContingentObligation" xlink:label="loc_wizpPercentageOfContingentObligation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementTextualAbstract" xlink:to="loc_wizpPercentageOfContingentObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PenaltyPayment" xlink:label="loc_wizpPenaltyPayment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicenseAgreementTextualAbstract" xlink:to="loc_wizpPenaltyPayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationDetails" xlink:title="00000045 - Disclosure - License Purchase Obligation (Details)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationAbstract" xlink:label="loc_wizpLicensePurchaseObligationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicensePurchaseObligationAbstract" xlink:to="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="loc_us-gaapPurchaseObligationDueInNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" xlink:to="loc_us-gaapPurchaseObligationDueInNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaapPurchaseObligationDueInSecondYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" xlink:to="loc_us-gaapPurchaseObligationDueInSecondYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationCurrent" xlink:label="loc_wizpLicensePurchaseObligationCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" xlink:to="loc_wizpLicensePurchaseObligationCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationNet" xlink:label="loc_wizpLicensePurchaseObligationNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" xlink:to="loc_wizpLicensePurchaseObligationNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationLiabilities" xlink:label="loc_wizpLicensePurchaseObligationLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPurchaseObligationFiscalYearMaturityAbstract" xlink:to="loc_wizpLicensePurchaseObligationLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual" xlink:title="00000046 - Disclosure - License Purchase Obligation (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationAbstract" xlink:label="loc_wizpLicensePurchaseObligationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicensePurchaseObligationAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapMarketableSecuritiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicenseAgreementMember" xlink:label="loc_wizpLicenseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_wizpLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LicensePurchaseObligationTextualAbstract" xlink:label="loc_wizpLicensePurchaseObligationTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_wizpLicensePurchaseObligationTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MinimumCommitmentAmount" xlink:label="loc_wizpMinimumCommitmentAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicensePurchaseObligationTextualAbstract" xlink:to="loc_wizpMinimumCommitmentAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReducedAnnualRoyaltiesDescription" xlink:label="loc_wizpReducedAnnualRoyaltiesDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLicensePurchaseObligationTextualAbstract" xlink:to="loc_wizpReducedAnnualRoyaltiesDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/AccountsPayableDetails" xlink:title="00000047 - Disclosure - Accounts Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherAccountsPayableAbstract" xlink:label="loc_wizpOtherAccountsPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpOtherAccountsPayableAbstract" xlink:to="loc_us-gaapOtherEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiabilityValue" xlink:label="loc_wizpLiabilityValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpOtherAccountsPayableAbstract" xlink:to="loc_wizpLiabilityValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpOtherAccountsPayableAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TradePayables" xlink:label="loc_wizpTradePayables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpOtherAccountsPayableAbstract" xlink:to="loc_wizpTradePayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpOtherAccountsPayableAbstract" xlink:to="loc_us-gaapAccountsPayableOtherCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetails" xlink:title="00000048 - Disclosure - Convertible Loans (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleDebtOneMember" xlink:label="loc_wizpConvertibleDebtOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpConvertibleDebtOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtMember" xlink:label="loc_us-gaapDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AggregatePrincipalAmount" xlink:label="loc_wizpAggregatePrincipalAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpAggregatePrincipalAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AggregateMaximumOfRightToFutureInvestment" xlink:label="loc_wizpAggregateMaximumOfRightToFutureInvestment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpAggregateMaximumOfRightToFutureInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExercisePriceOfRightToFutureInvestment" xlink:label="loc_wizpExercisePriceOfRightToFutureInvestment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpExercisePriceOfRightToFutureInvestment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetails1" xlink:title="00000049 - Disclosure - Convertible Loans (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanRollForwardAbstract" xlink:label="loc_wizpLoanRollForwardAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpLoanRollForwardAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_us-gaapDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoans" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoans" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoan" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoan" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DerecognitionLoanUponExtinguishment" xlink:label="loc_wizpDerecognitionLoanUponExtinguishment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpDerecognitionLoanUponExtinguishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnLoan" xlink:label="loc_wizpAccruedInterestOnLoan" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpAccruedInterestOnLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoan" xlink:label="loc_wizpAmountAllocatedToLoan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpAmountAllocatedToLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansOne" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DerecognitionLoanUponExtinguishmentOne" xlink:label="loc_wizpDerecognitionLoanUponExtinguishmentOne" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpDerecognitionLoanUponExtinguishmentOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountAllocatedToLoanOne" xlink:label="loc_wizpAmountAllocatedToLoanOne" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpAmountAllocatedToLoanOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo" xlink:label="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansTwo" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_wizpAmortizationOfPremiumRelatedToConvertibleLoansTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpLoanRollForwardAbstract" xlink:to="loc_us-gaapDebtCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ConvertibleLoansDetailsTextual" xlink:title="00000050 - Disclosure - Convertible Loans (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleDebtOneMember" xlink:label="loc_wizpConvertibleDebtOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpConvertibleDebtOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneSevenLoanAmendmentMember" xlink:label="loc_wizpTwoZeroOneSevenLoanAmendmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroOneSevenLoanAmendmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneNineLoanAmendmentMember" xlink:label="loc_wizpTwoZeroOneNineLoanAmendmentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroOneNineLoanAmendmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneSixLoanAmendmentMember" xlink:label="loc_wizpTwoZeroOneSixLoanAmendmentMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroOneSixLoanAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MayTwoThousandNineteenAmendmentMember" xlink:label="loc_wizpMayTwoThousandNineteenAmendmentMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpMayTwoThousandNineteenAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WizeIsraelMember" xlink:label="loc_wizpWizeIsraelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpWizeIsraelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LendersMember" xlink:label="loc_wizpLendersMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpLendersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldMember" xlink:label="loc_wizpRimonGoldMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpRimonGoldMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldAndFisherMember" xlink:label="loc_wizpRimonGoldAndFisherMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpRimonGoldAndFisherMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyAxis" xlink:label="loc_wizpTypesOfCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_wizpTypesOfCurrencyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_NisMember" xlink:label="loc_wizpNisMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypesOfCurrencyDomain" xlink:to="loc_wizpNisMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtMember" xlink:label="loc_us-gaapDebtMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ConvertibleLoansTextualAbstract" xlink:label="loc_wizpConvertibleLoansTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_wizpConvertibleLoansTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount" xlink:label="loc_us-gaapInvestmentCompanyFinancialCommitmentToInvesteeFutureAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapInvestmentCompanyFinancialCommitmentToInvesteeFutureAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription" xlink:label="loc_us-gaapDebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaapDeferredCostsCurrentAndNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDeferredCostsCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LoanAmendmentDescription" xlink:label="loc_wizpLoanAmendmentDescription" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_wizpLoanAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="loc_us-gaapProceedsFromLoanOriginations1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapProceedsFromLoanOriginations1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeemedDividend" xlink:label="loc_wizpDeemedDividend" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_wizpDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnLoan" xlink:label="loc_wizpAccruedInterestOnLoan" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_wizpAccruedInterestOnLoan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOptionExercisePrice" xlink:label="loc_wizpInvestmentOptionExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_wizpInvestmentOptionExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpConvertibleLoansTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/ShortTermLoanPayableDetails" xlink:title="00000051 - Disclosure - Short Term Loan Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OcuwizeMember" xlink:label="loc_wizpOcuwizeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpOcuwizeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroTwoZeroLoanMember" xlink:label="loc_wizpTwoZeroTwoZeroLoanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_wizpTwoZeroTwoZeroLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyAxis" xlink:label="loc_wizpTypesOfCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_wizpTypesOfCurrencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ILSMember" xlink:label="loc_wizpILSMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypesOfCurrencyDomain" xlink:to="loc_wizpILSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ShortTermLoanPayableTextual" xlink:label="loc_wizpShortTermLoanPayableTextual" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpShortTermLoanPayableTextual" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BankAccount" xlink:label="loc_wizpBankAccount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpBankAccount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsDetails" xlink:title="00000052 - Disclosure - Significant Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsAbstract" xlink:label="loc_wizpSignificantTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MandatorilyRedeemableSeriesBLiability" xlink:label="loc_wizpMandatorilyRedeemableSeriesBLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpMandatorilyRedeemableSeriesBLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesBPreferredStock" xlink:label="loc_wizpSeriesBPreferredStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="loc_wizpLossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpLossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:label="loc_wizpChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock" xlink:label="loc_wizpRedemptionOfMandatorilyRedeemableSeriesBPreferredStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpRedemptionOfMandatorilyRedeemableSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_EscrowAmount" xlink:label="loc_wizpEscrowAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpEscrowAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_MandatorilyRedeemableSeriesBLiability" xlink:label="loc_wizpMandatorilyRedeemableSeriesBLiability_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsAbstract" xlink:to="loc_wizpMandatorilyRedeemableSeriesBLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SignificantTransactionsDetailsTextual" xlink:title="00000053 - Disclosure - Significant Transactions (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementAxis" xlink:label="loc_wizpTypeOfAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_wizpTypeOfAgreementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementDomain" xlink:label="loc_wizpTypeOfAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementAxis" xlink:to="loc_wizpTypeOfAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusExchangeAgreementMember" xlink:label="loc_wizpBonusExchangeAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpBonusExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusAgreementsMember" xlink:label="loc_wizpBonusAgreementsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpBonusAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesBPurchaseAgreementMember" xlink:label="loc_wizpSeriesBPurchaseAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpSeriesBPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SettlementSharesMember" xlink:label="loc_wizpSettlementSharesMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpSettlementSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyAxis" xlink:label="loc_wizpTypesOfCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_wizpTypesOfCurrencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypesOfCurrencyDomain" xlink:label="loc_wizpTypesOfCurrencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypesOfCurrencyAxis" xlink:to="loc_wizpTypesOfCurrencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IsraeliShekelMember" xlink:label="loc_wizpIsraeliShekelMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypesOfCurrencyDomain" xlink:to="loc_wizpIsraeliShekelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SignificantTransactionsTextualAbstract" xlink:label="loc_wizpSignificantTransactionsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpSignificantTransactionsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SecuritiesPurchaseAgreementDescription" xlink:label="loc_wizpSecuritiesPurchaseAgreementDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpSecuritiesPurchaseAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WarrantTermDescription" xlink:label="loc_wizpWarrantTermDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpWarrantTermDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_EscrowAmount" xlink:label="loc_wizpEscrowAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpEscrowAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PricePerShareAtDateOfAgreement" xlink:label="loc_wizpPricePerShareAtDateOfAgreement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpPricePerShareAtDateOfAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PricePerShareAtClosingDate" xlink:label="loc_wizpPricePerShareAtClosingDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpPricePerShareAtClosingDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OutstandingShareCapitalPercentage" xlink:label="loc_wizpOutstandingShareCapitalPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpOutstandingShareCapitalPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AdditionalOrdinaryShares" xlink:label="loc_wizpAdditionalOrdinaryShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpAdditionalOrdinaryShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusSharesHeldInEscrow" xlink:label="loc_wizpBonusSharesHeldInEscrow" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpBonusSharesHeldInEscrow" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentInMarketableSecuritiesBonusShares" xlink:label="loc_wizpInvestmentInMarketableSecuritiesBonusShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpInvestmentInMarketableSecuritiesBonusShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemableFairValue" xlink:label="loc_wizpRedeemableFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpRedeemableFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemablePreferredStockLiability" xlink:label="loc_wizpRedeemablePreferredStockLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpRedeemablePreferredStockLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceExpenses" xlink:label="loc_wizpFinanceExpenses" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpFinanceExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_InvestmentOfMarketableSecuritiesPercentage" xlink:label="loc_wizpInvestmentOfMarketableSecuritiesPercentage" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpInvestmentOfMarketableSecuritiesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CashOfInvestment" xlink:label="loc_wizpCashOfInvestment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpCashOfInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinancialIncome" xlink:label="loc_wizpFinancialIncome" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpFinancialIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossDueToRevaluation" xlink:label="loc_wizpLossDueToRevaluation" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpLossDueToRevaluation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParticipationRights" xlink:label="loc_us-gaapPreferredStockParticipationRights" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_us-gaapPreferredStockParticipationRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FairValueOfBonusSharesAndAmount" xlink:label="loc_wizpFairValueOfBonusSharesAndAmount" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpFairValueOfBonusSharesAndAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ReceivedCashProceeds" xlink:label="loc_wizpReceivedCashProceeds" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpReceivedCashProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RedeemAllOfSeriesBPreferredStockDescription" xlink:label="loc_wizpRedeemAllOfSeriesBPreferredStockDescription" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpRedeemAllOfSeriesBPreferredStockDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DescriptionOfBonusAgreements" xlink:label="loc_wizpDescriptionOfBonusAgreements" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpDescriptionOfBonusAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransaction" xlink:label="loc_wizpBonusTransaction" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpBonusTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusSharesOfSeriesBPreferredStock." xlink:label="loc_wizpBonusSharesOfSeriesBPreferredStock." />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSignificantTransactionsTextualAbstract" xlink:to="loc_wizpBonusSharesOfSeriesBPreferredStock." xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails" xlink:title="00000054 - Disclosure - Taxes on Income (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails1" xlink:title="00000055 - Disclosure - Taxes on Income (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DeferredTaxAssetsReservesAndAllowances" xlink:label="loc_wizpDeferredTaxAssetsReservesAndAllowances" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_wizpDeferredTaxAssetsReservesAndAllowances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetails2" xlink:title="00000056 - Disclosure - Taxes on Income (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossBeforeTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExpensesNotDeductibleForTaxPurposes" xlink:label="loc_wizpExpensesNotDeductibleForTaxPurposes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_wizpExpensesNotDeductibleForTaxPurposes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" xlink:label="loc_wizpIncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_wizpIncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/TaxesOnIncomeDetailsTextual" xlink:title="00000057 - Disclosure - Taxes on Income (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IL" xlink:label="loc_countryIL" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryIL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OcuwizeMember" xlink:label="loc_wizpOcuwizeMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpOcuwizeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WizeIsraelMember" xlink:label="loc_wizpWizeIsraelMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_wizpWizeIsraelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TaxesOnIncomeTextualAbstract" xlink:label="loc_wizpTaxesOnIncomeTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpTaxesOnIncomeTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_IncomeTaxRatePercentageDescription" xlink:label="loc_wizpIncomeTaxRatePercentageDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_wizpIncomeTaxRatePercentageDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CorporateAndDeferredTaxDescription" xlink:label="loc_wizpCorporateAndDeferredTaxDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_wizpCorporateAndDeferredTaxDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CorporateTaxRate" xlink:label="loc_wizpCorporateTaxRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_wizpCorporateTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_us-gaapFederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTaxesOnIncomeTextualAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000058 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases" xlink:label="loc_us-gaapDescriptionOfLessorLeasingArrangementsOperatingLeases" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapDescriptionOfLessorLeasingArrangementsOperatingLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FindersFeeAgreementDescription" xlink:label="loc_wizpFindersFeeAgreementDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_wizpFindersFeeAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetails" xlink:title="00000059 - Disclosure - Stockholders&apos; Equity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneTwoPlanMember" xlink:label="loc_wizpTwoZeroOneTwoPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneTwoPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetails1" xlink:title="00000060 - Disclosure - Stockholders&apos; Equity (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoZeroOneEightPlanMember" xlink:label="loc_wizpTwoZeroOneEightPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwoZeroOneEightPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_wizpSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/StockholdersEquityDetailsTextual" xlink:title="00000061 - Disclosure - Stockholders&apos; Equity (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwentyTwelveStockIncentivePlanMember" xlink:label="loc_wizpTwentyTwelveStockIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_wizpTwentyTwelveStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SeriesAWarrantsMember" xlink:label="loc_wizpSeriesAWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_wizpSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaapPreferredClassAMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapPreferredClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TwoThousandTwelvePlanMemberrMember" xlink:label="loc_wizpTwoThousandTwelvePlanMemberrMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_wizpTwoThousandTwelvePlanMemberrMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_EmployeeStockOptionTwoMember" xlink:label="loc_wizpEmployeeStockOptionTwoMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_wizpEmployeeStockOptionTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RimonGoldAndFisherMember" xlink:label="loc_wizpRimonGoldAndFisherMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_wizpRimonGoldAndFisherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockholdersEquityTextualAbstract" xlink:label="loc_wizpStockholdersEquityTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_wizpStockholdersEquityTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RegistrationStatementDescription" xlink:label="loc_wizpRegistrationStatementDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpRegistrationStatementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SecuritiesPurchaseAgreementDescription" xlink:label="loc_wizpSecuritiesPurchaseAgreementDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpSecuritiesPurchaseAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WarrantTermDescription" xlink:label="loc_wizpWarrantTermDescription" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpWarrantTermDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfTradingActivitiesAndManagementOfRelatedRisks" xlink:label="loc_us-gaapDescriptionOfTradingActivitiesAndManagementOfRelatedRisks" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapDescriptionOfTradingActivitiesAndManagementOfRelatedRisks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceExpense" xlink:label="loc_wizpFinanceExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpFinanceExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockDesignated" xlink:label="loc_wizpPreferredStockDesignated" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpPreferredStockDesignated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PreferredStockDesignatedStock" xlink:label="loc_wizpPreferredStockDesignatedStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpPreferredStockDesignatedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapDividendsCommonStockStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LiquidatedDamagesToInvestorsDescription" xlink:label="loc_wizpLiquidatedDamagesToInvestorsDescription" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpLiquidatedDamagesToInvestorsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PlacementAgencyAgreementDescription" xlink:label="loc_wizpPlacementAgencyAgreementDescription" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpPlacementAgencyAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PlacementAgentWarrantsDescription" xlink:label="loc_wizpPlacementAgentWarrantsDescription" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpPlacementAgentWarrantsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_JointVentureAgreementDescription" xlink:label="loc_wizpJointVentureAgreementDescription" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpJointVentureAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaapChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChairmanAppointmentAgreementDescription" xlink:label="loc_wizpChairmanAppointmentAgreementDescription" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpChairmanAppointmentAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockOptionsGrantedDuringVestingPeriod" xlink:label="loc_wizpStockOptionsGrantedDuringVestingPeriod" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpStockOptionsGrantedDuringVestingPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuanceToConsultantRelatedDescription" xlink:label="loc_wizpStockIssuanceToConsultantRelatedDescription" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpStockIssuanceToConsultantRelatedDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExtinguishmentOfLoansDescription" xlink:label="loc_wizpExtinguishmentOfLoansDescription" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpExtinguishmentOfLoansDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockOutstandingRelatedDescription" xlink:label="loc_wizpStockOutstandingRelatedDescription" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpStockOutstandingRelatedDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuanceToEmployeesRelatedDescription" xlink:label="loc_wizpStockIssuanceToEmployeesRelatedDescription" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpStockIssuanceToEmployeesRelatedDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossOfChangeInFairValue" xlink:label="loc_wizpLossOfChangeInFairValue" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpLossOfChangeInFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_WeightedaveragePeriod" xlink:label="loc_wizpWeightedaveragePeriod" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpStockholdersEquityTextualAbstract" xlink:to="loc_wizpWeightedaveragePeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails" xlink:title="00000062 - Disclosure - Selected Statements of Operations Data (Details)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SelectedStatementsOfOperationsDataAbstract" xlink:label="loc_wizpSelectedStatementsOfOperationsDataAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSelectedStatementsOfOperationsDataAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:label="loc_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="loc_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OverseasTravelMember" xlink:label="loc_wizpOverseasTravelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpOverseasTravelMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ShareBasedPaymentMember" xlink:label="loc_wizpShareBasedPaymentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpShareBasedPaymentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RentAndOfficeMaintenanceMember" xlink:label="loc_wizpRentAndOfficeMaintenanceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpRentAndOfficeMaintenanceMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PayrollAndBenefitsMember" xlink:label="loc_wizpPayrollAndBenefitsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpPayrollAndBenefitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ProfessionalServicesAndConsultationMember" xlink:label="loc_wizpProfessionalServicesAndConsultationMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpProfessionalServicesAndConsultationMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransactionCostsMember" xlink:label="loc_wizpBonusTransactionCostsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpBonusTransactionCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TaxesAndTollsMember" xlink:label="loc_wizpTaxesAndTollsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpTaxesAndTollsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_DirectorSalaryAndInsuranceMember" xlink:label="loc_wizpDirectorSalaryAndInsuranceMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpDirectorSalaryAndInsuranceMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OtherExpensesMember" xlink:label="loc_wizpOtherExpensesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_wizpOtherExpensesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1" xlink:title="00000063 - Disclosure - Selected Statements of Operations Data (Details 1)">
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SelectedStatementsOfOperationsDataAbstract" xlink:label="loc_wizpSelectedStatementsOfOperationsDataAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:label="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSelectedStatementsOfOperationsDataAbstract" xlink:to="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ChangeInFairValueOfMarketableSecurities" xlink:label="loc_wizpChangeInFairValueOfMarketableSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" xlink:to="loc_wizpChangeInFairValueOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExchangeRateGainsNet" xlink:label="loc_wizpExchangeRateGainsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" xlink:to="loc_wizpExchangeRateGainsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GainFromCompletionOfMilestoneClosing" xlink:label="loc_wizpGainFromCompletionOfMilestoneClosing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" xlink:to="loc_wizpGainFromCompletionOfMilestoneClosing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_GainFromSettlementShares" xlink:label="loc_wizpGainFromSettlementShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" xlink:to="loc_wizpGainFromSettlementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeDisclosureNonoperatingAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:label="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSelectedStatementsOfOperationsDataAbstract" xlink:to="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnConvertibleLoans" xlink:label="loc_wizpAccruedInterestOnConvertibleLoans" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_wizpAccruedInterestOnConvertibleLoans" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AccruedInterestOnLoans" xlink:label="loc_wizpAccruedInterestOnLoans" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_wizpAccruedInterestOnLoans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock" xlink:label="loc_wizpLossFromRecognitionOfMandatorilyRedeemablePreferredStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_wizpLossFromRecognitionOfMandatorilyRedeemablePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" xlink:label="loc_wizpLossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_wizpLossFromRevaluationOfContingentObligationWithRespectToFutureRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RevaluationOfMandatorilyRedeemablePreferredStock" xlink:label="loc_wizpRevaluationOfMandatorilyRedeemablePreferredStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_wizpRevaluationOfMandatorilyRedeemablePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusTransactionCosts" xlink:label="loc_wizpBonusTransactionCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_wizpBonusTransactionCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesGainLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaapExtinguishmentOfDebtAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_us-gaapExtinguishmentOfDebtAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpenseDisclosureNonoperatingAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails" xlink:title="00000064 - Disclosure - Related Parties Balances and Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BalancesWithRelatedPartiesAbstract" xlink:label="loc_wizpBalancesWithRelatedPartiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_wizpBalancesWithRelatedPartiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaapOtherReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpBalancesWithRelatedPartiesAbstract" xlink:to="loc_us-gaapOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpBalancesWithRelatedPartiesAbstract" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpBalancesWithRelatedPartiesAbstract" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1" xlink:title="00000065 - Disclosure - Related Parties Balances and Transactions (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_AmountsChargedAbstract" xlink:label="loc_wizpAmountsChargedAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_wizpAmountsChargedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpAmountsChargedAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_FinanceIncomeNet" xlink:label="loc_wizpFinanceIncomeNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpAmountsChargedAbstract" xlink:to="loc_wizpFinanceIncomeNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual" xlink:title="00000066 - Disclosure - Related Parties Balances and Transactions (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract" xlink:label="loc_wizpRelatedPartiesBalancesAndTransactionsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_wizpRelatedPartiesBalancesAndTransactionsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpRelatedPartiesBalancesAndTransactionsTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://ophthalic.com/role/SubsequentEventsDetails" xlink:title="00000067 - Disclosure - Subsequent Events (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementAxis" xlink:label="loc_wizpTypeOfAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_wizpTypeOfAgreementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TypeOfAgreementDomain" xlink:label="loc_wizpTypeOfAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementAxis" xlink:to="loc_wizpTypeOfAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BidAgreementMember" xlink:label="loc_wizpBidAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpBidAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_PIPEAgreementsMember" xlink:label="loc_wizpPIPEAgreementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpPIPEAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockRestrictionAgreementMember" xlink:label="loc_wizpStockRestrictionAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpStockRestrictionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CVRAgreementMember" xlink:label="loc_wizpCVRAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpTypeOfAgreementDomain" xlink:to="loc_wizpCVRAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CosmosConvertibleNotesMember" xlink:label="loc_wizpCosmosConvertibleNotesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_wizpCosmosConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_SubsequentEventsTextualAbstract" xlink:label="loc_wizpSubsequentEventsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_wizpSubsequentEventsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_CosmosTransactionDescription" xlink:label="loc_wizpCosmosTransactionDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpCosmosTransactionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OfferDescription" xlink:label="loc_wizpOfferDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpOfferDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndBenefitsTrust" xlink:label="loc_us-gaapCompensationAndBenefitsTrust" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapCompensationAndBenefitsTrust" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_BonusPurchaseAgreements" xlink:label="loc_wizpBonusPurchaseAgreements" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpBonusPurchaseAgreements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_OrdinarySharesOfBonus" xlink:label="loc_wizpOrdinarySharesOfBonus" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpOrdinarySharesOfBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_TotalProceedsPayable" xlink:label="loc_wizpTotalProceedsPayable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpTotalProceedsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleTermsOfConversionFeature" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleTermsOfConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_StockIssuedDuringPeriodSharesRestrictedStockAwardGrant" xlink:label="loc_wizpStockIssuedDuringPeriodSharesRestrictedStockAwardGrant" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpStockIssuedDuringPeriodSharesRestrictedStockAwardGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_RestrictedStockUnitsVestTerm" xlink:label="loc_wizpRestrictedStockUnitsVestTerm" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpRestrictedStockUnitsVestTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="wizp-20201231.xsd#wizp_ExpressedBonusAmount" xlink:label="loc_wizpExpressedBonusAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_wizpExpressedBonusAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wizpSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771462621672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Wize Pharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001218683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-52545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,961,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,052,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771464323912">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Restricted cash deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MarketableSecuritiesEquitySecuritieCurrent', window );">Marketable equity securities (Notes 3,10)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets (Note 4)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,160<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Account payable (Note 7)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,306<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationCurrent', window );">Current portion of license purchase obligation (Note 6)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short term loan payable (Note 9)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">265<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,843<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent obligation with respect to future revenues (Note 10)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,494<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,494<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Note 13):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock A, with $0.001 par value per share ("Series A Preferred Stock") Authorized: 1,000,000 shares at December 31, 2020 and 2019; Issued and outstanding: 178 shares at December 31, 2020 and 2019.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, with $0.001 par value per share ("Common Stock") 500,000,000 shares authorized at December 31, 2020 and 2019; 32,783,495 and 15,873,128 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,110<span></span>
</td>
<td class="nump">34,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39,218)<span></span>
</td>
<td class="num">(33,899)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,148)<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="nump">$ 1,176<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1 thousand.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license purchase obligation current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_MarketableSecuritiesEquitySecuritieCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in equity securities and other forms of securities that provide ownership interests expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_MarketableSecuritiesEquitySecuritieCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771462549400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock A, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock A, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock A, shares issued</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock A, shares outstanding</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">32,783,495<span></span>
</td>
<td class="nump">15,873,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">32,783,495<span></span>
</td>
<td class="nump">15,873,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463504552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses (Note 14a)</a></td>
<td class="nump">2,008<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(2,442)<span></span>
</td>
<td class="num">(3,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expense, net (Note 14b)</a></td>
<td class="num">(2,487)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,929)<span></span>
</td>
<td class="num">(3,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AdditionToNetLossAbstract', window );"><strong>Addition to net loss (for EPS purpose)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Deemed dividend with respect to the repurchase of right for future investment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants', window );">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed dividend due to exercise price adjustment of warrants</a></td>
<td class="num">(390)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to stockholders of Common Stock</a></td>
<td class="num">(5,319)<span></span>
</td>
<td class="num">(3,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (4,929)<span></span>
</td>
<td class="num">$ (3,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares of common stock used in computing basic and diluted net loss per share</a></td>
<td class="nump">16,669,628<span></span>
</td>
<td class="nump">10,519,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock dividends and adjustments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 5.Q)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187283-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AdditionToNetLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AdditionToNetLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsAntiDilutionProtectionPriceProtectionFeaturesOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461775720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Series A Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 30,272<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="num">$ (29,997)<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="nump">910<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,957,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment', window );">Amounts that were allocated to recognition of the right for future investment and warrants - 2016 Loan (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne', window );">Amounts that were allocated to recognition of the right for future investment and warrants - 2017 Loan (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u', window );">Issuance of Common Stock and warrants for cash (Note 13n)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares', window );">Issuance of Common Stock and warrants for cash (Note 13n), Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,037,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t', window );">Issuance of Common Stock and warrants due to 2016 Loan and 2017 Loan repayment (Note 13e)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares', window );">Issuance of Common Stock and warrants due to 2016 Loan and 2017 Loan repayment (Note 13e), Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,816,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment', window );">Terms modification and cancellation of existing financial instruments due to 2016 and 2017 loan repayment (Note 8e)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock (Note 13b)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock (Note 13b), Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConversionOfPreferredStockIntoCommonStock', window );">Conversion of Preferred stock into Common Stock (Note 13c)</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConversionOfPreferredStockIntoCommonStockShares', window );">Conversion of Preferred stock into Common Stock (Note 13c), Shares</a></td>
<td class="num">(732)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants', window );">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment', window );">Deemed dividends with respect to the repurchase of right for future investment (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">430,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,450)<span></span>
</td>
<td class="num">(3,450)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">34,491<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(33,899)<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="nump">178<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,873,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote', window );">Issuance of shares with respect to exercise of warrants (Notes 13p, 13q)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares', window );">Issuance of shares with respect to exercise of warrants (Notes 13p, 13q), Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,332,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote', window );">Deemed dividend due to exercise price adjustment of warrants (Notes 13p, 13q)</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Stock-based compensation, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">577,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,929)<span></span>
</td>
<td class="num">(4,929)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 35,110<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="num">$ (39,218)<span></span>
</td>
<td class="num">$ (4,148)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">178<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">32,783,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Representing amount less than $1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital Amount that was allocated to the right for future investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital Amount that was allocated to the right for future investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AdjustmentsToAdditionalPaidInCapitalRightForFutureInvestmentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ConversionOfPreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ConversionOfPreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ConversionOfPreferredStockIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ConversionOfPreferredStockIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend due to exercise price adjustment of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownroundAntidilutionProtectionPriceProtectionFeaturesIncludedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11t</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfCommonStockAndWarrantsDueTo2016LoanAnd2017LoanRepaymentNote11tShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfCommonStockAndWarrantsForCashNote11u</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfCommonStockAndWarrantsForCashNote11uShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares with respect to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares with respect to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfSharesWithRespectToExerciseOfWarrantsNoteShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_StockIssuedDuringPeriodValueDeemedDividendsWithRespectToRepurchaseOfRightForFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TermsModificationandCancellationExistingFinancialInstrumentsLoanRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463694392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (4,929)<span></span>
</td>
<td class="num">$ (3,450)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Income (loss) from marketable equity securities sale and revaluation</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium related to convertible loans (Notes 8 and 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AccruedInterestOnConvertibleLoans', window );">Accrued interest on convertible loans (Notes 8 and 13b)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of convertible loans (Notes 8 and 13b)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">977<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_GainFromCompletionOfMilestoneClosingNote10', window );">Gain from completion of milestone closing (Note 10)</a></td>
<td class="num">(847)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet', window );">Gain from settlement shares</a></td>
<td class="num">(100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10', window );">Loss from recognition of mandatorily redeemable Series B Preferred Stock (Note 10)</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10', window );">Change from revaluation of mandatorily redeemable Series B Preferred Stock (Note 10)</a></td>
<td class="nump">597<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10', window );">Change from revaluation of contingent obligation with respect to future revenues (Note 10)</a></td>
<td class="nump">435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IncreaseDecreaseInLicensePurchaseObligation', window );">Increase in license purchase obligation (Note 6)</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_FinancialExpenses', window );">Financial expenses</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,519)<span></span>
</td>
<td class="num">(2,064)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PurchaseOfPropertyAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sale of marketable equity securities</a></td>
<td class="nump">824<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">823<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ProceedsFromIssuanceOfSharesAndWarrants', window );">Proceeds from issuance of shares and warrants (Note 13n)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment', window );">Net proceeds from issuance of mandatorily redeemable Series B Preferred Stock</a></td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanReceived', window );">Loan received</a></td>
<td class="nump">247<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Convertible loan repayment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(760)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ProceedsFromRepaymentOfLicensePurchaseObligation', window );">Repayment of license purchase obligation</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">197<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate change on cash, cash equivalents and restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(499)<span></span>
</td>
<td class="num">(2,424)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities', window );">Ordinary shares issued through receipt of marketable securities (Note 13b)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment', window );">Amount allocated to the&#160;repurchase right for existing right for future investment related to the 2016 Loan and the 2017 Loan - March 2019 Loan Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(481)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountThatWasAllocatedToRightForFutureInvestment', window );">Amounts that were allocated to the recognition of right for future investment - 2016 Loan - March 2019 Loan Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment', window );">Amounts that were allocated to the recognition of right for future investment - 2017 Loan - March 2019 Loan Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan', window );">Deemed dividends with respect to the repurchase of&#160;right for future investment - March 2019 Loan Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment', window );">Amount allocated to the&#160;repurchase right for existing right to future investment related to the 2016 Loan and the 2017 Loan - May 2019 Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne', window );">Amounts that were allocated to the right for future investment and warrants - 2016 Loan - May 2019 Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo', window );">Amounts that were allocated to the right for future investment and warrants - 2017 Loan - May 2019 Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne', window );">Deemed dividends with respect to the repurchase of&#160;right for future investment - May 2019 Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountAllocatedToLoanAmendment', window );">Amount allocated to the 2016 Loan - March 2019 Loan Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountAllocatedToLoanAmendmentOne', window );">Amount allocated to the 2017 Loan - March 2019 Loan Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountAllocatedToLoanExtension', window );">Amount allocated to the 2016 Loan - May 2019 Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountAllocatedToLoanExtensionOne', window );">Amount allocated to the 2017 Loan - May 2019 Amendment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RepaymentOfConvertibleLoansThroughCommonStock', window );">Repayment of convertible loans through Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants', window );">Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SELLOFCANNABICSSHARETHROUGHABROKER', window );">Sell of Cannabics's shares through a broker</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow', window );">Amounts transferred from Series B Preferred Stock proceeds to restricted deposit held in escrow</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_InvestmentInMarketableSecuritiesBonusShares', window );">Investment in marketable securities - Bonus Shares</a></td>
<td class="nump">13,851<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues', window );">Recognition of contingent obligation with respect to future revenues</a></td>
<td class="nump">5,059<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock', window );">Issuance of mandatorily redeemable Series B Preferred Stock</a></td>
<td class="nump">7,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares', window );">Settlement of mandatorily redeemable series B Preferred Stock through distribution of Bonus Shares</a></td>
<td class="nump">7,604<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants', window );">Deemed dividend due to exercise price adjustment of warrants</a></td>
<td class="nump">390<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants', window );">Issuance of shares with respect to exercise of warrants</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LiabilityToHcw', window );">Transaction costs liability, see note 10</a></td>
<td class="nump">350<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ReleaseOfEscrowAccountBonusShares', window );">Release of escrow account &#8211; Bonus Shares</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Representing amount less than $1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain and losses (whether realized or unrealized) on all derivative instruments held for trading purposes whether or not settled physically.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=117331979&amp;loc=d3e41322-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AccruedInterestOnConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AccruedInterestOnConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountAllocatedToLoanAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountAllocatedToLoanAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountAllocatedToLoanAmendmentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountAllocatedToLoanAmendmentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountAllocatedToLoanExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountAllocatedToLoanExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountAllocatedToLoanExtensionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountAllocatedToLoanExtensionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to the repurchase right to existing right to future investment related to 2016 and 2017 loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountAllocatedToRepurchaseRightToExistingRightToFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountLoanAllocatedToRepurchaseRightToExistingRightToFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountThatWasAllocatedToRightForFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount that was allocated to the right for future investment - loan 2016.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountThatWasAllocatedToRightForFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountThatWasAllocatedToRightForFutureInvestmentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountThatWasAllocatedToRightForFutureInvestmentTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts that were allocated to the recognition of right for future investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountsAllocatedToTheRecognitionOfRightForFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts transferred from Series B Preferred Stock investment to restricted deposit held in escrow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountsTransferredFromSeriesBPreferredStockInvestmentToRestrictedDepositHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change from revaluation of contingent obligation with respect to future revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ChangeFromRevaluationOfContingentObligationWithRespectToFutureRevenuesNote10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change from revaluation of mandatorily redeemable Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend due to exercise price adjustment of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendDueToExercisePriceAdjustmentOfWarrantsResultOfCertainDownRoundAntiDilutionProtectionPriceProtectionFeaturesIncludedInTheWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendWithRespectToRepurchaseOfRightForFutureInvestmentOneLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_FinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_FinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_GainFromCompletionOfMilestoneClosingNote10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain from completion of milestone closing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_GainFromCompletionOfMilestoneClosingNote10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IncreaseDecreaseInLicensePurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in license purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IncreaseDecreaseInLicensePurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_InvestmentInMarketableSecuritiesBonusShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Investment in marketable securities (Bonus shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_InvestmentInMarketableSecuritiesBonusShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of mandatorily redeemable Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfMandatorilyRedeemableSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares with respect to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IssuanceOfSharesWithRespectToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LiabilityToHcw">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability to HCW.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LiabilityToHcw</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LoanReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LoanReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss from recognition of mandatorily redeemable Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of ordinary shares issued through receipt of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OrdinarySharesIssuedThroughReceiptOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ProceedsFromIssuanceOfSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ProceedsFromIssuanceOfSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of shares with respect to exercise of PIPE warrants and right for future investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ProceedsFromIssuanceOfSharesRespectToExerciseOfPipeWarrantsAndRightForFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ProceedsFromRepaymentOfLicensePurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ProceedsFromRepaymentOfLicensePurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PurchaseOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PurchaseOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition of contingent obligation with respect to future revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RecognitionOfContingentObligationWithRespectToFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ReleaseOfEscrowAccountBonusShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release of escrow account Bonus shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ReleaseOfEscrowAccountBonusShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RepaymentOfConvertibleLoansThroughCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of convertible loans through Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RepaymentOfConvertibleLoansThroughCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SELLOFCANNABICSSHARETHROUGHABROKER">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SELLOFCANNABICSSHARETHROUGHABROKER</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of mandatorily redeemable series B Preferred Stock through distribution of Bonus shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SettlementOfMandatorilyRedeemableSeriesBPreferredStockThroughDistributionOfBonusShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467461912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>GENERAL</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Wize Pharma, Inc. (the "<b>Company</b>" or "<b>Wize</b>") was incorporated in the State of Delaware.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Wize, through its wholly-owned Delaware subsidiary, Wize NC
Inc. ("<b>Wize NC</b>"), and the wholly-owned subsidiary of Wize NC, OcuWize Ltd. ("<b>OcuWize</b>"), is
a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome
("<b>DES</b>").</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Commencing August 30, 2016, Wize Pharma Ltd., a wholly owned
subsidiary of the Company ("<b>Wize Israel</b>") manages most of its activity through OcuWize Ltd. ("<b>OcuWize</b>"),
a wholly owned Israeli subsidiary of Wize Israel, which manages and develops most of the Company's activity under an existing
license agreement. In May 2015, Wize Israel entered into an Exclusive Distribution and Licensing Agreement (as amended, the "<b>License
Agreement</b>"), with Resdevco Research and Development Company Ltd. ("<b>Resdevco</b>"). Pursuant to the License
Agreement, Resdevco granted to Wize Israel (and thereafter, to OcuWize) an exclusive license to develop in the United States, under
the LO2A licensed technology, products in the field of ophthalmic disorders, to mutually agree upon a manufacturer and to purchase,
market, sell and distribute LO2A in finished product form in the licensed territories in the field of ophthalmic disorders, see
also note 5.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For discussion regarding the issuance
of the Series B Preferred Stock (as described in Note 10 below) as a partial financing, concurrently with the recognition of an
obligation with respect to 37% of future revenues of LO2A-based products ("<b>LO2A Proceeds</b>") (if any) and the
purchase of shares of Bonus BioGroup Ltd. ("<b>Bonus</b>"), classified as marketable equity securities that was completed
in February 2020, see also Note 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On December 30, 2020, the Company entered into a Bid Implementation
Agreement (as amended, the "Bid Agreement") with Cosmos Capital Limited, a digital infrastructure provider based in
Sydney, Australia ("Cosmos"). Pursuant to the Bid Agreement, the Company commenced an off-market takeover offer under applicable
Australian laws (the "Offer"), whereby it offers 61.11 shares of  common stock in exchange for each one outstanding
share of Cosmos. Immediately following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos
shareholders are expected to own approximately 87.65% of the outstanding common stock of Wize, while Wize existing stockholders
are expected to remain the owners of approximately 10.75% of the outstanding common stock of Wize, each on a fully diluted basis
and including warrants to be issued to Wize's financial advisor to the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the Bid Agreement, prior to the Closing
Date, Wize will enter into a Contingent Value Rights Agreement (the "CVR Agreement") with  certain of Wize's
subsidiaries (the "Wize Subsidiaries"), a person designated by Wize prior to the Closing Date as the Holders'
Representative (as defined herein), and the Rights Agent (as defined therein). Pursuant to the CVR Agreement, at the Closing Date,
each Wize pre-Closing securityholder will receive one non-transferable CVR for each outstanding share of common stock of Wize and
for each share of common stock of Wize underlying other convertible securities and warrants, held as of 4:01 p.m. Eastern Time
on the day immediately before the Effective Time (as defined in the CVR Agreement). See also note 10c.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Going concern uncertainty and management plans:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has not yet generated any material revenues from
its current operations, and therefore is dependent upon external sources for financing its operations. As of December 31, 2020,
the Company has an accumulated deficit of $39,218 and a total stockholders' deficit of $4,148.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, in each of the years
ended December 31, 2020 and 2019, the Company reported losses and negative cash flows from operating activities.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management considered the significance
of such conditions in relation to the Company's ability to meet its current and future obligations and determined that such
conditions raise substantial doubt about the Company's ability to continue as a going concern.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The accompanying financial statements
do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the
amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Until such time as the
Company generates sufficient revenue to fund its operations (if ever), the Company plans to finance its operations through
the sale of Bonus Shares (as hereinafter defined), and, to the extent available, short-term and long-term loans as well as
equity financings. There can be no assurance that the Company will succeed in obtaining the necessary financing to continue
its operations as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding the issuance, and subsequent
redemption, of the Series B Preferred Stock concurrently with the transaction with Bonus in February 2020, see also Note 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding the transaction with
Cosmos on December 30, 2020, see note 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Risk factors:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company had an accumulated deficit
of $39,218 and a total stockholders' deficit of $4,148. The Company has historically incurred net losses and is not able
to determine whether or when it will become profitable, if ever. To date, the Company has not commercialized any products or generated
any material revenues from product sales and accordingly it does not have a revenue stream to support its cost structure. The Company's
losses (other than financing related income and expenses) have resulted principally from costs incurred in development and discovery
activities and general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company expects to continue
to incur losses for the foreseeable future, and these losses will likely increase as it:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">initiates and manages further development and clinical trials for LO2A;</font></td></tr>
</table>
<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">seeks regulatory approvals for LO2A;</font></td></tr>
</table>
<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">implements internal systems and infrastructures;</font></td></tr>
</table>
<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">seeks to license additional technologies to develop;</font></td></tr>
</table>
<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">pays royalties related to the License Agreement and in connection with the obligation with respect to future revenues;</font></td></tr>
</table>
<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">hires management and other personnel;</font></td></tr>
</table>
<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">moves
    towards commercialization; and</font></td></tr>
</table>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Risks related to the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic, including on our clinical trials, the demand for our products, our ability to operate and on overall economic conditions.</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">No certainty exists that the Company
will be able to complete the development of LO2A for Conjunctivochalasis ("<b>CCH</b>"), Sj&#246;gren's syndrome
("<b>Sj&#246;gren's</b>") or any other ophthalmic disorder, due to financial, technological or other difficulties.
If LO2A fails in clinical trials or does not gain regulatory clearance or approval, or if LO2A does not achieve market acceptance,
the Company may never become profitable. In addition, while the Company explores license and other strategic transactions in an
attempt to monetize the LO2A, there is no assurance that the Company will be successful in doing so and, even if is able to do
so, what the timing or terms thereof may be of such licenses or strategic transactions.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company's inability to
achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash
flows. Moreover, the Company's prospects must be considered in light of the risks and uncertainties encountered by an early-stage
company and in a highly regulated and competitive market, such as the biopharmaceutical market, where regulatory approval and market
acceptance of its products are uncertain, and the other risks set forth in the Company's filings with the U.S. Securities
and Exchange Commission ("<b>SEC</b>"), including risks and uncertainties relating to the outbreak of the COVID-19
pandemic. There can be no assurance that the Company's efforts will ultimately be successful or result in revenues or profits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In light of the pending transaction
with Bonus (see note 10), there are also risks relating to, among other things, the timing and anticipated completion of such
transaction and whether the expected benefits of and potential value created by the transaction will materialize.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466390952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>SIGNIFICANT ACCOUNTING POLICIES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated Financial Statements
have been prepared in accordance with accounting principles generally accepted in the United States ("<b>U.S. GAAP</b>").</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Use of estimates in preparation of Financial Statements:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company's
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time
they are made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As applicable to the consolidated Financial Statements, the
most significant estimates and assumptions relate to the going concern assumptions, determining the fair value of embedded and
freestanding financial instruments related to convertible loans and rights to future investment as part of modification or the
settlement of the convertible loans determining the fair value of the contingent obligation with respect to future revenues and
whether modification of terms of financial instruments is considered substantial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Principles of consolidation:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated Financial Statements
include the accounts of the Company and its wholly owned subsidiaries. Inter-company balances and transactions have been eliminated
upon consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Functional currency:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company aims to direct
its main operations in the United States market. In addition, the convertible loans were denominated in U.S. dollars.
Similarly, the Company issued warrants eligible for exercise for the Company's shares of Common Stock at an exercise
price denominated in U.S. dollars and during January 2020 the Company completed the issuance of 7,500 Series B Non-Voting
Redeemable Preferred Stock for a purchase price of $1 per share for total gross proceeds of $7,500. Also, the management
believes the Company will raise funds through private investment rounds and / or from issuance of equity in dollar amounts by
approaching the market in the United States. As a result, it was determined that the U.S dollar is the currency of the
primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.
Thus, the functional currency of the Company is the U.S. dollar. The Company maintains its books and records in local
currency, which is NIS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Balances denominated in, or linked
to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date.&#160;&#160;For foreign
currency transactions included in the consolidated statement of comprehensive loss, the exchange rates applicable on the relevant
transaction dates are used.&#160;&#160;Transaction gains or losses arising from changes in the exchange rates used in the translation
of such balances are carried to financing income or expenses as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The following table presents data
regarding the dollar exchange rate of relevant currencies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">USD 1 = NIS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.9</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.8</td><td style="text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">d.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cash equivalents are short-term
highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For presentation of statement of
cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total
amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">December&#160;31</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">718</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">260</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">759</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">e.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted bank deposit:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Restricted bank deposit is a deposit
with maturities of more than three months and up to one year. The restricted bank deposit was presented at its cost, including
accrued interest and represents cash which is used as collateral for Wize Israel's credit card used for certain corporate
business expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">f.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Marketable equity securities:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company's investment in marketable equity securities
which is based on equity securities with readily determinable fair values was classified as financial instruments at fair value
with any changes in fair value recognized periodically in earnings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">g.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives
of the assets at the following rates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Computers and electronic equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">h.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Impairment of long-lived assets:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company's long-lived assets are reviewed for impairment
in accordance with Accounting Standards Codification ("<b>ASC</b>") 360, "Property, Plant and Equipment",
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds its fair value. Assets to be disposed of are reported at the lower
of the carrying amount or fair value less costs to sell. During the years ended December 31, 2020 and 2019, no impairment losses
have been identified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">i.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Research and development expenses:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Research and development expenses
are charged to the statement of comprehensive loss as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In-Process Research and Development
assets, acquired in an asset acquisition (<i>i.e.</i>, assets acquired outside a business combination transactions) that are to
be used in a research and development project which are determined not to have an alternative future use are charged to expense
at the acquisition date in accordance with ASC 730, "Research and Development".</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">j.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Severance pay:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Wize Israel has two employee as
of December 31, 2020 and 2019. Wize Israel's liability for severance pay is subject to Section 14 of Israel's the Severance
Compensation Act, 1963 ("<b>Section 14</b>"), pursuant to which all Wize Israel's employees are included under
Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee's
name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release Wize Israel from any
future severance payments in respect of those employees. Wize Israel has made all of the required payments as of December 31, 2020
and 2019.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fund is made available to the
employee at the time the employer-employee relationship is terminated, regardless of cause of termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The severance pay liabilities and
deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably
transferred to the severance funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Severance expenses for the years
ended December&#160;31, 2020 and 2019 amounted to $16 and $17, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">k.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Income taxes:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for income
taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred
tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets
to amounts more likely than not to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company implements a two-step
approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to
be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on
an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized tax positions
has been recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">l.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Concentrations of credit risk:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and restricted
bank deposits. Cash and cash equivalents and restricted bank deposits are invested in banks in Israel and the U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management believes that the financial
institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with
respect to these investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has no off-balance-sheet
concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">m.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Convertible loans: &#160;&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><u>Allocation of proceeds:</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The proceeds received upon the
original issuance of the 2016 Loan (as defined below) together with a freestanding derivative financial instrument (derivative
liability for right to future investment) were allocated to the financial instruments issued based on the residual value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The detachable derivative financial
instrument related to the 2016 Loan was recognized based on its fair value and the remaining amount of the proceeds was allocated
to the 2016 Loan component.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2017 Loan (as defined below)
was not issued with any detachable instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><u>Beneficial Conversion Features
("BCFs"):</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px">&#160;</td>
    <td style="width: 29px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the Company has considered the provisions of ASC 815-40, "Derivatives and Hedging &#8211; Contracts in Entity's Own Equity" ("<b>ASC 815-40</b>"), and determined that the embedded conversion feature of the 2016 Loan should not be separated from the host instrument because it qualifies for equity classification. Furthermore, the Company applied ASC 470-20, "Debt &#8211; Debt with Conversion and Other Options" ("<b>ASC 470-20</b>) which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios, and has applied the BCFs guidance to determine whether the conversion feature is beneficial to the investor.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">The BCFs was calculated by allocating
the proceeds received in financing transactions to the 2016 Loan and to any detachable freestanding financial instrument (derivative
liability for future investment) included in the transaction, and by measuring the intrinsic value of the conversion option based
on the effective conversion price as a result of the allocated proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">The intrinsic value of the conversion
option with respect to the 2016 Loan was recorded as a discount on the 2016 Loan with a corresponding amount credited directly
to equity as additional paid-in capital. After the initial recognition, the discount on the 2016 Loan was amortized as interest
expense over the contractual term of the 2016 Loan (before its modification) by using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px">&#160;</td>
    <td style="width: 29px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the Company has considered the provisions of ASC 815-15,&#160;"Derivatives and Hedging - Embedded Derivatives", and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, did not meet the definition of a derivative in accordance with the provisions of ASC 815-10, "Derivatives and Hedging"&#160;&#160;since its terms did not require or permit net settlement. Thus, it was determined that the conversion feature does not meet the characteristic of being readily convertible to cash.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Furthermore, the Company applied
ASC 470-20 which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Pursuant to ASC 470-20-30, the
amount of the BCFs with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion
price (<i>i.e.</i>, the entire proceeds received for the 2017 Loan) and the aggregate fair value of the Common Stock and other
securities (which consist of the future Investment Rights) into which the 2017 Loan was convertible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">As such difference was determined
to be greater than the amount of the entire proceeds originally received for the 2017 Loan, the amount of the discount assigned
to the BCFs was limited to the amount of the entire proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Following modifications or exchanges of convertible loans that were accounted for as an extinguishment (see below), upon each additional recognition of the convertible loans based on their modified terms, the Company applied ASC 470-20, "Debt &#8211; Debt with conversion and other options" to determine whether the conversion feature is considered beneficial to the investors. However, due to the fact that following each of the extinguishments of the convertible loans, such modified convertible loans were recognized based on their fair value as of the modification date, the conversion terms were not considered beneficial to the investors.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">d.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Modifications or Exchanges</u>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Modifications to, or exchanges
of, financial instruments such as convertible loans, are accounted for as a modification or an extinguishment, following to provisions
of ASC 470-50, "Debt- Modification and Extinguishments" ("<b>ASC 470-50</b>"). Such an assessment done
by management either qualitatively or quantitatively based on the facts and circumstances of each transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Under ASC 470-50, modifications
or exchanges are generally considered extinguishments with gains or losses recognized in current earnings if the terms of the new
debt and original instrument are substantially different. The instruments are considered "substantially different"
when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present
value of the remaining cash flows under the terms of the original instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">If the terms of a debt instrument
are changed or modified and the present value of the cash flows under the terms of the new debt instrument is less than 10%, the
debt instruments are not considered to be substantially different, except in the following two circumstances (i)&#160;&#160;The
transaction significantly affects the terms of an embedded conversion option, such that the change in the fair value of the embedded
conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and
after the modification or exchange) is at least 10% of the carrying amount of the original debt instrument immediately before the
modification or exchange or (ii)&#160;&#160;The transaction adds a substantive conversion option or eliminates a conversion option
that was substantive at the date of the modification or exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If the original and new debt
instruments are considered as "substantially different", the original debt is derecognized and the new debt is initially
recorded at fair value, with the difference recognized as an extinguishment gain or loss under financial expense or income as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If a convertible debt instrument
with a beneficial conversion option that was separately accounted for in equity, is extinguished prior to its conversion or stated
maturity date, a portion of the reacquisition price is allocated to the repurchase of the beneficial conversion option. The amount
of the reacquisition price allocated to the beneficial conversion option is measured using the intrinsic value of that conversion
option at the extinguishment date. The residual amount, if any, is allocated to the convertible debt instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">The gain or loss on the extinguishment
of the convertible debt instrument is determined based on the difference between the carrying amount and the fair value of the
allocated reacquisition price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Modifications to, or exchanges
of equity financial instruments such as right to future investment, are accounted for as a modification or an extinguishment in
a similar manner as described above. Such an assessment is done by management either qualitatively or quantitatively based on the
facts and circumstances of each transaction. Among others, management considers whether, the fair value of the financial instruments
before and after the modification or exchange are substantially different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If the original and new equity
instruments are considered as "substantially different", the excess fair value of the allocated reacquisition price
over the fair value of the modified financial instrument before the modification, is recognized directly to retained earnings as
a deemed dividend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"><u>Issuance costs of convertible
loan:</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2016 Loan (or costs allocated to such component in a package issuance) were presented as a direct deduction from the amount of the 2016 Loan and in subsequent periods such costs (together with the discount created by BCFs if applicable) expensed as financing expenses over the contractual term of the 2016 Loan by using the effective interest method. Any such costs that were allocated to the derivative component were expensed as incurred.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2017 Loan (or costs allocated to such component in a package issuance) were presented as a deferred asset since the 2017 Loan was completely discounted at the initial recognition. In subsequent periods, such expenses were amortized ratably over the original term of the 2017 Loan.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"><u>Extinguishment of convertible
loans:</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Upon the final extinguishment
of the convertible loans upon their maturity, the difference between the reacquisition price which consist of the cash paid, the
fair value of instruments issued (shares and warrants) and the modification of loans and cancellation of existing financial instruments)
and the carrying amounts of the convertible loans being extinguished was recognized as a gain or loss in the period of extinguishment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">n.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Fair value of financial instruments:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">ASC 820, "Fair Value Measurements
and Disclosures" ("<b>ASC 820</b>"), defines fair value as the price that would be received to sell an asset
or paid to transfer a liability (<i>i.e.</i>, the "exit price") in an orderly transaction between market participants
at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In determining fair value, the
Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used
when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based
on market data obtained from sources independent of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Unobservable inputs are inputs
that reflect the Company's assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The hierarchy is broken down into
three levels based on the inputs as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 48px"><font style="font: 10pt Times New Roman, Times, Serif">Level&#160;1&#160;</font></td>
    <td style="width: 19px"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level&#160;2&#160;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level&#160;3&#160;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The availability of observable
inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of
investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based
on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment
and the investments are categorized as Level&#160;3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The carrying amounts of cash and
cash equivalents, short-term bank deposits, other accounts receivable, trade payables and other accounts payable approximate their
fair value due to the short-term maturities of such instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Fair value of the marketable equity
securities is determined based on a Level 1 input.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">o.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Legal and other contingencies:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450 "Contingencies". A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed
and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information
and events pertaining to a particular matter. As of December&#160;31, 2020, the Company is not a party to any litigation that could
have a material adverse effect on the Company's business, financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Legal costs incurred in connection
with loss contingencies are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">p.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Leases:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Effective January 1, 2019, the Company accounts for its leases
under ASC 842, "Leases". Under this guidance, arrangements meeting the definition of a lease are classified as operating
or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated
by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing
rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results
in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In calculating the right of use
asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases
having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on
a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recognized&#160;$42
of operating lease right of use assets and operating lease liabilities at January 1, 2019. As of December 31, 2020 and 2019, total
of right-of-use assets related to the Company's operating leases and operating lease liabilities was $22.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recorded an amortization
of $20 in right of use assets and operating lease liabilities for the year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">q.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Series A Warrants and December 2019 Warrants with Down-Round Protection:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Commencing January 1, 2018 and
following the early adoption of Accounting Standard Update ("<b>ASU</b>") No. 2017-11, "I. Accounting for certain
financial instruments with Down Round Features" (ASU 2017-11), the Company disregards certain down-round features when assessing
whether a financial instrument is indexed to its own stock, for purposes of determining liability or equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Based on its evaluation,
management has determined that the Series A Warrants and warrants that were issued in October 2018 (the "<b>October
2018 Warrants</b>") and in December 2019 (the "<b>December 2019 Warrants</b>"), as part of a private
placement, as described in Note&#160;13n, respectively, which include a down-round protection that would adjust the exercise
price of the Series A Warrants based on the price at which the Company subsequently issues shares or other equity-linked
financial instruments, if that price is less than the original exercise price of the Series A Warrants, are eligible for
equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In accordance with the provisions
of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (<i>i.e.</i>, when the exercise price of
the Series A Warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend
and as a reduction of income available (increase of loss applicable) to common shareholders for purposes of basic earnings per
share (EPS) calculation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding a triggering event that required down-round adjustment
of the exercise price of the warrants during 2020 and 2019, see Note 13p and 13q, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Modifications to the terms of warrants that are classified
as equity and remains to be classified in equity after the modification, are accounted for in a similar manner to share-based compensation
guidance with respect to modifications. Accordingly, the incremental fair value from the modification (the change in the fair value
of the warrant before and after the modification) is recognized in retained earnings as a deemed dividend (e.g., dividends to a
particular class of equity holders).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">r.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Basic and diluted loss per share:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Basic loss per share is computed
by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares of Common Stock
outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Series
A Preferred Stock) are considered in the computation of basic income (loss) per share using the two-class method. In periods of
net loss, such participating securities are included in the computation, since the holders of such securities have a contractual
obligation to share the losses of the Company (as the convertible Series A Preferred Stock do not have a right to receive any mandatory
redemption amount and as they are entitled only to dividends on an as-converted basis together with the common shares).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In computing diluted loss per share,
basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of options, warrants and
rights for future investment issued or granted using the "treasury stock method" and upon the conversion of 2017 Loan
and 2016 Loan using the "if-converted method", if the effect of each of such financial instruments is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For the year ended
December&#160;31, 2020 and 2019, all outstanding warrants, stock options and other convertible instruments have been excluded
from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The loss and the weighted average
number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2020 and 2019, is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,929</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,450</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Add: Loss attributed to preferred stock (*)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">136</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to right for future investment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(185</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend due to down round adjustment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(267</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to stockholders of Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,266</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,766</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shares of Common Stock used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,669,628</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,519,682</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss per share of Common Stock, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.36</td><td style="text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
                                         the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase
                                         Agreement (as defined below). These shares of preferred stock are participating securities. During
                                         the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
                                         ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December
                                         31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Number of shares:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Common shares used
    in computing basic and diluted loss per share</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">16,669,628</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">10,519,682</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Preferred Stock and options excluded
    from the calculations of diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">614,763</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,931,097</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">s.</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other comprehensive loss</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The components of accumulated
other comprehensive loss which resulted from foreign currency translation adjustment as of December&#160;31, 2020 and 2019 were
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br /> accumulated <br />
    other <br /> comprehensive <br /> income (loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2020</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(73</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(73</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><font style="font-size: 6pt"><b>&#160;</b></font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">t.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"><font style="font-size: 6pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Stock-based compensation to employees
is accounted for in accordance with ASC 718, "Compensation - Stock Compensation" ("<b>ASC 718</b>"), which
requires estimation of the fair value of equity - based payment awards on the date of grant using an option pricing model. The
value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 6pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Stock-based compensation expense
is recognized for the value of awards granted based on the accelerated method over the requisite service period of each of the
awards, net of estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fair value of stock options
granted to Wize Israel employees was estimated using the Black- Scholes option pricing model, which requires a number of assumptions,
of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated
based upon historical volatilities of the Company on a weekly basis since the marketability of Wize Israel is less than the expected
option term. The expected option term represents the period that Wize Israel's stock options are expected to be outstanding
and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The expected dividend yield assumption
is based on Wize Israel's historical experience and expectation of no future dividend payouts. Wize Israel has historically
not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Following the adoption of ASU 2018-07 in January 2018, all equity-classified
nonemployee share-based payment are accounted for in accordance with the provisions of ASC 718 and accordingly, awards granted
during 2019 and 2020 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">u.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Recent Accounting Pronouncements not adopted
    yet</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"><font style="font-size: 7pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.5in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">ASU 2016-13, "Financial Instruments &#8211; Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13")</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On June 2016, the FASB issued ASU Update 2016-13,
"Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU
2016-13") ASU Update 2016-13 revised the criteria for the measurement, recognition, and reporting of credit losses on financial
instruments to be recognized when expected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On November 2019, the FASB issued
ASU 2019-10, "Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic
842) &#8211; Effective Dates," which, among other provisions, the effective date of ASU 2016-13 was amended as follows</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">1. Public
business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (SRCs)
as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">2. All
other entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">As the Company is eligible to be considered as smaller reporting
company, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal
years, with early adoption permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is in the process
of evaluating the effect that ASU 2016-13 will have on the results of operations and financial statements, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt"></font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.5in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">ASU 2020-06&#8212;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts
in an Entity's Own Equity</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In August 2020, the FASB issued
ASU 2020-06&#8212;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity
(ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes from
GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and beneficial conversion
feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for
such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life
of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument
contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt
instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to
calculate the impact of convertible instruments on diluted earnings per share (EPS).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The amendments in ASU 2020-06
are effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding
entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021,
including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning
after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">ASU 2020-06 can be adopted
on either a fully retrospective or modified retrospective basis. The adoption of this standard is not expected to result in a
material impact to the Company's financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">v.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Contingent obligation with respect to future
    revenues</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company's contingent
obligation to payment of 37% of the future LO2A Proceeds, if any, was accounted for as long-term debt in accordance with the provisions
of Accounting Standards Codification ("ASC") 470-10-25, "Sales of Future Revenues or Various other Measures
of Income," which relates to cash received in exchange for payments of a specified percentage or amount of revenue or other
measure of income of a particular product line, business segment, trademark, patent, or contractual right.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Such repayment obligations are
contingent upon the receipt by the Company of any future proceeds from LO2A sales, license or other, as described in Note 5 below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company elected to measure
the contingent payment obligation in its entirety, at its fair value (the "Fair Value Option") in accordance with
ASC 825-10, "Financial Instruments" due to the variable and contingent nature of the repayment provisions of such
financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fair value of such
liability was measured upon its initial recognition at its fair value, based on the difference between the fair value of the
marketable securities received by the Company, less the amount of cash paid by the Company. In subsequent periods, the fair
value of the liability for contingent payment obligation is based on management estimate. As of December 31, 2020, the
Company revalued the liability to its fair value with the assistance of an external valuation specialist, pursuant to the
Company's estimations and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined
that the inputs used in measuring the fair value of the contingent payment obligation fall within Level 3 in the fair value
hierarchy which involves significant estimations and assumptions regarding any projected future proceeds from the LO2A,
including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product
into the U.S. market - 12%, the patent expiration date (2038), the operational profit estimated rate - 26%, the probabilities
for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined that the inputs used in measuring
the fair value of the contingent payment obligation fall within Level 3 in the fair value hierarchy which involves significant
estimates and assumptions including, among others, any projected future proceeds from the LO2A, the risk-adjusted rate for discounting
future cash flows and other relevant assumptions, see Note 10.&#160;&#160;Actual results could differ from the estimates made.
Changes in fair value (including the component related to imputed interest), would be included in the consolidated statements of
comprehensive loss as part of financial income (loss) under the heading "Changes in fair value of contingent payment obligation
with respect to future revenues."</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">w.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Mandatorily Redeemable Series B Preferred
    Stock</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company classified its formerly
outstanding Series B Preferred Stock as a liability, as their terms embody an unconditional obligation of the Company to redeem
the shares by transferring cash or other assets that equal (i) 80% of the proceeds received by the Company through future sales
of the Bonus Shares issued to the Company under the Bonus Agreements (as hereinafter defined) and (ii) 80% of any cash dividends
received by the Company on such Bonus Shares) at a specified or determinable date or dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company elected to measure
this liability in its entirety, at its fair value (the "Fair Value Option") in accordance with ASC 825-10, "Financial
Instruments" due to the variable and contingent nature of the redemption price of such financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Upon initial recognition and in
subsequent periods, the Company measured the&#160;fair value of the liability related to the Series B Preferred Stock based on
the value of the Bonus Shares and the cash amount that the Company was required to transfer to the Series B investors upon the
redemption of the Series B Preferred Stock. The difference between the amount received by the Company upon the issuance of the
Series B Preferred Stock and their fair value as of that date was carried immediately to the consolidated statements of comprehensive
loss as part of financial income (loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The issuance costs of the Series
B Preferred Stock were recognized immediately as an expense during the three months ended March 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On July 8, 2020, the Company elected
to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares to the (now former)
holders of Series B Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 29, 2020, Wize entered into an Addendum (the "Addendum")
with Bonus, whereby, among other things, Bonus agreed to issue to the Company additional ordinary shares of Bonus (the "Bonus
Shares", the total number of which consists of (i) the Milestone Settlement Shares, which, as defined in the Addendum, means
Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum)
by NIS 0.50, and (ii) the HCW Settlement Shares, as defined in note 10a (together with the Milestone Settlement Shares, the "Settlement
Shares"), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed
in NIS (based on the exchange rate set in the Addendum) by NIS 0.50. In consideration for the Settlement Shares, the Company agreed
to make certain amendments to the Bonus Agreements, including the following key modifications: (i) the Company will waive the requirement
that Bonus will affect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing, which means that US$3.7 million
were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq
Milestone Shares") were released to the Company and to its former holders of Series B Preferred Stock (the "Former
Series B Holders"); (ii) the Company will waive approximately US$120 in liquidated damages that accrued as a result of the
delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli
subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under the Bonus Exchange Agreement,
including certain related negative covenants. The closing occurred on December 29, 2020. It should be noted that, in accordance
with the obligations of the Company to the Former Series B Holders (see below), the Company has transferred 80% of the Milestone
Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the entire
balance of the Series B preferred stock was extinguished.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467535384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Equity Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE EQUITY SECURITIES</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>MARKETABLE EQUITY SECURITIES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company owned 52,249 ordinary shares of Can-Fite representing
approximately 0.04% of Can-Fite&#8217;s issued and outstanding share capital as of December 31, 2019. As of December 31, 2019,
the investment amounted to $6. During the year ended December 31, 2019 the Company recorded a loss of $26. During 2020 the Company
sold all of its Can-Fite ordinary shares for net proceeds of approximately $3. </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2019 the Company held 25,000 ordinary shares
of Cannabics Pharmaceuticals, Inc. (&#8220;<b>Cannabics</b>&#8221;) representing less than 1% of its issued and outstanding share
capital as of that day. As of December 31, 2019, the investment amounted to $3. During 2020 the Company sold all of its Cannabics
ordinary shares for net proceeds of approximately $260.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.95in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the fourth quarter of 2019, the Company sold 2,238,944 shares
of Cannabics through a broker at the amount of $260 (see also Note 4) which were received as of the date of Financial Statements.
The Company made a payment of $1 to the broker as a deposit for the Broker&#8217;s activity. During 2019 the Company recorded a
loss of $501.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company owns 18,822,533 ordinary shares of Bonus representing
approximately 1.9% of Bonus&#8217;s issued and outstanding share capital as of December 31, 2020. As of December 31, 2020, the
fair value of the investment, based on the quoted market price on TASE, amounts to $2,834 and is presented as Marketable equity
securities in the accompanying consolidated balance sheet. During 2020 the Company recorded an income from sale of shares and revaluation
of $1,197 with respect to this investment, see also Note 10.</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467760520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 4:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>OTHER CURRENT ASSETS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Governmental authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivable (Note 3c)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">66</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">378</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467416424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicenseAgreementTextBlock', window );">LICENSE AGREEMENT</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>LICENSE AGREEMENT</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In May 2015, Wize Israel
entered into an Exclusive Distribution and Licensing Agreement (as amended, the &#8220;<b>License Agreement</b>&#8221;) with
Resdevco Ltd. (&#8220;<b>Resdevco</b>&#8221;), whereby Resdevco granted to Wize Israel (and thereafter, to OcuWize) an
exclusive license to purchase, market, sell and distribute a formula known as LO2A (&#8220;<b>LO2A</b>&#8221;) in the United
States and China as well as a contingent right to do the same in other countries. LO2A is a drug developed for the treatment
of DES, and other ophthalmological illnesses, including CCH and Sj&#246;gren&#8217;s. Pursuant to the LO2A License Agreement,
Wize Israel is required to pay Resdevco royalties for sales in the licensed territories, payable on a semi-annual basis,
subject to making certain minimum royalty payments as set forth in the LO2A License Agreement. In January 2020 and January
2021, the Company paid Resdevco royalties in the amount of $150.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the License Agreement,
the minimum royalties payable by Wize Israel to Resdevco shall be $150 per year through 2021. A one-time payment to Resdevco by
Wize Israel in an amount of $650 shall be due no later than the second anniversary of the receipt of Food and Drug Administration
(&#8220;<b>FDA</b>&#8221;) approval (the &#8220;<b>Deferred Amount</b>&#8221;); however, following FDA approval, if annual royalties
due to Resdevco by Wize Israel exceed the Minimum Royalties (as defined in the License Agreement), an amount equal to 50% of such
excess shall be added towards settlement of the Deferred Amount. As to royalty payments, Resdevco shall be entitled to the greater
of $0.60 per unit sold, or a percentage of revenues, not to exceed 10%, from sales made in the United States and other countries,
excluding Israel, China and Ukraine, but not less than the Minimum Royalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined not
to pursue currently any activities outside the USA until the Company will obtain from Resdevco satisfactory registration file
including DES and at least one more indication such as CCH or Sj&#246;gren&#8217;s. The Company seeks to approve a proposed regulatory
strategy acceptable to the Chinese market based on the regulatory files provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The LO2A License Agreement has
an initial term of seven years that expires in May 2022, and, unless Wize Israel provides prior notice of at least twelve (12)
months terminating the agreement, the LO2A License Agreement renews automatically each year. Wize Israel may terminate the LO2A
License Agreement prior to May 2022, subject to certain conditions, including, a 180 days prior notice to Resdevco, and penalty
payment of $100,000, depending on the timing of termination. The LO2A License Agreement may also be terminated by either party
upon the occurrence of certain other customary termination triggers, including material breaches of the LO2A License Agreement
by either party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On May 4, 2020, the Company and
Resdevco entered into a further amendment to the License Agreement, whereby the parties agreed, among other things, that if (i)
within 3 months after we receive a pre-Investigational New Drug (&#8220;IND&#8221;) with respect to the LO2A, or (ii) in case of
proven inability to receive such Pre-IND as a direct result of the COVID-19, in both cases not later than December 31, 2021, we
provide Resdevco with a written termination notice, the License Agreement shall be terminated immediately, and to the extent we
exercise such termination right before the end of 2021, no minimum royalty fee shall be due for the year 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of the date of these Financial
Statements, the Company had not received FDA approval for LO2A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">See Note 10 below regarding the Company&#8217;s contingent obligation
for the payment of 37% of the future Lo2A proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2020, the Company has recognized a liability
of $250, representing the minimum commitment to pay royalties to Resdevco based on the upcoming January 2021 payment in an amount
of $150 and an amount of $100 which represents a termination fee payable to Resdevco if the Company exercises its right to terminate
the License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2020 and 2019, the current liability to pay
future royalties amounts to $250 (for additional information and minimum royalties see also Note 6).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473234536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Purchase Obligation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationAbstract', window );"><strong>License Purchase Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationTextBlock', window );">LICENSE PURCHASE OBLIGATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 6:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>LICENSE PURCHASE OBLIGATION</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In July 2017, Wize
    Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 were reduced to $150
    for 2018 and 2019. In addition, If Wize Israel would have obtained an FDA marketing license during 2019, the Company was also
    required to pay Resdevco the remainder of the payment of 2019, however, such approval was not achieved in 2019. Consequently,
    during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the
    2018 minimum commitment, which was paid during the third quarter of 2018. In addition, during the third quarter of 2018 and
    2019, the Company has recognized an amount of $150 as a liability in respect to the 2019 and 2020, respectively, minimum commitment.
    Such amount was reflected as an expense under research and development expenses in 2018 and 2019 as applicable. In February
    2019, the Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through
    2021, and thereafter annual payments of $475,000 per year, and shall pay Resdevco $650,000 within two years after receipt
    of FDA approval for eye drops utilizing the licensed technology.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following table
    details the repayment dates of the remaining Minimal Commitment on the financial liability and the balance in the consolidated
    Financial Statements:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">Repayment dates:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 9pt">January 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">January 1, 2021 (see to Note 5)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">-</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Remaining balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of license purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461758568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OtherAccountsPayableTextBlock', window );">ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 7:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>ACCOUNTS PAYABLE</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Liability to HCW, see Note 10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Trade payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,306</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">369</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OtherAccountsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Accounts Payable text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OtherAccountsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771493299768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>CONVERTIBLE LOANS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On March 20, 2016, Wize Israel
entered into an agreement (as amended, the "<b>2016 Loan Agreement</b>") pursuant to which Rimon Gold Assets Ltd.
("<b>Rimon Gold</b>") extended a loan in the principal amount of up to NIS 2 million (approximately $531 according
to an exchange rate at 2016 loan originate date), which bears interest at an annual rate of 4% (the "<b>2016 Loan</b>").
Pursuant to the 2016 Loan Agreement, as modified by the 2017 Loan Agreement (as defined below) and the 2017 Loan Amendment (as
defined below), the 2016 Loan had a maturity date of December 31, 2018. Regarding the modifications of the maturity date of the
2016 Loan on October 2018, March 2019 and May 2019, see also Note 8a, 8b, 8c and 8d. Regarding loan extinguishment, refer to Note
8e.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the 2016 Loan Agreement,
Rimon Gold had the right, at its sole discretion, to convert any outstanding portion of the 2016 Loan, but not less than NIS 100,000
(approximately $26 according to an exchange rate at 2016 loan origination date), into Wize Israel ordinary shares at a conversion
price of NIS 15.2592 per share (approximately $3.84), subject to adjustments for stock splits and similar events set forth in
the 2016 Loan Agreement. As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016
Loan was adjusted to NIS 3.6 (approximately $0.96). As a result of the 2017 Loan Amendment, the aggregate principal amount of
the 2016 Loan was adjusted to $531 and the conversion price per share for the 2016 Loan was adjusted to $0.9768.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, under the 2016
Loan Agreement, as modified by the 2017 Loan Agreement and the 2017 Loan Amendment, Rimon Gold had the right (the "<b>2016
Investment Right</b>"), until June 30, 2019, to invest up to $797, in the aggregate, at an agreed price per share, which
was adjusted based on the Exchange Ratio (as defined in the Agreement and Plan of Merger with Bufiduck Ltd., a company formed
under the laws of the State of Israel and our wholly owned subsidiary and Wize Israel) from NIS 20.4 (approximately $6.00) to
NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment, from NIS 5.04 to $1.308 (subject to adjustments in case of
stock splits or similar events).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Rimon Gold was entitled, under
certain circumstances, to demand repayment of the 2016 Loan subject to certain conditions. However, as described in note 8e below
the convertible loan was extinguished in November 2019.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On January 15, 2017, Wize Israel
entered into the loan agreement (the "<b>2017 Loan Agreement</b>", and together with the 2016 Loan Agreement the "<b>Loan
Agreements</b>") with Ridge Valley Corporation ("<b>Ridge</b>"), and, by way of entering into assignments and
assumption agreements following such date, also with Rimon Gold and Shimshon Fisher ("<b>Fisher</b>", and together
with Ridge and Rimon Gold, the "<b>2017 Lenders</b>"), whereby each of the 2017 Lenders extended a loan in the principal
amount of up to NIS 1 million (approximately $274 according to an exchange rate at 2017 loan originate date) and in the aggregate
principal amount of up to NIS 3 million (approximately $822 according to an exchange rate at 2017 loan originate date), which
bears interest at an annual rate of 4% (the "<b>2017 Loan</b>", and together with the 2016 Loan, the "<b>Loans</b>").
Pursuant to the 2017 Loan Agreement and the 2017 Loan Amendment, the 2017 Loan had a maturity date of December 31, 2018. Regarding
the modification of the maturity date of the 2017 loan in October 2018, March 2019 and May 2019, see also Note 8b, 8c and 8d.
Regarding loan extinguishment, refer to Note 8e.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Under the 2017 Loan
Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017
Loan, but no less than NIS 100,000 (approximately $28 according to an exchange rate at 2017 loan originate date), that the
lender provided to Wize Israel (each such portion converted into Wize Israel ordinary shares at a conversion price per share
equal to the lower of (1) NIS 24 (approximately $6.72) and (2) the lowest price per share of Wize Israel in any offering made
by Wize Israel following the date of the 2017 Loan Agreement and through the date of such requested conversion, subject to
adjustments for stock splits and similar events set forth in the 2017 Loan Agreement (the "<b>2017 Loan Conversion
Price</b>"). As a result of the private placement agreement, dated June 23, 2017 between Wize Israel, and certain
investors (see also Note 12b to the 2018 consolidated Financial Statements), the 2017 Loan Conversion Price for Rimon Gold,
Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion
Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately
$1.15).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As a result of the 2017 Loan
Amendment, the aggregate principal amount of the 2017 Loan was adjusted to $822 and the 2017 Loan Conversion Price was adjusted
to $1.1112. See "2017 Loan Amendment" below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In addition, under the 2017
Loan Agreement, as modified by the 2017 Loan Amendment, the 2017 Lenders had the right (the "<b>2017 Investment Right</b>",
and together with the 2016 Investment Right the "<b>Investment Rights</b>"), until June 30, 2019, to invest up to
$1,233, in the aggregate, at an agreed price per share equal to 120% of the applicable 2017 Loan Conversion Price, which was adjusted
in December 2017, based on the 2017 Loan Amendment, to a fixed exercise price of $1.332 (subject to adjustments in case of stock
splits or similar events).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Ridge was entitled, under certain
circumstances, to demand repayment of the 2017 Loan subject to certain conditions. However, as described in note 8e below, the
convertible loan was extinguished on November 2019. On April 21, 2019, Ridge transferred the loan and the 2017 Investment Right
to Mobigo Inc, a company wholly owned by the Company's CEO, Noam Danenberg ("<b>Mobigo</b>"). Mr. Danenberg
waived a debt owed to him directly by Ridge (that did not involve the Company) as consideration for these derivative securities.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>2017 Loan Amendment</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On December 21, 2017, the Company
entered into an amendment (the "<b>2017 Loan Amendment</b>") to the 2016 Loan Agreement and the 2017 Loan Agreement.
Pursuant to&#160;the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31,
2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise
period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June
30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2017 Loan</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2016 Loan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Aggregate principal amount</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">822</td><td style="white-space: nowrap; width: 1%; padding-bottom: 4pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(*)</p></td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">531</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Conversion price per Company's share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.1112</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.9768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Aggregate maximum of Right to Future Investment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,233</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(**)</p></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">797</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercise price per Company's share of Right to Future Investment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.332</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.308</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Principal loan amount
    of $274 for each of the three 2017 Lenders.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px"><font style="font: 10pt Times New Roman, Times, Serif">(**)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Maximum of Right
    to Future Investment of $411 for each of the three 2017 Lenders.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Accordingly, each of the modified
financial instruments was initially recorded at fair value. Then, the total fair value of the modified financial instruments related
to the 2017 Loan and 2016 Loan (the "<b>Reacquisition Price</b>") was allocated to the original financial instruments
included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial instruments as of the
date of the extinguishment. As a result, an aggregate amount of $2,104 was allocated to the 2016 Loan and an aggregate amount
of $2,985 was allocated to the 2017 Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2017 Loan amendment was accounted
for as an extinguishment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>2018 Loan Amendment</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In connection with the Purchase
Agreement (as defined below), on October 19, 2018, the Company and Wize Israel entered into an amendment to the convertible loans
outstanding as of that date (the "<b>2018 Loan Amendment</b>"). Pursuant to the 2018 Loan Amendment, the maturity
date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following
the date that the registration statement the Company will file under the registration rights agreement dated October 22, 2018
(the "<b>Registration Rights Agreement</b>") covering the resale of all Common Stock, issued pursuant to the Purchase
Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Series A Warrants, are registered
for resale for investors who are not a party to the 2018 Loan Amendment, (b) 90 days following the date on which all securities
issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement,
and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the 2018 Loan Amendment, the expiration
date of the Investment Rights under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan
Agreements maturity date.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2018 Loan Amendment was accounted
for as an extinguishment on October 19, 2018.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to ASC 470-50, each
of the modified financial instruments were measured at fair value. Then, the Reacquisition Price was allocated to the original
financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative fair value of such financial
instruments as of the date of the extinguishment. As a result, an aggregate amount of $2,314 was allocated to the 2016 Loan and
its related right to future investment and an aggregate amount of $3,286 was allocated to the 2017 Loan and its related right
to future investment.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the Reacquisition
Price that was allocated to the Right to Future Investment amounting to $874 which was included in the 2016 Loan and its fair
value as of that date amounting to $764 was recorded directly to additional paid in capital (as a deemed dividend in an amount
of $110). In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $1,336 which
was included in the 2017 Loan and its fair value as of that date amounting to $1,154, was recorded directly to additional paid-in
capital (as a deemed dividend in an amount of $182). The difference between reacquisition price that was allocated to the 2017
Loan and to the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as a loss
on extinguishment amounting to $1,709 of the 2017 Loan and 2016 Loan.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2018 Loan Amendment became
effective in the fourth quarter of 2018 and all of the accounting effects were recognized in the fourth quarter of 2018.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>March 2019 Loan
    Amendment</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On March 4, 2019, the Company
and Wize Israel entered into another amendment to convertible loan agreements (the "<b>March 2019 Amendment</b>")
with Rimon Gold, Ridge and Fisher. Pursuant to the March 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement,
and (ii) 2017 Loan Agreement were extended to May 31, 2019 from March 4, 2019. The parties also agreed that Rimon Gold's,
Ridge's and Fisher's remaining 2016 Investment Rights (as of that date) under the 2016 Loan Agreement to invest up
to $512.8, in the aggregate, at $1.308 per share, and the expiration date of Rimon Gold's, Ridge's and Fisher's
remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at
$1.332 per share, be extended from June 30, 2019 to November 30, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The March 2019 Amendment was accounted
for as an extinguishment on March 4, 2019. Until that date, the 2017 Loan and the 2016 Loan were being accounted for under the
terms of the 2018 Loan Amendment discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to ASC 470-50, each
of the modified financial instruments were measured at fair value on the extinguishment date. Then, the Reacquisition Price was
allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative
fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $986 was allocated
to the 2016 Loan and its related right to future investment and an aggregate amount of $1,423 was allocated to the 2017 Loan and
its right to future investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the Reacquisition
Price that was allocated to the Right to Future Investment amounting to $237 which was included in the 2016 Loan and its fair
value as of that date amounting to $192 was recorded directly to additional paid-in capital (as a deemed dividend in an amount
of $45). In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $348 which was
included in the 2017 Loan and its fair value as of that date amounting to $289, was recorded directly to additional paid-in capital
(as a deemed dividend in an amount of $59). The difference between reacquisition price that was allocated to the 2017 Loan and
to the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as gain on extinguishment
amounting to $48 of the 2017 Loan and 2016 Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">d.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>May 2019 Amendment</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On May 31, 2019, the Company and Wize Israel entered into an
additional extension to convertible loan agreements (the "<b>May 2019 Amendment</b>") with Rimon Gold, Noam Danenberg
and Fisher. Pursuant to the May 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement
was extended to November 30, 2019 from May 31, 2019 (as previously described under the March 2019 Amendment). The parties also
agreed that the expiration date of Rimon Gold's, Mr. Danenberg's and Fisher's remaining 2016 Investment Rights
(as of that date) under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and Rimon Gold's,
Mr. Danenberg's and Fisher's remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest
up to $663.4, in the aggregate, at $1.332 per share, be extended from November 30, 2019 to May 31, 2021. As consideration for extending
the maturity date of the loans, the Company issued to Rimon Gold, Mr. Danenberg (through Mobigo, his wholly owned company), and
Fisher two-year warrants to purchase an aggregate of 868,034 shares of Common Stock at a fixed price of $1.10 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The May 2019 Amendment was accounted
for as an extinguishment on May 31, 2019. Until that date, the 2017 Loan and the 2016 Loan were being accounted for under the
terms of the March 2019 Loan Amendment discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to ASC 470-50, each
of the modified financial instruments were measured at fair value on the extinguishment date. Then, the Reacquisition Price was
allocated to the original financial instruments included in the 2017 Loan and 2016 Loan, as applicable, based on the relative
fair value of such financial instruments as of the date of the extinguishment. As a result, an aggregate amount of $1,015 was
allocated to the 2016 Loan and an aggregate amount of $1,498 was allocated to the 2017 Loan and its related right to future investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the Reacquisition
Price that was allocated to the Right to Future Investment amounting to $94 which was included in the 2016 Loan and its fair value
as of that date amounting to $61 was recorded directly to additional paid-in capital (as a deemed dividend in an amount of $33).
In addition, the Reacquisition Price that was allocated to the Right to Future Investment amounting to $139 which was included
in the 2017 Loan and its fair value as of that date amounting to $91, was recorded directly to additional paid-in capital (as
a deemed dividend in an amount of $48). The difference between reacquisition price that was allocated to the 2017 Loan and to
the 2016 Loan, respectively and their respective carrying value of the 2017 Loan and 2016 Loan was recorded as loss on extinguishment
amounting to $926 of the 2017 Loan and 2016 Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">e.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>November 2019
    Amendment</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Effective November 29, 2019, the
Company and Wize Israel entered into an amendment to convertible loan agreements (the "<b>November 2019 Amendment</b>")
with Rimon Gold, Mobigo and Fisher.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the November 2019
Amendment, the Company repaid in cash approximately $760 of the $1,520 ($1,353 of principal and $167 accrued interest) outstanding
under the loans on November 29, 2019 and Rimon Gold, Mobigo, and Fisher agreed to convert the remaining outstanding amounts of
the loans at a later date. On December 13, 2019, the Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196
shares of Common Stock upon conversion of the loans at a reduced conversion price of $0.27 per share and issued the December 2019
Warrants to purchase an aggregate of 5,632,392 shares of Common Stock at an exercise price of $0.27.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The December 2019 Warrants have a term of five years and will
be exercisable five days following the public announcement of positive clinical data results for LO2A. In addition, the parties
agreed that effective December 13, 2019, the exercise price or conversion price of all other convertible securities (rights for
future investment) previously issued to Rimon Gold, Mobigo, and Fisher in connection with the loans (the "<b>Existing Convertible
Securities</b>") shall be adjusted to $0.27 per share&#160;and that the aggregate number of shares of Common Stock issuable
upon exercise or conversion of a lender's Existing Convertible Securities shall be reduced in accordance with the percent
of such lender's conversion of its outstanding loan. In addition, it was agreed that in any case when the exercise price
of the October 2018 Warrants is reduced as a result of dilutive issuance to an exercise price lower than the exercise or conversion
price of the Investment Rights granted under the Loan Agreements, than the exercise or conversion price of the Investment Rights
shall be reduced to the new October 2018 Warrants exercise price ("<b>New Exercise Price</b>"). As of December 31,
2019, the New Exercise Price of such Investment Rights was $0.16. See Note 13n regarding the modification of the exercise price
of such warrants and their exercise into ordinary shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the aggregate
reacquisition price of the loans (<i>i.e</i>, the cash, the fair value of the shares and the December 2019 Warrants and the incremental
fair value related to the existing convertible loans) approximate $1,619 and the carrying amount of the convertible loans (principal
and accrued interest) was recognized as a loss from extinguishment in an amount of $99 as part of financial income (expense)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management considered the provisions
of ASC 815-40 and has determined that the December 2019 Warrants are considered indexed to the Company's stock and that
all other relevant criteria required for equity classifications are met. Accordingly, it was determined that the December 2019
Warrants are eligible for equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The below table describes the roll forward of 2017 Loan and
2016 Loan for the year ended December 31, 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Opening balance (including accrued interest)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,635</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of premium related to convertible loans prior to 2018 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of premium related to convertible loans following 2018 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(641</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &#8211; March 2019 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,873</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest on 2017 Loan and 2016 Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Amount allocated to 2016 Loan and 2017 Loan based on modified terms &#8211; March 2019 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,767</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of premium related to convertible loans following March 2019 modifications</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(413</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &#8211; May 2019 extension</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,353</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount allocated to 2016 Loan and 2017 Loan based on modified terms &#8211; May 2019 extension</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,556</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of premium related to convertible loans &#8211; May 2019 extension</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(203</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">November 2019 repayment in cash and Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,520</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463918024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short Term Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">SHORT TERM LOAN PAYABLE</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 9:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>SHORT TERM LOAN PAYABLE</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On July 15, 2020, OcuWize entered into a loan agreement with
Bank Hapoalim (the &#8220;Bank&#8221;), whereby the Bank extended a loan in the principal amount of NIS 850 (approximately $247)
(the &#8220;2020 Loan&#8221;), which is presented as a short term loan payable in the consolidated balance sheet. The 2020 Loan
bears interest at an annual rate of 5.45%, which is paid in monthly payments. The 2020 Loan has a maturity date of January 15,
2021. In order to secure its obligations and performance pursuant to the 2020 Loan, OcuWize recorded a pledge in favor of the Bank
and agreed that at all times, the value of all the assets in the OcuWize bank account will not be less than NIS 1,700 (approximately
$496). In order to satisfy this requirement, the Company loaned to OcuWize a portion of the Bonus Shares held by it. The 2020 Loan
including interest was fully paid on January 14, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771481529000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SignificantTransactionsTextBlock', window );">SIGNIFICANT TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 10:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>SIGNIFICANT TRANSACTIONS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>The Bonus/LO2A
    Transaction</b>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On January 9, 2020, the Company
entered into (i) an Exchange Agreement (the "Bonus Exchange Agreement"), with Bonus and (ii) a Share Purchase Agreement
(the "Bonus Purchase Agreement" and, together with the Bonus Exchange Agreement, the "Bonus Agreements")
with Bonus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the Bonus Agreements,
the Company agreed to grant Bonus, in consideration for the issuance of 62,370,000 ordinary shares of Bonus to the Company (the
"LO2A Shares"), the right to receive 37% of future LO2A Proceeds (if any), which, as more fully defined in the Bonus
Exchange Agreement, include proceeds generated by the Company, Wize Israel and OcuWize, as a result of (i) the sale, license or
other disposal of products or other rights underlying the LO2A technology licensed to OcuWize under the License Agreement; and
(ii) a Sale Transaction, which, as more fully defined in the Bonus Exchange Agreement, includes the sale of shares or assets of
Wize Israel and/or OcuWize. In addition, if the Sale Transaction involves a change of control of the Company, Bonus will be entitled
to elect, to either remain with its right to 37% of the LO2A Proceeds or receive a one-time payment equal to 37% of the value
attributed to Wize Israel out of the total proceeds payable for the Company in such transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, pursuant to the Bonus
Purchase Agreement, the Company agreed to purchase 51,282,000 ordinary shares of Bonus (the "PIPE Shares", and together
with the LO2A Shares, the "Bonus Shares"), for an aggregate purchase price of $7,400 in cash, which funds were deposited
directly into an escrow account (the "Bonus Escrow Account"), of which (i) $500 was paid to Bonus as an advance promptly
following execution of the Bonus Purchase Agreement, (ii) $3,200 was released to Bonus concurrently with the closing of the transactions
contemplated by the Bonus Agreements in exchange for 50% of the PIPE Shares and (iii) $3,700 was released to Bonus upon the Milestone
Closing (as defined in the Bonus Purchase Agreement), in exchange for the remaining 50% of the PIPE Shares that were issued by
Bonus and deposited into the escrow at the closing. The Company's obligation to consummate the Milestone Closing is conditioned
upon the satisfaction by Bonus of certain conditions, including the listing of its ordinary shares (or, if an ADR Program is to
be implemented by Bonus, the American Depositary Shares representing such ordinary shares) on the Nasdaq Capital Market (or another
superior tier of the Nasdaq market) (the "Nasdaq Listing").</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, pursuant to the Bonus
Agreements (as amended as of June 24, 2020), Bonus agreed to cover nearly 50% of the Company's fees and expenses payable
by the Company in cash, Bonus shares and/or a combination thereof to H.C. Wainwright &#38; Co., LLC ("HCW") in connection
with the transactions contemplated by the Bonus Agreements and the Series B Purchase Agreement (as defined below). In particular,
Bonus agreed to reimburse the Company or pay HCW directly $350 in cash, Bonus shares and/or a combination thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding the release of the remaining escrow amount of $3,700
to the Series B investors upon settlement agreement between the parties, see below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">According to the Bonus Agreements,
as amended, the total number of Bonus Shares issuable to the Company (including the shares to be released at the Milestone Closing)
was computed as the number of ordinary shares of Bonus equal to the quotient obtained by dividing (A) $16,400 expressed in NIS
(based on the exchange rate between NIS and the dollar as of January 8, 2020) by (B) NIS 0.50. As of January 9, 2020, such total
number of Bonus Shares represented (on a post-issuance basis) approximately 12% of the outstanding share capital of Bonus. The
fair value of Bonus shares based on a quote of the share price on January 9, 2020, the date of signing the Bonus Agreements, was
$0.12 per share and, as of the date of the closing was $0.11 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>The Bonus/LO2A
Transaction</b>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The transactions contemplated
by the Bonus Agreements were completed on February 19, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of the date of closing of the
Bonus Agreements, the Company received 85,239,000 of Bonus Shares. Pursuant to the Bonus Agreements, an additional 28,413,000
Bonus Shares were to be released to the Company upon the Nasdaq Listing and concurrently with the release of the $3,700 from the
escrow account to Bonus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As the Bonus Shares represent marketable securities with readily
determinable fair value, Bonus shares issued to the Company were recognized upon initial recognition based on their quoted price
(less applicable non-marketability discount) as of the date of the completion of the Bonus Agreements at an aggregate amount of
$8,759. The difference between the fair value of Bonus shares and the amount of cash that was transferred directly to Bonus from
an escrow account was recognized as financial liability, representing the Company's obligation to Bonus with respect to the
LO2A Proceeds in an amount of $5,059 (see Note 2v).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 29, 2020, the
Company entered into an Addendum (the "Addendum") with Bonus, whereby the parties agreed to amend certain
provisions of the Bonus Agreements. Under the Addendum, at the Closing, Bonus will issue to the Company ordinary shares of
Bonus (the "Bonus Shares"), the total number of which consists of (i) the Milestone Settlement Shares, which, as
defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing $500 expressed in NIS (based on the
exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement
Shares, the "Settlement Shares"), which, as defined in the Addendum, means Bonus Shares equal to the quotient
obtained by dividing $350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In consideration for the
Settlement Shares, the Company agreed to make certain amendments to the Bonus Agreements, including the following key
modifications: (i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto,
conduct the Milestone Closing (as defined in the Bonus Agreements), which means that, at the Closing, $3.7 million will be
released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq
Milestone Shares") will be released to the Company (20% of the shares) and to the Company's former holders of
Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive approximately $120 in
liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend
the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of
Bonus to secure the Company's obligations under the Bonus Exchange Agreement, including certain related negative
covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Closing was subject to customary conditions, including obtaining
the approval of the Tel-Aviv Stock Exchange ("TASE"), and occurred on December 30, 2020. It should be noted that, in
accordance with the Securities Purchase Agreement, dated January 9, 2020 (as amended), by and among the Company and the Former
Series B Holders, the Company was required to transfer 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares
to such investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, during the period
from completion of the Bonus Agreements (February 19, 2020) and through December 31, 2020, the Company recognized financial income
from both sales of Bonus marketable securities and revaluation of its remaining investment in Bonus marketable securities as of
December 31, 2020, in an amount of $1,197 due to the change in the quoted market price of these shares on TASE. Such amount was
presented as part of financial expenses, net.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">During the year ended December 31, 2020, the Company received
cash proceeds of $821 from sales of 5,871,260 of Bonus Shares, which are marketable securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>The Mandatorily
    Redeemable Series B Investment</b>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In order to finance the transactions
contemplated by the Bonus Purchase Agreement, on January 9, 2020, the Company entered into a Securities Purchase Agreement (the
"Series B Purchase Agreement") with certain accredited investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the Series B Purchase
Agreement, the Company agreed to sell to the investors, and the investors agreed to purchase from the Company, in a private placement,
an aggregate of 7,500 shares of newly created Series B Non-Voting Redeemable Preferred Stock, par value $0.001 per share, of the
Company ("Series B Preferred Stock") for a purchase price of $1.00 per share, for aggregate gross proceeds under the
Series B Purchase Agreement of $7,500, which funds were deposited into an escrow account, of which (i) $500 was to be paid to
the Bonus Escrow Account and $100 was paid directly to the Company to cover certain of its transactions expenses, in each case,
promptly following the execution of the Series B Purchase Agreement, and (ii) the remaining $6,900 was to be released to the Bonus
Escrow Account upon the closing of the transactions contemplated by the Series B Purchase Agreement (of which, as described above,
$3,200 was to be released upon the earlier of the Milestone Closing or upon written consent of the holders of at least a majority
of the Series B Preferred Stock).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Series B Purchase Agreement
contained customary covenants, representations and warranties of the parties thereto, including, among others, (i) a covenant
by the investors not to transfer the Series B Preferred Stock without the approval of the Company; (ii) a covenant by the Company,
for as long as any Series B Preferred Stock remain outstanding, not to sell any Bonus Shares for a price per share equal to less
than NIS 0.40 (the "Price Restriction"); and (iii) a covenant by the Company, simultaneously with, or promptly after,
the redemption of the Series B Preferred Stock, to assign certain rights under the Bonus Purchase Agreement, such as the right
to liquidated damages in the event of delayed Nasdaq Listing, and under the Bonus Registration Rights Agreement, to the investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In connection with the Series
B Purchase Agreement, the Company agreed to file, at the closing, a Certificate of Designations of Series B Non-Voting Redeemable
Preferred Stock with the Secretary of State of Delaware (the "Series B Certificate of Designations"). Pursuant to
the Series B Certificate of Designations, the Company designated 7,500 shares of preferred stock as Series B Preferred Stock.
The Series B Preferred Stock were not convertible into shares of Common Stock of the Company and have no voting powers, except
as related to certain rights to protect the rights and preferences of the Series B Preferred Stock and with respect to sales or
dispositions of the Series B Preferred Stock at a price per share below the Price Restriction. The Series B Preferred Stock entitled
its holders to (i) 80% of the proceeds received by the Company through future sales of the Bonus Shares issued to the Company
under the Bonus Agreements and (ii) 80% of any cash dividends received by the Company on such Bonus Shares. Under the Series B
Certificate of Designations, the Company had the option to redeem the Series B Preferred Stock at any time by distributing to
holders of the Series B Preferred Stock (i) 80% of the Bonus Shares then held by the Company and (ii) 80% of all dividends received
by the Company but not yet paid to holders of the Series B Preferred Stock (the "Redemption Payment"). The Company
was required to redeem the Series B Preferred Stock through payment of the Redemption Payment upon the earlier of (i) 60 days
following the Nasdaq Listing of the Bonus Shares, and (ii) December 28, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">However, until the completion of the Nasdaq Listing, an amount
of $3,700 was required to remain in an escrow account and, upon the failure of such listing by Bonus by the Milestone End Date,
such amount shall be required to be released in its entirety to the Series B investors. This escrow account of $3,700 was presented
as restricted deposit in the Company' consolidated balance sheet commencing upon the closing of the transaction and until
December 29, 2020, following the Addendum with Bonus described in Note 10a above, and the same amount was reflected as part of
the liability with respect to the mandatorily redeemable series B preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of the completion date (February 19, 2020), the Company recognized
a liability in light of its obligation to redeem the Series B Preferred Stock at its fair value in an amount of $10,707, representing
the sum of the remaining escrow amount of $3,700 (which, in case the Milestone Closing will not be met, will be paid to the Series
B investors) and 80% of the Company's investment in Bonus marketable shares, see Note 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The difference between the amount
of the liability recognized with respect to the Series B Preferred Stock ($10,707) and the cash amount actually invested by such
preferred stock investors ($7,500), amounting to $3,207 was recognized immediately as financial expense, net upon the completion
of the Bonus agreement and the Series B Purchase Agreement, within financial income (loss), net.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, from the date of
the completion of the Bonus agreements and until the redemption, the Company recognized a loss in an amount of $597, net due to
the revaluation of the mandatorily redeemable Series B Preferred Stock liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On July 8, 2020, the Company elected to redeem all of the Series
B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares representing an amount of $6,597 to the holders
of Series B Preferred Stock representing 80% of the Bonus shares then held by the Company. As a result of such distribution, as
of the date of these financial statements, the Company owns the remaining 18,822,533 Bonus Shares, representing approximately 1.61%
of the outstanding shares of Bonus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As discussed above, on November
29, 2020, the Company entered into an Addendum (the "Addendum") with Bonus, whereby, among other things, Bonus agreed
to issue to the Company's ordinary shares of Bonus (the "Bonus Shares"), the total number of which consists of
(i) the Milestone Settlement Shares, which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing
US$500 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together
with the Milestone Settlement Shares, the "Settlement Shares"), which, as defined in the Addendum, means Bonus Shares
equal to the quotient obtained by dividing US$350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.
In consideration for the Settlement Shares, the Company agreed to make certain amendments to the Bonus Agreements, including the
following key modifications: (i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation
thereto, conduct the Milestone Closing, which means that US$3.7 million were released from an existing escrow account to Bonus,
whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq Milestone Shares") were released to the Company
and to its former holders of Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive
approximately US$120 in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus
agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens
in favor of Bonus to secure obligations under the Bonus Exchange Agreement, including certain related negative covenants. The closing
occurred on December 29, 2020. It should be noted that, in accordance with the obligations of the Company to the Former Series
B Holders (see below), the Company has transferred 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares
to such investors. As a result of the transactions above, the Company redeemed all of the outstanding shares of Series B Preferred
Stock, and had satisfied its obligation under the Series B Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As a result of the Bonus transaction,
the company received an aggregate amount of 119,294,300 Bonus shares, out of which a total number of 93,576,800 Bonus shares were
distributes to the holders of Series B Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The below table describes the
roll forward of Mandatorily Redeemable Series B liability for the year ended December 31, 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Opening balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Series B Preferred Stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,500</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from initial recognition of mandatorily redeemable Series B Preferred Stock at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,207</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revaluation of mandatorily redeemable Series B Preferred
    Stock </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(597</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Redemption of mandatorily redeemable Series B Preferred Stock with Bonus Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,604</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Extinguishment of mandatorily redeemable Series B Preferred Stock by release of escrow account</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>The Cosmos Transaction</b>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On December 30, 2020, the Company
or "Wize", entered into a Bid Implementation Agreement (the "Bid Agreement") with Cosmos Capital Limited,
a digital infrastructure provider based in Sydney, Australia ("Cosmos"), whereby the parties agreed that the Company
would commence an off-market takeover offer under applicable Australian laws (the "Offer") to acquire all of the outstanding
shares of Cosmos in exchange for common shares of the Company. For more information, about the Cosmos transaction, CVR agreement
and PIPE Agreements, see Note 16 below.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473209656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 11:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>TAXES ON INCOME </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Tax rates applicable to the Company:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On December 22, 2017, the Tax
Cuts and Jobs Act was enacted and made key changes to US tax law which include (i) establish a flat corporate income tax rate
of 21% to replace previous rates that ranged from 15% to 39% and eliminates the corporate alternative minimum tax; (ii) create
a territorial tax system rather than a worldwide system, which will generally allow companies to repatriate future foreign source
earnings without incurring additional US taxes by providing a 100% exemption for the foreign source portion of dividends from
certain foreign subsidiaries; (iii) subject certain foreign earnings on which US income tax is currently deferred to a one-time
transition tax; (iv) create a "minimum tax" on certain foreign earnings and a new base erosion anti-abuse tax that
subjects certain payments made by a US company to a related foreign company to additional taxes; (v) create an incentive for US
companies to sell, lease or license goods and services abroad by effectively taxing them at a reduced rate; (vi) reduce the maximum
deduction for Net Operating Loss ("<b>NOL</b>") carryforwards arising in tax years beginning after 2017 to a percentage
of the taxpayer's taxable income, allows any NOLs generated in tax years beginning after December 31, 2017 to be carried
forward indefinitely and generally repeals carrybacks;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(vii) elimination of foreign tax
credits or deductions for taxes (including withholding taxes) paid or accrued with respect to any dividend to which the new exemption
applies, but foreign tax credits will continue to be allowed to offset tax on foreign income taxed to the US shareholder subject
to limitations; (viii) limit the deduction for net interest expense incurred by US corporations, (ix) allow businesses to immediately
write off (or expense) the cost of new investments in certain qualified depreciable assets made after September 27, 2017 (but
would be phased down starting in 2023); (x) may require certain changes in tax accounting methods for revenue recognition; (xi)
repeal the Section 199 domestic production deductions beginning in 2018; (xii) eliminate or reduce certain deductions, exclusions
and credits, and adds other provisions that broaden the tax base.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has calculated an
estimate of the impact of the Tax Act in our year-end income tax provision in accordance with our understanding of the Tax Act
and guidance available as of December 31, 2020. The provisional amount related to the re-measurement of the Company's net
U.S. deferred tax asset, based on the rate at which they are now expected to reverse in the future, considered immaterial, but
which was fully and equally offset by a corresponding reduction in the Company's valuation allowance. The effect of the
change in federal corporate tax rate from 39% to 21% is subject to change based on resolution of estimates used in determining
the amounts of deferred tax assets and liabilities that were re-measured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Tax rates applicable to Wize Israel and OcuWize:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In December 2016, the Israeli
Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018
Budget Years), a reduction of the corporate tax rate in 2017 from 25% to 24%, and in 2018 and thereafter from 24% to 23%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Accordingly, taxable income of
the Israeli Subsidiary is subject to the Israeli Corporate tax rate,which was 23% in 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carry forward:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company has NOL carry forwards
for federal income tax purposes of approximately $7,570.&#160; The application of the NOL carry forwards is limited due to IRC
section 382 limitation. The annual NOL carry forward (pre-merger, approximately $4,784) is limited to $10.965 per year.&#160;The
balance as of December 31, 2020 of the NOL carry forwards of approximately $4,786 is available in full.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December&#160;31, 2020, the Company's subsidiaries,
Wize Israel and OcuWize have accumulated losses for tax purposes in the amount of approximately $5,476 and $5,366 respectively,
which may be carried forward and offset against taxable income in the future for an indefinite period in Israel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">d.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2020, Wize Israel's
    2011 tax assessment was considered final. OcuWize has not received final tax assessment since its inception.</font></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">e.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Loss before taxes on income consists of the
    following:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,318</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,709</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign (*)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,842</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,613</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,160</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,322</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Relates to Wize Israel and OcuWize.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: 0.7in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">f.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Deferred income taxes:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Deferred income taxes reflect
the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes
and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,974</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves and allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,108</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,165</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In assessing the realization of
deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets
will not be realized.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The ultimate realization of the
deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences
are deductible and NOLs are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance
at December&#160;31, 2020 and 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">g.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Below is the reconciliation
    between the "theoretical" income tax expense or benefit, assuming that all the income was taxed at the regular
    tax rate applicable to companies in Israel and the taxes recorded in the statements of comprehensive loss in the reporting
    year:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before taxes on income, as reported in the statements of comprehensive loss</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(4,929</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(3,450</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Theoretical tax benefit on this loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">725</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses not deductible for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(983</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(639</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473152936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 12:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>COMMITMENTS AND CONTINGENCIES </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Agreements</u>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Starting November
    22, 2020, the Company rents its offices from a third party for a rental monthly fee of $2. The rent period is for a period
    of 12 months.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For the Company&#8217;s
    engagement in a License Agreement to market a drug and amendment to such an agreement, see also Notes 5 and 6 above.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 19, 2017 (the &#8220;<b>Effective
        Date</b>&#8221;), Wize Israel entered into a finder&#8217;s fee agreement with a service provider (through his wholly
        owned company), who is also a director of the Company (the &#8220;<b>Vendor</b>&#8221;), pursuant to which the Vendor
        is entitle to receive a royalty rate of 5% on all of Wize Israel&#8217;s revenues to the extent such revenues are earned
        from relationships initiated by the Vendor and agreed to by Wize Israel. The term of the agreement is for 12 months unless
        earlier terminated. Either party may terminate upon 21 days&#8217; notice. The service provider will be entitled to the
        finder fee of 5% even if the agreement will be terminated.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Vendor introduced Wize Israel
        and the Company to the Chinese Distributor (see also Note 5). During the period commencing the Effective Date and ending
        December 31, 2019 and 2020, the Vendor has not earned any royalties, and the Company has no obligation to pay any royalties.</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">4.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For discussion regarding Bonus transaction, see Note 10 above.</font></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466478088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 13:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>STOCKHOLDERS' EQUITY </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Common Stock
    confers upon their holders the right to participate and vote in general shareholder meetings of the Company and to share in
    the distribution of dividends, if any, declared by the Company, and rights to receive a distribution of assets upon liquidation.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 71px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2019, the Company entered
        into a joint venture agreement with Cannabics traded on the Over-The-Counter (OTC) markets in the United States.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement, the parties
        agreed to form a new joint venture company for the purpose of researching, developing and administering cannabinoid formulations
        to treat ophthalmic conditions. The new company will initially be owned 50% each by the Company and Cannabics.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 1, 2019, the Company's joint
        venture agreement with Cannabics became effective. Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000
        shares of its Common Stock and Cannabics issued to the Company 2,263,944 shares of Cannabics' common stock, which represented
        a holding percentage less than 5 percent of Cannabic's then outstanding share capital. The joint venture currently has no
        assets or liabilities and has not started conducting any of its planned operations.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the foregoing, the Company
        relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions
        not involving a public offering.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the share issuance, the
        Company recorded an amount of $765 as an increase to Common Stock (at par value) and additional paid-in capital with a corresponding
        amount of $765 as an investment in marketable securities. Such amount was based on the fair value of Cannabics' shares as
        of the date at which the agreement became effective. The investment in marketable securities was remeasured in subsequent periods
        at fair value with changes carried to profit or loss. During the year ended December 31, 2019 the Company recognized loss of $501
        due to the change in fair value from March 1, 2019 to December 31, 2019.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 13, 2019, the Company determined
        to terminate all activities under the joint venture until such time as the parties jointly determine that no uncertainty remains
        with respect to U.S. federal enforcement of the cannabis industry.</p></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In March 2019, the Company issued 60,000 shares of Common Stock to certain investors in exchange for conversion of 60 shares of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 71px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">d.</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt">In April 29,
        2019, the Company issued 336,000 shares of Common Stock to certain investors in exchange for conversion of 336 shares
        of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9pt">In May 7,
        2019, the Company issued 336,000 shares of Common Stock to certain investors in exchange for conversion of 336 shares
        of Preferred A stock, which was in accordance with the terms of the Purchase Agreement.</p></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0.9pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">e.</font></td>
    <td style="text-align: justify; text-indent: 0.9pt"><font style="font: 10pt Times New Roman, Times, Serif">On
    April 23, 2019, the Company's Board appointed Mark Sieczkarek as the Company's Chairman of the Board (the "<b>Chairman
    Appointment</b>").</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify; text-indent: 0.9pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">f.</font></td>
    <td style="text-align: justify; text-indent: 0.9pt"><font style="font: 10pt Times New Roman, Times, Serif">On
    July 18, 2019, the Company issued to a consultant, 6,945 shares of Common Stock in exchange for its services provided in the
    three months ended September 30, 2019. The Company recognized an amount of $3 in the year ended December 31, 2019.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">g.</font></td>
    <td style="text-align: justify; text-indent: 0.9pt"><font style="font: 10pt Times New Roman, Times, Serif">On
    August 20, 2019, the Company issued to a consultant, 45,000 shares of Common Stock in exchange for its services provided in
    2019. The Company recognized an amount of $18 in the year ended December 31, 2019.</font></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">h.</font></td>
    <td>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection
        with Mr. Sieczkarek's appointment, the Company and Mr. Sieczkarek entered into a Chairman Agreement (the "<b>Chairman
        Agreement</b>") whereby Mr. Sieczkarek shall receive 202,399 restricted stock units ("<b>RSUs</b>") and options
        to purchase 102,222 shares of the Company's Common Stock at an exercise price of $2.00 per share (the "Chairman Awards").
        The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and subsequently in seven equal quarterly installments
        commencing July 1, 2019. The Chairman Agreement has an initial term of two years (the "Term") and provides that in
        the event of a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as
        of that date. The Chairman Agreement also contains standard representations and warranties regarding confidential information,
        non-competition and non-solicitation.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Total value of
        the options granted is $29, which is recorded quarterly over the vesting period. The total value of the share based expense related
        to the RSU is $185, which is being recognized ratably over the vesting period.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On August 11, 2020, the Company's Board of Directors approved
the equity grant of 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of
Directors of the Company, see also note 13p below.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On January 6,
        2020, April 15, 2020, July 1, 2020 and October 1, 2020 the Company issued 25,300, 25,300, 25,300 and 44,050, respectively, shares
        to the Chairman pursuant to the agreement above following the vesting of certain portions of the RSUs.&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company
recognized $46 during the year ended December 31, 2020 as a share-based expense in connection to the RSU's and options granted.</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">i.</font></td>
    <td style="text-align: justify; text-indent: 0.9pt"><font style="font: 10pt Times New Roman, Times, Serif">In
    April 2019, Mr. Danenberg purchased directly from Ridge all Ridge's rights under the second convertible loan agreement.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">j.</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2019, the Company issued
        to a consultant, 135,000 shares of restricted Common Stock which is due and issuable according to the following schedule:
        25% as of May 1, 2019 and additional 25% every quarter following May 1, 2019. The aggregate fair value of these shares
        of RSUs at grant date issued was $106, and is being recognized over a period of 1 year following May 1, 2019.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recognized $104 and $2 during the years ended December
31, 2019 and 2020, respectively as a share-based expense in connection to the RSU's.</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">k.</font></td>
    <td style="text-align: justify; text-indent: 0.9pt"><font style="font: 10pt Times New Roman, Times, Serif">On
    May 15, 2019, the Company granted to a consultant, 10,000 fully vested RSUs. The Company determined the fair value of the
    RSUs to be the quoted market price of the Company's Common Stock on the date of issuance. The aggregate fair value of
    these RSUs issued at grant date was $5, and was recognized during the year ended December 31, 2019.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">l.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On May 19, 2019,
    the Company granted to one of its directors certain options exercisable into 30,000 shares of Common Stock with an exercise
    price of $0.58 per share. The options will vest monthly over a period of six (6) months. The Company recognized $13 of
    share-based compensation expense during year ended December 31, 2019.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">m.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 13,
    2019, the Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196 shares of Common Stock as part of the
    extinguishment of the loans, see also Note 8e.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">n.</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2019, the Company
        entered into a securities purchase agreement (the "2019 Purchase Agreement") with an accredited investor.
        Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase
        from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27
        per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to
        the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock.
        The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public
        announcement of positive clinical data results for LO2A.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The December 2019 Warrants will
        be exercisable on a cashless basis in the event that, six months after issuance, there is not an effective registration
        statement for the resale of the shares underlying the December 2019 Warrants.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management considered the provisions
        of ASC 815-40, and has determined that the December 2019 Warrants are considered indexed to the Company's stock
        and that all other relevant criteria required for equity classification are met. Accordingly, it was determined that the
        December 2019 Warrants are eligible for equity classification.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2019, the December 2019 Warrants exercise price
was reduced to $0.16 due to the triggering of certain down-round anti-dilution protection or price protection features included
in the original terms of these warrants. The difference between the fair value of the warrants and the incremental fair value resulting
from the triggering of the above mentioned features was recognized as a deemed dividend and as an increase of the loss applicable
to common stockholders in an amount of $15. See also note 13p and 13q below.</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">o.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 11, 2020, the Company's Board of Directors approved
the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of
the Board of Directors of the Company and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each
of the other three non-executive directors. The aggregate fair value of these shares of RSUs at grant date issued was $73, and
is being recognized over a period of 2 years following August 11, 2020. The Company recognized $34 during the year ended December
31, 2020, as a share-based expense in connection to the RSU's.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">p.</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 8, 2020, the Company
        entered into exchange agreements (the "Exchange Agreements") with certain holders (the "Series A
        Holders") of 3,000,000 Series A Warrants.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exchange
        Agreements, the Holders agreed to surrender their Warrants for cancellation and received, as consideration for such cancellation,
        an aggregate of 3,000,000 shares of common stock. The securities issued pursuant to the foregoing are exempt
        from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant
        to Section 3(a)(9) and/or Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder
        because, among other things, the transaction did not involve a public offering and the warrant holders are accredited
        investors. The difference between the fair value of the warrants before the exchange and the fair value of the shares
        was recognized as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $63.</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">q.</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 24, 2020, the Company entered into an agreement (the
"Agreement") with certain holders (the "Series A Holders") representing a majority of the Series A Warrants.
Pursuant to the terms of the Agreement, the Company and Series A Holders mutually agreed that the Company would voluntarily reduce
the exercise price of the Warrants to $0.001 per share until January 7, 2021, after which such exercise price shall revert back
to $0.16 per share.</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the adjustment
        to the exercise price of the Series A Warrants, the exercise price of the warrants issued in November 2017 (the "2017
        Warrants"), the placement agent warrants issued in October 2018 (the "2018 Placement Agent Warrants"),
        the warrants issued to certain lenders in May 2019 (the "May 2019 Warrants"), the warrants issued to certain
        lenders in November 2019 (the "November 2019 Warrants"), the warrants issued to certain purchasers from the
        private placement in December 2019 (the "December 2019 Warrants") and certain investment rights issued on
        January 2017 (the "Investment Rights") were also adjusted to reflect a reduced exercise price of $0.001 per
        share (collectively, the "Warrant Adjustments"). As a result of the Warrant Adjustments, on December 29, 2020
        an aggregate of 13,332,654 shares of common stock were issued as a result of the exercise of such warrants, each on a
        cashless basis. Among others, such warrant exercises also included warrants beneficially owned by our Chief Executive
        Officer, Noam Dannenberg. The difference between the fair value of the warrants before and after the adjustment was recognized
        as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $327.</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">r.</font></td>
    <td>Stock based-compensation:</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><u>The 2012 Plan</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In 2012, the Company's Board
approved the adoption of the 2012 Stock Incentive Plan (the "<b>2012 Plan</b>").</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">An Israeli annex was subsequently
adopted in 2013 to comply with the requirements set by the Israeli law in general and in particular with the provisions of section
102 of the Israeli tax ordinance. Under the 2012 Plan and Israeli annex, the Company may grant its officers, directors, employees
and consultants, stock options, restricted stocks and RSUs of the Company. Each Stock option granted shall be exercisable at such
times and terms and conditions as the Company's Board may specify in the applicable option agreement, provided that no option
will be granted with a term in excess of 10 years. Upon the adoption of the 2012 Plan, the Company reserved for issuance 45,370
shares of Common Stock, $0.001 par value each.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company
has 40,474 shares of Common Stock available for future grant under the 2012 Plan. As of December 31, 2020, under the 2012 Plan,
the Company had options exercisable into 4,896 shares of Common Stock outstanding and exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><u>The 2018 Plan</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 22, 2018, the Company's
Board approved the adoption of the 2018 Stock Incentive Plan (the "<b>2018 Plan</b>"), including an Israeli annex
to comply with Israeli law, in particular the provisions of section 102 of the Israeli Income Tax Ordinance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the 2018 Plan, the Company
may grant its employees, directors, consultants and/or contractors' stock options, shares of Common Stock, restricted stock
and RSUs of the Company. The Compensation Committee of the Board is currently serving as the administrator of the 2018 Plan. Each
stock option granted is exercisable, unless otherwise determined by the administrator, in twelve equal installments over the three
- year period from the date of grant. Unless otherwise determined by the administrator, the term of each award will be seven years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The exercise price per share subject
to each option will be determined by the administrator, subject to applicable laws and to guidelines adopted by the Board from
time to time. In the event the exercise price is not determined by the administrator, the exercise price of an option will be
equal to the closing stock price of the Common Stock on the last trading day prior to the date of grant.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Upon the adoption of the 2018
Plan, the Board reserved for issuance 435,053 shares of Common Stock. On August 15, 2018, the Company amended the 2018 Plan to
increase the number of shares issuable under the Plan to 2,500,000 shares of Common Stock. In addition, the Board approved to
increase the number of shares issuable under the Plan on the first day of each fiscal year beginning with the 2019 fiscal year,
by an amount equal to the lesser of (i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately
preceding fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the Company
has 2,184,813 shares of Common Stock available for future grant under the 2018 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Through December 31, 2020, 290,222
options to directors, officers and consultants are outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><u>Grants under the 2018 Plan</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 4, 2018,
    the Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with
    an exercise price of $3.59 per share. The options will vest quarterly over a period of 36 months. The Company recognized $51
    and $154 during the year ended December 31, 2020 and 2019, respectively.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation:</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 31, 2019, the Company's
        Board approved the following:</p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">1.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">To grant to each
    of Company's four directors 100,000 RSUs. The RSUs will vest quarterly over a period of 24 months.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 120px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">2.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">To grant to each
    its officers (Company's Chief executive officer and to Company's Chief financial officer)&#160;140,000 RSU's.
    The RSU's will vest quarterly over a period of 24 months.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company determined the fair
value of the RSUs to be the quoted market price of the Company's Common Stock on the date of grant. The aggregate fair value
of these RSUs issued was $476. The Company is recognizing this amount ratably over the vesting period of 24 months following March
31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In connections with the above,
on July 25, 2019 (the initial quarterly vesting date) the Company issued 85,000 Common shares to its officers and directors.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recognized $132 and
$337 during the year ended December 31, 2020 and 2019 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">3.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On April 18, 2019,
    the Company granted to its employee, 21,600 options exercisable into 21,600 shares of Common Stock at an exercise price of
    $0.75 per share of Common Stock. The options began vesting quarterly over a period of 36 months commencing April 18, 2019.
    The Company recognized $2 during the year ended December 31, 2019 as a share-based expense. The total value of the share based
    expense is $10, which is recorded quarterly over the vesting period. Since the Company has terminated its employment agreement
    in December 2019, as of December 31, 2020, all of the options were forfeited. </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions related to the grant of options to employees and
directors under the 2012 Plan during the year ended December&#160;31, 2020 and 2019, were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options outstanding and exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,352</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">81.81</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.32</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options outstanding and exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,896</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">190.7</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.86</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions related to the grant
of options to employees and directors under the 2018 Plan during the year ended December&#160;31, 2020 and 2019, were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options outstanding as of December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">352,072</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.91</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,850</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options outstanding as of December 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">290,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.64</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options exercisable as of December 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">255,459</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.56</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.82</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options outstanding as of December 31, 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">255,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.68</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.55</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options outstanding as of December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">352,072</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options exercisable as of December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">181,799</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.75</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">At December 31, 2020, there was
$3 of total unrecognized compensation cost related to non-vested option grants that is expected to be recognized over a weighted-average
period of 0.5 years. The intrinsic value of options outstanding and exercisable at December 31, 2020 was not significant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company uses the Black-Scholes
option-pricing model to estimate fair value of grants of stock options. With respect to grants of options, the risk-free rate
of interest was based on the U.S. Treasury rates appropriate for the contractual term of the grant, expected volatility was calculated
based on average volatility of the Company and five representative companies and expected term of stock-based grants of 7 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473135816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Statements of Operations Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SelectedStatementsOfOperationsDataAbstract', window );"><strong>Selected Statements of Operations Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SelectedStatementsOfOperationsDataTextBlock', window );">SELECTED STATEMENTS OF OPERATIONS DATA</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 14:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>SELECTED STATEMENTS OF OPERATIONS DATA</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">General and administrative expenses:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Overseas travel</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">103</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">688</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rent and office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payroll and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional services and consultation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">953</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Taxes and tolls</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director salary and insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,008</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,678</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Financial expense, net:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Income from sale and revaluation of marketable securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Exchange rate gains, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gain from completion of milestone closing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">847</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gain from settlement shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Amortization of premium related to convertible loans</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,257</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,144</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Financial expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued interest on convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued interest on loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from recognition of mandatorily redeemable Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,207</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from revaluation of contingent obligation with respect to future revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(435</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revaluation of mandatorily redeemable Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(597</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bonus transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(350</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Change in the fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(527</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bank commissions and exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from extinguishment of convertible loans (Note 8c, 8d, 8e)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(977</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,631</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,552</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total financial expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,487</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(280</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SelectedStatementsOfOperationsDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SelectedStatementsOfOperationsDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SelectedStatementsOfOperationsDataTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of Selected Statements Of Operations Data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SelectedStatementsOfOperationsDataTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473127208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES BALANCES AND TRANSACTIONS</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 15:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>RELATED PARTIES BALANCES AND TRANSACTIONS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Balances with interested and related parties:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Other receivables</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">52</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Accounts payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">439</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">104</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Convertible Loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Transactions with interested and related parties:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Amounts charged to:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">General and administrative expenses*</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,212</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,140</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Finance expenses, net (income)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(625</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in">* Including an amount of $76 with respect to stock-based compensation</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466398712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 16:-</b></font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><b>SUBSEQUENT EVENTS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>The Cosmos Transaction</b>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On
December 30, 2020, the Company entered into the Bid Agreement with Cosmos, which was subsequently amended on January 18, 2021 for
the primary purpose of simplifying the Offer structure. Under the Bid Agreement (as amended), the parties agreed that the Company
would commence the Offer, an off-market takeover offer under applicable Australian laws, to acquire all of the Cosmos Shares in
exchange for 61.11 Company's shares of common stock for each Cosmos Share, being the Offer Consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under
the Bid Agreement, 22.33 Company shares of common stock out of the Offer Consideration will be "Restricted Stock" subject
to a Stock Restriction Agreement to be entered into at the Closing Date and 38.78 Company shares of common stock will be "Covered
Securities". A Cosmos shareholder who accepts the Offer (an "Accepting Shareholder") will not be permitted to
sell or encumber their Restricted Stock until December 31, 2021 (the "Milestone Date"). In addition, an Accepting Shareholders
may not exercise voting rights in respect of Restricted Stock from the date of issuance of the Offer Consideration until the Milestone
Date. An Accepting Shareholder is entitled to sell or encumber its Covered Securities. However, if (subject to certain limited
exceptions) an Accepting Shareholder sells or encumbers any of its Covered Securities before the Milestone Date, the Company has
an option to repurchase a pro rata proportion of the Restricted Stock for the lower of $0.0001 and the fair market value of the
Restricted Stock. The Restricted Stock (and any dividends thereon) will be held by the Company in escrow for the Accepting Shareholder's
benefit until such time as the Restricted Stock is repurchased by Wize or all restrictions thereon lapse. If any Restricted Stock
is repurchased under the Company's repurchase option, a pro rata proportion of the dividend on the Restricted Stock shall
be retained by the Company.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Immediately
following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos shareholders are expected
to own approximately 87.65% of the outstanding common stock of the Company, while the Company's existing stockholders are expected
to remain the owners of approximately 10.75% of the outstanding common stock of the Company, each on a fully diluted basis and
including warrants to be issued to the Company's financial advisor to the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Pursuant to the Bid Agreement,
prior to the Closing Date, the Company will enter into a Contingent Value Rights Agreement (the "CVR Agreement") with
Cosmos, certain of the Company's subsidiaries (the "Wize Subsidiaries"), a person designated by the Company
prior to the Closing Date as the Holders' Representative (as defined herein), and the Rights Agent (as defined therein).
Pursuant to the CVR Agreement, at the Closing Date, each Wize pre-Closing security holder will receive one non-transferable CVR
for each outstanding share of common stock of the Company and for each share of common stock of the Company underlying other convertible
securities and warrants, held as of 4:01&#160;p.m. Eastern Time on the day immediately&#160;<font style="background-color: white">before
the Effective Time (as defined in the CVR Agreement). Each CVR will represent the right to receive a pro rata share of any consideration
that may be received by the Company or the Company Subsidiaries in connection with the Company's existing LO2A business.
In particular, CVR holders will be entitled to any consideration (whether cash, stock, assets or otherwise) that the Company or
the Company Subsidiaries (or any of its Affiliates or shareholders) receives in connection with an LO2A Transaction, which,
as defined in the CVR Agreement, includes (i) a sale of any of the Company Subsidiaries to a third party and/or (ii) the partnering,
licensing, sublicensing, distribution, reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third
party, less transaction expenses and customary deductions as detailed in the CVR agreement, including a deduction of up to $300,000
that the Company Subsidiaries undertook to incur in the development of the LO2A Technology at the request of the Holders'
Representative.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="background-color: white">The
Bid Agreement also contains certain covenants to be performed at or following the Closing Date, including, among others, (i) agreement
that the Board of Directors of the Company immediately following the Closing Date will consist, subject to certain exceptions,
of three members to be designated by Cosmos and one member to be designated by the Company; (ii) covenants that the Company will
seek, following the Closing Date, stockholder approval to be renamed Cosmos Capital, Inc. (or similar name), and to effect a reverse
share split of the Company's common stock; (iii) covenants that the Company will establish an incentive compensation program
with respect to 40,000,000 shares of its common stock, to be granted promptly following the Closing Date, in the form of performance-based
RSUs, performance rights or indeterminate rights based on the performance milestone criteria and allocation set in the Bid Agreement
(the "Post-Closing Incentive Plan"), 50% of which are to be granted to personnel specified by the Company prior to
the Closing Date and the remainder to be granted to personnel of Cosmos (see also Item 9B below); (iv) an obligation by the Company
to terminate or procure the termination of each of the current employment or consulting agreements of the Company with Mr. Mark
Sieczkarek, the Chairman of the Company Board of Directors, Mr. Noam Danenberg, the Chief Executive Officer of the Company, Mr.
Or Eisenberg, the Chief Financial Officer of the Company, and another part-time employee related to Mr. Danenberg; and (v) an
obligation by the Company to use its reasonable commercial efforts to enter into new, part time, consulting agreements with Mr.
Danenberg and Mr. Eisenberg in a form to be agreed between the Company and Cosmos.&#160;In this respect, it should be noted that
the Company, Cosmos and each of Mr. Danenberg and Mr. Eisenberg agreed on the form of such consulting agreements, whereby Mr.
Danenberg and Mr. Eisenberg will provide part time consulting services to the Company following the Closing Date for monthly compensation
of US$10,000 and US$7,500, respectively.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="background-color: white">Concurrently
with the execution of the Bid Agreement, the Company entered into Securities Purchase Agreements (the "PIPE Agreements") with
certain accredited investors (the "PIPE Investors"), including Mr. Noam Danenberg, our CEO. Pursuant to the PIPE Agreements,
we agreed to sell to the PIPE Investors, and the PIPE Investors agreed to purchase from us, in a private placement, an aggregate
of 25,000,000 shares of common stock for a purchase price of $0.12 per share, or aggregate gross proceeds of $3.0 million, which,
in the case of Mr. Danenberg, may be satisfied by waiving outstanding amounts owed by the Company or its subsidiaries to Mr. Danenberg
pursuant to his consulting agreement with our subsidiary.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 1, 2021, we lodged
a Bidder's Statement with the Australian Securities and Investments Commission to commence the Offer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 15, 2021, Cosmos informed the Company that
Cosmos completed the issuance of convertible notes (the "Cosmos Convertible Notes") with an aggregate principal amount
of approximately US$21 million to several non-U.S. sophisticated or professional investors (the "Purchasers"). The
Cosmos Convertible Notes are unsecured and shall initially be convertible into shares of Cosmos at a conversion price of AU$23.58
per share (equivalent to US$18.16), reflecting a pre-money valuation of Cosmos of approximately US$185 million. The Cosmos Convertible
Notes will automatically convert to shares six months after the date of issuance. Cosmos is obligated to pay interest to the Purchasers
on the outstanding principal amount of the Cosmos Convertible Notes at the rate of 8% per annum, payable on the conversion date,
in cash or, at Cosmos' option, in shares of Cosmos. Redemption of the Cosmos Convertible Notes occurs only if an insolvency
event occurs in respect of Cosmos.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Cosmos Convertible Notes also provide that, subject
to, among other things, the consummation of the Offer before May 31, 2021, Cosmos will cause the Company to assume the Cosmos Convertible
Notes by way of entering into an amended and restate convertible note on substantially the same terms as the Cosmos Convertible
Note (the "Wize Convertible Notes"), except that, at such time, they shall be convertible, upon the earlier of six
(6) months from the issuance of the Cosmos Convertible Notes and an uplisting of the common stock of the Company to Nasdaq, into
shares of common stock of the Company at a conversion price of US$0.339 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cosmos plans to use the proceeds
of the Cosmos Convertible Notes for the purchase of additional application-specific integrated circuit (ASIC) mining hardware,
modular data centers, associated infrastructure and capital raising costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">February
16, 2021, we announced that the Offer became unconditional and that we plan to consummate the transactions contemplated by the
Bid Agreement and the Offer on or about March 9, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467666840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in preparation of Financial Statements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Use of estimates in preparation of Financial Statements:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The preparation of the financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company's
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time
they are made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
dates of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Actual results
could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As applicable to the consolidated Financial Statements, the
most significant estimates and assumptions relate to the going concern assumptions, determining the fair value of embedded and
freestanding financial instruments related to convertible loans and rights to future investment as part of modification or the
settlement of the convertible loans determining the fair value of the contingent obligation with respect to future revenues and
whether modification of terms of financial instruments is considered substantial.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Principles of consolidation:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated Financial Statements
include the accounts of the Company and its wholly owned subsidiaries. Inter-company balances and transactions have been eliminated
upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Functional currency:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company aims to direct
its main operations in the United States market. In addition, the convertible loans were denominated in U.S. dollars.
Similarly, the Company issued warrants eligible for exercise for the Company's shares of Common Stock at an exercise
price denominated in U.S. dollars and during January 2020 the Company completed the issuance of 7,500 Series B Non-Voting
Redeemable Preferred Stock for a purchase price of $1 per share for total gross proceeds of $7,500. Also, the management
believes the Company will raise funds through private investment rounds and / or from issuance of equity in dollar amounts by
approaching the market in the United States. As a result, it was determined that the U.S dollar is the currency of the
primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future.
Thus, the functional currency of the Company is the U.S. dollar. The Company maintains its books and records in local
currency, which is NIS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Balances denominated in, or linked
to foreign currency are stated on the basis of the exchange rates prevailing at the balance sheet date.&#160;&#160;For foreign
currency transactions included in the consolidated statement of comprehensive loss, the exchange rates applicable on the relevant
transaction dates are used.&#160;&#160;Transaction gains or losses arising from changes in the exchange rates used in the translation
of such balances are carried to financing income or expenses as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The following table presents data
regarding the dollar exchange rate of relevant currencies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">USD 1 = NIS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.9</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.8</td><td style="text-align: left">)</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">d.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cash equivalents are short-term
highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For presentation of statement of
cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total
amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">December&#160;31</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">718</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">260</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">759</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RestrictedBankDepositPolicyTextBlock', window );">Restricted bank deposit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">e.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Restricted bank deposit:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Restricted bank deposit is a deposit
with maturities of more than three months and up to one year. The restricted bank deposit was presented at its cost, including
accrued interest and represents cash which is used as collateral for Wize Israel's credit card used for certain corporate
business expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable equity securities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">f.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Marketable equity securities:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company's investment in marketable equity securities
which is based on equity securities with readily determinable fair values was classified as financial instruments at fair value
with any changes in fair value recognized periodically in earnings.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">g.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment, net:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Property and equipment are stated
at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives
of the assets at the following rates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Computers and electronic equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">h.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Impairment of long-lived assets:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company's long-lived assets are reviewed for impairment
in accordance with Accounting Standards Codification ("<b>ASC</b>") 360, "Property, Plant and Equipment",
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability
of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows
expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds its fair value. Assets to be disposed of are reported at the lower
of the carrying amount or fair value less costs to sell. During the years ended December 31, 2020 and 2019, no impairment losses
have been identified.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">i.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Research and development expenses:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Research and development expenses
are charged to the statement of comprehensive loss as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In-Process Research and Development
assets, acquired in an asset acquisition (<i>i.e.</i>, assets acquired outside a business combination transactions) that are to
be used in a research and development project which are determined not to have an alternative future use are charged to expense
at the acquisition date in accordance with ASC 730, "Research and Development".</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">j.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Severance pay:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Wize Israel has two employee as
of December 31, 2020 and 2019. Wize Israel's liability for severance pay is subject to Section 14 of Israel's the Severance
Compensation Act, 1963 ("<b>Section 14</b>"), pursuant to which all Wize Israel's employees are included under
Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee's
name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release Wize Israel from any
future severance payments in respect of those employees. Wize Israel has made all of the required payments as of December 31, 2020
and 2019.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fund is made available to the
employee at the time the employer-employee relationship is terminated, regardless of cause of termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The severance pay liabilities and
deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably
transferred to the severance funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Severance expenses for the years
ended December&#160;31, 2020 and 2019 amounted to $16 and $17, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">k.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Income taxes:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for income
taxes in accordance with ASC 740, "Income Taxes". This topic prescribes the use of the liability method whereby deferred
tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected
to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets
to amounts more likely than not to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company implements a two-step
approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to
be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on
an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative
basis) likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized tax positions
has been recognized.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">l.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Concentrations of credit risk:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and restricted
bank deposits. Cash and cash equivalents and restricted bank deposits are invested in banks in Israel and the U.S.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management believes that the financial
institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with
respect to these investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has no off-balance-sheet
concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoanCommitmentsPolicy', window );">Convertible loans</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">m.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Convertible loans: &#160;&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><u>Allocation of proceeds:</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The proceeds received upon the
original issuance of the 2016 Loan (as defined below) together with a freestanding derivative financial instrument (derivative
liability for right to future investment) were allocated to the financial instruments issued based on the residual value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The detachable derivative financial
instrument related to the 2016 Loan was recognized based on its fair value and the remaining amount of the proceeds was allocated
to the 2016 Loan component.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The 2017 Loan (as defined below)
was not issued with any detachable instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><u>Beneficial Conversion Features
("BCFs"):</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px">&#160;</td>
    <td style="width: 29px"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the Company has considered the provisions of ASC 815-40, "Derivatives and Hedging &#8211; Contracts in Entity's Own Equity" ("<b>ASC 815-40</b>"), and determined that the embedded conversion feature of the 2016 Loan should not be separated from the host instrument because it qualifies for equity classification. Furthermore, the Company applied ASC 470-20, "Debt &#8211; Debt with Conversion and Other Options" ("<b>ASC 470-20</b>) which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios, and has applied the BCFs guidance to determine whether the conversion feature is beneficial to the investor.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">The BCFs was calculated by allocating
the proceeds received in financing transactions to the 2016 Loan and to any detachable freestanding financial instrument (derivative
liability for future investment) included in the transaction, and by measuring the intrinsic value of the conversion option based
on the effective conversion price as a result of the allocated proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">The intrinsic value of the conversion
option with respect to the 2016 Loan was recorded as a discount on the 2016 Loan with a corresponding amount credited directly
to equity as additional paid-in capital. After the initial recognition, the discount on the 2016 Loan was amortized as interest
expense over the contractual term of the 2016 Loan (before its modification) by using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px">&#160;</td>
    <td style="width: 29px"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, the Company has considered the provisions of ASC 815-15,&#160;"Derivatives and Hedging - Embedded Derivatives", and determined that the embedded conversion feature of the 2017 Loan cannot be considered as clearly and closely related to the host debt instrument, However, it was determined that the embedded conversion feature should not be separated from the host instrument because the embedded conversion option, if freestanding, did not meet the definition of a derivative in accordance with the provisions of ASC 815-10, "Derivatives and Hedging"&#160;&#160;since its terms did not require or permit net settlement. Thus, it was determined that the conversion feature does not meet the characteristic of being readily convertible to cash.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Furthermore, the Company applied
ASC 470-20 which clarifies the accounting for instruments with BCFs or contingently adjustable conversion ratios.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Pursuant to ASC 470-20-30, the
amount of the BCFs with respect to the 2017 Loan was calculated at the commitment date, as the difference between the conversion
price (<i>i.e.</i>, the entire proceeds received for the 2017 Loan) and the aggregate fair value of the Common Stock and other
securities (which consist of the future Investment Rights) into which the 2017 Loan was convertible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">As such difference was determined
to be greater than the amount of the entire proceeds originally received for the 2017 Loan, the amount of the discount assigned
to the BCFs was limited to the amount of the entire proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">c.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Following modifications or exchanges of convertible loans that were accounted for as an extinguishment (see below), upon each additional recognition of the convertible loans based on their modified terms, the Company applied ASC 470-20, "Debt &#8211; Debt with conversion and other options" to determine whether the conversion feature is considered beneficial to the investors. However, due to the fact that following each of the extinguishments of the convertible loans, such modified convertible loans were recognized based on their fair value as of the modification date, the conversion terms were not considered beneficial to the investors.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">d.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><u>Modifications or Exchanges</u>:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Modifications to, or exchanges
of, financial instruments such as convertible loans, are accounted for as a modification or an extinguishment, following to provisions
of ASC 470-50, "Debt- Modification and Extinguishments" ("<b>ASC 470-50</b>"). Such an assessment done
by management either qualitatively or quantitatively based on the facts and circumstances of each transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">Under ASC 470-50, modifications
or exchanges are generally considered extinguishments with gains or losses recognized in current earnings if the terms of the new
debt and original instrument are substantially different. The instruments are considered "substantially different"
when the present value of the cash flows under the terms of the new debt instrument is at least 10% different from the present
value of the remaining cash flows under the terms of the original instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">If the terms of a debt instrument
are changed or modified and the present value of the cash flows under the terms of the new debt instrument is less than 10%, the
debt instruments are not considered to be substantially different, except in the following two circumstances (i)&#160;&#160;The
transaction significantly affects the terms of an embedded conversion option, such that the change in the fair value of the embedded
conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and
after the modification or exchange) is at least 10% of the carrying amount of the original debt instrument immediately before the
modification or exchange or (ii)&#160;&#160;The transaction adds a substantive conversion option or eliminates a conversion option
that was substantive at the date of the modification or exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If the original and new debt
instruments are considered as "substantially different", the original debt is derecognized and the new debt is initially
recorded at fair value, with the difference recognized as an extinguishment gain or loss under financial expense or income as applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If a convertible debt instrument
with a beneficial conversion option that was separately accounted for in equity, is extinguished prior to its conversion or stated
maturity date, a portion of the reacquisition price is allocated to the repurchase of the beneficial conversion option. The amount
of the reacquisition price allocated to the beneficial conversion option is measured using the intrinsic value of that conversion
option at the extinguishment date. The residual amount, if any, is allocated to the convertible debt instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">The gain or loss on the extinguishment
of the convertible debt instrument is determined based on the difference between the carrying amount and the fair value of the
allocated reacquisition price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.6in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Modifications to, or exchanges
of equity financial instruments such as right to future investment, are accounted for as a modification or an extinguishment in
a similar manner as described above. Such an assessment is done by management either qualitatively or quantitatively based on the
facts and circumstances of each transaction. Among others, management considers whether, the fair value of the financial instruments
before and after the modification or exchange are substantially different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">If the original and new equity
instruments are considered as "substantially different", the excess fair value of the allocated reacquisition price
over the fair value of the modified financial instrument before the modification, is recognized directly to retained earnings as
a deemed dividend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"><u>Issuance costs of convertible
loan:</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">a.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2016 Loan (or costs allocated to such component in a package issuance) were presented as a direct deduction from the amount of the 2016 Loan and in subsequent periods such costs (together with the discount created by BCFs if applicable) expensed as financing expenses over the contractual term of the 2016 Loan by using the effective interest method. Any such costs that were allocated to the derivative component were expensed as incurred.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 125px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">b.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Upon initial recognition, costs incurred in respect of obtaining financing through issuance of the 2017 Loan (or costs allocated to such component in a package issuance) were presented as a deferred asset since the 2017 Loan was completely discounted at the initial recognition. In subsequent periods, such expenses were amortized ratably over the original term of the 2017 Loan.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify"><u>Extinguishment of convertible
loans:</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Upon the final extinguishment
of the convertible loans upon their maturity, the difference between the reacquisition price which consist of the cash paid, the
fair value of instruments issued (shares and warrants) and the modification of loans and cancellation of existing financial instruments)
and the carrying amounts of the convertible loans being extinguished was recognized as a gain or loss in the period of extinguishment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">n.</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Fair value of financial instruments:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">ASC 820, "Fair Value Measurements
and Disclosures" ("<b>ASC 820</b>"), defines fair value as the price that would be received to sell an asset
or paid to transfer a liability (<i>i.e.</i>, the "exit price") in an orderly transaction between market participants
at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In determining fair value, the
Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes
the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used
when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based
on market data obtained from sources independent of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Unobservable inputs are inputs
that reflect the Company's assumptions about the assumptions market participants would use in pricing the asset or liability
developed based on the best information available in the circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The hierarchy is broken down into
three levels based on the inputs as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 96px">&#160;</td>
    <td style="width: 48px"><font style="font: 10pt Times New Roman, Times, Serif">Level&#160;1&#160;</font></td>
    <td style="width: 19px"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level&#160;2&#160;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Level&#160;3&#160;</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The availability of observable
inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of
investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based
on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment
and the investments are categorized as Level&#160;3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The carrying amounts of cash and
cash equivalents, short-term bank deposits, other accounts receivable, trade payables and other accounts payable approximate their
fair value due to the short-term maturities of such instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Fair value of the marketable equity
securities is determined based on a Level 1 input.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LegalAndOtherContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">o.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Legal and other contingencies:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450 "Contingencies". A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed
and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information
and events pertaining to a particular matter. As of December&#160;31, 2020, the Company is not a party to any litigation that could
have a material adverse effect on the Company's business, financial position, results of operations or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Legal costs incurred in connection
with loss contingencies are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">p.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Leases:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Effective January 1, 2019, the Company accounts for its leases
under ASC 842, "Leases". Under this guidance, arrangements meeting the definition of a lease are classified as operating
or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated
by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing
rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results
in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In calculating the right of use
asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases
having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on
a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recognized&#160;$42
of operating lease right of use assets and operating lease liabilities at January 1, 2019. As of December 31, 2020 and 2019, total
of right-of-use assets related to the Company's operating leases and operating lease liabilities was $22.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company recorded an amortization
of $20 in right of use assets and operating lease liabilities for the year ended December 31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock', window );">Series A Warrants and December 2019 Warrants with Down-Round Protection</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">q.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Series A Warrants and December 2019 Warrants with Down-Round Protection:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Commencing January 1, 2018 and
following the early adoption of Accounting Standard Update ("<b>ASU</b>") No. 2017-11, "I. Accounting for certain
financial instruments with Down Round Features" (ASU 2017-11), the Company disregards certain down-round features when assessing
whether a financial instrument is indexed to its own stock, for purposes of determining liability or equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Based on its evaluation,
management has determined that the Series A Warrants and warrants that were issued in October 2018 (the "<b>October
2018 Warrants</b>") and in December 2019 (the "<b>December 2019 Warrants</b>"), as part of a private
placement, as described in Note&#160;13n, respectively, which include a down-round protection that would adjust the exercise
price of the Series A Warrants based on the price at which the Company subsequently issues shares or other equity-linked
financial instruments, if that price is less than the original exercise price of the Series A Warrants, are eligible for
equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In accordance with the provisions
of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (<i>i.e.</i>, when the exercise price of
the Series A Warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend
and as a reduction of income available (increase of loss applicable) to common shareholders for purposes of basic earnings per
share (EPS) calculation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Regarding a triggering event that required down-round adjustment
of the exercise price of the warrants during 2020 and 2019, see Note 13p and 13q, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Modifications to the terms of warrants that are classified
as equity and remains to be classified in equity after the modification, are accounted for in a similar manner to share-based compensation
guidance with respect to modifications. Accordingly, the incremental fair value from the modification (the change in the fair value
of the warrant before and after the modification) is recognized in retained earnings as a deemed dividend (e.g., dividends to a
particular class of equity holders).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">r.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Basic and diluted loss per share:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Basic loss per share is computed
by dividing the loss for the period applicable to Ordinary Shareholders by the weighted average number of shares of Common Stock
outstanding during the period. Securities that may participate in dividends with the Common Stock (such as the convertible Series
A Preferred Stock) are considered in the computation of basic income (loss) per share using the two-class method. In periods of
net loss, such participating securities are included in the computation, since the holders of such securities have a contractual
obligation to share the losses of the Company (as the convertible Series A Preferred Stock do not have a right to receive any mandatory
redemption amount and as they are entitled only to dividends on an as-converted basis together with the common shares).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In computing diluted loss per share,
basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise of options, warrants and
rights for future investment issued or granted using the "treasury stock method" and upon the conversion of 2017 Loan
and 2016 Loan using the "if-converted method", if the effect of each of such financial instruments is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For the year ended
December&#160;31, 2020 and 2019, all outstanding warrants, stock options and other convertible instruments have been excluded
from the calculation of the diluted net loss per share as all such securities are anti-dilutive for all years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The loss and the weighted average
number of shares used in computing basic and diluted net loss per share for the years ended December 31, 2020 and 2019, is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,929</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,450</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Add: Loss attributed to preferred stock (*)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">136</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to right for future investment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(185</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend due to down round adjustment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(267</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to stockholders of Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,266</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,766</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shares of Common Stock used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,669,628</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,519,682</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss per share of Common Stock, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.36</td><td style="text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
                                         the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase
                                         Agreement (as defined below). These shares of preferred stock are participating securities. During
                                         the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
                                         ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December
                                         31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Number of shares:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Common shares used
    in computing basic and diluted loss per share</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">16,669,628</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">10,519,682</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Preferred Stock and options excluded
    from the calculations of diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">614,763</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,931,097</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">s.</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other comprehensive loss</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The components of accumulated
other comprehensive loss which resulted from foreign currency translation adjustment as of December&#160;31, 2020 and 2019 were
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br /> accumulated <br />
    other <br /> comprehensive <br /> income (loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2020</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(73</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(73</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other comprehensive loss</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px; font-size: 10pt"></td>
    <td style="width: 24px; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">s.</font></td>
    <td style="font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other comprehensive loss</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The components of accumulated
other comprehensive loss which resulted from foreign currency translation adjustment as of December&#160;31, 2020 and 2019 were
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br /> accumulated <br />
    other <br /> comprehensive <br /> income (loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2020</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(73</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(73</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">t.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"><font style="font-size: 6pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Stock-based compensation to employees
is accounted for in accordance with ASC 718, "Compensation - Stock Compensation" ("<b>ASC 718</b>"), which
requires estimation of the fair value of equity - based payment awards on the date of grant using an option pricing model. The
value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 6pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Stock-based compensation expense
is recognized for the value of awards granted based on the accelerated method over the requisite service period of each of the
awards, net of estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fair value of stock options
granted to Wize Israel employees was estimated using the Black- Scholes option pricing model, which requires a number of assumptions,
of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated
based upon historical volatilities of the Company on a weekly basis since the marketability of Wize Israel is less than the expected
option term. The expected option term represents the period that Wize Israel's stock options are expected to be outstanding
and is determined based on the simplified method until sufficient historical exercise data will support using expected life assumptions.
The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The expected dividend yield assumption
is based on Wize Israel's historical experience and expectation of no future dividend payouts. Wize Israel has historically
not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Following the adoption of ASU 2018-07 in January 2018, all equity-classified
nonemployee share-based payment are accounted for in accordance with the provisions of ASC 718 and accordingly, awards granted
during 2019 and 2020 were measured at grant-date fair value of the equity instruments that the Company is obligated to issue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements not adopted yet</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt"></font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">u.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Recent Accounting Pronouncements not adopted
    yet</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt"><font style="font-size: 7pt">&#160;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1.5in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">ASU 2016-13, "Financial Instruments &#8211; Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13")</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On June 2016, the FASB issued ASU Update 2016-13,
"Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU
2016-13") ASU Update 2016-13 revised the criteria for the measurement, recognition, and reporting of credit losses on financial
instruments to be recognized when expected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">On November 2019, the FASB issued
ASU 2019-10, "Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic
842) &#8211; Effective Dates," which, among other provisions, the effective date of ASU 2016-13 was amended as follows</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">1. Public
business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (SRCs)
as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">2. All
other entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">As the Company is eligible to be considered as smaller reporting
company, ASU 2016-13 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal
years, with early adoption permitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The Company is in the process
of evaluating the effect that ASU 2016-13 will have on the results of operations and financial statements, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt"></font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 1.5in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">ASU 2020-06&#8212;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts
in an Entity's Own Equity</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">In August 2020, the FASB issued
ASU 2020-06&#8212;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts
in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity
(ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts in an entity's own equity. Among other changes, ASU 2020-06 removes from
GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and beneficial conversion
feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for
such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life
of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument
contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt
instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to
calculate the impact of convertible instruments on diluted earnings per share (EPS).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">The amendments in ASU 2020-06
are effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding
entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021,
including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning
after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">ASU 2020-06 can be adopted
on either a fully retrospective or modified retrospective basis. The adoption of this standard is not expected to result in a
material impact to the Company's financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock', window );">Contingent obligation with respect to future revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt"></font></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">v.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Contingent obligation with respect to future
    revenues</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company's contingent
obligation to payment of 37% of the future LO2A Proceeds, if any, was accounted for as long-term debt in accordance with the provisions
of Accounting Standards Codification ("ASC") 470-10-25, "Sales of Future Revenues or Various other Measures
of Income," which relates to cash received in exchange for payments of a specified percentage or amount of revenue or other
measure of income of a particular product line, business segment, trademark, patent, or contractual right.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Such repayment obligations are
contingent upon the receipt by the Company of any future proceeds from LO2A sales, license or other, as described in Note 5 below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company elected to measure
the contingent payment obligation in its entirety, at its fair value (the "Fair Value Option") in accordance with
ASC 825-10, "Financial Instruments" due to the variable and contingent nature of the repayment provisions of such
financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-size: 7pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The fair value of such
liability was measured upon its initial recognition at its fair value, based on the difference between the fair value of the
marketable securities received by the Company, less the amount of cash paid by the Company. In subsequent periods, the fair
value of the liability for contingent payment obligation is based on management estimate. As of December 31, 2020, the
Company revalued the liability to its fair value with the assistance of an external valuation specialist, pursuant to the
Company's estimations and assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined
that the inputs used in measuring the fair value of the contingent payment obligation fall within Level 3 in the fair value
hierarchy which involves significant estimations and assumptions regarding any projected future proceeds from the LO2A,
including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product
into the U.S. market - 12%, the patent expiration date (2038), the operational profit estimated rate - 26%, the probabilities
for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has determined that the inputs used in measuring
the fair value of the contingent payment obligation fall within Level 3 in the fair value hierarchy which involves significant
estimates and assumptions including, among others, any projected future proceeds from the LO2A, the risk-adjusted rate for discounting
future cash flows and other relevant assumptions, see Note 10.&#160;&#160;Actual results could differ from the estimates made.
Changes in fair value (including the component related to imputed interest), would be included in the consolidated statements of
comprehensive loss as part of financial income (loss) under the heading "Changes in fair value of contingent payment obligation
with respect to future revenues."</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock', window );">Mandatorily Redeemable Series B Preferred Stock</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px"></td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">w.</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif"><u>Mandatorily Redeemable Series B Preferred
    Stock</u></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company classified its formerly
outstanding Series B Preferred Stock as a liability, as their terms embody an unconditional obligation of the Company to redeem
the shares by transferring cash or other assets that equal (i) 80% of the proceeds received by the Company through future sales
of the Bonus Shares issued to the Company under the Bonus Agreements (as hereinafter defined) and (ii) 80% of any cash dividends
received by the Company on such Bonus Shares) at a specified or determinable date or dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company elected to measure
this liability in its entirety, at its fair value (the "Fair Value Option") in accordance with ASC 825-10, "Financial
Instruments" due to the variable and contingent nature of the redemption price of such financial liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Upon initial recognition and in
subsequent periods, the Company measured the&#160;fair value of the liability related to the Series B Preferred Stock based on
the value of the Bonus Shares and the cash amount that the Company was required to transfer to the Series B investors upon the
redemption of the Series B Preferred Stock. The difference between the amount received by the Company upon the issuance of the
Series B Preferred Stock and their fair value as of that date was carried immediately to the consolidated statements of comprehensive
loss as part of financial income (loss).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The issuance costs of the Series
B Preferred Stock were recognized immediately as an expense during the three months ended March 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On July 8, 2020, the Company elected
to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares to the (now former)
holders of Series B Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 29, 2020, Wize entered into an Addendum (the "Addendum")
with Bonus, whereby, among other things, Bonus agreed to issue to the Company additional ordinary shares of Bonus (the "Bonus
Shares", the total number of which consists of (i) the Milestone Settlement Shares, which, as defined in the Addendum, means
Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum)
by NIS 0.50, and (ii) the HCW Settlement Shares, as defined in note 10a (together with the Milestone Settlement Shares, the "Settlement
Shares"), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed
in NIS (based on the exchange rate set in the Addendum) by NIS 0.50. In consideration for the Settlement Shares, the Company agreed
to make certain amendments to the Bonus Agreements, including the following key modifications: (i) the Company will waive the requirement
that Bonus will affect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing, which means that US$3.7 million
were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq
Milestone Shares") were released to the Company and to its former holders of Series B Preferred Stock (the "Former
Series B Holders"); (ii) the Company will waive approximately US$120 in liquidated damages that accrued as a result of the
delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli
subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under the Bonus Exchange Agreement,
including certain related negative covenants. The closing occurred on December 29, 2020. It should be noted that, in accordance
with the obligations of the Company to the Former Series B Holders (see below), the Company has transferred 80% of the Milestone
Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2020, the entire
balance of the Series B preferred stock was extinguished.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanCommitmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for loan commitments accounted for as derivatives, including the methods and assumptions used to estimate fair value and any associated hedging strategies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116879480&amp;loc=d3e417888-122833<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.DD)<br> -URI http://asc.fasb.org/extlink&amp;oid=116879480&amp;loc=d3e417888-122833<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanCommitmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ContingentObligationWithRespectToFutureRevenuesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LegalAndOtherContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LegalAndOtherContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_MandatorilyRedeemableSeriesBPreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RestrictedBankDepositPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RestrictedBankDepositPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SeriesAWarrantsWithDownRoundProtectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466226504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfXchangeRateOfRelevantCurrencies', window );">Schedule of exchange rate of relevant currencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">USD 1 = NIS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.9</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.8</td><td style="text-align: left">)</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfCashAndCashEquivalents', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: right">December&#160;31</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">247</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">718</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">260</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">759</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfEstimatedUsefulLivesOfAssets', window );">Schedule of estimated useful lives of the assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -56.7pt"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">%</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Computers and electronic equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br /> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,929</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,450</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Add: Loss attributed to preferred stock (*)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">136</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend with respect to right for future investment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(185</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Less: Deemed dividend due to down round adjustment</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(267</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to stockholders of Common Stock</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,266</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,766</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shares of Common Stock used in computing basic and diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,669,628</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,519,682</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss per share of Common Stock, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.32</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.36</td><td style="text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;&#160;&#160;&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td><td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During
                                         the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase
                                         Agreement (as defined below). These preferred stock are participating securities. During
                                         the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.</font></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year
                                         ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December
                                         31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Number of shares:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Common shares used
    in computing basic and diluted loss per share</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">16,669,628</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">10,519,682</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Preferred Stock and options excluded
    from the calculations of diluted loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">614,763</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,931,097</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br /> accumulated <br />
    other <br /> comprehensive <br /> income (loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2020</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(73</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(73</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfEstimatedUsefulLivesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfEstimatedUsefulLivesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfXchangeRateOfRelevantCurrencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfXchangeRateOfRelevantCurrencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473138088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of other current assets</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Governmental authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivable (Note 3c)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">260</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">66</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">378</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466440904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Purchase Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationAbstract', window );"><strong>License Purchase Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock', window );">Schedule of repayment dates of the remaining minimal commitment on the financial liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">Repayment dates:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 9pt">January 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">250</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">January 1, 2021 (see to Note 5)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">-</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Remaining balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Non-current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of repayment dates of remaining Minimal Commitment on the financial liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfRepaymentDatesOfRemainingMinimalCommitmentOnFinancialLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466437016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfOtherAccountsPayableTableTextBlock', window );">Schedule of accounts payable</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">475</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Liability to HCW, see Note 10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Trade payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,306</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">369</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfOtherAccountsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of other accounts payable table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfOtherAccountsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467413560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock', window );">Schedule of 2017 loan and 2016 loan that were amended to be denominated in U.S. dollars instead of NIS</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2017 Loan</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2016 Loan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Aggregate principal amount</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">822</td><td style="white-space: nowrap; width: 1%; padding-bottom: 4pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(*)</p></td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">531</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Conversion price per Company's share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.1112</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">0.9768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Aggregate maximum of Right to Future Investment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,233</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(**)</p></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">797</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercise price per Company's share of Right to Future Investment</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.332</td><td style="white-space: nowrap; padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.308</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Principal loan amount
    of $274 for each of the three 2017 Lenders.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px"><font style="font: 10pt Times New Roman, Times, Serif">(**)</font></td>
    <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Maximum of Right
    to Future Investment of $411 for each of the three 2017 Lenders.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of roll forward of 2017 loan and 2016 loan</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Opening balance (including accrued interest)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,635</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of premium related to convertible loans prior to 2018 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of premium related to convertible loans following 2018 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(641</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &#8211; March 2019 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,873</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued interest on 2017 Loan and 2016 Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Amount allocated to 2016 Loan and 2017 Loan based on modified terms &#8211; March 2019 modification</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,767</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of premium related to convertible loans following March 2019 modifications</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(413</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments &#8211; May 2019 extension</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,353</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amount allocated to 2016 Loan and 2017 Loan based on modified terms &#8211; May 2019 extension</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,556</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of premium related to convertible loans &#8211; May 2019 extension</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(203</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">November 2019 repayment in cash and Common Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,520</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the U.S. dollar denominated balances, balances reported for financial reporting purposes and the differences between the two balances by each relevant line item on the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDifferencesBetweenReportedAmountAndReportingCurrencyDenominatedAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473074504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability', window );">Schedule of mandatorily redeemable series B liability</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Opening balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Series B Preferred Stock issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,500</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from initial recognition of mandatorily redeemable Series B Preferred Stock at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,207</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revaluation of mandatorily redeemable Series B Preferred
    Stock </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(597</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Redemption of mandatorily redeemable Series B Preferred Stock with Bonus Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,604</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Extinguishment of mandatorily redeemable Series B Preferred Stock by release of escrow account</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,700</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;Ending balance</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of mandatorily redeemable series B liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfMandatorilyRedeemableSeriesBLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467435496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before taxes on income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -10pt; padding-left: 10pt">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,318</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,709</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Foreign (*)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,842</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,613</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,160</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,322</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">Relates to Wize Israel and OcuWize.</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income taxes</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,974</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves and allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,108</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,165</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expense or benefit</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before taxes on income, as reported in the statements of comprehensive loss</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(4,929</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(3,450</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Theoretical tax benefit on this loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">725</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Expenses not deductible for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(983</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(639</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463431368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wizp_TwoZeroOneEightPlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of grant of options to employees and directors</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options outstanding as of December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">352,072</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.91</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,850</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options outstanding as of December 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">290,222</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.64</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options exercisable as of December 31, 2020</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">255,459</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.56</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.82</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Options outstanding as of December 31, 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">255,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.68</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.55</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,822</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options outstanding as of December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">352,072</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.91</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Options exercisable as of December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">181,799</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.75</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.72</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wizp_TwoZeroOneTwoPlanMember', window );">2012 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of grant of options to employees and directors</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options outstanding and exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,352</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">81.81</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.32</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number <br /> of options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> exercise <br /> price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> average <br /> remaining <br /> contractual <br /> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Options outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,896</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">190.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.86</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Options outstanding and exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,896</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">190.7</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.86</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wizp_TwoZeroOneEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wizp_TwoZeroOneEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wizp_TwoZeroOneTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wizp_TwoZeroOneTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466273832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Statements of Operations Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SelectedStatementsOfOperationsDataAbstract', window );"><strong>Selected Statements of Operations Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of general and administrative expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Overseas travel</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">103</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">688</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rent and office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payroll and benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional services and consultation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">517</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">953</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Taxes and tolls</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director salary and insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,008</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,678</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ScheduleOfFinancingExpensesNetTableTextBlock', window );">Schedule of financing expenses net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>Year ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Income from sale and revaluation of marketable securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Exchange rate gains, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gain from completion of milestone closing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">847</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Gain from settlement shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Amortization of premium related to convertible loans</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,257</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total financial income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,144</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Financial expense:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued interest on convertible loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued interest on loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from recognition of mandatorily redeemable Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,207</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from revaluation of contingent obligation with respect to future revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(435</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Revaluation of mandatorily redeemable Series B Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(597</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bonus transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(350</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Change in the fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(527</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Bank commissions and exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from extinguishment of convertible loans (Note 8c, 8d, 8e)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(977</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,631</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,552</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total financial expense, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,487</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(280</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfFinancingExpensesNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of financing expenses net..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfFinancingExpensesNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SelectedStatementsOfOperationsDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SelectedStatementsOfOperationsDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771462559816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock', window );">Schedule of interested and related parties</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Other receivables</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">-</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">52</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Accounts payable</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">439</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">104</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Convertible Loans</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>
<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of transactions with interested and related parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Amounts charged to:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">General and administrative expenses*</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,212</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">1,140</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Finance expenses, net (income)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(625</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.3in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in">* Including an amount of $76 with respect to stock-based compensation</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balances with interested and related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_BalancesWithInterestedAndRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463731416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_GeneralTextualAbstract', window );"><strong>General (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (39,218)<span></span>
</td>
<td class="num">$ (33,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ExchangeOfCommonStock', window );">Exchange of common stock</a></td>
<td class="nump">61.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Shareholders outstanding percentage</a></td>
<td class="nump">87.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ReminingOutstandingOwnersPercentage', window );">Percentage of expected ownership remains</a></td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,148)<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ExchangeOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ExchangeOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_GeneralTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General Textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_GeneralTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ReminingOutstandingOwnersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remining outstanding owners percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ReminingOutstandingOwnersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467410808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ForeignCurrencyExchangeRateTranslation', window );">Currencies</a></td>
<td class="nump">&#8362; 3.215<span></span>
</td>
<td class="nump">&#8362; 3.456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CurrencyExchangeRatePercentage', window );">Currencies percentage</a></td>
<td class="num">(6.90%)<span></span>
</td>
<td class="num">(7.80%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_CurrencyExchangeRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_CurrencyExchangeRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ForeignCurrencyExchangeRateTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ForeignCurrencyExchangeRateTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463874936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Restricted cash deposit</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466284072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details 2)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and electronic equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Estimated useful lives</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Estimated useful lives</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463861304">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details 3) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,929)<span></span>
</td>
<td class="num">$ (3,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_NetIncomeAttributedToPreferredStock', window );">Add: Loss attributed to preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Less: Deemed dividend with respect to exercise price adjustment of warrants (Note 13r)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(390)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendWithRespectToRightForFutureInvestment', window );">Less: Deemed dividend with respect to right for future investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividendDueToDownRoundAdjustment', window );">Less: Deemed dividend due to down round adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss applicable to stockholders of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,266)<span></span>
</td>
<td class="num">$ (3,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares of Common Stock used in computing basic and diluted net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,669,628<span></span>
</td>
<td class="nump">10,519,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_NetLossPerShareOfCommonStockBasicAndDiluted', window );">Net loss per share of Common Stock, basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the year ended December 31, 2018 the Company issued preferred A stock pursuant to the Purchase Agreement (as defined below). These preferred stock are participating securities. During the years ended December 31, 2020 and 2019 there were no other potentially dilutive instruments.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendDueToDownRoundAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendDueToDownRoundAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividendWithRespectToRightForFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividendWithRespectToRightForFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_NetIncomeAttributedToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_NetIncomeAttributedToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_NetLossPerShareOfCommonStockBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss per share of Common stock, basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_NetLossPerShareOfCommonStockBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467760520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details 4) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Number of shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare', window );">Common shares used in computing basic and diluted loss per share</a></td>
<td class="nump">16,669,628<span></span>
</td>
<td class="nump">10,519,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare', window );">Preferred Stock and options excluded from the calculations of diluted loss per share</a></td>
<td class="nump">614,763<span></span>
</td>
<td class="nump">16,931,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, options and warrants excluded from the calculations of diluted income (loss) per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PreferredStockOptionsAndWarrantsExcludedFromCalculationsOfDilutedIncomeLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771469729096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details 5) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Total accumulated other comprehensive income (loss)</a></td>
<td class="num">$ (73)<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461381064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SignificantAccountingPoliciesTextualAbstract', window );"><strong>Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease right of use assets and operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DepositPercentage', window );">Percentage of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax benefit, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Amortization of right use assets and operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aggregate purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PurchasePricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LeastPercentageOfCarryingAmount', window );">Least percentage of carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Percentage of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PercentageOfContingentObligation', window );">Percentage of contingent obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DescriptionOfContingentObligation', window );">Description of contingent obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Including, among others, the dry eye US market size in 2025 (USD 2.9 Billion), the maximum penetration rate of the product into the U.S. market - 12%, the patent expiration date (2038), the operational profit rate - 26%, the probabilities for FDA phases approvals, and the risk-adjusted rate for discounting future cash flows - 20.3%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PercentageOfBonueAgreement', window );">Bonus agreements percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PolicyholderDividendsRateOnPolicyEarnings', window );">Cash dividends received, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DescriptionOfBonusAgreements', window );">Description of bonus agreements</a></td>
<td class="text">(i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing (as defined in the Bonus Agreements), which means that, at the Closing, $3.7 million will be released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq Milestone Shares") will be released to the Company (20% of the shares) and to the Company's former holders of Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive approximately $120in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of Bonus to secure the Company's obligations under the Bonus Exchange Agreement, including certain related negative covenants. The Closing was subject to customary conditions, including obtaining the approval of the TASE, and occurred on December 30, 2020. It should be noted that, in accordance with the Securities Purchase Agreement, dated January 9, 2020 (as amended), by and among the Company and the Former Series B Holders, the Company was required to transfer 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SignificantAccountingPoliciesTextualAbstract', window );"><strong>Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PresentValueOfDebtInstrumentPercentage', window );">Present value of debt instrument percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SignificantAccountingPoliciesTextualAbstract', window );"><strong>Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_NumberOfBonusSharesDistributedByCompany', window );">Number of bonus shares distributed by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,191,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RedeemAllOfSeriesBPreferredStockDescription', window );">Redeem Series B Preferred Stock, description</a></td>
<td class="text">(i) the Milestone Settlement Shares, which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement Shares, the &#8220;Settlement Shares&#8221;), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtInterestRateOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderDividendsRateOnPolicyEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of earnings allocable to participating policyholders based on earnings of such policies for payment of dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(14)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderDividendsRateOnPolicyEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmortizationOfRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DepositPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DepositPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DescriptionOfBonusAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of bonus agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DescriptionOfBonusAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DescriptionOfContingentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DescriptionOfContingentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LeastPercentageOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Least percentage of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LeastPercentageOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_NumberOfBonusSharesDistributedByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_NumberOfBonusSharesDistributedByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PercentageOfBonueAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PercentageOfBonueAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PercentageOfContingentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PercentageOfContingentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PresentValueOfDebtInstrumentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of debt instrument percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PresentValueOfDebtInstrumentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RedeemAllOfSeriesBPreferredStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeem all of the Series B Preferred Stock, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RedeemAllOfSeriesBPreferredStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771462487304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MarketableEquitySecuritiesTextualAbstract', window );"><strong>Marketable Equity Securities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Ordinary shares investment holding</a></td>
<td class="nump">18,822,533<span></span>
</td>
<td class="nump">52,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_InvestmentOwnershipPercentage', window );">Percentage of issued and outstanding share capital</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable investment amount</a></td>
<td class="nump">$ 2,834<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Marketable securities loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MarketableEquityDescription', window );">Marketable equity, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company sold 2,238,944 shares of Cannabics through a broker at the amount of $260 (see also Note 4) which were received as of the date of Financial Statements. The Company made a payment of $1 to the broker as a deposit for the Broker&#8217;s activity. During 2019 the Company recorded a loss of $501.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IncomeFromChangeInFairValue', window );">Income from sale of shares</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_CannabicsMember', window );">Cannabics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MarketableEquitySecuritiesTextualAbstract', window );"><strong>Marketable Equity Securities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Ordinary shares investment holding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital', window );">Minimum percentage of issued and outstanding share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Less than 1%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IncomeFromChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IncomeFromChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment, ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_MarketableEquityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_MarketableEquityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_MarketableEquitySecuritiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_MarketableEquitySecuritiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of issued and outstanding share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_MinimumPercentageOfIssuedAndOutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_CannabicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_CannabicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473842328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OtherGovernmentalAuthoritiesCurrent', window );">Governmental authorities</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OtherReceivable', window );">Other receivable (Note 3c)</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OtherGovernmentalAuthoritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to government authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OtherGovernmentalAuthoritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OtherReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OtherReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463594936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicenseAgreementTextualAbstract', window );"><strong>License Agreement (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PercentageOfDiscountRate', window );">Percentage of discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for future royalties amounts</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsAndOtherAssets', window );">Deferred Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicenseAgreementDescription', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A one-time payment to Resdevco by Wize Israel in an amount of $650 shall be due no later than the second anniversary of the receipt of Food and Drug Administration (&#8220;FDA&#8221;) approval (the &#8220;Deferred Amount&#8221;); however, following FDA approval, if annual royalties due to Resdevco by Wize Israel exceed the Minimum Royalties (as defined in the License Agreement), an amount equal to 50% of such excess shall be added towards settlement of the Deferred Amount. As to royalty payments, Resdevco shall be entitled to the greater of $0.60 per unit sold, or a percentage of revenues, not to exceed 10%, from sales made in the United States and other countries, excluding Israel, China and Ukraine, but not less than the Minimum Royalties.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RecognizedLeaseLiability', window );">Recognized liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PercentageOfContingentObligation', window );">Percentage of contingent obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PenaltyPayment', window );">Penalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicenseAgreementTextualAbstract', window );"><strong>License Agreement (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicenseAgreementDescription', window );">License agreement, description</a></td>
<td class="text">Representing the minimum commitment to pay royalties based on the upcoming January 2021 payment in an amount of $150 and an amount of $100 which represents a termination fee payable to Resdevco if the Company exercises its right to terminate the License Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost assets and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicenseAgreementTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicenseAgreementTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PenaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PenaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PercentageOfContingentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PercentageOfContingentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PercentageOfDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PercentageOfDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RecognizedLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognized liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RecognizedLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463906728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Purchase Obligation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Repayment dates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">January 1, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">January 1, 2021 (see to Note 5)</a></td>
<td class="nump">250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Remaining balance</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationCurrent', window );">Current liability</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationNet', window );">Non-current liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationLiabilities', window );">Total</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license purchase obligation current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license purchase obligation net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463585880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Purchase Obligation (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationTextualAbstract', window );"><strong>License Purchase Obligation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ReducedAnnualRoyaltiesDescription', window );">Reduced annual royalties description</a></td>
<td class="text">The Company and Resdevco agreed that the Company shall pay Resdevco minimum yearly payments of $150,000 per year through 2021, and thereafter annual payments of $475,000 per year, and shall pay Resdevco $650,000 within two years after receipt of FDA approval for eye drops utilizing the licensed technology.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=wizp_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LicensePurchaseObligationTextualAbstract', window );"><strong>License Purchase Obligation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MinimumCommitmentAmount', window );">Minimum commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ReducedAnnualRoyaltiesDescription', window );">Reduced annual royalties description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Wize Israel and Resdevco amended the License Agreement pursuant to which the annual royalties amount of $475 were reduced to $150 for 2018 and 2019. In addition, If Wize Israel would have obtained an FDA marketing license during 2019, the Company was also required to pay Resdevco the remainder of the payment of 2019, however, such approval was not achieved in 2019. Consequently, during the third quarter of 2017 the Company has recognized an amount of $150 as an additional liability with respect to the 2018 minimum commitment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LicensePurchaseObligationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LicensePurchaseObligationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_MinimumCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_MinimumCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ReducedAnnualRoyaltiesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced annual royalties description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ReducedAnnualRoyaltiesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=wizp_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=wizp_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771462567784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OtherAccountsPayableAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LiabilityValue', window );">Liability to HCW, see Note 10</a></td>
<td class="nump">700<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TradePayables', window );">Trade payables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Total accounts payable</a></td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TradePayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TradePayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461291912">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Convertible Loans (Details) - Dec. 31, 2020 - 2017 loan amendment [Member]<br> $ in Thousands</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>&#8362; / shares</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AggregatePrincipalAmount', window );">Aggregate principal amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per Company's share | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1.1112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AggregateMaximumOfRightToFutureInvestment', window );">Aggregate maximum of Right to Future Investment | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ExercisePriceOfRightToFutureInvestment', window );">Exercise price per Company's share of Right to Future Investment | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember', window );">2016 Loan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AggregatePrincipalAmount', window );">Aggregate principal amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per Company's share | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AggregateMaximumOfRightToFutureInvestment', window );">Aggregate maximum of Right to Future Investment | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ExercisePriceOfRightToFutureInvestment', window );">Exercise price per Company's share of Right to Future Investment | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1.308<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Principal loan amount of $274 for each of the three 2017 Lenders.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Maximum of Right to Future Investment of $411 for each of the three 2017 Lenders.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AggregateMaximumOfRightToFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate maximum of right to future investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AggregateMaximumOfRightToFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ExercisePriceOfRightToFutureInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of right to future investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ExercisePriceOfRightToFutureInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461239080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loans (Details 1) - 2017 Loan [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanRollForwardAbstract', window );"><strong>Roll forward of 2017 Loan and 2016 Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Opening balance (including accrued interest)</a></td>
<td class="nump">$ 2,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoans', window );">Amortization of premium related to convertible loans prior to 2018 modification</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoan', window );">Amortization of premium related to convertible loans following 2018 modification</a></td>
<td class="num">(641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DerecognitionLoanUponExtinguishment', window );">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments - March 2019 modification</a></td>
<td class="num">(1,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AccruedInterestOnLoan', window );">Accrued interest on 2017 Loan and 2016 Loan</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountAllocatedToLoan', window );">Amount allocated to 2016 Loan and 2017 Loan based on modified terms - March 2019 modification</a></td>
<td class="nump">1,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne', window );">Amortization of premium related to convertible loans following March 2019 modifications</a></td>
<td class="num">(413)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DerecognitionLoanUponExtinguishmentOne', window );">Derecognition of carrying amount of 2016 Loan and 2017 Loan upon extinguishments - May 2019 extension</a></td>
<td class="num">(1,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountAllocatedToLoanOne', window );">Amount allocated to 2016 Loan and 2017 Loan based on modified terms - May 2019 extension</a></td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo', window );">Amortization of premium related to convertible loans - May 2019 extension</a></td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">November 2019 repayment in cash and Common Stock</a></td>
<td class="num">(1,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AccruedInterestOnLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AccruedInterestOnLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of premium related to convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmortizationOfPremiumRelatedToConvertibleLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of premium related to convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmortizationOfPremiumRelatedToConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of premium related to convertible loans following 2019 modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmortizationOfPremiumRelatedToConvertibleLoansOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmortizationOfPremiumRelatedToConvertibleLoansTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountAllocatedToLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountAllocatedToLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountAllocatedToLoanOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountAllocatedToLoanOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DerecognitionLoanUponExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The derecognition of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DerecognitionLoanUponExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DerecognitionLoanUponExtinguishmentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DerecognitionLoanUponExtinguishmentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LoanRollForwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LoanRollForwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771383629368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loans (Details Textual)<br> &#8362; / shares in Units, $ / shares in Units, &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 13, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 21, 2017</div></th>
<th class="th">
<div>Jan. 15, 2017 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Mar. 20, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 20, 2016 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Nov. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 19, 2018</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jan. 15, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 15, 2017 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Mar. 20, 2016 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanAmendmentDescription', window );">Loan amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the May 2019 Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement was extended to November 30, 2019 from May 31, 2019 (as previously described under the March 2019 Amendment).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the 2018 Loan Amendment, the maturity date under the (i) 2016 Loan Agreement, and (ii) 2017 Loan Agreement, was amended to be the earliest of (a) 90 days following the date that the registration statement the Company will file under the registration rights agreement dated October 22, 2018 (the "Registration Rights Agreement") covering the resale of all Common Stock, issued pursuant to the Purchase Agreement, and issuable upon conversion of the Series A Preferred Stock and exercise of the Series A Warrants, are registered for resale for investors who are not a party to the 2018 Loan Amendment, (b) 90 days following the date on which all securities issued to investors under the Purchase Agreement are no longer deemed registrable securities under the Registration Rights Agreement, and (c) one year following the closing under the Purchase Agreement. In addition, pursuant to the 2018 Loan Amendment, the expiration date of the Investment Rights under the 2016 Loan Agreement and the 2017 Loan Agreement was amended to be 180 days after the Loan Agreements maturity date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_InvestmentOptionExercisePrice', window );">New exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_LendersMember', window );">Lenders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount', window );">Right future investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount', window );">Right future investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanAmendmentDescription', window );">Loan amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a result, an aggregate amount of $1,015 was allocated to the 2016 Loan and an aggregate amount of $1,498 was allocated to the 2017 Loan and its related right to future investment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Aggregate amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repayment in cash and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AccruedInterestOnLoan', window );">Accrued interest on loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | 2017 loan amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1.1112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | Lenders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted instrument, amount | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount', window );">Right future investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Exchange ratio, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2017 Loan Conversion Price for Rimon Gold, Fisher and Ridge was adjusted to NIS 16.8 (approximately $4.80), and as a result of the Merger, the 2017 Loan Conversion Price of NIS16.8 (approximately $4.8) was adjusted in accordance with the Exchange Ratio to NIS 4.05 (approximately $1.15).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription', window );">Converted debt, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2017 Loan Conversion Price was adjusted to $1.1112.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Fixed exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | Lenders [Member] | NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | Rimon Gold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount', window );">Right future investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Exchange ratio, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Exchange Ratio (as defined in the Agreement and Plan of Merger with Bufiduck Ltd., a company formed under the laws of the State of Israel and our wholly owned subsidiary and Wize Israel) from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment, from NIS 5.04 to $1.308 (subject to adjustments in case of stock splits or similar events).<span></span>
</td>
<td class="text">The Exchange Ratio (as defined in the Agreement and Plan of Merger with Bufiduck Ltd., a company formed under the laws of the State of Israel and our wholly owned subsidiary and Wize Israel) from NIS 20.4 (approximately $6.00) to NIS 5.04 (approximately $1.44) and based on the 2017 Loan Amendment, from NIS 5.04 to $1.308 (subject to adjustments in case of stock splits or similar events).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | Rimon Gold and Shimshon Fisher [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | Rimon Gold and Shimshon Fisher [Member] | NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | Wize Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription', window );">Converted debt, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the 2017 Loan Agreement, each of the 2017 Lenders had the right, at its sole discretion, to convert any outstanding portion of the 2017 Loan, but no less than NIS 100,000 (approximately $28 according to an exchange rate at 2017 loan originate date).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">2017 Loan [Member] | Wize Israel [Member] | NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember', window );">2016 Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount', window );">Right future investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanAmendmentDescription', window );">Loan amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a result, an aggregate amount of $1,015 was allocated to the 2016 Loan and an aggregate amount of $1,498 was allocated to the 2017 Loan and its related right to future investment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Aggregate amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember', window );">2016 Loan [Member] | 2017 loan amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.9768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember', window );">2016 Loan [Member] | Rimon Gold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Exchange ratio, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.6 (approximately $0.96).<span></span>
</td>
<td class="text">As a result of the Merger and based on the Exchange Ratio, the conversion price per share for the 2016 Loan was adjusted to NIS 3.6 (approximately $0.96).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember', window );">2016 Loan [Member] | Rimon Gold [Member] | NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted instrument, amount | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 15.2592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember', window );">2016 Loan [Member] | Wize Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember', window );">2016 Loan [Member] | Wize Israel [Member] | NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroOneSevenLoanAmendmentMember', window );">2017 Loan Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanAmendmentDescription', window );">Loan amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into an amendment (the "2017 Loan Amendment") to the 2016 Loan Agreement and the 2017 Loan Agreement. Pursuant to the 2017 Loan Amendment, (i) the maturity date of the Loans was extended from December 31, 2017 to December 31, 2018; (ii) the exercise period of the 2016 Investment Right was amended so that it shall expire on June 30, 2019; (iii) the exercise period of the 2017 Investment Right was amended so that it shall expire, without the need to first convert the 2017 Loan, on June 30, 2019; and (iv) the below terms of the Loans were amended to be denominated in U.S. dollars instead of NIS.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroOneNineLoanAmendmentMember', window );">2019 Loan Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription', window );">Converted debt, description</a></td>
<td class="text">The Company issued to Rimon Gold, Mobigo, and Fisher an aggregate of 2,816,196 shares of Common Stock upon conversion of the loans at a reduced conversion price of $0.27 per share and issued the December 2019 Warrants to purchase an aggregate of 5,632,392 shares of Common Stock at an exercise price of $0.27.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanAmendmentDescription', window );">Loan amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The parties also agreed that Rimon Gold's, Ridge's and Fisher's remaining 2016 Investment Rights (as of that date) under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and the expiration date of Rimon Gold's, Ridge's and Fisher's remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at $1.332 per share, be extended from June 30, 2019 to November 30, 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repayment in cash and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AccruedInterestOnLoan', window );">Accrued interest on loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=wizp_MayTwoThousandNineteenAmendmentMember', window );">May 2019 Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ConvertibleLoansTextualAbstract', window );"><strong>Convertible Loans (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LoanAmendmentDescription', window );">Loan amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The parties also agreed that the expiration date of Rimon Gold's, Mr. Danenberg's and Fisher's remaining 2016 Investment Rights (as of that date) under the 2016 Loan Agreement to invest up to $512.8, in the aggregate, at $1.308 per share, and Rimon Gold's, Mr. Danenberg's and Fisher's remaining 2017 Investment Rights (as of that date) under the 2017 Loan Agreement to invest up to $663.4, in the aggregate, at $1.332 per share, be extended from November 30, 2019 to May 31, 2021. As consideration for extending the maturity date of the loans, the Company issued to Rimon Gold, Mr. Danenberg (through Mobigo, his wholly owned company), and Fisher two-year warrants to purchase an aggregate of 868,034 shares of Common Stock at a fixed price of $1.10 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about derivative transactions entered into in connection with convertible debt instruments which may be settled in cash upon conversion, including partial cash settlement. Descriptions include the terms of such transactions, how the derivative transaction(s) relate to the convertible debt instrument, the number of underlying shares and the reasons for entering into the derivative transaction(s). An example of a derivative transaction entered into in connection with the issuance of the convertible debt instrument is the purchase of call options that are expected to substantially offset changes in the fair value of the conversion option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleAssociatedDerivativeTransactionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of financial support to be provided in future by investment company to investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 20<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66023616&amp;loc=SL35737436-115832<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyFinancialCommitmentToInvesteeFutureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoanOriginations1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoanOriginations1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AccruedInterestOnLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AccruedInterestOnLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ConvertibleLoansTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ConvertibleLoansTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_InvestmentOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_InvestmentOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LoanAmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about loan amendment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LoanAmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_LendersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_LendersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypesOfCurrencyAxis=wizp_NisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypesOfCurrencyAxis=wizp_NisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_RimonGoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_RimonGoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_RimonGoldAndFisherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_RimonGoldAndFisherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wizp_WizeIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wizp_WizeIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=wizp_ConvertibleDebtOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroOneSevenLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroOneSevenLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroOneNineLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroOneNineLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=wizp_MayTwoThousandNineteenAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=wizp_MayTwoThousandNineteenAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771465019576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short Term Loan Payable (Details) - OcuWize [Member] - 2020 Loan [Member]<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Jul. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2020 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | $</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Annual rate</a></td>
<td class="nump">5.45%<span></span>
</td>
<td class="nump">5.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Jan. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_BankAccount', window );">Bank account | $</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=wizp_OcuwizeMember', window );">NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_BankAccount', window );">Bank account | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_BankAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_BankAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wizp_OcuwizeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wizp_OcuwizeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroTwoZeroLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=wizp_TwoZeroTwoZeroLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypesOfCurrencyAxis=wizp_ILSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypesOfCurrencyAxis=wizp_ILSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771498789416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MandatorilyRedeemableSeriesBLiability', window );">Opening balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SeriesBPreferredStock', window );">Series B Preferred Stock issued</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10', window );">Loss from initial recognition of mandatorily redeemable Series B Preferred Stock at fair value</a></td>
<td class="num">(3,207)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10', window );">Revaluation of mandatorily redeemable Series B Preferred Stock</a></td>
<td class="nump">597<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock', window );">Redemption of mandatorily redeemable Series B Preferred Stock with Bonus Shares</a></td>
<td class="nump">7,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_EscrowAmount', window );">Extinguishment of mandatorily redeemable Series B Preferred Stock by release of escrow account</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_MandatorilyRedeemableSeriesBLiability', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change from revaluation of mandatorily redeemable Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ChangeFromRevaluationOfMandatorilyRedeemableSeriesBPreferredStockNote10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_EscrowAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_EscrowAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss from recognition of mandatorily redeemable Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LossFromRecognitionOfMandatorilyRedeemableSeriesBPreferredStockNote10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_MandatorilyRedeemableSeriesBLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_MandatorilyRedeemableSeriesBLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes from redemption of mandatorily redeemable series B preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RedemptionOfMandatorilyRedeemableSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Series B preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771383170840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Details Textual)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 07, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 29, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 19, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 20, 2019</div></th>
<th class="th">
<div>Apr. 29, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SecuritiesPurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into a securities purchase agreement (the "2019 Purchase Agreement") with an accredited investor. Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27 per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock. The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public announcement of positive clinical data results for LO2A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_EscrowAmount', window );">Escrow amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Amount of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Company recognized a loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_InvestmentInMarketableSecuritiesBonusShares', window );">Investment in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,851<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParticipationRights', window );">Preferred stock description</a></td>
<td class="text"> The Company elected to redeem all of the Series B Preferred Stock. As a result, the Company distributed 68,191,200 Bonus Shares representing an amount of $6,597 to the holders of Series B Preferred Stock representing 80% of the Bonus shares then held by the Company. As a result of such distribution, as of the date of these financial statements, the Company owns the remaining 18,822,533 Bonus Shares, representing approximately 1.61% of the outstanding shares of Bonus.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ReceivedCashProceeds', window );">Received cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DescriptionOfBonusAgreements', window );">Description of bonus agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing (as defined in the Bonus Agreements), which means that, at the Closing, $3.7 million will be released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the "Nasdaq Milestone Shares") will be released to the Company (20% of the shares) and to the Company's former holders of Series B Preferred Stock (the "Former Series B Holders"); (ii) the Company will waive approximately $120in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of Bonus to secure the Company's obligations under the Bonus Exchange Agreement, including certain related negative covenants. The Closing was subject to customary conditions, including obtaining the approval of the TASE, and occurred on December 30, 2020. It should be noted that, in accordance with the Securities Purchase Agreement, dated January 9, 2020 (as amended), by and among the Company and the Former Series B Holders, the Company was required to transfer 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SecuritiesPurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company agreed to sell to the investors, and the investors agreed to purchase from the Company, in a private placement, an aggregate of 7,500 shares of newly created Series B Non-Voting Redeemable Preferred Stock, par value $0.001 per share, of the Company ("Series B Preferred Stock") for a purchase price of $1.00 per share, for aggregate gross proceeds under the Series B Purchase Agreement of $7,500, which funds were deposited into an escrow account, of which (i) $500 was to be paid to the Bonus Escrow Account and $100 was paid directly to the Company to cover certain of its transactions expenses, in each case, promptly following the execution of the Series B Purchase Agreement, and (ii) the remaining $6,900 was to be released to the Bonus Escrow Account upon the closing of the transactions contemplated by the Series B Purchase Agreement (of which, as described above, $3,200 was to be released upon the earlier of the Milestone Closing or upon written consent of the holders of at least a majority of the Series B Preferred Stock).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_EscrowAmount', window );">Escrow amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RedeemableFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_FinanceExpenses', window );">Finance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_InvestmentOfMarketableSecuritiesPercentage', window );">Investment of marketable securities percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RedeemAllOfSeriesBPreferredStockDescription', window );">Redeem Series B Preferred Stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the Milestone Settlement Shares, which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$500 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50, and (ii) the HCW Settlement Shares (together with the Milestone Settlement Shares, the &#8220;Settlement Shares&#8221;), which, as defined in the Addendum, means Bonus Shares equal to the quotient obtained by dividing US$350 expressed in NIS (based on the exchange rate set in the Addendum) by NIS 0.50.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_BonusExchangeAgreementMember', window );">Bonus Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SecuritiesPurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company agreed to purchase 51,282,000 ordinary shares of Bonus (the "PIPE Shares", and together with the LO2A Shares, the "Bonus Shares"), for an aggregate purchase price of $7,400 in cash, which funds were deposited directly into an escrow account (the "Bonus Escrow Account"), of which (i) $500 was paid to Bonus as an advance promptly following execution of the Bonus Purchase Agreement, (ii) $3,200 was released to Bonus concurrently with the closing of the transactions contemplated by the Bonus Agreements in exchange for 50% of the PIPE Shares and (iii) $3,700 was released to Bonus upon the Milestone Closing (as defined in the Bonus Purchase Agreement), in exchange for the remaining 50% of the PIPE Shares that were issued by Bonus and deposited into the escrow at the closing. The Company's obligation to consummate the Milestone Closing is conditioned upon the satisfaction by Bonus of certain conditions, including the listing of its ordinary shares (or, if an ADR Program is to be implemented by Bonus, the American Depositary Shares representing such ordinary shares) on the Nasdaq Capital Market (or another superior tier of the Nasdaq market) (the "Nasdaq Listing").<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_EscrowAmount', window );">Escrow amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AdditionalOrdinaryShares', window );">Additional ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_InvestmentInMarketableSecuritiesBonusShares', window );">Investment in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,871,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LossDueToRevaluation', window );">Loss due to revaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_FairValueOfBonusSharesAndAmount', window );">Fair value of bonus shares and amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ReceivedCashProceeds', window );">Received cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_BonusExchangeAgreementMember', window );">Bonus Exchange Agreement [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SecuritiesPurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Bonus Agreements (as amended as of June 24, 2020), Bonus agreed to cover nearly 50% of the Company's fees and expenses payable by the Company in cash, Bonus shares and/or a combination thereof to H.C. Wainwright & Co., LLC ("HCW") in connection with the transactions contemplated by the Bonus Agreements and the Series B Purchase Agreement (as defined below). In particular, Bonus agreed to reimburse the Company or pay HCW directly $350 in cash, Bonus shares and/or a combination thereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_EscrowAmount', window );">Escrow amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_BonusAgreementsMember', window );">Bonus Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SecuritiesPurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Bonus Agreements, the Company agreed to grant Bonus, in consideration for the issuance of 62,370,000 ordinary shares of Bonus to the Company (the "LO2A Shares"), the right to receive 37% of future LO2A Proceeds (if any), which, as more fully defined in the Bonus Exchange Agreement, include proceeds generated by the Company, Wize Israel and OcuWize, as a result of (i) the sale, license or other disposal of products or other rights underlying the LO2A technology licensed to OcuWize under the License Agreement; and (ii) a Sale Transaction, which, as more fully defined in the Bonus Exchange Agreement, includes the sale of shares or assets of Wize Israel and/or OcuWize. In addition, if the Sale Transaction involves a change of control of the Company, Bonus will be entitled to elect, to either remain with its right to 37% of the LO2A Proceeds or receive a one-time payment equal to 37% of the value attributed to Wize Israel out of the total proceeds payable for the Company in such transaction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PricePerShareAtDateOfAgreement', window );">Price per share at the date of agreement | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_PricePerShareAtClosingDate', window );">Price per share at the closing date | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OutstandingShareCapitalPercentage', window );">Outstanding share capital percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Amount of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_BonusAgreementsMember', window );">Bonus Agreements [Member] | NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_BonusAgreementsMember', window );">Bonus Agreements [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_BonusTransaction', window );">Bonus transaction | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,294,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_BonusSharesOfSeriesBPreferredStock.', window );">Bonus shares series B Preferred stock. | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,576,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_SeriesBPurchaseAgreementMember', window );">Series B Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SecuritiesPurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Series B Certificate of Designations, the Company designated 7,500 shares of preferred stock as Series B Preferred Stock. The Series B Preferred Stock were not convertible into shares of Common Stock of the Company and have no voting powers, except as related to certain rights to protect the rights and preferences of the Series B Preferred Stock and with respect to sales or dispositions of the Series B Preferred Stock at a price per share below the Price Restriction. The Series B Preferred Stock entitled its holders to (i) 80% of the proceeds received by the Company through future sales of the Bonus Shares issued to the Company under the Bonus Agreements and (ii) 80% of any cash dividends received by the Company on such Bonus Shares. Under the Series B Certificate of Designations, the Company had the option to redeem the Series B Preferred Stock at any time by distributing to holders of the Series B Preferred Stock (i) 80% of the Bonus Shares then held by the Company and (ii) 80% of all dividends received by the Company but not yet paid to holders of the Series B Preferred Stock (the "Redemption Payment"). The Company was required to redeem the Series B Preferred Stock through payment of the Redemption Payment upon the earlier of (i) 60 days following the Nasdaq Listing of the Bonus Shares, and (ii) December 28, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CashOfInvestment', window );">Cash of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_SettlementSharesMember', window );">Settlement Shares [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DescriptionOfBonusAgreements', window );">Description of bonus agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the Company will waive the requirement that Bonus will effect the Nasdaq Listing and, in relation thereto, conduct the Milestone Closing, which means that US$3.7 million were released from an existing escrow account to Bonus, whereas the 28,413,000 Bonus Shares held in such escrow (the &#8220;Nasdaq Milestone Shares&#8221;) were released to the Company and to its former holders of Series B Preferred Stock (the &#8220;Former Series B Holders&#8221;); (ii) the Company will waive approximately US$120 in liquidated damages that accrued as a result of the delay in effecting the Nasdaq Listing; and (iii) Bonus agreed to extend the period for the Company to create, and cause its Israeli subsidiaries to create, certain first priority liens in favor of Bonus to secure obligations under the Bonus Exchange Agreement, including certain related negative covenants. The closing occurred on December 29, 2020. It should be noted that, in accordance with the obligations of the Company to the Former Series B Holders (see below), the Company has transferred 80% of the Milestone Settlement Shares and 80% of the Nasdaq Milestone Shares to such investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the contractual rights of preferred stockholders to receive dividends or returns from the entity's profits, cash flows, or returns on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AdditionalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AdditionalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_BonusSharesOfSeriesBPreferredStock.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonus shares series B Preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_BonusSharesOfSeriesBPreferredStock.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_BonusTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonus transaction by shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_BonusTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_CashOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_CashOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DescriptionOfBonusAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of bonus agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DescriptionOfBonusAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_EscrowAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_EscrowAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_FairValueOfBonusSharesAndAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of bonus shares and amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_FairValueOfBonusSharesAndAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_FinanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_FinanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_InvestmentInMarketableSecuritiesBonusShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Investment in marketable securities (Bonus shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_InvestmentInMarketableSecuritiesBonusShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_InvestmentOfMarketableSecuritiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_InvestmentOfMarketableSecuritiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LossDueToRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss due to revaluation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LossDueToRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OutstandingShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OutstandingShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PricePerShareAtClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share at the closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PricePerShareAtClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_PricePerShareAtDateOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share at the date of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_PricePerShareAtDateOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ReceivedCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Received cash proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ReceivedCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RedeemAllOfSeriesBPreferredStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeem all of the Series B Preferred Stock, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RedeemAllOfSeriesBPreferredStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RedeemableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RedeemableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SecuritiesPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SecuritiesPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_BonusExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_BonusExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_BonusAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_BonusAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypesOfCurrencyAxis=wizp_IsraeliShekelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypesOfCurrencyAxis=wizp_IsraeliShekelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_SeriesBPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_SeriesBPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_SettlementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_SettlementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771466315560">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,318)<span></span>
</td>
<td class="num">$ (1,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(10,842)<span></span>
</td>
<td class="num">(9,613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (12,160)<span></span>
</td>
<td class="num">$ (11,322)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Relates to Wize Israel  and OcuWize.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771480528248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carry forwards</a></td>
<td class="nump">$ 2,899<span></span>
</td>
<td class="nump">$ 2,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_DeferredTaxAssetsReservesAndAllowances', window );">Reserves and allowances</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Net deferred tax asset before valuation allowance</a></td>
<td class="nump">3,165<span></span>
</td>
<td class="nump">3,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(3,165)<span></span>
</td>
<td class="num">(3,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_DeferredTaxAssetsReservesAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets reserves and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_DeferredTaxAssetsReservesAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463841384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Loss before taxes on income, as reported in the statements of comprehensive loss</a></td>
<td class="num">$ (4,929)<span></span>
</td>
<td class="num">$ (3,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Theoretical tax benefit on this loss</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ExpensesNotDeductibleForTaxPurposes', window );">Expenses not deductible for tax purposes</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized', window );">Increase in taxes resulting mainly from taxable losses in the reported year for which no net deferred tax assets were recognized</a></td>
<td class="num">(983)<span></span>
</td>
<td class="num">(639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ExpensesNotDeductibleForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses not deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ExpensesNotDeductibleForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ncrease in taxes resulting mainly from taxable losses in the reported year for which no deferred tax assets were recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IncreaseInTaxesResultingMainlyFromTaxableLossesInReportedYearForWhichNoDeferredTaxAssetsWereRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771390094232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TaxesOnIncomeTextualAbstract', window );"><strong>Taxes on Income (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_IncomeTaxRatePercentageDescription', window );">Percentage of income tax, description</a></td>
<td class="text">(i) establish a flat corporate income tax rate of 21% to replace previous rates that ranged from 15% to 39% and eliminates the corporate alternative minimum tax; (ii) create a territorial tax system rather than a worldwide system, which will generally allow companies to repatriate future foreign source earnings without incurring additional US taxes by providing a 100% exemption for the foreign source portion of dividends from certain foreign subsidiaries; (iii) subject certain foreign earnings on which US income tax is currently deferred to a one-time transition tax; (iv) create a "minimum tax" on certain foreign earnings and a new base erosion anti-abuse tax that subjects certain payments made by a US company to a related foreign company to additional taxes; (v) create an incentive for US companies to sell, lease or license goods and services abroad by effectively taxing them at a reduced rate; (vi) reduce the maximum deduction for Net Operating Loss ("NOL") carryforwards arising in tax years beginning after 2017 to a percentage of the taxpayer's taxable income, allows any NOLs generated in tax years beginning after December 31, 2017 to be carried forward indefinitely and generally repeals carrybacks; (vii) elimination of foreign tax credits or deductions for taxes (including withholding taxes) paid or accrued with respect to any dividend to which the new exemption applies, but foreign tax credits will continue to be allowed to offset tax on foreign income taxed to the US shareholder subject to limitations; (viii) limit the deduction for net interest expense incurred by US corporations, (ix) allow businesses to immediately write off (or expense) the cost of new investments in certain qualified depreciable assets made after September 27, 2017 (but would be phased down starting in 2023); (x) may require certain changes in tax accounting methods for revenue recognition; (xi) repeal the Section 199 domestic production deductions beginning in 2018; (xii) eliminate or reduce certain deductions, exclusions and credits, and adds other provisions that broaden the tax base.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CorporateAndDeferredTaxDescription', window );">Corporate and deferred tax, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> The provisional amount related to the re-measurement of the Company's net U.S. deferred tax asset, based on the rate at which they are now expected to reverse in the future, considered immaterial, but which was fully and equally offset by a corresponding reduction in the Company's valuation allowance. The effect of the change in federal corporate tax rate from 39% to 21% is subject to change based on resolution of estimates used in determining the amounts of deferred tax assets and liabilities that were re-measured.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Net operating loss carryforwards for federal income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax credit carryforward, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The annual NOL carry forward (pre-merger, approximately $4,784) is limited to $10.965 per year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, limitations on use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">NOL carry forwards of approximately $4,786 is available in full.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses for tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=wizp_OcuwizeMember', window );">OcuWize [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TaxesOnIncomeTextualAbstract', window );"><strong>Taxes on Income (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses for tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=wizp_WizeIsraelMember', window );">Wize Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TaxesOnIncomeTextualAbstract', window );"><strong>Taxes on Income (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses for tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TaxesOnIncomeTextualAbstract', window );"><strong>Taxes on Income (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CorporateTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TaxesOnIncomeTextualAbstract', window );"><strong>Taxes on Income (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CorporateTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">ISRAEL | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TaxesOnIncomeTextualAbstract', window );"><strong>Taxes on Income (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CorporateTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_CorporateAndDeferredTaxDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description related to deferred and corporate tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_CorporateAndDeferredTaxDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_CorporateTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_CorporateTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_IncomeTaxRatePercentageDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about income tax rate percentage description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_IncomeTaxRatePercentageDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TaxesOnIncomeTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TaxesOnIncomeTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wizp_OcuwizeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wizp_OcuwizeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wizp_WizeIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wizp_WizeIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771463451624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2020</div></th>
<th class="th"><div>Jun. 19, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases', window );">Rent agreement, description</a></td>
<td class="text">The Company rents its offices from a third party for a rental monthly fee of $2. The rent period is for a period of 12 months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_FindersFeeAgreementDescription', window );">Finder's fee agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The service provider will be entitled to the finder fee of 5% even if the agreement will be terminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A general description of the nature of the existing leasing arrangements of a lessor for all operating leases including, but not limited to: (1) guarantees or indemnities; (2) restrictions imposed by lease arrangements; (3) unusual provisions or conditions; (4) contingent rentals; and (5) lease expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121555071&amp;loc=d3e37045-112695<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfLessorLeasingArrangementsOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_FindersFeeAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_FindersFeeAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461720776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - 2012 Plan [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options outstanding and exercisable at end of year</a></td>
<td class="nump">4,352<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 190.7<span></span>
</td>
<td class="nump">$ 190.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options outstanding and exercisable at end of year</a></td>
<td class="nump">$ 81.81<span></span>
</td>
<td class="nump">$ 190.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at beginning of year</a></td>
<td class="text">3 years 10 months 10 days<span></span>
</td>
<td class="text">3 years 10 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options outstanding and exercisable at end of year</a></td>
<td class="text">3 years 3 months 26 days<span></span>
</td>
<td class="text">2 years 10 months 10 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wizp_TwoZeroOneTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wizp_TwoZeroOneTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771464358680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 1) - 2018 Plan [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Beginning balance</a></td>
<td class="nump">352,072<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">153,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="num">(61,850)<span></span>
</td>
<td class="num">(56,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Ending balance</a></td>
<td class="nump">290,222<span></span>
</td>
<td class="nump">352,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable</a></td>
<td class="nump">255,459<span></span>
</td>
<td class="nump">181,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 3.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">2.97<span></span>
</td>
<td class="nump">2.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">2.64<span></span>
</td>
<td class="nump">2.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Options outstanding</a></td>
<td class="text">5 years 8 months 19 days<span></span>
</td>
<td class="text">5 years 6 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted average remaining contractual life, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, Options outstanding</a></td>
<td class="text">5 years 10 months 3 days<span></span>
</td>
<td class="text">5 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, Options exercisable</a></td>
<td class="text">5 years 9 months 25 days<span></span>
</td>
<td class="text">5 years 8 months 19 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wizp_TwoZeroOneEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wizp_TwoZeroOneEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771384374536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 08, 2020</div></th>
<th class="th"><div>Aug. 11, 2020</div></th>
<th class="th"><div>Jul. 18, 2019</div></th>
<th class="th"><div>May 19, 2019</div></th>
<th class="th"><div>May 15, 2019</div></th>
<th class="th"><div>May 14, 2019</div></th>
<th class="th"><div>May 07, 2019</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
<th class="th"><div>Aug. 15, 2018</div></th>
<th class="th"><div>Apr. 04, 2018</div></th>
<th class="th"><div>Dec. 20, 2019</div></th>
<th class="th"><div>Aug. 20, 2019</div></th>
<th class="th"><div>Apr. 29, 2019</div></th>
<th class="th"><div>Apr. 18, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 24, 2020</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Jul. 01, 2020</div></th>
<th class="th"><div>Apr. 15, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 06, 2020</div></th>
<th class="th"><div>Dec. 13, 2019</div></th>
<th class="th"><div>Feb. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,783,495<span></span>
</td>
<td class="nump">15,873,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock value issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SecuritiesPurchaseAgreementDescription', window );">Purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company entered into a securities purchase agreement (the "2019 Purchase Agreement") with an accredited investor. Pursuant to the 2019 Purchase Agreement, the Company agreed to sell to the investor, and the investor agreed to purchase from the Company, in a private placement, an aggregate of 2,037,037 shares of Common Stock for a purchase price of $0.27 per share, for aggregate gross proceeds under the 2019 Purchase Agreement of $550. The Company also agreed to issue to the investor the December 2019 Warrants, a five-year warrants to purchase an aggregate of 4,074,047 shares of Common Stock. The December 2019 Warrants have an exercise price of $0.27 per share and will be exercisable five days following the public announcement of positive clinical data results for LO2A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_JointVentureAgreementDescription', window );">Joint venture agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the terms of the agreement, the Company issued to Cannabics 900,000 shares of its Common Stock and Cannabics issued to the Company 2,263,944 shares of Cannabics' common stock, which represented a holding percentage less than 5 percent of Cannabic's then outstanding share capital. The joint venture currently has no assets or liabilities and has not started conducting any of its planned operations.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,110<span></span>
</td>
<td class="nump">$ 34,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ChairmanAppointmentAgreementDescription', window );">Chairman appointment agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company and Mr. Sieczkarek entered into a Chairman Agreement (the "Chairman Agreement") whereby Mr. Sieczkarek shall receive 202,399 restricted stock units ("RSUs") and options to purchase 102,222 shares of the Company's Common Stock at an exercise price of $2.00 per share (the "Chairman Awards"). The Chairman Awards shall vest 1/8 on the effective date of the Chairman Agreement and subsequently in seven equal quarterly installments commencing July 1, 2019. The Chairman Agreement has an initial term of two years (the "Term") and provides that in the event of a change of control (as defined in the Chairman Agreement) the Chairman Awards shall automatically vest in full as of that date. The Chairman Agreement also contains standard representations and warranties regarding confidential information, non-competition and non-solicitation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockOptionsGrantedDuringVestingPeriod', window );">Stock options granted during the vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based expense related to RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockIssuanceToEmployeesRelatedDescription', window );">Company stock grants to its employee related, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company's Board of Directors approved the following equity grants: (i) 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors of the Company and (ii) 100,000 restricted stock units vesting quarterly over a period of two years to each of the other three non-executive directors. The aggregate fair value of these shares of RSUs at grant date issued was $73, and is being recognized over a period of 2 years following August 11, 2020. The Company recognized $34 during the year ended December 31, 2020, as a share-based expense in connection to the RSU's.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company granted to its employee, 21,600 options exercisable into 21,600 shares of Common Stock at an exercise price of $0.75 per share of Common Stock. The options began vesting quarterly over a period of 36 months commencing April 18, 2019. The Company recognized $2 during the year ended December 31, 2019 as a share-based expense. The total value of the share based expense is $10, which is recorded quarterly over the vesting period. Since the Company has terminated its employment agreement in December 2019, as of December 31, 2020, all of the options were forfeited.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Contractual term of stock-based grants, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company and five representative companies and expected term of stock-based grants of 7 years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stockholders amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LossOfChangeInFairValue', window );">Loss of change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_WeightedaveragePeriod', window );">Weighted average period for non vested optons</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_RimonGoldAndFisherMember', window );">Rimon Gold And Fisher [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockIssuanceToConsultantRelatedDescription', window );">Stock issuance to consultant related, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company granted to one of its directors certain options exercisable into 30,000 shares of Common Stock with an exercise price of $0.58 per share. The options will vest monthly over a period of six (6) months. The Company recognized $13 of share-based compensation expense during year ended December 31, 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wizp_TwoThousandTwelvePlanMemberrMember', window );">2012 Plan [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wizp_EmployeeStockOptionTwoMember', window );">2018 Plan [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based expense related to RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Description of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) 1,000,000 shares or (ii) 5% of the outstanding shares on the last day of the immediately preceding fiscal year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember', window );">Preferred Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted instrument shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stockholders amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=wizp_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockIssuanceToEmployeesRelatedDescription', window );">Company stock grants to its employee related, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company granted to its officers, directors and a consultant options exercisable into 229,500 shares of Common Stock with an exercise price of $3.59 per share. The options will vest quarterly over a period of 36 months. The Company recognized $51 and $154 during the year ended December 31, 2020 and 2019, respectively.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stockholders amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wizp_TwentyTwelveStockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based expense related to RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,050<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockIssuanceToConsultantRelatedDescription', window );">Stock issuance to consultant related, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company granted to a consultant, 10,000 fully vested RSUs. The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of issuance. The aggregate fair value of these RSUs issued at grant date was $5, and was recognized during the year ended December 31, 2019.<span></span>
</td>
<td class="text">The Company issued to a consultant, 135,000 shares of restricted Common Stock which is due and issuable according to the following schedule: 25% as of May 1, 2019 and additional 25% every quarter following May 1, 2019. The aggregate fair value of these shares of RSUs at grant date issued was $106, and is being recognized over a period of 1 year following May 1, 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company determined the fair value of the RSUs to be the quoted market price of the Company's Common Stock on the date of grant. The aggregate fair value of these RSUs issued was $476. The Company is recognizing this amount ratably over the vesting period of 24 months following March 31, 2019. In connections with the above, on July 25, 2019 (the initial quarterly vesting date) the Company issued 85,000 Common shares to its officers and directors. The Company recognized $132 and $337 during the year ended December 31, 2020 and 2019 respectively.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockIssuanceToEmployeesRelatedDescription', window );">Company stock grants to its employee related, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company's Board of Directors approved the equity grant of 150,000 restricted stock units vesting quarterly over a period of two years to the Chairman of the Board of Directors of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1. To grant to each of Company's four directors 100,000 RSUs. The RSUs will vest quarterly over a period of 24 months. 2. To grant to each its officers (Company's Chief executive officer and to Company's Chief financial officer)&#160;140,000 RSU's. The RSU's will vest quarterly over a period of 24 months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_StockholdersEquityTextualAbstract', window );"><strong>Stockholders' Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised shares of common stock</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_WarrantTermDescription', window );">Warrant, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The warrants issued to certain purchasers from the private placement in December 2019 (the "December 2019 Warrants") and certain investment rights issued on January 2017 (the "Investment Rights") were also adjusted to reflect a reduced exercise price of $0.001 per share (collectively, the "Warrant Adjustments"). As a result of the Warrant Adjustments, on December 29, 2020 an aggregate of 13,332,654 shares of common stock were issued as a result of the exercise of such warrants, each on a cashless basis. Among others, such warrant exercises also included warrants beneficially owned by our Chief Executive Officer, Noam Dannenberg. The difference between the fair value of the warrants before and after the adjustment was recognized as a deemed dividend and as an increase of the loss applicable to common stockholders in an amount of $327.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LossOfChangeInFairValue', window );">Loss of change in fair value</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ChairmanAppointmentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ChairmanAppointmentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_JointVentureAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_JointVentureAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LossOfChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LossOfChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SecuritiesPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SecuritiesPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_StockIssuanceToConsultantRelatedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_StockIssuanceToConsultantRelatedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_StockIssuanceToEmployeesRelatedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_StockIssuanceToEmployeesRelatedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_StockOptionsGrantedDuringVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_StockOptionsGrantedDuringVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_WarrantTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant term, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_WarrantTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_WeightedaveragePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_WeightedaveragePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_RimonGoldAndFisherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=wizp_RimonGoldAndFisherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wizp_TwoThousandTwelvePlanMemberrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wizp_TwoThousandTwelvePlanMemberrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wizp_EmployeeStockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wizp_EmployeeStockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=wizp_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=wizp_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wizp_TwentyTwelveStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wizp_TwentyTwelveStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771384282280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Statements of Operations Data (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 2,008<span></span>
</td>
<td class="nump">$ 2,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_OverseasTravelMember', window );">Overseas travel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_ShareBasedPaymentMember', window );">Stock-based compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_RentAndOfficeMaintenanceMember', window );">Rent and office maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_PayrollAndBenefitsMember', window );">Payroll and benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_ProfessionalServicesAndConsultationMember', window );">Professional services and consultation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_TaxesAndTollsMember', window );">Taxes and tolls [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_DirectorSalaryAndInsuranceMember', window );">Director salary and insurance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=wizp_OtherExpensesMember', window );">Others [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems', window );"><strong>Research and Development Assets Acquired Other than Through Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_OverseasTravelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_OverseasTravelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_ShareBasedPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_ShareBasedPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_RentAndOfficeMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_RentAndOfficeMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_PayrollAndBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_PayrollAndBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_ProfessionalServicesAndConsultationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_ProfessionalServicesAndConsultationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_TaxesAndTollsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_TaxesAndTollsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_DirectorSalaryAndInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_DirectorSalaryAndInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=wizp_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=wizp_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461279160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Statements of Operations Data (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Financial income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ChangeInFairValueOfMarketableSecurities', window );">Income from sale and revaluation of marketable securities</a></td>
<td class="nump">$ 1,197<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_ExchangeRateGainsNet', window );">Exchange rate gains, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_GainFromCompletionOfMilestoneClosing', window );">Gain from completion of milestone closing</a></td>
<td class="nump">847<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_GainFromSettlementShares', window );">Gain from settlement shares</a></td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium related to convertible loans</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Total financial income</a></td>
<td class="nump">2,144<span></span>
</td>
<td class="nump">1,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract', window );"><strong>Financial expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AccruedInterestOnConvertibleLoans', window );">Accrued interest on convertible loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AccruedInterestOnLoans', window );">Accrued interest on loans</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock', window );">Loss from recognition of mandatorily redeemable Series B Preferred Stock</a></td>
<td class="num">(3,207)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues', window );">Loss from revaluation of contingent obligation with respect to future revenues</a></td>
<td class="num">(435)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RevaluationOfMandatorilyRedeemablePreferredStock', window );">Revaluation of mandatorily redeemable Series B Preferred Stock</a></td>
<td class="num">(597)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_BonusTransactionCosts', window );">Bonus transaction costs</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Change in the fair value of marketable securities</a></td>
<td class="nump">1,197<span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Bank commissions and exchange rates</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Loss from extinguishment of convertible loans (Note 8c,8d,8e)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Total financial expense</a></td>
<td class="num">(4,631)<span></span>
</td>
<td class="num">(1,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financial expense, net</a></td>
<td class="num">$ (2,487)<span></span>
</td>
<td class="num">$ (280)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenseDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AccruedInterestOnConvertibleLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on convertible loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AccruedInterestOnConvertibleLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AccruedInterestOnLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest on loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AccruedInterestOnLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_BonusTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonus transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_BonusTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ChangeInFairValueOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ChangeInFairValueOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_ExchangeRateGainsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange rate gains, net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_ExchangeRateGainsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_GainFromCompletionOfMilestoneClosing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain from completion of milestone closing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_GainFromCompletionOfMilestoneClosing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_GainFromSettlementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain from settlement shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_GainFromSettlementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss from recognition of mandatorily redeemable Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LossFromRecognitionOfMandatorilyRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss from revaluation of contingent obligation with respect to future revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_LossFromRevaluationOfContingentObligationWithRespectToFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RevaluationOfMandatorilyRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of mandatorily redeemable Series B Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RevaluationOfMandatorilyRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467494040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_BalancesWithRelatedPartiesAbstract', window );"><strong>Balances with interested and related parties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Loans</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_BalancesWithRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_BalancesWithRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771467461912">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_AmountsChargedAbstract', window );"><strong>Amounts charged to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,212<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_FinanceIncomeNet', window );">Finance expenses, net (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (625)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Including an amount of $76 with respect to stock-based compensation</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_AmountsChargedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_AmountsChargedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_FinanceIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance income net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_FinanceIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771473093048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract', window );"><strong>Related Parties Balances and Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 818<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_RelatedPartiesBalancesAndTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139771461514232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CosmosTransactionDescription', window );">Cosmos transaction, description</a></td>
<td class="text">(i) agreement that the Board of Directors of The Company immediately following the Closing Date will consist, subject to certain exceptions, of three members to be designated by Cosmos and one member to be designated by The Company; (ii) covenants that The Company will seek, following the Closing Date, stockholder approval to be renamed Cosmos Capital, Inc. (or similar name), and to effect a reverse share split of The Company&#8217;s common stock; (iii) covenants that The Company will establish an incentive compensation program with respect to 40,000,000 shares of its common stock, to be granted promptly following the Closing Date, in the form of performance-based RSUs, performance rights or indeterminate rights based on the performance milestone criteria and allocation set in the Bid Agreement (the &#8220;Post-Closing Incentive Plan&#8221;), 50% of which are to be granted to personnel specified by The Company prior to the Closing Date and the remainder to be granted to personnel of Cosmos (see also Item 9B below); (iv) an obligation by The Company to terminate or procure the termination of each of the current employment or consulting agreements of The Company with Mr. Mark Sieczkarek, the Chairman of The Company Board of Directors, Mr. Noam Danenberg, the Chief Executive Officer of The Company, Mr. Or Eisenberg, the Chief Financial Officer of The Company, and another part-time employee related to Mr. Danenberg; and (v) an obligation by The Company to use its reasonable commercial efforts to enter into new,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OfferDescription', window );">Offer, description</a></td>
<td class="text">Immediately following the Closing Date, and assuming all of the holders of Cosmos Shares accept the Offer, Cosmos shareholders are expected to own approximately 87.65% of the outstanding common stock of the Company, while the Company's existing stockholders are expected to remain the owners of approximately 10.75% of the outstanding common stock of the Company, each on a fully diluted basis and including warrants to be issued to the Company's financial advisor to the transaction.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership, percentage</a></td>
<td class="nump">87.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aggregate shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock A, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock A, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=wizp_CosmosConvertibleNotesMember', window );">Cosmos Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CosmosTransactionDescription', window );">Cosmos transaction, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February 15, 2021, Cosmos informed the Company that Cosmos completed the issuance of convertible notes (the "Cosmos Convertible Notes") with an aggregate principal amount of approximately US$21 million to several non-U.S. sophisticated or professional investors (the "Purchasers"). The Cosmos Convertible Notes are unsecured and shall initially be convertible into shares of Cosmos at a conversion price of AU$23.58 per share (equivalent to US$18.16), reflecting a pre-money valuation of Cosmos of approximately US$185 million. The Cosmos Convertible Notes will automatically convert to shares six months after the date of issuance. Cosmos is obligated to pay interest to the Purchasers on the outstanding principal amount of the Cosmos Convertible Notes at the rate of 8% per annum, payable on the conversion date, in cash or, at Cosmos' option, in shares of Cosmos. Redemption of the Cosmos Convertible Notes occurs only if an insolvency event occurs in respect of Cosmos.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Conversion price | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndBenefitsTrust', window );">Monthly compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndBenefitsTrust', window );">Monthly compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_BidAgreementMember', window );">Bid Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CosmosTransactionDescription', window );">Cosmos transaction, description</a></td>
<td class="text">Under the Bid Agreement (as amended), the parties agreed that the Company would commence the Offer, an off-market takeover offer under applicable Australian laws, to acquire all of the Cosmos Shares in exchange for 61.11 Company's shares of common stock for each Cosmos Share, being the Offer Consideration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_PIPEAgreementsMember', window );">PIPE Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_StockRestrictionAgreementMember', window );">Stock Restriction Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_OfferDescription', window );">Offer, description</a></td>
<td class="text">Under the Bid Agreement, 22.33 Company shares of common stock out of the Offer Consideration will be &#8220;Restricted Stock&#8221; subject to a Stock Restriction Agreement to be entered into at the Closing Date and 38.78 Company shares of common stock will be &#8220;Covered Securities&#8221;. A Cosmos shareholder who accepts the Offer (an &#8220;Accepting Shareholder&#8221;) will not be permitted to sell or encumber their Restricted Stock until December 31, 2021 (the &#8220;Milestone Date&#8221;). In addition, an Accepting Shareholders may not exercise voting rights in respect of Restricted Stock from the date of issuance of the Offer Consideration until the Milestone Date. An Accepting Shareholder is entitled to sell or encumber its Covered Securities. However, if (subject to certain limited exceptions) an Accepting Shareholder sells or encumbers any of its Covered Securities before the Milestone Date, the Company has an option to repurchase a pro rata proportion of the Restricted Stock for the lower of $0.0001 and the fair market value of the Restricted Stock. The Restricted Stock (and any dividends thereon) will be held by the Company in escrow for the Accepting Shareholder&#8217;s benefit until such time as the Restricted Stock is repurchased by Wize or all restrictions thereon lapse. If any Restricted Stock is repurchased under the Company&#8217;s repurchase option, a pro rata proportion of the dividend on the Restricted Stock shall be retained by the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_TypeOfAgreementAxis=wizp_CVRAgreementMember', window );">CVR Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_wizp_CosmosTransactionDescription', window );">Cosmos transaction, description</a></td>
<td class="text">Pursuant to the Bid Agreement, prior to the Closing Date, the Company will enter into a Contingent Value Rights Agreement (the "CVR Agreement") with Cosmos, certain of the Company's subsidiaries (the "Wize Subsidiaries"), a person designated by the Company prior to the Closing Date as the Holders' Representative (as defined herein), and the Rights Agent (as defined therein). Pursuant to the CVR Agreement, at the Closing Date, each Wize pre-Closing security holder will receive one non-transferable CVR for each outstanding share of common stock of the Company and for each share of common stock of the Company underlying other convertible securities and warrants, held as of 4:01 p.m. Eastern Time on the day immediately before the Effective Time (as defined in the CVR Agreement). Each CVR will represent the right to receive a pro rata share of any consideration that may be received by the Company or the Company Subsidiaries in connection with the Company's existing LO2A business. In particular, CVR holders will be entitled to any consideration (whether cash, stock, assets or otherwise) that the Company or the Company Subsidiaries (or any of its Affiliates or shareholders) receives in connection with an LO2A Transaction, which, as defined in the CVR Agreement, includes (i) a sale of any of the Company Subsidiaries to a third party and/or (ii) the partnering, licensing, sublicensing, distribution, reselling or sale of all or any part of the LO2A Technology or LO2A Products to a third party, less transaction expenses and customary deductions as detailed in the CVR agreement, including a deduction of up to $300,000 that the Company Subsidiaries undertook to incur in the development of the LO2A Technology at the request of the Holders' Representative.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndBenefitsTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndBenefitsTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_CosmosTransactionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cosmos transaction, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_CosmosTransactionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_OfferDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offer, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_OfferDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wizp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=wizp_CosmosConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=wizp_CosmosConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_BidAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_BidAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_PIPEAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_PIPEAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_StockRestrictionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_StockRestrictionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wizp_TypeOfAgreementAxis=wizp_CVRAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wizp_TypeOfAgreementAxis=wizp_CVRAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $2%85('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !$A6%2+'9*%>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NFG9#E&7"]-.("$Q"<0M2KPMHFFBQ*C=V].&K1."!^ 8^\_G
MSY);'83V$9^C#QC)8KH;7=<GH<.&G8B" $CZA$ZE<DKT4_/@HU,T/>,1@M(?
MZHA05]4:')(RBA3,P"(L1"9;HX6.J,C'"][H!1\^8Y=A1@-VZ+"G!+SDP.0\
M,9S'KH4;8(811I>^"V@68J[^B<T=8)?DF.R2&H:A')J<FW;@\/;T^)+7+6R?
M2/4:IU_)"CH'W+#KY-?F8;O?,5E7-2^JIJCXGJ_%/1>KU?OL^L/O)NR\L0?[
MCXVO@K*%7W<AOP!02P,$%     @ 1(5A4IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>2-W65%/-B]M\FTQ([_\_.O(,^#.&GEA"7U=0+,CT)21SS(S&PVXD8A^!/"
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M##3P0!N+JJ8(V9NB21!076A4'DXP#3HT!CY.J,K+1IB&J;8'8;WS,9%YWNA
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MK<M>'8YAFBO;5R8WO%0DAS6&#&Y'N#2RN04U+UI4]B*Q$AJO)?8QPYLC2&.
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MZ^O[+X)NZ\O07ZD0M*@_;@A."5,"\OV:RN*H^:(:./PG@KO_ E!+ P04
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M".@:P0U%1[QCR2?B>Q\)'=.Q1:#;O;M[9X@X?J=07XWGNQ0JM3976IN7Q9+
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M0&<=H#,4T/6R*"O^/R68=&Q@%$M>+T'>3+D],$DPTV<&C23"K(AS0=Y_+2H
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M#%DF)XP_]XNSC?R^&8FID3#BDQPAOX[I/A[3;WO9/F"!Z.X*!OA@!QBC;S*
MX21R6*.O.8"/<X"'M?#2^!!:;,5FI0%]2]O5:EOPC1HXGK=;G?7[ELE\V,-3
MM1C,?-XL&%H:#7VG[C6]\/'@_/-\+O,L4#S[GC34&.@7(^UG64H#@!\;F#+
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MD_L(H^,0LG7JDCRU(,H]"-*,PJ0!&("/EF85SIL9\*/FH6N.88SS-I<1-(
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MQ7(=881I7U@/]="2!29+KIZ$NHSQ%DH-L%I+9\JB:VH^K7M6&XC7(1<.Y8,
MK^@OMF20*3OXCZT6],E$G%NT,8E)RWH)QIM;()6-P<3OW\&DKYP\B2D^Q6,$
MZ_@+R! 4N[ /4&\!3*0W4MDYFE ((MM. K[]"H0*PCQAA(%9B78,GK"<CXBQ
MA/UA%*(@E)!R>"$/;BSB1*)Z S"2P=Z"8(&]@477Z-/>H\!I!>4#P)3&EVV
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M"QY+_6B1'LQ0JY,N0#!0'TP'0L9%?![I/%J]$M(K>+._BO=^*QF"V3-$A9\
MD>0!)&H#]/#I7"^!168O+L[PG-3CG]A\SG$!#(*I0!ECW83MA, 9,P/_T)SX
M$10<00-S76S)XF9Q _R"6AFM(U+SI'EZ#J^Z(<2A"$R\[4'@S(@> *E=Y8!2
MM1&DEZKN,.V"?+7'MHW,9:*8;F=-L#N_Z"A  01U7Z,9^,C&K'B4CBK]P^3>
M:1+QMJ3SH5'!M<9BFN$ 78A3QTL\F5W0#T]FEZD+X #%EX]3\P6IG.S6+OLZ
M4"4A4$*\3<,,#1N+G /C)I?/3M-D(A-^PI$3/!$\QGH+,@K5Y[(I%N+>NO.#
M/P/=BKP$ZZFQ"U0XC"I<>"RTZ:&,K33EAWK5QB%'2V,6MGO @PE**@0N*9H#
MJ^&#*@IKQJ*P%/BU&89AM0JP54;T@],$/[7,'L3L)8=^0:ZIY0@P68MD]"LH
M<79V;MGUPU!;TX)M]7>*F5-0&C4$[[NH?'0.@':(2S3B&G0XZOLB9X$-%L\*
ME!Y*.'"_TX26R'N*N>P\C0"X4 &98F7Q!6B(+3)D&_A]0=9\B1H[]HT+#,&(
M!8 2[J3M[-:'&WAAT?6$*L$I\*BSD! 08MR0!U@5#<9Z82:2%+7/);"040_
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M%2<G*'1)P_].PW]FLY(U*M7I^BO2(: $3W$0&VA4UWAI)P1/QL5+>R35^PP
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MT_G%A</Y)?X)W"2]+O%\;L?;POY!8II=I!<7+]*+^?-D=IJ> [U</)\'T,/
MP7KIR/0 \>GT;,ZPPU\(.I+!:S(0S&%'#%R)."Y)PC%0U;70U5;= L,'/DJU
MIKF^:RR[/[NWNUW/\6#-#,F5VK[LT>'3X0Z^S74(6F/==1818ZKMA9>>41*
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M,;;! ?#[J@:))Q]P@8>Z^4+@_?C_ 5!+ P04    " !$A6%20? \.%P$
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M%CS6<$][.8NQ-#QF&5%Z*JA?/MK"1,&7G:"WEZNE+)5)X;EDRI #A.>R?>"
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M'DF%8AL+ E'LK*1D6E*FT .=UWKCZ819L6/ ?P*G^4696"W!JVW^H5N7DMJ
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MLJR$";MFE';HZN) IG1E#UE1U(B=<5B4A)Y@C!?OKQ&N(**O49"J8("""FR
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M#'X"TVB#\U^N;MAP1O)9O/"XCGS;:QB>\Z:90@05I7-@F]^=61?&98?O]FG
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MN=(*94D+\'QA;=7\( 7M%\"K_P)02P,$%     @ 1(5A4G8LHY:& P  8 <
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M\$%@D9!EI\]$>K#:%/<:PC6ZT38'P&4%T0#RO(2(&P7%\U9F<>J=@N:H!*L
M&V-9E!#ZET@&S $T(U*C$ );\4*?1C<COI8)11PR XV+C0!8&;$^"CUJ O%N
M\3!B,1D/0YKCRUK3.R>+[1M:7WO@8(N:%:F\()\M[RTO4//!/(&3US;BF/O
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MB 4 ?"5IP9<J1T FY0,/#(ZX8^J>=RHR-ATEYF$=PB;@)P6!&4&@LRW#VU)
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MHX];*<#\XP+X?IU#<F/_P /J7_MZ_3]02P,$%     @ 1(5A4BQ:3SR>!
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M,>3LIB%;H2[7%/-YHLO,-$QH(RM42Y0'."T1_GF,&HJTT"5@44L#4+[3CH+
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MNIL;^2%&_%+;-;]#-K<U\@I_7"F)TH<6X/>%A3N$+W1 ^U+A^_\!4$L#!!0
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MCKP<F!)2#D_DEQMS6F'L7BV.1('7JUAN;&#2-5K3]\AP&@%Y9V%*#Y)M@/H
M:X5#H29.6*W#/:-""QA0O]T1]!%:, D]E3>DG> 9X,D\K^S,3MJQ_$33%<1:
M#:R_V0&.@LB!F1? [G+6:T3*PR0 D&IC$^)[HBUF>E=,+"L@G.J!SA=M=8M$
MB:</]I6!K7&7U4MW^N301"M%@#JX.!( [G5EK@GA8*2BDE:3H?H-09_>-<05
M9R?3UXG_RWR^?9M,D^^0^)+3R6QZ!O^^.CM/#L\GKY.CY/!B<ID<C4C*"R\I
M+T:%W$W6K.DD+/ /Y#^@@PV9FJ-#H9_HJMEF"_O= 4&NOK<'WP,5#$YQQ3^I
M;_B\K$%W/T9>9=:@@X+64>3PR%)Q4F<1LL6TS(O'2' BL\&125>L0)'-D7>
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MYXT8!+-%6JKH(595I3!$5!&E:VN&Y.A:;'D1WTWJ1$7R#I0M$=E"/HS5/G7
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M=M_=TW? Q&\]Z*0K9X<?8(KLS["B9'JZI:^GI[]WVPQTH]QLICON&^,FUF=
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MVS ,ON=7$$(/'5#4CZ1)6R0!DG2O0[>@W>,P[*#8="Q4ECQ)3KK]^E&RZV5
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M&GJ@VMEK#2-KU^^I-#0];EO0<X7*.M#]2I+0SK $_0,X^P-02P,$%     @
M1(5A4G%Z-UDS!   ]@H  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MM59=;]LV%'W7KR"T8$L&U_KR5S+;@).T6("U"^IU>QCV0$O7%E%)5$DJ3O;K
M=TC9FI<F;M!M#XE)BO?<<\^]E^1T*]5'G1,9=E\6E9[YN3'U11#H-*>2Z[ZL
MJ<*7M50E-YBJ3:!K13QS1F41Q&$X"DHN*G\^=6NW:CZ5C2E$1;>*Z:8LN7JX
MI$)N9W[D[Q?>BTUN[$(PG]9\0TLR'^I;A5G0H62BI$H+63%%ZYF_B"XNAW:_
MV_"KH*T^&#,;R4K*CW9RD\W\T!*B@E)C$3A^[NB*BL("@<:G':;?N;2&A^,]
M^AL7.V)9<4U7LOA-9":?^1.?9;3F36'>R^V/M(O'$4QEH=U_MMWM#7V6-MK(
M<F<,!J6HVE]^O]/A)0;QSB!VO%M'CN4U-WP^57++E-T--#MPH3IKD!.53<K2
M*'P5L#/S*UG=D3)B51#[2?)*L]-?.";Z;!H8X-M=0;K#NFRQXF>PHIB]E97)
M-7M=993]$R  L8Y=O&=W&1]%O*:TSY*HQ^(P#H_@)5VTB<-+GL5;&78M=%I(
MW2ABOR]6VBA4QA]'P <=^,"!#YX!7Z)AL@8ZRC7X1F-60$_&J\S.1NW,Y-RP
M+<$U1V5#)&8D6Q'JJ)+(+C=8$17[T%_V62:+@BN-N39H-PO[[F;Y5%J.\K)M
M?:%KGM+,1]]J4G?DSUN&-N,M.SOR%IN-H@U(L%J)*A4U+\!3-I5A)VP2Q^ST
M^S.,ADGDM77C6A-[4UB08E>RK'GU\)UF.N>(\81%_2A"69RPL'\^'DT./*"&
M1=F4-BIW$E@AWC3&9N4&T-I '^LVZL5) L?.\_A\[+V^)Y4*34?\?A&SGR1Q
M^QM./!O4;1=OFS07M ><DW@\8#C[&/$TM\ F)_PIHIV"-HM*]SW'\.VCH+PG
M"5C8012]!/9(60Z[LAR^N"P52LJZW7*5'2G3IVKLJ).G:PS=2^4*^4$'>P _
M]W[&72*J#<[1@E=(WBE4+YK,+O$T58VK?H/VT,:F.^Z-DJ&W*"4.J#^Y.\5!
M&@Y* 9$5%:Y?H'%Z<(H5[A1#<4!=?(+?"2ME)M8B;2%>?1WB&MK)K:7Z.>3I
M:!"Q,^\:S%.YJ<0>..5*/;CHVBYJ)6^[;2_YK@N;&B9T;["[$3JWA:+9M]],
MXBCZ 76E4"96PD=^H]YDG,#SXI%Z3%8'V%URW6S@)+5T.")*]Q$_1\S>>9G%
M:SW;S:3*+W.+>N/1^-]*_0PX;JE!E/R_BC^T;K%A]P2!V,G0B?V?JO>9GZ@W
M'(Z^3KAC[./0<G\G[]J>=)\5U?S!G4FX=%*N<\<>QVD)BZ61Z4<;]3 .88D[
M_;!U3]@K]M3I%!R\14I2&_?BTN *R=IG2;?:/>H6[5OF[^WMBQ#)W^#R8P6M
M81KVQSB#5/O*:B=&UNYELY(&[R0WS'%3DK(;\'TMI=E/K(/NJ3O_"U!+ P04
M    " !$A6%2'8O, , "  !;!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6R=55%OVC 0?N=7G*(]4(DU(4#I*D J;:=-6C54NNUAVH.37!*KCIW9
M3FG__<X.9&PJ2.T+\=EWW_?=V7?,-DH_F!+1PE,EI)D'I;7U11B:M,2*F5-5
MHZ237.F*63)U$9I:(\M\4"7".(K.PHIQ&2QF?F^E%S/56,$EKC28IJJ8?EZB
M4)MY, QV&W>\**W;"!>SFA6X1ONM7FFRP@XEXQ5*PY4$C?D\N!Q>+,?.WSM\
MY[@Q>VMPF21*/3CC<S8/(B<(!:;6(3#Z/.(5"N& 2,;O+6;04;K _?4._://
MG7))F,$K)7[PS);SX#R #'/6"'NG-I]PF\_$X:5*&/\+F]9W,@X@;8Q5U3:8
M%%1<ME_VM*W#7L!Y=" @W@;$7G=+Y%5>,\L6,ZTVH)TWH;F%3]5'DS@NW:6L
MK:933G%VL>:%Y#E/F;1PKYDTS%?+0/^>)0+-R2RT1..<PW0+N6PAXP.0PQAN
ME;2E@1N98?8O0$CZ.I'Q3N0R/HIXC>DIC(8#B*,X.H(WZI(>>;S1:Y/^>9D8
MJ\GZ=81EW+&,/<OX$ LU4-8(!)73C<F,6:6Y>*:GG"%U%E47#&J.!I8@.$NX
MX/;YI7(?I7%=>V%JEN(\H+8DQ$<,7,6P2E"[JO5<U7I?J8VY+.@)"R93A'?P
MOK?>T:^H%5"3,%A;E3X -Z8AHS\=3*((3GI?E#&0:U4!E]QR)BB)5!5N39UU
M.+^#!,Q"SKB&1R8:A/YH$$=3XKE#M\%>C=IK4?N3#RU*AE7]5FD;;DM8*MD8
M6)>,*@K3P5DT[MT\6:I?PTU),\F^!3EQ;@)IAKAH-*E[4"Q-54-XH\$TBGK4
M,?]=$KST$L.]AJ]0%WZL&?!(;>]WN]WDO&P'QE_W=NS>,EUP>OH"<PJ-3J>3
M '0[REK#JMJ/CT19&D9^6=+T1^T<Z#Q7RNX,1]#]GRS^ %!+ P04    " !$
MA6%2#B<3+-X#  #U"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R-
M5M]OVT8,?M=?00A]L <W^F%;L0/;0-)T6(!U#9*LQ3#LX2S1EE#I3KL[V<G^
M^I$G6?4PV^B#K=,=^9'\R".UV"O]S>2(%EZK4IJEGUM;WP2!27.LA+E2-4HZ
MV2A="4NO>AN86J/(G%)5!G$8)D$E"NFO%F[O4:\6JK%E(?%1@VFJ2NBW.RS5
M?NE'_F'CJ=CFEC>"U:(66WQ&^WO]J.DMZ%&RHD)I"B5!XV;IWT8W=PG+.X$O
M!>[-T1HXDK52W_CE(5OZ(3N$)::6$00]=O@!RY*!R(V_.TR_-\F*Q^L#^L\N
M=HIE+0Q^4.77(K/YTI_YD.%&-*5]4OM?L(MGRGBI*HW[AWTK.XE]2!MC5=4I
MDP=5(=NG>.UX.%*8A6<4XDXA=GZWAIR7]\**U4*K/6B6)C1>N%"=-CE72$[*
ML]5T6I">7;V(5S1 ]#S(5%4(@Q>Q+M$,%X$E=)8)T@[IKD6*SR!%,7Q2TN8&
M/LH,L_\"!.16[UM\\.TNOHAXC^D5C*,1Q&$<7L ;][&.'=[X#%X7(H4,]X5)
M2V4:C?#G[=I83=7QUP43D][$Q)F8G#'Q3)<F:TH$M0'"-[!&NC@(]D!SX7PX
MQ>YE8.("JS5JYL-C/HB4:.[=$YBQ10KO8!"-QM$,ANWR.IS#T*/"I;*4,/AI
M2)OA:#:)26 P'R71F(Y9,AY%2=AI$4), AZ+/V$I+/EL%7PM_D%X,%I@"4)F
M\#EM>.OJ E_3GJ_I#_-%=PFUQJSCJ.7L%%,7(;F+W9A:I+CTJ4T9U#OTS])W
M,$FV0!B#UMQXGVO4PA9RVV8P%5J_ 65Q+W1FB*=X-)O/W7-^/?&>6A/&,2-*
M:G)"IO0ZA<2="9WF[BS#';7 FAJ:A3B)((IGWF_4=;/_^7 HFITH&]'VK@,N
MC"E=4_X/9]Z7$^>#5F#H%B&5PSD;[^"]^UU(8M(G,?GA)'[/'> K30Y#N]0W
M4>*FL*>2>1'Z=#+_(%(!N<G F;S^>O[JC2A^FB:UTM:5&M@<P5BJ=<Z,X1A(
MC(SE/'EVV!;!8#*:Q_.6ULF4[HOWDB.AT]43I8NV"Y$-V;PPK5HT"L=3N(ZG
MWL>6# -2<3JRAJ81-5JN*Z=>-[I6?#Z8NBLZ2\@&-2P:M$0AN^G"( YHW'!M
M\L MJ2ZUJOB,N[:S24)=4'V0;\P7&]KG!16C5"!/UH2!/6K62]56T@7/J%/,
MQNQ-,N9N\G(4YOLSI1,<C:(*]=8-7+I$JI&VG4K];C_3;]M1]EV\_2#X)/2V
MD,0D;D@UO+JF>Z_;(=N^6%6[P;96EL:D6^;T78*:!>A\HY0]O+"!_DMG]2]0
M2P,$%     @ 1(5A4ISO#!L\ P  @0D  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&ULO5;;CMLV$'WW5PR$ DD U1)I2986MH%L[@_;+K)M@B+( RV-
M;6$E4B'I>/?O.Z1LQ2EB9QNDA0&+0\XY<^$,AK.=TK=F@VCAKFVDF0<;:[N+
M*#+E!EMAQJI#22<KI5MA2=3KR'0:1>5!;1/Q.,ZB5M0R6,S\WK5>S-36-K7$
M:PUFV[9"WU]BHW;S@ 6'C;?U>F/=1K28=6*--VC_[*XU2=' 4M4M2E,K"1I7
M\^ IN[C,G+Y7>%?CSARMP46R5.K6"6^J>1 [A[#!TCH&09_/^ R;QA&1&Y_V
MG,%@T@&/UP?VESYVBF4I##Y3S?NZLIMYD =0X4IL&_M6[5[C/I[4\96J,?X?
M=KUNF@50;HU5[1Y,'K2U[+_B;I^'(T >GP#P/8![OWM#WLOGPHK%3*L=:*=-
M;&[A0_5H<JZ6[E)NK*;3FG!V<6-5>;M1387:/((7G[:UO8?'?XAE@^;)++)D
MPBE&Y9[NLJ?C)^@8ARLE[<; "UEA]35!1+X-#O*#@Y?\+.-S+,<P82'PF,=G
M^"9#P!//EYS@XS'+X;H1$CY<8;M$_?$,:3*0)F=);ZA7JFV#H%:PUD):MU"=
MJSL#5@&V7:/N$0T(64%5:ZI)I<VW\GO6D&O1"].)$N<!]:!!_1F#Q5\H=)]O
MH&SYH(:,C7[;>OF]+T_2."Q&O^_=HTXUEMRJY1J$<8[_@X05,$EY&$\Y_ )\
M7#!(QU,^>N7B),)?W6]$+;+"VLF/,Q;F:0Q/>NTI'3[8%(^!%W'(>6\J2\A4
MG@QXO$-=UL85YVE\FH9)6GA\FCD\'YU.$"M^1H)R;S6.8[(Z&6<Y64W3(4$L
MG80Y1<1H$Z;'F4JS<.HS1:$6_R9/)Z[DP7DB/,M9."WZ/$U3CX<SG9 .G9!^
MK[WX@]LK&TBS_ZN]SAKZS]O+PA+7M91.H!#N'7,2YD5&U\"*>#RE\LFSTZV5
M)DG?5RP[52Z4@*^NWP+2UA=C5#=$D+-QSLC8Y*<VQP^%]T-1''-RXOQFZ49'
M8[%%O?;#WT"IMM+V$W+8'=X73_NQ^D6]?YQ<"4V!&6AP15"R2EV@^X'?"U9U
M?L@NE:61[9<;>B.A=@ITOE+*'@1G8'AU+?X&4$L#!!0    ( $2%85+UB<4"
ME00  "\*   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;*56WT\C-Q!^
MW[]B%/$0I$#V9[(@B$2XN]Y)O8* MJJJ/CB[LXF%UTYM+X'^]9WQAL!Q0%OU
M(5E[/9[OFV]FO#[9&'OK5H@>[ENEW>E@Y?WZ>#QVU0I;X0[-&C6M-,:VPM/4
M+L=N;5'485.KQFD<3\:MD'HP.PGO+NWLQ'1>28V7%ES7ML(^S%&9S>D@&3R^
MN)++E><7X]G)6BSQ&OW/ZTM+L_'.2RU;U$X:#1:;T\%9<CPOV#X8_")QXYZ-
M@2-9&'/+DR_UZ2!F0JBP\NQ!T.,.SU$I=D0T_MSZ'.P@>>/S\:/W3R%VBF4A
M')X;]:NL_>IT4 Z@QD9TRE^9S6?<QA,(5D:Y\ ^;WK:(!U!USIMVNYD8M%+W
M3W&_U>'9AO*M#>EV0QIX]T"!Y0?AQ>S$F@U8MB9O/ BAAMU$3FI.RK6WM"II
MGY]=!WVPAFLO/)+:WH%IX&*-5K!L#M@M#&_$0J';/QE[ N6MXVH+,.\!TC<
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MZ3)H%6!"]<%:2*Z^$H63DV] @>,,74U!8I*):W2#7A=3='5QC2X0H>@E9:7
M-!$C6ZK]-,J.:^[[BML[P>VB)T9E*M C32 YQ-M*9R/6VXF]]SH)IQ#WD.]\
M19[C.2UZ'LZ!NR?AT[/A;M0"?^R&SV#90\[@)'QV_N[#CECZ3>)]P^=_EO@7
MV,H29]<=G$'#&1C.X 3G71R7>9EA"8FN;A(3V9:EBB0T)/KB>Y_<^)&GO7K?
MST:;F3^,HL;L0&/8: P[-<Z!QT"ENC016Z%5*4L.ZH9\!UI"F]AN-G_0<YS+
MCM#U&UG]3J+';9QB6HF*69ZK2U?5?OS65G454[07F+[;<]WVN P: 8-. 8L4
M<TA9E@ 72'4@(571$[I&11.P-BW=I,-!KQ]>MM5*-RYT/@GKL/%J^!_9AFVA
M&IHZG&RC#K](2:$RK[MOZ^76S>PZO<&Q:P<2HT9BU$GTPJ0J0Y/L.OQ?NHHG
M^E@5@1L<U\Y'J] /#VUF'VT\USLZ1/9>9\F!K\T;0*@36E)9-9EFM7EFW)GN
M:O\SK]XH3YBO5:11!BL%U=&S$*_Z?C61K#!]:LFDZGIFF*JG$G!MH+ZO&).[
MB=Z@>7Q-_@)02P,$%     @ 1(5A4ES>-) B @  +P4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&ULC51=;],P%/TK5A!HDR#.5[MNI)&Z5@@>D*I5
MP /BP4UO$FN.'6RG&?\>VTFC3J1C+[&O?<^YYSB^3CLA'U4%H-%3S;A:>I76
MS1W&*J^@)LH7#7"S4PA9$VU"66+52" '!ZH9CH)@CFM"N9>E;FTKLU2TFE$.
M6XE46]=$_KD')KJE%WJGA0=:5MHNX"QM2 D[T-^:K301'ED.M :NJ.!(0K'T
M5N'=.K'Y+N$[A4Z=S9%ULA?BT09?#DLOL(* 0:XM S'#$=; F"4R,GX/G-Y8
MT@+/YR?V3\Z[\;(G"M:"_: '72V]A8<.4)"6Z0?1?8;!S\SRY8(I]T5=GSN;
M>2AOE1;U #8*:LK[D3P-YW &"),+@&@ 1*\%Q ,@=D9[9<[6AFB2I5)T2-IL
MPV8G[FP<VKBAW/[%G99FEQJ<SG:TY+2@.>$:K?)<M%Q37J*M8#2GH-#5!C2A
M3%VC#^C=FT4\CSXBC%1%)*@4:Z/ \N!\J';?5XLN5-M [J,X?(^B( HFX.M7
MP\/;YW!L?(_FH]%\Y/CB"WQ3AG^N]DI+<[M^O5 @'@O$KD!RH<"ZE1*XY9TZ
MJQX;!@YLV^V8Q7X4SE)\/#^3R;1D-A_3GDE+1FG)*Z6A!F0.7)NFG5+Y,LW5
MW+\-WEY/_<O_ &_\Q3_ W@D^N\[V*?E*9$FY0@P*0Q7X-Z;Y9-^>?:!%XV[X
M7FC3+VY:F1<-I$TP^X40^A38IAG?R.PO4$L#!!0    ( $2%85*I\OR]9@(
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MI2H0] C@7!%0GX0R=QFD$S?FW$N[=(JGY"3?FRK.N+%]'S^8WPM"7KX[<86
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MPIPX3%OC]\M@-@O#<10MO/NVUYX?'(?A:-Z<^H;SN.$\[N5\C2HF@G1!@-P
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M 7I_S75)NXEI.OT_)OD/4$L#!!0    ( $2%85(J&0IN%@4  !,/   9
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M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6RE55UOVC 4_2M741]
M6AM("&4((JV@:9NZ#M%V>S;)A5AU[,QVH/WWLYTT BE$5'N)O^XY]QS'UYX=
MA'Q1&:*&UYQQ-?<RK8NI[ZLDPYRH&U$@-RM;(7.BS5#N?%5()*D#Y<P/!H.Q
MGQ/*O7CFYE8RGHE2,\IQ)4&5>4[DVQTR<9A[0^]]8DUWF;83?CPKR X?43\7
M*VE&?L.2TARYHH*#Q.W<^S*<+B8VW@7\IGA01WVP3C9"O-C!]W3N#:P@9)AH
MRT!,L\<%,F:)C(R_-:?7I+3 X_X[^U?GW7C9$(4+P?[05&=S;^)!BEM2,KT6
MAV]8^XDL7R*8<E\X5+'CT(.D5%KD-=@HR"FO6O):[\,18#@Z PAJ0' I(*P!
MH3-:*7.VED23>";% :2--FRVX_;&H8T;RNU??-32K%*#T_$]3<PO05B5,LG,
M=L"O#:,[XK:XMT1-*%-]N(;GQR7TKOIP!93#4R9*17BJ9KXV&BR3G]3Y[JI\
MP9E\2TQN(!Q^@F 0#%K@BXOAP\^G<-\X;^P'C?W \85G^-98D#=S*#6D1*.:
M=E"&#67H*$=G*'\07IIZ@/,>[SH);-U.54$2G'NF,!7*/7HQM.U5Q1,Y'ENN
M^SB(3,)]B_I1HW[T ?5#Z"E$T (>A$:(^FUN*L+Q&165TLZD%SD^<1,U;J).
M-VNT%QGE.U/JC/ $V_1'%^COCCG1-FZTC3NU+4HI[<%CE&PHH_JM3=OX FW=
M,2?:;AMMMYW:'@2_3B[1UTGS@9/\_SPG/B>-STFGSR>A"6OS->FLK$IS=TRE
MQS^ZF>VK^)/('>4*&&X-:G!S:^"R>FFJ@1:%NZPW0INKWW4S\SBCM %F?2M,
M(=8#>_\WSWW\#U!+ P04    " !$A6%2;G^'&C $   _"P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T-BYX;6RU5EM/XS@4_BM'%0\S$MND-]I%;25H0<MH
MT2)@=AY6^^ FIXF%8P?;:>C\^CUVTM!"B=!*\]+&]OF^<[?/M%3ZR:2(%EXR
M(<VLDUJ;GP>!B5+,F.FJ'"6=K)7.F*6E3@*3:V2Q!V4BZ(?A69 Q+COSJ=^[
MT_.I*JS@$N\TF"++F-Y>HE#EK-/K[#;N>9):MQ',ISE+\ 'M]_Q.TRIH6&*>
MH31<2="XGG4N>N=7$R?O!?[F6)J];W">K)1Z<HN;>-8)G4$H,+*.@='?!A<H
MA",B,YYKSDZCT@'WOW?LU]YW\F7%#"Z4^,%CF\XZDP[$N&:%L/>J_ -K?T:.
M+U+"^%\H*]DQ:8P*8U56@VF=<5G]LY<Z#GN 2?@!H%\#^I\%#&K X V@-_P
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MV].=?8Z:^ES'\%PP;2M][D4YL)D:P#6^2B2%PSN]%UX72>?3:^3(#,'9BJX
MN_7W"(%-3H.6<]7Q^J!G[RK_6#L%>Y-"ACKQ(YHA$*FOWMIFMYD"+_SP\V;_
MLG>^J(:Y5YIJM+QE.N'2@, U48;=,36/KL:U:F%5[N>1E;(TW?C/E"9<U$Z
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M@6F7N3[24)@ _7[)=4,W&S,UVT,R^0]02P,$%     @ 1(5A4L8[QQ*8 P
MLPP  !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULS5=M;YM($/XK*RZZ
M:Z76L("QD[,MU7:K1DJDJ+FV'Z)^6..Q6158;G>)4ZD_OK,+P;0'Q*IZI_N
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MB-@16R2)%N1-J4MD>(E6*&V3HL?APTKN_$Z'5Z"H;9$?!-WV3!I[)H.J7C^
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M%R -5Y)H6,V"Z_CJ)AXY [_B+PY;<]0FCLI2J2?7^2V;!9%#! 4PZUQ0_-O
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M;@'.KY2R^XX+T'R"S/\#4$L#!!0    ( $2%85):B85)*1   )=7   9
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M,;UJ7MQ%;RIL+$Q-76B.VJ<PU2EJ'DPL59$M1ZQ4KJ<J+WFWZVQ('#4E?8V
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M!\)LT.M+SM538,[0YLJ<_ -02P,$%     @ 1(5A4HPY29LL P  ] D  !D
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MU=!I5M%L.KSF>Z/YZVJFC<+>[QHOK<I+RWEI'?'R'>\P$W,\OIR*& [M0RV
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M^1;])9,[^N,62YEE<DL?-X+#0G$ _+Z2H$OS!?]>1OE'=%[\$U!+ P04
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M "DX\'IEK3\8H>%T_Y?9'U!+ P04    " !$A6%2#O70:VD#  #;#   &0
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M)97TRYPN/M3.@;XOE;+;C3N@N4HGOP%02P,$%     @ 1(5A4H1^.=<] @
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M]/7<6[Y<<NV^I.UC X_DC499]6"CH&*B^].7O@]G@'!\ 1#U@.@U(+D B'M
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M(<0WZ&L4N[8B8Z>?@08\T\40>NIB7"B(D+DSQIHP*$9E:A +O!L5J!BL*7]
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M#$W%6V>7'SI=5VA DN75R83*"R!M@9B6J2*WF_C[<'\0!EA2IIB3 ?$,5N]
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M4B "  #0)P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[;MM
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MC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*%%D%BJP"15:!(JM
MD56@R"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL"D56A2*K
M0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM&D56CR*I19-4HLFH4636*K!I%5HTB
MJT:15:/(:E!D-2BR&A19#8JL!D56@R*K09'5_*>L]\ZM_SA^?):=;?JW?#;^
M(V[Q E!+ 0(4 Q0    ( $2%85('04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 1(5A4BQV2A7O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ 1(5A4IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !$A6%2D5]A?U$$  !P$   &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ 1(5A4C5/.*Z1!@  :1D  !@              ("!E0P  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $2%85(D2WP\QP(  %4)
M   8              " @5P3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " !$A6%2PP%Z>)$$  "7#@  &               @(%9%@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 1(5A4N'CMF8D
M"   4#   !@              ("!(!L  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( $2%85+6.JKV&PL  .$Z   8              "
M@7HC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !$A6%2
MX!?>*T0,  !W'0  &               @('++@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ 1(5A4A 1O.#Z*   I80  !@
M     ("!13L  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M $2%85)!\#PX7 0    *   8              " @75D  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " !$A6%2G&@49X4"   G!0  &0
M            @($':0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( $2%85((<D_1[08  +X/   9              " @<-K  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 1(5A4L6:5W#9!
MU0H  !D              ("!YW(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " !$A6%2'?-W<7<"   1!0  &0              @('W
M=P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $2%85)D
M6R$I40T  ,<S   9              " @:5Z  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ 1(5A4H58IP_1 P  Z0<  !D
M     ("!+8@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M" !$A6%2.,/:GZ85  "(20  &0              @($UC   >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $2%85++4<T'T0L   T<   9
M              " @1*B  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!
M A0#%     @ 1(5A4G8LHY:& P  8 <  !D              ("!&JX  'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !$A6%2-PNPDB$7
M  #Y2P  &0              @('7L0  >&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;%!+ 0(4 Q0    ( $2%85(L6D\\G@0  .4)   9              "
M@2_)  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 1(5A
M4B"5W-'V @  6 8  !D              ("!!,X  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " !$A6%2WPG4+MX.  !@*   &0
M        @($QT0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( $2%85+[37Q.QR\  )2E   9              " @4;@  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 1(5A4L7WFN4S!0  Q0P
M !D              ("!1! ! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " !$A6%2%:,VCGP"   >!0  &0              @(&N%0$
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $2%85+14.5>
MB@(  (D%   9              " @6$8 0!X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ 1(5A4AG'/8!O @  # 4  !D
M ("!(AL! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !$
MA6%2<7HW63,$  #V"@  &0              @('('0$ >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $2%85(=B\P P (  %L&   9
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M970S,RYX;6Q02P$"% ,4    " !$A6%2ZSS-: T#  "("0  &0
M    @(&:- $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M $2%85)<WC20(@(  "\%   9              " @=XW 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ 1(5A4JGR_+UF @  ]P4  !D
M             ("!-SH! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " !$A6%2<'QB! H"  #B!   &0              @('4/ $ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $2%85+$_HF(BP0
M *$-   9              " @14_ 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ 1(5A4DBS7-6, @  %@8  !D              ("!
MUT,! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !$A6%2
M:G[5Z#$"  "V!   &0              @(&:1@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( $2%85*)FWD&RP@  '<=   9
M      " @0)) 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ 1(5A4KR>3\\E!   ^@P  !D              ("!!%(! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !$A6%2<6N"_H<"  !O!@
M&0              @(%@5@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( $2%85(J&0IN%@4  !,/   9              " @1Y9 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 1(5A4MQ9I36-
M @  ^@<  !D              ("!:UX! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " !$A6%2;G^'&C $   _"P  &0
M@($O80$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $2%
M85)+ZRE#I (  # '   9              " @99E 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ 1(5A4L8[QQ*8 P  LPP  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( $2%85*C[A_)DA$  %!'   9
M  " @;.& 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M1(5A4A''-NK  @  >@<  !D              ("!?)@! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " !$A6%21*H(3:T"  #L!P  &0
M            @(%SFP$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( $2%85*L0IJU0@,  )8(   9              " @5>> 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 1(5A4F0$'S'1"
ME!L  !D              ("!T*$! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " !$A6%2$FET/)T"  !K!@  &0              @('8
MJ@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( $2%85(.
M]=!K:0,  -L,   9              " @:RM 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ 1(5A4EU-CTT%!   M1   !D
M     ("!3+$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M" !$A6%24!-)3Y41   63P  &0              @(&(M0$ >&PO=V]R:W-H
M965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( $2%85)RO:V4*00  #X3   9
M              " @53' 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L!
M A0#%     @ 1(5A4K(DEX'C!   O!(  !D              ("!M,L! 'AL
M+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !$A6%2YDC&XU\"
M   G!@  &0              @('.T $ >&PO=V]R:W-H965T<R]S:&5E=#8T
M+GAM;%!+ 0(4 Q0    ( $2%85+QB)!UX (  %8'   9              "
M@633 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ 1(5A
M4H1^.=<] @  /P4  !D              ("!>]8! 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    " !$A6%25'K])^$-  "W+@  &0
M        @('OV $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( $2%85(>4^^"J (  %D2   -              "  0?G 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ 1(5A4I>*NQS     $P(   L
M ( !VND! %]R96QS+RYR96QS4$L! A0#%     @ 1(5A4L$PL]_@!   8"P
M  \              ( !P^H! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M $2%85+(7,%2( (  - G   :              "  =#O 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $2%85+B(3)"\0$  !DG   3
M              "  2CR 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !+
- $L A!0  $KT 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>202</ContextCount>
  <ElementCount>466</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Marketable Equity Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/MarketableEquitySecurities</Role>
      <ShortName>Marketable Equity Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/LicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - License Purchase Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/LicensePurchaseObligation</Role>
      <ShortName>License Purchase Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/AccountsPayable</Role>
      <ShortName>Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Convertible Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/ConvertibleLoans</Role>
      <ShortName>Convertible Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Short Term Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/ShortTermLoanPayable</Role>
      <ShortName>Short Term Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Significant Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantTransactions</Role>
      <ShortName>Significant Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/TaxesOnIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Selected Statements of Operations Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SelectedStatementsOfOperationsData</Role>
      <ShortName>Selected Statements of Operations Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Related Parties Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions</Role>
      <ShortName>Related Parties Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/OtherCurrentAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - License Purchase Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/LicensePurchaseObligationTables</Role>
      <ShortName>License Purchase Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/LicensePurchaseObligation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/AccountsPayableTables</Role>
      <ShortName>Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/AccountsPayable</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Convertible Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/ConvertibleLoansTables</Role>
      <ShortName>Convertible Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/ConvertibleLoans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Significant Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantTransactionsTables</Role>
      <ShortName>Significant Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/TaxesOnIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/TaxesOnIncome</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Selected Statements of Operations Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables</Role>
      <ShortName>Selected Statements of Operations Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SelectedStatementsOfOperationsData</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Related Parties Balances and Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables</Role>
      <ShortName>Related Parties Balances and Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/General</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesDetails1</Role>
      <ShortName>Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesDetails2</Role>
      <ShortName>Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesDetails3</Role>
      <ShortName>Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Significant Accounting Policies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesDetails4</Role>
      <ShortName>Significant Accounting Policies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Significant Accounting Policies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesDetails5</Role>
      <ShortName>Significant Accounting Policies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Marketable Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/MarketableEquitySecuritiesDetails</Role>
      <ShortName>Marketable Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/MarketableEquitySecurities</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/LicenseAgreementDetails</Role>
      <ShortName>License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/LicenseAgreement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - License Purchase Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/LicensePurchaseObligationDetails</Role>
      <ShortName>License Purchase Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/LicensePurchaseObligationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - License Purchase Obligation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/LicensePurchaseObligationDetailsTextual</Role>
      <ShortName>License Purchase Obligation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/LicensePurchaseObligationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/AccountsPayableDetails</Role>
      <ShortName>Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/AccountsPayableTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Convertible Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/ConvertibleLoansDetails</Role>
      <ShortName>Convertible Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/ConvertibleLoansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Convertible Loans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/ConvertibleLoansDetails1</Role>
      <ShortName>Convertible Loans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/ConvertibleLoansTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Convertible Loans (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/ConvertibleLoansDetailsTextual</Role>
      <ShortName>Convertible Loans (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/ConvertibleLoansTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Short Term Loan Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/ShortTermLoanPayableDetails</Role>
      <ShortName>Short Term Loan Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/ShortTermLoanPayable</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Significant Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantTransactionsDetails</Role>
      <ShortName>Significant Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantTransactionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Significant Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SignificantTransactionsDetailsTextual</Role>
      <ShortName>Significant Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SignificantTransactionsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/TaxesOnIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Taxes on Income (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/TaxesOnIncomeDetails1</Role>
      <ShortName>Taxes on Income (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Taxes on Income (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/TaxesOnIncomeDetails2</Role>
      <ShortName>Taxes on Income (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Taxes on Income (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/TaxesOnIncomeDetailsTextual</Role>
      <ShortName>Taxes on Income (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/StockholdersEquityTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/StockholdersEquityTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/StockholdersEquityTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Selected Statements of Operations Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails</Role>
      <ShortName>Selected Statements of Operations Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Selected Statements of Operations Data (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SelectedStatementsOfOperationsDataDetails1</Role>
      <ShortName>Selected Statements of Operations Data (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SelectedStatementsOfOperationsDataTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Related Parties Balances and Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Related Parties Balances and Transactions (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetails1</Role>
      <ShortName>Related Parties Balances and Transactions (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Related Parties Balances and Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsDetailsTextual</Role>
      <ShortName>Related Parties Balances and Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/RelatedPartiesBalancesAndTransactionsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="wizp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ophthalic.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ophthalic.com/role/SubsequentEvents</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>wizp-20201231.xml</File>
    <File>wizp-20201231.xsd</File>
    <File>wizp-20201231_cal.xml</File>
    <File>wizp-20201231_def.xml</File>
    <File>wizp-20201231_lab.xml</File>
    <File>wizp-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001213900-21-012577-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-012577-xbrl.zip
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MF_IQ6Y>/NVR2"7+O'?PJ'S0]I]/2^\O6QY^0+P3>\;UAS,,7)H8WI(?%#RG
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MW"6?#?<[VKKNFLWO_)^[Z]3OCS2<DP9!;J2-V<B<&9;WZ]%Q^^BW=E?7X7X
M67,%-%L!^H*-$+A!$NB%[U< W>F<ZF4!G2A,N!20?J^[#ABAG96TW*^&>^V2
MY6S\#\,*V%?FTK$M9?\5KJ"LY>K+1Q 33IHH/!4#LHREK4DENUT:/>)=>5[
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MVO!9HZ J[H#33%LSX)\9N@XT9Z+]!*!KWM2P+&W(M#$P"MO1T&WC:OX4G@3
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M VZ%9(Z[K41)B<)PE+&0==IX];>U$+F#^)ZL4'P]45[[ "QE!$=HDXU88N,
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M8'C3AHBAFP3VV.-1<F-N28.5C"FWU7J&AV%1,"XBT7G4#![U(R#G,%SRGT1
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M1>E:U%[*Q):X!X6EAC_-31YH8$DYE_-@:)DCK%, @N<HQ!B_+A]0  4Y=F0
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M[MR("N@1#&<>+PLI79EZ(W-MJ0M)F6O)V@X;5^3>Y,>P9"0EE:O#I-A6*;N
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M1/HN[XOM:5>>:S#+#!4B.+H&(4-Y0YZ1B>EZ/J\7B=J.!4>?/#P3X\%QHTN
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M:G@^,CYMYKA(06.0&.@]/#1X1:*< (2Y7$Q0$> Q]H.."><*E +O.G,'KW6
M#,N7.N+6)"#9/6)AQ.:^;%)-2P9:Q*Y>(J<VEFX;C4*KPTQ:YP$P-Z[),$.
M0:KDN=68]&MB$S(4L6;$'9'%B+YF5'B$/<U-ETLJ7&%IM4B\; !%$A]0.;=
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M%:XHR-#]F0I&8L6L2:S>JHHH65\M45&#&$WXF^'"#X9KLW$,$+K'78SMP8)
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MMG8/!A8=L&"66E.VF\ ?Y>4GOE+)R7FM]PP;2(<S98$WP<JPZCO: H9#0'+
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MD::1,@A(R0Q<L!0-:#!,2?&??_,&XF1]= 9Q+@FPKUJE7E?6S1QF!2B6V"1
M#8S-@9/'T[RX:PFP].]_=6JUZH=81''_"'UM?< 4H#^1@U.P)_>X:"!K"2X<
MY\G$K&CN4-".U3N5=F<9^"GXSM%3@< !1POH3BT@! Z:<4J EGUQG$(-!<?
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MB,#^U,60ERJ(BWECB&QF\K6R8Z1B64"MFXZGE%9-#*KOB-C*KEFS.J*\!L]
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M>*5T^AI-RZQU:HM9(!>%-U<WEY+?"9>"D'ZQ"%,T)2LO:$(O9I6XWVC\>7C
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M<,S)0FA)./C9&%A2']Z]X#C"@;-*R1!+3DU](EU_7^UP8/]MB#@L@X=H(V
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M9 R[&.J]3BR]U(FE-!^J%!Y@)<$D"T'5LG8N9V $^IACT@D\:((EKLP6C64
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MG=,;I2>1VJ]K$E4LHPH'T"A*PU3DJA9$"<Y.%N"']F)L#<I]M,I4'_8<_QF
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M(2B*+!I,!>B8:*R+W<K.?U6W<MF-6W*WZK?HZ&"A+^CGKT*KK7+^O8/C%;W
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M!6TYPS"+Y!H%RGI'N"S'*>X,!I%I\+^?GW]AWNQ(!?/-_+P\G 1\HW+R Z]
MPRPY_LR118N2^"H,*,")CQV$28A!=%@U\PF:AWS*5\S9@=SKOEAXRA3SC5]
MED"2>C&\,]8;\UPQ\TLR!W"EY$5PP<! '(TH+ZDR-W@MF@6QW(Y _+O>932.
M8K0"!4J8\>W21,#L#<9HW_Z;&LUB6(O+:8+<!/@K>6>8'J!,(?RW6=DNB7<8
MC,KO+I+)S+O.MN K6$\ P4ZQOQQYQ?"7:4+I&9W>;NE[YBMBF2<HZ[EZ4W'E
M)?7%&T17TVPH17*X92-]]F$(^ >%'#78TP@(^<A]W>F7)X-3+8&"A-D(B@H3
M"2BIJ@B8K1MV?1Q-QW *P++ 26&@O"S^DK1#!YN[X=NYA#6DV& ,\%JH;!K^
M(!BS3)#==!K@H:HD'IP)]%7L_JZ==U\NUTW@_CQN+?0-"(43,O'$WC"V2+*P
MY M."&WRED2:8(Z&OAJD[]T/5I'4:1>$"C_7N7QWL5M!HV@:#T&D5@1#]7OE
MFV)Q5 .3&)E<W$%56*M9"U]=Y?H9\I;4SO+@8;B+]\YUMJ/<^-L^;'*!NA4=
M\HA4I1#;+[5^^ZU$A)[%^;35YQ"NT4'HA,0QM3<BR0J\JRE>,EE89"D1;Z$@
M@1R!Y<#I=.Y?**.0$P#MG!G8"\SI@P.*:=T1!^'MC#ZV"\@*HAE@#F=&=ACK
M9&DN*W@#&$AU,,"+<O^W.2;+9G[<;BS'!#T1V $*RG*F$\IYF9Z.\^[TV%EX
M&R;3\%'](%8@R\\6K?KFG/^AW@+66&8;.!=21<P/3G[6=2V<D_GQ<_\<<X*&
M83C2R*'/@4,G_PY^@<;_'F4NB_$])R-/V?J65WLI6B^'R8\H1YQFB1'ZBYU=
M\K)[X&C#E;9S&<2<K_V>9_I5) ;U[3\#N->FN5SXDA:@Q_M OHB*GX*HH4U+
MP79RW#*X.4$[$T-&J PDLKEXH;C7AH>2RTH=;E',H@JN2=>#XS/EU109QE_2
M1%A7\V3P[^(3T=.X(3=8UQ3"'4WA4,1@-/G&PLO#:\XN !]X%&+RN0_?*NA7
M[)*2<XQE%%2:^:+T^P;*=J8D"OHPZ"-"=J'V!46140T!0^\@+/!LL6UUW0"=
M$W6()G)^.'&=CE2.TNO#'@_9!Q81\=E>SH=9-& ))#[8(V[NOMW2A^I \%BT
M]20GD"9"N3QF6ZN[CUL0%>Q?@?&&J<(%_<+*]NW@4W;>XR_^2;]@>!#T554%
M"@1YX9WVCV9DE^PH(DTN"P/C#NT;!8+);!/&7D1A&]EU<YX1T!%W00VD@:ZM
M0#VV\$HMKL$.\6K4&>*D)R)RZB-":*S4L*HD^6ZQ"U? 4=W$("SNPC"IJ3A5
MY7RJ&BD.+3H'<Y>Y^LE7Q4FA=5W1Y4?%%.Z'$7RS2O>4T^CKR=#X3N*[60U!
M2V<=,*N$!+8(;E'ZA*I-ZWKG3L<IW8G%UZ^NSGA&\5/)T#-30/31/;#:%@ER
M<, *.IR<B ,;'V8)%H5Q)!:;"N,]#\*0PSU;HN^P1__%+@[.!<.U*IV>[J"U
MI&)1[=)-8!>>B1:6HH@HF4R+7/.3\3%2X?!J?<5LP;I"R$>0C8]@BL7>@2[R
MT8^B\6^B, NRX<V]6(11<IO&B-#:E8HS=A<D[SJ@6A*Z]4'__HMOF]K['R>
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MV&JF)X$Q?/Q-&-!<=^K?AF-+S9)&<Z@'DC2 U-VI/7VK/X=G_6Z#X;K%*U>
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MLNA/..GGS'(_8S'TNU0([9<BOF^(".$W'EPYH&(N#;4!]5(XCWYGX='?&GX
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MH$MN+MV_]X179!+<L[=]1W0^TN62>(?@P]0D4SI9!HD@U=17 '\S3D=A3&F
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M_?5C9C   8JT^  EI+*[$@3,]/3T]+M[G,YQUSGX&6%8^Y5A_G,KA?"?6$C
MV4T75^>6X[QETKK6F'J\T&%],%R=_;_S2^OBD_7AT[N+W\ZM)4 I84BUN'9N
M?ZEI5X4U[K*%-4^>"9B2%8'*;);0%G)4WM:!X&J?'V>6!<C[>DXXD0U0S(4R
MJ<Q.^V=X'5MG(T['$8$[0HL%_S!UQ\+Z)AZLT:T;W C*N?]Z:26P1[Y[+TLB
M93DD]2(1,:+;0X79FH#E \(DFH6XGRKS*Y'[JW*:.LY/."IHW"!>A4Z/EC1
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MF;4@L%Z2M[;,?L4/ZR^]F@7532[/&YK% ]Y;24Z76I_Y)A9HC6+/M\?LT!)
MUL-982!K'*8 RIH9:]7 IO7:[7=66?'Z1-/VT+>B1'\<:T.G-72>.]8V1W3=
M5G>C-/=8"+A.<> FO+AOX47G=%5=M'[._KT-XS3AQ2:\N.?X;<*+34BOCK T
MX<55]>HFO-B$%YOPXE("Z<E1Q\;!W40(&@3N,0)WXDANHBW-@O9I0=N+0S8A
MENV%6!9I\,\D6+#V$,MB"^"98&US1-=99$'L48BETN&V^0J[ZJDW-.$:2OI4
M*X:JLCZKHJ1ON%\E?69CMO7W8&L"<?L1B&OJ_'88\&@"<4T@;L_QVP3BFN!7
M'6'972"NVIPO:]:Q(!&FYN&5?L=NGU2GH-4ZOO2$J%JG=5J=M5CK1:]CU_NM
M36SY1CUV^*@IPVO6L;UUU*(,CSYXP05V \<>]E<V;E]XC5WK='EW<1,!WM<(
M\$)165ONW 0^7]R"=BU(>XN"L^6M%Y<^_<\B0"9O\EIAS?L885Q[7+;3&BQ?
M_;^G2-L<U?5;PXUBKQ&QC41Z,0NJFXC-Y3LU(O8O@$^[UU^^6G)/I<4&1&S_
MV>>+;53$/I_B\B;1954MY#DFNC05YTOM2Y/H4B>\-8DNM<%OD^C2))?4$9:]
M27095IZ&>J<\H 76;E=;G;7.^7A"HDNW-5ABR^JXZ/4DNO3[ZU_]"TUT<?I=
M>[@@3K!?/CAG$6GLUU*JH_W[Y45L,EZPI?3 /GG>&2\;Q%ZG-5C90="DOC2I
M+_L9]6D65/<%[5JBKISZLH)_]3E$2!XK?W@F(:8-Q.46E$\\$Z1M,BZW69)K
M1&PCD5[,@NHF8A]-?7EA(M89.O;):9/ZLKJ(/:GV3ST3I#T?$5OG>Q4V#\-9
M,I_?9V/OG$A8]VY,D+SJ(B],PL3UK32(Q"B\";P_!<;6IC,1Q"ZR3_@E3LQV
M/D$8'-^)&'_C- -N[A/#X&YB><AN9V(D7[X6EC%N"/S?<JU[&1P^EO%@ F8&
MRPRI!UN[U:<&/W'+NKH5EA<DD1?$WLBZ<_U4&.D-C_5TFT, KAS@3ZP8\.5-
M0!(%26MW>U0'.D$,OX/M=H,'*XU%3.V5Z$@?7XYN0U\PJ3#&CS'K 9$]#<?"
MI_Y-,-(4*,.:N%Z4;9"D"/@I3D+@#G+#6M:_O>06*")&"L'OLQ?E*T2CP#7B
M;\>32,!/,+CJ&^5A>@',2-MX[<9(40&]_[5U"<02"3=.HP?Z)K;<V2P* 6""
M+N1F4F92 8PU)?I7[:GLC'+O0B!WS_>2!YH+-)912@> 0-%3JWP&XW4YH$(I
M4N7$N\-3, /019# BW>"3I@;>++O579B)$R$M6.>)T/1B3P6&;7\]4T:']^X
M[NSM)7X!^P6<.3[_(P50/H6)>._%(S\$I(@KV/]??'CGY__Y/U!6_/7>^Q.^
M$CY-? E@B2E %U],+N DTLF/W[N)J[\CW,$O7\3D;P>_1N$4#]1QVX'_)R']
M['2.N\[!S^N@VY6[FV5I@V::8#&-<&6@?B W, EG2T3Y3SJS[WI!",^JL.4S
M+#]=7)U;3N\M.XJS!$L<+9./9=K"^F"X//]X_N[J_+UU>75V=?[;^:>K2^OB
M5^OB\_F7LZL/%Y\NK?=G5V=+ +B$+%\#B2W)@?>7L%:/^W=ZZR!*M[4MTON[
M"(!5^<1"W?'4"[PXB9B_(D<-0)R]W3&5-9=P/>:=6E/L3J>##5;(9UP@9-:R
M\9W6<"X<5YB'6.%_LG:6!?Y(Y&!M'2!3<RZ#:&V[^ />HB?0V-ZET6ZAC>1>
M8^<YU!X\!9M-]NV:LV]/!E6IAQ<P;PP&I@4JQIWP*^FNEBFGU0DDM<XW?<H=
M3>WN^M>\DPL0Z-U+PR%@>N=^_ 1O))34Z577ANY74&PPK,[1KG<TK!2Z+R U
MR4X*)Q-O)"PLN4E$X 8E14R[17R_.HMAORBH5ZV;[ O7^>P^1& 4$N%<@[$]
M\9+YFL+=8GG8K6Y9LF?T<E*MZN\AQ_D<A1,1QR"C7-^*170';(>]W:,PB%,_
MJ:/\ZCOK2MS?]4I.^]7ZS[ZPGROWNR29!+A0W3C/X+F02F=='+06?.>]O$/&
MBEW?C3@"YP'#B6JHZS@GSX6&G.%>L9MJO]8%IDBLV#AA/:DY.ZTP<9SEF_HT
M13KE;+1=;3'6IDQG&?9::T;39-_6DH$N3E!\PJ?U3@BUVRL<^CW-"-T U@8G
M&\7:4IF@6XSP^T_J@];DG2R7#7*]M;R37SUTG'JNK]),;"L029-JTJ2:-*DF
M3:K)WB93-*DF3:I)-3:;5).-NBTSG<(+1N%4O'WN9NJS6]!6[.Y'TY0^$/58
MDRB<H@=<D/\[$EB9P^5<X02%]3?!JEXL1FGD)9ZH=GG6NYV<8SL+KM:J=7;3
M.I:_@<2N7;/#8D/Q4Y2E2L3B"X /J1F<?Q_=NL$-5XE9-ZZ']6-@BM6,U3R7
M:QR==77GVTE(>06Z^CM0$K-0S+7SA6:<GB_B) S 1/;#&+ZKV08->\\EGKBO
M-X:NA>ABD20^E6-:\:T;E<CF'?.!!4U[&S+;(D-;%%9<AN3.IB% ]Z=6#&>1
MF'KIU*SV'X4!+0&513]T5[U38%MQW?5?V;KAGHLUP=LF4PJ 66[XTMN=</=E
M#E9M&5YCQC]35GY%75PF!2_2BV,Z'=OI+7^'9<.YJSCW"JV:&LZ]GXSNV2VH
M[EZ%N;2!QL>_;PO:(W?"V6@4I6*<-<VB5FZ/&7//PQS?]3H.>RMZ2HO70M2=
ME9415QT)ZG#%<N3YZSF>QX'8([[U,8QC=H/*QI%9U#(8NTD8>?X#_&DLQ)0B
MF)B )&+K%^MS)"8B@K]85"Q?LYT\[-J=]HK>^88:=\/=3!+,!<ZQ!2*\CH[Y
M\!J&YC_<%WI:3M(DC;#CXYT(TMHY[P][W2<*IUVOH$YDN"6F^*68P+'7K+"_
M(&.CH< :,<)?PB"EAD=![(YT,^C:<;3N@LO9&GJJ)T=[QXD['O=OSG>/7BX_
M[7ELV:[7<=CO/)$9UYZ)N0$VKYY./>I&HCIN&YEC=:.MP^Z>FZV'*S8#V 1)
M/8V//34<EYD0\ 7\.?7B6TKH82LB[X6S#K%7NS4<V=9P#/^(EW=+:)-M\40$
M'IXNZ"7RE!MJM\?>F_#<LU[0_C/U8HZ%#..]/%[3LP?=Y2^;;.[#SB'/L?O]
M]617-*RZ'ISMV2VH?JRZMPY&75X;5'7R]KC#RF''[@V75P>K6ZPLSY[W&EO#
MY2O?E\>5.D3TH^KV\=<WJ]Z[E;^O:W0KQJDO+B8RF2BX.9<WW7P2R17.HC_<
MZH5=RW7!:5J.-"U'FI8CFZ*Q/6RJT;0<:5J.5&-S96UW;V#9M8)-[S8M1_9]
M04W+D:;ER-:7W[0<:5J.;&T=3<N1IN7(GAV9/6)F3<N1ETUF3<N1)\0(FY8C
MM8NM-BU':LCP&C/^F;+RIN4(^VF;EB-KX=Q-RY%GS^B>W8+J[E5H6H[L_8+V
MR)W0M!S98<E-TW*D)ANQY[5;=?)/-2U'GD2)3<N1O>%N3<N1A@SKQ12;EB.U
M6D&=*+!I.=*T'-E#CM:T'*G'.IJ6(TW+D0TL8/<DU;0<J5YO_4).3;;%$Q'8
MM!S9+<MK8B?U5TZ;EB-KXC5-RY&FY4C#JI_O@NK'JIN6(TW+D>?4<F2%UB&J
MYT@:']^X+GR;7L?BCQ0.P?D=-BO1+^Y=CQ&SITBQY\C*T/U (Y$DG"WB2JK6
MMC/[KA>$\*P*F_[X&G_X='%U;CF#MVSQ7FM,X6@9O90=F_7!</GUE\OS__OU
M_-.5=?XO^/?E$K"4B(6,K/6C+9!5GL$\*P);O;BXTUL+<>8G?IP4RP1W\>P_
MG4RO;H7U+HRG86Q=93&HC%;?/@-BW3P,%P%-EO79:=L62@.;(B_OPNG,#1XL
M:G7"&5TA_>$7;VR=W42"ZQ IQX'WPK;N;[W1K77OQE:L99'_8+E3[BL4!M8_
MW2!UHP?+&=)<CC4)(X("1YY%WA3_.$NC61A3Q"?VIC,? (;#29-?3"8"3U64
MCC"7HF5]A9&C$K@. 0@Y[Q$O:.9&&"ZR7'QG#(_<Q%PH07$?IOZ88@(B&(EL
M1MMR,;X^.>8(E)6XWT0(AQJ?P;]3 L*= :@CXC%G@.8(4 Y?^>X]8 9PYX[^
M2+U(6*[OX\J2C(8OJ983,$PPZ @$H,8:."W'42"^CF79)SN+IU- :(QQ?'I5
MN*/;W(BV=2WR>'L7!K$WE@W,6INBO((^WF[UD0KG#8'[S**LP6D@0M*DF",F
M(-5.J]O51Z)B$\(T41M;@FXX*;#QU\(Z^"* .#QL+,=9& =X6OXK1@G/#I3"
MSRWU(GZ=43:\ */DCJ6B9*X]M]YCTP,,9G6'K9/A8V!KN-XA18LQ07&IPZL'
M+>M,D16-<!OZ2.WWMTC2(S%+8F/)AT#Q!V?T&"&YS#XX..*9@C#!V68BFGH)
MUY+2C+' <X$MR$8IL2,8U(NL(K+@K"6>;YG-P9B1'"(0![_I0GQ$PL%1R_H0
M6"C<$8ETBDN!BPF$J?M X(GO(AIYP(#N0GJ1+ (\GSJ9"W X!Q@%=1"(,:(?
MWO#B.'61C2P@"EX-_E5#SDP9Q@#$5X +0R,!>(G/M;ASN/, 7+F=5K:5+>L?
MX;VX0W;F3:Q#2754S OZ"5:9^QYLBB0!X$,X,X![5(DWFCDVI\8HZ@.MOA0$
MV'K@52*_8MJKO-2Y=7E+D.T2$ AE)$ R '.$G7%!6(08HZ4?9EBMS!E0.,C\
MUH0L(GQ8/O)LZU6[U6ZW'3HD.LU \G:=;0!_(!B*P[6LJ[))#G$PA'WLW<$&
M!V,Z%Y$(@R-]QFX%B)?KA]Q2 >TB'D7AO0:S%-6O&2'7(A 3+Y&$$Z? \Q-@
M>Y8;ER\=*"5#&\W];^]/@3N&<BC*.(R&UJ(&C'!P)K2:XH@$16'45 OA3%(9
MF\4[:"_>-(4UU!)*5P+,Q_<E#F!TI%=11&9K\Y)D/Z7;!]!HQAX<,Y\5G4GH
MPV%0VH$I.&PZ%"[PKBD^,K05R2KQU[SBPF+ U);FY06\!<<>_6TCQ6#@1(?W
M :I-4?@=-#\$SAJ>M ;]G]24(%+C!.!!2/*R=F)N.VF>OBA0H/CNQ72*Z)-%
M8$1BZLJ$(X!(KC$/E]-NG?P 7*24P5]=:Y+Z/O(&/T62OG9CCQ).^#@%(S^E
MP>[=" P:%*DDY5&$,(O/+RWS8+KC.R]&OL&O&"EYC7Z7.P&?TPC%<6*5F3$V
M 0+V1X;)_)DP&38Q<]*_I/:%,EVE?_^+I,<7UA@,<X2TDW?_^I(](X4HN:69
ME0&EY'">C%ZS/>7! :8\7AZ,^/BE\?S@B%@LD"\0W%C$@ )JUI%GD8M7JN3(
M/_BTO 8V/(,C#N""OG(GR*P:@P!"UHOBP@N.;"U%]:J5 :;>3.2K+9J\N!,Y
MK-AERJP\1[1B .=8_4TF 3Y82B?U2*:-!(**BD40!L=T)( KD6$&<TG^)PTF
M\R03NYI7ZW-[08O57R_U!4E'GTS8$#%AYOE(U5>K1SBZX@$VJPLN<:/>V[:3
M':-9:]JRSMT8:#"@8Z&DYAA46,_@];F#9SI>%AU7UM&T+70./'U$NT\SF1LK
MF69N!X\0,C1%X:'<$$E"]"XITZS-\3X96H%&)Z)M9"K*$AB@#53220&@K^>T
MJ3"GA^3.!T(+@P9BE%5G5$B,CQ>=,^LZ!2(3<<Q4"W8$>1!&J>^BA(/5*9&B
MM#M3)9];@75X?RMX^]WXUF92L5'0BH0T:**->S [CN9\$Y;A)"E=V2'J<YG>
M?3:9>#Y2  UL2N$CA;A2;("V32LWG&K2J<,,\I&=MRT69 B0!T8#]YF4VUDX
M%#GPB8DFMUXT)AS3(7L#D!]ZWI'VW8!<AJUA0'QO) )D 39R1N.WL8=:XW7*
MH"/9^3X=O"@#AFTE! *'58#QPL7H-H#C<$.$1(\^1^$X'24FD,Q"$5#; A,F
MGP@O0XI\E$<@@$+R:8T%CL)IIHA%8/-^'HUN$8VD?F4?(J#I#,%XU6VW;;!?
MLD-1B5GB/4D8?L/O8-@T4E..P1#TPYG*/2Q#@1PX0D=>K-]2HD':1J9X:,W[
M77<BZ^N@;ZS"<*^DI9EW8;I^3&VV4".(M6HP ILZ,%1$D/? K8'CXW8!T2[2
M[#5= =\!<27E$2R1CJN:.$]6OX0N'$O8^_<>L(XD9.4X9\!F\F;![,PEB27&
MB6V5.!\RAP,?<IH&8+*F@CT+O."\9B,M#9<,1_5JZ9L&R']ASF*@LGB($%@I
MFP5PZ45(-:P+MAGN0"UG "(8'G=& OG.G7F)Z]O6AV#4(IX=>U,/Q(F%KRE%
M*K0$"5PX^U@I&,5222#9&,]\+YE7#TWU@Q;W^.HL.-*@$GDQL7V@#)1>((ZQ
ML24P,)99L)J;R)VR;[Q0S=@C'H3_&)Y%E#XF,+;$Q UJ-( )&' Z2Q82BJUK
M/X"LJ?D<4SBZTHZOT=_ G.?R*Q"N\3?EI@N1Q0&#10<C;KYZ3I\J/<G\SFC>
M"5H8'':736  <,1H !&M@,H=40*$M?'/89QHO?2#QN9GWPU0+^^WR7;D  EN
M9!XM\!OK[8'P+<2P-_'F=1NEM6>Z0-'AR^P:C=FQ/@6E<V0V_"%0.+.:#XF8
M6J>_P#>P,T=(1G?D^3,J6DM,"53B-:H!/-CA42H]?.H/4GJQPLVT"^]$R.3$
M=.:'#RR%2#..4Y]4,,V.YO@-$>)O4<OZS8W8'77IB=&?WP"MWZ2E=NMZN+G%
M+^=YF4T#?0K=*2 Q$ $PCQLUAB<FUOEWT,UI)R] IQJQ]S!GX</W!,-%9)V#
M\C8W0M;<I6H$]ANR:8!:Q3$Y]!@Q0I@]%Q%6#>9?Z,-#VB/FEU7[A)^FL:##
M&0D72( #X1CFBC@/:@*G@46*8=@&XMYF'0DALBMV1VV']%M+Z @XA%<C!4^0
MRX>:"5,&XJY%<B]$,&=D,7T:'KT/^ YY'HD' 9_ -J@4L;M&4R^14;VBJFR;
M0D+18 Z5)<!*X,(\*R)_:RD:4$\&(Q<0OPPJB &CJ #S(,.P.7(LHCN@EKC@
M^UDD8-$J!<:;W/H/.2ZNA.G7RU<.\VL$"'X[L?O P!4^@<C]A^UH</OI05I%
MHWL7!I+#28>KMC8%<Y3,\5T(-5;&WHT@RF?E63_+CJ$40Q\^GQM/31^34K/<
MT0C&Q# /C'N'DB_*??U!/42YE5DB97PR!'/BW?E%RRJZ= I@L#YWKX^\"EF9
M;^MI,W]2_KGQL8XL4,PMC6WF+2 ?[_ @S'QWI)Q)\/P&O@.^*-0YZ/1+%)>Y
M<+J;S0+C<A3O5;OE=%"*\H<VV9%J>!"T6-N%\@_ I$%?=5MM5"_\HB$ME8F1
MRUD..69D*Q<'GMY8Z0'WKG='AJSAKP(=/B7Y>%_J!T%V'Q?,[-Q,;,<:6X?<
MM8R[,8_'W=;C;9=3Y$]C&?NH#9>X"*Q?Q77$62X<FX:MQ]CC^$:JKBZ>>0KI
M6?IJN<P=9>2.7.8=@WP4^+B_TW6KW(RYF+&R,>__?EC?N5WHJVV0>H 72(LY
MIR,IS4&^)!O\R[?,6+Y9IHE:A^*>RLHS_HSEFXH)YW@1\A30"F<8P:%3K)A3
M/NH$0KKC* [";!/&=GUR;']M7;:L.)S=HM-R1#HBZ]\3081!S5X+#%ZR-&3N
M%,8V5SP'.!DJ:4#N:?0O  E2$!:&!:)T,9YU+7+H($&5,56E=Z$MRZ_%;%5*
M?GKV]56GV^H/F1$IMFH=BC]2X.2^S'9!O678<@9'J*I,\$I&]HQA) !XMGBP
M<CU0Y*1EN'2&?85,#N+/KYQ X=63DN:FZ,"CY$U2J^A%*UME['UGI0N6.4ED
M%+R8 =+2E!<K:TH*,G37JU9I2AKJ/6*:".8BCD7:*:23E>RC=.1)L(8_D0QS
M@R"=HH+_0.: G,C8)UR&EE?HM0;ZHO@,3_1:!_;AS\5-;UE?Q!AL&%/3J80O
M' &%P7\"0+$W87]$'/IWP-)8>\*.28EZ+9^'H\R$#;.:VG"V<K)5&XUVO+(K
MD*/9A=RRG.,/S:G@)K;5OL?I=.J:&\892S)EYS>@U:Y38*7LU'/1NBP8G)1!
M("KVW3AEI-M0>("T7:1OCJH&.F^4;ZJ*453.,5\D6U1*X&Q(EH0SQNZ4O0^Q
M"F@N@,&,IY8P;ULZ)B4^@?QUU@UA[D$RQ3PKM*UT)D^4<"/?8[L?N 7[C 9'
MBFOHM+%BNECU)I._ ,;W9;1*N506Q" !H9_<>.S^81-V,X]B21IC(=Y9Q;R!
MG[9;W>YII@^_G$,H]P8,C2!6WA5R*TKE/_-?+]A'E>Z5Y4E-=*HB\G9.)\;?
MCJ5+<$3"XB8B\3'RHE'J)=;AV>6'=T!.()2!%F ?QO=HFW!&8SC&<"5R<E?>
M6AE3S#$<>2Y;@)/(U>G4'+-B+S5("R_F_)8XV3Q_74J=K,'.*ZV2IG0&AH(/
MXA2$\<A,+5?\<X3L"/X6!MGN!O*]>[)7I18O6; HYO+$7,(%&JD1S2@+&4G+
MF2=&1@YB_AH3DW]S@<BL4X;7V,V_OGFT?&RNSLS%^C1*RON,S."SB"@1+%=F
M=A9?3++2LM\Y$/H[GP7C*-!)^(V"-@> (8\__O#Q\G?@*K_3L ?6&(A_"J(-
M_O#IUX.?B>L8<%> H\ >"^_M.4;F'SY3J/A7/P2TE\+:'AQWVP8<7R_?F[.W
M#WYV3@>.,X#92T?-W0+^#A0F_.=<*[-92B,^/PO&^0?9BW$.O'?\\^]G\>\7
MD]\!F;"7O^.]LU?M]N_\_ZN+TN?52SGN'OS<&;3A?[+P\"G0;FG9[\4(ES<L
M+GON^>)EG_1/U[MLWPN^O9V$88+ZR$?XQ?I.CY*'&7 B6 )I,0?R:10B?[I-
MDMG;-V_N[^];WZ\COQ5&-V\Z[7;W#?[Y#;YX((=7$\!)S(U+P:DP4L/>1KC<
M__4K@''<!DI6SWWW6OA_.Y#/?X>O#JPW3QK:665HA9:S*#\%<",U#/SX"$[D
M&V\FP R/U8CJ<]2?"D#(B4)^C"\?MT\.+"H"_MN!\S0$.!6X=9Z.6Z<"MQ5#
M;Q>W3C5N!^O";:<"MYVGX[93@=NU#-W9W-#=58;>+D5TJBFBNRZ*Z%901/?I
MN.U64$3%T-O%;;<:M_UUX;97@=O>TW';J\!MQ=#;Q6VO&K>]=>&V7X';?AT0
MT*]&0&=="!A4(&!0!P0,JA'@+$* &C,'8B3B$"QX/=$R"EX1. -%&HSO4Q^>
M8U,"$1Q_O3SX^3?WNS=-*0_ABTJB_I5;RF>1(0H[]APGRU&7;@A.I0,]^<3Z
MB II%+?^^B:WJITMME.RV,_:QXV=, U']ZO.26^?%M<M69S.FLVBN#*1^!;6
M^LJI"^R]4MA]2BP'XB./Z8<X<H5OD>OA8I3BL]K@OE\"_T>-9P?^$Z8Q %X;
M@ <E +]/(Y7N\R!<K+1%GWBA -H9YE-RN6YLIMO]GTGG[JR8J#&729*K[^!4
M0(J541Z$&HX'0Y\/UT3 04V,@ARJ-2[ '9<#WN%L)'1;<)F0=8__"D(9HI@!
M7I1GGXKG,!?/"]!E28'PVFS=2<G6?<CR^',L[&0P=S<(89336W/)6^7+*SS]
M"+_ 7_[Z!@'WWN*_X=?_#U!+ P04    " !$A6%2T(IXR7<=   <;0$ $0
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M Q^^??OV@-86H +D_4T<%%V_/,#J&R<A9<]0ZVO@_3!)G=#EX+VT;% '?GW
M*CE07PKZAH'Z!:A'&G )<5\LHML#J#C <;%_.-Q_.2S LV1_X3CKLLG<26YH
MUWF%O$D<!221MJ$UDD9)G(KP4"@'W4\?UK(/E%629F$4AME*SG\OC0^PW0$
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MC" &9S%S KS&9UB&KGOY](:#OBC](5G^LC^6O[2"Y?\;^6'Z%8K (=2]E6D
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MO-V.GMC[-QG:Y&5%7J?87ZX"HI%W;=D\<0*JT[L%0DDLXHO9N M&;IR(B+]
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MA4>M:0?ODW(TV$R#6.@%8^QYJ>:<X,;QO<OPU%GYB1.(@.&235D3MV$@B04
M5R7-@+GN>KE.O;%9+E1Y2Y>%!87@R78Q94W>I@'92!APE=(+ZBWU2H?(.W>B
MT _GL0A!=OOIL?EP<3B'L#G6BPU\5)&UA=IM._VD!Y,&&UTFRV::#JGW*)ZL
MD[2@$!D_'"AVFYJ/!)-C<!G2_U)<QO$:>6?KB*8YH\C'7EJG*$N.HUL4ZL+<
M),K5RS< [T_;;LT'>&_IP.6KY6"HQTOI-\0H_.]UG"7NW&/ 4KKUYXOD D<7
MZV0=D87V$644#'!IG_MT:2ZP2B0#USUS0)V$+&?OOM*37E\OM(5P$+H?U*)+
MIQ4:L4JC1L7V<QQZOSM1Y!#^"8>T#M(U3M#!P1H LUDG9F/70A8(JH\ZH<JL
M B6 95V])MA*$D'@?>H7O+,UNL>$Z"/-N"??DS\_T3]OT<IYH=)GG$/+I*KN
M[0:YD900\)_-!'ZO][G90_X:@T!B#OBB=BB<9@XG_Q&=SV;(3;9FP@5119H1
MZ9<S>W9 EB4W&[Y&4O"BY]V\I-FH^-U/%K<H7A'^[O'Y,XI</R8_%D.,C*J&
MVQAU#S ;7<5R*@]^=(X_,=\E9VIE3_JKC(BJP.#0:.O@$@Z-'T2?,4TD\V-Z
M(*FR_MRAB-;WJL13B2@T:]Q=T/230KYKE$QF19^G.$[$ Z6CY]HR;+H4'QQ$
MJAUC2WJJ>QRD-,B[Q] 8+^R6'RL<DK\_IS8,^<'CN<B4=&[V<% H(XBY:K]9
M Y8_=8DYW/GKP5P@(XBY8F\:/3(??\=>>L([=?J%WBF=<H(@_7C^G$UB%S[Y
MQ?6=X#*,DRC-T(\K>Q0 =F7]FXV\6C%!\!7[YW:*.YP_4Q;7?KS@ ,JE,1LD
M,>N@XCOSK4F9F'3_K\8ZISV9#5);@4#H.O..2?.G<GNU[>_5P2BS56KKW^H^
M%^ :/:6_M(SY;\C-A;6Q%&!"A]Y$:4" ;/BUAW&'WE8<66* 0"IV:I530ZI;
MY,LPP:5=--<VD: W%YSF8H#@*'8K27/%7>X:]O)*@))8V@X5.W"XQFXI^%3>
MM+0Q^8&N; "NA40@>HI=,6>TJ*9WYC_Z'@J]-$!8&$TWD>^B;0QJ:T,1\VH=
MD,^G1#*BJ3/\%$9X'7KC,/$]/UA3(6XB8FBYV5^DF^W'"^10%T5\&;K!VD,;
M#0!#PAC^S!YG9JD)'+R*?4H\"[&JD>JVX!:MBHJGLX;1RBX?:?80ZUQR<-0H
M=D:U>5<XCI&VW9F-]EY2@4BV]6YUOZM.#:<3,D@]>N@&A7&Z%'^+2B5"FNVS
M.1V:B[P"N4#LV[K'>MB+JP1?V*.MZ,L)!L*OUZ%&#)>9GUQQ =VV,1ZB'58A
MI9?/FO[SW8X4Y!D_>ZE35+LKN%*.Z&.#<D2DIU'>56<EEG;O%JXP^XG6#?-C
M6I:&V"_DPZ9U=R6?I"X6KG#Y>9?+4A^C;2>C;2^=<2]QX7"%]2^[K&\[*.I-
ME;OHC&_.;<1E?@_>[_*;$HYRRE%!VAF?X"7%%2X/=KG,R48ENJY9Y-Q77.'U
M$.*UZ&!4[J$SKJ'KC"N\'NWR6E"--F2=,0C><%SA\'B7PQ+9**?K;NKBW7A<
M8?-#;<:BI"-*FW+9@SY%ER!7^/W(FV&KY)TQS+XBN<)F;;E*:48X'!54'0Y/
M\4W)%5YKBU:IA[1$YTX?'=98!.]1KC!<6ZK $HE=,BM_HW*9^</:NE5TM&-R
M;?L:99UU)DFS6Y8KPM26M[RO4=Y947HT&T<]O9[@C<P5UFNKW99L5-#I,2VY
M)N9A;>43F)BCOQ5_=5KIM<%5S15Q:LND4)RLMRZ%$=[F7)&@MH*R#-$^V):]
MWKG"?6T]Y1A]?0C!OP"ZPGIMC=VU ?O@5W M=(5AQD*[8Q+VP;'<-=$5QNL+
M+F!T]<$_[Q[I,M='M95VQP;K1=FBJZ4K'->64T[MYX)W RKS7@VEGX?2SQV@
M-'YR(N^>/(5?ZGFGF=FEG9DR&5F9K!9J&--8XSS;H9R\;-O<9,<:4LFVXH7>
M#3']KYTE$M4:[N9I>@I)L^%EE$;K2+OF9>):/Y1,KGJM:[AU4R0;.K_VA/^%
M(CP)T3E-8J&<@"5%TX-:4'M-Q:\[?=^QI-RJ%QHA5N2O!DA56NNJB]T_4'6Q
M09PT6P3N GGKH#CK4U-2NE&9K-)-X)CL!1^+G0Z]/^\D8.?S%VK?NV]=I9WE
MK7 U(D*#0UNR@= 'SMOMUCVP4I[P/K;M4BYQGFPU+ZVT8[P/\?+<B=WK(RL2
MU!RS.1&]=2HET^9.YK)=CV>*_,F&B'/ EH<;[^3),SK0+=$A6Z*:VU9:HL/!
MVS5XNUZMM^LFPF2A2UZH09C>K?G'VE]164Y>Q#XP*6*S/6,-Y#?-7P:R3AD7
M^2RDB/5XLYI (@EF72/&N:RZ1M-DAU*GB)M\M1K=C:T3%&W8EKC-BT6@R<?4
MY'VK7? %R6'F9#N9$5L12>/$;*[+P]0>)E@,0SU&H*AW3O#HS%%ZI.F&F!#D
M*_*QQ8S*[LAX7U ;>8QS_$AL_X[8V[^F1R2VV[\CW1O:8[9$W.P8KD3'NB7Z
MP)3HN)ZC*BO1!]T248?I&CA$=%S/KY&5*^]V<$ ,#HA7ZX#8\'X:.'$\F66%
MB^5N6:^3F.UL$,IJFM5;YE.T!V6UU>- $*L9"SDWU$NP'R F^P#V!\WDC7Y6
MG?VDV57J'*+I!SW[#<ZK@AOQ#N'T0>F$%T=)"2/R:1<?\M7TEB9: "L.^;WT
MLZ&K2Y5)<.;2HUAPD!=<%PUZ7BN82L-LUOI9#)3KU,CI7E[O/<[G4JK_3O2V
M7"]YRJ\TF7[I>8X&ABWFL >I]XOB##W^2;ULFSM^B)/(<<%*; VZF![H2N:3
M*ZW66!0)5YP.IWB6(Q7.KY 3HRO?>? #[N7N $'_<.V% I:7R<QM797EM$C?
M9/8C1NFI45GT=LA>$89,R52;56"QPA6._80;HLCJ]>VTLU/_'%' E5_S1NZ1
M#)7BYJP#^&79:6@G/#Q9('S:%BQ6@T]Q0/?Y_-E9^F&:P7N&8C?R5T AZIQ2
M0&@U?E*R@3MRY7>!18G_9\I#7B!V.]729&?V>NJ#A=_;=V@GIBIDAK!N6WE7
MX:F].*M$R9E82ZWL1! 4!()%\25119&-K,0WBE)&@+>+V=9.M0O$@92O^)HG
M^D*6;!U:+S.*7H@DV1U_  P"*GL!D1(,]%)HG:[.T$-2NJ@C\N=D:0WHMY=A
M@LBKG=PZ"9&(?@-/9TUZL1/FUH*"FV?%1WTKPZ^H.I?4"U?N3HT",CO1DI<,
MA$>Q[[!DJ3;"1TAG+T"2HH$(*79:E,?+"0[7]?JTG%>G2F O)B*90##T.C12
M*5^R:D^;"SW2F3C,?CIWHI!H@W<,2+8+.\%M)R4(M^(+G:[75/)LR&75^N,S
MGPCC/ZP3Y)V\T$Q[)V3YY"FY)+6=P#46$,1,L0_D%GED9A@'P63&S)/@.ZQH
M%PUZL!>[QD*"^"F_4:BT_*8C:S/7P_>:P23V(B26"H1$L4\CO9'D)L(N0AZ$
M0:6-O4IGB %J6;'S@KQ_,<$V/2R2[=2VU\T+0U9RQ/;BTD0^$+"22Z/7LS7P
MQ1V\PA?'M6HJO/L[2E4O#,@WOQH.- P'&CI J53%YZ5<8N?DI?P+_X1#DSX,
M34IM(0F(LC%XBE+N66WUG(%HH7<8.,,/1>R'D)%9LMVAV&L1S5,G#)T'WXVY
M!1EW6DV/]>1N<D8\YC,+J?-8L2<<-M+D4FBEZ:>?34Z?;28&!([>.6M[%_+D
M*41>7I@O<U#QDI1@JMXQ:PW%;G*20";59@'P<E7YB.*%OQ)N:;DTU@$B)Q%H
M!"B>Z[*S"N6H2I8J0[.;UDF<.*%']NCI.#EU5GZR/7Z_.^LU[\E*Z-K*"1H#
M6B?(K3:V>KC&H9M=< 1/D7PZZX"5EPHT0HR#\4<8(2?P_T3>-Z(Z_B7-<O2O
M"59 .@A>Q:&I7:'$H2@.A76PR,@# :$XQI3E;%\0T4X7]%#?97CA^%'J7 :-
M$9#"2B!$\D! M(TL*:M E@9F*-\T!G"-DFP=WIR?X"12"&FM [*99!"DGS5%
M1>IW,G*C(;7ZZ^Q+&7NH_;U[3SB7[5K1]=IUX4/D9HC<O/[(S<X5ON+ZUR"!
MV3$9@9RF!6 8[ IOY())-)6D$JA<")#A(1B5&)D<D%&$H]&EJJI,"XM4L9KK
M*D\E?G&X '59GPHZ#K9CJ,D%<@14TT\FAV]DF%<=M)$XN$ M8)KX15.ZH0PV
MH'GO^FZH1N"40DT$,]?__,J[^ )'M_C%"8"SX,5.D]':$GQ$$JB.O*@Z!IFE
M9*>[>!IJH'O>;*L+H\0AL@LLD2"J@RN2RXC8;<NAL 0!&2E4!T7  QTNGH?4
M9R^LA)4=;& WMTCQ7!%ZBE5T=6[7'A2D1.DI8'&#0K)6O>2K%ZC[<B.K-%UC
M7"+^T*NS.A>L*'&Q'05<YV_MZLK"^5OT,]IVU*?K&A2#>]="[>)*&6E,N&>!
M%0FN[:+DPN-71KB\69P)O-\<$F,<X5(X243Y+72/7_BA$[J^$VR/-?'=XR"!
M-O>X& DL)X&9.^4T19SL1^A&Y Y%C[Y+#(+)C"%%3%UC,?LGD>-6[5/T^.-%
MP.(.)3;4A6_?X#$Y4*!O@/5ZP&/7F.:>\V WUG4K8B<O-<<U8?[EB5G"U=:)
M3Y]$$> N\EPB:Q9Z"=%-\[L"+(LF8 &9GN581OU2@!F^QG:!F<FKH&)<+0J;
MVY@\U'32;)Q'I+ET^Y!'-.01&3(Q&IU'Q+?UZX[91CDK0G)=R2N-/'N-!8)
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M^8\.-13+J7DM\&[7N]T#8A^9H1'3MF24JI/I#ME!7,;Q&GGI$D:V#^EW\#
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MD-(^*.4D JT*$^)K,9G34[9C*0QY5/;A)Y8&7-Q,2>=),VGCRSA>(TZ93H#
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M'__DC+767=HW?O84%1P3>MU.^?1:N1/@,G0C1-X,8:2.264?LF)I0/#:NJJ
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M:O9U.+2F83;H)+?' (5M@/'E .$JN3.@$^GY]_0_M,@_^>;_ U!+ P04
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MXU-4;!&!O\<AF<M3M#D4APR3WSSBY% %AR$PD6%2 S#$6  PP];F%^S,/N(
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M]8^&(N^S]PSC'8WY+I6$K!6D??)CDQ!M4^;SI_PN,UI$=6&NF6PAQUCUZ^R
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M^N3+"U+6,SUY69%/LGB.<IE;9*'V]V^@94T= EK([T^+6;*"F&A%?L_JZ+!
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MZ9"AS$7V)36*<YU<WD4/2;2)0AJ@U50MIA4N:>H'\Q7S8?KN$LZ,Z%:3<&:
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MCFU3(*RK16>MK*FF'3#</0*\$/M&I +B6N"6CP&&UZT"\&4$SB)97Q.2&)(
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MS9/?H(C%>OG8Q:)[U?1H\K:)=5AN=/SN=I26KG[_3G+P/T&K #8L9^B,]+"
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MGP<,WL>[YXX?$?/4F(#6&>9G8P*^A?&=OOVL3<"W $R 6W<4D FP=D9U)@#
MZOZ_9A2>6T_5F-7;YRMP.8<!)O,KCA(#MNSRU/M)>.Q@.5:DX>_;-*:YJ<__
M<8B*%XNBH19*[OP<VPXT7HE)PSM_!\'L$ZVM]R?$-:>K)CI1N++0MUO\2&<E
M]H>[?:RL7VREZ30<V+XK'<-L5O-.P^%8Q:('3 [E5!#E5!)B\OHXR//EYM>
M3@S%,KNEEKKEPRA>BUG-:1)[RTYT$MD;=, PT!*H,.=R^;R<:Z?<VIB&>17
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M6.349,YB:*"RCTVXP83771*SP6:O=Z%7>%'8[KGB=LVM"BXUE;,HFVYH042
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M#%-NY^/DSQ&S5\'CI-I\^[DYWW8=C(H>1I4N7&80W_AQ4YX\I\R86N4/4FD
MWH?39.G;85Y%Y4#EL+(_EO>19?6T(G>\T89M[XN.)[RYUK32L=O% L.2H2@\
M4%TJ3KYK+A4YX:BD')6D[N;->>GX.XO3+"VS[=,_"+>B5AX-&#A%*OT&)OIU
MHW?'+JW^%K@0 UY%Y'A*#X1RTPK7BPG#5"TSB(WG"2&UL-S:1#UI3M22;+2C
M&]2=5A^38CX5KBA9\V%]?/6OJ)1>-"H$^JX6ELC'IV$9D0(K4N#5-/F#3),W
M'8PJ/0RO/NUAPI1;16=!R]N? ZJ[DA"!WNOE+Y@  &E@F FRBCXU_?_8U/\-
MU6A#-F3R$$&A(8V^JTD&S6PB^)).RS4T+A4<(NM:1A((^QC4NAG++=;K[YMZ
M72$;%70NSQ&/F=GQ0-S>H=5?'Q+ XI<2.+?V55@TC'@-UQBFQ_TB3IAEEBRY
MDBN7_A]:CG!..N*T^0SIM0,<)\K&\;W!@X\-XNB6M#^D::+F&<4LV;G=\\!L
M+W]!(=E+?E3=&-7(APP(%(]08RYIJ0:-611_3&<TZ<E<VDU N=<"!X%RP*#X
M#]X+22=14492K.ZMT(N<9A1'HY+*Y<4%'P ;C\FFH"1R6[*V.2[038J*ROEM
MB!:?=C5:K1 PS!O^5)06US3\#F;S&D :9G#2"C.H]##RHF!4[\-A2E\Y9R:S
MS+ ;ESF,(2,%S$33?AS/S4XX-U,6=Q(=AOF;Q^HOXI")."TN5<73MA6M4"7\
M=V\5IW\IHQ8<3MEB /HYV6SG\AC4DO]MG!&C^6;0A>.I)L:G>4@RE0B*:41"
MPM^D[@($)[.R4CBS>,^]S!-.JP^MF_U-1Z-=3Z-X-MKU-<H[&_2%E6[HNK.5
M00?#/@W3?5=[XC+IP>GARQBC^@,N8T%AF%-3$O*$,G=>DC\7]D+^D(7OKUK/
MQ(?6/7S9UZCL;+3I+;<X>[LJAJKFM^7W%>C:*$GUE$Z+%(H'9[3'&77B>)>#
MXM@J6&@L)PRS]'[]F))_K5E_%T\DDD2P?6B%$^S(1B6=0QNLP8)^PLDI7)J2
MC4%!3$<YB>-)I,.D:33J>$<Q550Q[<K'&1]:X0B:QQFC/VU^^H_C.XTA6/E<
MO![,Z)(MTHJ*3<UVA_;N0LPGDMJ$U4=:.3^O('>4B@J(C[446L8 082  Z[+
M."%LE2IB>_VZ*50:\6%Q! %CV:-+:(%C-$#W%A\.+2@+MC6K3X)G+XP<7,D8
M"[I&8NE<RNZ))(]Q2BP4*M^E83OUHB]E*C8]JL5C? @IN#R*<T3A/&&:EZ*4
M;,6 Y9-110-.2NH<+P SF("Z2^(52;+7NY"?&XIW="ONQ0.OH? >P%D^L(!H
M*AR7*^E T1'+E4>3//-2PDZ$;*'QPLGL.H[FU_2)!,43*K!J=.L-J";64EL9
MJTD?H>%8!=@&0]@8N,UP3IY(&.=:?O&RRA]>:-9M$#$05&MYKHQ!-1 )0@/J
MG@TYX7<0=]XKS&Y24@#1LY8DR\Q< C"/8]IMP[#@*ZJ4 NQJ<(^1EA=,&)W%
M3)&BK+C.G-+TRQF;W33C/RF]0G(B*%*HO$(Z&>  BS^@J$1+Z78N27,H0'B\
M.4J^<4!SR4RD7[UP32H)KZXBQM4:!!60' H='E>-D5QL9<XD<R_<9%BHQ1?"
M; <#>BA 2#POQI+!,=FN"3MSD&N>E1)^6E,207'#XX$!R,!:5G&>L7J\27O+
ML^)N:\I4ZL@ S?).?4'A0N!KZ<$EIBEWX241XS:](TF>]!4\[;2$4"SQ.$2
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M=B8[-S.E>B1)F4NB$J?:*,,EGT5=^P/".GR=>1U*\2#L83X$\'5A4VZM]HY
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M,/SO$NH37;2*N*W3"-V^TT3)OR69\PE7,5@FLTUJ-S9GU]+W)%HJIR&T?7$
MR@3'FG1.'K.S.&+V3<I7UX3.V489\M]NB@_QC)F3&?^-?,TRZ\6=WV>@1:V+
MT&PM>E4]BW->V#]W%0QDZY^6# H2/N<#C#_+)]BME6D$"X .B@L^SP*0P;U-
ME],X6I/Q/"%$\?1110"% J>W02\*'#M4SM)K\7QO\W SS=?7J/C3)DA7OCT9
M= '%%*VOPEA<EF;:)AB>JU9:G +.>6G8(@?!Z2N/J?,BD5>\?/@)HX;BA<])
M8<2F5:BF)& 3?QR&DYGP)ESM32JJ?ACT (4,IS.B@[#V863D&K1=P64N)#4)
M%!A\S@8];U:1^)3P]QI)[!,2R$3?: .5-4Y7@Y!A>T^8N&3RY&?%D>HJ8B-;
M<V"U5T108B@<.#T.9B+"\)#HQDN^D(P'"!5UA>Z)OTYREZVJ<,_W'YH!YKM^
M1D5'HUU/**KV5!+H<US*K'Y5AO51YB9]8(BT/<BH<W.@CE'H6((*\4>ARZIZ
MG[Y6_Z(.2S?IXX!0,V$+1^!Z=5RZP'516QS@F*ND KB!(MFE16&BR'ND?BH-
M+BUJGS1:.8M?4 BH;;Q)F+-D3<L-+UBDJ0']0829&LL#AU.T7AHW./5"'IY4
M>) @AJ2(RFFTJ3D.LBR:<H%8FE*F!9\YT3 5GNW<\72& L"8W;6M"-JO7FP4
M@2<\1&B7C257BC-O1;/=.^;F*M>E)Z>QI[U ZR$X',OACOL=W[=QY.OJ]NGH
MG :N]ET284+!"^#G*"%>2/\@P2=F.JESJ$/IG8:TV@!4+J0]&9#ZRR$EA=/
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MA^%EX3/L,=\[?@]]Z(-E_M^H3MVN)2O,\.+<?,KY\N1 E>IB?AM:](DUS--
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M4;& [KQDDN2W5L65L3Z@ D3L[OGF0-$Q.KD<_A7&+L_YG4?9Z;^,!Y(#+R4
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M:H8VZ@ZJ5&QS05DF01H_>TGPB9V]I ?]CIVY2P_7<??L)S5KN<!JW_T<L?/
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M,#(P,3(S,2YX;6Q02P$"% ,4    " !$A6%2T(IXR7<=   <;0$ $0
M        @ $*FP$ =VEZ<"TR,#(P,3(S,2YX<V102P$"% ,4    " !$A6%2
M>LSSJS$1   >W   %0              @ &PN $ =VEZ<"TR,#(P,3(S,5]C
M86PN>&UL4$L! A0#%     @ 1(5A4GSV<C_=-   LY # !4
M ( !%,H! '=I>G M,C R,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( $2%85)'
M+8^(H8L  /A@!P 5              "  23_ 0!W:7IP+3(P,C Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " !$A6%2MW](6R=5  "&I 4 %0
M@ 'XB@( =VEZ<"TR,#(P,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  %+@
$ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
